<SEC-DOCUMENT>0001564590-22-009488.txt : 20220310
<SEC-HEADER>0001564590-22-009488.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310082703
ACCESSION NUMBER:		0001564590-22-009488
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38997
		FILM NUMBER:		22727516

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rapt-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T13:05:30.1672510+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:rapt="http://www.rapt.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
rapt-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001673772_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001673772_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001673772_20210101_20211231">0001673772</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001673772_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000305" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231">http://fasb.org/us-gaap/2021-01-31#OtherAssets</ix:nonNumeric>
			<ix:nonNumeric id="F_000307" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231">http://fasb.org/us-gaap/2021-01-31#OtherAssets</ix:nonNumeric>
			<ix:nonNumeric id="F_000376" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_0001673772_20150501_20150531">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000377" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001673772_20150531">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000426" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">P6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001673772_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001673772_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:PreferredStockValue" contextRef="C_0001673772_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:PreferredStockValue" contextRef="C_0001673772_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000448" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">P8Y4M9D</ix:nonNumeric>
			<ix:nonNumeric id="F_000449" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">P8Y14D</ix:nonNumeric>
			<ix:nonNumeric id="F_000450" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">P8Y14D</ix:nonNumeric>
			<ix:nonNumeric id="F_000451" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">P7Y4M28D</ix:nonNumeric>
			<ix:nonNumeric id="F_000473" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">P3Y11M4D</ix:nonNumeric>
			<ix:nonNumeric id="F_000474" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">P5Y2M8D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000477" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF">0.810</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000478" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231" decimals="INF">0.840</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000481" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF">0.0055</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000482" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231" decimals="INF">0.0028</ix:nonFraction>
			<ix:nonNumeric id="F_000475" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">P6Y18D</ix:nonNumeric>
			<ix:nonNumeric id="F_000476" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">P6Y25D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000479" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF">0.869</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000480" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231" decimals="INF">0.870</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000483" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF">0.0126</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000484" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231" decimals="INF">0.0143</ix:nonFraction>
			<ix:nonNumeric id="F_000485" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">P3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000486" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">P3M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000492" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="INF">0.0005</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000493" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF">0.0011</ix:nonFraction>
			<ix:nonNumeric id="F_000487" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000488" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">P2Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000490" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="INF">0.713</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000491" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="INF">0.929</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000494" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="INF">0.0155</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000495" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF">0.0157</ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="rapt-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001673772_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_20220304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-04</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-01</xbrli:startDate>
					<xbrli:endDate>2021-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_raptInstitution">
				<xbrli:measure>rapt:Institution</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_srtStatementGeographicalAxis_raptSouthSanFranciscoAndCaliforniaMember_20150531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20150501_20150531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-05-01</xbrli:startDate>
					<xbrli:endDate>2015-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20180401_20180430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20150531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_20190201_20190228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-02-01</xbrli:startDate>
					<xbrli:endDate>2019-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_raptvote">
				<xbrli:measure>rapt:vote</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenStockPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapUnusualRiskOrUncertaintyByNatureAxis_raptCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">rapt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEarlyExercisedStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EarlyExercisedStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001673772</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001673772_20210101_20211231">10-K</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentAnnualReport" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Segoe UI Symbol;font-size:10pt;"><span style="font-weight:bold;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001673772_20210101_20211231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001673772_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:3pt;margin-bottom:0pt;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentTransitionReport" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:3pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Segoe UI Symbol;font-size:10pt;"><span style="font-weight:bold;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000015" name="dei:EntityFileNumber" contextRef="C_0001673772_20210101_20211231">001-38997</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001673772_20210101_20211231">RAPT THERAPEUTICS, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001673772_20210101_20211231">47-3313701</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressAddressLine1" contextRef="C_0001673772_20210101_20211231">561 Eccles Avenue</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityAddressCityOrTown" contextRef="C_0001673772_20210101_20211231">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000019" name="dei:EntityAddressStateOrProvince" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric id="F_000020" name="dei:EntityAddressPostalZipCode" contextRef="C_0001673772_20210101_20211231">94080</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices and zip code)</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric id="F_000021" name="dei:CityAreaCode" contextRef="C_0001673772_20210101_20211231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000022" name="dei:LocalPhoneNumber" contextRef="C_0001673772_20210101_20211231">489-9000</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:40%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of Each Class of Securities Registered</p></td>
<td valign="top" style="width:1%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:18%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="top" style="width:1%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Each Exchange on Which Registered</p></td>
</tr>
<tr>
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:Security12bTitle" contextRef="C_0001673772_20210101_20211231">Common Stock, par value $0.0001 per share</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001673772_20210101_20211231">RAPT</ix:nonNumeric></p></td>
<td valign="top" style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:SecurityExchangeName" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(g) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <span style="text-transform:uppercase;">Yes</span> <span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000030" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001673772_20210101_20211231">No</ix:nonNumeric></span><span style="color:#000000;font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. <span style="text-transform:uppercase;">Yes</span> <span style="font-family:Segoe UI Symbol;">&#9744;</span> <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000031" name="dei:EntityVoluntaryFilers" contextRef="C_0001673772_20210101_20211231">No</ix:nonNumeric></span> <span style="color:#000000;font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000013" name="dei:EntityCurrentReportingStatus" contextRef="C_0001673772_20210101_20211231">Yes</ix:nonNumeric></span> <span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span> <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). <span style="text-transform:uppercase;"><ix:nonNumeric id="F_000024" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001673772_20210101_20211231">Yes</ix:nonNumeric></span> <span style="font-family:Segoe UI Symbol;">&#9746;</span> <span style="text-transform:uppercase;">No</span> <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer </p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer </p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric> </p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company </p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company </p></td>
<td valign="top" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000012" name="dei:EntityExTransitionPeriod" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000032" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). <span style="text-transform:uppercase;">Yes</span> <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityShellCompany" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> <span style="text-transform:uppercase;">No</span> <span style="color:#000000;font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the common stock held by non-affiliates of the registrant as of June 30, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter) was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="dei:EntityPublicFloat" contextRef="C_0001673772_20210630" decimals="-6" scale="6">622</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock, as reported by the Nasdaq Global Market on June 30, 2021 of $31.79 per share. Shares of the registrant&#8217;s common stock held by each executive officer, director and holder of 5% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for any other purpose. </p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 4, 2022, the number of outstanding shares of the Registrant&#8217;s common stock, par value $0.0001 per share, was <ix:nonFraction unitRef="U_xbrlishares" id="F_000023" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001673772_20220304" decimals="INF" format="ixt:numdotdecimal">29,573,318</ix:nonFraction>.</p><ix:nonNumeric id="F_000229" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s Definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="TABLE_OF_CONTENTS">TABLE OF<span style="font-weight:normal;"> </span>CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PART II</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_RESERVED"><span style="text-decoration:underline;">[Reserved]</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item_7__Management_s_Discussion_and_Anal"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLO1"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 8.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9A.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9B.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR"><span style="text-decoration:underline;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PART III</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 10.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 11.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 12.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="bottom" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 13.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 14.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accountant Fees and Services</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PART IV</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:underline;">Exhibits and Financial Statement Schedules</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="4" valign="top" style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">SIGNATURES</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:10%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
</tr>
<tr>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:79%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">__________________________________</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context suggests otherwise, references in this Annual Report on Form 10-K (the &#8220;Annual Report&#8221;) to &#8220;us,&#8221; &#8220;our,&#8221; &#8220;RAPT,&#8221; &#8220;RAPT Therapeutics,&#8221; &#8220;we,&#8221; the &#8220;Company&#8221; and similar designations refer to RAPT Therapeutics, Inc. and, where appropriate, its subsidiary.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained in this Annual Report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. Forward-looking statements in this Annual Report include, but are not limited to, statements about:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">estimates of our total addressable market, future revenue, expenses, capital requirements and our needs for additional financing&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the initiation, cost, timing, progress and results of research and development activities, preclinical or and clinical trials with respect to RPT193, FLX475 and potential future drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to identify, develop and commercialize drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to advance RPT193, FLX475 or other future drug candidates into, and successfully complete, preclinical studies and clinical or field trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain and maintain regulatory approval of RPT193, FLX475 or other future drug candidates, and any related restrictions, limitations and/or warnings in the label of an approved drug candidate&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to develop and expand our drug discovery and development engine&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to identify drug candidates using our drug discovery and development engine&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain funding for our operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain and maintain intellectual property protection for our technology and any of our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to successfully commercialize any of our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the rate and degree of market acceptance of any of our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory developments in the United States and international jurisdictions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential liability lawsuits and penalties related to our technology, our drug candidates and our current and future relationships with third parties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to attract and retain key scientific and management personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to effectively manage the growth of our operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to compete effectively with existing competitors and new market entrants&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectations regarding uses of proceeds from our initial public offering and our follow-on offerings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">potential effects of extensive government regulation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our financial performance&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our expectation regarding the time during which we will be an emerging growth company under the JOBS Act&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the volatility of the trading price of our common stock&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">other risks and uncertainties, including those listed under the caption &#8220;Risk Factors.&#8221;</span></p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These statements are based on the beliefs and assumptions of our management, which are in turn based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled &#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; included under Part I, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. Some of these risks are:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We are a clinical stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability. Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. RPT193, FLX475 or other future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We may not be successful in our efforts to use and expand our proprietary drug discovery and development engine to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Even if regulatory approval is obtained for RPT193, FLX475 or any other potential drug candidate, the drug candidate we commercialize may not achieve market acceptance and we may not generate any revenue from the sale or licensing of our drug candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Undesirable side effects caused by RPT193, FLX475 or any other potential drug candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities, which could compromise our ability to market and derive revenue from our drug candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We will need substantial additional funds to advance development of drug candidates and our drug discovery and development engine, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Because we may rely on third parties for manufacturing and supply of our drug candidates, some of which are sole source vendors, our supply may become limited or interrupted or may not be of satisfactory quantity or quality.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">We face intense competition from companies that have developed or may develop biologics and small molecule drugs for the treatment of cancer and inflammatory diseases. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">The ongoing COVID-19 pandemic has materially affected and could continue to impact our operations, including at our headquarters in the San Francisco Bay Area and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our stock price may be volatile. Raising additional capital and other future issuances of our common stock or rights to purchase common stock could result in additional dilution and could cause our stock price to fall.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners.<span style="font-weight:bold;"> </span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ite</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">m 1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_BUSINESS">Business.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. Our lead inflammation drug candidate, RPT193, and our lead oncology drug candidate, FLX475, each target C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;), a drug target that potentially has broad applicability in inflammatory diseases and oncology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead inflammation drug candidate, RPT193, is designed to selectively inhibit the migration of type 2 T helper cells (&#8220;Th2 cells&#8221;) into inflamed tissues. Th2 cells are known to be drivers of inflammatory diseases, including atopic dermatitis (&#8220;AD&#8221;), asthma, chronic spontaneous urticaria (skin rash), allergic rhinitis, chronic rhinosinusitis and eosinophilic esophagitis (inflammation of the esophagus). We believe RPT193, if approved, could fill an unmet medical need for a safe and well-tolerated oral drug in the treatment of allergic disorders. In June 2021, we announced positive topline results from our randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with&#160;moderate-to-severe&#160;AD. After four weeks of treatment, patients who received RPT193 showed greater improvement from baseline compared to the placebo group in several standard measures of disease severity, including the Eczema Area and Severity Index (&#8220;EASI&#8221;) and the validated Investigator Global Assessment (&#8220;vIGA&#8221;). In the&#160;two-week&#160;period following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo in these measures. We believe the results from this Phase 1b trial provide clinical proof-of-concept (&#8220;PoC&#8221;) in AD and potentially additional Th2-driven allergic indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells (&#8220;T<sub style="font-size:85%; vertical-align:bottom">reg</sub>&#8221;) into tumors. We are conducting a Phase 1/2 clinical trial investigating FLX475 as a monotherapy and in combination with pembrolizumab (KEYTRUDA&#174;) to study the safety and potential clinical activity of FLX475 in patients with advanced cancer. In November 2020, we disclosed initial observations from the Phase&#160;2 portion of the trial that demonstrated clinical activity of FLX475 as a monotherapy as well as in combination with pembrolizumab. We believe these early initial observations establish initial clinical PoC for FLX475. As of February 2022, we are enrolling four expanded Stage 2 cohorts and one cohort is still enrolling in Stage 1. We are also enrolling a separate Phase 2 clinical trial investigating FLX475 in combination with ipilimumab (YERVOY&#174;) in patients with melanoma.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We internally discovered and designed all our drug candidates utilizing what we refer to as our &#8220;proprietary drug discovery and development engine.&#8221; Through our team&#8217;s deep expertise in immunology and drug discovery, supported by advanced computational biology and proprietary know-how, we are developing the ability to exploit difficult targets and generate drug candidates that we believe, if approved, will significantly improve treatment paradigms and outcomes for patients by fundamentally modulating the immune responses in a range of inflammatory diseases and cancers. We continue to invest in our proprietary discovery and development engine and are pursuing a range of targets to generate additional potential drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.84%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hold worldwide rights to each of our drug candidates, with the exception of the exclusive license granted to Hanmi Pharmaceutical Ltd. (&#8220;Hanmi&#8221;) for FLX475 in the Republic of Korea, the Republic of China (Taiwan), and the People&#8217;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#8220;Hanmi Territory&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Advance RPT193 through clinical development across multiple inflammatory diseases.</span> We are initially developing RPT193 for AD because we have established PoC and the characteristics of the disease are in-line with RPT193&#8217;s anti-inflammatory effect. In addition, we believe RPT193 has potential clinical translatability in a variety of inflammatory diseases beyond AD, including allergic </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asthma, chronic spontaneous urticaria, chronic rhinosinusitis, allergic rhinitis and eosinophilic esophagitis. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Advance FLX475 through clinical development to commercialization in charged tumor types, which represent cancer types we believe are most likely to respond to FLX475.</span> We are evaluating FLX475&#8217;s efficacy in multiple tumor types both as a single agent and in combination with other immuno-oncology agents such as a programmed cell death 1 (&#8220;PD-1&#8221;) and cytotoxic T-lymphocyte-associated protein 4 (&#8220;CTLA-4&#8221;) checkpoint inhibitors. Our goal is to expeditiously progress into registrational trials to ultimately enable treatment of cancer patients for whom current treatments are inadequate. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Develop and advance a preclinical hematopoietic progenitor kinase 1 (&#8220;HPK1&#8221;) inhibitor into clinical trials.</span> We view our preclinical programs as important drivers of long-term growth and stability of our company. Our goal is to rapidly advance our programs to generate validating preclinical data that warrant clinical development. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Expand our pipeline by leveraging our proprietary drug discovery and development engine and small molecule expertise.</span> We believe there are additional identifiable targets that will be important to fundamentally modulating the immune response in the treatment of cancer and inflammatory diseases. We will continue to invest in our proprietary discovery and development engine and investigate several of our identified targets as well as generate additional target and drug candidates. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.76%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.84%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Utilize collaborations in support of our long-term goals.</span> We plan to selectively use collaborations and partnerships as strategic tools to maximize the value of our drug candidates. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Drug Discovery and Development Engine </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We credit our rapid identification of therapeutic targets and drug candidate selection to our proprietary drug discovery and development engine, which relies on our team&#8217;s deep expertise in immunology and chemistry, supported by strong computational biology and the ability to exploit difficult targets. The key pillars of our proprietary drug discovery and development engine are as follows. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-weight:normal;"></span><span style="font-size:10pt;">Computationally-Driven Disease Target and Biomarker Identification. </span><span style="font-size:10pt;font-weight:normal;">We use proprietary methods to identify targets that we believe have a high propensity to drive the immune response in disease states by computationally screening a combination of proprietary and public databases. Through this process we also identify biomarkers that can guide our clinical development strategy and increase the probability of clinical success. A computational screen we designed to seek tumor-infiltrating lymphocyte modulating genes identified CCR4 and HPK1 as potential targets. In addition to well-known and clinically validated targets such as PD-1 and CTLA-4, our target identification approach has also uncovered what we believe are key immune drivers of pathology that have not been fully explored but which may offer significant therapeutic potential. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Efficient Design of Small Molecule Drug Properties. <span style="font-weight:normal;">Key to our rapid discovery of small molecules is our use of structure and pharmacophore-based drug design strategies, machine-learning assisted structure-activity-relationships to improve potency, selectivity and pharmacokinetic properties and early testing in physiologically-relevant immune assays to rapidly identify highly selective, orally-administered small molecules. This seamless integration of biology, chemistry and pharmacokinetic disciplines allows for rapid cycle times and quick iterations between hypothesis and compound selection. We use these strategies and novel structure-based drug design techniques to improve potency, selectivity and pharmacokinetic properties to identify leads in our discovery programs. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Data-Driven Patient Selection. <span style="font-weight:normal;">A key strategy for every program is to identify a patient selection and enrichment approach. Our proprietary drug discovery and development engine enables enrichment and prospective selection of patients in our early clinical trials that we believe increase the probability of clinical success. Using proprietary and public databases, we can mine contextually-rich molecular and clinical data from disease tissues to identify tumor types and inflammatory disease indications that we believe will be most likely to respond to our therapeutic agents. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nimble Clinical Execution. </span><span style="font-weight:normal;">We believe our precision medicine approach enables a rapid path to clinical PoC and the potential for accelerated regulatory approval. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Background on CCR4 in Allergic Inflammatory Disease and Oncology </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary drug discovery and development engine has identified the cell surface receptor CCR4 as a drug target that potentially has broad applicability in inflammatory diseases and oncology. Receptors such as CCR4 bind to chemokines that orchestrate migration and homing of immune cells to specific tissues throughout the body. Chemokines specific for CCR4 are secreted from inflamed tissues and tumors, but are not highly expressed in healthy tissues. Our approach is designed to enable selective restoration of the immune response within inflamed tissues or the tumor without systemically depleting immune cells and broadly suppressing the immune system. Each of our two drug candidates, RPT193 and FLX475, target CCR4 in a manner we believe is well suited for inflammatory disease and cancer, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The immune system is a series of complex interactions between different types of white blood cells. T&#160;cells are one category of these cells that play crucial roles in immunological memory, regulation and responses. Two T cell subsets of clinical interest are Th2 cells and T<sub style="font-size:85%; vertical-align:bottom">reg</sub>, and both express CCR4. The two chemokines that bind to CCR4, C-C motif chemokine ligand 17 (&#8220;CCL17&#8221;) and C-C motif chemokine ligand 22 (&#8220;CCL22&#8221;), are over expressed and secreted by allergically inflamed tissues and tumors. This overexpression allows for the theoretical manipulation of CCR4 and its two T cell subtypes to address diseases across the immunological continuum spanning overactive to underactive immune responses in allergic inflammatory disease and oncology. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Inflammation Drug Candidate&#8212;RPT193 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead inflammation drug candidate, RPT193, is a CCR4 antagonist designed to selectively inhibit the migration of Th2 cells into inflamed tissues. Th2 cells are known to be drivers of inflammatory diseases such as AD, asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis and eosinophilic esophagitis. The current standard of care for AD includes topical creams and steroids as well as the injectable biologic, dupilumab. Despite recent progress in the treatment of inflammatory diseases, including AD, we believe there remains a significant unmet need for a safe, oral treatment with an attractive efficacy profile and that RPT193, if approved, could fill this unmet need.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We hold worldwide rights to RPT193 and have submitted patent applications with respect to RPT193 that, if issued, would be scheduled to expire in 2039 (not including any applicable extensions, if approved). We own a granted US patent covering the composition of matter of RPT193. RPT193 is chemically distinct from FLX475, our CCR4 antagonist for oncology. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Background&#8212;Th2 Cells and Inflammatory Disease </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Th2 cells express high levels of CCR4 and are clinically validated drivers of many inflammatory diseases, including AD, asthma, chronic spontaneous urticaria, allergic rhinitis, rhinosinusitis and eosinophilic esophagitis. When a pathogen comes into contact with the skin or mucosal lining of the nose or lungs, innate immune cells and antibodies that recognize the pathogen initiate a release of inflammatory cytokines. While this Th2 response may be highly effective against foreign pathogens, particularly parasites, sometimes the body overreacts to benign substances in this way, resulting in a significant influx of Th2 cells, leading to highly inflammatory conditions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RPT193 Acts on a Well-Validated Th2 Pathway in AD and Asthma</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000001.jpg" title="" alt="" style="width:492px;height:228px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At a cellular and molecular level, the Th2 response is initiated and sustained when Th2 cells are recruited to the site of inflammation by the binding of CCL17 and CCL22 to CCR4. The Th2 cells secrete inflammatory cytokines, such as interleukin 4 (&#8220;IL-4&#8221;), interleukin 5 (&#8220;IL-5&#8221;) and interleukin 13 (&#8220;IL-13&#8221;), which furthers the inflammation and production of CCL17 and CCL22. Patients suffering from AD and other inflammatory diseases have significantly elevated levels of both CCL17 and CCL22, and CCL17 and CCL22 levels have been found to strongly correlate with the severity of AD and many inflammatory diseases. Dupilumab works by blocking the receptor for IL-4 and IL-13, two of the cytokines produced by Th2 cells, leading to a reduction in the level of inflammation. Dupilumab also indirectly leads to reductions in the level of CCL17, thus breaking the Th2-driven inflammatory cycle. We believe that inhibition of CCR4 will block the migration of Th2 cells into these inflammatory sites, leading to reductions in inflammation thereby blocking the secretion of IL-4, IL-5 and IL-13 before they can induce tissue damage. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Atopic Dermatitis Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AD is a chronic, inflammatory skin disease characterized by skin barrier disruption and immune dysregulation. Patients with AD have chronically inflamed skin lesions that cause, among other disabilities, debilitating pruritus (itch), which can severely impair quality of life. Onset of AD often occurs during childhood and can persist into adulthood. The estimated U.S. adult prevalence of AD is approximately 19&#160;million individuals, of which approximately 50% are diagnosed. An estimated 60% of these adults have disease characterized as moderate to severe. Furthermore, an estimated ten million children have AD, of which approximately 30% experience moderate-to-severe disease. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AD Standard of Care </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Creams, ointments and topical steroids, or other topical or systemic anti-inflammatory agents, are routinely used to manage skin health and reduce skin inflammation in patients with mild to moderate AD. Patients with mild-to-moderate AD who do not achieve sustained alleviation of symptoms with topical treatments have historically been prescribed systemic steroids or other systemic immunosuppressive agents such as cyclosporine. While these are effective as temporary treatments of flare-ups, extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, are not recommended to induce stable remission due to numerous side effects and the propensity of severe disease flares upon treatment cessation. Cyclosporine is also not suitable for long-term use as it has been associated with renal toxicity, hirsutism, nausea and lymphoma, and patients must discontinue use after one to two years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that topical immunosuppressive agents inadequately address the systemic nature of AD. Furthermore, safety issues associated with systemic immunosuppressants such as steroids and cyclosporine make </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them inappropriate for chronic administration. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The treatment paradigm in AD is evolving given the inadequacies of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">current</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> standard of care agents.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">AD Emerging Standard of Care </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two recent developments within the AD treatment landscape will shape the standard of care in the future: (i) the approval of the biologic agent dupilumab for moderate-to-severe AD in 2017&#59; and (ii) the clinical progress of the class of oral Janus kinase (&#8220;JAK&#8221;) inhibitors, some of which reached the market in 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dupilumab is an approved biologic for AD targeting the Th2 pathway. Dupilumab prevents T&#160;cell activation and amplification of proinflammatory signaling pathways by blocking IL-4 receptor alpha, (&#8220;IL-4Ra&#8221;), preventing IL-4 and IL-13 binding. Approximately 36% of patients receiving weekly or biweekly injections of dupilumab achieved significant improvement in disease symptoms. Dupilumab was approved for moderate-to-severe AD in the United States and Europe in 2017. Worldwide net sales of dupilumab were $3.9&#160;billion in 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Two orally administered JAK inhibitors (abrocitinib and upadacitinib) have been approved for use in patients who have had an inadequate response to, or are unable to take, alternative systemic medications. JAK inhibitors block the signaling pathway to multiple proinflammatory cytokines, including IL-4 and IL-13, thereby preventing the downstream signaling of Th2 cells at the sites of inflammation. While JAK inhibitors have demonstrated comparable clinical efficacy to that of dupilumab and offer the advantage of oral dosing, JAK inhibitors are broadly immunosuppressive and therefore may not be suitable for long-term dosing. Additionally, the FDA has placed black box warnings for JAK inhibitors approved in other indications due to the potential for serious infections, malignancies, increased mortality in certain patient groups, major adverse cardiovascular events and thromboembolic events. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite these recent developments, we believe that there remains significant unmet medical need and market potential for a safe and efficacious oral agent for the treatment of AD. We believe that preventing the migration of Th2 cells into inflamed tissues with an oral CCR4 antagonist represents a highly differentiated approach. We further believe that an oral agent with a favorable safety and efficacy profile would offer an attractive alternative for patients compared to the biweekly injections associated with dupilumab. While the JAK inhibitor agents are orally administered, they are broadly immunosuppressive and therefore may not be suitable for long-term dosing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview of Other Allergic Inflammatory Diseases </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to AD, a number of inflammatory diseases are characterized by an inflammatory response to cytokines produced by Th2 cells. These diseases include allergic asthma, chronic spontaneous urticaria, chronic rhinosinusitis, allergic rhinitis and eosinophilic esophagitis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Asthma </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asthma is a chronic inflammatory disease of the airways characterized by intermittent airway obstruction, swelling and hyperproduction of mucus, which can result in coughing, wheezing and difficulty breathing. Allergic asthma is triggered by the inhalation of allergens including dust, pollen and dander. An estimated 25.2&#160;million individuals in the United States have asthma, with allergic asthma as the most common subtype, constituting approximately 80% of asthmatic children and approximately 60% of asthmatic adults. Asthma is driven by both Th2 allergic and Th17 autoimmune mechanisms. An estimated 40% to 50% of patients with asthma fall within the Th2-high subtype characterized by elevated levels of IL-13 and IL-5. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard treatment of asthma includes inhaled beta2-agonists for the treatment of acute symptoms and in conjunction with daily low-dose inhaled corticosteroid (&#8220;ICS&#8221;) monotherapy as a first-line maintenance treatment. The anti-immunoglobin E (&#8220;Anti-IgE&#8221;) monoclonal antibody omalizumab and IL-4Ra antagonist dupilumab can be prescribed for individuals with asthma who are uncontrolled on ICS therapy. While these therapies are generally effective, they are administered via injection and their targets are downstream of CCR4, presenting a market opportunity for an oral, upstream alternative. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chronic Spontaneous Urticaria </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic spontaneous urticaria (&#8220;CSU&#8221;) is one of a group of skin conditions that are characterized by hives, redness, itching and swelling, lasting for greater than six weeks. The trigger for CSU is unknown. Symptoms result from the degranulation of dermal mast cells and IgE signaling likely contributes to inappropriate mast cell activation. CSU affects 1% of the general population, with women affected more often than men. Though both children and adults can be diagnosed with CSU, patients typically show initial symptoms in the third to fifth decades of life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current treatment guidelines for CSU recommend the use of oral H1-antihistamines as a first-line therapy, with dose escalation of up to four times the standard dose in lower responders. Up to 50% of patients with CSU do not respond to H1-antihistamines and can be prescribed omalizumab, an injected monoclonal antibody, which maintains an approximately 65% response rate as a second-line treatment. Dupilumab has also demonstrated clinical effects in CSU patients in Phase 3 trials, supporting a role for allergic inflammation in CSU. Given the responses observed with approved biologic drugs, there remains an unmet need for a safe, efficacious therapy with a favorable oral dosing profile. CCL17 and CCL22 are elevated in CSU, supporting the potential use of RPT193 in this indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Chronic Rhinosinusitis with Nasal Polyps </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chronic rhinosinusitis with Nasal Polyps (&#8220;CRSwNP&#8221;) is a disease characterized by sinonasal mucosal inflammation, which results in facial pain/pressure, nasal drainage, nasal obstruction and reduction or loss of smell, for at least 8-12 consecutive weeks. Confirmation of the disease using an objective measure such as a nasal endoscopy or CT scan is required, given lack of symptom specificity. It is believed that approximately 2-5% of the general population experiences CRSwNP. There is wide belief that CRSwNP is a heterogeneous condition and that the causes of inflammation are diverse and multifactorial, involving overlap between both host and environmental triggers. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard treatment of CRSwNP utilizes topical and oral steroids, antibiotics and ultimately surgical intervention if symptoms are not adequately controlled by available therapies. IgE antibodies may play a role in CRSwNP, with total IgE levels correlating with disease severity, as assessed by CT scan. As a result, anti-IgE antibody omalizumab and anti-IL-5 antibodies, including mepolizumab, have been evaluated as treatment alternatives for CRS, with mepolizumab now considered a recommended treatment for CRSwNP patients. Dupilumab has also demonstrated activity in CRSwNP in Phase 3 trials. Compared to these widely used injectable biologics, we believe that an orally dosed therapy with comparable safety and efficacy results would have a competitive profile. Given the activity of the Th2-targeted biologics, we believe that RPT193 represents a potential oral treatment for this indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Allergic Rhinitis </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allergic rhinitis is a disease of the lining of the nasal passages and, in some cases, can also extend to include the lining of the sinus cavities (allergic rhinosinusitis) or involve the eyes (allergic rhinoconjuctivitis). Allergic rhinitis is common, affecting 10-30% of children and adults. Allergic rhinitis is associated with symptoms including fits of sneezing, runny nose, nasal obstruction and itch. Patients often also experience cough, irritation of the back of the throat, irritability and/or fatigue. Clinical manifestations are typically caused by exposure to allergens. Allergens causing symptoms can be either seasonal or perennial and, similarly, patients demonstrate different temporal patterns of symptoms according to individual allergen reactivity profiles. Patients with a perennial pattern may also have seasonal exacerbations. Symptoms can range from mild, intermittent to severe, with the latter leading to significant morbidity, including sleep disturbance, impaired school/work performance or poor quality-of-life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current treatment paradigm for severe forms of perennial allergic rhinitis includes topical, corticosteroid nasal sprays to minimize the inflammatory effects of continued allergen exposure. Anti-histamine nasal sprays and non-sedating, systemic anti-histamines are also used in conjunction with corticosteroid nasal sprays. A significant number of patients remain refractory to these treatments. Systemic therapy options for such patients are limited and include montelukast, a leukotriene receptor antagonist. While used more commonly in the past, neuropsychiatric </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changes reported with montelukast led to a black box warning. We believe there is an unmet need in the tolerability and safety profiles of patients with severe refractory cases of allergic rhinitis given the dearth of systemic options available. CCL17 and CCL22 are elevated in allergic rhinitis, supporting the potential use of RPT193 in this indication</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Eosinophilic Esophagitis </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Eosinophilic esophagitis is a chronic inflammatory disease of the esophagus. It is estimated that eosinophilic esophagitis affects at least 150,000 people in the United States. Studies from Western Europe, Australia and North America estimate prevalence to be 50-100 cases per 100,000 persons. Eosinophilic esophagitis is caused by the presence of a large number of eosinophils in the esophagus, which stems from many factors such as immune hypersensitivity, environmental proteins and genetics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard treatment for eosinophilic esophagitis includes diet modification, esophageal dilation and drugs, with topical corticosteroids as a first-line medication. It is estimated that there is at least a partial symptomatic response seen in 60-75% of adults with eosinophilic esophagitis who take topical steroids. While steroids offer symptomatic relief once treated, patients are required to continue maintenance regimens as disease recurrence is common after discontinuation of treatment. Dupilumab has demonstrated activity in eosinophilic esophagitis in clinical trials, supporting the potential use of RPT193 in this indication. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Inflammatory Disease Solution: RPT193 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While there are marketed injectable biologics, as well as oral drug candidates and injectable biologics in clinical development, we believe there is an unmet need in the treatment landscape for a safe and efficacious oral therapy for the long-term treatment of AD. We believe RPT193, our oral, small molecule CCR4 antagonist designed to block the migration of inflammatory Th2 cells into inflamed tissues, can, if approved, fill this unmet need. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RPT193 Preclinical Data </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193 has demonstrated the ability to block the migration of mouse and human Th2 cells in vitro and in vivo and has demonstrated activity in multiple preclinical mouse models of AD and asthma. The observed activity in preclinical mouse models was similar to that of commercially available anti-mouse IL-13 and anti-IL-4 receptor antibodies, which we believe are representative of the class of biologics such as lebrikizumab, dupilumab and others targeting Th2-derived cytokines such as IL-4 and IL-13. We believe that the results observed in these models demonstrate the clinical potential to treat a number of Th2-driven diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RPT193 Reduces Skin Inflammation in a Therapeutic Th2-Driven AD Model</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a mouse model of AD, repeated systemic sensitization to fluorescein isothiocyanate (&#8220;FITC&#8221;), which induces a strong Th2 cell-mediated response leading to increased expression of Th2 cytokines IL-4, IL-5 and IL-13. This leads to inflammation resulting in swelling that is measured as ear thickness. In this therapeutic model, mice receive treatment 24&#160;hours following the allergen challenge when significant ear inflammation was already observed. Oral administration of RPT193 resulted in a statistically significant reduction in ear thickness compared to treatment control (p &#60; 0.05). When comparing to the respective vehicle or isotype control, RPT193, anti-IL-13 antibody and an anti-IL-4R antibody had similar effects. Therefore, the treatment effect of once daily dosing of RPT193 was comparable to that observed with the systemic administration anti-IL-13 and anti-IL-4R antibodies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">RPT193 Reduces Skin Inflammation in a Therapeutic Th2-Driven AD Model </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<img src="gbkyd1brmfwp000002.jpg" title="" alt="" style="width:605px;height:202px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">RPT193 Efficacy in a Preclinical Model of Allergic Asthma </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a model of allergic asthma induced by the allergen ovalbumin (&#8220;OVA&#8221;), mice treated with RPT193 showed significantly reduced immune cell migration into the lungs and reduced Th2-derived cytokines such as IL-5 and IL-13, which are drivers of the disease. Analysis of bronchoalveolar lavage fluid (&#8220;BALF&#8221;) taken from the lungs of the mice showed dose-dependent decreases in both IL-5 and IL-13. Not unexpectedly, anti-IL-13 had no effect on levels of IL-5 in the BALF. The reduction of the cellular infiltrate and the level of Th2-derived cytokines in the BALF supports the hypothesis that RPT193 was effective in reducing migration of Th2 cells into the lungs as evidenced by lowered overall allergic inflammation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the overall activity of RPT193 in this OVA-induced asthma model suggests that RPT193, if approved, could fill an unmet medical need for the treatment of allergic disorders and as an orally available therapy, could represent a significant advantage over biologics, which require regular injections.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RPT193: Clinical Trials </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We initiated a first-in-human Phase 1a/1b trial in August 2019. The blinded Phase 1a portion of the trial, which was conducted in healthy volunteers, focused on safety. Following successful completion of the Phase 1a portion, we progressed to Phase 1b and in June 2021, reported positive topline results from this randomized, placebo-controlled trial in patients with moderate-to-severe AD. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The blinded Phase 1a portion of the Phase 1a/1b trial was a standard single and multiple dose escalation (&#8220;SAD/MAD&#8221;) study. The data from the Phase 1a study demonstrated pharmacokinetics and pharmacodynamics that support once-daily oral dosing with RPT193, and blinded review of safety data supported initiation of the Phase 1b portion of the trial. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Phase 1a Data Supports Once-Daily Dose</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000003.jpg" title="" alt="" style="width:624px;height:198px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase 1b portion of the Phase 1a/1b trial was a randomized, double-blind, placebo-controlled study examining RPT193 as monotherapy in patients with moderate-to-severe AD. The study enrolled 31 patients who had an inadequate response to, or were intolerant of, topical corticosteroids. Of the 31 patients enrolled, 21 were treated with 400 mg of RPT193, administered orally once-daily for four weeks, while 10 patients received placebo. The Phase 1b trial was not powered to achieve statistical significance for any particular endpoint. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of the four-week treatment period, the RPT193 group showed clear improvement in key exploratory efficacy measures compared to placebo, including EASI, validated vIGA and pruritus Numerical Rating Scale (NRS).</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Patients treated with RPT193 achieved a 36.3% improvement in EASI score from baseline, compared with a 17.0% improvement in patients in the placebo group.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">42.9% of patients treated with RPT193 achieved a 50% improvement in EASI score (EASI-50), compared with 10.0% in the placebo group. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">4.8% of patients treated with RPT193 achieved a vIGA score of 0/1 and at least a two-point improvement over baseline, compared with 0.0% in the placebo group. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">45.0% of patients treated with RPT193 achieved at least a four-point reduction in the pruritus NRS score, compared with 22.2% in the placebo group.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients were also evaluated for exploratory endpoints at six weeks (two weeks after the end of treatment). At the six-week timepoint, patients treated with RPT193 showed further improvement in EASI score and vIGA:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Patients treated with RPT193 achieved a 53.2% improvement in EASI score from baseline, compared with a 9.6% improvement in patients in the placebo group. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">61.9% of patients treated with RPT193 achieved EASI-50, compared with 20.0% in the placebo group. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">14.3% of patients treated with RPT193 achieved a vIGA score of 0/1 and at least a two-point improvement over baseline, compared with 0.0% in the placebo group. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on exploratory statistical analyses, the difference between RPT193 and placebo on the percent change in EASI score was statistically significant at the six-week timepoint (p &#60; 0.05). No other endpoints or timepoints achieved statistical significance.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000004.jpg" title="" alt="" style="width:468px;height:372px;" /><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other measures of clinical effect commonly used in clinical trials for AD include EASI-50, EASI-75 (a 75% improvement in EASI score) and EASI-90 (a 90% improvement in EASI score) as well as vIGA 0/1 (achieving clear or almost clear skin on the vIGA). Data from the Phase 1b trial show that, at the six-week timepoint, the proportion of the RPT193 group who achieved EASI-50, EASI-75, EASI-90 and vIGA 0/1 were all greater than the proportion of the placebo group.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.77%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000005.jpg" title="" alt="" style="width:624px;height:344px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.84%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity. The overall safety profile of RPT193 from the Phase 1a study in healthy volunteers and from the Phase 1b study in patients with moderate-to-severe AD suggest RPT193 is a well-tolerated oral drug that would not require any laboratory safety monitoring.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Oncology Drug Candidate&#8212;FLX475 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead oncology drug candidate, FLX475, is designed to selectively inhibit the migration of immunosuppressive T<sub style="font-size:85%; vertical-align:bottom">reg</sub> into tumors, while sparing T<sub style="font-size:85%; vertical-align:bottom">reg</sub> in healthy tissues and without negatively impacting effector immune cells. T<sub style="font-size:85%; vertical-align:bottom">reg</sub> represent a dominant pathway for downregulating the immune response. We will initially develop FLX475 in charged tumors, in which we believe there remains significant unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We own an issued U.S. composition of matter patent directed to FLX475 that is scheduled to expire in 2037 (not including any applicable extensions, if approved). We have entered into a collaboration and license agreement with Hanmi, whereby we granted Hanmi the exclusive rights to develop, manufacture and commercialize FLX475 in the Hanmi Territory. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FLX475: Highly Selective Approach for Targeting Tumor T<sub style="font-size:85%; vertical-align:bottom">reg</sub></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000006.jpg" title="" alt="" style="width:375px;height:303px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CCR4 in Charged Tumors </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary drug discovery and development engine has identified certain tumors where we believe FLX475 has the greatest probability of demonstrating clinical benefit. We refer to these tumors as &#8220;charged&#8221; as defined by (i)&#160;their expression of high levels of CCR4 ligands, (ii)&#160;their enrichment for T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> and (iii)&#160;their enrichment for CD8 effector T cells. Tumors with high levels of these three parameters imply they have the necessary components to generate a potent immune response&#59; however, the presence of T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> dampens this response. Additionally, we have discovered that the presence of oncogenic viruses, such as Epstein Barr virus (EBV) and the human papilloma virus (HPV), is associated with tumors that are highly charged and can be prospectively selected. As shown in the diagram below, we have identified numerous tumors as being charged, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), gastric cancer, EBV<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup></span> Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) and cervical cancer. The data presented in the diagram below was derived from an in-house analysis of The Cancer Genome Atlas Database and additional published sources and confirmed by us through in situ hybridization of over 400 tumor microarray samples. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Identification and Characterization of Charged Tumors </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000007.jpg" title="" alt="" style="width:529px;height:417px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The graph above reflects a logarithmic scale on each axis. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Oncology Market Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant progress in cancer treatment has been made recently with the development of highly targeted and immuno-oncology-based therapies. Remarkable clinical response rates have been observed with targeted therapies in selective patient populations, while in a subset of a broad range of tumors, immuno-oncology products have demonstrated durable responses and possible cures. Although true breakthroughs have been achieved, often only a very narrow segment of the patient population can be treated or are responsive to these novel therapies. Hence, there remains a significant unmet medical need for a majority of tumor types including charged tumors in which we intend to develop FLX475 either as single agent or in combination with immune checkpoint inhibitors such as pembrolizumab or other agents. </p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Head and Neck Squamous Cell Carcinoma </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HNSCC represent a broad category of cancers that arise from different tissues that have been grouped anatomically in the head and neck region. HNSCC accounts for about 4% of all cancers in the United States with an estimated 53,000 new cases and 10,860 deaths in 2019. The five-year survival rate for people with head and neck cancer varies and depends on several factors making an overall five-year survival rate difficult to track accurately. Most cases of HNSCC are considered to be related to use of tobacco or alcohol or to exposure to HPV. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment for HNSCC can include surgery, radiation therapy, chemotherapy, targeted therapy or a combination of treatments. These tumors are believed to express a fair number of tumor-specific antigens, making them attractive targets for immunotherapies. Nivolumab and pembrolizumab have been approved for recurrent and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">metastatic HNSCC based on their ability to shrink tumors and increase median survival. However, treatment with either agent led to partial or complete tumor shrinkage in approximately 15% of treated HNSCC patients, indicating that over 80% of patients do not respond to therapy and that a significant unmet clinical need remains. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nasopharyngeal Cancer </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NPC is a cancer that forms in the tissues of the nasopharynx which is the upper part of the throat behind the nose. It is estimated that approximately 129,000 NPC patients worldwide were diagnosed and 72,900 NPC patients died in 2018. Approximately 39% of patients are diagnosed with late-stage NPC, in which the five-year survival rate is 38%. While there is no known cause of NPC, EBV is associated with a vast majority of cases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Standard treatment for NPC involves radiation therapy, chemotherapy and surgery. There is some evidence that NPC can be treated with immuno-oncology agents. A Phase 1b trial in patients with recurrent or metastatic NPC found an objective response rate of 26% with the PD-1 inhibitor pembrolizumab. While promising, novel therapies for NPC are still needed to improve overall responses and prolong survival. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hodgkin Lymphoma </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hodgkin lymphoma, formerly called Hodgkin&#8217;s disease, is a cancer of the lymphatic system that arises in immune cells called B cells. HL accounts for approximately 10% of all lymphomas and approximately 0.6% of all cancers diagnosed in the developed world annually. Approximately 8,100 people in the United States are estimated to be diagnosed with HL in 2019, with an estimated 1,000 deaths. EBV has been associated with approximately 30- 50% of HL. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While approximately 75% of patients can be cured with standard therapies including combination chemotherapy, radiation therapy, high-dose chemotherapy and stem cell transplantation, novel therapies are being developed to further improve clinical outcomes. The CD30-directed antibody-drug conjugate brentuximab vedotin (marketed as Adcetris) has been approved for certain adult patients with classical HL (&#8220;cHL&#8221;). Nivolumab and pembrolizumab are immunotherapies that have been granted accelerated approval for the treatment of patients with cHL that has recurred or progressed after multiple previous treatments, including autologous transplantation and post-transplant treatment with brentuximab vedotin. For both pembrolizumab and nivolumab, the overall response rate in these relapsed and refractory cHL was approximately 69%. However, the average duration of response to these anti-PD-1 therapies is less than a year, signifying the need for continued advances. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Non-Hodgkin Lymphoma </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NHL, another cancer of the lymphatic system, is not a single disease but rather a group of cancers affecting cells of the immune system. Although the various types of NHL have common elements, they differ in other areas, including their appearance under the microscope, their molecular features, their growth patterns, their impact on the body and treatment. According to the National Cancer Institute, in the United States approximately 74,200 patients were diagnosed with NHL in 2018 and 19,910 patients died as a result of NHL in 2018. The five-year survival rate is 71.4%. While there is no direct cause of NHL, it is generally linked to a weakened immune system and begins when the body produces too many abnormal lymphocytes. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a wide range of therapies available for the treatment of NHL depending on the subtype of the disease, its aggressiveness and the patient&#8217;s overall health. These include chemotherapy, radiation therapy, immunotherapy such as monoclonal antibodies, checkpoint inhibitors and chimeric antigen receptor T cells (&#8220;CAR-T cells&#8221;), targeted therapies and stem cell transplantation. Depending upon the analysis and subtype, EBV has been associated anywhere from less than 10% to greater than 90%, or approximately 12% of NHL, on average. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cervical Cancer </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cervical cancer begins with abnormal changes in the cervical tissue. In the United States, 13,170 patients are estimated to be diagnosed with cervical cancer in 2019 with cervical cancer leading to 4,250 deaths. The five-year survival rate is 65.8%. Cervical cancer is almost always associated with the presence of HPV. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advanced cervical cancer is treated by chemotherapy or radiation therapy. Pembrolizumab has been approved in those patients that express PD-L1 based on a Phase 2 trial in which the response rate was 14.3%. While the approval of pembrolizumab has been an advance in the treatment of cervical cancer, over 80% of patients do not respond to this therapy, indicating significant room for improvement. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our Oncology Solution: FLX475 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLX475 is an oral small molecule that is designed to selectively inhibit the migration of immunosuppressive T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> into tumors while sparing T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> in healthy tissues and without negatively impacting effector immune cells. T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> represent a dominant pathway for downregulating the immune response. Many current approaches to deplete T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> in the tumor have resulted in systemic T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> depletion, and such approaches been associated with serious safety issues (such as autoimmunity). In addition, these approaches have been associated with the depletion of effector immune cells, which has the potential to limit their efficacy. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will initially develop FLX475 in charged tumors, in which we believe there remains significant unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FLX475 Preclinical Data</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In preclinical studies, our drug candidate appears to selectively restore the immune response within the tumor microenvironment (&#8220;TME&#8221;) without systemically depleting T cells. We believe FLX475 has attractive characteristics for use as a single agent and in combination regimens with a variety of both conventional and immune-based therapies given its favorable safety profile observed in preclinical studies and early-stage clinical studies, as well as the synergistic nature of its mechanism of action as demonstrated in preclinical mouse models. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We evaluated the mechanism of action as well as the antitumor activity of FLX475 (or a preclinical tool CCR4 antagonist) in two kinds of preclinical mouse tumor models representing the human equivalent of (i)&#160;a &#8220;charged&#8221; tumor and (ii)&#160;tumors that accumulated T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> in the TME following checkpoint inhibitor treatment. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CCR4 Antagonist Single Agent Antitumor Activity in a Mouse Model of a Charged Tumor </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The antitumor activity of a CCR4 antagonist closely related to FLX475 was assessed in the Pan02 mouse tumor model. Oral administration of the CCR4 antagonist demonstrated single agent reduction in tumor growth, which was statistically significantly different from mice who received vehicle control (p &#60; 0.05) and observed antitumor activity was similar to an immune checkpoint inhibitor. Importantly, the combination of our CCR4 antagonist with the checkpoint inhibitor resulted in enhanced antitumor activity. Analysis of the TME in mice treated with our CCR4 antagonist showed a statistically significant increase in the CD8 : T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> ratio compared to vehicle control and similar activity compared to the checkpoint inhibitor. As with the antitumor activity, the combination of our CCR4 antagonist with the immune checkpoint inhibitor further increased the CD8 : T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> ratio. The increase of the CD8 : T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> ratio demonstrates a shift from an immune-suppressive to an immune-stimulatory environment. This ratio is a well-established biomarker in human clinical trials and has been demonstrated to correlate with clinical outcome. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CCR4 Antagonist: Single Agent Activity in a Mouse Model of a Charged Tumor </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000008.jpg" title="" alt="" style="width:613px;height:240px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Antitumor Activity of the Combination of a CCR4 Antagonist and Checkpoint Inhibitor in a Mouse Tumor Model </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The antitumor activity of a CCR4 antagonist closely related to FLX475 in combination with a checkpoint inhibitor was evaluated in the CT26 mouse tumor model. Single-agent activity of a checkpoint inhibitor resulted in modest antitumor activity and almost no cures. However, the combination of a CCR4 antagonist and a checkpoint inhibitor resulted in statistically significant (p &#60; 0.05) synergistic antitumor activity with 50% of all mice showing complete tumor regression in the experiment shown. In multiple experiments, an average of 39% experienced tumor regression. Mice treated with the combination approach were completely resistant to rechallenge with the same tumor, confirming that the antitumor effect observed during the treatment phase was immune-mediated and associated with long-term immune memory. In our mouse studies, the combination of a CCR4 antagonist with a checkpoint inhibitor demonstrated an increase in the ratio of effector T cells to T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span>. Previous studies have shown that this ratio is an indicator of prognosis in many cancers, including ovarian cancer, pancreatic cancer, lung cancer, glioblastoma, NHL and melanoma. We believe that the ability of a CCR4 antagonist to increase this ratio and provide therapeutic benefit will not be limited to a few select cancers, but may have broad implications across many tumor types. The ability of a CCR4 antagonist to prevent T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> migration suggests that combining FLX475 with a checkpoint inhibitor may provide highly effective antitumor activity by potentially deepening or broadening responses compared to checkpoint inhibitor alone. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Antitumor Activity of Our CCR4 Antagonist and Checkpoint Inhibitor </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">in Combination in a Mouse Tumor Model </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000009.jpg" title="" alt="" style="width:613px;height:229px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FLX475: Clinical Trials </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FLX475-01: A Phase 1 Clinical Trial of FLX475 in Healthy Volunteers </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We completed a placebo-controlled, double-blind dose-escalation Phase 1 clinical trial of FLX475 in 104 healthy volunteers. We designed and conducted the healthy volunteer study in order to (i)&#160;rapidly generate PK and receptor occupancy data that allow us to identify a therapeutic dose, (ii)&#160;corroborate in humans our observed favorable preclinical safety profile and (iii)&#160;allow us to accelerate the dose-escalation portion of our Phase 1/2 study and drive efficiencies in our clinical development going forward. In this Phase 1 study, FLX475 was well tolerated and demonstrated dose-dependent inhibition of CCR4 with no observed immune-related adverse events or significant clinical adverse events. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oral dosing of FLX475 led to linear PK and a clear dose-related inhibition of CCR4 with low subject-to-subject variability. Based on analysis of the multiple dose data, at the 75 mg once-daily dose, 75% receptor occupancy was achieved in six out of six healthy volunteers, which, in our preclinical studies, corresponded with 90% inhibition of in vitro T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> migration and the highest level of inhibition of in vivo T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> migration and antitumor activity. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475: Favorable Exposure in Healthy Volunteer Study </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000010.jpg" title="" alt="" style="width:413px;height:221px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">CCR4 Target Coverage Exceeded at 75 mg Once Daily Dosing with FLX475 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000011.jpg" title="" alt="" style="width:413px;height:229px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLX475 was well tolerated, with no significant lab abnormalities, serious adverse events or dose-limiting clinical adverse events. There was no evidence of autoimmunity or changes in peripheral blood immune cell populations. Sporadic Grade 1 corrected Q-T interval (&#8220;QTc&#8221;) prolongation was observed in nearly every cohort (including placebo). No QTc prolongation greater than Grade 1 was observed in 14-day multiple ascending dose cohort doses through 300/100 mg (300 mg Day 1 loading dose followed by 100 mg once daily), including the projected efficacious dose of 75 mg once daily. At the highest dose (300/150 mg) correlating with exposures three to five times that needed to achieve efficacious exposure, two subjects (out of six dosed with FLX475) met QTc stopping criteria (greater than 60 msec prolongation from baseline, one of whom also exhibited a transient Grade 2 QTc prolongation), which were asymptomatic and not associated with arrhythmia or any other adverse event. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">FLX475-02: A Phase 1/2 Dose Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting a Phase&#160;1/2 trial of FLX475 as a monotherapy and in combination with pembrolizumab. The Phase&#160;1 portion of the study is a standard dose escalation study intended primarily to evaluate safety, pharmacokinetics and pharmacodynamics in patients with multiple tumor types including some that may be charged. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We reported results from the Phase 1 portion of the trial in November 2020. A total of 37 patients with cancers of different types were enrolled. Nineteen patients were treated with one of four doses (25 mg, 50 mg, 75 mg or 100 mg once daily) of FLX475 monotherapy and 18 were treated with one of three doses (50 mg, 75 mg or 100 mg once daily) of FLX475 in combination with the standard dose of pembrolizumab. The Phase 1 results showed FLX475 had a favorable safety profile, with no maximum tolerated dose reached. Two dose-limiting toxicities (&#8220;DLTs&#8221;) of asymptomatic QTc prolongation were observed in the monotherapy cohorts, one in the 75 mg cohort and one in the 100 mg cohort. No DLTs were observed in the Phase 1 combination cohorts. Based on the Phase 1 data, 100 mg was selected as the recommended Phase 2 dose for both the monotherapy and combination therapy cohorts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug exposures were roughly dose-proportional and consistent with the previous Phase 1 study in healthy volunteers. The majority of patients on the 75 mg daily dose reached the targeted exposure level. Receptor occupancy of CCR4 on T<sub style="font-size:85%; vertical-align:bottom">reg</sub> was also proportional to FLX475 exposure levels and consistent with that previously observed in healthy volunteers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475 Phase 1 Pharmacokinetic Data</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000012.jpg" title="" alt="" style="width:374px;height:222px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475 Phase 1 Receptor Occupancy Data</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000013.jpg" title="" alt="" style="width:374px;height:250px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Phase 1 portion of the trial, of 17 evaluable monotherapy patients, there was one unconfirmed partial response in a patient with relapsed metastatic cervical cancer. Of 14 evaluable patients in the combination cohorts, there were two confirmed partial responses: a patient with NSCLC who had progressed on prior checkpoint treatment (atezolizumab) and who at the time was on study for 18 months of treatment, and a patient with checkpoint inhibitor-na&#239;ve urothelial cancer who at the time was on study for over nine months of treatment. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Phase&#160;2 portion of the Phase 1/2 trial is designed to evaluate FLX475 as a monotherapy and in combination with pembrolizumab specifically in patients with several types of charged tumors, which represent cancer types we believe are most likely to respond to FLX475. The Phase 2 portion of the trial is a gated two-stage design. In the first stage of Phase 2, eight cohorts of at least ten patients each will be dosed with FLX475 as monotherapy or in combination with pembrolizumab. In the four Phase 2 monotherapy cohorts patients will either have NPC or lymphoma confirmed to be EBV<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup></span>, cervical cancer that is HPV<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">+</sup></span> or HNSCC that is na&#239;ve to checkpoint therapy. In the four Phase 2 combination cohorts, patients will be NSCLC or HNSCC patients who have been previously treated with checkpoint inhibitors or TNBC or HNSCC patients na&#239;ve to checkpoint inhibitors. Cohorts in which promising activity is observed will then proceed to Stage 2 to enroll an additional 19 patients. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475 Phase 2 Trial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000014.jpg" title="" alt="" style="width:624px;height:243px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we reported initial observations from four of the eight cohorts in the Phase 2 portion of the trial: EBV+ lymphoma (monotherapy), NPC (monotherapy) and CPI-na&#239;ve HNSCC (monotherapy and combination). Based on the promising early results from these four cohorts, which we believe provide initial clinical PoC, we selected three indications to expand to Stage 2 EBV+ lymphoma (monotherapy, combination to follow), NPC (combination) and CPI-na&#239;ve HNSCC (combination).</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2021, we announced that we were expanding the CPI-experienced HNSSC cohort to Stage 2 and that we were not expanding the TNBC and CPI-experienced NSCLC cohorts to Stage 2. As of February 2022, we have expanded four indications to Stage 2: EBV+ lymphoma (monotherapy), NPC (combination), CPI-na&#239;ve HNSCC (combination) and CPI-experienced HNSCC (combination). One indication, cervical cancer (monotherapy), is still enrolling Stage 1.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000015.jpg" title="" alt="" style="width:546px;height:217px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">EBV+ Lymphoma</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we reported that early data from the first two patients with EBV+ lymphoma treated with FLX475 monotherapy show significant target tumor reduction, including one patient who achieved a durable complete metabolic response and was on study for more than nine months as of November 2020. We decided to expand the EBV+ lymphoma monotherapy cohort to Stage 2 and to initiate a separate expansion cohort in EBV+ lymphoma in combination with pembrolizumab. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are images of the screening and on-study positron emission tomography (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PET</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) scans from </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the patient who achieved a complete metabolic response. The patient is </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a 53-year-old with EBV+ NK/T cell lymphoma, previously treated with chemotherapy followed by progression of disease. Primary lesions noted behind the left ear and in the right thigh (bright signals in brain, kidneys and bladder are normal background) showed significant decrease in signal by 8 weeks of treatment with FLX475, consistent with complete metabolic response, which continued to improve by scan shown at 33 weeks on study.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Photographs of the subcutaneous lesion behind the left ear also show significant clinical improvement and visible resolution over the course of treatment.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475 Phase 2 EBV+ Lymphoma Patient PET Scans</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000016.jpg" title="" alt="" style="width:363px;height:347px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">FLX475 Phase 2 EBV+ Lymphoma Patient: Change in Subcutaneous Lesion</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000017.jpg" title="" alt="" style="width:437px;height:166px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Checkpoint Inhibitor-Na&#239;ve Nasopharyngeal Cancer</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 2020, 10 patients with NPC treated with FLX475 monotherapy were evaluable, of which seven exhibited stable disease as best response. Seven of the 10 crossed over to combination therapy where significant clinical activity has been observed. Of the seven patients who crossed over, six were evaluable at the time of the November 2020 disclosure and five of the six were checkpoint inhibitor na&#239;ve. All five of the checkpoint inhibitor-na&#239;ve patients demonstrated significant tumor shrinkage, with three of these patients showing a partial response (two confirmed and one unconfirmed). Given that the published overall response rate (&#8220;ORR&#8221;) of pembrolizumab alone in checkpoint-na&#239;ve NPC is 26%, the level of activity of combination therapy with FLX475 observed in this limited number of patients is promising. Based on these results, we decided to open a combination cohort in checkpoint inhibitor-na&#239;ve NPC to better evaluate the ORR of combination therapy. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Change in Target Lesion Measurements in Nasopharyngeal Cancer Patients after Crossover to FLX475/Pembrolizumab Combination Therapy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000018.jpg" title="" alt="" style="width:439px;height:263px;" /></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Checkpoint Inhibitor-Na&#239;ve Head and Neck Cancer</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, we disclosed initial observations on two cohorts in the Phase 2 trial with checkpoint inhibitor-na&#239;ve HNSCC patients, one treated with FLX475 monotherapy and one treated with FLX475 combined with pembrolizumab. Of the 10 evaluable patients with head and neck cancers treated with FLX475 monotherapy, five of 10 patients exhibited stable disease as best response. Six of the evaluable patients initially treated with monotherapy crossed over to combination therapy, with one achieving a partial response and a second patient with an unconfirmed partial response. Seventeen patients are enrolled in the separate combination treatment cohort, of which 10 were evaluable as of the November 2020 disclosure. Substantial tumor reduction has been observed in four of the 10, including one confirmed complete response and three patients with greater than 20 % tumor reduction. Based on these early results, we have expanded the combination cohort in checkpoint inhibitor-na&#239;ve head and neck cancers to Stage 2 to better evaluate the activity of combination therapy.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Best Overall Response in Checkpoint Inhibitor-Na&#239;ve HNSCC Patients</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000019.jpg" title="" alt="" style="width:460px;height:288px;" /></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The four Phase 2 cohorts reported in November 2020 included a total of 44 patients and FLX475 demonstrated a favorable safety profile with once-daily oral dosing both as monotherapy and in combination with pembrolizumab, with no new significant safety findings compared to the Phase 1 portion of the trial. For more information regarding the risks associated with our Phase&#160;1/2 clinical trial for FLX475, please see &#8220;Risk Factors&#8212;Risks Related to Our Business&#8212;RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, biomarker data obtained from the patients in the ongoing Phase 1/2 trial may inform the generation of a companion diagnostic that could potentially be used to prospectively select for patients who may be more likely to respond to FLX475 therapy in a future study, thus increasing the chances of a positive trial result and regulatory approval. Our comprehensive biomarker plan includes analysis of the TME in paired biopsies collected before and on treatment. Key biomarkers include (i)&#160;CD8 : T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span> ratio as detected by immunohistochemistry, (ii)&#160;peripheral blood analysis for CCL17 and CCL22 and (iii)&#160;exploratory analysis, including immune phenotyping, transcriptomics and T cell clonality. Preliminary data from our measure of CD8 and T<sub style="font-size:85%; vertical-align:bottom">reg</sub> by IHC indicate an increase in the CD8:T<sub style="font-size:85%; vertical-align:bottom">reg</sub> ratio in 9 of the 11 patients with paired tumor biopsies from both the Phase 1 and Phase 2 portions of the ongoing Phase 1/2 trial. This suggests activity consistent with our intended mechanism of action and potentially beneficial changes in the TME. For more information regarding the risks associated with our Phase 1/2 clinical trial for FLX475, please see &#8220;Risk Factors&#8212;Risks Related to Our Business.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Increases in the CD8:T</span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span><span style="font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"> Ratio Observed in Paired Tumor Biopsies from 9 of 11 Patients Treated with FLX475</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000020.jpg" title="" alt="" style="width:449px;height:273px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.77%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">FLX475-03: A Phase 2 Study of FLX475 in Combination with Ipilimumab in Melanoma </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently enrolling a Phase 2 clinical trial of FLX475 in combination with ipilimumab (YERVOY) in patients with advanced melanoma previously treated with an anti-PD-1 or anti-PD-L1 agent. Ipilimumab is an approved treatment for advanced melanoma, with reported response rates of up to 20% in patients who have not been previously treated with immunotherapies such as checkpoint inhibitors. Anti-PD-1 therapies such as pembrolizumab and nivolumab have become the most commonly used checkpoint inhibitors in patients with advanced melanoma. In such patients whose disease has recurred after such therapies, an overall response rate to ipilimumab alone has been reported at approximately 14%. Therefore, the goal of this Phase 2 trial is to provide preliminary clinical evidence in support of the clinical hypothesis that CCR4 blockade by FLX475 can significantly enhance the antitumor activity of an anti-CTLA-4 checkpoint inhibitor.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our HPK1 Program </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hematopoietic progenitor kinase 1 (&#8220;HPK1&#8221;) is a negative regulator of T cell activation, and the inhibition of HPK1 has the potential to enhance T cell function and the endogenous antitumor response alone or in combination with other immuno-oncology (&#8220;IO&#8221;) therapies. We identified HPK1 as a potential target in a computational screen that identified a number of targets, including PD-1 and CCR4. We have demonstrated that inhibition of HPK1 enhanced activation of primary mouse and human T cells in vitro, as well as antigen-specific CD8 T cell effector function in vivo. Oral administration of an HPK1 inhibitor resulted in single agent antitumor activity and complete tumor regression in multiple mice when dosed in combination with a checkpoint inhibitor. We are refining the chemical structure of our lead HPK1 compounds utilizing high resolution crystal structures with the goal of selecting a preclinical development candidate.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">HPK1 Inhibition has the Potential to Enhance Various IO Therapies</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000021.jpg" title="" alt="" style="width:206px;height:188px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical Data</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Inhibiting HPK1 In Vitro Enhances Antigen-Specific Stimulation of Mouse CD8 T cells</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stimulation of antigen-specific T cells depends on the strength of the interaction of the T cell receptor with its cognate peptide:MHC complex, costimulatory signals as well as other factors. It has been shown that HPK1 is a negative regulator of T cell stimulation and that activation of HPK1 following T cell receptor (&#8220;TCR&#8221;) signaling limits the extent of T cell activation, cytokine secretion and proliferation. In our in vitro studies of antigen-stimulated mouse T cells, pharmacologic inhibition of HPK1 resulted in a dose-dependent increase in cytokine-secreting CD8 T cells.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">HPK1 Inhibition Enhances Mouse CD8+ T Cell Activation In Vitro</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000022.jpg" title="" alt="" style="width:475px;height:215px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pharmacologic Inhibition HPK1 Enhances the Induction of Antigen-Specific CD4 and CD8 T Cells In Vivo</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our in vivo studies, pharmacologic inhibition of HPK1 resulted in the enhanced induction of antigen-specific CD4 and CD8 T cells. Mice were vaccinated either in the presence or absence of pharmacologic inhibition of HPK1 and antigen-specific CD4 and CD8 T cell immunity was determined 7 days later. HPK1 inhibition resulted in a two to three-fold increase in antigen specific T cell immunity.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Pharmacologic Inhibition of HPK1 Enhances the Induction of Antigen-Specific CD4+ and CD8+ T Cells In Vivo</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000023.jpg" title="" alt="" style="width:471px;height:174px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pharmacologic Inhibition HPK1 Enhances Anti-CTLA Antitumor Activity</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In a mouse model for colorectal cancer (&#8220;CT26&#8221;) pharmacologic inhibition of HPK1 alone resulted in modest tumor growth delay and enhanced survival. In combination with an immune checkpoint inhibitor, HPK1 inhibition resulted in complete tumor regression in a subset of mice and significant prolonged survival. Our work confirms the importance of HPK1 for T cell function and supports HPK1 as a promising immuno-oncology target.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Combination of HPK1 Inhibition and Checkpoint Blockade Enhances Antitumor Activity in the CT26 Mouse Tumor Model</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbkyd1brmfwp000024.jpg" title="" alt="" style="width:572px;height:200px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect the proprietary technology, inventions and improvements that are commercially important to our business, including obtaining, maintaining, enforcing and defending our intellectual property rights, including patent rights, whether developed internally or licensed from third parties. We rely, in part, on trade secrets and know-how relating to our proprietary technology and drug candidates and continuing innovation to develop, strengthen and maintain our proprietary position. We also plan to rely, in part, on data exclusivity, market exclusivity and patent term extensions if and when available. Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection for our technology, inventions and improvements&#59; to preserve the confidentiality of our trade secrets&#59; to defend and enforce our proprietary rights, including any patents that we own or may obtain in the future&#59; and to operate without infringing, misappropriating or otherwise violating the valid and enforceable patents and other intellectual property rights of third parties. Intellectual property rights may not address all potential threats to our competitive advantage. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">C-C Chemokine Receptor 4 (CCR4) Antagonist Franchise </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2021, our patent portfolio includes seven patent families directed to CCR4 inhibiting compounds and their therapeutic uses, four of which are directed to FLX475 and two of which are directed to RPT193, as discussed in more depth below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FLX475 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#8239;31, 2021, with respect to FLX475, we own two issued U.S. patents directed to FLX475 and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the same for the treatment of diseases including cancers, one corresponding pending patent application in the U.S. and 16 corresponding pending patent applications in Australia, Brazil, Canada, China, Hong Kong, the European Patent Convention, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa and Taiwan. Our issued U.S. patents, and any patents that may issue from our pending applications worldwide, are scheduled to expire in 2037, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance or annuity fees. We also own one pending U.S. patent application, one pending Patent Cooperation Treaty (&#8220;PCT&#8221;) patent application and one pending Taiwan patent application directed to polymorphic forms of FLX475 and formulations thereof. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2040, excluding any additional term for patent term adjustment(s) or extension(s). In addition to the composition of matter patent and patent applications described above, as of December&#8239;31, 2021, we own one pending U.S. patent application and 16 corresponding pending patent applications in Australia, Brazil, Canada, China, Hong Kong, the European Patent Convention, India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa and Taiwan, all directed to the use of CCR4 antagonists generally, including FLX475 specifically, in therapeutic methods of treating EBV positive cancers. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2038, excluding any additional term for patent term adjustment(s) or extension(s.) In addition to the composition of matter patent and patent applications described above, as of December&#8239;31, 2021, we own one pending U.S. provisional patent application directed to a combination treatment involving FLX475. Any patents that may issue claiming priority from this pending application, in the United States and worldwide, would be scheduled to expire in 2042, excluding any additional term for patent term adjustment(s) or extension(s). All of the above-mentioned patents and applications remain in force subject to us making timely payment of all applicable maintenance and annuity fees. Our pending PCT patent application is not eligible to become an issued patent until, among other things, we file a national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent application and any patent protection on the inventions disclosed in such PCT patent application.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RPT193 </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#8239;31, 2021, with respect to RPT193, we own two granted U.S. patents directed to RPT193 and other related compounds, pharmaceutical compositions comprising the same and therapeutic methods of using the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same for the treatment of diseases such as immune, inflammatory, metabolic diseases or cancers, two corresponding pending patent applications in the U.S. and 1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> corresponding pending patent applications in Australia, Brazil, Canada, China, the European Patent Convention, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hong Kong, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">India, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore, South Africa and Taiwan. Any patents that may issue from these pending applications, in the United States and worldwide, are scheduled to expire in 2039, excluding any additional term for patent term adjustment(s) or extension(s), and assuming payment of all applicable maintenance and annuity fees.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of our provisional patent applications are not eligible to become issued patents until, among other things, we file a non-provisional patent application within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent application, we may lose our priority date with respect to any such provisional patent application and any patent protection on the inventions disclosed in any such provisional patent application. With respect to our drug candidates, we intend to develop and commercialize in the normal course of business, we intend to pursue patent protection covering, when possible, compositions, methods of use, dosing and formulations. We may also pursue patent protection with respect to manufacturing and drug development processes and technologies. We do not currently own any patents or patent applications relating to our proprietary discovery and development engine. Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. We may not be able to obtain patent protections for our compositions, methods of use, dosing and formulations, manufacturing and drug development processes and technologies throughout the world. Issued patents can provide protection for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance and the legal term of patents in the countries in which they are obtained. In general, patents issued for applications filed in the United States expire 20 years after the earliest effective filing date. In addition, in certain instances, the term of an issued U.S. patent that covers or claims an FDA approved product can be extended to recapture a portion of the term effectively lost as a result of the FDA regulatory review period, which is called patent term extension. The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval. For more information regarding patent term extensions, please see &#8220;Business&#8212;U.S. Patent Term Restoration and Marketing Exclusivity&#8221; below. The term of patents outside of the United States varies in accordance with the laws of the foreign jurisdiction, but typically is also 20 years from the earliest effective filing date. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. The patent term may be inadequate to protect our competitive position on our products for an adequate amount of time. For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the field of biopharmaceuticals has emerged in the United States. The relevant patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our ability to protect our technology or drug candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining, maintaining, enforcing and defending patent claims that cover our technology, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications we may file in the future, nor can we ensure that any patents that may be granted to us in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, any issued patents we obtain do not guarantee us the right to practice our technology in relation to the commercialization of our products. Patent and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our drug candidates and practicing our proprietary technology, and our patent rights may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our drug candidates. In addition, the scope of the rights granted under any issued patent that we own or license, now or in the future, may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies that are outside the scope of the rights granted under any issued patents we obtain. For these reasons, we may face competition with respect to our drug candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular drug candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential information are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any future collaborators, scientific advisors, employees and consultants, and invention assignment agreement with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or drug candidates or obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. For more information regarding the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we entered into a Collaboration and License Agreement with Hanmi, a corporation organized under the laws of the Republic of Korea, pursuant to which we granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#8217;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#8220;Hanmi Territory&#8221;), and certain sublicense rights. In consideration of such rights, under the agreement we received $10.0&#160;million in an upfront payment and milestone payment, and will be eligible to receive (i)&#160;additional contingent payments of up to $108.0&#160;million upon the achievement of specified milestones, consisting of up to $48.0&#160;million based on the dosing of the first patient in a Phase 3 clinical trial in the Hanmi Territory and the filing and approval of a new drug application in the Hanmi Territory and up to $60.0&#160;million based on annual net sales, and (ii)&#160;low double-digit royalties on future net sales of FLX475 in the Hanmi Territory. Royalties will be payable on a product-by-product and country-by-country basis for a period commencing with the first commercial sale until the latest of (a)&#160;the expiration of the relevant patent right, (b)&#160;the expiration of regulatory or data exclusivity granted by the applicable governmental authority, and (c)&#160;five years from such first commercial sale (such period being the &#8220;Royalty Term&#8221; for such product and country)&#59; provided that the royalties will be reduced (x)&#160;by 50% if the product in question is not covered by a valid claim during the Royalty Term in the applicable country, (y)&#160;in connection with a license obtained from such third party in order to develop, manufacture or commercialize FLX475 in the Hanmi Territory and (z)&#160;by a percentage dependent on any generic products&#8217; market share in the Hanmi Territory. If we sponsor Phase&#160;3 clinical trials for FLX475 for human cancers, Hanmi will have the right to participate in such trials in the Hanmi Territory. We will supply FLX475 for use in Hanmi&#8217;s Phase 2 clinical trials and Hanmi will reimburse us for our manufacturing costs. If requested, we will facilitate technology transfer to Hanmi for their manufacture of FLX475 product for Phase 3 trials and commercialization. The term of the agreement will continue until Hanmi&#8217;s royalty payment obligations have expired, unless sooner terminated by Hanmi for convenience, safety reasons, if we abandon our development of FLX475 and related products, if we do not consent to Hanmi&#8217;s use of FLX475 in any study required by applicable governmental authorities, or breach by us of our representations and warranties under the agreement. The agreement may also be terminated by either party in connection with a material breach by, or insolvency of, the other party. If Hanmi terminates the agreement with cause or for our abandonment of development of FLX475 and related products, material breach or insolvency, Hanmi will retain a perpetual license to certain our intellectual property related to FLX475. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Collaboration and Supply Agreement </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, we entered into a clinical trial collaboration and supply agreement with MSD International GmbH, an affiliate of Merck (known as MSD outside the United States and Canada), under which we will conduct a clinical trial evaluating FLX475 as a monotherapy and in combination with pembrolizumab (KEYTRUDA<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span>), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. We are the sponsor of the clinical trial and are responsible for the costs of conducting it, and Merck will supply pembrolizumab for use in the clinical trial at no charge to us except that we may be required to reimburse Merck&#8217;s manufacturing costs upon certain early termination events. Neither party will have any other obligations to reimburse any costs or expenses incurred by the other party. We retain ownership of the quantities of FLX475 used in the clinical trial and we will own the quantities of pembrolizumab supplied to us by Merck for use in the clinical trial. The agreement provides for joint ownership of any inventions, clinical data and results generated in the clinical trial that relate to the combined use of the two drugs. Merck will solely own any inventions generated in the clinical trial that relate solely to pembrolizumab and all data resulting from testing performed by or on behalf of Merck upon samples collected during the clinical trial. We will solely own any inventions generated in the clinical trial that relate solely to FLX475, clinical data resulting from the use of FLX475 as a monotherapy, and from all data resulting from testing performed by or on behalf of us upon samples collected during the clinical trial. The term of the agreement will continue until delivery of the final report for the clinical trial, provided that either party may terminate the agreement due to the other party&#8217;s uncured material breach, a violation of anti-corruption obligations, patient safety concerns, regulatory action that prevents supply of such party&#8217;s compound, or such party&#8217;s termination of its compound&#8217;s development or withdrawal of its compound&#8217;s regulatory approval. Merck may also terminate the agreement if we fail to make any changes to the clinical trial protocol regarding the use of pembrolizumab that are reasonably requested by Merck to address any concern raised by Merck that pembrolizumab is being used in the clinical trial in an unsafe manner. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries, including the oncology and inflammatory disease fields, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property protection. We face substantial competition from many different sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. We believe that the key competitive factors affecting the success of any of our drug candidates will include patient selection strategies, efficacy (single and combination strategies), safety profile, method of administration, cost, level of promotional activity and intellectual property protection. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193 is a CCR4 antagonist intended to treat inflammatory disease, including AD and other inflammatory diseases. If approved for AD, we will face branded competition from dupilumab (marketed by Regeneron and Sanofi as Dupixent), a biologic approved in 2017. In addition, there are several companies developing treatments that may be approved for AD, including large pharmaceutical and biotechnology companies such as Pfizer, Sanofi, Lilly, Incyte, AbbVie and LEO Pharma.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several large and specialty pharmaceutical companies, as well as biotechnology companies with marketed or late-stage assets targeting the Th2 pathway, which includes Amgen, AstraZeneca, Chiesi Farmaceutici, GSK, Novartis, Roche, Sanofi and Teva Pharmaceuticals.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If approved, FLX475 will compete with current therapies approved for the treatment of cancer, particularly immuno-oncology. Potential immuno-oncology therapeutics are being developed or marketed by many large and specialty pharmaceutical and biotechnology companies such as Merck, Bristol-Myers Squibb, Novartis, AstraZeneca, Pfizer and Roche/Genentech. Additionally, there is one approved CCR4-targeting T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span>-depleting antibody, mogamulizumab developed by Kyowa Hakko Kirin, as well as other T<span style="font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">reg</sub></span>-targeting agents currently in early development by companies such as ChemoCentryx, Tusk/Roche and Agenus/Gilead. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trials sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities are subject to various laws, rules and regulations of the United States as well as of foreign governments. Compliance with these laws, rules and regulations has not had a material effect upon our capital expenditures, results of operations or competitive position, and we do not currently anticipate material capital expenditures for environmental control facilities. Nevertheless, compliance with existing or future governmental regulations, including, but not limited to, those pertaining to product development and approval, business acquisitions, healthcare, consumer and data protection, employee health and safety and taxes, could have a material impact on our business in subsequent periods. Refer to the sections captioned &#8220;Risk Factors&#8221; under Part I, Item IA and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; under Part II, Item 7 for a discussion of these potential impacts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Food and Drug Administration (&#8220;FDA&#8221;) and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drug products such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our drug candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before drug candidates may be marketed in the United States generally involves the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;), regulation&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;), which must become effective before clinical trials may begin and must be updated annually or when significant changes are made&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">approval by an independent Institutional Review Board (&#8220;IRB&#8221;) or ethics committee at each clinical site before the trial is commenced&#59; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:10.47%;text-indent:-5.24%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug candidate for its intended purpose&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">preparation of and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;)  after completion of all pivotal clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA Advisory Committee review, if applicable&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP, and of selected clinical investigation sites to assess compliance with Good Clinical Practices (&#8220;GCP&#8221;)&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical and Clinical Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to beginning the first clinical trial with a drug candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product&#59; chemistry, manufacturing and controls information&#59; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;">Phase 1&#8212;</span>The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses and, if possible, to gain early evidence on effectiveness.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;">Phase 2&#8212;</span>The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. Some trials may combine aspects of Phase 1 and Phase 2 into a single clinical trial, which we refer to as a &#8220;seamless&#8221; study that can examine both safety in healthy volunteers and safety and preliminary efficacy in patients with a specific disease. </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-style:italic;">Phase 3&#8212;</span>The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A registrational trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#8217;s efficacy and safety such that it can be used to justify the approval of the drug. Generally, registrational trials are Phase 3 trials but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the NDA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the drug candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NDA Submission and Review </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The NDA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls, and proposed labeling, among other things. A determination by the FDA within 60 days of the receipt of an NDA to file the application for review for its completeness is initiated at the time of submission. If the FDA determines there is significance to the missing or incomplete information in the context of the proposed drug product, the proposed indication(s) and the amount of time needed to address any given deficiency, it can issue a refusal-to-file letter. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an NDA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities where the product will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the NDA. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the NDA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers several expedited development and review programs for qualifying drug candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires, as a condition for accelerated approval, pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess new safety risks&#59; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">fines, warning letters or holds on post-approval clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">product seizure or detention, or refusal of the FDA to permit the import or export of products&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics and drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">FDA Regulation of Companion Diagnostics </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A therapeutic product may rely upon an in vitro companion diagnostic for use in selecting the patients that will be more likely to respond to that therapy. If an in vitro diagnostic is essential to the safe and effective use of the therapeutic product, then the FDA generally will require approval or clearance of the diagnostic at the same time that the FDA approves the therapeutic product. According to FDA guidance, a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an investigational device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;), regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational trial if the trial meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the trial plan and subjects, a sponsor may seek to submit an IND alone or both an IND and an IDE. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuing FDA approval of an in vitro companion diagnostic would require either a pre-market notification, also called 510(k) clearance, or a pre-market approval (&#8220;PMA&#8221;) for that diagnostic. The review of companion diagnostics involves coordination of review with the FDA&#8217;s Center for Devices and Radiological Health. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years or longer. The applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, including information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. In addition, PMAs for devices must generally include the results from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results. As part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation (&#8220;QSR&#8221;), which imposes elaborate testing, control, documentation and other quality assurance requirements. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Patent Term Restoration and Marketing Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a non-provisional patent application. Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, one or more issued U.S. patents we obtain may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent, limited to the approved indication (or any additional indications approved during the period of extension), as compensation for patent term lost during the FDA regulatory review process. The patent term restoration period granted on a patent covering a product is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date of that application. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for extension and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restoration of patent term for an issued patent we own and, if eligible for such restoration, to add patent term beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing exclusivity provisions under the United States Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) can also delay the submission or the approval of certain marketing applications for competing products. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) applications for drugs containing the active agent for the original indication or condition of use. Five-year a three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described below, may offer a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Drug Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, our future drugs may also be subject to extensive regulatory requirements. As in the United States, medicinal products can only be marketed if a marketing authorization from the competent regulatory agencies has been obtained. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, the various phases of preclinical and clinical research in Europe are subject to significant regulatory controls. Clinical Trials Regulation 536/2014 seeks to simplify and streamline the approval of clinical trials in the European Union. For example, the sponsor shall submit a single application for approval of a clinical trial via the EU Portal. As part of the application process, the sponsor shall propose a reporting Member State who will coordinate the validation and evaluation of the application. The reporting Member State shall consult and coordinate with the other concerned Member States. If an application is rejected, it can be amended and resubmitted through the EU Portal. If an approval is issued, the sponsor can start the clinical trial in all concerned Member States. However, a concerned Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that Member State. The Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Drug Review and Approval </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of marketing authorizations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of drugs, such as biotechnology medicinal drugs, orphan medicinal drugs and medicinal drugs containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The Centralized Procedure is optional for drugs containing a new active substance not yet authorized in the EEA or </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for drugs that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for drugs not falling within the mandatory scope of the Centralized Procedure. Where a drug has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in other Member States through the Mutual Recognition Procedure. If the drug has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure, an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). The competent authority of the RMS prepares a draft assessment report, a draft summary of the drug characteristics (&#8220;SPC&#8221;), and a draft of the labeling and package leaflet, which are sent to the other Member States (&#8220;Member States Concerned&#8221;) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling, or packaging proposed by the RMS, the drug is subsequently granted a national MA in all the Member States (<span style="font-style:italic;">i.e</span>., in the RMS and the Member States Concerned). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the drug on the basis of scientific criteria concerning its quality, safety and efficacy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Chemical Entity Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In Europe, new chemical entities, sometimes referred to as new active substances, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic application for eight years, after which generic marketing authorization can be submitted, and the innovator&#8217;s data may be referenced but not approved for two years. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">European Union General Data Protection Regulation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;). The GDPR went into effect on May&#160;25, 2018. The GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new EU data protection rules. Further, the United Kingdom&#8217;s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear whether the United Kingdom will enact data protection legislation equivalent to the GDPR and how data transfers to and from the United Kingdom will be regulated. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Rest of the World Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country. In all cases the clinical trials must be conducted in accordance with </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our drugs will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical drugs and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property protection, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower-cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but also have their own methods and approval process apart from Medicare determinations. Even if favorable coverage and reimbursement status is attained for our drug candidates, once approved, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to develop, either by ourselves or with collaborators, in vitro companion diagnostic tests for our drug candidates for certain indications. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal drugs for which their national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. A member state may approve a specific price for the medicinal drug or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal drug on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical drugs will allow favorable reimbursement and pricing arrangements for any of our drugs. Historically, drugs launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare Reform </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The biopharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (&#8220;ACA&#8221;) was enacted, which was intended to broaden access to health insurance, reduce or constrain the growth of healthcare </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacts the U.S. pharmaceutical industry. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial and Congressional efforts to modify, repeal or otherwise invalidate all, or certain provisions of, the ACA. For example, the Trump administration issued several executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. While Congress has not passed comprehensive repeal legislation, Congress enacted the Tax Cuts and Jobs Act of 2017, or the Tax Act, which, among other things, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which payment is commonly referred to as the &#8220;individual mandate&#8221;. Further, the 2020 federal spending package eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. The Budget Control Act of 2011 among other things, created measures for spending reductions by Congress, including aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and will remain in effect through 2031 unless additional Congressional action is taken. These reductions have been temporarily suspended from May 1, 2020 through March 31, 2022 by COVID-19 relief legislation. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Moreover, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently there has been heightened governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. However, certain recent initiatives have stalled. For example, the implementation of a new regulation removing safe harbor protection for certain price reductions from pharmaceutical manufacturers to plan sponsors under Part D has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. Other regulations, such as the new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers have been delayed until January 1, 2023. On November 20, 2020, Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;), issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HHS</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Further, it is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Healthcare Laws </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our drug candidates, if approved. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or paying remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The federal Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the federal Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. The majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalties law, prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the United States, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) also created additional federal civil and criminal penalties for, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has also been a recent trend of increased federal and state regulation of payments and other transfers of value made to physicians and other healthcare providers. The ACA, through the Physician Payments Sunshine Act, imposed new reporting requirements on drug manufacturers for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment interests held by physicians and their immediate family members. Drug manufacturers are required to submit annual reports to the government and these reports are posted on a website maintained by CMS.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to data privacy and security requirements that may impact the way in which we conduct research and operate our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their respective implementing regulations, including the final omnibus rule published on January 25, 2013, impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, as well as individuals and entities that provide services on behalf of a covered entity that involve individually identifiable health information, known as business associates, as well as their covered subcontractors. In addition, we may be directly subject to certain state laws concerning data privacy and security. For example, California recently enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA took effect on January 1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July 1, 2020. The CCPA was amended in September 2018 and November 2019, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Existing state laws governing the privacy and security of personally identifiable information, and, in some states, health information, impose differing requirements, thus complicating our compliance efforts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, additional reporting obligations and oversight obligations, and the curtailment or restructuring of our operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Human Capital Resources </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to achieve our goals and expectations, it is crucial that we continue to attract and retain top talent. To facilitate talent attraction and retention, we strive to make our Company a safe and rewarding workplace, with opportunities for our employees to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs, and by programs that build connections among our employees.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 81 employees, including 62 in research and development and 19 in general and administrative functions. As of December 31, 2021, 28 of our full-time employees had completed a Ph.D. or other advanced science or medical degree. We believe our employee relations are good.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The success of our business is fundamentally connected to the well-being of our employees. Accordingly, we are committed to their health, safety and wellness. We provide our employees and their families with access to a variety of innovative, flexible and convenient health and wellness programs, including benefits that provide protection and security so they can have peace of mind concerning events that may require time away from work or that impact their financial well-being&#59; that support their physical and mental health by providing tools and resources to help them improve or maintain their health status and encourage engagement in healthy behaviors&#59; and that offer choice where possible so they can customize their benefits to meet their needs and the needs of their families. In response to the COVID-19 pandemic, we implemented significant changes that we determined were in the best interest of our employees, as well as the communities in which we operate, and which comply with government regulations. This includes allowing our employees to work from home or remotely.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provide robust compensation and benefits programs to help meet the needs of our employees. In addition to salaries, these programs include </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitive compensation packages</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a 401(k) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lan, healthcare and insurance benefits</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">family leave, among others.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated under the laws of the state of Delaware in March 2015 under the name FLX Bio, Inc. In May 2019, we changed our name to RAPT Therapeutics, Inc. Our website address is <span style="color:#000000;font-size:12pt;">www.rapt.com</span>. Information contained on, or that can be accessed through, our website is not incorporated by reference into this report. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS">Risk Factors.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and investing in our common stock involve a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this Annual Report on Form 10-K, including our consolidated financial statements and related notes, our &#8216;&#8216;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; as well as our other public filings. The risks described below are not the only ones facing us. The occurrence of any of the following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, results of operations, prospects and stock price. In such case, the market price of our common stock could decline, and you may lose all or part of your original investment. This Annual Report on Form 10-K also contains forward-looking statements and estimates that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of specific factors, including the risks and uncertainties described below.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biopharmaceutical company with a history of losses. Since our inception, we have devoted substantially all of our resources to research and development, including our drug discovery and development engine, preclinical studies, clinical trials, raising capital, building our management team and our intellectual property portfolio. Our net loss was $69.2 million and $52.9<span style="font-size:12pt;"> </span>million for the year ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $284.0 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Furthermore, we do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials and the regulatory approval process for our current and potential future drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our net losses to increase substantially as we advance the clinical development of our lead drug candidates, RPT193 and FLX475. However, the amount of our future losses is uncertain. Our ability to generate revenue from product sales and achieve or sustain profitability, if ever, will depend on, among other things, successfully developing drug candidates, obtaining regulatory approvals to market and commercialize drug candidates, manufacturing any approved products on commercially reasonable terms, entering into any future collaborations or other partnerships, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient capital to finance our operations. If we, or any of our future partners, are unable to develop and commercialize one or more of our drug candidates, or if sales revenue from any drug candidate that receives regulatory approval is insufficient, we will not achieve or sustain profitability, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RPT193 and FLX475 are in clinical development, which may fail or suffer delays that materially and adversely affect their commercial viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no products on the market or that have gained regulatory approval. Other than RPT193 and FLX475, none of our drug candidates has ever been tested in humans. None of our drug candidates has advanced into late-stage development or a pivotal clinical trial and it may be years before any such trial is initiated, if at all. Our ability to achieve and sustain profitability depends on us developing, obtaining regulatory approval for and successfully commercializing one or more drug candidates, either alone or with partners. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining regulatory approval for any of our drug candidates, we must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Although we have successfully completed preclinical studies and a Phase 1 clinical trial with healthy volunteers for FLX475, are conducting a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab in a broad range of tumors and have completed a Phase 1a/1b trial of RPT193 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in healthy volunteers and patients with atopic dermatitis</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, more clinical trials are needed and there is no guarantee that the FDA will permit us to conduct additional clinical trials for </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193, FLX475</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other potential drug candidates. Further, we cannot be certain of the timely completion or outcome of our clinical trials and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs, or if the outcome of our preclinical studies or clinical trials will ultimately support the further development of </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193, FLX475</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or any other potential drug candidates. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193 and FLX475 are in clinical development, and we are subject to the risks of failure inherent in the development of drug candidates based on novel approaches, targets and mechanisms of action. Although FLX475 is currently in a Phase 1/2 clinical trial, there is no guarantee that FLX475 will benefit patients. In the ongoing Phase&#160;1/2 clinical trial of FLX475, responses have been observed<span style="font-size:12pt;"> </span>in a small number of patients. It is possible that no further responses will be observed in other patients or that the observed responses in patients who received FLX475 and pembrolizumab were caused solely by the pembrolizumab administered to the patient and not by FLX475, or that the responses were spontaneous and unrelated to either FLX475 or pembrolizumab. Additionally, although RPT193 has shown activity in several preclinical models and the Phase 1b portion of the Phase 1a/1b trial of <span style="color:#000000;">RPT193 </span>showed improvement compared to placebo in a common measure of disease severity <span style="Background-color:#FFFFFF;">in a small number of</span><span style="Background-color:#FFFFFF;color:#000000;"> patients with </span>atopic dermatitis, there is no guarantee that we will be able to proceed with clinical development of RPT193 or that it will benefit patients. Even though we have designed and selected our drug candidates to achieve an intended biological effect and to avoid certain others, and even if we have demonstrated this effect in preclinical models, there can be no assurance that the effect will be observed or avoided, as the case may be, in clinical trials or that the drug candidate will offer any significant clinical benefit to humans. Results in preclinical studies do not necessarily predict the results of clinical studies. Additionally, even though our drug candidates are designed to address the same indications as existing drugs and therapies, we have not conducted head-to-head clinical trials comparing our drug candidates with such existing drugs and therapies. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by clinical and preclinical stage biopharmaceutical companies such as ours. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLX475 is currently undergoing clinical development and testing as a single agent and in combination with pembrolizumab, which is supplied to us by Merck under our collaboration agreement with Merck.&#160;If Merck were to terminate our collaboration agreement, we may be forced to purchase pembrolizumab to continue our current and planned clinical trials or to pursue another anti-PD-1 therapy for co-administration with FLX475 in place of pembrolizumab, which may require us to restart preclinical studies or clinical trials, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects. In addition, if FLX475 is approved as a treatment in combination with pembrolizumab, then the availability of pembrolizumab for administration with FLX475 will affect our ability to commercialize FLX475. For example, if the supply of pembrolizumab were constrained for any reason it could have the effect of limiting the commercial uptake of FLX475, if approved for commercial sale. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have the financial resources to continue development of, or to enter into new collaborations for, RPT193, FLX475 or any potential future drug candidates. Our position may be exacerbated if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, a drug candidate, such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">negative or inconclusive results from our clinical trials or the clinical trials of others for drug candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product-related side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutics similar to ours&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays in submitting INDs or comparable foreign applications, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">conditions imposed by the FDA, or other regulatory authorities, regarding the scope or design of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays in enrolling research subjects in clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">high drop-out rates of research subjects&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">inadequate supply or quality of drug candidate components or materials or other supplies necessary for the conduct of our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">greater-than-anticipated clinical trial costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">poor effectiveness of our drug candidates during clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">unfavorable FDA or other regulatory agency inspections and review of a clinical trial or manufacturing site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delays and changes in regulatory requirements, policies and guidelines&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the FDA&#8217;s or other regulatory agencies&#8217; data interpretation. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtain regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RPT193, FLX475 or other future drug candidates may not demonstrate the safety and efficacy necessary to support further clinical development or commercial viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have completed a Phase 1 clinical trial with healthy volunteers for FLX475 and are conducting a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab. In addition, we have completed a Phase 1a/1b trial of RPT193<span style="Background-color:#FFFFFF;color:#000000;"> </span>in healthy volunteers and<span style="Background-color:#FFFFFF;color:#000000;"> in patients with </span>atopic dermatitis. We may ultimately discover that neither FLX475 nor RPT193 possesses certain properties that we currently believe are therapeutically effective or safe. For example, although RPT193 has exhibited encouraging results in preclinical models of atopic dermatitis and allergic asthma and showed improvement compared to placebo in a common measure of disease severity in a small number of patients with atopic dermatitis, it may not demonstrate the same properties in larger numbers of humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable product based on RPT193. If RPT193, FLX475 or any of our potential future drug candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could require us to change our focus and approach to small molecule discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The ongoing COVID-19 pandemic has materially affected and could continue to impact our operations, including at our headquarters in the San Francisco Bay Area and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic has caused widespread adverse impacts to the economy and financial markets, and to our employees, manufacturers, CROs and other parties with whom we do business. The ultimate extent to which the COVID-19 pandemic impacts our business, financial condition, results of operations and cash flows will depend on future developments, which are highly uncertain and cannot be predicted, including the duration and severity of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the pandemic, any worsening or recurrence of the pandemic and the success of actions taken to contain and limit its impact.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the public health directives and orders implemented in response to the COVID-19 pandemic, in March 2020 we transitioned to a remote working environment with limited lab operations. We re-started all lab operations and most of our lab-based personnel and certain essential personnel returned to work at our facility in the second quarter of 2020. Many of our other personnel are still working remotely. We do not know if and when we may have to close our laboratories and office location. The COVID-19 containment measures, including travel bans and restrictions, quarantines, social distancing requirements, shelter-in-place orders and business shutdowns, have disrupted and may continue to disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our suppliers of certain materials used in the production of our drug products are located in the Hanmi Territory, India and Germany. While many of these materials may be obtained by more than one supplier, including suppliers outside of the Hanmi Territory, India and Germany, port closures and other restrictions resulting from the COVID-19 pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for manufacture of our drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials have been affected and may continue to be affected by the COVID-19 pandemic. For example, in March 2020 we temporarily paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with atopic dermatitis due to circumstances and uncertainties created by the COVID-19 pandemic. Depending on the duration and severity of the pandemic, clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be impaired and would adversely impact our clinical trial operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic may materially affect us economically. While the potential economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 global pandemic continues to evolve. The potential impacts of the COVID-19 pandemic on us and third parties with whom we conduct business, including on our clinical studies and related timelines, as well as our preclinical activities, will depend on future developments that are highly uncertain and cannot be predicted, such as the ultimate geographic spread of the disease, the duration of the outbreak, containment measures and other limitations and restrictions, business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects, which could also have the effect of heightening many of the other risks and uncertainties described in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to use and expand our proprietary drug discovery and development engine to build a pipeline of drug candidates, and as an organization we have no history of successfully developing drugs. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A key element of our strategy is to use and expand our proprietary drug discovery and development engine to build a pipeline of potential drug candidates and advance these drug candidates through preclinical studies and clinical development for the treatment of various diseases. As an organization, we have never developed a drug candidate through to commercialization nor have we ever conducted a pivotal clinical trial. Although our research and development efforts to date have resulted in our identification and development of RPT193, FLX475 and other potential future drug candidates, neither our proprietary drug discovery and development engine nor our organization has a track record of success. Our current drug candidates may not be safe or effective therapeutics and we may not be able to develop any successful drug candidates. Our proprietary drug discovery and development engine is evolving and may not reach a state at which building a pipeline of drug candidates is possible. Even if we are successful in building our pipeline of drug candidates, the potential drug candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including unacceptable toxicity or other characteristics that indicate that the drug candidates are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. Even if the drug candidates we identify are suitable for clinical development, our lack of experience as an organization at developing drugs may cause us to fail in successfully developing the drug candidate through to commercialization. If we do not successfully develop and commercialize drug candidates, we will not be able to generate product revenue in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to successfully validate, develop and obtain regulatory approval for companion diagnostics for our drug candidates could harm our drug development strategy and operational results. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As one of the elements of our clinical development approach, we may seek to screen and identify subsets of patients who are more likely to benefit from our drug candidates. To achieve this, we may seek to develop and commercialize companion diagnostics by us or by third-party collaborators. Companion diagnostics are sometimes developed in conjunction with clinical programs for an associated product. The approval of a companion diagnostic as part of the product label would limit the use of the drug candidate to those patients who are more likely to benefit from our drug candidate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Companion diagnostics are subject to regulation by the FDA and other regulatory authorities as medical devices and require separate clearance or approval prior to their commercialization. To date, the FDA has required premarket approval of all companion diagnostics for oncology therapies. We may encounter difficulties in developing and obtaining approval for these companion diagnostics. Any delay or failure by us or third-party collaborators to develop or obtain regulatory approval of a companion diagnostic could delay or prevent approval of our related drug candidates. The time and cost associated with developing a companion diagnostic may not prove to have been necessary in order to successfully market the product. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market may not be receptive to our current or potential future drug candidates, and we may not generate any revenue from the sale or licensing of our drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if regulatory approval is obtained for a drug candidate, including RPT193 or FLX475, we may not generate or sustain revenue from sales of such products. Market acceptance of our current and potential future drug candidates will depend on, among other factors: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing of our receipt of any marketing and commercialization approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the terms of any approvals and the countries in which approvals are obtained&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the safety and efficacy of our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the prevalence and severity of any adverse side effects associated with our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">relative convenience and ease of administration of our drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the extent to which physicians recommend our products to their patients&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the availability of coverage and adequate government and third-party payor reimbursement&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the pricing of our products, particularly as compared to alternative treatments&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the availability of alternative effective treatments for the disease indications our drug candidates are intended to treat and the relative risks, benefits and costs of those treatments. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any drug candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in our efforts to expand indications for approved drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part of our drug development strategy is to clinically test and seek regulatory approval for our drug candidates in indications in which we believe there is the most evidence that we will be able to quickly generate proof-of-concept data. We then intend to expand clinical testing and seek regulatory approvals in other indications within oncology and inflammatory diseases. Conducting clinical trials for additional indications for our drug candidates requires substantial technical, financial and human resources and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be successful in our effort to obtain regulatory approval for our drug candidates for additional indications even if we obtain approval for an initial indication. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we or others later identify undesirable side effects caused by RPT193 or FLX475, our ability to market and derive revenue from the drug candidate could be compromised. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by RPT193, FLX475 or any other potential future drug candidate could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While we have not discovered any adverse side effects of RPT193 or FLX475 in healthy subjects that have limited our ability to test RPT193 or FLX475 in humans, it is possible that there will be undesirable side effects associated with their use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could order us to cease further development, or deny approval, of a drug candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may materially and adversely affect our business and financial condition and impair our ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a drug candidate may only be uncovered when a significantly larger number of patients are exposed to the drug candidate or when patients are exposed for a longer period of time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our current or potential future drug candidates receive regulatory approval and we or others identify undesirable side effects caused by one of these products, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory authorities may withdraw their approval of the product or seize the product&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may be required to recall the product or change the way the product is administered to patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we could be sued and held liable for harm caused to patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the product may become less competitive&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our reputation may suffer. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need substantial additional funds to advance development of drug candidates and our drug discovery and development engine, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have used substantial amounts of cash to fund our operations and expect our expenses to increase substantially in the foreseeable future. Developing our drug candidates and conducting clinical trials for the treatment of cancer, inflammatory diseases and any other indications that we may pursue in the future will require substantial amounts of capital. Accordingly, we expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate clinical trials of and seek marketing approval for, our drug candidates. In addition, if we obtain marketing approval for any of our drug candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect to continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had $189.7 million in cash and cash equivalents and marketable securities. Based on current business plans, we believe that our current cash and cash equivalents and marketable securities will provide sufficient funds to enable us to meet our obligations for at least the next 12 months from the date of this report. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our current and potential future drug candidates and the extent to which we may enter into collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies, clinical trials and any approved marketing and commercialization activities. The timing and amount of our operating expenditures will depend largely on: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing and progress of preclinical and clinical development activities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the timing and progress of the advancement of our drug discovery and development engine&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the price and pricing structure that we are able to obtain from our third-party contract manufacturers to manufacture our preclinical study and clinical trial materials and supplies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the number and scope of preclinical and clinical programs we decide to pursue&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to maintain our current licenses, collaboration and research and development programs, including the continued agreement of Merck to supply pembrolizumab to us for use in our clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to establish new collaborations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the progress of the development efforts of parties with whom we may in the future enter into collaboration and research and development agreements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost and timing of regulatory approvals&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our efforts to enhance operational systems, secure sufficient laboratory space and hire additional personnel, including personnel to support development of our drug candidates and satisfy our obligations as a public company. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have primarily financed our operations through the sale of equity securities. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We cannot assure you that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs or commercialization efforts. To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our current and potential future drug candidates, future revenue streams or research programs or to grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted and the terms of these securities may include liquidation preferences or other rights that adversely affect our and our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect to realize revenue from product sales in the foreseeable future, if at all, and unless and until our current and potential future drug candidates are clinically tested, approved for commercialization and successfully marketed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular drug candidate and fail to capitalize on drug candidates that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we intend to prioritize our efforts on specific research and development programs, including clinical development of RPT193, FLX475 or other future drug candidates. As a result, we may forgo or delay pursuit of other opportunities, including with potential future drug candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially viable drug candidates. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that drug candidate through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to enter into collaborations or strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future drug candidates, impact our cash position and increase our expenses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may consider strategic transactions, such as collaborations, acquisitions of companies, asset purchases, joint ventures and out- or in-licensing of drug candidates or technologies. For example, we entered a Collaboration and License Agreement with Hanmi in December 2019, pursuant to which we granted Hanmi the exclusive rights to develop, manufacture and commercialize FLX475 in the Hanmi Territory. The competition for partners is intense, and the negotiation process may be time-consuming and complex. If we are not able to enter into collaborations or other strategic transactions, or continue our existing collaboration, we may not have access to necessary capital or expertise to further develop our potential future drug candidates or our drug discovery and development engine. Any such collaboration or other strategic transaction may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. We may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we do enter into may be on terms that are not optimal for us. These transactions would entail numerous operational and financial risks, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">exposure to unknown liabilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, drug candidates or technologies&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges or increased amortization expenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the inability to retain key employees of any acquired business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, although there can be no assurance that we will undertake or successfully complete any collaborations or other strategic transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our drug candidates and have a negative impact on the competitiveness of any drug candidate that reaches market. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent that any of our current or future partners were to terminate a collaboration agreement, we may be forced to seek additional partnerships, which may be less favorable to us, or independently develop our current and future drug candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and obtaining, maintaining, enforcing and defending intellectual property rights or, in certain instances, abandoning drug candidates altogether, any of which could result in a change to our business plan and materially harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If third parties on which we rely to conduct certain preclinical studies and clinical trials do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse impacts on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had if we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA may require preclinical studies to be conducted in accordance with good laboratory practices and clinical trials to be conducted in accordance with good clinical practices, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials, to ensure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse impact on our commercial prospects and may impair our ability to generate revenue. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our current or potential future drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. For example, in March 2020 we temporarily paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with atopic dermatitis due to circumstances and uncertainties created by the COVID-19 pandemic. We cannot predict how difficult it will be to enroll patients for our clinical trials or whether we will be able to meet our anticipated timelines to provide initial data. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the severity of the disease under investigation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patient eligibility criteria defined in the clinical trial protocol&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the proximity and availability of clinical trial sites for prospective patients&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patient referral practices of physicians&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to recruit clinical trial investigators with the appropriate competencies and experience&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to obtain and maintain patient consents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">ramifications of the COVID-19 pandemic, including difficulties accessing clinical sites that are closed or operating on a restricted basis due to the pandemic and the reluctance of patients to participate in the trial or attend clinical sites due to concerns related to the pandemic&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our future clinical trials will compete with other clinical trials for drug candidates that are in the same therapeutic areas as our drug candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Additionally, because some of our clinical trials will be conducted in patients with advanced solid tumors, the patients are typically in the late stages of the disease and may experience disease progression or adverse events independent from our drug candidates, making them unevaluable for purposes of the trial and requiring additional enrollment. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our research and development activities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain laws and regulations relating to drug development require us to test our drug candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we may rely on third parties for manufacturing and supply of our drug candidates, some of which are or may be sole source vendors, for preclinical and clinical development materials and commercial supplies, our supply may become limited or interrupted or may not be of satisfactory quantity or quality. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely on third-party contract manufacturers for our current and future clinical trial product materials and supplies. We do not produce any meaningful quantity of our drug candidates for clinical development, and we do not currently own manufacturing facilities for producing such supplies. Furthermore, some of our manufacturers represent our sole source of supplies of current and future clinical development materials, including our source for the manufacture of RPT193 and FLX475. We cannot assure you that our preclinical or current or future clinical development product supplies and commercial supplies will not be limited or interrupted, especially with respect to our sole source third-party manufacturing and supply partners, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. For our current and future sole source third-party manufacturing and supply partners, we may be unable to negotiate binding agreements with them or find replacement manufacturers to support our preclinical and current and future clinical activities at commercially reasonable terms in the event that their services to us becomes interrupted for any reason. We do not always have arrangements in place for a redundant or second-source supply for our sole source vendors in the event they cease to provide their products or services to us or do not timely provide sufficient quantities to us. Establishing additional or replacement sole source vendors, if required, may not be accomplished quickly. Any delays resulting from manufacturing or supply interruptions associated with our reliance on third-party manufacturing and supply partners, including those that are sole source, could impede, delay, limit or prevent our drug development efforts, which could harm our business, result of operations, financial condition and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for a drug candidate is subject to FDA and other regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices (&#8220;cGMP&#8221;). If any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our current and future drug candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our drug candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop drug candidates in a timely manner or within budget. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to rely on third-party manufacturers if we receive regulatory approval for any drug candidate. We have existing, and may enter into future, manufacturing arrangements with third parties. We will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for any drug candidate, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our drug candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP could adversely affect our business in a number of ways, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">an inability to initiate or continue clinical trials of drug candidates under development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">delay in submitting regulatory applications, or receiving regulatory approvals, for drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">loss of the cooperation of a potential future partner&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">requirements to cease distribution or to recall batches of drug candidates&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">in the event of approval to market and commercialize a drug candidate, an inability to meet commercial demands for our products. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our third-party manufacturers may be unable to successfully scale manufacturing of RPT193, FLX475 or potential future drug candidates in sufficient quality and quantity, which would delay or prevent us from developing drug candidates and commercializing approved products, if any. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to conduct further clinical trials for RPT193 and FLX475, as well as any potential future drug candidates, we will need to manufacture large quantities of these drug candidates. We may continue to use third parties for our manufacturing needs. Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any current or potential future drug candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale the manufacture of any current or potential future drug candidate in sufficient quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or infeasible, and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the market opportunities for our current and potential future drug candidates, including RPT193 and FLX475, are smaller than we believe they are, our ability to generate product revenue may be adversely affected and our business may suffer. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our understanding of the number of people who suffer from certain types of inflammatory disease and cancers that RPT193 and FLX475, respectively, may have the potential to treat is based on estimates. These estimates may prove to be incorrect, and new studies may demonstrate or suggest a lower estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our current or potential future drug candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for our candidates may be further reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from RPT193 or FLX475. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, there are several factors that could contribute to making the actual number of patients who receive our current or potential future drug candidates less than the potentially addressable market, including the lack of widespread limited reimbursement for new therapies in many markets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face intense competition from entities that have developed or may develop drug candidates for the treatment of the diseases that we are currently targeting or may target in the future. If these companies develop technologies or drug candidates more rapidly than we do, or if their technologies or drug candidates are more effective, our ability to develop and successfully commercialize drug candidates may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors are often larger and better funded than we are. Our competitors have developed, are developing or will develop drug candidates and processes competitive with ours. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we are developing or may try to develop drug candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical, immuno-oncology and inflammation fields. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of numerous companies that are developing biologics and small molecule drugs for the treatment of cancer and inflammatory diseases. Many of these companies are well-capitalized and, in contrast to us, have significant clinical experience, and may include our future partners. In addition, these companies compete with us in recruiting scientific and managerial talent. Our success will partially depend on our ability to obtain, maintain, enforce and defend patents and other intellectual property rights with respect to small molecule drugs or biologics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective or less expensive than the drugs we develop are or become available. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to compete with small molecule, biologics and other therapeutic platforms and development companies, including, but not limited to, companies such as ChemoCentryx, Tusk/Roche and Agenus/Gilead for oncology, and Dermira/Lilly and AnaptysBio for inflammatory diseases. In addition, we expect to compete with large, multinational pharmaceutical companies that discover, develop and commercialize small molecule drugs and other therapeutics for use in treating cancer and inflammatory diseases such as AbbVie, Amgen, AstraZeneca plc, Bristol-Myers Squibb, GlaxoSmithKline, Incyte, Kyowa Hakko Kirin, Merck, Novartis, Pfizer, Roche/Genentech and Sanofi/Regeneron. If RPT193, FLX475 or any other future drug candidate is eventually approved, it will compete with a range of treatments that are either in development or currently marketed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any drug candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any product we develop obsolete or noncompetitive before we recover the expense of developing and commercializing such product. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Brian Wong, M.D., Ph.D., our President and Chief Executive Officer, Rodney Young, our Chief Financial Officer, William Ho, M.D., Ph.D., our Chief Medical Officer, and Dirk Brockstedt, Ph.D., our Chief Scientific Officer, as well as our ability to attract and retain other highly qualified personnel. The loss of one or more members of our executive team, management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our drug candidates and technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success will also depend in large part on our ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face significant competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 81 full-time employees. Our focus on the development of RPT193, FLX475 and other potential future drug candidates will require adequate staffing. We may need to hire and retain new employees to execute our future clinical development and manufacturing plans. We cannot provide assurance that we will be able to hire or retain adequate staffing levels to develop our current and potential future drug candidates or to run our operations or to accomplish all of our objectives. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may experience difficulties in managing our growth and expanding our operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in product development. As our current and potential future drug candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also experience difficulties in the discovery and development of potential future drug candidates using our drug discovery and development engine if we are unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and to secure adequate facilities for our operational needs. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of our drug candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no sales, marketing or distribution capabilities or experience. We will need to develop internal sales, marketing and distribution capabilities to commercialize each current and potential future drug candidate that gains FDA approval, which would be expensive and time-consuming, or enter into partnerships with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to co-promote products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business and results of operations could be materially and adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our present and potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and clinical trial centers are located outside of the United States, and we recently entered into an agreement with Hanmi with respect to clinical development and other activities in the Hanmi Territory. Furthermore, if we or any future collaborator succeeds in developing any products, we anticipate marketing them in the European Union and other jurisdictions in addition to the United States. If approved, we or our collaborator may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">rejection or qualification of foreign clinical trial data by the competent authorities of other countries&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">additional potentially relevant third-party patent and other intellectual property rights that may be necessary to develop and commercialize our products and drug candidates&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
</td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">complexities and difficulties in obtaining, maintaining, enforcing and defending our patent and other intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">difficulties in staffing and managing foreign operations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient&#160;self-pay&#160;systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">limits in our ability to penetrate international markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions and implementation of tariffs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">certain expenses, including, among others, expenses for travel, translation and insurance&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to develop and commercialize drug candidates in foreign markets for which we may rely on partnering with third parties. We will not be permitted to market or promote any drug candidate before we receive regulatory approval from the applicable regulatory authority in a foreign market, and we may never receive such regulatory approval for any drug candidate. To obtain separate regulatory approval in foreign countries, we generally must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy, and governing, among other things, clinical trials and commercial sales, pricing and distribution of a drug candidate, and we cannot predict success in these jurisdictions. If we obtain approval of any of our current or potential future drug candidates and ultimately commercialize any such drug candidate in foreign markets, we would be subject to risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Price controls imposed in foreign markets may adversely affect our future profitability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure exerted by governments and other stakeholders on prices and reimbursement levels, including as part of cost-containment measures. Political, economic and regulatory developments, in the United States or internationally, may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or future partners may be required to conduct clinical trials or other studies that compare the cost-effectiveness of a drug candidate to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any current or potential future drug candidate that is approved for marketing in the future is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business and results of operations or prospects could be materially and adversely affected and our ability to commercialize such drug candidate could be materially impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by natural or other disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current operations are concentrated in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather, medical epidemic, pandemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities or the manufacturing facilities of our third-party contract manufacturers, or lose our repository of preclinical and clinical human samples and other valuable laboratory samples, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis. Such an event would have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our drug candidates or interruption of our business operations. Natural disasters such as earthquakes or wildfires, both of which are prevalent in Northern California, floods or tsunamis could further disrupt our operations, and have a material negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business and financial condition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain, maintain, enforce or defend intellectual property rights related to our technology and current or future drug candidates, or if our intellectual property rights are inadequate, we may not be able to compete effectively. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in large part on our ability to obtain and maintain protection in the United States and other countries for our intellectual property rights and proprietary technology. We rely on patents and other forms of intellectual property rights to protect our current or future drug discovery and development engine, drug candidates, methods used to manufacture our current or future drug candidates and methods for treating patients using our current or future drug candidates. We do not currently own any patents or patent applications relating to our proprietary drug discovery and development engine. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. The patent applications that we own or may in-license may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or drug candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, although we make reasonable efforts to ensure patentability of our inventions, we cannot guarantee that all of the potentially relevant prior art relating to our patent applications and any issued patents we obtain has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug discovery and development engine, our drug candidates or the use of our technologies. We thus cannot know with certainty whether we or any of our future licensors were the first to make the inventions claimed in our pending patent applications or any issued patents we obtain, or that we or our any of our future licensors were the first to file for patent protection of such inventions. For this reason, and because there is no guarantee that any prior art search is absolutely correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent our pending patent applications from issuing as patents. Invalidation of any of our patent rights, including in-licensed patent rights, could materially harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the patent positions of biopharmaceutical companies are generally uncertain because they may involve complex legal and factual considerations that have, in recent years, been the subject of legal development and change. As a result, the issuance, scope, validity, enforceability and commercial value of our pending patent rights is uncertain. The standards applied by the United States Patent and Trademark Office (&#8220;USPTO&#8221;) and foreign patent offices in granting patents are not always certain and, moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patent rights or narrow the scope of our patent protection. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if patents do successfully issue and even if such patents cover our current or any future technologies or drug candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful challenge to any patents we own or may in-license could deprive us of rights necessary for the successful commercialization of any current or future technologies or drug candidates that we may develop. Likewise, if patent applications we own or may in-license with respect to our development programs and current or future technologies or drug candidates fail to issue, if their breadth or strength is threatened or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future technologies or drug candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain, or any loss of, patent protection could have a material adverse impact on our business and ability to achieve profitability. We may be unable to prevent competitors from entering the market with a product that is similar to or the same as RPT193, FLX475 or other future drug candidates that emerge from our discovery program. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by any of our future licensors may be challenged through third-party submissions, opposition or derivation proceedings. By further example, issued patents may be challenged through reexamination, inter partes review or post-grant review proceedings before the USPTO or patent offices in other jurisdictions or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our patent rights&#59; limit our ability to stop others from using or commercializing similar or identical products&#59; allow third parties to compete directly with us without payment to us&#59; or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patent rights is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, some of our intellectual property, including patents and patent applications, are or may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such intellectual property, including patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such co-owners of our patent rights to enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial conditions.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations under any license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or drug candidates or we could lose certain rights to grant sublicenses.<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any license, collaboration or other intellectual property-related agreements impose, and any future license, collaboration or other intellectual property-related agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license. In spite of our best efforts, any of our future licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technologies covered by these license agreements. Any license agreements we enter into may be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to obtain licenses from licensors in the future, however, we may be unable to obtain any such licenses at a reasonable cost or on reasonable terms, if at all. In addition, if any of our future licensors terminate any such license agreements, such license termination could result in our inability to develop, manufacture and sell products that are covered by the licensed technology or could enable a competitor to gain access to the licensed technology. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and ability to achieve profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce and defend patents we may in-license, or lose rights to licensed patents or patent applications, our license rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or drug candidates that is the subject of such licensed rights could be materially adversely affected. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights and the amount of any damages or future royalty obligations that would result if any such claims were successful would depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, the standard patent term is typically 20 years after filing. Various extensions may be available. Even so, the life of a patent and the protection it affords are limited. As a result, our patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing products similar or identical to ours. For example, given the large amount of time required for the research, development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extensions of patent term may be available, but there is no guarantee that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would lengthen the patent term for a sufficient period of time to exclude others from commercializing products similar or identical to ours. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the approved indication or any additional indications approved during the period of extension. A patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval&#59; only one patent may be extended&#59; and extension is available for only those claims covering the approved drug, a method for using it or a method for manufacturing it. The applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to any patents we obtain, or may grant more limited extensions than we request. An extension may not be granted or may be limited where there is, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply before expiration of relevant patents or some other failure to satisfy applicable requirements. If this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and clinical trials along with our clinical and preclinical data. This could have a material adverse effect on our business and ability to achieve profitability. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or drug candidates.<span style="font-size:8.5pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"> </sup></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.81%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time&#8208;consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs of, and may diminish our ability to protect, our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our owned and licensed patents. On September 16, <span style="color:#000000;">2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law, which has increased uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provided more efficient and cost-effective avenues for competitors to challenge the validity of patents. This included allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. In March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application would be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. This required us to be cognizant of the time from invention to filing of a patent application. The Leahy-Smith Act and its implementation results in uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse impact on our business prospects, financial condition and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As referenced above, for example, courts in the U.S. continue to refine the heavily fact-and-circumstance-dependent jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This creates uncertainty about our ability to obtain patents in the future and the value of such patents. We cannot provide assurance that future developments in U.S. Congress, the federal courts and the USPTO will not adversely impact our patent rights. The laws and regulations governing patents could change in unpredictable ways that could weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing patent rights or patent rights that we might obtain or in-license in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may have a material adverse effect on our and our licensors&#8217; ability to obtain new patents or to protect and enforce our owned or in-licensed patent rights or patent rights that we may obtain or in-license in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other companies or organizations may challenge our patent rights or may assert patent rights that prevent us from developing and commercializing our current or future products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may attempt to invalidate our intellectual property rights. Even if such rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse impact on our profitability, financial condition and prospects or ability to successfully compete. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we cannot guarantee that we are aware of all patents and patent applications potentially relevant to our technology or products. There may be issued and pending patents that claim aspects of our current or potential future drug candidates and modifications that we may need for our current or potential future drug candidates. We may not be aware of potentially relevant third-party patents or applications for several reasons. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug candidates or technologies could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our drug candidates or the use of our technologies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to priority disputes, inventorship disputes and similar proceedings that could, if resolved unfavorably, narrow the scope of our intellectual property protection. We cannot provide any assurances that third-party patents do not exist that might be enforced against our drug candidates or technologies or future methods or products, resulting in either an injunction prohibiting our manufacture or sales or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, drug candidates or the methods for manufacturing our drug candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, we may not be able to market such technology or drug candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on our ability to commercialize our drug candidates and our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on current or future technologies or drug candidates in all countries throughout the world would be prohibitively expensive. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export infringing products to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These products may compete with our products, and our patent or other intellectual property rights may not be effective or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Many companies have encountered significant difficulties in protecting and defending intellectual property rights in such foreign jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patent rights or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put our patent rights at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us or any of our future licensors. We may not prevail in any lawsuits or other adversarial proceedings that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects, financial condition and results of operations may be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, upon our ability or the ability of any of our future collaborators to develop, manufacture, market and sell our current or any future drug candidates and to use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or any of our future licensors or strategic partners, may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any potential future drug candidates and technologies, including derivation, reexamination, inter partes review, post-grant review or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United States, such as opposition proceedings. If we or our licensors or strategic partners are unsuccessful in any interference proceedings or other priority or validity disputes (including through any patent oppositions) to which we or they are subject, we may lose valuable intellectual property rights through the loss of one or more patents or our patent claims may be narrowed, invalidated or held unenforceable. In some instances, we may be required to indemnify our licensors or strategic partners for the costs associated with any such adversarial proceedings or litigation. Third parties may also assert infringement, misappropriation or other claims against us, our licensors or our strategic partners based on existing patents or patents that may be granted in the future, as well as other intellectual property rights, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors or our strategic partners to enforce or otherwise assert their patent rights or other intellectual property rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents and other intellectual property rights are valid, enforceable and infringed, which could have a material adverse impact on our ability to utilize our drug discovery and development engine or to commercialize our current or any future drug candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and convincing evidence of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and convincing, would invalidate the claims of any such U.S. patent. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we cannot guarantee that we will be able to successfully settle or otherwise resolve such adversarial proceedings or litigation. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we or any of our licensors or strategic partners are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, we could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed. In addition, we, or any of our licensors or strategic partners, may choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us, and we could be required to make substantial licensing and royalty payments. We also could be forced, including by court order, to cease utilizing, developing, manufacturing and commercializing our drug discovery and development engine or drug candidates deemed to be infringing. We may be forced to redesign current or future technologies or products. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we or our licensors or strategic partners may find it necessary to pursue claims or to initiate lawsuits to protect or enforce our patent or other intellectual property rights. If we or our licensors or strategic partners were to initiate legal proceedings against a third party to enforce a patent covering one of our drug candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description, non-enablement, anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensors or strategic partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection for one or more of our drug candidates. The narrowing or loss of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. All of these events could have a material adverse effect on our business, financial condition, results of operations and prospects. Patent and other intellectual property rights also will not protect our drug candidates and technologies if competitors or third parties design around such drug candidates and technologies without legally infringing, misappropriating or violating our patent or other intellectual property rights. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost to us in defending or initiating any litigation or other proceeding relating to our patent or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would divert our management&#8217;s attention and distract our personnel from their normal responsibilities. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be better able to sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required in connection with certain such proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, such announcements could have a material adverse effect on the price of our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or drug candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or drug candidates, which may not be available on commercially reasonable terms or at all. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the immuno-oncology and inflammation disease landscapes are still evolving, it is difficult to conclusively assess our freedom to operate. Thus, we may unknowingly pursue development of a product or technology that infringes, misappropriates or otherwise violates third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering immune-therapies generally or covering small molecules directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies, drug candidates or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies, drug candidates or elements thereof unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties, that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or drug candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or drug candidates. Should such an infringement claim be successfully brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies or drug candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party intellectual property right holders may also actively bring infringement, misappropriation or other claims alleging violations of intellectual property rights against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our drug candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or drug candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual property rights. We might, if possible, also be forced to redesign current or future technologies or drug candidates so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining necessary or exclusive rights to any drug candidates or products we may develop through acquisitions and in-licensing. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be unable to acquire or otherwise in-license any compositions, methods of use, processes or other intellectual property rights from third parties that we identify as necessary for drug candidates that we may wish to develop. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patent rights we may in-license in the future may be subject to a reservation of rights by one or more third parties. For example, the research resulting in any in-licensed patent rights and technology may be funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the government to use the invention for non-commercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As referenced above, in addition to seeking patent protection for certain aspects of our current or future technologies and drug candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. However, trade secrets and know-how can be difficult to protect. We protect and plan to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they are obligated to maintain confidentiality and to assign their inventions to us. Despite these efforts, we may not obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, individuals with whom we have such agreements may not comply with their terms. Any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such breaches. We may be forced to bring claims against third parties, including current or former employees or consultants, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property, including our patent rights. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret, or securing title to an employee- or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. If we are unsuccessful in any inventorship disputes to which we are subject, we may lose valuable intellectual property rights, such as ownership of our patent rights. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are unwilling to protect trade secrets. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent that competitor from using the technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217; or consultants&#8217; former employers or their clients. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees or consultants and our licensors&#8217; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that one or more of these employees or consultants or we have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of any such individual&#8217;s current or former employers. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or drug candidates, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to management. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our patent rights and any patent rights we may own or in-license in the future. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements, and we may also be dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products, which could have a material adverse effect on our business prospects and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We own a U.S. registered trademark for RAPT and a US registered trademark for a design used in our corporate logo. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we use for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be materially adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intellectual property rights do not necessarily address all potential threats to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may be able to make small molecule drugs, inhibitors or formulations that are similar to our drug candidates, but that are not covered by the claims of any patents that we own, license or control&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or any strategic partners might not have been the first to make the inventions covered by the patent rights that we own, license or control&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we or our licensors might not have been the first to file patent applications covering certain of our owned and in-licensed inventions&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">others may independently develop the same, similar or alternative technologies without infringing, misappropriating or violating our intellectual property rights&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">it is possible that our pending patent applications will not lead to issued patents&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">issued patents that we may own, in-license or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the patents of others may have an adverse effect on our business. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should any of these events occur, they could have a material adverse impact on our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legal and Regulatory Risks </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug candidates, RPT193 and FLX475, are in clinical development, and their risk of failure is high. It is impossible to predict when or if our candidates or any potential future drug candidates will prove effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of a drug candidate in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of our current or potential future drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are conducting a Phase 1/2 clinical trial investigating FLX475 as a single agent and in combination with pembrolizumab in a broad range of tumors. We may experience delays in initiating or completing our clinical trials. For example, in March 2020 we paused enrollment for a few months in the Phase 1b portion of our Phase 1a/1b trial to evaluate RPT193 in patients with atopic dermatitis due to circumstances and uncertainties created by the COVID-19 pandemic. We do not know whether planned clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed for a variety of reasons, including delays related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtaining regulatory approval to commence a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">obtaining institutional review board (&#8220;IRB&#8221;) approval at each clinical trial site&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">recruiting suitable patients to participate in a clinical trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">having patients complete a clinical trial or return for post-treatment follow-up&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trial sites deviating from trial protocol or dropping out of a trial&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">adding new clinical trial sites&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">manufacturing sufficient quantities of our drug candidates for use in clinical trials. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our current or potential future drug candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion, or termination, of any clinical trial of any of our current or potential future drug candidates, the commercial prospects of such drug candidate will be harmed, and our ability to generate product revenue from such drug candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our current or potential future drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize RPT193, FLX475 or other future drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193, FLX475 and other future drug candidates are and will be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug, therapeutic or biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the drug candidates we may develop will obtain the regulatory approvals necessary for us or our potential future partners to begin selling them. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the drug candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenue from the particular drug candidate for which we are seeking approval. Further, we and our potential future partners may never receive approval to market and commercialize any drug candidate. Even if we or a potential future partner obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or a potential future partner may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our drug candidates prove to be ineffective, unsafe or commercially unviable, we may have to re-engineer </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193, FLX475</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other future drug candidates, and our entire pipeline could have little, if any, value, which could require us to change our focus and approach to small molecule discovery and development, which would have a material and adverse effect on our business, financial condition, results of operations and prospects. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any of our current or potential future drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future drug candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we or potential future partners obtain for RPT193, FLX475 or other future drug candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#8220;Phase&#160;4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of such drug candidate. In addition, if the FDA or other regulatory authority approves RPT193, FLX475 or other future drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration and continued compliance with cGMP and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fines, warning letters or holds on clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">suspension or revocation of product license approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">product seizure or detention or refusal to permit the import or export of products&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March&#160;2010, ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control Act of 2011, among other things, includes aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year. These reductions went into effect on April&#160;1, 2013 and remain in effect through 2031, unless additional Congressional action is taken. These reductions have been temporarily suspended from May 1, 2020 through March 31, 2022 by COVID-19 relief legislation. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Presidential executive orders</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. However, certain recent initiatives have stalled. For example, the implementation of a new regulation removing safe harbor protection for certain price reductions from pharmaceutical manufacturers to plan sponsors under Part D has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. Other regulations, such as the new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers also have been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation (&#8220;MFN&#8221;) executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. </span><span style="color:#000000;">As a result of litigation challenging the MFN model, on </span><span style="color:#000000;">December 27</span><span style="color:#000000;">, 2021, CMS published a </span><span style="color:#000000;">final</span><span style="color:#000000;"> rule that rescind</span><span style="color:#000000;">ed</span><span style="color:#000000;"> the MFN model</span><span style="color:#000000;">&#8217;s</span><span style="color:#000000;"> interim final rule. In July 2021, the Biden administration released an executive order that included multiple provisions aimed at prescription drugs. In response to </span><span style="color:#000000;">President</span><span style="color:#000000;"> Biden&#8217;s executive order, on September 9, 2021, the HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles.&#160;No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of </span><span style="color:#000000;">other reform initiatives</span><span style="color:#000000;">.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. These new laws and initiatives may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future customers and accordingly, our financial operations. Further, it is possible that additional governmental action is taken in response to the ongoing COVID-19 pandemic.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we or potential future partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers and third-party payors, among others, will play a primary role in the prescription and recommendation of any drug candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute our drug candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act (discussed below)&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">federal civil and criminal false claims laws and civil monetary penalties laws, including the federal False Claims Act, which provides for civil whistleblower or qui tam actions, that impose penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">HIPAA, as amended by HITECH, and its implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans and healthcare clearinghouses as well as their business associates and subcontractors that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to CMS information related to payments and other transfers of value made by that entity to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services reimbursed by third-party payors, including private insurers&#59; local, state and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other healthcare providers and healthcare entities, marketing expenditures or drug pricing&#59; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the location and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government&#59; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations are found to be in violation of any such requirements, we may be subject to significant penalties, including criminal and significant civil monetary penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to allow us to enter into supply contracts, including government contracts, additional reporting requirements and oversight if subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive marketing and commercialization approval of a drug candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;), after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. We intend to rely on third-party manufacturers and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future partners, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers and health maintenance organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. We plan to develop, either by ourselves or with collaborators, in vitro companion diagnostic tests for our drug candidates for certain indications. We, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. The failure to obtain coverage reimbursement for the companion diagnostic tests may hinder our ability to commercialize our product candidates, once approved.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. Commercial third-party payors often rely upon Medicare coverage policy and payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Further, coverage policies and third&#8209;party reimbursement rates may change at any time. Thus, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. Coverage and reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any drug candidate for which we obtain marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize or have actual knowledge of such activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor, which can result in added costs and administrative burdens. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we conduct clinical trials of RPT193 and FLX475, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of cancer and inflammatory disease treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities, our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business and financial condition, including the imposition of significant criminal, civil and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our current and any of our future collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws (e.g., the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;)), state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, as amended by HITECH, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (&#8220;GDPR&#8221;), may also apply to health-related and other personal information obtained outside of the United States. The GDPR went into effect in May 2018. The GDPR introduced new data protection requirements in the European Union, as well as potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous new requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information (e.g., the right to access, correct and delete their data). In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. Further, the United Kingdom&#8217;s exit from the EU in January 2020, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which took effect on January 1, 2020, creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to opt-out of certain sales or transfers of personal information and provide consumers with additional causes of action. The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). The CCPA will likely impact our business activities and may increase our compliance costs and potential liability. If we fail to comply with the CCPA, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. For example, other states (such as Colorado and Virginia) have passed data privacy laws. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In the event that we are subject to HIPAA, the CCPA or other U.S. privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data or, in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or any of our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we, our CROs or our information technology (&#8220;IT&#8221;) vendors experience security or data privacy breaches or other unauthorized or improper access to, use of or destruction of personal data, we may face costs, significant liabilities, harm to our brand and business disruption. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our drug discovery and development engine and efforts, we or our CROs may collect and use a variety of personal data, such as name, mailing address, email addresses, phone number and clinical trial information. Although we have extensive measures in place to prevent the sharing and loss of patient data in our sample collection process associated with our drug discovery and development engine, any failure to prevent or mitigate security breaches or improper access to, use of or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state (e.g., breach notification laws), federal (e.g., HIPAA, as amended by HITECH) and international law (e.g., the GDPR). Any failure to prevent or mitigate security breaches or improper access to, use of or disclosure of our clinical data or patients&#8217; personal data may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business. We may also rely on third-party IT vendors to host or otherwise process some of our data and that of users, and any failure by such IT vendor to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We depend on sophisticated information technology systems to operate our business and a cyber-attack or other breach of these systems could have a material adverse effect on our business. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on information technology systems that we or our CROs or other vendors, contractors or consultants operate to process, transmit and store electronic information in our or their day-to-day operations. The size and complexity of such information technology systems makes them vulnerable to a cyber-attack, malicious intrusion, breakdown, destruction, loss of data privacy or other significant disruption. A successful attack could result in the theft or destruction of intellectual property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyber-attacks are becoming more sophisticated and frequent. We have invested in our systems and the protection and recoverability of our data to reduce the risk of an intrusion or interruption, and we monitor and test our systems on an ongoing basis for any current or potential threats. There can be no assurance that these measures and efforts will prevent future interruptions or breakdowns. If we or our CROs or other vendors, contractors or consultants fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to these systems, we or they could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions and delays in our research and development work. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing of these materials in our facilities comply with the relevant guidelines of the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although we have some environmental liability insurance covering certain of our facilities, we may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future, including as a result of the COVID&#8209;19 pandemic. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">variations in the level of expense related to the ongoing development of our drug candidates or future development programs&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any such potential future arrangements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">additions and departures of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">if any of our drug candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory developments affecting our drug candidates or those of our competitors&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in general market and economic conditions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has been and is likely to continue to be highly volatile. The market price for our common stock may be influenced by many factors, including the other risks described in this &#8220;Risk Factors&#8221; section and the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability to advance RPT193, FLX475 or other potential future drug candidates through clinical development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">results of our preclinical studies, non-clinical studies and clinical trials for our current and future drug candidates or those of our competitors or potential future partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of competitive products or technologies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">introductions and announcements of new products by us, our future commercialization partners or our competitors, and the timing of these introductions or announcements&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actions taken by regulatory agencies with respect to our products, clinical trials, manufacturing process or sales and marketing terms&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the success of our efforts to acquire or in-license additional technologies, products or drug candidates&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments concerning any future collaborations, including, but not limited to, those with our sources of manufacturing supply and our commercialization partners&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">developments, disputes or litigation matters concerning patents or other intellectual property rights, and our ability to obtain and maintain patent protection for our products&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the recruitment or departure of key personnel&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in the structure of healthcare payment systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">announcement and expectation of additional financing efforts&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">speculation in the press or investment community&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">trading volume of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">sales of our common stock by us or our stockholders, including after the expiration of the lockup agreements entered into in connection with our public offerings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the concentrated ownership of our common stock&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">changes in accounting principles&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">natural disasters, medical epidemics, pandemics and other calamities&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">general economic, industry and market conditions. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Substantial purchases of common stock by existing stockholders could reduce the liquidity of the trading market for our common stock and increase price volatility. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our company, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property rights or our common stock performance, or if our clinical studies and operating results fail to meet the expectations of the analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our executive officers and directors, together with holders of 5% or more of our capital stock and their respective affiliates, beneficially own a significant percentage of our common stock. As a result, these stockholders, if acting together, will have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The interests of these stockholders may not be the same as, and may even conflict with, your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; and our election of reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, or Section&#160;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We may take advantage of these provisions until December 31, 2024. However, we will cease to be an &#8220;emerging growth company&#8221; prior to December 31, 2024 if certain events occur, including if (i) we become a &#8220;large accelerated filer,&#8221; with at least $700 million of equity securities held by non-affiliates&#59; (ii) our annual gross revenues exceed $1.07 billion&#59; or (iii) we issue more than $1.0 billion of non-convertible debt in any three-year period. Even after we no longer qualify as an emerging growth company, we could still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section&#160;404 and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of an exemption that allows us to delay adopting new or revised accounting standards until such time as those standards apply to private companies. As a result, we will not be subject to the same new or revised accounting standards as other public companies that comply with the public company effective dates, including but not limited to the new lease accounting standard. We may elect to take advantage of other reduced reporting requirements in future filings. As a result of these elections, the information that we provide to our stockholders may be different than you might receive from other public reporting companies. However, if we later decide to opt out of the extended period for adopting new accounting standards, we would need to disclose such decision and it would be irrevocable. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to use net operating losses to offset future taxable income may be subject to certain limitations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our net operating loss carryforwards (&#8220;NOLs&#8221;) could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by the Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Act signed into law on March 27, 2020, NOLs arising in tax years beginning after December 31, 2017, and before January 1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, under the Tax Act as modified by the CARES Act, federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning after January 1, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In general, under Section&#160;382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; is subject to limitations on its ability to utilize its pre-change NOLs or tax credits to offset future taxable income. Our existing NOLs or credits may be subject to substantial limitations arising from previous ownership changes, and if we undergo an ownership change our ability to utilize NOLs or credits could be further limited by Section&#160;382 of the Code. In addition, future changes in our stock ownership, many of which are outside of our control, could result in an ownership change under Section&#160;382 of the Code. Our NOLs or credits may also be impaired under state law. Accordingly, we may not be able to utilize a material portion of our NOLs or credits. Furthermore, our ability to utilize our NOLs or credits is conditioned upon our attaining profitability and generating U.S. federal and state taxable income. As described above under &#8220;&#8212;Risks Related to Business,&#8221; we have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future&#59; thus, we do not know whether or when we will generate the U.S. federal or state taxable income necessary to utilize our NOLs or credits. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may incur significant costs from class action litigation due to the volatility of our stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts for our drug discovery and development engine and our drug candidates, the development efforts of future partners or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies. This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of our company or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chair of our board of directors, our chief executive officer or our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">division of our board of directors into three classes, serving staggered terms of three years each&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any derivative action or proceeding brought on our behalf&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a breach of fiduciary duty owed by any of our directors, officers, employees or agents to us or our stockholders&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a claim against us or any of our directors, officers or other employees arising under any provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws&#59; or </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act or the rules and regulations thereunder. However, these provisions apply to Securities Act claims and Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce a duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such provisions, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, subject to and contingent upon a final adjudication in the State of Delaware of the enforceability of such exclusive forum provision. These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive-forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. For example, the Court of Chancery of the State of Delaware recently determined that a provision stating that U.S. federal district courts are the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act is not enforceable. However, this decision may be reviewed and ultimately overturned by the Delaware Supreme Court. If the Court of Chancery&#8217;s decision were to be overturned, we would seek to enforce the federal district court exclusive forum provision in our amended and restated certificate of incorporation.</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 1B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">Unresolved Staff Comments.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES">Properties.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are located in South San Francisco, California, and comprise approximately 36,754 square feet of space, pursuant to an operating lease that expires in November 2026. This lease includes an option to extend for a further eight years, at market rates that prevail at the time of our election to extend.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that these facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGS">Legal Proceedings.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results of operations, financial condition or cash flows.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Mine Safety Disclosures.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock began trading on the Nasdaq Global Market under the symbol &#8220;RAPT&#8221; on October&#160;31,&#160;2019. Prior to that date, there was no public market for our common stock.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the close of business on March 4, 2022, there were 32 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination regarding the declaration and payment of dividends will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, we may enter into agreements in the future that could contain restrictions on payments of cash dividends.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Price Performance Graph</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a &#8220;smaller reporting company&#8221; as defined by Item 10 of Regulation S-K, we are not required to provide this information.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ite</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">m 6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_RESERVED">[Reserved] </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item_7__Management_s_Discussion_and_Anal">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs, and involve risks and uncertainties. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those discussed in the section titled &#8220;Risk Factors&#8221; included under Part I, Item 1A and elsewhere in this Annual Report. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Annual Report.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing our proprietary drug discovery and development engine, we are developing highly selective small molecules designed to modulate the critical immune responses underlying these diseases. Our two lead drug candidates each target C-C motif chemokine receptor 4 (&#8220;CCR4&#8221;), a drug target that potentially has broad applicability in inflammatory diseases and oncology.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In June 2021, we announced positive topline results from our randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with&#160;moderate-to-severe&#160;atopic dermatitis (AD). After four weeks of treatment, patients with&#160;moderate-to-severe&#160;AD who received RPT193 showed a 36.3% improvement from baseline in the Eczema Area and Severity Index (EASI) score, a standard measure of disease severity, compared to 17.0% in the placebo group. In the&#160;two-week&#160;period following the end of treatment, the RPT193 group showed continued improvement and further separation from placebo with a 53.2% improvement in the EASI score at the&#160;six-week&#160;time point compared to 9.6% in the placebo group. RPT193 was well tolerated in the Phase 1b study. No serious adverse events were reported, and all adverse events reported were mild or moderate in intensity</span><span style="color:#000000;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities and establishing our corporate infrastructure. As a result, we have incurred net losses since inception. As of December 31, 2021, we had an accumulated deficit of $284.0&#160;million. We have incurred net losses of $69.2&#160;million and $52.9&#160;million for the years ended <span style="color:#000000;">December 31</span>, 2021 and 2020, respectively. We do not expect to generate product revenue unless and until we obtain approval for the commercialization of a drug candidate, and we cannot assure you that we will ever generate significant product revenue or profits.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have financed our operations primarily through the sale of equity securities.<span style="font-size:12pt;"> </span>In June 2021, we completed an underwritten public offering (the &#8220;2021 Public Offering&#8221;) of 4,356,060 shares of common stock at a public offering price of $33.00 per share and <span style="color:#000000;">received approximately $134.8 million in net proceeds, after deducting underwriting discounts and other offering-related costs. </span>In February 2020, we completed an underwritten follow-on public offering (&#8220;Follow on Offering&#8221;) of 2,500,000 shares of our common stock issued at an offering price of $30.00 per share and received approximately $69.8 million in net proceeds after deducting underwriting discounts and other offering related costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, we sold 214,971 and 188,700 shares of common stock in &#8220;at the market&#8221; offerings pursuant to a Controlled Equity Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup> Sales Agreement with Cantor Fitzgerald &#38; Co. and Stifel, Nicolaus &#38; Company, Incorporated (the &#8220;ATM Sales Agreement&#8221;), for net proceeds of $4.7 million and $3.8 million, respectively, after deducting commissions and other offering related costs. As of December 31, 2021, there was up to $90.9 million of shares of common stock available for future issuance under the ATM Sales Agreement. As of December 31, 2021, we had cash and cash equivalents and marketable securities of $189.7 million and working capital of $183.4 million. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our planned operations for a period of at least 12 months following the filing date of this report.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur substantial expenditures in the foreseeable future as we expand our pipeline and advance our drug candidates through clinical development, undergo the regulatory approval process and, if our drug candidates are approved, launch commercial activities. Specifically, in the near term, we expect to incur substantial expenses relating to our ongoing and planned clinical trials, the development and validation of our manufacturing processes and other development activities.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until we can generate significant revenue from sales of our drug candidates, if ever, we expect to finance our operations through equity or debt financings or other capital sources, including potential collaborations with other companies, or other strategic transactions. Adequate funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our drug candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties rights to develop or commercialize our drug candidates that we would prefer to retain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Impact of COVID-19 Pandemic</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been impacted and may continue to be impacted by the global pandemic of the disease referred to as COVID-19 and the responses by government entities to combat the pandemic. We continue to monitor the impact of COVID&#8209;19 on all aspects of our business and operations. Both the outbreak of the disease and the actions to slow its spread have had an adverse impact on our operations by, among other things, slowing recruitment in our clinical trials, limiting some of our employees from coming to work at our facility and delaying services from third-party service providers. We have instituted flexible work hours and protocols to protect the health of our employees, which has limited some of our operations. Depending on how long the pandemic continues or if it intensifies, it is<span style="font-size:12pt;color:#000000;"> </span>possible that these or other challenges may have a larger impact on our operations. Additionally, concerns over the economic impact of COVID-19 have caused extreme volatility in financial and other capital markets, which has adversely impacted, and may continue to adversely impact, our stock price and our ability to access capital markets. The situation surrounding COVID-19 remains fluid and we are actively managing our response and assessing potential impacts to our employees and operations, as well as to our financial condition, results of operations and our ability to access capital. The magnitude of any such adverse impact cannot currently be determined due to numerous uncertainties surrounding COVID-19 (refer to Item 1A. Risk Factors for related risks).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Operating Results</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue recognized during the periods presented relate to the Collaboration and License Agreement (the &#8220;Hanmi Agreement&#8221;) that we entered into with Hanmi Pharmaceutical Ltd. (&#8220;Hanmi&#8221;) in December 2019.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense both internal and external research and development costs as such expenses are incurred. We track the external research and development costs incurred for each of our drug candidates. However, we do not track our internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service have been performed rather than when the payment is made.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with the associated agreements. We use information received from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External research and development expenses consist primarily of costs incurred for the development of our drug candidates and include:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs incurred under agreements with CROs, investigative sites and consultants to conduct our clinical trials and preclinical and non-clinical studies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs to acquire, develop and manufacture supplies for clinical trials and other studies, including fees paid to contract manufacturing organizations (&#8220;CMOs&#8221;)&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>costs related to compliance with drug development regulatory requirements.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal research and development costs include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">salaries and related costs, including stock-based compensation and travel expenses, for personnel in our research and development functions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">depreciation and other allocated facility-related and overhead expenses.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially during the next few years as we seek to complete existing and initiate additional clinical trials, pursue regulatory approval of RPT193 and FLX475 and advance other programs into&#160;clinical development.&#160;Over the next few years, we expect our preclinical, clinical and contract manufacturing expenses to increase significantly relative to what we have incurred to date. Predicting the timing or the final cost to complete our clinical program or validation of our manufacturing and supply processes is difficult and delays may occur because of many factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist principally of personnel-related costs including payroll and stock&#8209;based compensation for personnel in executive, finance, human resources, business and corporate development and other administrative functions&#59; professional fees for legal, consulting and accounting services&#59; rent and other facilities costs, depreciation and other general operating expenses not otherwise classified as research and development expenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will increase substantially during the next few years as a result of staff expansion and additional occupancy costs, as well as costs associated with being a public company, including higher professional fees for legal, consulting and accounting services, investor relations costs, higher insurance premiums and other compliance costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents and marketable securities are invested in money market funds, corporate debt securities, commercial paper and U.S. government agency securities. Other income, net, consists primarily of interest earned on our cash and cash equivalents and marketable securities and remeasurement gains and losses on foreign currency transactions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies, Significant Judgments and Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are described in the notes to our consolidated financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our license and collaboration agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue when we transfer promised goods or services to customers or counterparties in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, we perform the following steps: (i) identification of the promised goods or services in the agreement&#59; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement&#59; (iii) measurement of the transaction price, including any constraint on variable consideration&#59; (iv) allocation of the transaction price to performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when (or as) we satisfy each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Licenses<span style="font-style:normal;">: If a license to our intellectual property is determined to be distinct from the other performance obligations identified in an agreement, we will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, we utilize judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments<span style="font-style:normal;">: If an agreement includes event-based or milestone payments, we evaluate whether the events or milestones are considered likely to be achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within our control are not included in the transaction price until they become likely to be achieved.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<span style="font-style:normal;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021 and 2020, deferred revenue was $1.5 million and $5.0 million, respectively, on the consolidated balance sheet related to our license and collaboration agreement with Hanmi. For the years ended December 31, 2021 and 2020, we recognized revenue of $3.8 million and $5.0 million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related costs. We account for non-refundable advance payments for goods or services that will be used in future research and development activities as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses when the related goods have been received or when the service has been performed rather than when the payment is made. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. We expense costs for our clinical trial activities performed by third parties, including CROs and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. We use information we receive from internal personnel and outside service providers to estimate the progress of services performed and the associated clinical trial costs incurred, which have inherent uncertainties and involve significant judgement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation arrangements with employees and non-employees in accordance with ASC 718, <span style="font-style:italic;">Stock Compensation</span>. Stock-based awards issued by us have been primarily stock options with time-based vesting or performance-based vesting. ASC 718 requires the recognition of compensation expense, using a fair value-based method, for costs related to all stock-based awards. To determine the grant-date fair value of stock-based awards with time-based vesting, we utilize the Black-Scholes option pricing model, which is impacted by the fair value of our common stock as well as other variables including, but not limited to, expected term that stock-based awards will remain outstanding, expected common stock price volatility over the term of the stock-based awards, risk-free interest rates and expected dividends. Prior to our initial public offering (&#8220;IPO&#8221;), there had been no public market for our common stock. As such, the estimated fair values of our common stock underlying our stock-based awards were determined at each grant date by our board of directors, with input from management, based on the information known to us on the grant date, including a review of any recent events and their potential impact on the estimated per share fair value of our common stock. Valuations of our common stock were prepared by a third-party valuation firm in accordance with the guidance outlined in the American Institute of Certified Public Accountants Technical Practice Aid, Valuation of Privately Held Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;). Following our IPO, the fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Market as reported on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For stock-based awards with time-based vesting, stock-based compensation is recognized over the period during which an awardee is required to provide services in exchange for the stock-based award, known as the requisite service period (usually the vesting period), on a straight-line basis. For stock-based awards with performance-based vesting, the fair value of the award is recognized as expense when the achievement of the associated performance criteria becomes probable, using an accelerated attribution method. For both time-based and performance-based stock-based awards, stock-based<span style="color:#000000;"> compensation expense is recognized based on the fair value determined on the date of grant. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimates of the fair value of stock-based awards as of the grant date using the Black-Scholes option pricing model are affected by assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation expense is recognized. These inputs are subjective and generally require significant analysis and judgment to develop. These inputs are: </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term<span style="font-style:normal;"> &#8211; The expected term represents the period that our stock-based awards granted is expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). We have very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock-based awards. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility<span style="font-style:normal;"> &#8211; Since we have only recently become a public company and have only a limited trading history for our common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies as well as our historical volatility over a period, where available, equal to the expected term of the stock-based awards. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate<span style="font-style:normal;color:#000000;"> </span>&#8211; <span style="font-style:normal;color:#000000;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock-based awards. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Dividend &#8211; </span><span style="font-style:normal;color:#000000;">We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each purchase under the employee stock purchase plan (&#8220;ESPP&#8221;) is estimated at the beginning of the offering period using the Black-Scholes option pricing model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of our stock options granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially different.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Common Stock Valuations </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO, the grant date fair value of our common stock was determined by our board of directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of our common stock was determined using valuation methodologies that utilize certain assumptions, including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and a discount for lack of marketability (Level 3 inputs). In determining the fair value of our common stock, the methodologies used to estimate our enterprise value were performed using methodologies, approaches and assumptions consistent with the Practice Aid. The methodology to determine the fair value of our common stock included estimating the fair value of the enterprise using a market approach, which estimates our fair value by including an estimation of the value of the business based on guideline public companies under a number of different scenarios. The assumptions used to determine the estimated fair value of our common stock are based on numerous objective and subjective factors, combined with management judgment, including external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry&#59; our stage of development&#59; the rights, preferences and privileges of our convertible preferred stock relative to those of our common stock&#59; the prices at which we sold shares of our convertible preferred stock&#59; our financial condition and operating results, including our levels of available capital resources&#59; the progress of our research and development efforts, our stage of development and business strategy&#59; equity market conditions affecting comparable public companies&#59; general U.S. market conditions&#59; and the lack of marketability of our common stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following our IPO, our board of directors determines the fair value of our common stock based on the closing price of our common stock on the date of grant. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards, and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the accounting standards for uncertain tax positions, we evaluate the recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our total deferred tax assets were $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61.5</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million. Due to our lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal and state tax net operating loss </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">carryforwards </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;NOLs&#8221;). Utilization of NOLs may be limited by the &#8220;ownership change&#8221; rules, as defined in Section 382 of the Internal Revenue Code. Similar</span><span style="color:#000000;"> rules may apply under state tax laws. Our ability to use our remaining NOLs may be further limited if we experience an ownership change as a result of future changes in our stock ownership. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the Years Ended December 31, 2021 and 2020 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the periods indicated (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:23%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.32%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,813</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,042</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,229</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,985</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,485</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,500</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,037</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,771</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,266</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,256</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,766</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,209</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,214</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,995</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,312</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,307</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.32%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,902</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,302</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(990</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.32%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,892</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,312</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.32%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.32%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.81%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*: Percentage not meaningful</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.84%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue for the year ended December 31, 2021 and 2020 was $3.8&#160;million and $5.0 million, respectively, and was entirely related to revenue recognized pursuant to the Hanmi Agreement. <span style="color:#000000;">Revenue pursuant to the Hanmi Agreement is recognized by applying the cost-based input method for the performance obligation over the estimated service period, as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses increased $11.5 million, or 25%, to $57.0 million for the year ended December 31, 2021 from $45.5 million for the year ended December 31, 2020. The increase in research and development expenses was primarily due to an increase of $5.3 million in development expenses relating to FLX475, an increase of $1.8 million in development expenses relating to RPT193, an increase of $1.8 million in personnel and other costs, an increase of $1.5 million in facilities costs, an increase of $0.7 million in stock-based compensation expense and an increase of $0.4 million in laboratory supplies and other expenses. We expect our research and development expenses to increase substantially during the next few years as we seek to complete </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing and initiate additional clinical trials, pursue regulatory approval of RPT193 and FLX475</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> advance other programs into the clinic</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following is a comparison of research and development expenses for the years ended December 31, 2021 and 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">External development expenses:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FLX475</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,520</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RPT193</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,393</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,592</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Programs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,908</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,051</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,753</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,985</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.76%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,485</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously noted, we do not track our own internal research and development costs by drug candidate, as the related efforts and their costs are typically spread across multiple drug candidates and programs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.84%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses increased $3.3 million, or 26%, to $16.0 million for the year ended December 31, 2021 from $12.8 million for the year ended December 31, 2020. The increase was primarily due to an increase of $0.9 million in insurance and corporate fees as a result of being a public company, an increase of $0.9 million in professional fees, an increase of $0.6 million in stock-based compensation expense and increase of $0.9 million in higher personnel and other costs. We expect our general and administrative expenses to increase substantially during the next few years as a result of staff expansion, costs associated with being a public company, including higher insurance premiums, legal and accounting fees and other compliance costs associated with operating a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Income, Net </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net decreased $1.3 million, or 100%, to $5,000 for the year ended December&#160;31, 2021 as compared to the year ended December&#160;31, 2020. The decrease was driven primarily by lower interest income for the year ended December 31, 2021 and remeasurement gains and losses related to foreign currency transactions for the year ended December 31, 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have financed our operations primarily through the sale of equity securities. <span style="color:#000000;">In June 2021, we completed the 2021 Public Offering of 4,356,060 shares of our common stock and </span>received approximately $134.8 million in net proceeds, after deducting underwriting discounts and other offering-related costs. <span style="color:#000000;">In February 2020, we completed the Follow-on Offering of 2,500,000 shares of our common stock and received approximately $69.8 million in net proceeds after deducting underwriting discounts and other offering related costs. During the years ended December 31, 2021 and 2020, we sold 214,971 and 188,700 shares of our common stock in &#8220;at the market&#8221; offerings pursuant to an ATM Sales Agreement, for net proceeds of $4.7 million and $3.8 million, respectively, after deducting commissions and other offering related costs. As of December 31, 2021, there was up to $90.9 million of shares of common stock available for future issuance under the ATM Sales Agreement. </span>We had cash and cash equivalents and marketable securities of $189.7&#160;million and working capital of $183.4&#160;million as of December&#160;31, 2021. <span style="Background-color:#FFFFFF;">Our cash equivalents and marketable securities consist of commercial paper, corporate bonds and U.S. government agency securities. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view towards liquidity and capital preservation. </span>Since inception, we have incurred net losses and negative cash flows from operations. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2021, we had an accumulated deficit of $284.0&#160;million. In addition, we expect to incur substantial costs in order to conduct research and development activities necessary to develop and commercialize </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our drug candidates. Additional capital will be needed to undertake these activities and we intend to raise such capital through the issuance of additional equity or debt, strategic alliances with other companies or other sources of financing. However, if such capital is not available at adequate levels or on acceptable terms, we could be required to significantly reduce operating expenses and delay or reduce the scope of, or eliminate, some of our development programs. We believe our current cash and cash equivalents and marketable securities will be sufficient to fund our anticipated level of operations through at least the next 12 months following the filing date of this report.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will continue to require additional capital to develop our drug candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with other companies, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. We anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, rate of progress and costs of our drug discovery, preclinical development activities, laboratory testing and clinical trials for our drug candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and scope of clinical programs we decide to pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope and costs of manufacturing development and commercial manufacturing activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which we acquire or in-license other drug candidates and technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost, timing and outcome of regulatory review of our drug candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost and timing of establishing sales and marketing capabilities, if any of our drug candidates receive marketing approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish and maintain collaborations on favorable terms, if at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our drug candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs associated with being a public company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost associated with commercializing our drug candidates, if they receive marketing approval.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See&#160;&#8220;Risk Factors&#8221;&#160;for additional risks associated with our substantial capital requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties&#8217; rights to develop or commercialize our drug candidates that we would prefer to retain.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary Consolidated Statements of Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,026</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,491</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(81,347</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,435</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,482</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,461</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net (decrease) increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(891</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,465</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Operating Activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $61.0&#160;million for the year ended December&#160;31, 2021, reflecting a net loss of $69.2&#160;million, partially offset by non-cash charges for primarily depreciation, amortization and stock-based compensation expense totaling $12.5 million and a net cash used by changes in operating assets and liabilities of $4.3 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $40.5 million for the year ended December 31, 2020, reflecting a net loss of $52.9 million, partially offset by non-cash charges for depreciation, amortization and stock-based compensation expense totaling $10.1 million and net cash provided by changes in operating assets and liabilities of $2.3&#160;million. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities was $81.3 million for the year ended December&#160;31, 2021, primarily for the purchase of marketable securities for $164.9 million and purchase of property and equipment of $0.8 million, offset by the proceeds from maturities of marketable securities of $84.4 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in investing activities was $87.4&#160;million for the year ended December&#160;31, 2020, primarily for the purchase of marketable securities for $139.3 million and purchase of property and equipment of $0.4 million, offset by the proceeds from maturities of marketable securities of $52.3 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financing Activities </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $141.5 million for the year ended December 31, 2021 primarily from the $134.8 million in net proceeds from our 2021 Public Offering, $4.7 million in net proceeds from the sale of shares under the ATM Sales Agreement and $2.0 million in net proceeds from our employee stock plans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $75.5 million for the year ended December 31, 2020, primarily from the receipt of $69.8 million in net proceeds from our February 2020 follow-on offering and $3.8 million in net proceeds from sales of common stock under our ATM Sales Agreement<span style="color:#000000;"> and $1.9 million in net proceeds from our employee stock plans</span>. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Material Cash Requirements</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Our material cash requirements in the short- and long-term consist of the following operational expenditures, a portion of which contain contractual or other obligations. </span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.77%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Operating expenditures</span><span style="Background-color:#FFFFFF;font-weight:normal;">. Our primary uses of cash and operating expenses relate to paying employees and consultants, administering clinical trials and providing technology and facility infrastructure to support our operations. Our research and development expenses in 2021 were $57.0&#160;million, and we expect to increase our investment in research and development expenses in 2022. Our general and administrative expenses were $16.0&#160;million in 2021, and we expect to increase our general and administrative expenses to support our business growth in 2022. On a long-term basis, we manage future cash requirements relative to our long-term business plans.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:5.77%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Operating costs also relate to our</span>&#160;building leases for our office and laboratory facilities expiring in 2022 through 2026 that contain rate escalations and options for us to extend the leases. Our future minimum lease payments as of December 31, 2021 were $10.7 million<span style="Background-color:#FFFFFF;">. Refer to Note 6 in the Notes to Financial Statements in Item 8 for further detail of our lease obligations.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JOBS Act Accounting Election</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Jumpstart Our Business Startups Act of 2012 (the&#160;&#8220;JOBS Act&#8221;), permits an&#160;&#8220;emerging growth company&#8221;&#160;such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to elect the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will remain an emerging growth company until the earliest of (1) the last day of our first fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million of the prior June 30th and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 7A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLO1">Quantitative and Qualitative Disclosures About Market Risk.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide this information.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 8. </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">Financial Statements and Supplementary Data.</p></td></tr></table></div>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.13%;"></td>
<td style="width:1.28%;"></td>
<td style="width:85.9%;"></td>
<td style="width:1.28%;"></td>
<td style="width:6.41%;"></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_AC"><span style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</span></a><span style="text-decoration:underline;"> (PCAOB ID:<ix:nonNumeric id="F_000034" name="dei:AuditorFirmId" contextRef="C_0001673772_20210101_20211231">42</ix:nonNumeric>)</span><span style="text-decoration:none;color:#auto;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Consolidated Balance Sheets</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Loss</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQI"><span style="text-decoration:underline;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_AC">Report of Independent Registered Public Accounting Firm</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of RAPT Therapeutics, Inc.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of RAPT Therapeutics, Inc. (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; /s/ <ix:nonNumeric id="F_000035" name="dei:AuditorName" contextRef="C_0001673772_20210101_20211231">Ernst&#160;&#38; Young LLP</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000036" name="dei:AuditorLocation" contextRef="C_0001673772_20210101_20211231">Redwood City, California</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">CONSOLIDATED BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data)</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-right:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.68%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%; border-top:solid 0.75pt #FFFFFF; border-bottom:solid 0.75pt #FFFFFF; border-left:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">165,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">192,973</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AssetsCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">115,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,922</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001673772_20201231" decimals="-3" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Assets" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">198,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:Assets" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,016</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" scale="3">254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" scale="3">328</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,742</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001673772_20211231" decimals="-3" scale="3">511</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:DeferredRevenueNoncurrent" contextRef="C_0001673772_20201231" decimals="-3" scale="3">863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,185</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:Liabilities" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:Liabilities" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,790</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments <span style="font-style:italic;">(see note 6)</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000067">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000068">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000083" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001673772_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000084" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001673772_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="U_xbrlishares" id="F_000085" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001673772_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000086" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001673772_20201231" decimals="INF" format="ixt:numdotdecimal">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000087" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001673772_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000088" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001673772_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001673772_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001673772_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000069">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000070">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000091" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001673772_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000092" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001673772_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001673772_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001673772_20201231" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001673772_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001673772_20211231" decimals="INF" format="ixt:numdotdecimal">29,555,119</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001673772_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001673772_20201231" decimals="INF" format="ixt:numdotdecimal">24,773,361</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021 and 2020, respectively</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:CommonStockValue" contextRef="C_0001673772_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:CommonStockValue" contextRef="C_0001673772_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">470,629</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">319,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001673772_20211231" decimals="-3" sign="-" scale="3">206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001673772_20201231" decimals="-3" sign="-" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001673772_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">284,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001673772_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">214,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.52%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">198,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,969</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000099" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000100" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">45,485</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:OperatingExpenses" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:OperatingExpenses" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">58,256</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">53,214</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss before taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Foreign currency translation gain (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" scale="3">249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Unrealized gain (loss) on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" scale="3">287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Total comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,233</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">53,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000122" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="C_0001673772_20210101_20211231" decimals="2" sign="-">2.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000123" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="C_0001673772_20200101_20201231" decimals="2" sign="-">2.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average number of shares used in computing net loss per</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000124" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001673772_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,390,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001673772_20200101_20201231" decimals="0" format="ixt:numdotdecimal">24,134,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQI">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">21,833,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">235,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">161,950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000132" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of common stock in "at the market" offerings, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000135" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">188,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock from employee stock plans</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">251,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" scale="3">249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" scale="3">52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000149" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">24,773,361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">319,196</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">214,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" scale="3">177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">104,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000155" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">4,356,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of common stock in "at the market" offerings, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">214,971</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuances of common stock from employee stock plans</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">210,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="rapt:StockIssuedDuringPeriodValueEmployeeStockPlans" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation gain</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" scale="3">287</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000173" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">29,555,119</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">470,629</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">284,046</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231" decimals="-3" sign="-" scale="3">206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">CONSOLIDATED STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:ProfitLoss" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProfitLoss" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium on marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:InvestmentIncomeAmortizationOfPremium" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:ShareBasedCompensation" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:ShareBasedCompensation" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on disposal of capital equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain (loss) on foreign currency translation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable, accrued expenses, and other current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,432</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="rapt:IncreaseDecreaseInDeferredRentNoncurrent" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="rapt:IncreaseDecreaseInDeferredRentNoncurrent" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">61,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">40,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">164,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">139,334</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of marketable securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">84,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,297</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">755</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">81,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from public offerings, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">73,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of common stock in "at the market" offerings, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuances of common stock under employee stock plans</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,022</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:ProceedsFromStockPlans" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">141,482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" scale="3">891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001673772_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">77,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,918</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of non-cash investing and financing information</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Offering costs included in accounts payable and accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.3%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes to consolidated financial statements.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><ix:nonNumeric id="F_000230" name="us-gaap:NatureOfOperations" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000230_dcnt_8add18d6-8709-4a3f-a1d2-08fde1eec10c">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of the Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc. (<span style="color:#000000;">&#8220;</span>RAPT<span style="color:#000000;">&#8221;</span> or the <span style="color:#000000;">&#8220;</span>Company<span style="color:#000000;">&#8221;</span>) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Financings</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In June 2021, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 16, 2020, the Company completed an underwritten public offering (&#8220;2021 Public Offering&#8221;) of&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000279" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630" decimals="INF" format="ixt:numdotdecimal">4,356,060</ix:nonFraction>&#160;shares of common stock, including&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000280" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630" decimals="INF" format="ixt:numdotdecimal">568,181</ix:nonFraction>&#160;shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000282" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210630" decimals="2">33.00</ix:nonFraction>&#160;per share. The Company received approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630" decimals="-5" scale="6">134.8</ix:nonFraction>&#160;million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed an underwritten follow-on public offering (&#8220;Follow&#8209;on Offering&#8221;) of <ix:nonFraction unitRef="U_xbrlishares" id="F_000278" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction> shares of its common stock issued at an offering price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000281" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200229" decimals="2">30.00</ix:nonFraction> per share. The Follow-on Offering generated approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229" decimals="-5" scale="6">69.8</ix:nonFraction> million in net proceeds after deducting underwriting discounts and other offering related costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering (a) up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="rapt:SecuritiesReservedForFutureIssuance" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130" decimals="-6" scale="6">350</ix:nonFraction>&#160;million of the Company&#8217;s securities, including up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="rapt:CommonStockCapitalValueReservedForFutureIssuance" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130" decimals="-6" scale="6">100</ix:nonFraction> million of shares of common stock that may be offered and sold from time to time in one or more &#8220;at-the-market&#8221; offerings pursuant to a Controlled Equity Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup>&#160;Sales Agreement (&#8220;ATM Sales Agreement&#8221;) with Cantor Fitzgerald &#38; Co. and Stifel, Nicolaus &#38; Company, Incorporated, and (b) up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000287" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130" decimals="INF" format="ixt:numdotdecimal">1,000,000</ix:nonFraction> shares of common stock that certain selling stockholders may offer and sell from time to time. During the year ended December 31, 2021, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000288" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">214,971</ix:nonFraction> shares under the ATM Sales Agreement resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231" decimals="-5" scale="6">4.7</ix:nonFraction> million after deducting underwriting discounts and commissions and other offering related costs. During the year ended December 31, 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000289" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">188,700</ix:nonFraction> shares under the ATM Sales Agreement resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231" decimals="-5" scale="6">3.8</ix:nonFraction> million after deducting underwriting discounts and commissions and other offering related costs. As of December 31, 2021, there was up to $<ix:nonFraction unitRef="U_xbrlishares" id="F_000292" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20211231" decimals="-5" scale="6">90.9</ix:nonFraction> million of shares of common stock available for future issuance under the ATM Sales Agreement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Management Plans </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2021, the Company incurred a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20210101_20211231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">69.2</ix:nonFraction> million and used $<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001673772_20210101_20211231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">61.0</ix:nonFraction> million of cash in operations. At December 31, 2021, the Company had cash and cash equivalents and marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001673772_20211231" decimals="-5" scale="6">189.7</ix:nonFraction>&#160;million and working capital of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="rapt:WorkingCapital" contextRef="C_0001673772_20211231" decimals="-5" scale="6">183.4</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#8217;s current cash and cash equivalents and marketable securities </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000230_dcnt_8add18d6-8709-4a3f-a1d2-08fde1eec10c">
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will provide sufficient funds to enable the Company to meet its obligations for at least </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months from the filing date of this report.</span></p></ix:continuation><ix:nonNumeric id="F_000231" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000231_dcnt_42aa2ecd-d385-4e48-9083-64dca7874684">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000241" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000242" name="us-gaap:UseOfEstimates" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions. </p></ix:nonNumeric><ix:nonNumeric id="F_000243" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by <ix:nonFraction unitRef="U_raptInstitution" id="F_000297" name="rapt:NumberOfFinancialInstitution" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</p></ix:nonNumeric><ix:nonNumeric id="F_000244" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</p></ix:nonNumeric><ix:nonNumeric id="F_000245" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000231_dcnt_42aa2ecd-d385-4e48-9083-64dca7874684" continuedAt="F_000231_dcnt_b184c642-fd87-41e5-a8e4-ba62b2f3b8e2"><ix:nonNumeric id="F_000246" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. </p></ix:nonNumeric><ix:nonNumeric id="F_000247" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities primarily consist of commercial paper, corporate bonds and <span style="Background-color:#FFFFFF;color:#000000;">U.S. government agency securities</span>. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the consolidated statements of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000248" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally <ix:nonNumeric id="F_000298" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20210101_20211231" format="ixt-sec:durwordsen" continuedAt="C_a84bc045-0bff-4459-afac-d0f96c74f4b0">three</ix:nonNumeric> to <ix:nonNumeric id="F_000299" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">five<ix:continuation id="C_a84bc045-0bff-4459-afac-d0f96c74f4b0"> years</ix:continuation></ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</p></ix:nonNumeric><ix:nonNumeric id="F_000249" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2021 and 2020, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" contextRef="C_0001673772_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record any impairment losses on long-lived assets.</p></ix:nonNumeric><ix:nonNumeric id="F_000250" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space and laboratory facilities under non-cancelable operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the lease. Funding of leasehold improvements by the Company&#8217;s landlord is accounted for as a tenant improvement allowance and recorded as current and non-current deferred rent liabilities and amortized on a straight-line basis as a reduction of rent expense over the term of the lease.</p></ix:nonNumeric>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000231_dcnt_b184c642-fd87-41e5-a8e4-ba62b2f3b8e2" continuedAt="F_000231_dcnt_378f81fb-514d-4307-b663-f1aae74c48ee">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000251" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaborative agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement&#59; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement&#59; (iii) measurement of the transaction price, including any constraint on variable consideration&#59; (iv) allocation of the transaction price to performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Licenses<span style="font-style:normal;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments<span style="font-style:normal;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<span style="font-style:normal;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p></ix:nonNumeric><ix:nonNumeric id="F_000252" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000231_dcnt_378f81fb-514d-4307-b663-f1aae74c48ee" continuedAt="F_000231_dcnt_f2db27ea-d641-4021-b072-4a12b8472182"><ix:nonNumeric id="F_000253" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant for the period prior to the IPO. The fair value of restricted stock awards granted after the IPO is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</p></ix:nonNumeric><ix:nonNumeric id="F_000254" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#8217;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</p></ix:nonNumeric><ix:nonNumeric id="F_000255" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</p></ix:nonNumeric><ix:nonNumeric id="F_000256" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000231_dcnt_f2db27ea-d641-4021-b072-4a12b8472182"><ix:nonNumeric id="F_000257" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric id="F_000258" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</p></ix:nonNumeric><ix:nonNumeric id="F_000259" name="rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU&#160;No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases</span>. ASU&#160;2016-02&#160;requires lessees to record most leases on their balance sheet while recognizing expense in a manner similar to the accounting under the original lease guidance (Topic 840). ASU&#160;2016&#8209;02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a&#160;right-to-use&#160;asset for the right to use the underlying asset for the lease term. ASU&#160;2016-02 is effective for the Company&#8217;s fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company intends to adopt the new standard as of January 1, 2022. <span style="color:#000000;">The adoption of the new standard will have a material impact on the Company&#8217;s consolidated balance sheet as of January 1, 2022, as we will recognize the right-of-use assets and liabilities for our operating leases. We expect to record lease liabilities of approximately&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231" decimals="-6" scale="6">8</ix:nonFraction> - $<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231" decimals="-6" scale="6">9</ix:nonFraction> million&#160;based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We also expect to record corresponding right-of-use assets of approximately&#160;$<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231" decimals="-6" scale="6">6</ix:nonFraction> - <ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231" decimals="-6" scale="6">7</ix:nonFraction> million, based on the operating lease liabilities adjusted for unamortized deferred rent and lease incentives. The Company, however, does not expect a material impact to its consolidated statements of operations and consolidated statements of cash flow.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. ASU 2016-13 amended guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span>, to increase awareness of the amendments and to expedite improvements to Topic 326. In May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses, Topic 326</span>, providing companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13&#59; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU&#160;No.&#160;2019-10, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</span> and ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses</span>, which defer the effective date of the new credit loss standard. ASU&#160;2016-13 and its related amendments are effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company is currently assessing the timing of adoption of ASU 2016-13 and the impact that adoption will have on its consolidated financial statements and related disclosures<span style="color:#000000;">.</span></p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000232" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000232_dcnt_fcdb9025-2041-42bc-a60c-9c790671c002">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000232_dcnt_fcdb9025-2041-42bc-a60c-9c790671c002" continuedAt="F_000232_dcnt_76b2883b-7edf-42af-9b9e-f12b9dd2b302">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalents, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketable securities, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounts payable and accrued </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that approximate fair value due to their relatively short maturities. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date&#59; </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities&#59; and </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-size:10pt;font-family:Calibri;">To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and <span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;">U.S. government agency securities </span>using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.<span style="font-family:Times New Roman;"> </span></p><ix:nonNumeric id="F_000260" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000260_dcnt_cc02c27b-3839-4770-a80f-0d2fa4cf338f">
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,658</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,565</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,532</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" scale="3">75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,669</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_20211231" decimals="-3" scale="3">235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,285</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000232_dcnt_76b2883b-7edf-42af-9b9e-f12b9dd2b302"><ix:continuation id="F_000260_dcnt_cc02c27b-3839-4770-a80f-0d2fa4cf338f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,212</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,368</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,047</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001673772_20201231" decimals="-3" scale="3">53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001673772_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December&#160;31, 2021 were temporary in nature.</span></p><ix:nonNumeric id="F_000261" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of December 31, 2021 (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than one year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">132,804</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in more than one year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,285</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000233" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Property and Equipment </p><ix:nonNumeric id="F_000262" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,966</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231" decimals="-3" scale="3">482</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231" decimals="-3" scale="3">447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231" decimals="-3" scale="3">357</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" scale="3">357</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,064</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,082</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expenses were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001673772_20210101_20211231" decimals="-5" scale="6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:DepreciationAndAmortization" contextRef="C_0001673772_20200101_20201231" decimals="-5" scale="6">1.1</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000234" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued Expenses </p><ix:nonNumeric id="F_000263" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="rapt:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="rapt:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:WorkersCompensationLiabilityCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001673772_20211231" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001673772_20201231" decimals="-3" scale="3">129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" scale="3">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000368" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" scale="3">263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,935</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000235" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Commitments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, the Company entered into an operating lease for <ix:nonFraction unitRef="U_utrsqft" id="F_000371" name="rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" contextRef="C_0001673772_srtStatementGeographicalAxis_raptSouthSanFranciscoAndCaliforniaMember_20150531" decimals="INF" format="ixt:numdotdecimal">30,376</ix:nonFraction> square feet of laboratory and office facilities in South San Francisco, California, which expires in <ix:nonNumeric id="F_000372" name="rapt:OperatingLeaseExpirationYear" contextRef="C_0001673772_20150501_20150531" format="ixt:datemonthyearen">May 2022</ix:nonNumeric>. In April 2018, the Company amended the lease agreement to include an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000373" name="rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" contextRef="C_0001673772_20180430" decimals="INF" format="ixt:numdotdecimal">6,378</ix:nonFraction> square feet of laboratory and office space increasing the total leased premises to <ix:nonFraction unitRef="U_utrsqft" id="F_000374" name="rapt:IncreasedAreaOfLeasedPremises" contextRef="C_0001673772_20180430" decimals="INF" format="ixt:numdotdecimal">36,754</ix:nonFraction> square feet. The lease amendment extended the lease term to <ix:nonNumeric id="F_000375" name="rapt:LesseeOperatingLeaseExtendedLeaseTerm" contextRef="C_0001673772_20180401_20180430" format="ixt:datemonthyearen">November 2026</ix:nonNumeric> and contained scheduled rent increases over the lease term and an option for the Company to extend the lease for an additional <span style="-sec-ix-hidden:F_000377">five-year</span> term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an agreement to sublease its facility lease of <ix:nonFraction unitRef="U_utrsqft" id="F_000378" name="rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" contextRef="C_0001673772_20190228" decimals="INF" format="ixt:numdotdecimal">6,378</ix:nonFraction> square feet of laboratory and office space, which terminated in <ix:nonNumeric id="F_000379" name="rapt:LeaseTerminationMonthAndYear" contextRef="C_0001673772_20190201_20190228" format="ixt:datemonthyearen">July 2020</ix:nonNumeric>.</p><ix:nonNumeric id="F_000264" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum non-cancelable lease payments, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,037</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the lease agreement provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. Rent expense includes certain monthly charges that do not represent non-cancelable obligations, as defined. These costs are determined based on actual charges incurred. In addition, <span style="color:#000000;">tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001673772_20210101_20211231" decimals="-5" scale="6">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001673772_20200101_20201231" decimals="-5" scale="6">2.1</ix:nonFraction> million in the years ended December 31, 2021 and 2020, respectively. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and <ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:LossContingencyAccrualPayments" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:LossContingencyAccrualPayments" contextRef="C_0001673772_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> contingency losses were accrued at either December 31, 2021 or 2020.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000236" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Collaboration Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Hanmi</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (&#8220;Hanmi Agreement&#8221;),<span style="Background-color:#FFFFFF;"> pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#8217;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#8220;Hanmi Territory&#8221;), and certain sublicense</span> rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="rapt:UpfrontMilestonePayment" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million, which consisted of an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="rapt:UpfrontFees" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million and a development milestone payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="rapt:DevelopmentMilestonePayment" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200430" decimals="-5" scale="6">6.0</ix:nonFraction>&#160;million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="INF" scale="6">108.0</ix:nonFraction> million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) </span>the exclusive development, manufacturing and commercialization license in the Hanmi Territory&#59; (2) the transfer of know-how, technology, research data and information, and any improvements in technology&#59; (3) the obligation to participate in the joint steering committee and appoint an alliance manager&#59; (4) <span style="color:#000000;">the responsibility to complete certain Phase 2 clinical trials&#59; and (5) the supply of FLX475 for use in Hanmi&#8217;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the transaction price as of December 31, 2019 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="rapt:UpfrontMilestonePayment" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million, which consisted of the upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="rapt:UpfrontFees" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million and an unconstrained development milestone payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="rapt:UnconstrainedDevelopmentMilestonePayment" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">6.0</ix:nonFraction>&#160;million. In December 2020, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="rapt:UnconstrainedDevelopmentMilestonePayment" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20201231" decimals="-5" scale="6">0.4</ix:nonFraction> million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#8217;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20210101_20211231" decimals="-5" scale="6">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">5.0</ix:nonFraction> million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of December 31, 2021, deferred revenue related to the Hanmi Agreement was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:DeferredRevenue" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:DeferredRevenue" contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231" decimals="-5" scale="6">1.5</ix:nonFraction></ix:nonFraction> million and is expected to be recognized over the over the remaining period of the Company&#8217;s Phase&#160;1/2 clinical trial of FLX475.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Collaboration and Supply Agreement with Merck</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000237" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Common Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000402" name="us-gaap:CommonStockVotingRights" contextRef="C_0001673772_20210101_20211231">The holders of the Company&#8217;s common stock have <ix:nonFraction unitRef="U_raptvote" id="F_000403" name="rapt:CommonStockNumberOfVotesPerShare" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> vote for each share of common stock held by them</ix:nonNumeric>. Holders of shares of the Company&#8217;s common stock are entitled to dividends when, as and if declared by the board of directors. <ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:DividendsCommonStock" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:DividendsCommonStock" contextRef="C_0001673772_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction> dividends had been declared as of December 31, 2021 or December 31, 2020.</p><ix:nonNumeric id="F_000265" name="rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows: </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000406" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000407" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,481,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000408" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">40,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000409" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">56,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000410" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,688,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000411" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,415,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the 2019 Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000412" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">316,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000413" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">153,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000414" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_20211231" decimals="INF" format="ixt:numdotdecimal">5,070,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000415" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001673772_20201231" decimals="INF" format="ixt:numdotdecimal">4,106,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000238" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000238_dcnt_09271cdf-05ce-4ccc-922e-eabaafe57f07">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the consummation of the IPO in November 2019, the Company&#8217;s board of directors adopted the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221; and collectively with the 2015 Plan, the &#8220;Option Plans&#8221;). Upon the effectiveness of the 2019 Plan, the Company&#8217;s 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2021, the Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,688,372</ix:nonFraction> shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the Company&#8217;s 2019 Plan will automatically increase on January 1 of each year beginning January 1, 2020 by a number equal to (i) <ix:nonFraction unitRef="U_xbrlipure" id="F_000417" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenStockPlanMember_20211231" decimals="2" scale="-2">4</ix:nonFraction>% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#8217;s board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Option Plans provided for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over <ix:nonNumeric id="F_000418" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric id="F_000419" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant. As a private company, the estimated fair value of the Company&#8217;s underlying common stock was determined by the board of directors. Following the Company&#8217;s IPO in November 2019 the fair value of the Company&#8217;s common stock is based on the closing price of its common stock on the date of grant.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The Company reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000420" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction> shares of common stock pursuant to purchase rights to be granted to the Company&#8217;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) <ix:nonFraction unitRef="U_xbrlipure" id="F_000422" name="rapt:PercentageOfIncreaseInSharesReservedForIssuance" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031" decimals="3" scale="-2">1.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) <ix:nonFraction unitRef="U_xbrlishares" id="F_000423" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction> shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, 2021, an additional <ix:nonFraction unitRef="U_xbrlishares" id="F_000421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101" decimals="INF" format="ixt:numdotdecimal">240,336</ix:nonFraction> shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000238_dcnt_09271cdf-05ce-4ccc-922e-eabaafe57f07" continuedAt="F_000238_dcnt_169dba75-929b-41a6-a014-06b0ef4f0d8f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed <ix:nonFraction unitRef="U_xbrlipure" id="F_000424" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031" decimals="INF" scale="-2">15</ix:nonFraction>% of each employee&#8217;s compensation. The 2019 ESPP generally provides for a <ix:nonNumeric id="F_000425" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" format="ixt-sec:durmonth">24</ix:nonNumeric>-month offering period, which includes four <span style="-sec-ix-hidden:F_000426">six-month</span> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at <ix:nonFraction unitRef="U_xbrlipure" id="F_000427" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031" decimals="INF" scale="-2">85</ix:nonFraction>% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended December 31, 2021 and 2020, employees purchased <ix:nonFraction unitRef="U_xbrlishares" id="F_000430" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">76,424</ix:nonFraction> shares at weighted average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20211231" decimals="2">10.80</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000431" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">87,325</ix:nonFraction> shares at a weighted average exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000433" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231" decimals="2">10.27</ix:nonFraction>, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231" decimals="-5" scale="6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="-5" scale="6">2.7</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively.</p><ix:nonNumeric id="F_000266" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the Options Plan is set forth below for the year ended December 31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,481,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231" decimals="2">16.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000448">8.36</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000435" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">794,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000442" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="2">21.62</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000436" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">120,178</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000443" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="2">9.88</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000437" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">130,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000444" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231" decimals="2">21.30</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000438" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000445" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="2">18.33</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000449">8.04</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,417</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2021</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000439" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000446" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="2">18.33</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000450">8.04</span></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,417</ix:nonFraction></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">1,028,650</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000447" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="2">14.75</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000451">7.41</span></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,142</ix:nonFraction></p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock, as determined by the board of directors, as of December 31, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options granted in the years ended December 31, 2021 and 2020 had a weighted average per share grant-date fair value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001673772_20210101_20211231" decimals="2">15.04</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001673772_20200101_20201231" decimals="2">24.57</ix:nonFraction>, respectively, and a total grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" contextRef="C_0001673772_20211231" decimals="-5" scale="6">11.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" contextRef="C_0001673772_20201231" decimals="-5" scale="6">8.7</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001673772_20210101_20211231" decimals="-5" scale="6">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001673772_20200101_20201231" decimals="-5" scale="6">2.4</ix:nonFraction> million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate fair value of options that vested in the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001673772_20210101_20211231" decimals="-5" scale="6">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001673772_20200101_20201231" decimals="-5" scale="6">5.4</ix:nonFraction>&#160;million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted <span style="color:#000000;">Stock Units</span></p><ix:nonNumeric id="F_000267" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended December 31, 2021:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000464" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">56,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000468" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231" decimals="2">44.66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000465" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">14,125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000469" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231" decimals="2">44.66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000466" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000470" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231" decimals="2">44.66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000467" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">40,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000471" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231" decimals="2">44.66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000238_dcnt_169dba75-929b-41a6-a014-06b0ef4f0d8f" continuedAt="F_000238_dcnt_70f8f711-ee01-4a59-8be2-57f5b112172f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee stock option valuation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the grant date fair value of the shares of common stock underlying stock options was determined by the Company&#8217;s board of directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of common stock was determined using valuation methodologies by considering a number of objective and subjective factors including important developments in the Company&#8217;s operations, valuations performed by independent third parties, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies and the lack of liquidity of the Company&#8217;s common stock, among other factors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">zero</ix:nonFraction>. </p><ix:nonNumeric id="F_000268" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20210101_20211231" escape="true" continuedAt="F_000268_dcnt_abaa4dd4-cc63-4cc1-889c-99fc9f600108">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended December 31, 2021 and 2020, using the Black-Scholes option pricing model, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">3.93 - 6.05</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.19 - 6.07</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000477">81.0%&#160;-&#160;86.9%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">84.0%&#160;-&#160;87.0%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000481">0.55% - 1.26%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">0.28% - 1.43%</span></p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000238_dcnt_70f8f711-ee01-4a59-8be2-57f5b112172f"><ix:continuation id="F_000268_dcnt_abaa4dd4-cc63-4cc1-889c-99fc9f600108">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-style:italic;color:#000000;">Employee stock purchase plan</span></p><ix:nonNumeric id="F_000269" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000485">0.25 - 2.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000486">0.25 - 2.00</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.3% - 92.9%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000489" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231" decimals="INF" scale="-2">84.0</ix:nonFraction>%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000492">0.05% - 1.55%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000493">0.11% - 1.57%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Early exercise of stock options </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the 2015 Plan permitted option holders to exercise stock options before they are vested, subject to certain limitations. Such unvested shares were subject to repurchase by the Company at the original exercise price in the event the option holder&#8217;s service to the Company was terminated either voluntarily or involuntarily. As a result of early exercises under the 2015 Plan, approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000496" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231" decimals="INF">0</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000497" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">3,000</ix:nonFraction> shares were subject to repurchase as of December 31, 2021 and 2020, respectively. The Company treats cash received from the exercise of unvested options as a refundable deposit and classifies such amounts as a liability in its balance sheet. As of December 31, 2021 and 2020, the Company included cash received for the early exercise of unvested options of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231" decimals="-3" scale="3">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,000</ix:nonFraction>, respectively, in other current liabilities. Amounts included in liabilities were transferred into common stock and additional paid-in capital as the shares vested, which was generally over a period of <ix:nonNumeric id="F_000500" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20210101_20211231" format="ixt-sec:durmonth">48</ix:nonNumeric> months.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense </p><ix:nonNumeric id="F_000270" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,642</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,952</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001673772_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:2pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001673772_20211231" decimals="-5" scale="6">15.7</ix:nonFraction> million. This unrecognized stock-based compensation cost is expected to be recognized over <span><span style="color:#000000;"><ix:nonNumeric id="F_000508" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001673772_20210101_20211231" format="ixt-sec:duryear">2.6</ix:nonNumeric></span> years</span>.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000239" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true" continuedAt="F_000239_dcnt_9c9c24dd-5763-4ec5-8746-384dff1dd9e4">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p><ix:nonNumeric id="F_000271" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">66,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">49,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">51,902</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000239_dcnt_9c9c24dd-5763-4ec5-8746-384dff1dd9e4" continuedAt="F_000239_dcnt_efc47c3b-3618-4191-8ea4-b61fe283b1ab">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000272" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the provision for income taxes related to Korean withholding taxes on the near-term milestone payment the Company received pursuant to the Hanmi Agreement are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000273" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000517" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001673772_20210101_20211231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000518" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001673772_20200101_20201231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000519" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001673772_20210101_20211231" decimals="4" sign="-" scale="-2">0.76</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000520" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001673772_20200101_20201231" decimals="4" sign="-" scale="-2">0.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000521" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001673772_20210101_20211231" decimals="4" scale="-2">2.39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000522" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="C_0001673772_20200101_20201231" decimals="4" scale="-2">2.83</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign losses not benefited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000523" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" contextRef="C_0001673772_20210101_20211231" decimals="4" sign="-" scale="-2">2.14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding taxes, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000524" name="rapt:EffectiveIncomeTaxRateReconciliationWithholdingTaxes" contextRef="C_0001673772_20200101_20201231" decimals="4" sign="-" scale="-2">1.51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000525" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001673772_20210101_20211231" decimals="4" sign="-" scale="-2">20.86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000526" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001673772_20200101_20201231" decimals="4" sign="-" scale="-2">23.99</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000527" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001673772_20210101_20211231" decimals="4" scale="-2">0.37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000528" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001673772_20200101_20201231" decimals="4" scale="-2">0.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000529" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001673772_20200101_20201231" decimals="4" sign="-" scale="-2">1.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </p><ix:nonNumeric id="F_000274" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,665</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state research and development tax credits</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and reserves</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,644</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,331</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,522</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,488</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization" contextRef="C_0001673772_20211231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization" contextRef="C_0001673772_20201231" decimals="-3" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001673772_20211231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001673772_20201231" decimals="-3" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001673772_20210101_20211231" decimals="-5" scale="6">14.4</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001673772_20200101_20201231" decimals="-5" scale="6">12.5</ix:nonFraction> million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is mainly related to the increase in net operating loss carryforwards incurred during the respective taxable years. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000239_dcnt_efc47c3b-3618-4191-8ea4-b61fe283b1ab" continuedAt="F_000239_dcnt_ae6ddd1b-026f-47eb-a16f-6f7cd83ca454">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">233.1</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">177.2</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are carried forward indefinitely, while all others</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000552" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2035</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> state net operating loss carryforwards of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">12.1</ix:nonFraction></ix:nonFraction></span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which begin to expire in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000555" name="rapt:OperatingLossCarryforwardsExpirationBeginningYear" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2035</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and are available to offset future taxable income. As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research and development tax credit carryforwards of approximately</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-5" scale="6">6.1</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">4.8</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Company had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state research and development tax credit carryforwards of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231" decimals="-5" scale="6">5.5</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">4.3</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Moreover, as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded federal and state reserves of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="rapt:UncertainTaxPositionsReserves" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="rapt:UncertainTaxPositionsReserves" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">1.5</ix:nonFraction></ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="rapt:UncertainTaxPositions" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="rapt:UncertainTaxPositions" contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">1.4</ix:nonFraction></ix:nonFraction></span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The tax relief measures under the CARES Act for businesses include a five-year net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act did not have a material effect on the realizability of deferred income tax assets or tax expense in 2021. The Company claimed employee retention tax credits in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="rapt:EmployeeRetentionTaxCredits" contextRef="C_0001673772_us-gaapUnusualRiskOrUncertaintyByNatureAxis_raptCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231" decimals="-5" scale="6">0.4</ix:nonFraction> million for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#8217;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite&#59; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#8220;SB 113&#8221; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#8217;s expected loss position in the current year, the new legislations will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods..</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50&#160;percent likely of being realized upon effective settlement.</p><ix:nonNumeric id="F_000275" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed for both US and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001673772_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,747</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to prior years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="C_0001673772_20210101_20211231" decimals="-3" scale="3">807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001673772_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001673772_20200101_20201231" decimals="-3" scale="3">544</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001673772_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001673772_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000239_dcnt_ae6ddd1b-026f-47eb-a16f-6f7cd83ca454">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="C_0001673772_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> interest expense or penalties related to unrecognized tax benefits through December&#160;31,&#160;2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</p></ix:continuation><ix:nonNumeric id="F_000240" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss Per Share </p><ix:nonNumeric id="F_000276" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended December 31, 2021 and 2020 (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">69,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:NetIncomeLoss" contextRef="C_0001673772_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">52,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000575" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_0001673772_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,390,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000576" name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="C_0001673772_20200101_20201231" decimals="0" format="ixt:numdotdecimal">24,164,828</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested early</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; exercised common shares subject to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; repurchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000577" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEarlyExercisedStockMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">30,523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000578" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001673772_20210101_20211231" decimals="0" format="ixt:numdotdecimal">27,390,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000579" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001673772_20200101_20201231" decimals="0" format="ixt:numdotdecimal">24,134,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000580" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001673772_20210101_20211231" decimals="2" sign="-">2.53</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000581" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001673772_20200101_20201231" decimals="2" sign="-">2.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000277" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001673772_20210101_20211231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding under the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Equity Incentive Plan and 2015 Stock Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000582" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,024,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000583" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,481,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated shares issuable under the 2019 ESPP</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000584" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">6,592</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000585" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">15,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs subject to future vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000586" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20210101_20211231" decimals="0" format="ixt:numdotdecimal">40,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000587" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">56,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000588" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_20210101_20211231" decimals="0" format="ixt:numdotdecimal">2,071,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000589" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001673772_20200101_20201231" decimals="0" format="ixt:numdotdecimal">1,553,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES">Controls and Procedures.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021, the end of the period covered by this Annual Report on Form 10-K. Management&#8217;s assessment of internal control over financial reporting was conducted using the criteria defined in the <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets&#59; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors&#59; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-weight:normal;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <span style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in Internal Control &#8211; Integrated Framework, management concluded that our internal control over financial reporting was effective as of December 31, 2021.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &#8220;emerging growth companies.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including our Chief Executive Officer and our Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by the collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions&#59; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OR_INFORMATION">Other Information.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ite</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">m 9</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9C_DISCLOSURE_REGARDING_FOREIGN_JUR">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 10.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Directors, Executive Officers and Corporate Governance.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item will be included in the section entitled &#8220;Corporate Governance and Board Matters&#8221; of our definitive Proxy Statement for the 2022 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Conduct and Ethics that applies to all directors, officers and employees of the Company, which is available on our website at&#160;www.rapt.com.&#160;If we make any substantive amendments to our Code of Conduct and Ethics or grant any waivers to our directors or executive officers, we will disclose it on our website or in a Current Report on Form 8-K.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">Executive Compensation.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be included in the sections entitled &#8220;Executive Officers&#8221; and &#8220;Executive Compensation&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 12. </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be included in the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 13. </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Certain Relationships and Related Transactions, and Director Independence.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be included in the sections entitled &#8220;Transactions with Related Persons and Indemnification&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ite</span><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">m 14.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">Principal Accountant Fees and Services.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be included in the section entitled &#8220;Corporate Governance and Board Matters&#8221; set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 15.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">Exhibits, Financial Statement Schedules.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span>The following documents are filed as part of this Annual Report:</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Financial Statements.</span><span style="color:#000000;"> </span><span style="Background-color:#FFFFFF;">See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Financial Statement Schedules</span><span style="color:#000000;">. None. All financial statement schedules are omitted because they are not applicable, not required under the instructions or the requested information is included in the consolidated financial statements or notes thereto.</span><span style="font-style:italic;color:#000000;"></span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Exhibits</span><span style="color:#000000;">. The following is a list of exhibits filed with this report or incorporated herein by reference:</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:3.85%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="EXHIBIT_INDEX">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;width:9.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;width:35.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="9" valign="bottom" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:52.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schedule</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filing</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/04/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519283350/d825897dex32.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/04/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex42_1343.htm"><span style="text-decoration:underline;">Description of Registrant&#8217;s Securities</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/30/20</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex101.htm"><span style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement by and among RAPT Therapeutics, Inc. and certain of its stockholders, dated December 18, 2018</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex102.htm"><span style="text-decoration:underline;">2015 Stock Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex103.htm"><span style="text-decoration:underline;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2015 Stock Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex104.htm"><span style="text-decoration:underline;">2019 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex105.htm"><span style="text-decoration:underline;">Forms of Stock Option Agreement, Notice of Stock Option Grant and Notice of Stock Option Exercise under the 2019 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex106.htm"><span style="text-decoration:underline;">Forms of Restricted Stock Unit Agreement and Notice of Grant of Restricted Stock Unit under the Amended and Restated 2019 Equity Incentive Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex107.htm"><span style="text-decoration:underline;">2019 Employee Stock Purchase Plan</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex108.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement, by and between RAPT Therapeutics, Inc. and each of its directors and executive officers</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex109.htm"><span style="text-decoration:underline;">Amended and Restated Employee Offer Letter, by and between Brian Wong and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1010.htm"><span style="text-decoration:underline;">Amended and Restated Employee Offer Letter, by and between William Ho and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519198410/d723949dex1011.htm"><span style="text-decoration:underline;">Amended and Restated Employee Offer Letter, by and between Dirk Brockstedt and RAPT Therapeutics, Inc., dated July 20, 2019</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/22/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519306278/d832916dex101.htm"><span style="text-decoration:underline;">Offer Letter, by and between Rodney Young and RAPT Therapeutics, Inc., dated November 11, 2019</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/04/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex1013_1043.htm"><span style="text-decoration:underline;">Offer Letter, by and between Karen Lam and RAPT Therapeutics, Inc., dated July&#160;10,&#160;2019</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/30/20</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000156459020014162/rapt-ex1014_1403.htm"><span style="text-decoration:underline;">Amended and Restated Non-Employee Director Compensation Policy</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-38997</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">03/30/20</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1021.htm"><span style="text-decoration:underline;">Lease, by and between HCP, Inc. and Flexus Biosciences, Inc., dated October 10, 2014</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1022.htm"><span style="text-decoration:underline;">First Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 29, 2015</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1023.htm"><span style="text-decoration:underline;">Second Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated April 16, 2018</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1024.htm"><span style="text-decoration:underline;">Third Amendment to Lease, by and between HCP, Inc. and RAPT Therapeutics, Inc., dated December 13, 2018</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19#</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312519189775/d723949dex1025.htm"><span style="text-decoration:underline;">Clinical Trial Collaboration and Supply Agreement, dated as of November 1, 2018, by and between MSD International GmbH and RAPT Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-232572</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">07/05/19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20#</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1673772/000119312520024342/d131169dex1019.htm"><span style="text-decoration:underline;">Collaboration and License Agreement, dated as of December 1, 2019, by and between Hanmi Pharmaceutical Co., Ltd and RAPT Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-236256</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">02/04/20</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex211_234.htm"><span style="text-decoration:underline;">List of Subsidiaries</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex231_8.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Power of Attorney (included on signature page)</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex311_9.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex312_6.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1<span style="color:#000000;">&#8224;</span></p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2<span style="color:#000000;">&#8224;</span></p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="rapt-ex322_10.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Fata File because its EBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-left:2pt;padding-Right:1pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:7.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:12.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:6.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;padding-Top:0pt;padding-Bottom:0pt;width:11.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="background-color:#FEFEFE;width:10.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:81.2%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted as we have determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to us if publicly disclosed.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#160;&#160; </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications attached as Exhibit 32.1 and Exhibit 32.2 accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of RAPT Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10&#8209;K, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 16. </span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_16_FORM_10K_SUMMARY">Form 10-K Summary.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:58.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:58.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="middle" style="width:4.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:37.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:58.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <span style="color:#000000;">March 10, 2022</span></p></td>
<td colspan="2" valign="bottom" style="width:0.82%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:36.66%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian Wong, M.D. Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:58.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:36.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Wong, M.D. Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:58.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:0.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:36.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;">&#160;</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">POWER OF ATTORNEY</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Wong and Rodney Young, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:26.4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian Wong, M.D., Ph.D.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-top:solid 1pt #000000; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:17.85pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Wong, M.D., Ph.D.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal executive officer)</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:3.4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rodney Young</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Secretary</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:24.85pt;">
<td valign="top" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rodney Young</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(principal financial officer and principal accounting officer)</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ William Rieflin</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chair of the Board of Directors</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">William Rieflin</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Michael F. Giordano, M.D.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Michael F. Giordano, M.D.</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Mary Ann Gray, Ph.D.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mary Ann Gray, Ph.D.</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Linda Kozick.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Linda Kozick</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Lori Lyons-Williams</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lori Lyons-Williams</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Wendye Robbins, M.D.&#160;&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:45%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;width:0.84%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:23.02%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022</p></td>
</tr>
<tr style="height:15pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:3pt;width:30.3%;">
<p style="text-align:center;margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wendye Robbins, M.D.</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:45%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:0.84%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;width:23.02%;">
<p style="margin-bottom:2pt;margin-top:2pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>rapt-ex211_234.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex211_234.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SUBSIDIARIES of RAPT THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(as of December 31, 2021)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NAME OF SUBSIDIARY<font style="font-weight:normal;margin-left:36pt;"></font>COUNTRY OF FORMATION</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> RAPT Therapeutics Australia Pty. Ltd<font style="margin-left:36pt;">Australia</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>rapt-ex231_8.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex231_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-left:3.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><a name="_Hlk65780421"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Registration Statement (Form S-8 No. 333-234448) pertaining to the 2015 Stock Plan, the <a name="_Hlk65780421"></a>2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc.,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Registration Statement (Form S-8 No. 333-237487) pertaining to the 2019 Equity Incentive Plan of RAPT Therapeutics, Inc.,</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(3)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Registration Statement (Form S-8 No. 333-254127) pertaining to the 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan of RAPT Therapeutics, Inc., and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.67%;white-space:nowrap">
<p style="text-align:justify;margin-top:0pt;margin-bottom:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(4)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-top:0pt;margin-bottom:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;font-family:Times New Roman;color:#000000;">Registration Statement (Form S-3 No. 333-249848) of RAPT Therapeutics, Inc.;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;margin-left:3.67%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our report dated March 10, 2022, with respect to the consolidated financial statements of RAPT Therapeutics, Inc. included in this Annual Report (Form 10-K) of RAPT Therapeutics, Inc. for the year ended December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk66212244"></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-family:Times New Roman;color:#000000;">/s/ Ernst &amp; Young LLP</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 10, 2022 <font style="margin-left:36pt;"></font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>rapt-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION&#160;302 OF THE SARBANES&#8209;OXLEY ACT OF&#160;2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Brian Wong, M.D. Ph.D., certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form&#160;10&#8209;K of RAPT Therapeutics, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a&#8209;15(e) and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a&#8209;15(f) and 15d&#8209;15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian Wong, M.D. Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Wong, M.D. Ph.D. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>rapt-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;31.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO SECTION&#160;302 OF THE SARBANES&#8209;OXLEY ACT OF&#160;2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Rodney Young, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form&#160;10&#8209;K of RAPT Therapeutics,&#160;Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules13a&#8209;15(e) and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a&#8209;15(f) and 15d&#8209;15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rodney Young</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rodney Young</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Secretary</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>rapt-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.1</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION&#160;906 OF THE SARBANES&#8209;OXLEY ACT OF&#160;2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Brian Wong, M.D. Ph.D., certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Annual Report of RAPT Therapeutics,&#160;Inc. on Form&#160;10&#8209;K for the year ended December&#160;31, 2021 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in such Form&#160;10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of RAPT Therapeutics,&#160;Inc.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="bottom"  style="width:48.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian Wong, M.D. Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Wong, M.D. Ph.D. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>rapt-ex322_10.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
rapt-ex322_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;32.2</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION&#160;906 OF THE SARBANES&#8209;OXLEY ACT OF&#160;2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Rodney Young, certify pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes&#8209;Oxley Act of 2002, that, to my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Annual Report of RAPT Therapeutics,&#160;Inc. on Form&#160;10&#8209;K for the year ended December&#160;31, 2021 fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in such Form&#160;10&#8209;K fairly presents, in all material respects, the financial condition and results of operations of RAPT Therapeutics,&#160;Inc.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100.04%;">
<tr>
<td valign="bottom"  style="width:48.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 10, 2022</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.96%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Rodney Young</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:48.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:45.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rodney Young</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Chief Financial Officer and Secretary</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gbkyd1brmfwp000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &H GH# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@"G9ZMIVH33165_;7,D!Q*D,JN8ST^8
M\=#5RO#?@;_R.WCK_KY'_HR2N_\ $6GPZQX\T73[Q[@VIT^[E,<5P\0+J\(!
M.PC. Q_.@#LZ*YC_ (5_X?\ ^>5]_P"#*X_^+H_X5_X?_P">5]_X,KC_ .+H
M Z>BN8_X5_X?_P">5]_X,KC_ .+H_P"%?^'_ /GE??\ @RN/_BZ .GHKF/\
MA7_A_P#YY7W_ (,KC_XNC_A7_A__ )Y7W_@RN/\ XN@#IZ*YC_A7_A__ )Y7
MW_@RN/\ XNC_ (5_X?\ ^>5]_P"#*X_^+H Z>BN8_P"%?^'_ /GE??\ @RN/
M_BZ/^%?^'_\ GE??^#*X_P#BZ .GHKF/^%?^'_\ GE??^#*X_P#BZ/\ A7_A
M_P#YY7W_ (,KC_XN@#IZ*YC_ (5_X?\ ^>5]_P"#*X_^+H_X5_X?_P">5]_X
M,KC_ .+H Z>BN8_X5_X?_P">5]_X,KC_ .+H_P"%?^'_ /GE??\ @RN/_BZ
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M32UT] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM9C!.$.?+D !*GWY'YUX=>ZCK7B#3+:RO=3U&)]/\56MM#+<6\:7&UP"ID4
MC<I)(]<\BM:_\8:Y:W%UI-K/<^=<^(9[/[19VB23K#'"C'8N &<D]3G SZ4
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0H))P!R:
M%HJL+E]BRM#MA;'.[D ]"15F@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \,U'Q7H_@_P#:%UO4-:N'@MWTZ*)66-GRQ6,XP/8&NL_X7KX!_P"@I/\
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M** "BBB@ HJ*2X6-]FUW;&2$7.!4<MY'''&R R-*<1JO\1_I0!9H[XKD]?\
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M0+S5OL\-R8;=)8[=SM$@]<C/'M7+>!/BA-XR\41Z(^G)8PS12,\B2&0\?-@
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M[?R%EMY(^,A,;1WR3UJ_;P^1&5+ER3DL>IJ6B@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **K7
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MQW'U_ ]J ,3P-\;;^/2?)UK2]6U>Z>Z;%U#$NU4.,+P!TY_.O?:\K_9_8/\
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M09H @%UF7R_(FW8ST&,?G5BO&;;]H#2;C7X[(:'?"265;8,9$P"6QG]:]FH
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MR2O<J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD,2ONFD@.$.TD9^M?1BQR:DT:S1F/RFY+IN)(]^.*GF@GMI6F2YQO^^2O7\
M#V[U;LV0P )SW)Y.<]\D<T .2-XH0D8CW ^FT5\P7GQL\:V>NW-A#>6HABNG
MB4?9E) #D=:^I:XF7X2>!Y[I[F30HVF=S(S>:_+$Y)^]ZT =28[O>9+=X@LB
M@L'!/..O%1Q1(=Z7$I#1'(P^,=]WXDFM    #H.*X_XC>)_^$/\ #PUF73XK
MV..=(Q&7VD[L^QH Z3SR]AR&=W0@;%SGT/MFI"^^PD&UUQ&0=RX[5YK\-/BK
M;^,]2NK'^RDT\6\'F^890V[YL8Z#UK,^/?B?6?#UKHIT?4Y[/[0THD\EL;P
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M)8KC(^4LK<DCL ,8 .:OVZL86D4_O7.3O7 _(&GV\<L0*NR,I)/RJ0<DY]:
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MB0<#O_RUKUJ@ HHHH **** "BBB@ KS+QO\ !Z'QIXD?6'UZYLV:)(_*CB#
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M .,^!O\ R.WCK_KY'_HR2O<J\$^ %]%?>*_&%S$&"7#K,@8<A2[D9]^:][H
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M((_%FI)'K&I+&M[*J@7#@ ;SP.>E 'VC145N<VT1)SE!_*I: "BBB@ HHHH
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M3J<;9\I"VW.<L%Z4]I#'-<,H!8E% /3)XJD(WCU%[7*?OUW%PG*]>!0!:C0
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M&: ,KQ#XQN?C)):>%O#.CW<>G-<I+>WURF B*<]B0/7KD\#%>\(BQQJB_=4
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M9,*/O$<U++"DR[9 2/0,1_*I** &1Q+$N$SCW8G^=/HHH HOY#3S?:GVD'Y
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M('>,JC;<!2"> ?7WJS56%I(I3YT843/E2&S@X'!_*K5 !1110 4444 %%%%
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MJUGJZ(;NRDN!"\<J# =6/&",_F: ,*/79O"'CGXE7UE8O?+"+.X^R1L1ND?
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MN_\ A!IRY WPBY;<B]F/[OON_#%>QW$$DXVK,8UXZ+DYS4"?:&06K@;DVEI
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M+]UG_H0;O_O^_P#\:KHM4\$ZY=?';3/%44,9TFWA"/(90&!\MU^[UZL*]1H
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M\0WD$:Z;?K(('64%FRZD97J. :YSX+?\E)\>?]?!_P#1LE 'N5%%% !1110
M4444 <-XD^$OA7Q5K<VKZI!<M=S*JN8YRH.T #CZ 5Y1K&F? _1=2FL)IM3G
MFA8I(;>1W56'4;NA_"OHR=&DMY41MKLA"MZ''6O$_@W+X4TG2+_2M:;3H/$$
M%Y(MT;PIN< \%6;JOT/7GO0!RENWP/\ M,7EIK>_>-N=V,YKZ;'2L!;WP@6
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M,;@X7H#T'Y^M5/AUX2T;QQX;U3Q#XCL8[^^U:\FS++RT48.U50_PXP>GMZ4
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MK0!%'_Q^3?[J_P!:6:#SL9ED4#!PI'8Y]*K >7''<+,SR2%0<GA\]@.W>K]
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M%_NU/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,?-C('''/N2HH ]-3QWX>D\'MXK6];^QU)!F,3@Y#[/NXS][VKG?^%Y_#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 445YEXW\0_$K3?$CV_A?P_#>Z8(D*S/'D
MEC]X??'\J .:^!O_ ".WCK_KY'_HR2O<NU>-?!3PWXET?7/$=]K^ER6)ORDB
M[L89BSDXP3P,U[+0!5C:7[2[&W<*X49)7C&?>K$C,JY1-Y],XIU% %>T$J0K
M')'MVC&=P.:L444 %%%% !1110 4444 %%%% !1110 5SGC_ /Y)YXB_[!T_
M_H!KHZHZSI<6MZ)?:7.[I#>0/ [QXW*&&"1GOS0!Y1\)? 7A36_AMI=_J>AV
MES=R&7?+(IW-B1@._H *]-T/PIH7AHSG1=+M[(S[?-,0QOQG&?ID_G3/"7AF
MU\(>&[;1+.:::"W+E7FQN.YBQS@ =ZVZ /&_@_\ \E!^(7_7_P#^U)*]DKRN
M_P#@5HU]K%]J2Z[K-O+>S--(L$J*,L2<?=Z<U)IOP4LM*U&&^MO$^O>?"2T9
M>9& .,9P5YQ0!D?$C7K[QMXGA^&_AJ4@,V[5;I?NQH.2I]AW]3A?6LG37N/@
M?\0%TRZFEE\(ZN08IY.?)?@;CVR.A]5(/:O4?!/P^TGP-%>&QDN+FZO'WS75
MTP:1O;( XSD_4U?\7>$M,\::#)I.J*WELP>.6/ >)QT92>_4?0F@#S?XE:-X
MRUKQUI=[IVAQ:OH>GHLT$#SJL4DISEF&X$XX]L#W-<CXRUOQW<^//"5QJOAF
MUM=2@F8V%NDP*SMN7()W''./3K7OOAK0_P#A'-!MM)6^N;V.V79'+<D%PO9<
M@#@=![50U[P58^(/$NB:Y<7-Q'/I$ADACC*[7)(/S9&>W;% %_2=0OSX9AU#
M7;1+*]6%I+F!&W+'C).#D]AZUYG\#;1]6F\1>-;P;KK4[QHXR>JH#N('MD@?
M\ KU?5+!-4TF\T^21XTNH'@9X\;E#*02,]^:S?"'A:S\&^'(-%L99IH(6=A)
M-C<Q9B3G  [T 8GC_6O".G7NAVGBK2_M:W=P5M97A5XX6RH)8DC Y'KP*F^*
M4>F'X9:V-16+R5M6,.X#B7'[O;[[L8K6\5>$])\9:.VF:O 9(MV^-T.UXV_O
M*>Q_2N&A^!NFR36ZZMXBUK5+"V(,5E<3_(,=!]/IB@#;^#@NE^%.AB[W;O+<
MINZ[/,;;^F,>V*YO]H52/"6CRL,PQZHAD'ML>O6X88K>"."&-8XHU"(BC 50
M,  >E<S\1/#)\7>!M2TJ,#[0R>9;Y_YZ*<J/QQC\: (_B6RO\+_$#*05-BY!
M'IBH/A*BI\*_#X48!MR?Q+L35#P=<P?$/X3#2[V62&?R#IU\$P)(W0;3P>A(
MP>1WKK_#FAV_AKP]9:-:RR2P6D?EH\N-Q&2>< #O0!\WK:SW'PM^(0MU8B+6
MDDD51_ 'Y_ <'\*^@?".JZ;-X TF_@N(EL8["/<^0%C"H P/IC!!^E8)\-Z=
M\-_"?B:_M[:ZUB&[=KFZM)2OS*>& PO0 D\YZ5YI9:/\)9]'_M8^)K^SL9%\
MZ;0_MHSO[ILQN;GC/ZT 6_AOK\&B_#CQ]K5MA(TNI'MQTP67$8_,BNLTW13H
M7[.=W;.I6:72)[F7/7=(C-S] 0/PKF/AGX!_X2GX97]O=O/I]AJ&JBYC55R9
M(D'"\]L]_P#9KVS5](@UC0+S1Y&>*WNK=K=C'C*JR[>,\=* .2^#<:I\)-$"
M@#<DI/N3*]<]^SRBCP7JC <MJ<F3_P  2O1O#'AZV\*^&[31+2666"U5E5Y2
M-QRQ;G  [U2\$^"K'P-I5QI]A<W$\<]PUPS3E<@D 8& ..* /-_!7_(Z_%C_
M 'W_ )RUL_L^_P#),A_U^R_R6NHTKP#I^DZMXCU"&ZNGDUXDW"N5Q'G=]S _
MVCUS7&P_L^Z+;Q^7!XBUV),YVI,BC]%H ]>KR#XH_O?BK\/(8B!.+LN3_L[T
M_P #72>#_A?9>#M9;4[?6M6O':%HO+NY0R8)!S@ <\5@:)&?&_QLO_$2_/I/
MAZ+[#:OU628@[B/7&YO_ !V@#UJBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@"C9:-ING7EY=V5G%!<7KB2Y>-<&5AW/OR
M:O444 (0""",@]0:YR3X?>#Y;S[6_AK3#.6W%OLZ\GUQTHHH Z)$2*-8XT5$
M4 *JC  '8"G444 %%%% !1110 C*'1E895A@BJ>E:1IVAV"V.EV<-I:J2PBB
M7 R>2?K110!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gbkyd1brmfwp000024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000024.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Y!:,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ HHHH HWVCV&I7-K<7ELLLMJ^^%B2-IX]#ST'6KW48-%% &
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_ !'\"_\
M"P/#UOI/]H_8/)NUN?-\CS<X1UVXW+_?SG/:NPK'\1^*=&\):='?ZY>?9+62
M40J_E/)ER"0,(">BG\J /"/#/@7_ (5_^T!X;TG^T?M_G6DUSYOD>5C,4Z[<
M;F_N9SGO7T?7A"^*=&\6_M(>%[_0[S[7:QZ?+"S^4\>'$=P2,. >C#\Z]WH
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M0RVLDDDC85%"2DDGL * /4J*\^'QB\/,/M(T_7?[)W8_M?\ LY_LO7'WNO\
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MPKIO_I;#704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSG'OBLGQE_R [;_L*Z;_ .EL- '04444 %%%% !1110 4444 %%%% !1110
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M#V"BO'_^&CO!_P#T#=<_[\0__':/^&CO!_\ T#=<_P"_$/\ \=H ]@HKQ_\
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MW;5E ##:Q4YP2.H/>KA6IS=HNYSXG+L5A8<]:#BMM31HHHK0X@HHHH ****
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M33_[8L )TU!VEV_;8=I\LP@9/&1OXR>3CGM*Y_QE_P @.V_["NF_^EL-=!0
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MH*KW'A[5X]&O@^C7L@U33=0MK&%8"QADFNVDC5Q_RR!4JV6P!MP2" *]PHH
M\OT_1]3B\8VD$MC<^=!KUQJ,MX8F\HV[VI12)>A))5=N=WR\C !K<\63Z\T%
MO'/INFII_P#;%@!.FH.TNW[;#M/EF$#)XR-_&3R<<]I7/^,O^0';?]A73?\
MTMAH Z"BBB@ HHHH **** "BBB@ HHHH ***9)(D,3RR,%1%+,3V ZT; E<C
M6YWWTELJ9$:!G?/0DG _($_EZU/5+3(W%J9Y5*S7+&9P>HST'X* /PJ[TJ(-
MN-V7424K+H%5-3G>"PD,1Q,^(XO]]C@?D3G\*FMYTNK>.>//ER*&4D8R#T-5
M9O\ 2-8@A_@MD,[_ .\<JOZ;S^5*<KQ]WJ53C:?O=/T_JQ;MX$MK:*",82-
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M  (>B_(****S-S)\4_\ (H:U_P!>$_\ Z+:LCX9?\D]TO_MK_P"C7K7\4_\
M(H:U_P!>$_\ Z+:LCX9?\D]TO_MK_P"C7K!_QUZ/\T>K'_D52_Z^1_\ 29'6
MT445N>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M04 %%%% !1110 4444 %%%% !1110!1UG5;?0]%O-4NSB"UA:5@.K8'0>Y/
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M<C@[(\!C@\%L]01BJWQ4^R+X+:2\N;2)([J)UBO(I)(;EP?EB=8_F()YX!Z
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MCV5O<<K]E<WHT/:W]Y*W=V.GEE2"%Y9&VHBEF)[ 4RTNHKVTCN8&W1R+E37
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MCYZ@[1NSZ5Z'7F?PRBU#^VM4E<^-/[.^SQ+'_P )._S^;N;=L7TQMY^M>F4
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MWGT(7J3M $M/^*BU"+4V_P"07:N6LE_Y[R8(\X_[(!(3UR6Y^4CH*15"J%4
M*!@ #@4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GW
MQ0TG17L;?5=0L)KR\,D=E;(-0>UCW.W!=@0 !SR0>PJI\+(+*QU'6M/335L]
M1@2!IV@U-KV%T;?LP6/RL,-D?0\UL^/K&>2Q:[.OZ;960C\N>RU>!)+.XY)&
M[)#*V>ZGL.*H_"O6-/U#3[VVTWPW%I4,#@FYM(V^RW;'(W1NRJS8V]QQQS0!
MZ#113)HS+#)&'9"ZE=Z'!7/<>] $3W]G''/(]W J6YQ,QD $1P#\Q[<$=?6D
M?4;&-('>\MU6X($):50)2>@7GG\*\ELO#D^CVVK0165]+86WBNWNI?,5Y9)H
M0L9:4YR9/G^8XST/I6=<:-J:Z-=>9I%\ZW^F7\&F1BV9C%)+=EXE(QF(E2C9
M;  4Y(Q0![:+RU-XUF+F$W2KO,(<;POKMZX]ZQO&7_(#MO\ L*Z;_P"EL-<9
MIVF:A'XVMHI;&Y%Y%KMQ>SW1B;8UJUKL4^;C!!)5=N<Y4\8&:V_$ESXDDT^S
M6_TK2H+4ZKIV^2#4Y)77_3(<84P*#SC^(>O/2@#N**** "BBB@ HHHH ****
M "L>&Y,=G<ZDJ[Y;J0"W4_Q#[L8^A^]_P(U:U-V-L+6)B)KD^4I'50?O-^ R
M?KCUID2+/J("*!;6(V(!T\PCG_OE3C_@1]*PJ-N5E_3?^2.FFDH7?])?YNWW
M%JSMA:6L<(8L0,LYZLQY)_$DFIBP52S$!0,DGM2UGWK"ZG^Q$@0*OF73$\;>
MR_CW]@?6M&U"-D913J2N_F%JPD,FJ3D(C+B+=QLBZY/H6QD^V!VI PES?W>8
M[>(%XD<8P/[[#U]!V^O1R*=0=9G!%JIW1(1_K#V8^WH/Q],#_P"GWWE=;:V8
M-)Z/)U"_0<$^^/0UET7]7??T_KL;:7?]67;U_KN-B;R(9M3O 4=DR$QS&G91
M[GOZGCL*J:4A?S=8O2J[P73)X5<=?I@8'L,_Q&B_SK&JKIJ$_9;?$ERP[G^%
M/\_S%7' OKKR% ^RVY'F8Z.XZ+]!U/O@>M9_%+39;>;ZOY&C]V.NC>_E'HOG
M_D/L(W9IKR52LEP055ARB#[H/OU/U8TNHRNMN8(#_I4X*1X_A]6^@Z_D.XJ6
MYN1;HH"F25SB.,'EC_0>I[4EK;&(M+*PDN)/OOCCV4>@'_UZWMIR+Y_UW.>^
MOM)?)?UT)88DMX(X8QMCC4*H] !@4^BBM4K:(R;;=V%,FE2"%YI6"QHI9B>P
M%$TT5O$99I$CC7JSM@"J#2?VI+$D<<@M$82/(ZE1(1RJ@'DC/)/3COFHG.VB
MW+A"^KV_K\2;3HG6%KB=2MQ<-YC@]5'\*_@,#ZY/>KE%%.,>56)E)R=PHHHJ
MB0HHHH **** "BBB@ HHHH **** "BBL:[\5Z)8^)[/PW<WNS5KR/S8+?RG.
M]?FYW ;1]QNI[4 >+^(/ABOP]=M3\.?$ :*QY6#4)MGF>V5^_P#38:O_  M^
M+WB#Q'XIM_#>J6]M?HXD!U&!&C("(S;F7&"&( '"]?PKD="TSX1PW'VWQ/XS
MNM:O'.74VMS'&3[G9O;Z[A]*]C\(^.OAW<WMMX?\+75O'--N\JV@L980VU2Q
M))0#. 3DF@#O:*** "BBB@ HHHH *YOQKXUTWP)HT.J:I!=S02W"VZK:HK,&
M*LV3N91C"'OZ5TE% 'SYI?C73?'?[1'AG5-+@NX8(K*6W9;I%5BPCN&R-K,,
M8<=_6OH.O'_$/_)T/A/_ +!3_P#H-U7L% !1110 4444 %%%% !1110 4444
M %%%% '/^._^2>^)?^P5=?\ HIJY_P""7_)(=#_[>/\ T?)70>._^2>^)?\
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M#8)I=U;1"'&JZ=IYM%G8[B8R.C%.#D?W^: /4**** "BBB@ KG_&7_(#MO\
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M:Z@D@GBL(DDBE0JR,%&00>0:Z*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *X[XFS7$/@U_LTFHK))=6\9336*W$JM*H9$8?=)
M&>?P[UV-<K\0]+N=8\)RVEIIESJ,QFC<6]M?+:.=K @B1@0,$ _A0!C?#FW\
MF^OC]@\76V8UYUZ?S$//\')P?6O0Z\Q^&D.I6/B#4[#5=-U:QN%M8I0E_KBW
MX969@"H"C;RIYS_2O3J "L3Q;KQ\-^&[C4U2.21'CCC21B%+/(J#)'./FS^%
M;=4M5L'U&Q,$5Y+:2ATD2:)58JRL&&0P((XY'\NM '&W_P 0+BUM=]G'I^HM
M%I]UJ<\D$S+'Y4#*K(O!.\EB.>F*LVWCU[K6X8DL4_LV74AI:RF0^;YIM_/W
M;<8VX^7KGO[4DGPTL9+>8#4KQ+F[2ZCOKA0FZX2X8-*,8PO*C&!P!WJ]%X&L
M(-:CO8KB=;>.\%^MGQL^T"'R0^<9QL[9Z\^U %GQE_R [;_L*Z;_ .EL-=!7
M#^)/"?AO3-/L[RP\/Z5:74>JZ=LF@LHXW7-Y"#A@,C()'XUW% !1110 4444
M %%%17-S#9VLUU<R+%!"ADD=CPJ@9)/X4 8OBC4/*MTTV*Y^SR72.\UQNQ]F
MMD&99<]C@A0?[S ] :\P\3ZR\BVXL(4A\U39V%LXV)#%'@_-G@*NT22'H/+1
M"#MDJW>ZNFLQW.MZBT\.DRSJACB_U]\ZD^39P@<X4Y9V'\;, <(6%/P_X7O/
M%GB6WO=8BB2W:,.UM"/W4-JI'EPKVVLP&/[P5R."I8 W_AGX+\BP&J7H=H9W
M$\"RC#W&.5FE'J22X4YP6&22J[?1[_4+73+4W-Y,(HP0HX)+,>BJ!RS'L "3
M5/4-:%O<_8+&$WNI,H86ZMA8U/1I&_@7\R<':#@TEAHICNAJ.I3"\U+!"R%<
M1P ]5B7^$>IY8]SC   S3;.>[OFUC48S',5*6ENW_+O$>I/^VV 3Z#"]B3<U
M+5+;2X4:<NTDC;(8(EW23-_=5>Y_0#DD $U5O]8<73:=I<*W>H@#>"<16X/1
MI6'3V4?,?89(DTW1TLIGO+F9KS495VR74BX./[J+T1/]D?4DGF@"K#I=SJDZ
M7FN!=J,'@T]&W1Q$=&<_\M'[_P!U3T!(W'=HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B_B?-<1>%85MGU/?+?01M%
MI;%;B92WS(K#[O&3GOMQQFJGPXM_)GU'_0?%EME8^=?G\P-RW^KY.#Z_A6C\
M1M*N]8\+K;66EW6I3+<QRB"UU!;-QMR0WF,".#@X]<'M6'\,8M1L]8UBPU33
MM5L;F.&"3R[_ %M;_*L9 "N -OW3ZY_"@#TJBBB@#"\7:^WAO0#?QQQ23-<0
MV\:RL0N9)%3)(!. "3QZ5SM_\0I[2T\^TBL-12#3Y=2N9K>=@AB239L3@_/]
M[.<8*X[\=CJMA)J-HL4-Y+:2I*DJ2QJK<J<X(8$$'O\ H17*R?#+3WMGC&HW
MB/<Q3PW\@V9NDFD\R3(QA3NS@KC )'O0!-:>.);KQ#%:_84&G3ZC+IL4WF'S
M/-2'S"Q7&-IPR]<\ ]\#2\9?\@.V_P"PKIO_ *6PU!;^";.VUY=22ZN/)CNW
MOH[0[=B3O'Y;-G&<;<G&>K$^@&=XD\)^&],T^SO+#P_I5I=1ZKIVR:"RCC=<
MWD(.& R,@D?C0!W%%%% !1110 4444 ([K&C.[!549))X KE(KAM0NY+^1S'
M"SA8CMRP ^Z%'=SDD#MG)SQB75+N?7+MM)TT;[=&Q=SYPG^YG^>/IZU;CMXK
M<.J3!1$I6>\8[1&.ZIV'N?S)-<%6;JSM'X5^+_X!Z5*FJ,+R^)].R_X/];C!
M!<:A_HD>ZUM(^'5#DCV9OXF/<<@=RW2H/^)5I\8545+7.%5!NDNV'8#J5!_
MGT'5PEN]8B%MI4?V32P-IN9%.9!_L+UQ[GK^ALVNFP"9TM=YQ\D]XYS(^/X%
M/8=CC '0<](4>9WBK^;_ $\ON3]-"G)05INWDOS?G][7KJ4)'U;7Y&3[,8;$
M':4,NS?ZAB,D^X [D=1FM>#2YEA6*2[,4*C AM%\I?SY;\016BB)%&L<:A44
M850, "G5TPPZ3YI-M_U^!RU,4VN6"22_K[_,K6]A:6C%H8$5SU?&6/U8\FK-
M%%="BHJR1S2DY.[=PHJG+JME$_E^>LDO_/.(&1_^^5R:9]KOI_\ CWL#&O\
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M,H4G9ON=&%G3IU5.HKI'FVCO,;Z.VCOYK-9F"EXR>O;(!'?^==C_ ,(QJ?\
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MQ/<G)/>K-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'E_Q%U&TF\30Z#K6@:QKVCR6 NOL6EVY=TF$A42,596
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MGPZU*TUBY^)6HV$OG6ES<&2*3:5W*4?!P0"/Q% '1_\ "[?AY_T,/_DE<?\
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M0<NYZ=!DFNTO/'?@G['+]I\3:'+ 5.^,7D<FX=QM!)/TQ0!>U#Q5H>E^'?\
MA(+K48O[)PI%U$#*I#' QL!)Y..*UT=9(U=#E6&0?:OG>\MY8OV=O$,PADAT
M^ZU<SZ;&X(VVS2Q[,#L,AC^.>]?0=E_QXV__ %R7^5 $]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5Y9_9]W_PGW_'G/\ ;SXE^U?:/*./L/V+
M9]_&-N[Y<9ZUZG10!P_C.Y\2?V>BC2M*-J-5L?*D.IR;VQ>1;-R^1A<G;G#'
M;DD;L8,5[_PMF:6868\&VT+$^6'DN9'0=LMM )_X#^%;7B[5-$LK.W@UFYGA
M4S)>*((FD8"WD28N0JMA 57<2.AQD$BNACD26-9(V5T<!E93D$'H10!XU?\
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MG_MGC#_H!:'_ .#F;_Y%H^V>,/\ H!:'_P"#F;_Y%KH** .?^V>,/^@%H?\
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MH\,ZI]GU![VYC.DW"7*1M;R(TAE22"/",NYPWF-C;U('TH O_;/&'_0"T/\
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M HHHH **** "BBB@ HHHH **** "BBB@#G_'?_)/?$O_ &"KK_T4U<_\$O\
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M#UZS52'2].MGNG@L+6)[MMURR0JIF/J^!\QY/7UH \R^$'A/PWJ?PMT>\O\
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M+]3U2BBBN@\8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU"N8\,?\AOQ!_P!?/_LSUT]<QX8_Y#?B#_KY_P#9GK'$_P"\T?5_^DLUP_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#R6E_^(K7_ .$6\/?] '2__ ./_"C_ (1;P]_T =+_ / ./_"JM7[K\?\
M,RYLJ_EJ??'_ .1,C_A9GA#_ *"__DM+_P#$4?\ "S/"'_07_P#):7_XBM?_
M (1;P]_T =+_ / ./_"C_A%O#W_0!TO_ , X_P#"BU?NOQ_S#FRK^6I]\?\
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MS[H/T%=MX*L/B[!XNL9/%%\LNC#S/M"!X#G]VVW[HS][;TH ]=HHHH ****
M"BBB@ KF_&OB34O"^C0WNE^'KO79Y+A8FMK4MN12K'>=J,< J!T_B'-=)10!
M\^:7XDU+Q1^T1X9O=4\/7>A3QV4L2VUT6W.HCN#O&Y%."6(Z?PGFOH.O'_$/
M_)T/A/\ [!3_ /H-U7L% !1110 4444 %%%% !1110 4444 %%%% '/^._\
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MA9>>'-<?Q'XCUI]6UIHC$C%V=8@>IWO\S'&1T'!/K0!Z=1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW!(PX!Z,/SKW>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_^-O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBB@ HHHH *SX)Y;C6[M%<_9[:-(ROK(WS'\E*?\ ?1J[+(D,3RR,%1%+,Q[
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M]F>N'$_[Q1]7_P"DL[,/_ J^B_\ 2D=/1117<<84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<;\4%M3X(G:[N(HE2XA>-)K
M=IXYW$@*Q/&O+*QP,#Z]J[*N+^*3RQ^"V:&2ZB87EL3)9P>;-&HE4EHQV8 9
MS0!S'P>:>>_OY[U8XKB.TBMD@MK"6WA6-7=@<R %F^?& . !7K=>??#O4/MM
M]?+_ &]K^I;8U.W5++R%3GJIVC)KT&@!KML1FVEMHSA1DGZ5YN/B)K!T7Q+>
M7&E1V5S87MO:VEL\;3./.\L*9%0_,W[S.U<?W>3R?2JP#X2M1+J\UO?ZC:SZ
MG<1W,DL$P5HG154;?EP1A1E6# Y.1CB@#E+WQ_J4=F3IMUIE_):Z?>:E=2M9
M2P K;LJM (VD+1R98Y+$XQ]TYJ[:^.KZ[UV K;VRZ3+JBZ2(RK>>)#;>?YF[
M=MV_P[=N>^>U79OAQI$UMY9N]06:59TN[E95\R\28@RI)\N,,57[H4C'RD5=
MC\%:7%KB:G&]PJ).+I;(,OD"X$?E"7&W=NV<8W;>^,\T 9WBSQ+H-S!;Z7!K
M>FRZ@-8L$-HETC2AEO8=PV YR,'(QQ@UVE<_XR_Y =M_V%=-_P#2V&N@H **
M** "BBB@ HHHH **** "BBB@#*UYA):16)('VR41/G_GF,M)GVV*P_$4NCJ;
M@3ZFX(:[(,0(Y6$?<'XY+?\  S67J9.I^(_[/0G:L7DN1_"K8:7\=OE+G_II
M6QJL\D5LEK:G9<W+>3"0/N<<M_P%03]0!WK2UDEW.=.\W/M_7]>IC"]CO/%4
M]_,X6PTFV?:QZ;V)#/\ ^..OX>];%KJT<N@1ZO<+]GB,'GNN[=L7&?SQ7$WV
MR\\O0;([!J-UM.#RMO'\@_,1N^?7KUKI]2BBN;S3_#L"*MLJK<7" <+#&1L3
M_@3 #Z*U7**T_K0RIU)>\U_P[>WW*Q9\/VLL=D][=(5O+]_M$RGJF1A4_P"
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M3[MR^]V_3\0HHHK0Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH JZE>#3]+N[UAN6WA>4CUVJ3_2OG#P_P"
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M)?#S_H7O_)VX_P#CE><?#CX=^%=>\9>.K#4]+\^UTO4!#9I]HE7RD\R88RK
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M\*>1Q0!]C?\ "=^#_P#H:]#_ /!C#_\ %4?\)WX/_P"AKT/_ ,&,/_Q5<_\
M\*2^'G_0O?\ D[<?_'*\X^''P[\*Z]XR\=6&IZ7Y]KI>H"&S3[1*OE)YDPQE
M6!/"+USTH ]G_P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*KP#
MXY^"?#O@[^P?[!T_[']J^T>=^^DDW;?+V_?8XQN/3UKU_P#X4E\//^A>_P#)
MVX_^.4 =!_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&O0__  8P_P#Q5>,?!3X=
M^%?%O@V\O]<TO[7=1Z@\*O\ :)8\((XR!A& ZL?SH^(_P[\*Z#XR\"V&F:7Y
M%KJFH&&\3[1*WFIYD(QEF)'#MTQUH ]G_P"$[\'_ /0UZ'_X,8?_ (JC_A._
M!_\ T->A_P#@QA_^*KB/%GP@\":9X-UR_L]"\NZM=/GFA?[7.=KK&Q4X+X."
M!UKC_@I\._"OB[P;>7^N:7]KNH]0>%7^T2QX01QD#",!U8_G0!V_C;QX/.LA
MX7U^TN%(;SOL<T<V#QC.,X[US]WK^N:7"+FUO&CEF.;E@H.YNN>GJ6_.H]8\
M(:%X9\?KIVB6JVL+V$4XM_.>1I)"\H)&XD]$'3TJW>6;M9S">&1(@A+NR$!0
M.<D]L=:\G'X_V6*HJ,+J&LM.^GX+4Z\'ETJV'Q#<[.=E'7M9_B]#O-(\>>&S
MHUD=0\4:.E[Y">>LM]$CA\#=E<C!SVJ[_P )WX/_ .AKT/\ \&,/_P 57GO@
M;X6^"_$7A.WU75-)6[O)Y[D23K=S*'VSR*" K@=%'05P7_"$^'?^&C?^$4_L
M_P#XDG_/KYTG_/IYGW]V[[_/7VZ5Z[:;NCB@FHI2W/?_ /A._!__ $->A_\
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MPT:RM'.7AA1'/JP')_$YJMJW[[4](M.S7#3N/]F-#C_Q]DK6K&\Q6\47,\C
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MTS5;#6;".^TR\AN[63[LL+AE/J/J/2K= !1110 4444 %%%% !1110 4444
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M)QDD@]^*]@HH \2NM#U9+/4;E](OI;?5++6;>Q@6V9GADN9P\.],9B!4$Y;
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M*YSSGIC@\]*[,*H8D* 6ZD#K6!XA_P"0YX3_ .PJ_P#Z175 '04444 %%%%
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MV .RCD\DE=@/^[7L]>6?!_PYK%K<^(?%.O6;65YKESYJ6T@(>--S,<@\C)?
M!Y^6O4Z "BBB@ HHHH **** "BBB@ HHHH \2^+>NWGBN;4_".ARE;32;.6_
MUFY"Y7]VA=(<^I(&??\ W6%9?AW4I])_9;U2ZMF*REY(0P."!)*L9(/T8U8U
M3X/>)M&T7Q#=:?XPG:.YBGN+BSAMFW7?RL=A^8EB<D=#UJ/X?_#[7M2^%&MZ
M??7=Q"M_$R6NFW431B"5'W*_/9B!SC\Z *&N>!=#LOV=K/7(;&)-52*WNFNQ
MGS&,DB@@GTP_3H,5[CX-U";5?!6AZA<G=/<6,,DC>K%!D_B:\'N+KQUK'@.S
M^&I\&WT-RCI#)?2*PB\M'#+D[=H' ^;<1QQUX^A-#TQ-%T#3M*C.Y+.VC@#8
M^]M4#/XXH OT444 %%%% !1110 4444 %%%% 'G'QRU2XTSX87HMW9&NY8[9
MF4\[&.6'XA2/QKQR&Z\!3:/X?L[_ ,/:WI,,93/B"W4(T\N/G.6#97=R,$D
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M0RB-MZ[1M)RK#!/!(.".;_B'_D.>$_\ L*O_ .D5U0!T%%%% !1110 4444
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MD+.-BSF6XE.Z:8C!=OZ = .PJU0K]1SY4[1_X<****9 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ!-JYR><EB>I)/))]34U%%24DDK(****!A1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7B<'CSQ[X]\0ZK:^"1I=C8:=)L,EW@R/DD D$'KM)X7CUKVMF5$+NP5
M5&22< "O ]:^#]Y-KESXB^'/B6W4O*S-%%<E3$QY*K(F1CD?*<<=S0!V7@?Q
M9XTD\4W/AKQCHA62-"T6HVT+"%R #@M]TY!X(QR,$9Z%Q\4HE^+4/A99].BT
MJ.)FGO'G!W/LW!0<X7!ZCD_2N?\  _Q"\8:9XVMO!?CJTS<W*GR+G:H?."5)
M*?*RG:1D<YZ]\<W=>!/#]W^T--X?FM';39H3</%YS@ES'O)W9S][G% 'T(-5
MTYKU+);^U-TXW+ )EWL,9R%SGIS]*5M2L$OEL7O;9;QQE;<RJ)#WX7.:\0DA
M2W_:LTR"(8CCMMBC.< 6C@5-KW_)T^A_]>X_]%24 >U7>H66GHKWMW;VRL<*
MTTH0$^V37FFJ>.=9M_CGI?AF"ZB_L>Y@$CIY:DG,;MD-UQE17&6.BV_Q1^.'
MB.#Q#+<26.DF6*&V20J,))Y8&1T'5CC!)-16WA:U\(?M'Z'IEA-*]F8S+"DK
MES$IBD^3/ID$CV- 'T'9ZC8ZC&SV-Y;W2*<,T$JN ?0X-(NI6#WS6*WMLUXH
MRUN)5,@&,\KG/0BO&/!\\/P\^,OB7P]<L(-+U")KZV).%4*#)@#L ID'_ !5
MOX)64VN:OXD\>7J$2ZC<M#;[NJIG<P'J/N+_ , - 'J^N74MCX?U*[@(6:"U
MEEC)&<,J$CCZBOGS0/'7QD\4:?)?Z+%%=VT<IB9U@@7#@ D88@]&'YU[YXH_
MY%+6?^O&?_T6U>:_LX_\D]U#_L*R?^BHJ $^'7Q7U?4O%+^$O&%@MGJQ)$+B
M,QDL%W;74]"1D@C@\>HSZM>:II^G;?MU_:VN[[OGS*F?IDUX;\0\O^T?X3%B
M1YRK:>=M'/\ KG+9_P"V?Z5>OG\$2>.]:9M/UCQMK4S^7);I:K-%9X)&T,=H
M4#A<\XQUSF@#V:34;&*R^VR7ENEIQ^_:50G)P/FSCK4L-Q#<0+/!-'+"XW+(
MC!E8>H(XQ7SS\%M-;Q)X7\=>&;IF2TD$2Q0NVX02-YOS#W!1#_P$4OAGQU+H
M?P,\0Z5<L8M5TJ5K")"WSKYQ('XJ?-_[XH ]_M-3L+^)Y;.^MKF.,X=X95<+
M]2#Q4=OK6E7=Q]GMM3LII\X\N.X5F_('->*7'@'7K;]GNSTW1(I&U&ZF2_OX
M(SM>9&!^3'<@>7D=]A^E<W96/PK6>PMM9L/$OAG4864N]P6 =AZG!(&>X5<>
MU 'T[145L\3VL+PR^=$R*4D#;MZXX.>^?6I: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *C\B$W N#$GGA"@DVC<%)!(SUQD#CVJ2B@ H
MHHH **** "H/MEK]L^R?:8?M6W?Y.\;]OKMZX]ZGKR[^R[[_ (3O;]AN/M7_
M  DO]H?:O);9]C^Q>7_K<8^]\NW.?:@#L?&7_(#MO^PKIO\ Z6PUT%<-XVN/
M$W]E[(M+T@0C4[(6\S:E(6+?:XO++IY& "VW< QP"<$XYAO(/BI<E3%-X:M,
M=1#/*=WUWPM^E4DGN[$3DX[1;^[]6COZH7NN:5IS,MYJ5I ZC)2290WY9S7G
MC^#?&5]$R:K/%=JQRR#7I40G_=-J0*EM_ -S !O\+Z/.1WDU^X_I;"K4::W?
MX&+GB'\,$O5_Y&W>_$[PY:X$,MQ=L>T,)&/^^L?IFN;N?BGJ5ZYBTRPM+7MO
MNIQG]2H'ZUNP:!J=M'Y<7A'P\$_NG6IR/UMJG32=5C.5\%^% 3U/]H/D_4_9
M*M3HQ^S<QG2Q<]YI>B.*33[O6[Y9M2U>.XE?YIA;1-.J@C&,Q?>;T5<J,<GG
M!['3-'T^P@:*&PUJZB<YD4Q+ C_5?DR.O!R*L:-K7B?5-#T_4;/P]HL5K=VT
M=Q%&VKRJ55U# $"V(!P>U7OMGC#_ * 6A_\ @YF_^1:4J[EH52P48.[=V6DU
M988UC_LC4(448"K;@A1[;2?TIW]OVH^_;:DI_P"P=.W\D-4_MGC#_H!:'_X.
M9O\ Y%H^V>,/^@%H?_@YF_\ D6LKKL=/+-;/\"Y_;>[_ %.F:E+_ -N^S_T,
MK1_:MZ.6T'4 OM) 2/J!)_+-4_MGC#_H!:'_ .#F;_Y%JG'KOBJ76;G2UT#1
MO/M[>&X=CK$NTK(TBJ!_HV<YB;/'<?@778?++^8V/[=@3_7V>HP_6SD<#\4!
M%'_"2:,/]9J,$/\ UW/E?^A8JG]L\8?] +0__!S-_P#(M'VSQA_T M#_ /!S
M-_\ (M%X]@M/O^'_  36AU*PN/\ 4WMM)_N2J?Y&H[G5[.VF,'F--<C_ )80
M*9'_ ! ^Z/<X%8<T'B"X_P!=X5\-2?[^J2'^=K4EL?$]E"(;7PUX=@B'1(M6
ME51^ M:/=#W_ "-+=J][]U8].A/=\2S'\!\JG\6JS9Z=#9NTH,DUPXP\\S;G
M8>F>@'L ![5SUYKOBJQNM.MY= T8O?W!MXBNL2X#"*27+?Z-TVQMTSR1]:N?
M;/&'_0"T/_P<S?\ R+2<@4%>[U.@HKG_ +9XP_Z 6A_^#F;_ .1:/MGC#_H!
M:'_X.9O_ )%I%G045S_VSQA_T M#_P#!S-_\BU3U;7?%6C:-?:I<:!HS065O
M)<2+'K$I8JBEB!FV S@>HH ZRBN?^V>,/^@%H?\ X.9O_D6C[9XP_P"@%H?_
M (.9O_D6@#H**Y_[9XP_Z 6A_P#@YF_^1:/MGC#_ * 6A_\ @YF_^1: .@HK
MG_MGC#_H!:'_ .#F;_Y%JQH.K7FIMJ4%_906EU878MG6"Y,R-F*.4,&*(>DH
M&,=J -BBBB@ HHHH **** "BBB@ HHHH A6UMTNY+M;>);F1%1Y@@WLJY(!/
M4@9.![FIJ** "BBB@ HHHH @BO+6>>:"&YADEA.)8T<%D/\ M =/QK&\0_\
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M[9XP_P"@%H?_ (.9O_D6C[9XP_Z 6A_^#F;_ .1: .@HKG_MGC#_ * 6A_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,'?NPH!)!').>* /3**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMD0,,94X.#SP: .2C\<^&]0OY[^S@NKR\L+IM'@,(&9Y)-KLD>6"D?N@=S8
MV$@XY/4Z/JUKKFE0:C9E_)FS@.N&5E)5E([$,"#[BO/K'X9ZGI%Y/<VFI1W"
MV^I6][8V\Y2-'6. PE9#'$-AVL0"H(X7C.:[;PIHLGA_PY;:=-*DLRO++*R
M[=\DC2,!GG +D#/84 ;-%%% !1110!A:GXHM]-U9=-2QU"^N D<DPLX1)Y$;
MOL5W&0<9!X4$@ G&!FJ>@^)-%6ZMO#NG6UU!;0+):64KC,4OV?".B,6+$KTR
MP&<$@G!K)\7^ KO7=??4K%[..2>W@@^TREA-9&*4OYD.%.6(8K@E?J02*L:-
MX-U#3_$5M/-/;-I]C<WMS;,A;S9&N6W;74C"A,L,@G=QPO0@';T444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML=KKB.UK,+I9-FQ"Y\P87:, \C/OBM7PQX;GT#0KG3I]1>[,TTDB%BY6!6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gbkyd1brmfwp000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000008.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #N ET# 1$  A$! Q$!_\0
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M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*IM9^(>2!A/=V@OD]80+71R@B3S+2
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MD9$2!(O:W=1D%7(V95 ^X;QN7NB@_*%+'[P)%0F4G!!7XV"Q3!V'#=F)'SD
M?+VSFI_DG08Y(5%%C[98Q<W[,O%K0+#L00%7%W:ZJY_3CY55F(5\L4K]GLT<
MBR),4\3:(+HP02/.NLA&F)\B!"V"254\X4GEBJ[V P" 57&0Q4Y('<XH9ER
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MQQ@$;5();=D YRQ8@\<X/O\ =[ZC\?RGBEX/:9H/5)$]D%]DX5VJ5?Z"*O\
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M/ *7X?\ !0_ZDOCE]"ZZA,(6?J%DH\P_+-6:<].=CP6B;LUUE(M<E%-#UEY
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MU<!B7C\H<@9?+A(EF)7R8&8W!&XJ2?+@&@ND) "O^T#$A0$+NT8#>;.0Z$'
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M8PH="A:3QX\-K#$8Y-B/$TNB8T&-N+(3)2\T^CXZ%)=WM6()':YB)9O/.C,
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M:1;C/+2/FK8L6)V0N -H..64$D $A02"Q ()"@D C/>L#(JL$.=QYX5B #D
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MC:GIA0T5I4.VQQ0J$PA<F>5G;8'#XC;LN=*CQ677D6"!F.$>)V/ 42+N)XX
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M?4S,G3?4#HS*ZZ'JS*RDJRLMA<%65A@A@0""#D'D5_/7_"?TK_*'>?XVG_\
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MW]?7W]"J:,'O">'/.%B1F=OJ=^9W-+3Y1&7MEOZF^&UN3,=>>^&W[E>Q'O\
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MTPJ TF%"9&R-T5O,7R#AL@$$9&"P[U"W+E5.P$E4\Q;'FD0LOE"=LC!.1WR
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MEB<#E3SLQCL#G!]V!C& )%\T_P D'RA_0#UO^@QS,;;]<0?=4_G"IN?UO/\
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M;WV0X(MX<@CZ;/W&/VL%<*0@SRX(/TN'L<^LU6MS7J^JR^:?Y(/E#^@'K?\
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MS:)_\ZKO\#NKO]%NH_\ 8FI__%I^%GE?^4OG_P#'*N?^98_Z1/9__IUT=_\
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M%]-:WQ/JCK;IWI"VDGUB^1)D@DN5L86C>\>"(9DN'5Y(XK2SB',U_?36MA
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M'[&J]^\8G^81\J/<_.?SU:.P^8?FK.9%33%*8I3%*8I3%*8I51O.G\F'H?\
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M,K JRL 592,%6!R""#@@\$<&LXY)(9(YH9'BEB=9(I8V9)(Y$8,DD;J0R.C
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M(X;87-T!,X3?>77BJ;N7:_@PA0M6 YOQ3G?)YEA)4L:<;+6M@+%L)NSWB]]
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M-U?I#6KW?]A=O_\ A<__ *IEYRWH']G?17\;>G/ZXLZX_P!6?L5ZF_B_K/\
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MX\>JVX>YZ_ZQZ(T&UW!BH-MT+IKZ_JE_>;B&L[6YU2:(W(@$L04.RZGX_P#
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MOA<I #"-P-P(9,;@VWABA4\%%(P0<CG(XK7^"Q DKN4DJ00V=I7=RH8,.=S
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M+P\RVHLXY]+?6O$\:WN)FTH+\',C#<LZ4KTU71[Z)S\N7E7[S](_JZL^=O\
ML*^N7HO[VU?^JKNO-_T6?UC.J_WYTW_Q'I=?7UGOFOQ_J/>N?M4]._1[=/Z-
MDLW=-_SC8?OVU_IXZ^%U1^QGJ+^ M7_J^XK^=#GN.OPDIBE,4IBE?9#]!_\
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MI(/J#@\$$'D&H#J1NS@ X.X;2#[B&P1GT]X((X-?NH]:H=X,G0%;+RI1&O\
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M-O"_VDN/?HMY_P#T3$Y^[GLB^M1[,O\ P^Z-_P"'=.K\I_:#^SWK?^-_4O\
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M/18@F&,4)<-309=PJZ-B2\H8?%()(9CN'Q@NT8&W@9RQ!R><9&,G%8RI^,"
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M#6X8X):J#RNH10DU$I#RRL670*L GRWW6$JB*CSGWXB6W-N)9T\E*]8R21N
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M7'VNOY<?H4_"IYE_FB<Z_E51O[$L>';_ &PWY _IT\2X^UU_+C]"GX5/,O\
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M3F=(Z?&EBM,U]Q[46.*O, <_\VVP]]80YFVVU1O@O.9M':*L;$W&)%+C CR
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MRP!X) SQ7!G^X!^27^6OA_\ W=]_X9SN/_IHN?\ L:#\M)^E7C#_ !).GO\
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M9'9?1DK,C!E.&'(/_P#!X/R@\$<&L64.I5AD'@CD?RC!'R$'(]*AH-XC^/H
M_2K2,HCR;!0'I,P$4F7&^%)$TG*L-GMRCER^M+/,;Z-8HULNMOM ZQ=!19S@
MFQ68V:&$(A(C)DN6&XF(92_#]QM4<85<+A?(-JJI";00 ","L!#$"I"\KV.Y
MN^2<MD^<Y9B"V2"21R:LAE-6TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2N>'DOW?L
MO+NT!>0U.>S\?R0KE' < )N5V!/;IG10721X?MDLFXJ(\T4A"N2VX=TP9#.(
MD-;<I%BBQTNL/K8;W((HWC,C#ZBS&4;B-R%"8\<C&9%*$C'QA6K+(Z.$!^JA
M1%P.'# 2=^#A"'&<_%/WXFE?2!W^_P YP#S3G@>NEX7=^9T@7NP6]3NSU>,=
MU.<@L 2]0Y5"W.YZ2)KKSTYHC6870V!T220AL3U6*OR1TG,6B*,NY/TIW.%[
M$1+(I4[L./-C#;#D<X!XK^$NW"JH/B(H);.09?#.X;05SC((##!..1BLH/\
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M0#A!Q5I# S3D&!6F@L/<DC#^MFYK$P=9-L6H>=@P]6YC6*4*GQ3'&P\P8^9
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M&&E,N5$DG*K'/XM ZHSG;A&12 ZDG>I8$;201@>ASSVX;$B9&=4&XEE9@2K
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M9)%4",F'!W.?8:;=E[APT(BQ=R%.;CQD)89]C2=)U623@$DX[9/;/)Q\YJP
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G)'G;GE54Y.?BECGYR78GWDU/65593%*8I3%*8I3%*8I3%*8I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gbkyd1brmfwp000023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (,!8@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BO(?%MG\5]%\67^L>&9X]1T
MB=U=+!I!)Y8" $;&P1R"<(>^?6JVE_'V&UNEL/&/A^]TB[&-S+&Q ]RC891]
M-U 'L]%8V@^+- \3PF31=6MKS"AF2-\.@/3<APR_B!6S0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y;\3O$?@/
MPC.)=5\,Z9JVMW:[Q$UK$791P&D=E) XP.IXX'!KA-&^)O@274X[77_AMI.F
M0RD8N$LXI @/&64QJ=ON,_2M;[1IEC^T[J,OB5HDC>V0:=)<_P"K639'M()X
M' D /][WKJ_C5?\ AQOAW>PZC-:RW;@&Q3<K2>;D89.X '4^F1WQ0!Z'I]O9
M6NGP0Z;#;PV07,*6Z!8PIY^4+Q@YSQ5FN2^&"W*_#'PZ+K/F?8D(S_</W/\
MQW;76T %%%% !1110 4444 %%%% !7@'PL_Y.%\:_P#;]_Z5I7O]> ?"S_DX
M7QK_ -OW_I6E 'O]%%% !1110!7OK.'4=/N;&X!,%S$T,@!P2K @\_0UYU_P
MHWPS_P _VK_]_H__ (W7IM% 'F7_  HWPS_S_:O_ -_H_P#XW1_PHWPS_P _
MVK_]_H__ (W7IM%.X6/,O^%&^&?^?[5_^_T?_P ;K>\*?#G1O!^HS7VGSWLL
MTL)A/VB12 I()P%4=U%=?12N%@HHHH *Y;QOX,C\8V%M"+UK*XMY"R7"Q[R%
M889<9'!X[]JZ&]O[/3;?[1?7<%K""%\R>0(N3T&3Q4ZLKJ&4AE(R"#D$4 4K
M32K2ST2'24C!M(X!;[#W7&.?K7)V/@+6-*A_L_3/&5[;:/N.VV%K&TB ]0LI
MY7\!78WVHV.F0":_O+>TB+;0\\JQJ3Z9)Z\&K/49% ')^%_ \/A36=2N[2^D
MEM;Y4S!,I9U9>K%\_-DECT[U4/@&]T^YNCX:\2W.CV=TYDEM!;I,BL>ICR1L
M_#V]!7;T4 8NA^%]-T+0FTF%#/#+N-PT_P S3LPPQ;UR./I7.+\/-1M+632]
M,\6WUIHDA.;,P)(ZJ>JI*3E1^'YUWM% '/7GA&S?P3+X7L'^R6S0^4DA7>5Y
MR6(R,DG)/(ZU6UCP9_:WAO1](^W^5_9LL$GF^3N\SRU*XQN&,_4XKI;FY@L[
M=[BZGC@@C&7DE<*JCW)X%.BECGA2:&19(W4,CH<A@>A![B@"AK^E?VYH%]I?
MG>1]JB,?F;-VW/?&1G\ZSKGP;8:CX/L_#NH,TT=K#'&EP@V.KHN Z]<'VYZU
MT=% '"R^!=<OK7^SM2\;7MSI1&UX$M4CD=?1I<DGWR.:[.RL[?3K*"SM(A%;
MP((XT'\*CI4]% !1110 445%<W,%G;O<74\<$$8R\DKA54>Y/ H EHID,T5Q
M!'/!(DL,BADD1@RL#T((ZBHKB_L[2>""YNX(9KAML,<D@5I3Z*#U/(Z>M %B
MBJ%_K>DZ7(D>HZI96;N-RK<7"1EAZ@,1FJ\7BKP[/*L4.O:7)(YPJ)>1DD^P
M!H UZ*BN;F"SMWN+J>."",9>25PJJ/<G@4Z*6.>%)H9%DC=0R.AR&!Z$'N*
M'T53DU;38M033Y-0M$O7&4MFF42-]%SD]*N$@#). * "BHK:ZM[RW2XM9XIX
M'&4DB<,K?0C@TR"^L[J>>"WNH)IK=@LT<<@9HR>S =#]: +%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%4='U.+6=(MM0A&U)TW;<YVGH1^!R*O4 %%%% !1110 4444 %%%% !1110
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MWX.L_P#DJ>H_]@]/YK53PKJ-KX>NM5T;5KB*TF6Z>>)YF"+*C8P03QV_7V-
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M+!*DL9Z.C!@?Q% "7%M!>0-!<P1SPM]Z.5 RG\#3XXTBC6.-%1$ 5548  Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.PR#6_0 4444 %%%% !1110 4444 %> ?"S_ ).%\:_]OW_I6E>_UX!\+/\
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MSZ987-PEQ/8VTLZ?=DDB5F7Z$C-2S6UO<^7Y\$4OEN)$\Q VUAT(ST/O4M%
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MX?M],MDA#0R11.A=\CCEV[5Z#10 4444 %%%% !1110 4444 %%%% !1110
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MU_[?O_2M* /?Z*** "BBB@ HHHH *YVY\"^&[NZFN9].WS3.9)&\^098G).
MWK7144 <Q_PKWPM_T"__ "8E_P#BJ/\ A7OA;_H%_P#DQ+_\573T4[L5D<Q_
MPKWPM_T"_P#R8E_^*H_X5[X6_P"@7_Y,2_\ Q5=/11=A9',?\*]\+?\ 0+_\
MF)?_ (JC_A7OA;_H%_\ DQ+_ /%5T]%%V%D<Q_PKWPM_T"__ "8E_P#BJ/\
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M7M%#N(_N3)G&\#M@X!'N,=<#TF@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %> ?"S_DX7QK_P!OW_I6E>_UX!\+/^3A?&O_ &_?^E:4 >_T444
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M, ]JUJS= T6U\.:!8Z/9[C;VD0C1G/S-CJ3[DY/XUI4 %%%% !1110 4444
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M/A?<^"8KG5=7,?\ :MW&(A%&^X0QY!*DC@L2!G&1\HP>:]6H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#G_'?_)//$W_8*NO_ $4U?/'P4_YCG_;O_P"U*^A_'?\ R3SQ-_V"KK_T
M4U?/'P4_YCG_ &[_ /M2N',O]UE\OS1V9?\ [S'Y_DSM_&OAUO$_AR6RB8+<
M(PFA)Z%P",'Z@D5X/+X6UZ"[-J^CWOG D;5A9LX[@@8(]Q7TU17AX7,)X>+@
ME='L8G!0KRYF[,XSX=>%)_#.D3/>@+>W;!I$!R$5<[1]>3^=8O@'_DHOB[_K
MO+_Z-:O1KN\MK"UDNKN>."",99W; %>3^!=?TJ'Q]K\\M[''%?S.;9W!4/F0
ML.2..#WQ6E*52M"M4:NVE^9%2,*,Z4$]G^AZ_2*BHNU%"KZ 8I:*\P] *\$T
MW_DN-G_V,B?^E(KWNO!--_Y+C9_]C(G_ *4BO9R;^)+T/)S7X(^I]DT445]
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M3T(.12T %> ?"S_DX7QK_P!OW_I6E>_UX!\+/^3A?&O_ &_?^E:4 >_T444
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M]"-5_#5W<S^)?$D4UQ+)'#<((D=R0@P> #T_"K'@;_D2],_ZYG_T(U1\*?\
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MSPM[21,2"OTP: /0J*R]$U=M3AFBN8E@U"U81W4*ME02,JZ'NC#D'\.HK4H
M*.@R:P-:U:Y^VG2M,ECAG6,37=XZ[EM(SP,+_%(V#M'MDUS4FGZ4TA::R>_D
M/WI]0F>5V/KC("_0"@#K/%2.OAVYNXO]?8E;V$^C1$/^H!'XUZ-;3I=6T5Q$
M<QRH'4^Q&17ARP7%O:7,6B22(TL3(=.GF:2"<$$$(6R8WYXP<'H17K'@FZCO
M/!&B2QOOVV44;YZAU4*P/H0P(/N* -ZBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBFET5U0LH9L[5)Y..N* '4444 %%%% !1110
M 5\R?$*:TN/B-J\MC(DD)90S(<C>$4-_X\#7JOQ5\<'P_IG]D:=+C5+Q<%E/
M,,9X+>Q/0?B>PKP:.,1KCOW-<V*J*-/EZL]'+:$JE936T1]%%,D?8A/?M7DQ
MBY.R/I9S4(N4MD>F_!'2Q<^(-3U9R,6L0A1?=SU_)"/QKW*O/_A%X;DT/PH;
MRY0K=:DPF*GJL8'R CUY)_X%[5Z!7O)<J21\7.3G)R?4****9(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'B'Q&^'?C)O&=]XA\&.&_M:U^RWL
M:RI&ZJ5"M]_ VD*IR#D&JM_\/O%OASX76/A30H8[F\U>Z9M6>,<("%P-YX50
M% )[\XZT_P ::]XZ\3_%&^\)>$;\V,6G6XD?;((]_P JEF+8SU=5 'U]:XF&
M?XI7W@>X\4V_B6^ET^!G2>-+QQ-%M.&)&!C&0>#D#F@#Z4\*:$/#/A33-%$@
MD-G L;.!@,W5B!Z$DUL5S?@")H? >CAM1.I%[<2_:VW9EWDMD[N<\]^:Z2@
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M_P"%O?\ 4#_\F_\ ["NZ_P"$;T+_ * NG?\ @*G^%'_"-Z%_T!=._P# 5/\
M"BZ"S.%_X6]_U __ ";_ /L*/^%O?]0/_P F_P#["NZ_X1O0O^@+IW_@*G^%
M'_"-Z%_T!=._\!4_PHN@LSA?^%O?]0/_ ,F__L*/^%O?]0/_ ,F__L*[K_A&
M]"_Z NG?^ J?X4?\(WH7_0%T[_P%3_"BZ"S.%_X6]_U _P#R;_\ L*/^%O?]
M0/\ \F__ +"NZ_X1O0O^@+IW_@*G^%'_  C>A?\ 0%T[_P !4_PHN@LSA?\
MA;W_ % __)O_ .PH_P"%O?\ 4#_\F_\ ["NZ_P"$;T+_ * NG?\ @*G^%'_"
M-Z%_T!=._P# 5/\ "BZ"S.%_X6]_U __ ";_ /L*/^%O?]0/_P F_P#["NZ_
MX1O0O^@+IW_@*G^%'_"-Z%_T!=._\!4_PHN@LSA?^%O?]0/_ ,F__L*/^%O?
M]0/_ ,F__L*[K_A&]"_Z NG?^ J?X4?\(WH7_0%T[_P%3_"BZ"S.%_X6]_U
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M>LT445\H?2A1110 4444 %>":;_R7&S_ .QD3_TI%>]UX)IO_)<;/_L9$_\
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MC69IGBK1-8N3;6.H1RS=D*LI/TW 9_"@#8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,U?
MQ!I>@B$ZE=>1YV?+_=LV<8S]T'U% &G17.V_CKPU=3K#%JL8=C@>9&Z#\V %
M=%0 4444 %%%5[Z^MM-LI;R[D\NWB&7?:3CG'0<T 6*0@$$$9!Z@US/_  L+
MPM_T%/\ R7E_^)K>L+^VU2RCO+.7S;>4$H^TKG!QT//:BS"Y'9:/I>FR226.
MFV=J\GWV@@5"WU('-7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#WUC-7:* "LNUT9;3Q#J&JI,<7T4*20[> \>X;\YZD,!T_A%:E% !1110
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MOKC3/!NN7]G)Y=U:Z?/-"^T':ZQL5.#P<$#K6Q7/^._^2>>)O^P5=?\ HIJ
M/GBV\7?$?Q%I]O>R:YITT9),8N;"!BI!(S_J3CD5I_\ "6?%@# \467_ ("Q
M?_&:RO!W_(JV7_ __0VK=KTZ>%IR@FSYG$9IB(59035DVMO,K_\ "6_%G_H:
M;+_P%B_^,UA>++GX@^)='%MK>KV^HVT,@G6"*)$8L 1D;8UR<,>,UTM%7]3I
M&2SC$WUM]QXSI^EWFI7PMK:(F0'YB1@)[MZ5ZXGBKXKQQJB^*;/:H &;:(\?
M]^:Y7PA_R,6M_P#70_\ H9KM*QH86$H7D=>-S.M2J\D+)67XE?\ X2WXL_\
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M_P!*17O=>":;_P EQL_^QD3_ -*17LY-_$EZ'DYK\$?4^R:***^@/$"BBB@
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M5.3DSJHXCVDU3C2C=^7_  3EK"S\5:==W%S;V.)+@YDW;2.N?7WK0^V^-O\
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MKK_T4U?/'P4_YCG_ &[_ /M2OH?QW_R3SQ-_V"KK_P!%-7SQ\%/^8Y_V[_\
MM2N',O\ =9?+\T=F7_[S'Y_DSUFBBBOE#Z4**** "BBB@ KP33?^2XV?_8R)
M_P"E(KWNO!--_P"2XV?_ &,B?^E(KV<F_B2]#R<U^"/J?9-%%%?0'B!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 445YY\3/A=_PL6?39/[8_L_[$LBX^R^;OW%?]M<8V^_6
M@#T.BODY_@^9_B.W@[2]=2ZFM[;[1>W,EKY:P#Y< #>VX_.GI][ZU?\ &OP'
MO_"GARXUFUUJ+48[4!YXFMS"P3."5^9@<>G'&?I0!]145ROPUMK:T^'&A16=
MTUU;_9@R2M'Y9(8EL%<G!&<=3TKJJ "BBB@ HHHH **** "BBB@ KP#X6?\
M)POC7_M^_P#2M*]_KP#X6?\ )POC7_M^_P#2M* /?Z*** "N?\=_\D\\3?\
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MQK_Y@?\ V\?^TZ[LM_WJ/S_)G'F'^[2^7YH]G^"7_)(="_[>/_1\E>@5Y_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9=K$X.0"1CJ*Z_\ X9Q\'_\ 02US_O\ P_\ QJC_ (9Q\'_]!+7/^_\ #_\
M&J /0/\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ\_P#^&<?!
M_P#T$M<_[_P__&J/^&<?!_\ T$M<_P"_\/\ \:H ] _X3OP?_P!#7H?_ (,8
M?_BJP_&?C3PK=>!?$-O;^)=&FGETRY2..._B9G8Q,   V22>U<W_ ,,X^#_^
M@EKG_?\ A_\ C5'_  SCX/\ ^@EKG_?^'_XU0!Y9X4U33[?PU:13WUK%(N_*
M/,JD?.W8FMG^V]*_Z"=E_P"!"_XUW7_#./@__H):Y_W_ (?_ (U1_P ,X^#_
M /H):Y_W_A_^-5V1QDHQ4;;'CU<GA4FYN3U=SA?[;TK_ *"=E_X$+_C1_;>E
M?]!.R_\  A?\:[K_ (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&JK
MZ]+L9_V'3_G9PO\ ;>E?]!.R_P# A?\ &C^V]*_Z"=E_X$+_ (UW7_#./@__
M *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\ A_\ C5'UZ78/[#I_SLX7^V]*_P"@
MG9?^!"_XT?VWI7_03LO_  (7_&NZ_P"&<?!__02US_O_  __ !JC_AG'P?\
M]!+7/^_\/_QJCZ]+L']AT_YV>?>&-9TNW^-N@7\VI6<=E%;RK)</.HC0F.8
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M_?\ A_\ C5'_  SCX/\ ^@EKG_?^'_XU0!PO]MZ5_P!!.R_\"%_QH_MO2O\
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M1'_PE/A[_H/:7_X&1_XT?\)3X>_Z#VE_^!D?^-2?\,X^#_\ H):Y_P!_X?\
MXU1_PSCX/_Z"6N?]_P"'_P"-4?V-3_F8?VK/^5$?_"4^'O\ H/:7_P"!D?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^20Z[_V[_P#H^.CX)?\ )(="_P"WC_T?)7H%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 > ?%/\ Y.%\%?\ ;C_Z5O7O]%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5SWB;P-X<\8O;/KVG?:VM@PA/GR1[0
MV,_<89Z#K70T4 >?_P#"DOAY_P!"]_Y.W'_QRC_A27P\_P"A>_\ )VX_^.5Z
M!10!2TC2+'0=*M]+TV#R+.W7;%'O9MHR3U8DGDGJ:NT44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6+XM\0Q>%?"FI:Y,@=;2
M'<J$XWN2%1<]LL0,^];5<!\:;.>]^%&LK A=HQ%,RCKM612Q_ 9/X4 >6:#X
M/\<?%RTD\1ZIXE>QLY9&%M'EBIP2#LC! 50<C.<G!SZGJ/AU:_$'PCXZF\-Z
MPEYJFALI(O26>*(XRK*[<CIM*=B<^YZ7X):Q9ZE\,M-MH)D-S9!X;B(-ED.]
MB"1Z$$'\_2KR_%#1Y?B(O@VW@N;FZ/RFX@VM$K!2S!N<\ <D9YX[4 >0^,-!
MOO%_[0>J:!;ZM+8B1(W#C<RKMMD;[H(ZTSQ+X%\;?"NS3Q)I?B:6ZMH)%$Y0
MLFS<0!N1B5922!]2..XZ.T_Y.TOO^N _])$KLOC9J=K8?"[5(9I(Q-=^7#!&
MS %VWJ3@=\ $_A0!TW@_Q%'XJ\(:;KB((_M4.Z1,\(X)5Q] P-?.?Q*\>7GB
MKQO9R:?-,FA6MU]EM71L).ZLID?(ZYW)^&WIDUK7?B+4/"7[.FAZ? KPW.LO
M.OF]"D)=B<>[ @#V8]\5ROB_Q'X6GT?PAIGAQ;HPZ.96N7FA"-*SF,ENIR24
M;Z<"@#Z]HK(\,>)+#Q;H,&LZ:)?LLS,J>:NUOE8J>,GN*UZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR
M/XS>.]7T6?3?"WAMBFK:I@F5#B1%9MB*F> 6;(SVQ[Y'KE?/WQ7F&A?'3PKK
MEX-E@$@+2GH LK;_ /OD,#^(H @O/@MXZL=,DU>V\6RSZPB>:T,<TH9B!DA9
M<Y+<<9 R?2O0?#&K>)=3^$>IR^)[&YM-3AM+A!)-'Y;3*(R5?;P5/8\#IGO7
M:ZIKNG:1H,^M7-U%]AAA,WFJX(<8R-I[D]L=<UR6F>.+/Q[\.-?U*RLKNUCB
MMIX6%P%P6\HD[2"<CD>E 'BOP\^&>J^/_#]QJL?B>6R$-TUMY;(SYPB-G.\?
MW_TKH/#>J>*OA7\2[#POK^HR7^DZBR)&2Y=/G.U77=RN&X(],]>#74_LX_\
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M^-?@E=^*_&M]XBM_$2V)N?+VQBV+,FV-4^\&'7;^M9^F_LYPG48[C7O$D]_
MF,PQPE&< YP7+$@=>@SSU%>Y44 01V5K#;0VT=M$L$*!(HP@VHH&  .PQ7"_
M$3X9CQQ=:+-;WT-@-.>1V7[/O\W<4..",8V>_6O0:* &HB1KM1551V48%.HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N=\9>"])\<:-_9VJQL-IWPSQG$D+>H/\P>#^5=%10!X)'^S:
M?M"1W'BR1[%&R(UM,-CVRY /O@_2O7;7PI8:7X-E\-:4@MK5K:2!&/S'+@@L
MWJ<G)K>HH \ A_9SU.W0I#XQ\M2<D):L!G\)*[/X??!G2O!&H#5)[Q]2U-5*
MQRM$(TBSP2JY/..,D_E7IE% 'GGCCX56_BK6H-?TW5;C1M<A  NH!D/CH2 0
M00.,@]/6HO!?PFC\.^))?$NLZS/K>M/G9/*A4)D;2>223CC.< '&*](HH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HK!UWQIX?\ #5U';:OJ(MII4\Q$\IW)7.,_*IQR#UK=
M5E=%="&5AD$=Q0 M%%% !1110 4444 %%%% !1110 445#=W4-C9SW=R^R""
M-I)&P3M4#).!STH FHK,T/Q#I7B2S>[TBZ^TP)(8V?RV3#  XPP!Z$5E2_$7
MPE%J7]GMK,1N=_E[4C=ANZ8W!2OZT =116-8>*]$U36[K1K.]\W4+7=YT/E.
MNW:P4\D 'DCH:V: "BBB@ HKG-:\=^&_#VH?8=5U+[/<[ ^SR)'X/0Y52*S_
M /A:_@G_ *#7_DK-_P#$4 =G16;HFOZ9XCL6O=)N?M%NKF,OY;)\P )&& /<
M5I4 %%%% !116-KWBK1?# M_[8O?LWV@L(OW3ONQC/W0<=1UH V:*QM=\5Z)
MX:6W;5[W[,+G/E?NG?=C&?N@XZCK6P"" 1T- "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gbkyd1brmfwp000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000009.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #> ET# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            <(!@D$!0H# 0+_Q !<$  !! ,  0$$ P@)
M#P@'"0 $ @,%!@ !!P@1$A,4%0D6(1<8(C$W.%=X&4%887:5M;?6"B,D,C51
M<71WD9:TMKC3)2<Y0G6!E](S8G*2E-'7)B@T4X*8L;+!_\0 '0$!  (" P$!
M              (# 00%!@<("?_$ & 1  (! P,!! 4##@@+ @P' 0$" P $
M$042(083(C%!!Q0R46%3<7,(%2,S-%)R@9&3H;&RTS="DK.TM='2%C94571U
M=I2CP=078B0E0U:#E<+#X>+P\1@X1%=C@J+5_]H # ,!  (1 Q$ /P#W\8I3
M%*8I3%*8I3%*8I3%*8I3%*8I3%*UF]<L-ZZ?Y-]KY47Y&W+QEH_"_'^C=1KA
M]+<J$>19I>W'7CZP=%MA-J@Y9R=H?/$U:-B3ZT&_%Q9!1I*I.2:?>']UN1JJ
M0QR=DLS22LA#;C@*%PB[2,,V2<G)]PQFM.1F>:1#*T*1Q*X*E1DL6RS%@<JN
M ,<#WGPKI+AYXV^ABVR0KT'1^S<X\?.?>/%D[3U/=F(I-CZ8UW,0-<7:>+4*
M-@[+!$B+CGFK(@*8MD>)+&G*J<"3L@+X]V2VJO@$O&\K3+$FW<J&+Q65R5/C
MD<*2,;CXXK#7+*&("R)$L32/G:7$F.]&N"#P0<%ADG:*XK_G7WF4Z"NF5#BW
M*R09SL?E/Q6FRMAZC:8TE<QXRZEIB2L]ECX_G4HV'$6"NPQ@P,1&&GG[L&V=
M$' Q;BB6WJT03<TC]V."5P$4\3$ *"7'()!)(\/(FGK,I;"QH09)HURY!S#G
M+'N$8(4\ YSYXJ'&/I NQL2/1>^154KLUR.&\3_%7O5GYA8[\1$2U3&Z#)7Q
MBX#<X6)4#6;/8#]:"1\7.DP4>O=>B M"H,L"?@;/58R$BW$.9YXE<)G=L"[=
M_>[H'N&3R3Y<U^M29>7:"@@@E9"QRH?=NV=W!/AR<#@#SR)EA/+CK3?0YGF'
M/JE'W>SW?R<\HZ! E]9Z 5$P53C.+T"E709H-57YX1)"U\IF6,$CJZ^'*R81
MRDZ+L[PY3A$=68(]H=VVA886.Q 2QD=D\W )XR3D ^0J8N'W%44,6FF4%V("
MB-%;/"YQSPOZ:QT[Z3:><J_%;U <QK$E!W2F\%M72J\S/] E;525=ROVJ"$Q
MN5@N8G<]KX8!:7)&O/\ 0+A6I6^H;) @X,=T)PEW(LAF12[!E:0(V$"MV:[O
M OO.? [%(3Q)YK!O#B-@BX98F=<N67M&V^(38,>*[F!89  (..AJOEWVF-MH
M$MV(CXF!A_+WS%H+$=S6:'::*I?".1=0LGU9GH.0H0C]E"C7:B+NK/"SD+-R
MLRXS-3IJ&V%01<C;QE2(_$P6[9<>#2N@W A^,Y[W! &0 ?&L"XD# OX>L7"#
M8?XL2/P04Y'=[O()/).>*R.0^D<Z=5:.79;AQ6B+F;-P'G'DMRR)J'49.=CS
M*)T#J]!YGJK7V6-I,3N!N$;OH,3)CGPH<Y7I=3$L**\UN(><?CZI&6"K*V%E
M>&0M& =RH[[D&XY4[",$AAQ[ZEZVX4L8URT:2H%?/=9T3:YV@!AO!R,@\^ZK
ML>.O:KKU&5[?3>CU&LU.[<0Z</0I;5+LDI:*O-"2]'J=]AI2.D)JOUB4:>3&
MVMF/D!B8IM/Q8*R6%Z:)T.-K31J@B9&9ED3<-RA6!#%2" S#Q7(Y\#6Q%(SF
M5755:-PIVDLIRJL""0I\&P>/$9^%:M/%:_\ EU8/&MWR$FICR%FI?[@G3+K$
MV[H?6.$&\,F;%%PLXF-*9Y]6*R9UD%8OPJC(=F596,F7C6]2_P#R<3]N],L
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MB*P^53X@A<+$4APAZI0X6W1EZ1$0+Y+A$?%JTL!HE+!&QU/BC.,S[>8 @2N
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MQI][:EH""&8UO2&DZU668A022%&%!/ !).![N235@506( !8@L0/$@8!/O.
M!\PJ ZIX4>)%%F/K!3O'7DM:F]QLW#[E(>FQ(1NXJR0YU?GH_P!^RPE?PLO"
M24A%GL^OLDA&$,.:VAQ6MVM<SL,-+(1D'!8XR""#^(@$?$ U4MO IRL48.",
MA0#@C!&<>8)!]]2$=P+BDG'DQ,AR^E&1IE"K7+2@2(()P8CG5-/>E*K2W6E-
M[2NNU^1(?-BHS>OAPR'7'6D)4K>\B)9 <AV!W%\@G.]AAFS]\1P34NRC^\7E
M0AX'L+R%^8>0K@G>-W 9._RW4Y+C?.9#H<]&'P\W;CJG#ES$K'RL,NN2C,@^
M^*XDIR3KKBZ](%/(66; K7#$ONQJE"[":4((Q(X0'(4,< YSQ[N>?GYH88BQ
M<QJ7(P6P,GC;S^+C/CCCPK'H_P 0O%^*K-CIL?PCF0M8MX-?CK1#HJT=L6?%
MJ11AM4^:[6TIXTBKDGE.5PUYU1L'[:6XL@5MEA#<C<3EE8RON4DJ<\KN]K'X
M7F/ ^=1$$(!41)AL C:.=IRN?P3X>[RK%ICP]YS(W3@$E&?!57E_CA*&V[GW
M%JQ4ZO%U5OH9 \Z,-<3)=N/W8-+!^?D2FHD,L40^RBA6"3<,,;>T_D7#A9<Y
M:28;7E9F+;..Z!G'.,9.2%X&*P;="T1&%2$[EC55"[L$;LXSQG.!C) )Y%6V
MRBKZ8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*QNWT^J7^M3%-O-;@[?4[ )L&;K=DC YF$E1-K0[[@Z-/9?
M%)0AYMI]KWC2MM/M-/M;0ZTVM.59E(9258>!!((^8BL,JL"K ,I\00"#\X-0
MNWXB>+[7.5<B;X-RY/,W+"W;7Z7]48K<$7:&AUB-6$X7;&_CYIH1Q0;<D:M\
MM FD"I=TPTVVBWUB;?VG:OOQMW;CD#W#W#SP.,\U7V$.W9V2;,[MNT8+>\CS
M/Q-=D[XM^.+O-F>/?<0YBSS :818QJ0)3X8*!%L;>E)38QA Q6/A[#[M2V53
MC*T2K@[CHZRU,.N-JQV\V_M.T??C&[<2<?>_@_#P^%.PAV"/LTV Y"[1C/O^
M?XUG1/*.9E\\9Y*_0ZJKF(T9'0H]!3" M50>)B'QBHR.8A&66P&@P20Q7QF&
MV4H;>8;<3KVD^N0WOO[3<V_).[)W9/B<^-3V)L[/:NS &W VX'@,>%=S<Z74
M^B5B8I5ZKT3;*E8!DAS==G0VI")E!4/M$I'-#?2II]I)##+VD+3O6G&D*_&G
M6%9D8,I*L/ C@BC*KJ58!E/!!\"/C5..^>#\3V^;NEG^N@<!8+;8J=*H*D*8
MJQ"#P56H,]2GJC)-#6NMR4I#&R,T/?@-!2\'\GO-:JD[[N0)@A59?%<F,*NT
MD*K#AMIRSAMPRK $ %.0<HS#C)JB6V$A8[L%BIY7(PJE=I&Y<C)##D895/E7
M&\>O&_H_+_(;IU_L3]=(IDI'7F/KLPDTN3OUL<NW0P+J(;=I=]"')=56C0?J
MQ![/:&)@*ZW"U8-V=$AEV&0S-,CQ(BYW#:2,85=J;2%'EN/>./%LMQG 11.D
MKLVW:=V#DEFW-NRQ\\ 8'F!M7G;DVBDN&\>F*[8ZE*<VIY]:MUS>Z+984F$#
M<!F;X_)AS3MP-:VW^'8URP 4A\W3M)J2QFGDO:4GUR@2R A@[!E78#GD+C&W
MYL'&/"KC%&05**59MY&."V<[OGR,Y\:Q83Q5\;@)JP6(/B'-1YNULV\6QR3=
M4BM$S(70!R!;O'G*VQO3L;:VBR]ST;[.@))\PLHH=PHHAYR7;S$ =H^%VD#<
M>"OLGYU\CXC  X%1[&$$D1ID[@3M'(;VA\S>8\#7T8\7/'4>JS=';XQSQ52L
MD'5JW/0+]; * E82D$2)=.!-;);>4\FK&2\D9 /*7\3$F&/%A/,D*TYIV\VX
M/VC;@68'.""P 8\??  'W@8IV$.TKV:;2%!&!@A?9'XO+W5)-"Y[1N6U>.I/
M.:G TFI1/Q&X^OUN-&BHP=PM]PLPC0PK;:7"SBWGBSC'O>%&E.NDE/.ON+<5
M!W:1BSL68^)8Y/'SU-45!M10JCR P.?'\OG68Y&I4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*
M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H>[19.Q5F!@B>+\\@
MNC3YMM@P)N.G[0BK"1%4V_LNP3*25C$;+(U'"$18++&G"!Y64CI#X"5$$, =
MLC6-B>T<H I((7=EO!1XCS()^ /(\:KD9U [- Y) ()P /$GP.?# ^)'C416
M3H_EZ /U!ZO>/=+FG('H5<$YD,YTT8-ZZ\S4ZIFTRAJG@4,1-E3\I,)B6#70
M1F6+3#(=$D7*^=N?L5+<E-TK %3O[GLO_%'CRO(R?>#R,C$"\XWXB4X8;._[
M2>9.0,-QQ\X\:E>A67M,KT+H\)?^<UVKT&"^1[Y]<(BV_.RKC\:)M<JA^)4
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M_ .:?$D0JTXS8I&-99VX9)1D"ZW,R8(Q $8M)I+&\M@^W1=[9WU[PQD<^6>
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ME4T_:J!@C#EER<[5*(NT>X97=QQDYQG-6PP=DQ;(Y0*V!C+!W;<??PP7/C@
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MQL4WM\8#*S0,6V1,[;9A'B0(IV1=60V._)HV1*X,QV]LZ-C=M"-&P'ANR(^
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MD]KO- U:YNIKB'K?J;3H97+)96=GT:]K;+@#LX7U#I.^O&08SFXNYY,D]_&
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M>JV_R2_I_MI^Q[>&_P"@V!_CVY?TDQZY<_*G^2G]VGJMO\DOZ?[:?L>WAO\
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MD=G8DVS^EGTD3SS7#]8ZXK3RR3-''=M' C2.7*0VZXAAB4MB.*-%CC4!44*
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M0R/N.6LG)U;4MH7UZZX).1/+N.<<$[N0,<>[)]]8_P 'M"R3]:--Y &/4K;
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MI5FHC;3%?E&FP:[>G7M&':"3"0$:]GDY#;68GR&'5=N/,D'/B.2OEXS,C"0
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M#BO95K?IO,@D$$'!!!!]Q'(-8(!!!&0001[P>"*HJOP&JKW/[3S:U][[Y:J
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M0C(\9\_FSCY%R,=EYN5E"SI,Y[21&!:Y9C(%4(J*I9@J[L;GQN8EF8\X&!G
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M/*CD*^;KYC$:J8_&P?'&VV#F-I#.!H3%P6Y(]+#B:[ VMZTOQ,\08-61&2I
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M8PYMPHAR89;9G&QY)F0GDRN]FD5""$=GVY4$+P&![N>,$>[PXJ)@CPVQ1&S
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MD:"TP& "(PA#(P@K+3##2$MM-I0G6M8)+$EB22<DDY))\22>2:R      .
L, #W #PKM,Q6:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gbkyd1brmfwp000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (,!&H# 2(  A$! Q$!_\0
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M/GU&WC_ZXVIS^;,?Y5HT4 9@TR]/W];O#_NQPC_V2G?V.K?ZV^U"3_MY9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]XT[2U7PMXXUS2]/3;IITW^T4M@25CD!VD#GC/)Q]/2B,VM^['.E!_#O9/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&7^AI/)D/;/N"Q_EF@+%G[5:+TCE/_ __KTGV^W_ .>+_C(:J& YYDQ]0_\
MA2"VS_RV'_?+?X47861>%_!_SP'XM_\ 6I?M\'_/"/\ ,?X546S'_/9/QS_C
M3OLN#Q=QK]'Q1=A9%P7D?_/O&/\ @0%+]L4<_9D_!UJA+&P'_'RK_P#;;/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRWMRR,N2""ZODL2>V!6K;Z3J F\',UJRBPA=+G+#]V?+"COSR.U&@CL:QM2
M-WT'W16S7)>(9I$U0A7P-@XSBLY.R-8*[+:J"<?)^) I^%!Y,8_X&#_6N=$T
MYZR-^#4%YSTD?_OHU',:\AT3"(_QK^G_ ,53=D7=E_,?XU@ 38YE;_OHTF),
M\S<?4T<P<IO8@'5OTS_6E#6P]3^!']:P"FX?ZPGZ#-(L1'=S_P !I<P<OF=
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M?93_ %%'D%>MJQ_WE8?UK*;4;QSSQ_OOG^M1M=3G_GD/P/\ C2NA\K-G:/\
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M.Q(/X": *_D*QX)_[YJ.YVVUNTK/M51D\"K3=/F4BL"Z?^U=16UB/^C1',K
MC!-)NQK2ASO79;DVF6SW+-?SK\S_ .KXZ+6IY1Z<_E2*L2J%7: !@#<*>N/X
M2OX,*$K"J3<Y7(_(YY_E3MD8ZU)@^OZ49/HU,S(O+1CQO_#%+L7IL/YU)\WH
M?^^C33^'\Z &%%_N_J:!#&>H_4TO/8D?0"G#'=C^E QOE(/X3^1H\M/1J=@>
M_P#WU3EW < D>YH$-$48Y&\4NWCB5Q3\D]5IOR^A_ T ,RXZ3O\ ]]&D,ET.
MCDC_ 'O\:>1_UT'Z_P Z3 SPY_%10 @N+@<&3]!2&>ZSP[?@HI_/^U2C/O\
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M '1^*T )Y( XX_"F" YRT@J49QR%_"C\ORH 88UQ_K%'UH6!1SO'/H*>"/\
M*T[- $'D8.=\A]L4[8,<@CZFI"2?X::=W<#\,T#(3''G)D_44\>7C );Z&G<
M>C?D?\*>-V.!@>YQ0 Q40_P#\33_ "_15'X4Y23P9(\^S4OEY_C_ "H$-V'V
M_E32/?\ \>IS;%ZL?^^:8'C;HV?I0 T[>Y7\Z>, =J,#T/Z?X4\  ?=8_B*
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M"O\ C0 _8H'W"/H:82%/$3GWXQ3PP7JLA^HS2"9';:$8D>JT &4;[QQ_P/\
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MR1(?S_\ U5*')/$;8]210 O*CIDU&7.?]2OU)_\ K5-SW I"H(Y /XT 1"9
M?F\M?^!8IVZ)^C@_1J&BQ]Q0/H<5'^]4YSC\"?ZT#)!&/X2PIV'7I@_4U$)3
MGYIE'X ?UJ02QG@.&^G- B-IL'#E<^@KK]#YTN/ QR:Y0DD?+D?E76:)D:9'
MGKDU<-R*FQHT445H8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%E:K]VVA'TC%*;.U/6VA/_;,5-13%<J-IE@_6TA_! *K2Z!9/S'YD)_V'/\
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M_(FMFBBP<QBMIFH=I;7_ +Y-1FQU).?)MI/]UR#^M;U%%@YCG7GO8!^^T^0
M=U^8?I59-1MY)<O&@_#D5U=5[BPM;L?OH$8_WL8/YTK FC-21&7*$$>U&^-C
MUQ^-0W'AZ2([[&<C'\#G^M4&N+FT?9>P,/\ :QU_&BX[)[&JT9(X*D>A%-\L
M$?,@!]< U7ANX'Y2;'L14SW,&W#,#[8S0%F.$;+TV_J*D!/\0Q]*KHC,-\4S
M!#T!&:E D'613_P'_P"O0(#)$K88@$^HI'W$?(S9^E/>-)%P_(IHACC^XBT
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M_P#CQJ>5E\Z,:BMG[#;?\\__ !XT?8;;_GG_ ./&CE8<Z,:BMG[#;?\ //\
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M,/:KL<.-,U1C]^V0>Q)_I4G]B74@_>Z@0.X5/\37:?8;;_GG_P"/&C[#;?\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(2%4LQ
M &230 M%5[.^M;^U6ZM)TF@;.'0Y!P<&GV]Q%=V\=Q!()(I%W(Z]"/6@"6BB
MB@ HHJ*"XAN5=H9 X1VC8CLP."/P- $M%%% !14%W>6]A:O=74JQ01XW.W09
M./YFLR+Q=X?FE2*/5;=I'8*JANI/04 ;5%9U[K^D:=<"WO-1MH)CCY'D (^O
MI^-6C>6PDMXS,FZX!,(!SOP,G'X<T 3T56OM0M-,MOM%[.D$.0N]SQDU7T_7
M])U69HK&_@GD4;BB-SCUQ0!HT4R::.W@DFE<)'&I=V/0 <DTQ+NWDG$*2JTA
MC$H4==A. ?I0!-152_U.QTN 37UU%;QD[09&QD^@]:&U6P33O[0:\@%GC(GW
MC8>W7Z\4 6Z*K6.H6>I6_P!HLKF*XBSC=&V0#Z'T-6: "C.!DUG:Y-=0Z5-]
MBADDN'&Q=@R5SU/^>^*YS3=/U'7H#'J5Y-#! 1&;<+M9L#J<_P SGO32%<V+
M[Q196S^3;;KRX/"QP\C/U_PS5/[%KVM\WLXL+5O^6,?WB/0__7_*MRPTNRTU
M-MK J$C!;JQ^IJY1>VP6[F?INBV.E*?LT6'(PTC'+'\?\*T***0PHHHH I:O
M_P @6_\ ^O>3_P!!-<OX#_UE]]$_]FKJ-7_Y M__ ->\G_H)KE_ ?^LOOHG_
M +-5+X27N=K117.>+M6NK*"RT_3G$=_J,PABD(XC7^)OPR/SJ2CHZ*Y/_A7V
ME.OFRW-])?\ 4WIN&\S=ZCM5FSN]4T'PM>3ZVRSS66_RY W,R#[I/H2:=A'1
MT5Q&E^%D\1Z9!JGB*YN+N>Y7S4B$I2.%6Y 4#VQ_GDZ>BZ1J>B:S+;1W#W&A
MM%NB$\FYX7S]T?[/_P!;WR6"YTE%<EX-=FU+Q*&8G;J3@9/3DUU;ML1F"EL
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMX\ELS-#<FY?SD+=?GSG';%'_",Z3_97]G"V(A\SSMP<^9YG]_?G.[WS[=*
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ME/+! \F9H\Y]<=:YGP]HD.HKJ1N+N_/D7\L$>+IQA%QCO1.K.,U%1O?S_P"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWIK]3GK_ /Y'_2/^O::N;DQ_P@^N93>/[6.5'?YTXKT8Q1M*LIC0R*,*Y49
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M(%R?PK.&&G%QUVMWZ?/KYFE3%PFI>[O=ZVW?RNK>6_4FKG/"'W-:_P"PK/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVC9KZ&QRDH? QD<-MSN_SBK4>@>(;73_ .R+76+==/ V).T3?:(T_N@@XZ<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6K_P#(%O\ _KWD_P#0
M37+^ _\ 67WT3_V:M#Q:=3@M&FM9S]E=3'/%L!P#QG.,X/2N5T"74_MWV;39
M?+>;&]MH( '<Y';-6EH2WJ>GT4V-62-59R[  %B!D^_%.J"@HHHH ***@N;V
MULTWW5S# OK(X4?K2;25V-)MV1/17+WGC_0[8[());R0G 6",_S.!^6:J?\
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M+0_^@SIW_@4G^-%PYH]S3HK,_P"$BT/_ *#.G?\ @4G^-'_"1:'_ -!G3O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &2K&T3K*%,9!#!NA'O6;HND66F)*]HXE\U
MB=^<X7LOX5YOX]UJZO-=FL/,9;6V(41@X#-@$L?6L71-<O=#O5GM'."</$3\
MKCT(_K7DU,WA"JZ?+HM+_P# /<IY'.I053FU:O;_ ()[O3)9HH(S)-(D:#JS
ML !^)KC_ +-XWU4DS75KI<1X*1@,WUSS_,4^'X?VDDBRZKJ%YJ$@Z^8Y /\
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M="D]2>> ,=ZZ>7Q+IT%G!<L\ACF#%0(R2 OWB1VQ7,:3X=>]U*--1LGABM4
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M_O\ 2?\ Q5'_  @7AG_H%K_W^D_^*KHZ*+(/9P[(YS_A O#/_0+7_O\ 2?\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV.\HK*T?5_MRM;W $=[%_K(_7W'M6K748!1110 4444 %%%% !1110 4444
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M&,8P<*1VIM =K138T$<:H,X4 #)R:;/*(+>28C(12V/7%0VHJ[&DV[(LV_\
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MH_V#TKRZD+,[X2N=311161H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M*H_\(-IW_/Q=?]]+_A1_P@VG?\_%U_WTO^%'NAJ7O^$KT3_G]_\ (3_X4?\
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M(4445(!1110 445%)=013)%)/&DDGW$9P"WT'>@"6BBB@ HHI"0H))  Y)-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEK_S+[O^"<]_PL/P]_S\3?\ ?EJZ:*59H8Y4.4=0R_0U%]AM/^?6#_OV*G
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M2CC@E:$6\,$;[]B9W'+=R3Z5N5E.USIHWY=?Z04445)J%%%% !1110 4444
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M7GOAS_D;S_O2_P C7H5>>^'/^1O/^]+_ "-5'9DO='H5%%%24%%%% !1110
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MK9:C/=0VDPE>U?RY< X5O3/?\*!E;R=?_P"@AIG_ ( R?_':/)U__H(:9_X
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M?_Z"&F?^ ,G_ ,=H\G7_ /H(:9_X R?_ !VM6BBX&5Y.O_\ 00TS_P  9/\
MX[1Y.O\ _00TS_P!D_\ CM:M%%P,KR=?_P"@AIG_ ( R?_':/)U__H(:9_X
MR?\ QVM6JD>I6DDMY&)0#9D"<L"H3(W=3QTI@5?)U_\ Z"&F?^ ,G_QVCR=?
M_P"@AIG_ ( R?_':TH9H[B".>%P\4BAT8=&!&0:?2 RO)U__ *"&F?\ @#)_
M\=H\G7_^@AIG_@#)_P#':U:*+@97DZ__ -!#3/\ P!D_^.T>3K__ $$-,_\
M &3_ ..UJT47 RO)U_\ Z"&F?^ ,G_QVCR=?_P"@AIG_ ( R?_':O6UY;7@E
M-M,DHBD,3E#D*PQD?49J>F!E>3K_ /T$-,_\ 9/_ ([1Y.O_ /00TS_P!D_^
M.UJT4K@4=(NI[S3_ #+GRS,LTT3&-2JG9(R9 ))&=N>IJ]69H/\ R#I?^OV[
M_P#2B2M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KSWPY_R-Y_WI?Y&O0J\]\.?\C>?]Z7^1JH[,E[H]"HHHJ2
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\/?ZG4/\ L(7'_H=;
M%8_A[_4ZA_V$+C_T.@#*\3J+WQ7X;TV<!K22269T(X=D7*Y_7\ZZ6^LK?4;&
M:SNHP\$RE77_ #WK,\1Z-/J<=K<V,J0ZC92^;;NXRI]5/L>/RK.NI_%VIVLE
M@NDVVG^:NQ[QKL2  ]2J@9SCIFF(@UNTB_X2'PKH94MIZ&1_+<YW&-/DSZX_
MK75WUE;ZE8S6=U&'@F4JZ_Y[UA:CX8D.E:8FF3JE_I9!MI91D/QA@WLW>H+N
M?Q;JEK)8+I-MI_FKL>[:[$@"GJ54#.<=,T 0>(]FD:EX62"WN)X[9Y$2*(;I
M& C  &2,_G4.N^()=;@D\/6VC745Y>)A?M^R)0O=A\QW$8S@>GM6K/H$T5WX
M;6U^>WTTL)7=N2"F ?<DU:\3Z'_;>F;86\J^MV\ZTFZ%)!TY]#_]?M3NA%2_
MFN+&PT_P[I\V=1EA6,S8_P!3$H :4_R'N?:H?"5E;Z;J^O65L-L,4L*J,\G]
MT.3[GJ:L2>%[#7XK>\U_3%.HB(1R;9V &,]-K 8Y)_&JV@^#+'2-?O+Y;,1J
MCC[$PF8[5*8;C/J3US1I89MZ_=36/A_4+JW;9-#;NZ-@'! XX-<[_:NM:3X9
MD\0:C?17/FP(T-F(0BQLY&W+=3P>?QKHM>M)K_0+^T@ ,TT#H@)P"2.*I7^A
MRZCX/CTHR"*Y6"(*_4+(F"/PR,4D#.=F\4SZ5#%?/XGL-3 =1/9QQHIVDX/E
MD<DCWK9N;[4]6\1W.E:7>K8PV42///Y*R,[OR% ;C&.]18\37GE6O]DV6GD,
MOG7HE24,HZ[$QU/O3KF"[L?%5U>:,+:ZFGA07EG)-Y;#'".#@\8XIB*UEJ^M
M17?B:TOKJ.633K97@=(@HR49@V/4\9'(SFM*35+Q?A^-5$H^V?V>)_,VC[^S
M.<=.M8^A6UYJ'B'Q9%?F))9XHH7,)+*F4( !/4@8S[TGV#Q3+X8?PZVGVT2Q
MVYB%Z+D$2*.BA,9!( &3ZY]J +D\KS>+?"LLAR[VDS,<=247--U"^U*.[N6O
M?$MEHJK(1;VX2.5F3LS;N<GG@5>.D7?]M^'[K8OE65M)',=PX8H ,>O(K)TW
M2=8TB[NPFAV5Y=2SO+'J<LZCACQN&"PQZ#_Z] &=KNHWNN?#&/4);A482A9U
M2,8EQ(%!]N@/%;.LZY<Z7=:?HKZO!!<2QM+<:A/$H"J"<87.,DC'X57_ .$8
MU5OA[<:*RQ?;1,70[_ED'F!\Y[9YZU=OM.U:XN]/U^+3X/[0BB:&XL9)@5="
M21A\8R#S^/M1H&HS0_$+MX@&DR:M;ZM'-"9(KF)%5E8=58+QTY!XK-L]>U34
M@[1^(K6TU,2,O]E7-NJ*"&QL+'YB<=Q70Z5'K5SJ375[:P:;:+'L2U1DD=F_
MO%P...PK$U/3=>U*Q?3K_0K&^N"K1QZH9D4*#G#;=NX$<<"C0#N4W%%+@!L<
M@'O7-ZW_ ,CMX6^MU_Z*K<T^V>STVUM7E,KPQ+&TC=7( &?QK.U/3;FZ\3:%
M?1*I@LS/YQ+8(WI@8'?FDALSO''VGR]$^Q^7]I_M.+RO-SMW;6QG'.*5;G6=
M(\2Z997VIK?V^H"1<&W6(Q,B[LC'4'WK1U_3KG4)=(:W52+:_CGDRV,( V?Y
MTW5M,N;OQ%H=Y$JF&S>8S$M@C<F!@=^: '7#:5X6MKW4)3L^TS&60DY>1R.%
M7U]A]:A\(6-S9Z3-)=0"WDO+F2Z%N/\ ED&QA?TK&DL?$3^)9M4N-(@O5C8K
M9+)=A5@7/4+@_,>.:ZO3)]0N+9GU&SCM)@Y 1)?,!7 YS@=\\>U# RM8U&_F
MU^UT+3+A+69X&N9[AHPY1 < *#P23ZTW[9J^@VNI3ZK*E]:6\/FPW 58W9NZ
M,H_#G%/UC3;^/7+77=+ABN+B*%K>:WDDV>9&3D;6Z @^M0C3-7UV+4/[7_T&
MWN;;R(K-)!)L/7>Q P3TZ4 81\47D.F+JA\3:=+<!!*VF") OJ4# [L@?7D5
MMK=1WWC+1KR'/E3Z9)*FX<X8J1G\ZK1Q>*4L(],72;%)T01_VD9E9./XMA7)
M.*UVTNY'B;3[W(>""S>%W. 2Q*XX'T/2F(YZUU*ZTKP?J=U:+^\&IS*TFS?Y
M2F3!?;WP*T]"OKVZU"(P>(+35[)E;S@46.6(_P ) 7J"?6EL]+UNPT.ZCLI(
M8KTW\EPBOAEDC+YVD]LCOUJG;Z-?W_B.QU&30K;1_LKL\LL<RN\^1C'R#I[G
MF@#<\57]QIGAF^O;1PD\2 HQ4''S =#]:QK[5M6T'0I-4O[Z*>:[,:VULT(2
M.W=N2"P.6 '<^GO6UXHT^XU7PU>V5JH:>5 $#' ^\#U_"H_$&BR:QH<=M$ZQ
MW<#I- S_ '1(O3/MU%)#9SK>)Y=+GM9F\36>KQ23+'/;I$B,@;C<A4]CC@YK
M7GNM6U;Q#>Z=I]\EA;V"Q^9*(5E>1W&X !N  /\ /I&H\1W]Q;PMI5II<22!
MI[CS$F\Q1U5%QQGU/2I;JTU?2M>O-3TRRCOX;Y(_-@,PB='0;003P1BF(JZK
MJ7B#1_"]S-<M"UY#<HD,R*,3QE@,E?X2<XI-0N->T2/3/M.K)<R7FIPPN%ME
M0(C9W(/4=.>O%.OM(UW4] N5O'C:[N+J.5+=7&R!%8':&[G Y/K6CXJTFZU7
M3[=K(I]JL[J.ZB1SA7*Y^4GMUH&2:Q?W-IJ^BP0R;8[JX9)1M!W (3^'([5E
M7]W?7]KXLM!=^4MJH$1$:G"F+<R_CR,]LTXV^OZOK.DWMYIT-C!9S,S0BX$K
M-E2-V0,8Z<=>35N/1KHS^)=P15U$ 0,6_P"F6WGTYI 837NLZ+X.\/-:WJ3S
M7<]O%&)(555C:/B,XZC('S=:MW,_B33M=LM+.K0W7]HH^R62U5?(*8)("_>X
MZ GK33I&M7FB:%9W%C'!)IM];EL3A@\4:X+^Q]JVM2TVYN?%.B7\:J;>T$XE
M);!&Y0!@=^:8BCINI:CIVM:CIVK7JWL=O:B[2<0B-@O((('':L6'Q1=WM@VI
M?\)/I]G,P9X].:)&  SM5F)W9.!R/6NE?1YI_%5Y=RJ/L5QIXMB0W).XY&/H
M:R+2T\1Z1IPTB#2+.[\L&."_,ZJ%7G:60C)(XX'I1H!)<^)+^]L_#MQI>R)M
M2=HY%D7<%.T@GU^4Y/;.*E2?7-.\0VVE7>J+>1W\$IBG^SJC0R*,YP.".1U_
M_7;GTB_>Y\/N\B3M92,US( $!)0C(4>YJ?4-.N;CQ3HU_&JF"U2<2DMR-R@#
MCOTH&8WP_@NHX=5>6],L8OY4,?E!<N",OD>OITKLZYOPS8:EI-YJ=K<VJ?9)
M;J2YAN5E!W;B,*5ZCCO724GN"V"BBBD,S-!_Y!TO_7[=_P#I1)6G69H/_(.E
M_P"OV[_]*)*TZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,O6M7?1X4G^R--$3AF5\;3VSQ7 :9JJZ?K/V\Q%QEC
ML#8ZY[UZ?/!%<P/!,@>-QM93W%<EIOA!H=:D>YP]I"=T6?\ EIZ9^G>JBU8E
MIW.HL+F2[LX[B6 P%QD(6R0.V:LT45)04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5C^'O]3J'_80N/\ T.MBL?P]_J=0_P"PA<?^AT ;%%8NIW%I
M'XDT6&9[L7$IF\E8FQ&<*-V\=^.GO5?_ (2^WDN;JVM=.U&[FM)6BF6"(';M
M[Y+ 8/.._!XIV"YT5%<CX@\3>=X&EU32?M \W""15 :$[@&W9/'<<9Y(^M:M
MUXDM[*UM9+BTNTN;IBD-D$#3,0>> <8[YSWHL*YLT5DZ=X@@O[^2PDMKJSO$
M3S!#<H%++_>4@D$9]Z7Q'/;6^C/)=M<K")(P3;-M?)< <^F<9]LTK#-6BL74
M?$MMI^JC3/LMW<7C1"5(X(PVX$D>HQC!ZX%-M_$L5Y9WSPV5X+JS(66T>,"4
M9Z'&<8[]>U.P7-RBO*+9I#\/-2UC%^FHRJOF7CRG;+F;^#!XP!@\"O0=0UV#
M3;BWLQ;W-W>3J66"W0,VT=6.2 !^-%A7-:LO4O#^GZI<QW,Z2I<QKL6:&5HW
MV^F5/(IFE^(+?4[NZM#;7-K=VP#/#<( VT]",$@BLQ/'EA+8?;X[#4GLUQYL
MZPC;$<XP?FY[=,]:+,-#=TS2K+1[4V]C (D+%F.22S'J23R35VN>_P"$PLO.
MM\V=\+2YE$4-X8<1.QZ=\X/KBKFHZ]!87L5BEM<W=Y(GF""V0$JG3<22 !GC
MK19@:M%9-GXBL+JTNYW,EJUEG[3%<)M>+C.2.>".1C.:Y;Q;XJ-QX2G:"SU.
MR\_88+F1-@;YP>"#D9&3SC(HL%SOZ*I:G=266DW%S%#+-(D>56( MGUY...O
MX5R^FZN+KP9I]QJ@U!6-Q$OG(P#2L7X.<_=SP?Y46"YVM%8]YX@BMM1>P@L;
MR]N(T#RK;(I$8/3)9AR?2HQXJT]M&7452X(:;[.+?R_WOFYQLV^OXT6'<W**
MQ[+Q#%=:D-/GL;RRN6C,D:W** X'7!4D9'I5C2]7M]6TE=1@2186WX5P WRD
M@]#[4K :%%8Q\36"Z#;ZNRS"*XP(8@F9)&/10!U)Q2V?B*&XU!+&XL[RQN)5
M+0K=1@"7'7:02,CTHL%S8HK!N/%,4<UVMOINH7<=HY2::WC4JK <@98$D=\"
MM>RO(=0LH;NW;=#,@=#C'!HL!/161?>(8;34O[/AL[N]N@GF.EL@/EJ>FXL0
M!FH[7Q/9W6G:A=^3<Q-IX8W%O*@$BX&>F<<@''-.P7-NBN8_X3>R^RQWK:?J
M2V#E0;LPCRUSZ\YP#QD#&>F:T]4UVWTN:WMS#<7-U<$^5;VZ;G('5N2  /<T
M68KFI17':9J[ZE\1)D"W4"1Z;A[:<;2CB0<XR1T(Y'8UT^H:A;:782WMW)L@
MB&6.,GT 'N318=RU16%;^*(9+NUM[G3M0L?M1VP/<Q!5=NNW@G!/H<42^*(O
MM=S;V>G7]^;5MDSVT:E5;NN2PR1Z"BPKF[16(?%6G?\ ".?VY^^^R;@K#;AT
M)8*01GL3447BRV:\M8)[#4+6.[?9!//$%1R>@ZY!/;(HL%SH**1F5%+,0JJ,
MDD\ 5SO_  F=F8#>+8:@VGAMIO1"/+QG&[KNV^^*0SHZ*QM5\2V6DS644D<\
M[7JL8/LZ!]^ .!SWW#']*=IOB&'4-0ET][2[L[N.,2^5<H%+)G&002",T6"Y
MKT5P^@^)S:Z9=(]GJ-^\%S,9GA3>(QO. 2Q&>.PSQ703>)M.AT2WU4/)+#<E
M5@2-<O(QX"@>O7\J=A7-BBL2V\2QRZI;Z?<Z=?V4UP&,)N(U"O@9(!5CSBF3
M>*K==0NK"WL+^[N;9MLB01 X& <Y) QSCUX/%%AW-ZBLBU\2Z;=:')JYE:&V
MA)682C#1L.JD>O3CW%5H?%EN\UHESI^H6<=VP2":XB 1F/0<,2">V118+G04
M5BW7B2"'4)K&VLKV^G@ ,PM8P1'GH"21S["KNEZI:ZO9"ZM68KDJRN,,C#JK
M#L12 NT444 9F@_\@Z7_ *_;O_THDK3K,T'_ )!TO_7[=_\ I1)6G0 4444
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MO^N\'_HU:W;>UM[2+RK:"*&,'.R- H_(4]T21=KHK+Z,,BBX6.<0?\7+E/\
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M0=+_ -?MW_Z425IUF:#_ ,@Z7_K]N_\ THDK3H **** "BBB@ HHHH ****
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MA;F/:V/G7.,^W-5=3\-VFI7@O%GN[.[V[#/9S&-F7T/8_E4OGZ[_ - [3O\
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M 8 ;UQ5G1M#LM!MIK>Q5UCEE,I#MNP2 ./;@4GGZ[_T#M._\#W_^,T>?KO\
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M$8F:>:5A$Q91OD9P 2!G ;'05?H **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gbkyd1brmfwp000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000011.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" (- [(# 2(  A$! Q$!_\0
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MH_X*O9_X:B^%./\ GSF_]&U]S^"?^1-T?_L&0?\ HM:^&/\ @J]_R=#\*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.KS6?F7<*R30'! W>]>B^'-1L=&TJ;4M3NHX8(8]TTDAP%'K7)?$#Q;^S?\
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M ,B;H_\ V#(/_1:T :M%%-#G/(H =103@9IJMDXQ0 ZBD9MO:EH ***"0.M
M!1110 4444 %%%-W^HH =1130^3C% #J*** "BC('4T4 %%!.!G%-W^HH =1
M0QP,XH4Y&<4 %%(S8I: "BC/:B@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBC- !1110 449HSGI0 4444 %%%% !111GM0 4449H **** "BBB@ HHHH
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MF3C_ &A0!-134DC?_5NI^E.H 15VTM%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(W_  4BTO\
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MQ,VGIX@6XS&KGYQ@'_ZU?2G[*OQ>^'-Y\+;/1['Q'"\UON,D?=0:WQRK8?\
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MP+>_";2_C+INH^*]'MUTV'1VCN@Y^4S8'7\16F'Q%&I3FW'FLW9]0:<=BW\
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M/^M_!;]H/0_@G^S9XR:%?$2R/<,U\(U7!QU!P.*^K/V^/V,OB)^T%KVF>*_
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M-PS0Q;=U=8-W05@^#/\ 5-70*"!@USS;<KMEQV&A,'.:=114C"BBB@ HHHH
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M -%B@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=Q,C8+^I_&OK;X.?M!^!_B5H]JMOKL+7TO#6^[)!KY9_X5S\&/C)XZU*2'Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO?\ )T/PJ_Z\YO\ T;7W/X)_Y$W1_P#L&0?^BUKX8_X*O?\ )T/PJ_Z\YO\
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M[XB\$^%-2CL?B%:I'=W'[RV\L[N?>NK\:7/P=\5^+?!NE> _#TJ2-=*NH?\
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M3G.>M?4OQ&T?4M=\(WVEZ9$&GFMI%B5FV@L5..:^4_&>E_M4^!O@5>^#-=\
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MJ]M?Z;*?*MKR)S_=20&K!4'FIE+F81CRH6BBBI*"BBB@ HHHH **** /@/\
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M>VIQ=Q(T5L\P;[J$]/05\X:=H$_[3/B^^G\::NR:/8W3VZVL$K1R%E.,Y_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ0+LB0*/84UCN-24ULYX%# \(_;JA8^#=#O)-'GO8;76HI9X;>V,K% P)^4
MUP<'C;P7\2OVA_ MW\._ &H:='8WQ-])-H[P#OW*BOJ^XM8+@;)H5=?[K*#3
M8]/L86WI8PJ5Z%8Q7H4<=&G04.777KIKY&<H7=R10=N"*=&,#-.'2CIT%><:
M#7!/04GS+S3Z1AD4P%!SS7GOQIM_$,^I:$=$\/:3?*NI*;AM2V[HES]Z//\
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M^1-T?_L&0?\ HM:^&/\ @J]_R=#\*O\ KSF_]&U]S^"?^1-T?_L&0?\ HM:
M-6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\$_\B;H__8,@_P#1:U\,?\%7O^3H?A5_UYS?^C:^Y_!/_(FZ/_V#(/\ T6M
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M;!<7G]N*RW$JY9&"N:]>_P""??QCO/AK^PU>>,[VUENO[/U>]**D;.2JD8
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ME!Q@MGT-?8W['?[/T?P+^!MK\.]:AM[IFGDN9U:,%2TF"1@YKUXJQ.<4X#'
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M/_V#(/\ T6M?#'_!5[_DZ'X5?]><W_HVON?P3_R)NC_]@R#_ -%K0!JT444
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MK9Q-]JZHOF<?I2]G'F:[![27*GW/OKX;_M-_"_XHO?)X8UF)UT]RMQ(9E*C
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MF?8^J_!9S"36_EO[M?*'AGX$_MW2)_HG[4^FH/\ L&/6P/@)^WYCC]K#3/\
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MS:O<0JQMUF!CV[B.,]>M?;$'_!,C]FAHE)T:XSMY^84 )_P]9_8I_P"BFO\
M^ 9_QH_X>L_L4_\ 137_ / ,_P"-//\ P3'_ &: ,_V-<?\ ?0_PH7_@F3^S
M.W31KC_OH?X4 1O_ ,%6/V*B,#XF29_Z]#_C7@7Q&_X*)_ ?2_C*WQ"\">,Y
M+J-K)H?]05ZU]!?\.Q_V:/\ H#3_ /?0J*^_X)A_LURVDD2:/<!F0A2&'^%;
M4,1+#R;77N*2YE8\9_9M_P""C/[+WA[QGKWBWQG\0S#<:FJ9B%N6VX/UKV9?
M^"K'[%(_YJ:W_@(?\:\G^!W_  1=^$?P_P#BSXI\9^)9;JZL=8\L65NUWN\O
M!R>#TKUP?\$R/V:.IT6X_P"^A16K2KU.9@E8C/\ P59_8I_Z*<W_ (!G_&F-
M_P %8/V($?RI/BIM8]%-J1G]:F/_  3)_9F/!T:X_P"^A7D?Q2_X(O\ PE\7
M_&[1_B!HDUU;Z;8VVRXM1>E=[?0$9K$9ZRO_  58_8HQD?$UO_ ,_P"-))_P
M5=_8EB&^7XHLH]6M3_C2VG_!,+]FF&W2)M'N"RJ 3O!KD_CG_P $C_@1\0_A
M_<^&/#-M<6MW-(K1S";9C!]1S0!U2?\ !5_]B209C^*+-[K:G_&B7_@K!^Q%
M"N^?XI%!_>:U(_K7+?!+_@DA\!O '@F/P_XCMKBZN$<EI6GWY_$UA?M0?\$;
M_@S\7? DGAOP6;JQNF92LRW1CQALGD$4 >C+_P %6/V)]H9/B@Q5NFVT//ZT
MV/\ X*P_L0RR-#'\5-SK]Y%MCD?K57PG_P $LOV<M$\)Z=HM_I=Q)<6MC%#,
MYD#;F50"<G.>E>9_!C_@BW\)? ?Q_P#B#\2O$=Q=7.E^)KE'TFT-X7^S@8S\
MIR%_*@#U@_\ !6']B%'\I_BIM;^Z;4Y_G3'_ ."KW[$4,BB;XJ[=WW=UJ1GZ
M<UY3\1O^"+/PD\4_'6P^(FD3W4.EVMFL4MJ+PJ&;(_A!Q^E,_:#_ ."+'PE^
M)WCOP+XC\*W-U:6GAW4&GU2$7I03J4(Q@?>Y]: /6G_X*O\ [$$9V2?%/:S=
MFM>3^M _X*P_L/QML/Q5^;T^S?\ UZ\F^,W_  1:^$_COQ?I>N>'+FZMH+-%
M$T?VPKNP<] :\*^(?_!.SPKI_P"W%8^'].\+:S)H*M:K)-'O,1^7GGI0!]I?
M\/6/V*2=W_"SG_\  ,_XUPOQ>_X*:?L3ZYJ&BS/\?KS2_L^H*^RWL-WVCG[A
MST%=ZO\ P3)_9G;_ )@MQ_WV*BF_X)@?LO3NOVGP_))M.5\S:<?I0 0_\%6/
MV*!& /B<_P#X!G_&J/B/_@J=^Q==VOEQ?$N0GT^R'_&M1?\ @F/^S.1\NCW'
M_?0I?^'8_P"S/WT6X_[Z% '"'_@IM^Q_U_X6*_\ X"G_ !IL/_!3[]C>X_U'
MQ,WX/\-L3C]:[>^_X)@_LTW%K-;QZ+/N>)E5MXX)'TKR7]F+_@BS\)?A'_;2
M^-)KF^_M#6)[FWS>&39&[$A>>E6IM$\ITK?\%-?V/R./B))_X"G_ !I!_P %
M-?V0-N/^%C-_X"G_ !KNQ_P3&_9F/_,#F_[Z%#?\$Q?V9>^B3?\ ?0I^T8<I
MS_AC_@JC^Q7IJ>3>_%'8S'Y5-N<G]:W1_P %6?V*?^BFR?\ @&?\:\?^(W_!
M%7X4>*/C3HOC[2;BXATW3]0$UQ;B\*[TVL"-H.#UKV-?^"9/[,S+G^QKC_OH
M?X5F40R_\%7OV)(E,DWQ0957^)K4C^M.B_X*N?L2R1B2+XH,RGHRVI(/ZUQO
MQ[_X)&_ KXC_  YU#PKX6M[JUO+FW9(9OM&S:Q[Y&,5:^!O_  24^ ?P]^$^
MA^"_$MI<75]I]DL5Q<&;=O89YR22: .EF_X*P?L108,_Q3V;CA=UJ1G]:>O_
M  5:_8I(S_PLUO\ P$./YUY3^U+_ ,$8?A!\7XO#B>"I[JP;2M:CNKS;=F/S
M8P02O!&?I7IMG_P2Z_9OMM%_L]]*N/,\DIN\SN1CM0!+'_P5>_8BG.$^*NXC
M^[:G_&AO^"L?[$*/Y+?%3#?W?LIS_.O*_@'_ ,$7?A%\-O$6I:GXKGNKN.ZN
MI'AC^V%]JD\#G_"J_C3_ ((K?";7_CEHOQ#TVYNHM.T^9FN+7[80''IMR ?R
MH ]>?_@K!^Q#$VR3XJ;6_NM:G_&F2_\ !6#]B!&6-_BIM9ONAK<C/ZUY5\9?
M^"+WPE\>?$+3_$WAZ:XM;6VV>;#]K*[L'T! -0_%_P#X(L?"CQO\5/!OC'P_
M=75O9:#=>;J-O]L*^<OI@$;OQH ^D?@M^V[^SI\??$7_  B7PR\;K?7[*SK;
MM#M) Z]Z]=4Y%?FU\)?V9[GX%_\ !7K06\!Z!JT/AIO"]R;BX97-OYFW@$_=
MS7Z1DD+Q0 [-5[VUM[Z"2TNDW1R+M96[BID!^]0P4<]Z /E'XD_\$SKCQ1X^
MU'QQX"^..J>%_P"TK@RW%KI]O&0Q( P2P/;BO3_V6_V1?"?[,VBR6NG7YU'4
M)Y'>?4IH]LDFXY.<5[",XYH4Y[53G*UB5&*=QL>X<%:<3@44$9&#4E #D9%-
MW-NQBG 8&!10 U^N:%<]#2E<G.:4*!R!0 4444 %%%% !1110 4444 %%%%
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M+"BBB@ HZ]1110 4TL0V*=10 4444 %%-<D#BA"2.: '4UMV>*<<XXIH+DT
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M%(QXZ4M%2 U6[8IU%% #6^5L@4[CK110 UF(/%.!R,T44 %%%% !2?-FEHH
M*S_$_B/2O"FB7'B#7+I8;6UCWS2OT5?6KS#/!/6OFG_@H)\%/B?\6/! B\-:
M_+8Z7:J[:B8;HQNZ$<#&>><544I2LR9-QC='KWP=^/\ \./CAI^I:IX U^&_
MM]+N_(N9(6SM;&<&N'^)/[>'[+'PL\=?\(5XQ^(^GVNJ*P\R&5OF7-?/O_!)
MRQD\(?L_?$[3X;N21K'5I@LK-\S$0L<YKRGX%>!_#_Q=^&_Q+^(GC&QCO-2%
MI<+#/<(&:(K(P!4GI6JIQNTWL9NI+E5NI^CUQ\9?AS9> 4^)UQXDA&BR0^;'
M?%OE*GO7 _"[]O;]F?XN^*F\'>#OB387=\K[?L\4G.?2OS\UCXK^*Y?V-)?!
M+ZG/Y,&H6T"2;SG;N Q7:_M"_#3PY\#[CX6^,O ]LMG=7VK6ANGMUVF0$#.<
M=:?LDMQ>T9^FT9!7*]Z=6/X"U2;6O"=GJ<_WIH03^5;%<^QN!SVIJL3P:=2-
MN[4 +10,]Z* &DDG -. "]*** #'M32Q#8 IU% "%0>M+TX%%% #2F>0:CGE
M2UB::5@ O)-3'D8KR_\ :>^'OQ"^)'@2Y\-> ]3^R/-$PDF6?RV7Z'/6G'5B
M>Q:\$?M,_"7X@^/KCX=>&/%%O=:G:EA-;HWS*5ZUG?'+]L/X"?L]7$=I\3/'
MEIILTN0L=PV,FOC#_@G7X#O/AA^UKK&C7^ISW=S';S&>2XEW'<"<\]ZTK/PM
MI7QZ_P""A'C#P_X]@^V6.GS1FWMYE#*N5]#6_LX.1E[22C='VU\,OC/\*/B]
MX;?X@> _$5M?6<,9,UU$WRH,9.:X.+_@HC^RG=>/%^'4/Q3T]M0DG$4<.[YF
M?TKXB^%7Q%\0?"^V^)W@GP]=R1V::W=Q0QJVT1K\P  '2H$^%GANV_8#L_C#
M':1C7K>:YG74%4>86!X^;VH]E$GVLC](_B9\??A;\'_!_P#PG/CSQ1;V&FE5
M*W$S87GI6%\#?VOO@1^T3<S6'PP\=6FI7%NN^:&W;)5<XS7P7\9O&.J_$5O@
MQX!\07<DEGJWAM9[R-VRKLLBC)!^M=5=:/I_P3_X*!V&F^ [==/M-0TG3X9K
M6W7:AR&R2!W-'L[+4I5)<Q^CJ@@8-+2*VY<TM<YL%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 C-BE!R,TUSQBG*<C- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4C$XXI:* &H2>M.HHH *1EW4M% "
M*NWO2D \D444 %%%% !1110 4444 %(V<<4M% #4)/6G444 %%%% !M .0*/
MPHHH *3;\VZEHH *#G'%%% "+N_BI&7)S3J*   #I1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXZ^+NI:A+)9ZM+:6D>GWSPJL0)QD#J>.M5[/EU9/.?5MEJFFZBN[3[^&<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6-M%Y;7<:W4RX_Y:.-S?J:[RH;:%+6-;:(86,!5'M4U0W=FFP4444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gbkyd1brmfwp000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000010.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" 'Q [<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MBB@ HHHH #R,5D>-_&&E?#_PE?\ C#6Y-MKI]NTTWS8^45KGI69XK\+Z/XTT
M"Z\,^(]/CNK*\A,5Q;R+\KJ>H-'4#X:\4?\ !8#59_$%[>^!OA!KU]H6FW'E
MW.H6ZJT9SR#G'3%?3_[/'[6O@+X__"63XJ:.K6L%JKBZ@N)@60H/F)P..:^<
M?V^HM"_93^%$GPV^#/P8L6L=>A\V\F@WKY.TE>@/I7%_L=)X4\'_ + _BZ^\
M*^)FNKRZAU!KB)E"F)FR2/P)(KI<82A=(YU*<96;.Q^*'_!7*2S\:ZGHWPP^
M&&M:QI^BS;+Z_LMKQD=CG'%?17[,/[7W@;]H_P"&UQX[TF)[-K$,+RUN)070
MHI+'@<=#7QY_P2'\!Z!XH^ OBJYUNRCN)-0MXVN'D7[QP.M<%^PGXRU/PIK'
MQ2\*:>[):I'K)6-3P/DEQ3E3AJET%&I-6;ZGOWQ@_P""M!TOQYJ7A;X4_#36
M-:M]%;-_>V&UXPO3/3CFO?OV0OVO_!_[5/A";6-'LY;&\LYA#=6=S("^_!)X
M XZ5\=?\$>O!>B>*O!7C:_UNSCN);^S F:0<M^\%5O\ @F%KMQX<_; \:>#;
M)MEBFK7DGDK]WY1Q1.G"S2Z#C.5TV]S],J1LD<5\I_&[_@J;\,?@O\0+OX?Z
MU9;KBU52S>4YZY]#[5!\&?\ @J_\)/C!\0K/X=Z3'&MU>!C&"K \?4^]8^RJ
M6O8U]I"]KGUH,XYHIEM,MS;QW"])$##\13ZS+"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFC_\@FU_Z]T_]!%6*KZ/_P @FU_Z]T_]!%6*Q-@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8GQ!\;Z+\-?!]_XW\0S%+/3X3+<,O4+6W7FG[7OP^UCXJ?
ML[>*O ?A_=]LU'36B@VCG=D5K0C"=:,9NR;5_2YRXZI6HX&K4HJ\U%M+NTG9
M?>?%OC'_ (+>OIGQ&DT;0M)ADT>.Y,;3/:G>5W#D<>E?<7[.WQS\,?M"?#*R
M^(WA65FM[K*[9%VL& &>/QK\,/$W[+/QQT#QK-X0N/ &H-<+<>6A\L?/SC<.
M:_7?_@F#\%?%_P &?V;]-T;QI;26]XTDC-:S+AD!VD&OK>(,MRK"X*$\.US:
M=;W7<_'O#SB;BS-L\K4,PBW3LWJFN5W5DO\ (^DZ***^-/VL**"0.M(>5^6@
M#XR_:I_X)^?%7]I3]HVP\6:UJ\9\(P7^^:W^V#<(R#G"9KYQ_P""EWP!^$7[
M/FJ^&U^%M[]GUR.XM56.U90S#S5SG:<YK[>_;F_;6\*?LH^ )KV:\635KB)A
M8VJR8=G'89KX^_9)_96^(_[9OQ67]H_]HR:1--BF+Z;IUXA!920R,",C (KJ
MIN7*I2>B.>I&-^5;GJ/[5GQ0\1>&O^">=O;>*IW6\U>PDMW\PG+#:A'6ODO]
MF72_V$?^$.L+/XO/X@CU2ZC3=-;V!,*MT.6Z"OTF_;'\"_LMZ]\/=)\+_M ^
M)=/TO38G*:?]LD9%=MN"!M!["O'OV@OV*/V1=)_9)F\4>!M*M_LXMT>SU*.8
M[7&&P1QFBG4CRVUU8IPES7TT1]"?L??#;X1_#?X4VVF?!S5?M6DR2-+')YBL
M=S8)!VDUWGQ'\7Q^!O!]YXG<;A:Q[L8S7Q)_P1/\8>)KSP+J'A&ZN))-,M+V
MZ-N['(R)".OT KZ[_:54+\&M8(_Y]S_(UC./[RS-8RO3NCY,A_X+':/J5OJ6
MF:!X3U&]U2SO)8A#:Z3)*-JL1D[5/I4?PY_X+1^%;E-2TCXC>&=2@UBV4"WL
M;72I/,9O3;MS^E>>_P#!'3PCH6I?%?Q5K-_I\<LQO+Z/=(H(QYC^M<;/X,T3
M4?\ @LW+I<]DGV6/Q$@\G:-I&#QBNCDI\S5MD8\]3E3ONSW+PA_P6-CC^)UI
MX4^(WA&^TVQU&94LVFTN2-SN8*F=RCN:^C/VJ/VT/A[^S+\/+;QAK]RTDFI1
M_P#$OA@3S"S;0V"![5\6_P#!9CP[I&D_&SP9+IMC'"8Y[)5\M0O'GIZ5RO\
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M?[0'_!1RZU7P7_I%I"UPZW$/*NH?.?R%53YY1?-L*IRJ2Y2O^UYX1TCXC?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444V>98(6F?HHR:
M'45YCXI_:P^%_A#4KC2]:O?)DMWVR,T@ S6[\.?C7X2^)MP;?P],6.S=G<#D
M57+):D\T3L:***DH0L!P:^</VL/^2W>&?^O1O_0UKZ0*@]17S?\ M8?\EO\
M#/\ UZ'_ -#6KI_$34^$^B-(_P"03:_]>Z?^@BK%5])_Y!5K_P!>Z?\ H(JQ
M4%!5+7_#NB^*=+ET7Q!I\=U:SKMF@E^ZP]#5VB@#X_U7X%_"-?\ @H[I?AI?
M EB+%O!TTK6NT[2^T<]>M?6'AWPOH7A+2X]#\.:9'9V<7^KMX1A5KY[U<?\
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M SCFB@ HI&W?PT4 >%?M[_'KQC^SY\++?Q9X,M9)KB2:12L3;3PH/]:^!O\
MA\#^TS_T+M]_X$?_ %Z_6'7_  OX=\56HL?$FBV]]"IRL=U$'4?@:\X^*^@_
MLQ?!KPK<>+_&W@#0;>UMURP^Q1!C] >M;4Y0BK-7,:D9R=T['YR?\/@OVER<
M?\(Y??\ @0/\:\C^+/[1/Q8_:L^*WA_5_&&BW"?8;ABOF/NZU]Q:A_P4M_X)
MIZ=>26DOPX5FC8J2F@ @X./2K7AG_@I1_P $XM:UNWTW1_AULN)6Q&W]@!<'
MZXK=/EU4#&W-HYGUU\&HVB^%/AV-UPRZ1 #_ -\"NFK/\+ZKIFM>'K'5=%BV
M6EQ;));KMQA",@8[<5H5Q/<[ HHHH **** "BBB@ HHHH *_-O\ :'_Y28^$
M?^N%S_Z&M?I)7YM_M#_\I,?"/_7"Y_\ 0UK:C\7R,:VR]3]'-'_Y!-K_ ->Z
M?^@BK%5]'_Y!-K_U[I_Z"*L5B;!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%0SZC86IVW5]#&?^FD@7^=,36=(D;9'JMLS>BSK_C0!9HH
M!!&0:* "BBJ]QJVF6K^7<:C!&W]UYE!_G0!8HJM#J^F7#!+?4+>1C_"DRDU9
M!R,T %-EB2>-H95RK##"G44 ?*W[?GP*^%L'PZOO$\7A2!;Z9E:2?N3NKVKX
M#_"3X?\ @7P;H^J^%O#T-K<3:5"9)(^K9C&:X/\ X*!?\D<N?HO_ *%7L'PU
M_P"2>:'_ -@FW_\ 1:UI)OV:(27.S;HHHK,L*^;_ -K#_DM_AG_KT/\ Z&M?
M2%?-_P"UA_R6_P ,_P#7H?\ T-:NG\1,_A/HC2?^05:_]>Z?^@BK%5])_P"0
M5:_]>Z?^@BK%04%%%% 'S9J__*3C2?\ L29__017TG7S9J__ "DXTG_L29__
M $$5])U<^GH3'KZA2%0>32TUBV>*@HR_%/A70?%NG266OZ>EQ'Y9^5J^7?@I
M\(?A_)^U?JUA+X=A:*/3-R+Z'+5]:W'_ ![R?[A_E7SA\$O^3N]8_P"P2?YM
M6D/A9$MT?1>FZ=9Z39II^GP".&,81%[5/0<XXI%+=ZS+%Z=!1110 4444 %%
M%% !45W>6]C US=2;8T&68]JEKQ_]N[4]0T?]EWQ=J.E7LEO<1:4QCFA8JRG
M<.0:Y\7B/JN%G6M?E3=O17.S+L'_ &ACZ6&3MSRC&_:[2O\ B>D?\)WX5_Z"
MT=:&GZK8ZK%Y]C.)%/\ $*_!_P#X7%\50/\ DH6K?^!K_P"-?IU_P2C\2:_X
MD^!EO>:_J]Q>2[I/WEQ(6/4>M?'Y#QG'/,=]65)QTO>]^Q^E\8>&-3A7*?KK
MQ"GJE;EMO\SZNHHHK[@_* HHHH ^3_\ @IY^V%XP_98T305\#/(;[6))(T6*
M3:2P!/\ 2OGWPA^UK_P4H\1MI^I0?#37)+&\DC83"48,98<]?2M'_@K-\.?C
M'\6_C#X;TKP+X>DNAI^H.;=I(7,8RK=3C&*XV\^/7[9/[%4^AW7Q7\)Z*VCR
M>3%NBS)L1F ].#79",?9JR5SEE)^T=[V/L?X^_M=W_[.'[-D/C[Q[:-'K5W"
MZV]O-)AFE"@X!_.OC]_V\OV\O#OAZ']H#Q%X7U>/P;-)&ZEYAY0C<\<Y]C5C
M_@KM\8].^,_P,^'?B/P](5L;W5I VT8!/E#(_.O;?C1X<TE_^"3VC6IM8]O]
MCVQSM'.-]3&,8Q5UNRI2E*32>R/HW]E3]H'1_P!I3X16/Q*T8*$F;RI%5MV)
M% W?K7I5?#?_  1&UB[?X#2:(\C>3#JETR@GI\]?5O[0]_>:;\)=6OM/NGAE
M2#Y9(VP1P:QJ1Y:C1K&5Z:;.TGE2*,R2'@<YJ.TNH;V+SK:7<I[U^1G[)VD?
MM,?M5^+O$GP]MOB5J<6GV^H7<D=P-499 5=OESGIQ6/X/\1?M/?#7]J_4OV.
MM$\>WU[+J%XMG]HO-19C%WRK9XZ5I]7Z7,_;;.Q^Q4-_9W$QBBFW,O5:F95
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M>/Q%?I]KWA3P[XGT23PWKFDPW-G-'Y<EO,N5*^F*\=LO^">/[-%EXI_X2=/
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MKE?B5\%_AM\6[-M/\?>$++4E(^4W4.[;QU%<].IR:/9FU2'-L?G!\>/^"O\
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MM-$TFWT>PC58;:%8XE7H% X%6JYCH"BBB@ HHHH **** "BBB@ K\V_VA_\
ME)CX1_ZX7/\ Z&M?I)7YM_M#_P#*3'PC_P!<+G_T-:VH_%\C&MLO4_1S1_\
MD$VO_7NG_H(JQ5?1_P#D$VO_ %[I_P"@BK%8FP4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !@>E9?B?PAH7C"T2QUVS6:.-MRJ0.M:E!;'6@#Y'_93^%G@[4_VG
MOC!IM[IWF0V.M1K:QMC"#:O3BOK2UMHK.VCM(%VI&H51Z 5\V_LC''[5GQK)
M_P"@Y'_Z M?2H<$XJZGQ$4_A%HHHJ"SF_B]_R3/6O^O%OZ5YE^Q(,>'=9P/^
M7Q/_ $&O3?B]_P DSUK_ *\6_I7F7[$O_(NZS_U^+_Z#6B_ALG[1[C111690
M5Y/^W!_R:SXP_P"P6W\Q7K%>3_MP?\FL^,/^P6W\Q50^)$R^%FM^R^,_!30<
MC_F&P_\ H->A5Y[^R_\ \D4T'_L&P_\ H->A42^)CC\(4C'Y:6@C(Q4C/ _V
M_O\ DC=SG_9_]"KV'X:_\D\T/_L$V_\ Z+6O)/V[8+>_^&,FDM<;7F"[??YJ
M]:^'6V/P)H\4;AMNFP+GZ(*QCC,-4K/#QDG..K75)[7];&DL/7A35:46HRT3
MZ-K<W** <C-%;&95UC4DTK39M0=&?R4W;5ZFOSU_:%\4>,/%/Q7FU"^LKA!!
M<'["K#DID&OT0N((+B-H+A-RL/F4]Z^9?VI_#6AV?QI\.P6NG1HLEJ3(J_Q'
M>*^'XUX1Q/&&'IX:-?V<(N[5MWT^X^HX9XBH\.5IUI4N>35EY(],_93\;ZUX
ML^&]JOB&SEBNHRRGS!CY0 !7J59?A70]*TC2K?\ LZQ2'-NF=HZ_**U*^GRG
M"8C 9;2P]:?/*"2<N]NIX>88BCB\9.M2CRJ3;MVN%-<D'@TZN;^*6M:KX?\
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M]6T^Q'_!3#2;0647E?\ "%SGR_+&W.T<XKZ4AM+>W79!$J+_ '57 KYPU?\
MY2<:3_V),_\ Z"*^DZ<H0C:RZ"C*4KW?4*"H/444')'%(9YS^TKXOUWPQ\-;
MQ_#FFW%Q>,H\L0QEO7TKX?\ AAJ?CG0_BG%J>GZ5>-=-="2ZA2-MVPMD\>E?
MI!=P+);.&'\)_E7S?\$K>+_AKC6$*\?V2?YM7Y[Q1P#4XHS2EC7BY4_96Y8J
M*:3O=N]UN?89%Q9#(\!4PRPZG[3=MM:6VVZ'T)X2UR3Q'X?M]9EM9(6F7)CD
M7:R_45I4T!8UP!3@V>E??4XRA349.[2U??S/D:DHRFW%67;L%%%%:$A1110
M4444 %!('4T4UQWH =17*ZK\6O"^C^.K7P'>WT:75U;M*BD\X!'^-=4K!E#+
MT/-<]'%8?$2G&E)-P=I6Z/>S-JF'K48Q<XM*2NO-=PHHHKH,0HHHH X_Q/\
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M>_LO_P#)%-!_[!L/_H->A41HT:-XTXJ*\DE^02J5*EG-M^KN%%%%42>"?\%
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MNJNG:)I6D#;IFG6]NO\ =AA51^@JU4/R*6P44$X&:0,",F@#YMU?_E)QI/\
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M-'_Y!-K_ ->Z?^@BK%5]'_Y!-K_U[I_Z"*L5B;!1110 4444 %%%% !1110
M4444 %%%% !1110 49HI N#G- 'AGQA_;,L?A%J;6FK:$AB5MOFMNY.:T?@I
M^U;!\8[T0V.AI'"V-LB[N?SIG[:&@Z++\*UN)-(M6D_M&']XT"EOO>N*WOV9
M=!T>V^%.GW%MI=O'(=WSQP*#V[@5I[O)>QG[W/8](I&4MTI:*S- (##!KYC_
M ."B7AO0X/#W@F6+3HU:3QG;;V Z_.M?3:[L_-7SE_P49_Y%KP/_ -CI:_\
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M "BBB@ KG?BIX.UOQ[X'O_"WAWQ==:%>74.R'5+, R0'^\,@BNBHH ^2I/\
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M,>(_!UC_ ,)='>2-;WRA6CW\  YK\GP]3C+_ %]EB9T)?5)+DWT26JE;O?\
M _0*U/AO_5.-"-5?6$^;SOLU?M8^E!1GM2 $+BD"\8S7ZP?GX.I8X(XKYM_X
M*):?90>'/!+06R*S>,K8-M4#/SK7TD.!C-?./_!18D>&_ Y8?\SI:_\ H:TX
MQC*2NKDRE*,79GT)I.GV5I OV>W1#WVJ!5PKNZU#9 ?9U/M4Q;'6I48Q5D5=
MO<!QQ0<XXH!SS6;XIU#5M,T>:[T6U6:X528XW. 3BF!\]?M4AO\ A=?@O/\
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MTT_QMXSCME3S?%4WV,JO'E'=C%?:0X&*FK\=D.G\-^X4445F:!1110 4444
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MG?H!M%2:7K6F:W:+?Z5>QSPR+E)(VR"*\[^/OPR\7_%#X,KX6\'>*+K3;UK
M*MQ:@;G.P#'(-9O['?P8\>_!GX4VOACQ_P"+;S5+Q+959KK;E#^ %9V7+>YI
M=GJ7_"3:!_:O]B?VM#]KV[OL^[YMOK4FJZSI6B6C7VK7T=O"BY:21L "OF^+
M]ECXR1?M3_\ "TG^)NIG1OL97[-A-F<_=^[FNX_;%^#'CWXT_"^X\,^ /%UY
MI=X;=E5K7;F0_B#3Y8W2N'-*ST/6K2_L=3M5O;&Z62%EW+(O0CUJ"T\3^'[S
M49-'M-7ADNH5!EA5OF4>]<-^SQ\+O%_PU^$<?@_Q7XJNM0OOL83[1< ;HVVD
M<8 [UY9\(_V5?C'X/_:3UKXCZ[\3M4N=)NH8Q#;RA-K88DC[OO248ZZA>6FA
M]'ZQK^BZ#!]HUG4HK:/.-TK8'-31W,$MN+J"=6C*YWKTQZUX;^VU^S]\3OCC
MX=M[7X=>.;[2I(9(_,BL]O[S#9).0>U>A>"/ 'B70?A*O@S4_$MQ<7_V,1_;
MI -ZMM ],<$4<JY;W'=W.FL/$NA:O=36.EZK#--;MMFCC;E#Z&C5?$>B:"8_
M[9U6&W\Q@J>:V-S'H*\ _9<_9F^+OPK^+/B;Q;XS^(FI:A8ZAJ"RVL%P%VLN
MT#L!4W[9G[-WQ7^-.MZ1J7@#Q]J&FPVNH6\DUO:[=I56&3R#Z57+'FM<7-+E
MO8^A9+FW$/GM,H3KN[53TCQ!HFNB1M(U.&X\E]LGEMG:WI7,W_@+Q)/\))/!
M,?BBY74&MO+74L#S WKTQ7F/[&7[.WQ4^"UUK5S\0/'VH:FMYJ4DMO#=A<;3
MG'0"ILN5L.:5UH>YW_B;0M,NXK'4-6AAFG?;#'(V"[>@JK\0+F&#P1J4T\H5
M?L<OS'_<->!?M'_LN?&/XE?''P_X^\)?$K4[+3;'4Q+<6, 7RU4*1W&>]>G_
M !Y\">(_$?P(OO"NE^)KBUO5M26OH\;SA6SVQS3M%6U"[UT.&_X)M7,$_P"S
MY,8I W_%2ZAT_P"NM>Y2^)]"M=3CT>XU6%;J;_5P,_S-]*^9?^"4W@?Q#X7^
M \TNL^(+BY4Z]?)Y,P& 1)][IWJ]X^_96^,OB#]J+2OBCI?Q.U2'1[>:1Y;.
M-4\M >B_=S3ERRJ/4F+E&"T/I6]U*QTZV-Y?W2PQJ,EW/ IFFZMI>N6::CI-
M]'<0R#*21G(:O//VDOA5XR^)_P *&\'^#_%MUIM\L>/M5J!O?Y<=P>M4/V/?
M@_X[^#/PAT[PKX_\5W>J7T,&V1KK;E3^ %39<M[E7?-8H_ME>)?#\WPY714U
M:%KK[?$WV?=\V W6ND^ .L:9HOP:L+S5+Z.WC7<2\C8 Z5\F_M2?LJ_&72?B
MA_PM2]^*.J3:*UQM%HRIY:EF&%^[G]:]8\:?!3XA?&G]ES3O#OP_\8WFDW:Q
MR!I+/;F3('!R#6G+'E2N9IRYF['TS9:A9W]DM]9W*R1.NY9%/!'K52R\3:!?
MZE)I-GJT,ES$NZ2%6^91ZUR/P)^''BKP!\';'P=XF\17%]J$.FB*2XGQN5MI
M&>![UY#\#OV5OC-X"_:,UKXB^)?B?JEYI-Y:JMO;S!-F0['' ]"*SY8ZZFG,
M]-#Z-U_Q!I/ARS>YU34HK<;#M:1L<U\>?M-:5^TG\:%TVULX +32-<6^MY#9
MG#*K9'?T%>K_ +<'[/GQ0^.^BV5O\-O'FH:.]LH$L5F%_>_-G)R#VKTGPUX$
M\1Z5\(U\&7GB*XFO_P"RU@^VL!O5_+"YZ8SFKCRQ5R9)RT.1_9I^)GQ"\;7F
MH:=XUN8V:T*@(D.TKTZ\UZEJ?B/0M#94UG5(;<R,%3S6QDGH*^?OV1?V8_B_
M\'/B+XC\0^//B/J6JVM_.C6L=V%Q@8ST I?VR_V:/BY\:O%FCZU\/_B%J.EV
M]G>6SW%K:;=KJDBLQ.0>P-*2BYVOH"<E'8^C);JWAMS<R2JL:C)8] *K:7KV
MAZ^DATK4(;@0MME\ML[6]#7/>*?!.OZM\)+SP58Z_<1:A<6/E1Z@H'F(W'S=
M,=J\M_8N_9W^*?P137A\1/'^H:M]NU3S;=;S;]S!'8"ILN6]RKN]K'MU]K7A
M33KN.QO[NUBFE;;'&X&6/I5F>:QTVW:YN9(X8E^\QX%?-_[0W[+7QD^(WQ^T
M7XB>%/B;JECI-G?123Z=;A/+VJ#GJ,\_6O6_CG\.O%/C_P"#MYX&\,>*;FQU
M"9 (]0M\>8,9]1BGRQTUW"[UT.QTG7-*URW^V:/J$=S$K%?,B;(R.U-D\4:!
M#J2:--JL*W4C8C@+?,QKR+]B/X&?$?X&?#F;P[\1O&5[JUT^I3RK)>;=VQF)
M'0"N/\;?LL?&76_VL--^+FG?$W5(=#AOVEDTY GEJOI]W./QHY8\SU#FERIV
M/I34-3L-,MC=7]VD,8_C<X%)I6JZ?K%FM_IEXEQ"_P!V2-L@UYM^U!\)?&OQ
M7^$K>#_!7B^[TJ^WJWVRT WL .G(/6F_LA?"7QM\'/A!I_A#QWXJNM5OH%82
M37>-W7V I<JY;W"[YK6/1(/$V@RZG_8R:M"UT1D6^[YN.O%3:KK.E:-;_:-5
MOX[>,_Q2-@5\T^"OV4?C3H/[6;?%S4OBEJMQH;QW&W3Y GEIOQ@?=SQCUKM?
MVU/@9\1OCGX L_#WPY\<WVB75O*S236(7=(" ,'<#3Y8\R5PYG;8]CLKRTO[
M9+ZTN%DA==R2+T(]:@L_$N@ZG>OIEAJL,MPBY:%6^8"N4^!G@#Q-X ^"VE>"
MO$^OW%]J%KI?D375QC>7YYX'7FOFG1OV*OVG='^+VJ>,;+X\:]%9W:MY,:B/
M"@L3@?+[T1C%WU!REIH?8>J:_HVA1B36=2BMU;[IE;&:LBZMY+7[9',IC*[A
M(#QM]:_.74_A)^U7^T;\2O%7PTL?C;KEO_PAUZMNTD90F?.#DY7CK7W=X=\%
M:_I?PAC\&WFNS37XT;[-]L?&\2>7MW=.N>:<H*-M0C+FZ'0:9XAT;69I+?2M
M4BN'A_UBQOG;1J?B30='F6+5M5AMV?&Q9&QFO ?V-OV8_BY\$_&_B37/B!\3
M-2UJVU)5%I'>A,)AL\;0*K_MF?LN?&/XV_$30_$_P]^)FJ:/9Z>T7VFSLU39
M+MD5B3E3V!HY8\UKAS2Y;V.J_:C\'?&74=#NO%7PZ\9V.GP6L/FLMQ"S9'X$
M5Y+^RMH_[3'Q+O+G6M4^)VES6VGW"I+'';MDY&?[U?1'QE\/ZG-^SQK7AY-3
MD2Z.B^5]J&-P8!1GZ\5X7_P2X^&WBSX?^&?%0\2^*KK4C=:K&\)N /D79T&
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M74GVC?0^O-3U;3M'M6O-4O$@B!QYDAP,FC3M0M-4MUO+"Z6:)N!(C9!KS/\
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MITZ#5[:AG/2LWQ1;:I?:+-;Z,0MPRGRRS8&<5I 8X%(2!P*!GQ1\6M=_:Q\
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M_015BJ^C_P#()M?^O=/_ $$58K$V"BBB@ HHHH *:V3U%.H(SP: (;UB;.8
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M(Z5X5U;P[\-M-M+C4O%\,=]-#&V9E=QN!Y[Y-?9$]QY,#S;"=JEL#O@5\/\
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M#"VY"N=W>OF3]D?]GS3/B%?7VN3WRQR:3KDT,?R]1%(0/Y5]$?M(?M5_#O\
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M/,A>'P$K233:O;F7;]?D?'W_  2,^/WQ'T;X^6W@"'5IIM)N+65Y++=\NX#
M;\,U^PL#F6!)"/O*#^E?(O\ P3D_8-^&WP7\/6/Q4MWFN-3O+0.//PP4.O..
M:^O  !@"GQ!C,+CL=ST%I:U^[#P^R7-LBR%8?'RO*[:5[\J=M+A6?XHEOX=
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ML$H1D<S\*_AAX6^$?A&W\'^%K!+>&&-5;RQPQ ZUTP&.!35&3EA3J@H****
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MH_%\C&MLO4_1S1_^03:_]>Z?^@BK%5]'_P"03:_]>Z?^@BK%8FP449HSGI0
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M ]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7YM_M#_P#*3'PC_P!<+G_T-:_22OS;_:'_
M .4F/A'_ *X7/_H:UM1^+Y&-;9>I^CFC_P#()M?^O=/_ $$58JOH_P#R";7_
M *]T_P#015BL38",\&O,_P!J?XJQ?";X4ZEKJI)YRVK-"4'0BO3*^5O^"J>M
MZGI7P4D33[EHS);R!BM>=F]2G2RVK*<G%<KNUNKZ77F>MD>"K9AFU'#TDG*4
ME9/;Y^1\A>&/VEX+'XDQ^)[66;[5->*T@!YP6&:_3[X0>/K7XC^ ;'Q5:(RK
M-&%VN.<@"OPCTS4-8M];AU*/4&$PD7YOQ%?LM_P3\U&\U?\ 9DT6]U"8R2-)
M)EC^%?G7AYA<ER_$5J. JU)<_O-32M?NK-ZZGZ-XBY'Q!@\'1Q.8QII)\JY&
MV]NMTM-#VP $9 H "]33CP.*;DN,5^K'Y&?+W_!2WX/Z/\1_!MMKNL?$"XT6
M'3;5@PM]4:V,F2?[K#-? ?[''P3\'^._B5'8_P#"VM0L9K/6"\:OX@DC28+)
MQQN^8G'XU]-_\%SH/&Y\)Z'+HOF_V4MI)_:6S[OWCC-?G#\"(]=F^+?A\>']
M_P!H_M:#;LZ_?%?:93D='&96ZTIV>MO*W<_%>+?$+,,CXH6!HT4X+EO?>5[;
M']"/A?33I.B6^G-*9/+0#>S9S6AL7TK"^&W]MIX+L?\ A(PWVSRAYV_KTK>!
MR,U\;)<LFC]FIS]I34K6NA&^[7CW[2WQJ\$^"M,F\+>)O!%QJDEY8R&+;9B5
M0<$=P>YKV)AD8K'UOP)X7\1S+<:UI4<\B+A6;L*(OEE<J<>:-CY+_P"">OQE
M\'>$? :>"[_X:WMIJ5WKUT5N/[/"81Y,KD[<XK[,P"<XKGK/X8>!M,N4O+30
MHTD1LJP[5T-54ESRN33IQI1Y4K>@A7)R:4*!T%%%9FA7DTK3)FWS:?"S?WFB
M!I8=,TZW;?;V$,9]4C J>B@ HHHH *0KDY-+10   =****  J#U%%%% !111
M0   =!1110 48 .<444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +_46871T%%<_P#\+5^'/_0XV/\ W^H_X6K\.?\ H<;'_O\ 46871T%%<_\
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M4>WF'L:9^=?_  ZI_:-_Z.8\2?\ ?J+_ .(H_P"'5'[1G7_AICQ)_P!^HO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9^@NE%UTZ$3_ 'MOS58"C.X4;%' %+7$=84444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLWA#Q19^,M!A\06$,D<4ZY19!SC&?ZUIUG^%M'MM!\/6>DVL/EK#;1KM'J%
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M' HH!R,T5QG4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4T??HHH 'Z5YK^UE_R0W7/^P=/_Z+-%%5'XB9?"?E%_P3H_Y.
M3T__ +"0_F:_9[3/^/"'_<HHK;$?$8X?X2RG2G445SG0%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gbkyd1brmfwp000020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Y ZH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDTL=O!)-*X2
M.-2[L>B@<DT /HKQZT^(WCKQE/=W/@CP[8MI%M(8UN+]R&F(]/F7'&..<9&3
M74_#SX@'QDE_8W]@=.UK39/+N[4G(ZD9&>>H(([>^: .XHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>"*YMY()X
MUDAE4HZ.,AE(P01Z5)5/59;R#2+R;3H4FO8X7>")\[7< E5./4\4 <KXBU%_
MA]HEM;>%O"$U^LC2$6]BA5(CU+-@'J3^E<#\'=1MY[_Q?XHU"[5M?E#RW&G*
MAC:)%)8]>N3@>V!GK77^ /BKIOB71)'UN[L=,U:VD=;BWDD\H  \$;SG&.#Z
M$&N.\*R6GB[]H#6-9T:$2:+':-#<S!,1SDH$_'<1GW"YH =_PTMIW_0MW7_@
M2O\ \31_PTMIW_0MW7_@2O\ \37IW_"N_!G_ $*VD?\ @(G^%<!\9O!_AO1_
MAM>7FFZ%I]I<K-"%E@MU1@"X!Y H ] \#>+X?''AM=9@M'M4:5XO*=PQ!7W%
M=+7F'P" _P"%70>]W-_,5Z?0 4444 %%%% !7/>)?$3:3Y=I:(LE],I8!_NQ
MK_>;^@K7N1?^8/LK6P3'/FJQ.?P->?:U]H'BB^^UE#-Y<6W8"%VX[9]\UR8_
M$2P^'E4CNO\ ACHPM)5:JA+8:=5UQI/,.LSA^N%C0+^6*Z7PWXFFOKG^SM15
M!=[2T4J#"S =>.S#TKDJ=:^<=;TL6^WS_M(V;LXQ@YSCMBOG\MS/$SQ$85'S
M*1ZN,P5&-%R@K-'J=%5(!J/G#[0UJ8N_EJP/ZFK=?5GA!7D'B[5/&.H?%Z+P
MMX?\1#2X'T\7'S0)(,C=GJ"><#O7K]>&>+[/7+[]H*"#P]J46G:@=)!6>6,.
MH7YLC&#UH Z)?!_Q2#J6^(D!4'D?8$Z?]\U<T[Q'J\_QVU;P_)>,VE0::LT=
MOL7"N1'SG&?XCW[T_1?#_P 2K76K2?5O%]C=Z>DF9X$M ID7T!VC%8^D_P#)
MS.N_]@A/Y14 >L.I>-E#,I((W+U'N*\L\+>+M<T#X@77@OQE>&Z:Y/F:5?O&
MJ"9>RG: ,G'_ 'T".XKU6O&/CE):ZW<Z+X7TRT-WXHDF$MNT3;6MT[DGMG&?
M;;GL,@&K-XJUOQI\1AH?A:^:TT326SJE_&BMYK9_U:E@1V(R/]H]AGL/&OBR
MV\'>'9M1E7S;AB(K2V'WIYC]U0/U/L*XSX%ZGI?_  B$VBQ6OV+5M/F8:A"_
MWW<D_O#W[8]MN/2N8L/'OACQ-\1I?$7B35X[73M(8Q:/92(Y+-WG8 $9]/P_
MN\@'9_"#Q'KWBGPAJ=UK%WYFH)?2PHS1JHBPBD+@ < D]:H7ND_%33K&>]O/
M'>D0VT"&261K,850,D_<K.^ _B32#9ZGH_VY/[0N=2GN88-IR\>U?FSC'8UI
M?&.\N=7O- \!V$I276K@-<LO585/\LY/_ * (?AOXI\77WA/7?%'B.]2?38(
M':R)A6,OY88L^ !QP!SW!JIX63XL^*?#5GK4/BS3[:*[4LD4MFNX ,1DX3OC
M/XUZ%XC\,QW?P^NO#6FSPZ="UJMM%(XRL:# .>G4 C\:X%_@F;/PLLEOXIU;
M^VK2WW03I<%85*C(55ZA>W7W]J /4M M]5M=#M8-;O(KS4D4^?/$FQ7.3C P
M.V!^%:5<1\)O$][XK\ 6=_J+;[R-W@EEQCS"IX;ZD$9]\UV] !1110 4444
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M!27E(P9')RS>V2>GI6Y110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5YK\>/^257W_7>'_T,5Z57FOQX_Y)5??]=X?_
M $,4 1? +_DET'_7U-_.O3Z\P^ 7_)+H/^OJ;^=>GT %%%% !1110 444UW6
M-&=V"JHR68X % #J*PV\8^'DF\HZK!NSC(R1^>,5LPS17$2RPR))&PRKH<@_
MC0 ^BBB@ HHKGM9\<^&/#U]]AU?6;:TN=@?RY"<[3T/ ]C0!T-%<</BKX%)
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M4[!)?*>^MEDSC895!_+- %NB@$$9!R#10 4444 %%%% !1110 4444 %%%%
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MU_"@!%^)OC:XT@^([7P(&T  R!FNAY[1#^,+UQCGH?RYK.^('B.P\6:3\/\
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MM+@,LY8X&6YP.#R,]#TH*@_M"^'R1DCP_D>W^LJWKJ@_M'>%R0#C2YB/REH
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M^&/%=]HT'A62\BMF4+.)6&_*AN@0^N.O:N=F_:.U"V*B?PCY1;D"2Y9<_FE
M'J?_  K#P1Y>S_A&-.QZ^5S^?6L#6?@1X*U1'-K:SZ;,1P]M*2 ?]ULC\L5R
MB?'[7)(//3P+.T.,^8LKE<?7R\5:\,?'F^\2>);'28_"^T7$Z1R2)<,_E*2
M6(V=!F@"WI&C?$3X<ZI:6L%R?$OAN69(F5L^;;*6QN .2  <\$CV'6O8J**
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M2+RH(PBYR?4GU)ZD^YJ:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%49]0Q,UM:1_:+D?> .$C
M_P!]NWTZ^U %J>XAM86EGD6.->K,:HYO-2^[YEG:'^(C$LGT_N#]?I4D&G_O
MEN;R3[1<CE21A(_]Q>WUZ^]7J (K>VAM(1%!&L:#G [GU/J?>I:** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %17%S#:0F6>18T'<_
MR'J?:JT^H$S-;64?VBX7AN<)'_O-_0<TMOIX687-U)]HNAT=AA4]D7M]>OO0
M!#B\U+KYEG:'MTED'_L@_7Z5>@MX;6%8H(UCC'15%2T4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBTZPO/!4EM;7-PD4LY@F'EJ3@MDC''O69_PTHN6'_"*R?+U_TSI_XY5WP_\
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MX/!!_"N=\.^"_'_C'QWINN>.0T%IICB2-'V*6*G(543IE@"2>P^E 'OM%%%
M!1110 4444 %%%% !17#?$;XE:;X$TJ0"2*XUB1?]&L\Y.?[SXZ*/UZ#VW?!
MVLW'B'P=I6KW21I<7=NLLBQ@A03Z9S0!N5YK\>/^257W_7>'_P!#%>E5YK\>
M/^257W_7>'_T,4 1? +_ ))=!_U]3?SKT^O,/@%_R2Z#_KZF_G7I] !1110
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M 'VG^-<I\1?C1I7C3P=<:+:Z7>V\TLD;B25EVC:P/8U[3_PJ[P/_ -"SI_\
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MOCWQ%\1I]3T2*U4V146MQ!=113JNT$;OF#=2V,]CZ4 >HCX7>!P,?\(SI_\
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M+3!J$DUQ/"8RQ&T&0'/ /]W]: /J>BOGS_AH;7_^A03_ +^2?_$T?\-#:_\
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M****U("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH ]@L/#FD:7JU[JEC816]Y?!1<21C&_;TXZ?D.:U*** "BBB@ HHHH ****
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M> #_ ):I^\C_ #'(_$"@#1HID4L<\8DBD61#T93D&GT %%%% !1110 4444
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MUYA\ O\ DET'_7U-_.O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH HRZ5;M(98=]M,>LD!VD_4=#
M^(-,WZE:_P"LC2]C'\4>$D_[Y/!_ CZ5HT4 5+?4K6Y?RTDV3#K%("CC\#S5
MNH;BTM[N/9<0I(HZ;AG'T]*J?8KNVYLKLLO_ #QN<N/P;[P_'- &C16?_:GD
M<7]O):_]-/OQG_@0Z?B!5Y)$E0/&ZNC#(93D&@!U%%% !1110 4444 %%%%
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MX+P6K,678^Y@4*XR3[U[77CWPF^)6JZKJUQX1\5HR:S;!O*E==KR;?O(X_O
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M8H B^ 7_ "2Z#_KZF_G7I]>8? +_ ))=!_U]3?SKT^@ HHHH **** "BBB@
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MJO-?CQ_R2J^_Z[P_^AB@"+X!?\DN@_Z^IOYUZ?7F'P"_Y)=!_P!?4W\Z]/H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@$$$9!ZBEHH H-I,*,7LY'
MLY#R?)/RD^Z'C],TW[1J%K_Q\6PN8Q_RTMN&_%#_ $)^E:-% %>VOK:[R(9E
M9E^\AX9?JIY%6*KW-C;7F#/"K,OW7Z,OT(Y%5OLU_:_\>UR+B,?\LKGK^#CG
M\P: -&BL]=6B1@E[')9N>!YH^0_1QQ_*KX((!!!!Z$4 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$!E*L
M01@@]Z6B@#D-1^%W@C5)VGNO#EGYC'+-%NBR?^ $58TKX=>#]%G$]AX>LHY5
M^Z[IYC#Z%LXKIZ* "BBB@ HHHH *\\^(_P *;'QVT5_!<_8-7A7:MP%RLBCD
M!AUX[$<CWKT.B@#P ?##XN1)]CC\9C[+]T'^T)AQ_P!\YKJ? 'PNTGP/K*ZC
MK.L07WB"8$0^8X4)NX)0,=S,>F?KQ7JU>%?$P#_A?O@GC_GW_P#1[4 >ZT44
M4 %%%% !1110 4444 %%<IX]\>:9X$T-[NZ=);QU(M;0-AI6_HH[G^M:7A36
MG\1^%--UF2%8'O(%E,:MD+GMF@#9KS7X\?\ )*K[_KO#_P"ABO2J\U^/'_)*
MK[_KO#_Z&* (O@%_R2Z#_KZF_G7I]>8? +_DET'_ %]3?SKT^@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&4,I5@"IX((ZU0.E)
M$2UC-):,?X8^8S]4/'Y8K0HH SOM5]:\75KYR#_EK:\_FAY_(FK5M>VUXI-O
M,KX^\H/*_4=1^-3U6N;"UNV#RQ#S%^[(IVNOT8<T 6:*SO)U&U_U$ZW48_Y9
MW'RO^#@?S'XTY-6@#B.Z5[20\ 3C /T;[I_.@"_1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%K
M_P 8/"7AK7+G2-1GNEN[8@2!+<L!E0PY^A%9O_"_/ O_ #\WO_@*U.DMOAAX
ML\9ZG9:A8VK:_%-Y4R719&F*@ %><-P!TY]JV?\ A4O@/_H6K3_OI_\ XJ@#
M$_X7YX%_Y^;W_P !6KSOQ!XQTCQI\;/!]]HTDKP0RP0N98RAW>:3T/L17K__
M  J7P'_T+5I_WT__ ,55BR^&7@S3KZ"]L] MHKFWD$D4BELJP.0>M '645S.
MO>/O#OAW4+73KR^5]0N9DACM8/GDRQP"P_A'/?'XUTU !1110 4444 %%<=X
MZ\"R^-#8F/7[[2OLN_(M<_O-V.O(Z8_6J_@?X=S>#=2N;R3Q)J&J":'RA%<Y
MVKR#D<GGC% '$^/OAAI^G>&O%?BG4KVXU35)0TD#3$A+96D&%49YP#C)X] *
M[OX>7267PCT6[D#%(-.$K!>I"@DX_*CXM?\ )*_$'_7N/_0UI_PW@CN?A3H4
M$R!XI;!4=3W4@@B@#C?^&CO"W_0,U;_OB/\ ^+KDOB3\9-!\9>"[G1K&RU"*
MXEDC=6F5 H"L">C$UZU_PJ'P%_T+=O\ ]_)/_BJX3XO?#WPGX>^'EWJ.DZ-#
M:W:31*LJNY(!< ]2>U '0_ %L_"^$>EW,/U%>H5Y?\ 0!\+X<=[N;/YBO4*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #)(HYHS'*BNAZJPR#5+^S&M^;"Y>W_Z9-\\?_?)Z?@16
MA10!G?;KFVXOK1@H_P"6UOF1?Q'WA^1^M7+>Y@NH_,MYDE3U1LXJ6JEQIMK<
M2>;L,<__ #VB.Q_S'7\: +=%9^W4[3[K)>QCLV(Y/S^Z?TI\.J6TD@AD+6\Y
MZ13KL8_3L?P)H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>:_'C_DE5]_UWA_
M]#%>E5YK\>/^257W_7>'_P!#% $7P"_Y)=!_U]3?SKT^O,/@%_R2Z#_KZF_G
M7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4R:&*XC,<T:2(>JNN13Z* ,[^S
MI;;FPNGB _Y92_O(_P!>1^!H_M&:VXO[1XU'_+:',B?CCD?B/QK1HH CAGAN
M8Q)!*DB'HR-D5)5.;2[::0S*K03G_EK"VQC]<=?QS46=3M>HCO8QZ8CD_P#B
M3^E &C15.#4[:>00EFBG/_+&9=C_ ( ]?PS5R@ HHJB^M:7'-Y+ZC:K)G&TS
M+G^= %ZBD5@RAE((/(([TM !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %>:_'C_DE5]_UWA_\ 0Q7I5>:_'C_DE5]_
MUWA_]#% $7P"_P"270?]?4W\Z]/KS#X!?\DN@_Z^IOYUZ?0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 13V\-U'Y<\22H>SKFJ?V"XMN;&[
M95'_ "QGS(GX'[P_/\*T:* /,O'_ (HOX=ND(OV9RNZ=HY,[@>@!X(%>;[CG
M.:[CXG:=-#X@2]*DPW$8 ;MN7@C^5<-7IX6,?9WZGRF;U:OUAQ;LE:QW/P]\
M2W%IJL6E3R,]K<':BL<['[8]CTKUVO"_!&GS7_BJR\M3LA<2R-Z!>?YX%>Z5
MQXF,8U&HGMY94J5,,I5-_P! HHHK ] **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O-?CQ_R2J^_Z[P_^ABO2J\U^/'_ "2J
M^_Z[P_\ H8H B^ 7_)+H/^OJ;^=>GUYA\ O^270?]?4W\Z]/H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJ.FVFJV;6M["LL+=CU
M!]0>QKC9/A7IK3[DOKE8\_<(4G\__K5WM%4I2CLS.=*G4^.*?J9NC:#I^@VI
M@L8=N[EW8Y9_J:TJ**DT2MH@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI'=8T9W8*JC+,3@ 4 +17D[?&#4]9OKJ+P9X/N]:M+
M5]CW9D\M&/\ L\'\.<^U=#X#^)-GXTFN]/EL9M,UBR_U]E.<D#."0<#H>""
M1D4 =O7FOQX_Y)5??]=X?_0Q7I5>:_'C_DE5]_UWA_\ 0Q0!%\ O^270?]?4
MW\Z]/KS#X!?\DN@_Z^IOYUZ?0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<+/)(3!&I7#'CDL*[+_AHKPA_P ^>K?]^4_^+KH5^#'@!1C_ (1]#];B4_\
MLU+_ ,*:\ ?]"]'_ -_Y?_BJ .=_X:*\(?\ /GJW_?E/_BZ/^&BO"'_/GJW_
M 'Y3_P"+KHO^%-> /^A>C_[_ ,O_ ,51_P *:\ ?]"]'_P!_Y?\ XJ@#G?\
MAHKPA_SYZM_WY3_XNC_AHKPA_P ^>K?]^4_^+KHO^%-> /\ H7H_^_\ +_\
M%4?\*:\ ?]"]'_W_ )?_ (J@#G?^&BO"'_/GJW_?E/\ XNC_ (:*\(?\^>K?
M]^4_^+KHO^%-> /^A>C_ ._\O_Q5'_"FO '_ $+T?_?^7_XJ@#G?^&BO"'_/
MGJW_ 'Y3_P"+H_X:*\(?\^>K?]^4_P#BZZ+_ (4UX _Z%Z/_ +_R_P#Q5'_"
MFO '_0O1_P#?^7_XJ@#G?^&BO"'_ #YZM_WY3_XNC_AHKPA_SYZM_P!^4_\
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M_P#%4?\ "FO '_0O1_\ ?^7_ .*H YW_ (:*\(?\^>K?]^4_^+H_X:*\(?\
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MC_AHKPA_SYZM_P!^4_\ BZZ+_A37@#_H7H_^_P#+_P#%4?\ "FO '_0O1_\
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M 'Y3_P"+KHO^%-> /^A>C_[_ ,O_ ,51_P *:\ ?]"]'_P!_Y?\ XJ@#G?\
MAHKPA_SYZM_WY3_XNC_AHKPA_P ^>K?]^4_^+KHO^%-> /\ H7H_^_\ +_\
M%4?\*:\ ?]"]'_W_ )?_ (J@#G?^&BO"'_/GJW_?E/\ XNC_ (:*\(?\^>K?
M]^4_^+KHO^%-> /^A>C_ ._\O_Q5'_"FO '_ $+T?_?^7_XJ@#G?^&BO"'_/
MGJW_ 'Y3_P"+H_X:*\(?\^>K?]^4_P#BZZ+_ (4UX _Z%Z/_ +_R_P#Q5'_"
MFO '_0O1_P#?^7_XJ@#G?^&BO"'_ #YZM_WY3_XNC_AHKPA_SYZM_P!^4_\
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MHHH **** "J.L:3:Z[H]UI=Z'-K=1F.4(Q4E3UY%7J* /,O^%">!/^?.\_\
M IJV/#/PK\+>$M875=)M[A+I4:,-).SC!Z\&NUHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXVN=9N?CY8BSTB+5KRRLXWM[&:4(F=A8MDD#())_ >E:7C1?B3XU\.RZ1?>
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gbkyd1brmfwp000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000002.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% E,# 1$  A$! Q$!_\0
M'@ !  $% 0$! 0            0#!0<("08! @K_Q !E$   !@(  P0' P0)
M# T("P ! @,$!08 !P@1,1(3(7$4%4%1@;'!"18R(CA"81<9(UB1E:'6\!@D
M5&)U=WB3M+:WTC,V-T-24V-RE+7%T=,F)S5$@K+5X24T1U=G<X6'E[CQ_\0
M'0$!  $% 0$!              $" P0%!@<("?_$ %H1  $# P,!! <$!0,0
M" 4#!0$" P0 !1$&$B$Q!Q-!<10B,E%AL<$5@9'P(T*"H=$(%N$D,S0V-T-2
M4U1B<G5VD[+2%R4U<[.UMO%TA)2TTY+"PPE5=X.B_]H # ,!  (1 Q$ /P#^
MS#%8],4JN7H'D'RQ4JZGS/SJ07H'D'RQ5Y/0>0^52"] \@^6*FJA.H^7U#%*
MJXI4C%*JDZ#Y_0,4J23\(?'YCBH'57G]!4LO4/,/GBK:>B_+Z&I)/Q!\?D.*
M@>RK]GYU))U'R^H8JFJN*K1U/E]14C%0CVA]_P C54G0?/Z!BJS[:?+^-52?
MB#X_(<574DG4?+ZABJ5?J_Z0^M24_;\/KBH5U1Y_45))T'S^@8JE?4>7U-2B
M] \@^6*I5U/F?G4HO4/,/GB@Z_<KY&I1.H^7U#%3^I^U]*DI^WX?7%5^*/(_
M(5))T'S^@8JKQ/D/FJI:7Z/Q^N*FI&*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5IOBL>F*57+T#R#Y8J5=3YGYU(+T#
MR#Y8J\GH/(?*I!>@>0?+%350G4?+ZABE5<4J1BE52=!\_H&*5))^$/C\QQ4#
MJKS^@J67J'F'SQ5M/1?E]#4DGX@^/R'%0/95^S\ZDDZCY?4,5357%5HZGR^H
MJ1BH1[0^_P"1JJ3H/G] Q59]M/E_&JI/Q!\?D.*KJ23J/E]0Q5*OU?\ 2'UJ
M2G[?A]<5"NJ//ZBI).@^?T#%4KZCR^IJ47H'D'RQ5*NI\S\ZE%ZAYA\\4'7[
ME?(U*)U'R^H8J?U/VOI4E/V_#ZXJOQ1Y'Y"I).@^?T#%5>)\A\U5+2_1^/UQ
M4U(Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2M-\5CTQ2JY>@>0?+%2KJ?,_.I!>@>0?+%7D]!Y#Y5(+T#R#Y8J:J$ZC
MY?4,4JKBE2,4JJ3H/G] Q2I)/PA\?F.*@=5>?T%2R]0\P^>*MIZ+\OH:DD_$
M'Q^0XJ![*OV?G4DG4?+ZABJ:JXJM'4^7U%2,5"/:'W_(U5)T'S^@8JL^VGR_
MC54GX@^/R'%5U))U'R^H8JE7ZO\ I#ZU)3]OP^N*A75'G]14DG0?/Z!BJ5]1
MY?4U*+T#R#Y8JE74^9^=2B]0\P^>*#K]ROD:E$ZCY?4,5/ZG[7TJ2G[?A]<5
M7XH\C\A4DG0?/Z!BJO$^0^:JEI?H_'ZXJ:D8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I6F^*QZC.WC2/;J.W[ILR:(@
M K.G:Z39ND!C 0HJ++&(FF F,4H"8P )A  \1 , $\ 9/N%*G)'(JFFHF<JB
M:A"'34(8#D.0Y0,0Y#E$2F*8H@8IBB(& 0$!$!Q4GJ?,_.I1>@>0?+%7D]!Y
M#Y5^U%T4"IF7621*HHDBF*JA$P.LL8"))$$X@!E53B!$TPYF.80*4!$0#%35
M0%D2+)H'62*LL10R*)E"%55*CV.],DF(@=0J7>$[P2 ($[9.T(=H.:E2L4K]
MJK(H 05EDD055(BF*JA$P465'LIHD[8AVU5#>!$R\SG'P* CBE2B=!\_H&*5
M))^$/C\QQ4#JKS^@J67J'F'SQ5M/1?E]#4DGX@^/R'%0/95^S\ZDDZCY?4,5
M357%5HZGR^HJ1BH1[0^_Y&JI.@^?T#%5GVT^7\:\'?MK:[U66JJ[#ML55$[M
M;XBAU8\H=8I9BVSW?^JH=N***W=J.0;K&,Z<]PQ;%)VW;I IBB;/@6R?<S)$
M"*[*,.*[-DAL)_116<=XZK<4Y"=PPA.YQ1.$)5@UI+]JC3^F$VQ=_NL6UIO-
MUB6.V*DE8$NZSM_HL1&Q"]JG VLEQS8PV$Y==0""8TQNS5M<LC^I3=P81]CC
M);6\"_BU6TD=9M+[=EI"#UPR.HBR4;BI:96*D&;(Y%C)-U&QS2"C-(R:AZV;
M/<I$=N4S$6Y'=;GO-N!3>%-VMI#T]8!6% 1FG$+7D J"L-A9! Q9VLM,V^X/
M6J9=V&+A&F:=A/Q5-R"MN5JN5(A:>94I#*D%5SE19#+)"RE"FR7U-)*5'+B?
MM^'US6UTJNJ//ZBI).@^?T#%4KZCR^IJ47H'D'RQ5*NI\S\ZE%ZAYA\\4'7[
ME?(U*)U'R^H8J?U/VOI4E/V_#ZXJOQ1Y'Y"I).@^?T#%5>)\A\U5+2_1^/UQ
M4U(Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M8D^*>DJ;S)I 8.VIN5K1)4%K
M>3,X@:.[V+$Z\0VD_HJ;DDN>>+,(TA<98KM2#3AE7+5U$IR1I)(K5149^>/O
M/3PYJ/ \5=,LW$A<>&Z%BGSJQ4,K0EEG3V&@M6+9XZI\'= ;,JVZMJ.P)=!&
M-LL(U>2L547D.SDWAF3A^FHV=@@IU\?P\O'Y_A6T0*$$0 # (B'/E[>7/ET]
MGB/MQ4U^\4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KX)@*',1Y!
MT\<4KX!BFZ& 1]W/Q_@QD=,\^ZGAG!QY$?.OUBE,4IBE,4IBE,4IBE,4IBE,
M4IBE,4IBE,4K3?%8]:)\=U7C+-5=6FFD+*E%P6QS32LXTU$&_-?PCI.J6%@S
M/M;4:!7$K9*O(F?JQS"2BF#A>N6!>-DC+LOW-4V7$44J<QMR48P7.Y61N23W
M;O 2H8!() 4G(YK'D)"DHR%8"\\-]Z@'!'Z1OJ4G. 0,I40<CK6EK2^\55'U
MKIFMZXILMIRKIU+9*]6;0=-V8Z@[-?6^UEF]2;RU2GM4;VV#6JG9*HY&RPVL
MY1[KOL1<Q()QEPB6E=B8QKE[(ZUNEQ0=5N;R2IO*4%OUL*#C*%*"O5+@W\@9
M0223CA3R4-A"2V-KF,(60I07ZN4EMU:4J'(1E! . H  5M"QMW%$GL]O.N[)
M?%*\MQ5WW5"E$"A03NEL]3I:9D;3"VM-VG4H^VODVM[:M(^*LBMJ;13[DE"G
M*+EVZ%SC%,?N]NU 5Z.ES?WBM_>]]M*/;*.4<E(1G]8>&,C=("PH*64]^IO9
ML!2&^ZRE1]7/"^AW 'I6#*'L'B6N<+&0&P&%]OSV*WEPF2KFU3FMFJM:9"\V
MRFC>R15;M&B==3M)L$!%M4)F9;E"ZL]?I),I6&N\:NH1R[NK0PDY04(RU)&T
M.>L?T?J94EYQ*PHDA.-N_D*0<8%I"WUIVK"UX<CG<I'&2X O 4T@I( R0 K9
MC(4#R;9KM[LO7E?I#F=7WW-R%*=?: #<9YEJ6"G=JUB<7O\ 0GU'BZ#,3NJW
M3,QKZQ=ELS=<J4O6YZ6G)E!RL,'4V$%49<"%E6.Y3O\ 1-H[TI;4.[<WE82Y
MGU"-O@H #'*BI4H*T)3DO$H]+W*[L%Q)[Q!0$$HQZXRK'())SPD!-21W?Q1H
MZ'J:D1?M_P!EVG-AN"RO9,NEWM7;UJP0]:J\A0-1/B/.%V0>7=VU!^HNB^8U
M"CU6ZS(7 B^P(2'@V35I*6HY=5E#(;3W:0.]"MP*E!;N1( 0..A4M21M&Q15
MDP7G^Y3A;RG%=ZK/=$!) &Q']8RH\\':E*E;_72$X'JV)=MNMX3LM-$V)8'U
MKWQP-V\L/8=:M9:GQ=1>TN!6ND]7GKVAJMJRI3[(ZF($'3";9R];3;.G[SE.
M>L)U:/T89 &P!+,I.X+PLK"SM2H!8*MR=JL$$'( ]7":K'>%Q1.Y14[%4 49
M2$E(*BDE)QM)(R#E/7 .2?RWW1QE!3+W)1<EMV5V.AI#=D_LZIS6FFD57=,;
M:@IN+0U/!Z>D#:_8EO19E@K,()1IIK9"<Y#L6UH7<H*N.P=W4;>@$-!'>M!M
M27"5.MD'O%.C>=F#@YVMX.4C@5'>R=BR"X5]TZ7$J: 2TX% -I:.P;\C/4N9
M "CR:Z <.[W;36^[[IFQK-;KK7JO,ZW>T&TV^N0,([>(6S7D9.6Z-CWE9K=8
MA96+A[2=ZW:IHLG#J'*J,4\>+J(%-F(\&]C*D)2E2@X%I2HD>JLA)(4I1!*>
MO.#U  XK+9+F]Y*RI024%*E #.Y *@,)2" K@=2.F>*VW+U#S#YYCU6GHOR^
MAJ23\0?'Y#BH'LJ_9^=22=1\OJ&*IJKBJT=3Y?45(Q4(]H??\C54G0?/Z!BJ
MS[:?+^-<YN+7A:W#Q3;("/8V&H436=-U1.0E6EK/7%[JZF-A[$='2G[!"1T+
M=:J^JTQ2(>O5Q&NV65))E;/)F8,QA7R9EE"^@:7U):=-V_>MB5-N,RYLO2FH
MSXB(:@0$@L,/+>AR4269CK\@R([7=E2&F0MU!Q7SYVJ]F.K>TW4089GVJR:<
ML^EIL.URKE 7>'9>H-0.J3.GPH\*\6Q^V2[-$@6Y$"Y2A(#;TN7W$-]!6JO#
MHZ XE;M9F=]OM0BX^TRUC^SVG+81&T5QTBI(\/\ ?;E,;@DVPLY!1/T9-M*,
MYF):E$5WZ4B5BS(N\:N4D\XWW3T..J%"E..1FF=<-1B8TA)#=[AQ6K6VH*;!
MW%2%-.*/JMELK60E22>?&A.T6\W)F^WVU1H]SEW'L#FW0(N5O<0J1H.^7B7J
MR2WW,A:>[#<EJ9$:!*WTR PT%O-.)3BN$X/^+!.H[IA916?-:[36#0C^T--E
MPS!CM2RN=\5RY(71J#646GF<E#T:/FD6<Y8G50E8=O++T^-A)-@FR>M=D]JG
M3)E6AUL,>BQI >1'5;WEKML=-FD1%1%;F@PMMV8XR5LL)E-NJ:3*<?;7O0KE
MH?9/VHHM6KX4M4\W2YVY4)ZYM:BALL:FN+FMK?=F[PUW<I4YF1$LK$Q+,RX.
M6F5#1*7:8T.2PEE]JP;PK#*@<2CC5U1C?3)-]MK@\4U(W87JX1T_0=;QMGJJ
ME[I<'37R)C7&O2<FSL-XM,W%/)2KL4'[YU;I9A8JY&QBV59I*YVGTW*6[M;3
M;-5"YE<.*MB;<'(\D0YCTM"@(K[;2F(<9IU#<E:D(1%:6P^XZ-?K2W,6'M%<
MTU:XX=D/ZI[)SI9MF]W:/.L>GX]QMJ[W9X5G?03=H$F2U/O5SF17I5M90^\[
M=93$^W1HR_:-N$7BU3@>(QBL:;5N-QUUMVOMK>CL:!:16V+/;-D,[#19@K7U
MFYFF+ZN5M!9LPE[&-+5I[=T[J<0SFH9R1VSQ%:HTQW]A6.Z]$B3K6^8I@/*=
MMD>-;U,3&=W=(96B1(4"MICTM,I242G5LNI*5[-'99VHIA:_8<5,5=[M8M50
M6[LC4$)J-J>Y7343,^RR@T)#LMIVWVYM;3$NX&T+M*'7;7%9F1'0ZUT;X>-.
MSNG[_P 135%DO%ZNM=YH]BU='*V)Q.D32+JZIQ=[>@B^D9&1CG,G>6$P[?B_
M.FO*.S*2G[L5R"Q^$OMU9ND*Q**PY<8T.8Q<7 PEDD_:,ER$C*&VVW$MPUM(
M1L!#:0&^"G ][T'I2;I6^Z^;0RN-INYWBT3]-QU3W)J4I&FK9&O3VQ]]^0PY
M(O+$IU_OU!<ATJD>L' H[9DZCY?4,YNO2_U/VOI4E/V_#ZXJOQ1Y'Y"I).@^
M?T#%5>)\A\U5+2_1^/UQ4U(Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2M$;GL_8\==
MY6 <[AGXRP0R\?Z53]0\'^V]U4NM&EVR$G%0EYOL)$SOK27/%NV<@\] E=:/
M1B7K"14@8=L^:.7&4E""D*#8*3GUG)#;:E8R"4H)20,\#A8R",DUC*6L*(+A
M!&/5;8<<2G(! 4H!63X]4'!Z#@UNE6PLI81B2WG@UK&F5=*2<5M)^WA'ATG*
MR;=^Q92BKI_&E?LR-WB\2X?RHQ+E=:,3FIM)H26>8RMN3MSCPW8SY''!P?'
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MD D+2<> 4"?PXS^-1CCW]/W?=_[>%=@X64/,P[254C9.',];BN,9--BLI5D
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MT4U467.X.91T5$I&1$1-TT"-=I6L)MY4VW'M ML>&&T$@ORSW*N\QC!2@-N
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MA(];J@LA!@P9QTA R@SCL3KZ9*YKZWA'6+=>2Z@*;5ZP=!([Q8 *1L",H!!
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M@(\G"X> =%E/?_SLPUR'_6_3O<9Q^D7\?\ZJPTU_BF^I_43[S\*MJKIUV?\
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M56]&E1\IF17&%$D84D@  _$#]Q/[LG8!18B2?;./(H%\1,(%   .8B(F$.0
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MC>X;?0$5)?L-_O%.M$7R+I+NUX!,@MH)6-:&,B,=^Z<#=G!;(&U/5I.U'AX
MX^/CFI[AH$G:1D. ^L>CIW+ZGQ//PQQ@9K->OT*>UHM.9:^?QLG18^LP<;3W
M\1+)ST6ZK4;&MV,*JPFTG+TDLV&/;H E( [<B[*'?&75,<3C;7N*E%8(45$J
M!&"%$Y.1X<^'A5Q&T)2$$%(2 D@Y!2!@8/CQX^-7B<GH*L13N=LLU$UZ$8%2
M,^F9R19Q,4R*NNDU1,[D'ZS=HV*LY71;I"LL0%%UDDB"*BA"C !40$@DGH "
M2?(#FI) &20 .I)P/Q-7;(J:8I3%*8I3%*YE;ON5E<6[8D#7?O(]B]P0]#-
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M(-&Z:22)"E13+R2030((%(4/!),A"$#D <B 4H%    #ERS:8"?5 "0. !T
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M*-&J[MJC,-(4SM!,QD43G[)#=E=NS[4-GM[=S?:[UI](<<2V7G5M XP7$J
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MG3L>"I,PCU8D;"G%*/0!/Q) 'NR-V!6PMMJEW-P(C)"&\@*??REIL$\J<<Z
M <GJH@' )QGE)Q2;!VWNFLU-K)1,=K;6ULO<3#ULMU?##R<HJLV?K#9))OW+
MR1;5Z,:-72KIT+9L@0CIL9J$J@=1ZWY=%ZO4*3_.+428UAT^@) B2MKTWG_"
M3C:%$9.$DXXX\:]#LNC;;?6KS L:9U]NM@BFY2),9"T0IKK1 ,"V["KO$+4O
M:!*0OO2V<)RG;6).$S3%NLFP'U<:;%<5:MV#6R\]:I?7+L%K(>/;VE*-"DGL
M2B'8ITE+BT&4<N6+=]*KQ0 9B]C#+BHIODWB)J:=,@0I,F*J$@JD]RO8IP+]
M4)61D[CGG/K8R1CPOVRWJT-IYW5=ZM$*\761-5;+8)S7_4Z4)94O[4:B*P+L
MI'1*W0MDK'K9P17<'7&K:%JZ"2K5(K$; Q@"+A<K=#M.W[M7DHO(2L@N*K^5
MDG*O-5W(2+EV]<K&%19<P\LZ&+#CPF@W&:;91G)2VD)ROG*U8ZK))))R><YY
MKSN]:@NNH9ZIUUEO2Y!2&TN.K)"&D)2EMII'"6F4(2E#;:$I2E"4@#CG) II
MF'F)"B/9$O/EX]D>H>0Y?R??\?O]]:@  [@,'CGQ&.F/=]U?HI2D*!2@!2E
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MM&3@9.SQ\.*@RY:5)29;X4O.T>D. JVC)P-V3@=>*]2'"A8?#_S][RY<@_\
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MA2B2M;+#J(D<*)##:'2@@R'1756I5F.J,!&P,6W3;M(]JDW3(F4"EY)D*3H
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M&N:U!?[K=Y+9N<NXNL,MEFVQYK(99C1_6 ;CL);0PWQG)0WN/ *LFM\RE
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M5"6G'VN*2YK]<E_2;YK39!3'N[V,L1"5*Z)OET%:XSHT^",*X",%'[Q*RA%
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M5%1((_PCD_$_3W\?+ J-B,MG:G]&@H3Q@D'Q41C<1\>/A4P Y!U$?UCRY_R
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M)IE(=10YI^[D(0B8=HQU#&M0$*0I>8B8X@4  ?'%00/=GS)/X=3^'6L6Z/\
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M9.U'2L#LXBZ?>FW9KT?1&J=-7#0;=HCNV+4>IKW,G/VK6LJZF8E*)-I;E07
MZ_#5<XCMF8C6Q8C/J<3F#A[TA9= \/4_&5ZKU4=YRC.\2KYV1Z06=JM2DW:G
MM!)8; HCWRT?',).)CA,HDH6+CB+,VB!B(D3-OM*::F:6TI*9B0H7\YGV[D^
MZYWH+<V<9,YRU^ERRDJ4RRT]':R4J[AD%IM)" D\GVAZZMG:%VC6^5<;K=OY
MAQ'K!$894P>^M-I3!M+&H56ZW)<V(D29$69) 2M)ER2AYYP*<4H:FQO OO\
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M>F"1CFJ XVHE*5H4H=4A221CKD YXK(_9+SY]D.?AX\@Y^'3Q_5[/=E%5TY
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gbkyd1brmfwp000019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )A \H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBN#^,W_)*=8_W[;_THCH [RBH++_CPM_^N2_R%3T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,FACN8)()D#
MQ2*5=6'!!ZBGT4 <$/!OB#19I!X:UU8;5SD07(R$^GRL#]<"KFE^#[Z358=5
M\1ZG]ONH#F&)!B.,^O0?D .G>NQHIW8K(YW6_#US<ZK!K.DW26VI0IY9\U<Q
MRI_=;'/X_P#UJJCP]K&L:C:W/B.ZLS!:.)(K6R5MCN.A8MS^%=911<+&%=:+
M<S^,['6%>(6]O;O$RDG>2<]!C&.?6F^(]#N=8O-'FMY(56RNUGD$A()4$=,
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MQR TKQDMD-,&J:;]F"^7]K\M_/V=.GW<X_\ UU8O?"87P/)X?TUT5F"XDF)
M9MX8DX!]/3TKIZ*+A8J):NND+:$KY@@\O/;.W'Y5A:=X3 \#IX?U-T9L-EX2
M2%)<L",@=,CM74447'8Y :5XR6R&F#5--^S!?+^U^6_G[.G3[N<?_KJU=>%5
MC\$RZ!IS*&9,"28XW-N!). :Z6BBXK%>P@>UTZUMW(+Q0HC%>A( '%<_X?T/
M6-"U&YA6>RDTF:=YQPPF!8<#TQTKJ**5QA1110 4444 %%%% !1110 4444
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MK^=+D>HHVK_='Y48'I0 M%%% !1110 4444 %8^B>&=/\/W6I7%EYWF:C/\
M:)_,?<-_MZ"MBB@#A]5^%>@:EJMQJ$4VH:?-=?\ 'PMC<F))?4D8Z^];^F^%
M=%TKPZ=!M;&,:>RE9(FY\S/4L>Y/K6S10!PFF_"7PYINHVMTLFH7$=H_F6UK
M<7)>&)O9<=NU=W110!SOCS_D0M=_Z\I/Y5S_ ,$O^24Z3]9?_0VKH/'G_(A:
M[_UY2?RKG_@E_P DITGZR_\ H;4 >A4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS- #Z*9Y*>A_,T>2GH?S- #Z*9Y*>A_,T>2GH?S- #Z*9Y*>A_,T>2GH?S-
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MG1YD?]]?SIVU?[H_*C:O]T?E0 WS(_[Z_G1YD?\ ?7\Z=M7^Z/RHVK_='Y4
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M^OYT>;'_ 'U_.G;1Z#\J-H]!^5 #?-C_ +Z_G1YL?]]?SIVT>@_*C:/0?E0
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MYL?]]?SIVT>@_*C:/0?E0 WS8_[Z_G1YL?\ ?7\Z=M'H/RHVCT'Y4 -\V/\
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MA:[_ ->4G\JY_P""7_)*=)^LO_H;5T'CS_D0M=_Z\I/Y5S_P2_Y)3I/UE_\
M0VH ]"HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@_C-_R2G6/]^V_P#2
MB.N\K@_C-_R2G6/]^V_]*(Z ,WQ[_P PC_KU_P *XVNR\>_\PC_KU_PKC:]3
M#?PT?,9C_O,OE^04445N<04444 =Q\-/^0C?_P#7)?YUZ17F_P -/^0C?_\
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M(]:;Y2?W11Y2?W10 [(]:,CUIOE)_=%'E)_=% #LCUHR/6F^4G]T4>4G]T4
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M1YL?]]?SIV!Z"C ]!0 WS8_[Z_G1YL?]]?SIV!Z"C ]!0 WS8_[Z_G1YL?\
M?7\Z=@>@HP/04 -\V/\ OK^='FQ_WU_.G8'H*,#T% #?-C_OK^='FQ_WU_.G
M8'H*,#T% #?-C_OK^='FQ_WU_.G8'H*,#T% #?-C_OK^='FQ_P!]?SIV!Z"C
M ]!0 WS8_P"^OYT>;'_?7\Z=@>@HP/04 -\V/^^OYT>;'_?7\Z=@>@HP/04
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"^*=@>E&!Z4 -\Z/\ OBCSH_[XIV!Z48'I0 WSH_[XH\Z/^^*=@>E&!Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]\4^B@!GG1_WQ1YT?]\4^B@!GG1_WQ1YT?\ ?%/HH 9YT?\ ?%'G1_WQ3Z*
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M 'F)_?7\Z/,3^^OYT;%_NC\J-B_W1^5 !YB?WU_.CS$_OK^=&Q?[H_*C8O\
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M^]1YT?\ >I]% #/.C_O4>='_ 'J?10 SSH_[U'G1_P!ZGT4 ,\Z/^]1YT?\
M>I]% #/.C_O4>='_ 'J?10 SSH_[U.W C.:6B@ HHHH \ZN+.[U7Q#J::CXJ
MFTMH9RL%JDNS,6,JP^89R/;J*Z3PQIBZ<;K;KTVJ[]O^LEW^7C/N<9S^E<3,
M?"/_  D>M_\ "132S7'VL^6Z^9M"_P!WY>ZG(Y]!BNM\&_\ "+YO/^$<W9^3
MS]WF?[6W[_X]*I[$K<ZJBBBI*"BBB@"G=Z3IVH2))>V%K<NGW6FA5R/ID5;5
M%1 B*%4# 4#  J*[N[>PM)+J[F2&WB7<\CG 4>]%O=075K'=02K)!(N])%/!
M'K0!!!HVEVMT;JWTVTBN#UEC@56/X@9J[619>*M U'4'L+/6+.>[0X:%)06_
M^O6O0!SOCS_D0M=_Z\I/Y5S_ ,$O^24Z3]9?_0VKH/'G_(A:[_UY2?RKG_@E
M_P DITGZR_\ H;4 >A4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_N?C_P  ]U_M33_^?VW_ ._HH_M33_\ G]M_^_HKPK%&*/J?F']L?W/Q_P"
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MVCT'Y4 -\U/[PH\U/[PIVT>@_*C:/0?E0 WS4_O"CS4_O"G;1Z#\J-H]!^5
M#?-3^\*/-3^\*=M'H/RHVCT'Y4 -\U/[PH\U/[PIVT>@_*C:/0?E0 WS4_O"
MCS4_O"G;1Z#\J-H]!^5 #?-3^\*/-3^\*=M'H/RHVCT'Y4 -\U/[PH\U/[PI
MVT>@_*C:/0?E0 WS4_O"CS4_O"G;1Z#\J-H]!^5 #?-3^\*/-3^\*=M'H/RH
MVCT'Y4 -\U/[PH\U/[PIVT>@_*C:/0?E0 WS4_O"N$^,SK_PJ;67S\H:W)Q_
MU\1UWNT>@_*N#^,P'_"J-8&!C?;?^E$= &7XYD65-'=#D&U!''KBN0KL?'H
M&D # %K_ (5QU>IAOX:/F,Q_WF7R_(****W.(**** .W^&S!=0OB3C]TO\ZP
M?%9!\47Y'0R?TK?^&G_(1O\ _KDO\ZP/%G_(TZA_UT_I7)#_ 'B7]=CU:O\
MR+X>O^9C4445UGE!1110 5ZOX$D1?"T()P?,?M[UY17K'@5Q'X2C=N%5W)_.
MN3%_ CU,I_C/T_5'2>='_>_2CSH_[WZ5SG_"?:%_SUF_[]&C_A/M"_YZS?\
M?HUQ>SGV/:^L4?YE]YT?G1_WOTH\Z/\ O?I7.?\ "?:%_P ]9O\ OT:/^$^T
M+_GK-_WZ-'LY]@^L4?YU]YT?G1_WOTH\Z/\ O?I7.?\ "?:%_P ]9O\ OT:/
M^$_T+_GK-_WZ-'LY]@^L4?YU]YT?G1_WOTH\Z/\ O?I2PRI/!'-&<I(H93CL
M>:?4&Q'YT?\ >_2CSH_[WZ5)10!'YT?][]*/.C_O?I4E% $?G1_WOTH\Z/\
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MB,E)76P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S]8T6QUVS6UOXVDB5Q(
MKE>0".WU-:%% ')_\*W\-?\ /I+_ -_V_P :U=%\-Z9X?,QTZ%X_.V[]SELX
MSCK]37)ZAK6LW.OK-#>_9["#5XK#[,@&Y_[S,?0^G^3O^%]1U&6ZU+2M4EBN
M+BP=!]HB& ZL,@'W&.:IWL2K7.DHHHJ2@HHI&8(I9CA0,D^E 'FEO\,]%LX]
M;UKQK);ZG/<2O*US-D+!%V ST(]17&:5K.J:/\"]4DM9IUM[G46M=,ED)W+
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M6MX6FD^Z&C89_$BL3P#IUE>Z3.]S:Q3,LN 74$CBNP@TC3K:42P64$<@Z,J
M$5YE95?;.S5K]CZ;!RP7U."<9<]NZM?[MC+U+QMH.E7KV=W>%9D^\JQLV/Q
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M?6[6WW;G.?\ "Q_#'_/\_P#WY?\ PK3F\3Z1;Z-'JTEUBSDQL<*23GVZU/\
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M]5_F*\AKU[QQ_P BI=?5?YBO(:]#"?"SP,W_ (D?0****ZSR@HHHH ]&T/\
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M :W? # $[X ^M:T:7M':YRXO$_5X*5KW/5O^$Q\/_P#04B_)O\*/^$Q\/_\
M04B_)O\ "O&Z*Z/J?F>?_:_]S\3V3_A,?#__ $%(OR;_  H_X3'P_P#]!2+\
MF_PKQNBCZGYA_:_]S\3V4>+] 8X74HR?96_PI#XP\/@X.IQ _P"ZW^%<3\/$
M237)@Z*P\GHPSWK)\4@+XHU!5 4"3@ 8[5DJ%ZCA<ZI8ZV'5;EW>QZ9_PF/A
M_P#Z"D7Y-_A1_P )CX?_ .@I%^3?X5XW16OU/S.7^U_[GXGLG_"8^'_^@I%^
M3?X4?\)CX?\ ^@I%^3?X5XW11]3\P_M?^Y^)[(/&'A\G U.(GT"M_A0?&&@
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MU !''N::5Q-V/2:*HZ-J<>L:/:ZA%C;-&&('\+="/P.15ZD,*\-UK_D.W_\
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M)D7@J#DG![=,?C36XF95IIGCJRN[J>!M*7[3)YLD>3MWXP6'&03@=ZZ;0?\
MA(<S_P!N_8_X?)^S9]\YS^%3Z7IK6?AZWT]KJ21E@V&?C=R.H^F>*YKX>W%U
M&=6T:XG:>/3KCRXI#Z988^GRYQVS3W [>BBBI&%)N'J*6N!@^&%E9:JNJ'7]
M:8Q2F<QO=$IUS@CTH JVWP\\/Z';:YK7BY[;4Y;J5YI;JY3_ %<?91GH1[5P
MNFZAJ6C? C4Y+9YX;:^U)K?36<G<EN[  C/;K^M5M7\>Z+XQ\6S+XIN[RV\/
M6$W^C:=#;NWVI@?O2$=O:NZ\17FG_$7X7WZ>%(Y)/L+HT,+0&/+1X8*H/M0!
MG^./!&C^'/AG;ZII%G'::EHZQ3QW40VR.1C=N8<G.>]=1K/Q1T3PS9:2^KBZ
M\V_M$N5$$)<8(%<;XE\=6GC?P9:^%M&BN)-:U$QP3V[0LOD 8\PL3P,8KUJV
MT>SCTZSM9[>&?[- D*LZ \* ._TH \I\4_&KPIJWA75-/MA?^?<6SQIOMB!D
MCN:Z+X)2K_PJG2NO#RCIZ2&MCQSI6GQ^!=<=+&V5A9R$$1 $<5E?!+_DE.E?
M[TO_ *,:@#O_ #4]3^5'FIZG\J?10 SS4]3^5'FIZG\J?10 SS4]3^5'FIZG
M\J?10 SS4]3^5'FIZG\J?10 SS4]3^5'FIZG\J?10 SS4]3^5'FIZG\J?10
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M^^33Z* &><GO_P!\FCSD]_\ ODT^B@!GG)[_ /?)H\Y/?_ODT^B@!GG)[_\
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M"GS?E5_R(?\ GDG_ 'R*>$4+M"C;Z8XHA3Q";YYI_+_@@E4ZO\#G?^$UTO\
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M4%U)=1PW<=PY9A(+EOE8YY S[T <=\1+NX\>V^N16DS)X=T")FFE0_\ 'U=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@E*/^%4Z5PW#RCIZ2-70>.XHQX"UTB-!_H4G\(]*PO@E_P DITKZR_\ H;4
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M=XJN2,_=7J/:O7Z\A\<?\C7<_P"ZO\JZ<+_$/.S3_=_FCG:***](^<"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)9F/U_/\ZV** ,>_T2PU'5+/49HYUNK0_NWC)'?.#ZCK^9K5\T?W'_[YI]%
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M'YH_NO\ ]\FCS1_=?_ODU)10!'YH_NO_ -\FCS1_=?\ [Y-244 1^:/[K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUA\YQP>:]!HH B\UO^>3_I1YK?\ /)_TJ6B@"+S6_P">3_I1YK?\\G_2I:*
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MNHHK.I7E45F;X? TZ$N>%R+SA_<D_P"^#1YP_N2?]\&I:*Q.P**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 444A(52S$  9)/:@#'U?Q1IFB7]I9WLCK+<GY=JY"C.,MZ
M#/\ (ULUY4NE/X[E\0ZQABJ+Y-@/=>?U '_?9KM/!6M?VWX:MY9&S<0_N9L]
M=R]_Q&#^=-H29T-%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %4-;L;C4M&NK*VN!;R3IL\TKNP#UX]Q
MD?C5^B@#,\/Z/'H.B6^GQL',8)=\8WL3DFJ.B^&I-$U[4KR"Z4V=Z=_V;9C8
MV<Y!S[MV[CTKH:*=PL%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gbkyd1brmfwp000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *, SL# 2(  A$! Q$!_\0
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M!CTI_P!HXN]N;\$+^R\%9/DW\Y?YG>?\+3_Z@W_DU_\ 84?\+3_Z@W_DU_\
M85YU14_VGBOYOP7^17]D8/\ D_%_YGHO_"T_^H-_Y-?_ &%'_"T_^H-_Y-?_
M &%<]!X=TU=(L[_4-<^Q_:PQ2/[(TGW3@\@U3U#3M%MK1I++7OMDP( A^QO'
MD=SDG%;/%XV*NYKO]F_W;F$<%E\I<J@^WV[??L=;_P +3_Z@W_DU_P#84?\
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MRL@HHHKN/."BBB@ HHHH YSQ5XJ_X1G[)_H7VG[1O_Y:[-NW;['/WOTKG?\
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MDNF"JUM-O53G'S''%:2Q6/CN_P $91P66S^%?C+_ #.N_P"%I_\ 4&_\FO\
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MMY=T>7FV!P^'H*=*-G>V[[/N='1117MGSP4444 %%%% !1110 4444 %%%%
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MD8-:59PG'1QV71WT7I8SHTZD)6<9;OJK:M^=_P #H->_X1[9I7]J_P!I^?\
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MLJ0RC4I84MYYV VF-"<8.<Y.1FN6K&K5C"RHOK?_ "7R7YFU"C*I=UUTY?\
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M< 00"#D'H12:LQIW%HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** *.LI>2Z-=Q6 4W4D12/<V
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MX@V-STAU.V:W?T\Q/F4_7'%-"9U-%%%(844=!38R6B4GJ1DT .HHHH ****
M"BBD+ ,%[GI0 M%%% !1110 4444 %%%% !5#5M8LM%LS<WTP1>BJ.6<^BCN
M:H:SXD6RN1IVGP&^U:0?+;H>$']YS_"/\^],TGPVR7@U769Q?:H?NL1^[@'I
M&.WUZT[=Q%*/3-2\5R+<:VKV>E@[HM.5L-)Z&4_^R_Y/5Q11P1+%%&L<:#"H
MHP /0"GT47&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .$^'_ /HVK^)=/Z>3=Y4>V6']!7=UPFB?Z'\5=<MNBSP"
M4>Y^0_\ LQKNZ;W$@HID)S"F>H&*<2 ,DXI#%ILC%5R/4 _G3?.CZ!L_[O-,
MF=FA;;&W3.3Q0!/14?[T_P!Q1^)H\MC]Z5OPXH DJ!98UDD&X=<\<]J?Y,><
ME=W^\<T* L[ #&5!_G0 >83]V-S^&/YT9E/\*+]3FI** (&1_.3=(>01\H I
M_DI_$"W^\<T2??C/^UC]#4E "!57[J@?04QO]=&?J*DJ.3[T9_VOZ&@"2BBB
M@"-?]>_N ?YU)4?_ "\?5/ZU)0 C#*D>HIL1S"A_V13ZCA_U*?3% $E,_P"6
MY]U'\S3ZC_Y>![I_6@"2HY?X/]\5)4<OW5/HR_SH \XU3XAZO9:O>VD=O9&.
M"=XU+(^2%8@9^;KQ53_A9NM?\^MA_P!^W_\ BZR;O2[G6/&.IVMJ%W?:IF9W
M.%10YRS'L*LQ^&=+N9?LMGXDMYKX\)$8&5&;T#YP:^8=?&2D^66E^Z7W7W/L
M%A\#"*YX:V3V;^^VWS+C?$S664J;6PP1C_5O_P#%4#XF:T!C[-8<?],W_P#B
MZY&XMY;2YDMYT*2Q,4=3V(J*N=X[$IV<V=*R["-74$=I_P +-UK_ )];#_OV
M_P#\71_PLW6O^?6P_P"_;_\ Q=<712^O8G^=C_LW"?R([3_A9NM?\^MA_P!^
MW_\ BZ:?B7K)<-]FL,@$?ZM__BJY9X;4:?',MWNNF<J]OY9&U>S;NASZ56IO
M&XE?;$LOPC_Y=H[3_A9NM?\ /K8?]^W_ /BZ/^%FZU_SZV'_ '[?_P"+KBZT
M=#TO^VM8@T_SO)\W=\^W=C"D],CTIQQF*G)1C-W8IX#!PBY2@K(Z/_A9NM?\
M^MA_W[?_ .+H_P"%FZU_SZV'_?M__BZXQAM8CT.*T+[2_L>F:=>^=O\ MBNV
MS;C9M..N>?TH6,Q33:F] > P::3@M?\ ASH?^%EZSO+?9K#)&/\ 5O\ _%4[
M_A9NM?\ /K8?]^W_ /BZYRPTO[=IVHW?G;/L<:OMVYWY.,9SQ6G!X=TU=(L[
M_4-<^Q_:PQ2/[(TGW3@\@UI#$8R2NI>>Z76W7S,IX; 0=G#K;1-ZVOT\C0_X
M6;K7_/K8?]^W_P#BZ/\ A9NM?\^MA_W[?_XNLJ\\.VT>G_VC8:JE]9)(J3NL
M)1XL]]A/3\:I:[I#:+J;6AE\Y-BO'*%V[U(SG&3[C\*)XC&05W)V]5U"&%P$
MWRQ@K^C6WKZG1?\ "S=:_P"?6P_[]O\ _%TT_$O62ZM]FL,C/_+-_P#XJL2V
MT*2XT&34_,<,9U@MX%BW&9CUQSV^AHU#P[?Z=8V]U);7.R2/?+N@91"=Q #'
MWX/..M+ZQC+<W,[6N/ZK@.;EY5>]OF>T:7=/>Z197<@423P)(P4< LH)Q[<U
M;K.\/_\ (MZ7_P!><7_H K1KZBFVX)OL?'U4E4DEW844459F!Z4R'_4I_NBG
M-]QOI38O]4G^Z* 'T444 %%%% $<W,1'J0/UIQ13U4'\*;+]U1ZL/YU)0 SR
M8C_RS7\JYKQM:%-!74+=3Y^GSI=)@GHIY'Y$_E745#=6\=Y9S6THS'-&T;#V
M(P:$#$A\NXMXYXI',<BAU.[J",BG^6W:5_T_PK \$7+R>&TM)C_I%A(]I*/0
MH>/TQ71T,"%UD6-CYO0'JM*@E$:@,AP!V/\ C3IO]2_TQ3Z (\S?W4/XD?TH
MWR?\\OR:I** (_,;O$_X8_QH\T=T<?\  :DHH C\Z/N2/JI%,\Z,SK\Z\*>_
MTJ>HP 9V]E']: '!T/1E/XTZFF-#U13^%-\F+^XOX"@"2BH_)3MN'T8T>5Z.
MX_X%0!)5#4-:TW2MHOKV*!FZ*QY/X#FI;N1K2RGN [MY4;/C YP,^E>$W5W/
M?W4EW<R&2:4[F8_R^E<6,Q?L$DE=L]/+<O6+;<G9(]OT_6].U:0BPO(IP@RR
MJ>1^!YK'O-5U/6[R;3-"5K>&)S'<ZC*A 0CJL8/5O?M^1KRBUNY["ZCN[:1H
MYHCN5@?T^E>[VL\EQ:0SB- )45P-WJ,^E/!XOVZ::U09EEZPC3B[IE;1M#LM
M#MC%:H3(YW2SR'=)*WJQ[UI4BDD?,,'TSFEKL/,"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@M0)L_B]I\@
M7BZM"IR<9.''_LHKN<2GNB_09KB/&O\ HOB[PO?=!]H\ICZ#<O\ 1C7=TV)$
M$49(8-(YPQZ''\JD$,8.=@)]3S2)Q+(/<']/_K5)2&'3I2,,J1ZC%+10 R(Y
MB0_[(I]1P\1 >A(_6I* "HSQ.ONI_I4E1O\ ZV,^Y'Z4 24444 1R]%/HP_G
M4E1S?ZECZ<U)0 5'+T4^C#^=25'-_JB?3!_6@"2BBB@!A_UZ>ZG^E/J-_P#6
MQGZC]*DH *CA_P!7CT)'ZU)4<71AZ.?YT 25&W^O3_=/]*DJ-_\ 6Q_C_*@"
M2HYO]4?8C^=25%<,JPMN8#CN: /+^=WC;RO^/CS&QCKL\T[_ ,,5QD>_S4\K
M=YFX;=O7/;'O6Y=:M<:1XQU*[M2I)NIE9'&5=2YRI'I5F/Q/I=K-]JL_#5M%
M>CE9&G9T5O4)C _"ODJGLZCM*5K7[]V]+'V]+VE-7C'FYDNW9+6_33I<O>'+
M)K>ZUF_UB8P7EFB#SKB,SF-G/WBO\1P/UHU[4M+U#0YEN-;CU+4$96MY!8M
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MH>M#@6UUY$Q_Z9R#!)^G]:ZFFQ(CFYB(]2!^M25'+T4>KBI*0PHHHH ****
M"HT_ULA]P/TJ2HXOXSZN?\* )**** "BBB@!DL:S0O$XRCJ58>H->)Z]X=O=
M NVCEC9K8MB*<#Y6'8>Q]J]OKD?'69QHMC_S\7Z9'L/_ -=<./HQJ4^9[H]7
M*<5.E6Y%M+?Y' Z%X9O];O%C6"2*V!_>S.I  [@9ZFO:8HDAA2*,;410JCT
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M2=JD6O4DHJ/SE[AA]5-*)HC_ !K^)JS(?12!@>A!^AI: &2G$+G_ &33E&%
M]!3)O]41ZX'ZU)0 4444 %%%% !7':1_I/COQ!<=HQ%!_+/\J[&N.\&?Z1=:
MU>=1/J# 'V4'_&N>KK4@O-O\#LP^E&K+R2^]K_([&O/_ !RF[6X3_P!.R_\
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M$40*89F;!(P3QUJ9551A0!]!38^#(/\ :I] !4:?ZR0>X/Z5)48XG;W4'^=
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MKA;?'KWOJ4[S4+?[$+*PA>. MN=I""\A[9Q696]_PB=_OV^=;9QG[S?X4O\
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M[\/-%,[/]FE,:,QS\N 0/PS7F^GZ'J>J,!9V4LBEMADVX13WRW05Z_X;T1-
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M^RH_L?'_ ,GXK_,/[1PW\WX/_(XORZGLI/L=[!<[-_E.'VYQG%=;_P (6/\
MG_\ _(/_ -E1_P (6/\ G_\ _(/_ -E3CE.81:DH:KS7^8GC\*U9R_!_Y')2
M3.U^]W'F-S*9%P?NG.:TKS6VO-3LKU[<*UN!E0_#D'/IQ^M;?_"%C_G_ /\
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MY,?8;?\ =.*9-&PA?$C=#UYJ>F2_ZE_]TT )^]'=&_ BC>XZQ'_@)!IXZ4M
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M$>+/%PT:]6TL466]1?GDE&1$#V'?)X[^E<_9_$;6(;@-=)!<0Y^9 FP_@?\
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MB=!YWA!I,?ZFX1_YK_[-74Z?<?:]-M;G.?-A23/U -97C6#[3X-U1,9Q#O\
M^^2&_I2^#;C[3X.TN3.<0"/_ +Y)7^E/H+J;1XF0^H(I],DX:,_[7]*?2&%%
M%% $</$0'H2/UJ2HX^KCT8U)0 4P<3L/50?YT^HG=4F4L<94B@"6D)"C+$ >
MIIF9'^Z-@]6Z_E2B)0<MEF]6H C\QFG/EKG*CEN!3_*W<R,6]NWY4IXG7W4_
MTI]  .!@5''P9!_M5)4:?ZV0?0_I0!)3)O\ 4M[<T^F2\Q./]DT /HI <J#Z
MBEH 8GWY!_M?T%/IB_ZV3\*?0 QO]<GT/]*?4,KJLL?4MSP.M.VN_P!X[5]
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M_( MO^!?^A&O2R#_ 'F7^%_FCBS;^"O7]&:M%%%?7'SP4444 %%%% !1110
M4444 %%%% !1110!5U.#[5I5Y;XSYL#ICZJ17,?#*X\[P=''G_4SR1_KN_\
M9J[&N$^&_P#H[:[IW3[->'CTSE?_ &2GT%U.WF_U>?0@_K4E,E&8G'J#3E.5
M!]1FD,6BBH_-!XC!<^W3\Z !>)I!ZX/^?RI6E53MY9O[J\FH]C-/\[<%>B\=
M#Z_C4RJJC"@ >U #,2/U.P>@Y--\M4EC('))!)ZGBIJCEXV'T84 24444 ,?
M_61GW(_2GTR7^ ^C"GT %,'^O;W4?UI],_Y;CW4_SH ?2,,J1ZBEHH 9%S$G
M^Z*?44;JD*;CVP!ZTO[R3_IFOZ__ %J $+JDS9/)48 ZGK2XD?K\B^@ZFD5
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M(+920@3Y21ZDBC2?%>H:?<J;B>2YMB?G20Y('J#6".!BG1Q//(L42EY'.U5
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M[E8;<00L0.?4@"IK36?$,UG!%I_AIT1451+>3K&.G]WK7/R2>)YNBC^;_P"
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MSVMO^^F_^)KM**/[$PG9_>']IXCR^XXO_A$=0_Y[6W_?3?\ Q-'_  B.H?\
M/:V_[Z;_ .)KM**/[$PG9_>']IXCR^XXO_A$=0_Y[6W_ 'TW_P 31_PB.H?\
M]K;_ +Z;_P")KM**/[$PG9_>']IXCR^XXO\ X1'4/^>UM_WTW_Q-=/I-I)8:
M9#;2E2Z;LE3QRQ/]:NT5TX7+J&&FYT[WM8QKXRK7CRSV"BBBNXY0HHHH ***
M* "BBB@ HHHH **** "BBB@ KA/#/^B?$GQ)9]/- GQ^(/\ [/7=UP<N;3XP
MQ[3M-[9]<=<*?_C=-"9W;$*,L0![U#$[-$H1>@QN;@5(L2@Y.6;U:B+HP]&/
M^-(8GE;O]8Q?V[?E4E%% $;<2QGUR/\ /Y5)4<G!0^C"I* "F3?ZLGT(/ZT^
MF2C,3C_9- #Z*0'*@^HI: &3?ZO/H0?UI],F&87'L:>.1F@ IC?ZZ/Z$4YF5
M%RQ %0NSNT94;5W?>/7H>U $S.J#+'%,S(_3Y%]3UI5C53GJW]X]:?0!R7B?
M79-(C2TL_EN90S-*>2JY(_,UQJZUJB2B0:C<[@<Y,A(_+I6WXXM)$U..[P3%
M(NS/8,.WY&N6K:*5C&3=ST[PSKC:S;9F %S#\LF.C9Q@UOUQ7@.SECCGO'&(
MY2$3/?&<GZ5VM92W-8[#)?N@^C#^=/IDW^J)],']:?2&,F_U+?2GU'.56WD9
MB%4*223@"JG]IJPWQ6MS+#T$J)D'Z#.2/<"@#F_'&I11O9VT;9NH91.1CA1V
MS67'XXU,2YG2"2(D90*5./8YK/\ $S&3Q#=2$.%<J5WJ5., =#SV-9-;**L8
MN3N>B)X\TQG"O#<HIZL5! _(UTEO<0W4"3P2+)$XRK*>#7B]=Q\/YY"M[;DD
MQJ5=1GH3G/\ *IE%)7149-NS+OCN&230XY%Y2.8%_H01_,UYU7I_C&WDN/#D
M_E@DQLLA ] >:\PIPV%/<U_"W_(S67SA?F/7O\IXJGJOF?VQ>^;GS//?=GKU
MJ?P]!)<>(+%8AEEE#GV4<FNS\1>$TU.5KRUD6&X(^<,/E?W]C3;28DFT>=5)
M!/+;3I/ Y25#E6'44K6\R6T=PT;>3(2JOVR.H^M)!!-=3K!;QM)*QP%49-42
M-D=I9'D<Y=V+,?4FFUW%WX+@72X2LIBNH8"TK 95R.3_ (9JMX9\*6]_:P:C
M=3%XV)(@ P#@XY/IQ4\RL5RNY=^'_P#QYWW_ %U7^57/%7-]H:GH;P?TI/"8
M N]:   %V0 .W6E\4_\ (0T+_K\']*C[1?V3I:CC_P"6G^\:DJ.+^/\ WS4%
MBF&,G.P ^HXK'\2ILT63#,0648)SWK;K%\4G_B2L/611^M<N-_W:?HSHPG\>
M'JB35?,3P_/DJR^3CI@TV#4[73-$LY+R01(8E"D\[N.P'-2:YQX?N1_TS _4
M5YIJUW+=WQ\QCMA41(N>% &./YT4XWQ7_;J_-BG*V'_[>?Y'3O>Z)J.NVJP%
M1'([>;N4H&/:NSM[>&VB$<$:QH.RBO%Z]/\ "L[7^@0239,B$QE\X+8/!_*M
MHX6G2E*<5JS-XF=2*A)[%OQ&^SPUJ3>EL_\ *H/"*[/"6F#_ *8 _GS3/%H,
M?A/4R)&QY)&#SUJ;PZLL?AO35"J0+9.,X/2L_P#F(^7ZG3_S!_\ ;WZ&O3#_
M *]?]T_S%)YI'WHW'X9_E3!*C7'##[O?CO70<9/1110!#=-MLYV](V/Z5G^&
MUVZ%;^^X_J:MZJVS2;MO^F3?RJ+0UV:):#_IF#^=<CUQ2\HO\T=*TP[]5^3)
MM2D\K2KR3^[ Y_\ '36-X#C\OP=8Y_B#-^;&KWB63RO#.I/_ -.[C\QBHO"D
M7E^$M-C]8 ?SY_K5O7$+R3_-%K3"/SDOP3_S,C5O$5S)<O%9OY4*'&X=6]_I
M5>R\17UK,#-*T\6?F5^N/8UF3PO;W$D,@PZ,5(J/GH!DGH*^3GC,1[5S<FG_
M %T/=CA:/L^515CM=1U754DB32=&^VI+&'\][A8T7.>#GDGIT]:I_9_&5[_K
M+[3=-4]/(B,SCZ[N,UNZ;"UOIMM"_P!](P#]<5:K[*G)N";6I\O.*4FEL<Q_
MPAS7/.IZ[JEYGJ@F\J,_\!7_ !JSI_A'P_9KNBTJW9MQPTJ^8>OJV:WJCA_U
M*>XS5W9-D8_B14CTB."-517F10JC K;4;5"CH!BL77QYESI</]^X!_*MNN.E
MKB*C]%^OZG54THP7J_T_0****ZSF$) !)Z"N0\ CS-.NKKO/>RR9_(?UKI=4
MF^SZ3>3?\\X';\E-8G@6'RO"MCGJR,Y_X$Q_PKGEK7BNR?Z'93TPLWW:7YLZ
M:BBBN@XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *X3Q9_HGC_PQ>=/,<P9_P"! ?\
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M.I/G!,6T?B0/ZU8\.P?9]"LHL8VV\8/UV@G^=9/Q"<_\(R(%ZSW$<>/7G/\
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MX4LK*5('XUR8[_=Y?UU.G"?QHESQ.?\ B2/[NO\ .KUT=FDS'T@;_P!!K/\
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M%)YZ'^6:Q;2QNKZ816MO)*Y..!P/J>U=]J:^7XVT<@D;HY%Y.>QH\)%U?5T
M#;;QL\X-/FLA<MV:VAZ8-(TF*T+!G&6D(Z%CUK%\>(%T6!E4 BX7D?0UU'F
M?>#+]17->.B&\/H00<3KT^AJ(_$7+X0T8,/%^M -R5B//.>*Z7<XZIG_ '37
M,Z.P7Q?JA)X,$39_ 5TN&DY.57T[FE+<(['&:,__ !2>LJ.,R3')^E:7@;_D
M71_UV?\ I5'0O^19UT=A-/@?\!JWX&0-X>).<^<W(/TJGLQ+='07W_(/N?\
MKDW\C65X._Y%>T_X%_Z$:TKY7&GW.'R/*;J/8UE>#V8>&+3Y"1\W(/\ M&IZ
M%=2#PFBM+K&X _Z:U'B!<>(=  )_US=3G'2CPDZB;6,G&;UNM&OL)/$>@A2?
M]<W(_"J^T3]DZ$M+G:NUCW/3%07EXNG:=/<.C8B0OSW/_P"NKBJ%7"C JKJ=
MI]OTRYM<X,L94'T/:H19Y-?7]SJ5RUQ=2EW8\#/"^P'85)IUX]O=VX=V:W$J
MEHR<KUYXJK-#+;3O!.ACE0X96'(-3:=:&^U&WMU. \BJ6]!FM*B@X-3V,H.:
MDG'<] \0V%K!91-!$(F>95Q'\H/7MTJSK$%W;Z+>LM\TD8@;*S1@G&.Q&/US
M3/$8<6UFA(8&Y0=,'O4WB.<KH%^NQMWDG..0 :X:/^\U/^W?U.VK_ A\_P!#
M \*RRP/N6V>;%L@*QL,@>O)'Y5U(U:T7 F9[<GM.A0?F>/UK \'X$DO(X@C'
MZ5UM&$^&3_O2_-BQ'Q)>4?R1Q_C>6.XAT5(W5TDU!.5.1785Q?C"SMQJOA](
MX4C:6] 8QC:2..XKIOL-Q'_Q[ZA,!G[LP$@_H?UJJ?\ %G\OR-:_^[TEZ_F7
MJCBZ/_OFJOF:G%]^W@N!ZQ.4/Y-Q^M,CU2*)#]IAN(,$Y+Q$KU_O+D5T'&:-
M%1075O<C,$\<H'78X/\ *I: ,/767^T=*5B HF+$GL!BLB^\>QQW#1V5KYT:
MG'F.VT-]!CI3O'#.?)1,Y$3$X],C/Z5P=886*E4JR\TOP1KB9-0IQ7;]6=3_
M &TWB+Q1H+?9_)-O*Y<;L@Y'&/RKT2O&K!I%U&U:+/F"9-N/7(KV6M_9*$FU
MU(=:52$8O[.GXW,2_P#G\4::G]U'?_/Y5MUB/^\\8QC_ )YVQ_4__7K;KDPV
MLJC_ +WY)(WQ&D8+R_5A11176<Q&W,T?L":D)P,U'_R\?1/ZTV[?R[.=_P"[
M&Q_2E)V5QI7=C*\,#.GS2_\ /2=VK;K*\.)LT*W/=LL?S-:M<^"5L/#T1OBG
M>M+U"BBBNDYSCA_I/Q,NCSBVL53\6(_^*KL:X[P__I'C'Q%<YSMFCA'X9_\
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MAS-NRJ ,>^>@IJP*O()#>HX_2I  HP!@#L*6D,XCQ=H5E:V@OH8@DC3*KA>
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M+D=JT(+NWN1F">*7'78X-:0CRQ2[&567/.4N[9-1115$!1110 4444 %%%%
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MEFT.^0#&86.!WP,U#X:EDD\.6+@!AY07T/'']*?074V*HZS%YVB7T>,Y@?\
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MZTQUD9O+5PR]6W#MZ<4_>R_>C/\ P$YK<Q)*88D)SM&?4<4"5"<;L'T/%/H
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M^B@"/;*.CAO]X?X4>8P^]&?JIS4E% $?G1\Y8#'8\&EC!P6/WFY--D D<1D
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M+YJYPP*G_:%/I&8*N6.!0 M1[BYPG [M_A3/*\SD@HI_A'?ZU)B11QM8?E0
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MA']:9YB2OM)PH/(;C)J>@!" 1@C-4=558M)NV7*XB;[IQVJ_6;X@;;H5V?\
M9 _45CB'RT9OR?Y&M!7JQ7FA-)$D.AVQ!4@1;L'CWK,\%-LT%G*MB2=VR!G_
M #TK5!\GP[G^Y:Y_\=JEX.39X7M/]K<W_CQJZ"Y:,5Y+\B*KO5;]3<5U;[K
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M:;5A7+M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L$ECIT<4,[W\H@DC>7:1&V1GUYYYZ<5T=>6ZW>Z!K^J2P:Y;7FBZBA*0W+
ME64$[=P[?YYII"9+%X;\5Z!J<!T^*#5+:U61;0S2!1#OZG!(Y_,5V/A30Y-"
MT@PW$BR74\K3SLOW=[8X'MP*S/"\/B6SO%MKR\MM1T@QEHKQ7W,?0 YR?QST
MZUU]-L$@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH P]6\(Z)K4_P!HO+,&?&#)&Q1C]<=:K3>'
M5T31+I/#5E$M](NT.\A#<]3N/?TY KI:*=Q6. /@RUTWP+??;($FU!XC,\C
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MH 4X[8'.,?3)KN:BN83<6LL(<H70J&7J,]Z=Q6/.-3MXKGQ38>$O.^RZ5;Q
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M8,/1N#^='FX^^K+[]1^=244 (&##*D$>U+3#$A.<8/JO!I-LB_=8,/1AS^=
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K.\0?\ (MZI_P!><O\
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M0DJ^;$0P'3J>/PKKV\3:LF_=9Q+Y>-^8G&W/3//%1?\ "7:A_P \;;_OEO\
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M?L5RLDEO@ KYT(+8]2#D_B:C@T3QS;74%S# R2P0B"-A+#P@_A(S@_C70_\
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M*PZ#GG]!U-42=AI>AZ=HOGC3[98!.^]PI)YQVST'M[FM"BBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MKJ?_ "";S_K@_P#Z":M55U/_ )!-Y_UP?_T$UE6_A2]&72^->IYW;?\ 'W#_
M +Z_SK=UA%OIYIXP!/:R[)0/XDS\K?ATK A<1SQN<X5@3CZU?&J"/6Y+V-28
MI'.Y&_B0]0:^'P]6$:3ISV;7ZZ_)GU%:$G-3CND_^&+U_9P3ZQJ%Q=2.EO 5
MW;!EF) P!55M/LYEMY[.28P/,(9%EQO4GOQQ4CZM:S7U[YT,K6EUMR!@.I'0
MCM4;:A9PK;P6<4PA2=9I&D(WL1VXXKIJ2P\I2D[6;?>]^;3Y6_7J805:*2UV
M7I:WYW)9M,TX_;(;>>X-Q;*SDN!M8#J!WS5"&.\L)8KPV\R*C!@[(0#^/O4L
M=_$E[?S%7VW"2*@P,C<>,U4>\NI8A%)<S/&,81G)''M7-5G1NI15FKVMZZ;F
M].-3X9:KS_$TKG3Q<:^D<7^IN2)E/^P>3_6EN91J":G<K)(L<?EK&BMA2N<#
M(_6F0ZLD>E&$HYNE1HHY.P1B"?QZ_G52WNDAL+R!@Q:8)M(' P<G-:RJTKVB
M_BNWY.SLOD[_ (&<85.O2R7WJ[^XOW6G:=#>QV:S7/FEAN8KN !&<  9)Z?G
M3[_18(=-DNH4NXC&1D7 7Y@3CC'(_&H/[5B&O?;A&YB(VD=&'RX)'O4D^HZ?
M_9]S;P"\9YMI\R=@3D'..O2M;X62J7MUM]VGWOT\^Q%JZ<-^E_U+6H8SK.>F
MV#/Z51;2X5OYAOD^R)!YX?(W%2..<8ZG%%UJD$_]H;4D'VD1A,@<;<9SS4UW
M)+;>'H;>>(QSRMM^88;RU.1^IIU94JLI2>JC=_\ DTK+YW0H*I!*.S=E^"U^
M5F9+V=U'$)9+:9(SC#LA Y]ZZ2.RF%LFDFWD\MX"S2[#M$I^8<^V,5AVNH.)
MX1>3W$EJC F/<6!QT&"<4LFL7[7+2K=SJ"^X()#@<],>E88>KAZ*<M7?2VFW
M7[_\S6M3JU&EIIK_ )?<2Z5IB7C7!G$Q\@#,4(&\DGW]*>=+MWU:WM8I)XUE
MY99TVNGMZ'..,4IO]/?49KAHKF,2@,'A;:\;=\<X(-+>:M;7,MJC13SP0DY:
M9_WC9]QZ5:CA8T[-IM/SUU_#3U^\ENNYW5[-?=I^.OI]PW4M-MK6'=$MY%(&
MV[+A!A_H5XJ0Z=I<%PME<7-Q]J. SHH\M6/8]Z+K5[?^SY;:W:\E\S'-TX.S
M!SQB@ZCI<TZWMQ;7!NA@LB,/+9AW/>KE]6YWR\O3>]NM]NNW_#DKV_+[U^NV
M_2WRW(8M-M[>.:74I)0D<IA5(0-S,.IYXQ206UNUU>+:W4IA6V9U9?E)X'RM
MZBECU*VN8YHM1CE*23&96A(W*QZCGC%,CO;.&XN3!!)'#);M$@SN))[GG^59
M7H+EY;6^?-U^7]>II^]UO>_RMT+NGZ+:W<$1(O7>09,D:!8T]LMUQ[4C06L&
M@W,+F9I4NBF5Q@N 0/PQ2QZQ8'[-+,EYYL"JHB1P(LKW]:K/J-I+#>Q.LP\R
M<SPLH'#<\-[?2MW+#1A[EKV:_ RM6E+WKVNOS+G]@6Z,MO(M^;A@,RI#F)2?
MU(]ZHP:?;0P2SZC)*J)*852$ LS#KUXQ5TZY;2D32OJ*S8^:**?$;'\\C\*I
M0:A:RP2V]_',T;2F56B;+*3UZ]?QJ:GU3F7);K;>WE?^M]]!P^L6?-?I_P &
MQ+K*PKI^FBWD,D6U]K$8/WN_O4WA'_D+2_\ 7 _^A+5'4KVVN8+6&UB>-( P
MPW?)J]X1_P"0M+_UP/\ Z$M%"499C!QVTVVV058N.#DGY_F=I1117V9\V%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>7_%6ZCEN]/TZ&%7N<&1F5,O@\
M*N>O][CZ5ZA4*VELMT]TL$8N' #2[1N(';/7%-.S$U<\7T;P!XAOI(Y_*^P(
MI#+).2K#W"CG/Y5Z/9>%KA/%9US4;U+N18%CB CV;&Q@G&3[_P#?1KIZ*')L
M$D@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I&571D=0RL,$$9!%+2.ZQHSNP5
M5&2Q. !0!6_LRP_Y\;;_ +]+_A1_9EA_SXVW_?I?\*6VU"RO2PM+RWG*C+"*
M56Q]<&K!(52S$  9)/:LO8TOY5]Q?M9]V5O[,L/^?&V_[]+_ (4?V98?\^-M
M_P!^E_PJRKJZ*Z,&5AD,#D$4R>>.V@DGF<)%&I9F/8"CV-+^5?<'M9]V0_V9
M8?\ /C;?]^E_PH_LRP_Y\;;_ +]+_A4T$R7$*RH'"MTWHR'\F (J2CV-+^5?
M<'M9]V5?[,L/^?&V_P"_2_X4?V98?\^-M_WZ7_"K5(S*BEF(50,DDX %'L:7
M\J^X/:S[LK?V98?\^-M_WZ7_  H_LRP_Y\;;_OTO^%6$=)(U>-E9&&593D$>
MHIU'L:7\J^X/:S[LJ_V98?\ /C;?]^E_PI\ME:3MNEM89& QEXP3BGP3QW,"
M30MNC<94X(S^=24_94[6Y5]P>TGO<J_V98?\^-M_WZ7_  H_LRP_Y\;;_OTO
M^%6J*7L:7\J^X/:S[LJ_V98?\^-M_P!^E_PH_LRP_P"?&V_[]+_A5JBCV-+^
M5?<'M9]V5?[,L/\ GQMO^_2_X4?V98?\^-M_WZ7_  JU44]Q%;^7YK[?,<1K
MP3ECT%'L:7\J^X/:S[LB_LRP_P"?&V_[]+_A1_9EA_SXVW_?I?\ "K5,EEC@
MC:2618XUZLYP!^-'L:7\J^X/:S[L@_LRP_Y\;;_OTO\ A1_9EA_SXVW_ 'Z7
M_"K5%'L:7\J^X/:S[LJ_V98?\^-M_P!^E_PH_LRP_P"?&V_[]+_A0-0M3//%
MYA!MQF5BA")P#RV-N<$'&:;!JVFW,RPP:A:2RM]U(YE8G\ :/8TOY5]P>UGW
M8[^S+#_GQMO^_2_X4^&SM;=R\-M#$Q&"40 X_"DBO[.XG>"&[@DFCSOC20%E
MQP<@<BDBU"RGN6MXKRWDG7.Z))5+#'7(SFFJ5-.ZBON!U)M6;+-%1K/"T[0+
M*AE0 M&&&Y0>A(I[,%4L> !DUH0+13(9H[B".:)MT<BAE.,9!Y%*)$:1HPZE
MUP64'D9Z9H =14<\\5M$99FVH" 3@GDG _4U)0 4444 %%%% !113)94@A>6
M0[8T4LQQG '6@!]%,\Q/*\W<!'MW;CP,>M*CI)&KQLK(PRK*<@CU% #J**1F
M"J6/  R: %HID,T=Q!'-$VZ.10RG&,@\BGT %%11W-O,0(IXW)!(VN#D X)_
M/BE@GCN8$FA;=&XRIP1G\Z )***BDN88EF9Y%'DKOD .2HZY('/8T 2T4B,'
M174Y5AD&EH ***C6XB>XD@5LRQJK,N#P#G'\C0!)137D2,*7=5W$*-QQDGH/
MK3J "BBB@ HIJ2)(6".K;3M;!S@^A]Z=0 4444 %%%% !1110 4444 %%%%
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M]S0 _3)O/LP3)/(ZNR.9U4.&!P0=H"\>U7*9##%;Q+%!$D4:\*B*% ^@%/H
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M."[58/)EB$P$UR(W8'LBX.XC\.W)JVNH7$][-%;VBO!"XCDD:7:V2 3M7'(
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MIUU;2R+:7J1VLDAD,;0;F4DY8*VX  G)Y!QFK$EBDUZ\\A#(\'D-&5X()R:
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MFBN0D_VK[3&[1[@I*A2I&>01GN.M(VCRMBX^UK]N$_G^;Y/R9V[-NS.<;?\
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MHUCC1411@*HP!3J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (+FQM+T*+NU@G"_=$L8;'TS4RJ$4*H 4#  ' %+
M10 4444 %%%% !1110 4444 %%%% !1110 V.-(HUCC1411@*HP!3J** "BB
MB@ JO;V%E:.SVUI!"[_>:.,*6^N!5BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gbkyd1brmfwp000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ': DL# 2(  A$! Q$!_\0
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M>9<M&'^4''%'LH-\MB>5-V1))>ZFD?F?VWK 4GC-XW-4VUG5<X76]6_&[?\
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MD(6F.UB=+H\ GBIED!'&360Q93UHBO)8F^4YI;;&<D=+;R)(H7=R/:ED7!!
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MX-5WD*<8_&G=E*$3?M;S[3&0V ZG@#TJ92/-WA@S9Y -<NDK!LJY4G@D&MN
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M''I65(VZ4YK6N01G K+DC)8\8K1(&-7Y?G4X(J995F'S\'UJOY9'4XQ1&!O
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MQP*NLYD# =A4-G'%=7@CDD"(H[]_:O122]Y[(X:DK(S!I[3'A&)/H*K75E)
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M%ZH2"-U ZG/-9G]E2W+$\(O=FKGP>'5+WZFY*UV,A9W=PNPL2> !R:V;:U6
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MD<BE&5X)K19<#I26-C+JNI0V,,>9)6QG'W1W-%Q6L=7\/=%%Q,^KW"9CB.V
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MJ?;K6A)'D]*J31YZ#H:EJ[,ZD;E_2I]RA6[53\2EQJ$9/S(8_EYZ>M36*L.
M.]/\21I]BMKES@HVSZ@ULD<K5F<Z7R""!@CJ!41^Z< ^QJUN78 @'X4AVA/N
MX-:*.NH-%%$*-O<E1V]S6[I>J-;'"=2,'(K+DP4(/7UJYI>DW-TZ./DA[N?Z
M5,DFFF92TU.TL;AKNU+.H^4X#>]6$YA<CH3^'X4V&)+73Q"IX'<]_>JMS>$)
ML0@8';O7#"C:LY):%.;E22>XI'/]:#A5S6=]I<-]\U*)FE4C(W5V(R5EN$[D
M\"HE3 R30V @SU[U&&+'':F:1'\;_EXI9W**/I2)@2>M179)?':EU&R'=DYI
M-[#BFX]S36; YK0AFE;NSV>,\@U6>!G-.TR5&:2/=R>0*V;5+;),W7C'I64Y
M<JO:YFW8S+6!U8<5TMA8*4+SKU' /\ZDMXK27<8E4.#UJX<!,CDD8)KSJ^,<
MERQ31G*5S.GTY%5I$("YX%%I"-XJ_/M%OC!P.E16BY<&NW"SE.G>1DV;UA",
M#BMJ),"LZR'RBM1.E=1PUFQX%+14-U<Q65I+=3MLAB&YV/84)-NR.>S;LC+U
MVZL]/MI9[R*)D==N^1L;*\RUW3=.M[ 3VNHP//,=X"'IZ"M7Q+J-OXSTY3IT
MLDZJY5$*[ GN?6N(D>**!=)2X:>1)>97 "@^@KZO+<+*G!7;4NJ/?P]=THP]
MJU9K<Z,Z'-=0?VC&P3RH@'8L 2WM71^&;W5;/PH)WF#M(Y$2MEM@'?Z5YS&E
MY=BZMY)2K1C(49^8^E=GX)\1W%GH=[I-S!'&T1QBXX<@^F:,RI5)89J.KNNG
M0]#]TY1C.S\GU.C\*^([_4KF>TOT#O&V/,1<8KJG7VKSCPW?I?ZO<1:=YHDF
M0D+C&XBLM-5U+0O%3^?/(%*LTBR.2#[8KQ*&65:D7&>DDKV>[,\SP-&5?GPU
MDK;(]2,.>356XA&TXJ#P_P"(+?Q#8>?$NQQ]Y,YQ5^; 4YKSJE.=*?))6:/#
MG&47:6YSUQ&=U8&JP+&"6)YZ"NLGBX8USFI MD-SBK5A(Y"?+-@"NR\'>+[K
MP[:K;3(;BR9B1&3\R9ZE?\*YXVQ9^G&>:6Z86]N6.,J.![U3BG%W-8ZG?3:[
MX"O[D/)I,CW#G.Q+?EC] >:9K^H7NK:5_8^FZ;;Z7I;##R3LH;'H$'2N9T4+
M:Z1%<,!]JNB<NO55]!74^&;2.YG#2H)V!^ZQR!^%*E0@X.<GL>1C<PJTJRHT
MX[]65/"[7OA;]S9W5O=V[G=+"<KN/JI/>M"^\1>"[V=FU+2Y4NL_O 8<-GZ@
M\UH^)--W;6MX-I'\*K52S@GDLV9K5#=)P&D09-.5"$XJ<78BCFE6G4=.O&]M
MFM/D8VK>/;"+3)-+\/Z<MO!("KNZ <'KA?7W-1>%O%FG:9X7OM-N1.;B=I"F
MQ,K\R@#)SZUJOX;;68W6^MH8B!PZKAQ[\5S5]X*U"SRMK/%,<9P?E8UC.A;W
M=SU,-F&'K0]Z\'YE&(F-UDA<JRD%2#R#77:GXCTOQ%X:6UU.*9+^/[DD:9&\
M=_H>]<0(;FSD:*=2CCJK#FG[QM # 8.:X72E2ES0V/5;C52YOO*,D;(2K,IS
MTXKIO!VN6NA6^J17:3$W402/RTW<X/7GWKGI9 S]?QJ6-AC@5UV31#C=694^
MQ,<DG ]ZF0+$551DG\A0TF^0@]!T%*"%YICNV>JZ1\_A>R/_ $RJWC_1H_I5
M?2D:+PQ81N,,8@2/K5QQ^[4>@KDENSB>XR'H0:LJO%01BK<8RM9M 1J."?>I
M$3 R:E6+MBIA"%&78*/>ILV*Q1NE_P!'.:S6B\Q:V[H1M#M3<?<CBL=YUB^7
MN/2KM9:A?4DL+2/[0HE&4/!J\\(LYMBN,=N:RC=2MPGRCVZU)!&[ON=B3[FI
M=@U-U+S"\')KG?!/_(HV7^]+_P"C&K6&V--[L%0=2:R?!/\ R*-E_O2_^C&K
M2GL*1P-_HT]]K^M72?ZM-0G4GTPQ/]:R\;'*9) -=4]RT4VO1+U.J7!/YBL1
M-/\ .D^4]?6M4SZ'!/\ <QN0(P"\5>L='N]1^:-,)_>/2K]KH64W$;F R!2W
M-WJ]@H*QB*-#P.F:=^QU2GIH7CI<6F6I=U^<#D]JXNZ@%S=.R#@FNDG\5F[M
M'ADMDRRX8DYY]JJZ5"H4R]2 <#'>LZE14H.<NABN9NW4PO['<C.P_E6G:V9B
MMF5EY'Z5L2$Y4#&<98^AJE<K*T8="1D=,URX?&>WERVL.M2<(WN1:?;1,)&D
M0N!P #4=WIXVY459TH%9<,,A@01FK<N-P!R5(P314KNC7M+5/\!0CS1NMT<R
MEGF7!Z#K5.]A59,*,5L:I:36PWX(![US[S'?DFN^*N[DWNKEFR3:V3TJ/Q.@
M_L)03@>:#D]!5NSPRC(-6;R0+B(!64+\RD9!K=Z'-4W. 1S&H!<9SP1UI?-)
MF"$G<W R,YKH+K0K.Z_>6TA@/]W&5JSI6B):R&9W1Y1PI X7_P"O4\_4RNR&
MPT@0_OKH!F(^6''3W/O6XB>4 6P&QP!T44X(D?S$EF[57GEV\DY:IWW"$.K"
M>Z/3/2LR>1FYZ5([!SU[U4N9,M@=!5%-(FC82?*34Z?NG ;H>AK,16/S*:O1
M[V3:P/M4VU,FD7)T!42 Y7N*J/(!PO:K=ODJ8WZ$8K,GW0R-&PY!ZU;0D[%F
M&3]YS4UPF>1SFJ$1R<DXJ_%-&5VL:EZ.YH0;/84[R >M*Q ;@U:M8S,ZJ!DD
MX%5?2Y,M$9IM_+E61!M8'((K2CE\V/<O!'45IS:.P08P3CFJ7V":/?(B_='S
M5C&O3E\+,')$:7,D+;E8@CTJS'J<N1ER<'/)JMA)."-K4BVY#\<5HXQ>Z(DT
M;*7LDPPS$YK5LD)(/%8EK%@C)K=M.,5<8J*LCGD=!:\ <TNJZQ#I-A).P,LJ
MC*Q+U:H[9@ *S-=U72+:UN4NX;B28#AXUR%KJPU+VE1)IOT'1ITYS_>;'.^)
MO$>I7VF6^I6,LMK;XY2%N2>^34,>JCQ'I1LKT3W%U$@9%+;5/^\!]XUF>%=8
MTZ_N9-,N#.=.DF+["G(/H*MW%Q:6_CBV;2VD4+\I0IC*=Q7TOL(T_P!TH6<=
M4_\ @[GKQA1DERQT6Q!8VEKX3N0;H/<-=\2KOQ'&3T_&LV\L(O\ A+(5GM$<
MR."I^Z!Z5V?C:"PO=/\ ]'A-NR@$LQX/O63I^@ZKXACLYUB58D 4W$AP=H]!
M3HXA.'MZCM?1W_ )NE3C[R21M6_@,7DEU>M>>0TZXC2 <1GUSWKG7^'?B#[<
MT^HWL,]O&-IF+$N5]ACK7K5I;I:6L<"9*HN,GO4CHLB,C#*L,$5XL,WQ$).S
MNO3IY'SSQ,G64[Z)Z>AY1<M>:%9P-)"D0BD_T:2 ?,P]"?>M2ZM;:71'U&YM
M69[I,K=.>%'I7176A"UD%Q!"MPJ?=ADY"^]8;PRV6FL^J*[Z<TA9+,'G;W'L
M*[HXF-5*4=[_ #?E_6A]!2K0JJ\&8_@O68-'\NTF!,$[G9(!QG_"O1W0.NY>
M0>:\1\9FZM;BVNK81"TD/^C",Y"^P]Z]"\->*FN;F+3)HG=5B4K,4*DG'.0:
M69X)U(K$T^NYYM;FKS;C';S.C>'C&*P;^R+L5 R2<"N@OM1@LXBVP2/V&>M4
M+EK^:W#QVT&UAG<AY^E>'&G*2N>-6S&E2?*TV_(R;86U@61(HYI1]^1UR ?8
M5I266F:O$+>YT\-)MW.(5YQ6 LK12-\_RDX*GJ.:?_:US9W<EQ;2E64X;'<5
MTRA#2"1XD<3B7S5Y2=K[+]#:71]+F811RW,/D#:(B ,#Z46GV&SN@T,URS'@
MD?*/QK M-0D?41,6;YVY).>:Z;RTO-0AM[<QQ32+N9F_BH5.-.37<SG7JXBF
MIO5I]N^QK7,K/!^\NGC4#N.3["LU=6GB;R88P6Q_$<G'O1>6EU:WD4=U<K+M
M4OG/W169+@3F9'RQ-%.G%^:%B*\XJ]K/8TX;M;[>LZMYB LH5R*6+4;:[9(V
M4AU&T9;K5/3H&O/-DMODN8!N()X(JU:VUS>SLR6%B9,_?W8S]*J48IOR_ SI
M5)R4;J]_*]_^"4M7TB/5;)HDFV/&V49ADH>X/M7%ZCHUUI<'F7+@@G"E>0?Q
MKT2\>[T]Q)/IT<;'CS%;.:KL8-2A=H559<?-"PRC_A6$J/-[R/9P>;2P_P"Y
M:O;IJG\K_D>9Q8+C)S5SG;QQ6CK&D6T,(O;-&C4/LFB/\!]JS-Q"@9KEE%Q=
MF?4X>O#$4U4ALR"0E,YZFM#0+%M6U>WM!T=_F]E')JA-G&0*[KX::8<W>K2+
M@ >3%_-C6<GRJXZDN5';3(HVQJ,*H  ]A4;5*_+$U$W6N*^IR"H.:MQ#CGBJ
MZ#%6HCGD]!56 GP<9'RK^IIP\L#[I+>I-0F;FG!B,8Y8]!4W?0!ER<(W/05C
M&WW-DUM31A8OWC@#JS&L:YU:UA;9 /.?U[4I;@B:.V &<<5!=:E;V:D+^\?T
M7I5">[N+D?.YQ_=' JH8"QI<I0RXO;N_E^=L)GA1T%;'@G_D4;+_ 'I?_1C5
M4AM0 .*M^"?^11LO]Z7_ -&-6D-F1+<XN<K_ &QK09L#^TIS_P"/5%<7>P?N
M6 QWJIJSD>(=87/'V^<_^/FJA.5Y-;6/H\'']Q%F]8^)FT^)P\8F<CY>V#6+
MJNM7FIR%IWPG9%X JG(344:EY IS1H;-13N,$I!XK9TV^,3#GZU66VC'WHB<
MU.EM&.0K"I;35FB969M"1'92,$'EL=J:TJA=O13SL]#66!(O )"CUI&N53^+
M)KDA@J<9<R;'*I*2L:\06*-I",]L"EFPI'SD!ES]<5C+J6T_>X]Z6XUM6P0!
MD=ZSQ.#J5:G,G_P IU%3C9HMZG=[=-\N4[F_ASUQ7$2/^]XK0O;^6\;Y0S=N
M.@JFEC(QRYVKW(Y-=]&'LH*,GL<\I:MKJ;]E)'+91J%_>9Y/M1<QHTA8G&[O
M5:UGAM$V $@]\U; BN%^23 /;TK>4^8P]2HE@V_<LR[?6IU,=OGDL?>FLCP-
MST[&FE0XR2*B]MQI(CGO!D[?SJFTQ8@>M/>%G?$:DU-#IY0[Y3R.WI5I@VBO
M)MB3_:-9\I/7%:LT2\YSFLZ:,L>,TKF39+IT?G2*OJ<5T*P11QJ@4%A]XBL?
M3XFC<.F,CUK;3]X-Q&&QS[URXEU+>X.ER7]X@EB"G<H'MBLW4H/.B%POWDX<
M>HK8*Y5R3C;Q54*/WD;='&*WPU3GA9[D5(VD5M.MK:5?FC.[W-6+ZQ@CCW*P
M#"H[!?()C?AEZU9NUCD7)/:M.I"DS#W8;&<UL:3+$DZM+G:.F/6L9P$D(J6&
M?:>M5)*47$N6J.Y:4 9)!5AP:B8HJ8(.&Z'UKG5U61HA&[Y4=J1[S<N QX[9
MKR5@+;LP<6C5NX;2*!FV9<]#FLM)F5L<$>AJL\K-_$33%)!SFNZC'D5F[D6-
MRWG&1Q^M:UM.<C&!7,V\QS6W8OEQN.*Z49RBCI[0DX)I-5%X=/EM;>TAG@G^
M_N'S U);,GE BM*W?BMJ53DES6N<\FUJ>;ZQX<M-#TNW.E2[[B-Q+(Q'(?O^
M%5V@N-9UBUOM-MI#/)@,RK\B'N<UZ9>:/I^HJ5NK<.#U&<9K.U"_72HOL5DB
MQ(BX5$'2O7AFC<4K7GKJ_/\ ,VKYM"A2O%/0P[G4ELM0-G<Q1W/D* T3]#[U
M8B\06\%VLEDICC;[\.<J/I7-^(X2[13W#O:76/DF8?*WLU9=G=W%O=KYX0L
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M9YKK9(\1ZQ@?\O\ -_Z&:CAMY90,+R?6K.J1>9XEU@[@/]/F_P#0S5F(K&H
M.>*UN?085OV$4B&+3HHQOG()].U->6-6Q$JC'<"F7ET3QFJ\=]'&N-F32=SI
MY.Y:,I(R:B%T>0W%0F[1QGI5.:8G@4TFR>0O?:54_.Y JK=74<AQ$IQZFJ\$
M,MS*$16<U<FL5@?RPP>3'.WG!K2-*^K%S*)FNS'C--6VD<;W)6/]36HMI'"/
M,EY;LM5;J=GX' ^E$FEHB7>6I4FF"(%CX'H*K-J<T2%1C%)*0,YK,N9,D =*
MS>I$DB^E\'&#QFI8;R2)ADY'UK&Y"YJ_8NK865<KGUIF6QTEM=B:/"N/]QZL
M++$AP\('N*Q&6.-_W9./0U:C9G .336H61K^:N,J !41<D''-558X[TX2J 0
M3S5&;0L@4_>.*JR!!P*?*^>0:CX:F9MC4+*?EJ_!=N@PW(JJJ'&13MISBBR:
MU(-/S8I$^7Y3G)JM,PW_ "G-5@Q0]*:^XD,K8([5,*<82YD#D[68FHR%%2X3
M/]UL52-\67!)K3AE212KJ"#P0>]8>HVAL[G]WS$_*^WM6K[D=1YDWFI8HV:H
M+6,NPS78V6B1I!'+*26(R5S656O"DKR&YV.::)U'0TP;O0UU]_IS713RT (&
M/PJC-HZ6]JSR/^\SP%[5A'%4YI:ZOH0YG/EG49)I0SGJ3CWJQ);C/6F/$>,=
M*W6X$]N^"*W;.;Y0&'XUB6D+.X4#)K>%I)!&I9>OIVK1RBFDS.=C8M;CH 3B
MMNVGX'-<G;R[#S6O;7/3FM4<TE<Z:.3(ZUS/BNRN /M]I"\S ?.B=?K6K#<<
M=:LBX&.M+7='/.DI)I[,\IGU*?5%\A_.91P4F4Y%+8>$=;NHC(B!(@<H'/./
M:O4&,1;=Y4>?7:*>)*J<I5/B,\/A:=!-0Z^9Y]IFC:KI]U+<ZB&C@5-O(')]
MC71Z1_9<L<OVV],#H,KZ$>WJ:T=;M9=2T>>"!L38RGN?2O,(X_$37"V<FF2E
M@<$E>GOFKI55!.+9Q8_!2K34XI/U.AUO4[6S*K:RO-;JWWR,9)ING>*+I$5K
M.[*J.#$^"M:UCX#@DM)&OYI1-*FW8&^5?P]:XK6/">HZ+=,(F+KG*NAZCW%+
MZPXR=U=,3RY2IQ5[22Z':27[:M(#E;>5QAB&^3-0Z5X>/AC5'FN_+N/M0^1T
M^X%K!TY9K>QB6Z.V5\]ZT;G6KBXBBAE<YAX%>A1KRG2Y(OW7N88O,\90A["<
MF]M?T9#X@T#2X;W<]H8E=MV8'^7%5-1T?1;98[=8Y,3(&64M@BNFD@;6;)3
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M225+#KC/45Z QT7Q_81.LWD7\0P ?O*>XQ_$*ENSN*4^6HJMM&CSJU@4NO
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MDXS2N.QN135<2?,1^;'K[UCQR86I8+G@Y-*2O&P<O4@U2YN[.5KHH9K-C\X
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M;6(EN+-)8R"1UQ6#$W\)JQ%J,L$7ER1Y![GI4&U9'+1L.>U"$KHE[Y]*OPO
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M=Y(G2 H5&X8+$^U7A54^L0<%LS7F5K7.*1_*D##I6FEV\<0FA<E1]X>E9#Y
MQZ40S/'D(>O!4]"*^U,;FM)JHN%VRH#[U395SF-OPJL1CD*0/>I4^894].HI
MV*30[)SS2-S3@XZ,,FD..QH*N1N?E XI;>2-9OG4LOH#2,A8X%:NE:6)/WCX
M-)F<FD3QW$:)^XM"H/7GK4+1E2;E\(1T4#I6G=!;>'Y,#%<K>WDKLR;B1FDB
M$/O=2>52I/%9+ODT,2330I)SZ52&W9$\N4MT0G!/S&JU32NTA!;L,"F!:;)B
M-P:NVKEIX@YP5/!J&*/>X'O6_%HYECW)P0.*E@RW/=/:%'7[C<,M4;V$72^8
MI!!Z5(XD:U^SS@[T.4;^E5()=JM&_3/2E8$C-\O8^"*GBAW,.,U+(JE\XJ]9
M0C[V,T2=E<IH@>$>7@J#5!K8[\H"*W_+ .'(9CV6F!(MQX XX'?-<\<1!*X>
MSDC#99 06ZCO2E\X-:=U$-F[:%]JRRO.!71"2DKH$M;&GHEBVJ:M;V:@GS'^
M;'9>]>TRQ+%$D48PB*%4>PKD/AMHA2&75Y5Y?Y(<^G<UW;P;N36-:5W8Y:TK
MRMV,I+-[B4*H^I]*W;2TBLXMJ#GNWK201B)/<]:5Y<5@]#'<E:0 52ENAZTQ
MYB2:RIYV\UL<X/(]*$Q&B9<YYJNV<U7CE.,D594>8E7N PX IA.02.U(P*C!
MZU4O;GRK-P.">*AK4&]#!UN^W2&)#]*YD!9Y 6?8I^\<9Q4NH3&1F&XYSU]*
M2.ZC\N%9@7XRX7@L:Z:2Y6<%=\\;]1\4=I%,#N>51T++BJ=PP:8[><GBM&]O
M--EME%K"\4@Z[C5188WMFN"^%3[V:Z7))7.6,'*5B&ZN98&MVBD*,H/S UG2
M7$CR99F=CW)I\DGG3$*"<G@=:FM;8O-'&$QN89)/7_ZU9.6AO"-Y69>TZ%BF
MXX#$<9.,FMFRL3"<O@>U8Z%_MLY="LD0PD6/3_.:W+-Y# GF_>KGFGU.VG9[
M&G%BKL-9\9YJ_">E18W-2W.*T8I !61&^T<U,L^#2L!KF6JEQ/A3S4)G^6L^
M[N<*>:&A%*^EW9YJ_P""?^11LO\ >E_]&-7.75U\^/>NC\$_\BC9?[TO_HQJ
MJ&PF>?:FN?$&L<'_ )"$_3_?-:6@B);MI9I(HT52!O<#GZ&NWU/2-,DU*>23
M3K1W9MS,T"DDD<DG%5?[$TG_ *!=E_X#I_A6IU0QLH0Y$C*N&M9(SMNK?/;]
MZO\ C56PO(HIF2:Y!SPN6&T?C6__ &)I/_0+LO\ P'3_  H_L32?^@79?^ Z
M?X5<9V5@6.E:S1$EUI\D>W[; C#UE7_&KTM]IXBBB34+0E5 )\Y<?SJM_8FD
M_P#0+LO_  '3_"C^Q-)_Z!=E_P" Z?X57M60\7)N]B=[[3%&T:A 6_O+*M4;
MW5;2WM6>*YA>8G"['!Q[U/\ V)I/_0+LO_ =/\*/[$TG_H%V7_@.G^%5&NUT
M%]:EU10L=4AU"94N9H(U!^9I9 N1^-+K'B2(J\%HX/.W>IX ]JO?V)I/_0+L
MO_ =/\*/[$TG_H%V7_@.G^%5]9O*]@^LN][&1HU[;1'[3<W$:B/+%-PRWX5E
MZCK5Q?WAF,K*H;Y$SPHKJ_[$TG_H%V7_ (#I_A1_8FD_] NR_P# =/\ "J^M
M/FYFA?6'>]BNFH6BP)ONH"V!D"0<'\Z@FN+*[&V6Y@XZ-YHS5_\ L32?^@79
M?^ Z?X4?V)I/_0+LO_ =/\*S5=IW2%]8?8QK2\B5I89C;A40A6$P*M4T-U:6
M=JS?:87D/("N#BM/^Q-)_P"@79?^ Z?X4?V)I/\ T"[+_P !T_PIO$-] ==O
MH>=ZA<S7=PSR1L_/'M6AH+[%D6=DA0D%5)P*[3^Q-)_Z!=E_X#I_A1_8FD_]
M NR_\!T_PIO$M] ==OH<EK*+=I'%'<1;%89"N,$'K3PT4\HC$T<<48QDL!75
M?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X4+$M=!*LTMC#^VVT,+11R(R$8.
M7ZUESI80R!XK:*5ST)ES@UV']B:3_P! NR_\!T_PH_L32?\ H%V7_@.G^%<M
M2G1JRYJD$V"KR6QS!G)B#27,0?&,(PP/H*IW;1R0,N\2,1CDUV?]B:3_ - N
MR_\  =/\*/[$TG_H%V7_ (#I_A6OM-+)$^U=[GDDUI,C8,3,/51FJ<MG<!MR
M0RGVV&O9_P"Q-)_Z!=E_X#I_A1_8FD_] NR_\!T_PI<YI]9?8\=ABNL8:"4?
M5#4ZVTRMD1/[_*:];_L32?\ H%V7_@.G^%']B:3_ - NR_\  =/\*.</K,NQ
MY,UM*>1&^?\ =-1&WG_YY2?]\FO7O[$TG_H%V7_@.G^%']B:3_T"[+_P'3_"
MCG*^M2['D M[EAQ$X/NI%:6EW-S;'RW@?:>Y%>F_V)I/_0+LO_ =/\*/[$TG
M_H%V7_@.G^%+F)>);Z'G.I&:=. /HO-<_)9W!)_<RG_@!KV;^Q-)_P"@79?^
M Z?X4?V)I/\ T"[+_P !T_PIJ0+$M=#Q,V5P?^7>7_O@TX6-P%Q]GES_ +AK
MVK^Q-)_Z!=E_X#I_A1_8FD_] NR_\!T_PI^T!XAOH>(FSNL_\>TW_?!IPL[G
M'_'O+_WP:]L_L32?^@79?^ Z?X4?V)I/_0+LO_ =/\*7.'UA]CQ:.VN4<'[/
M+Q_L&NCTZ\ECCQ)"X/NIKT;^Q-)_Z!=E_P" Z?X4?V)I/_0+LO\ P'3_  HY
MP>(;Z'FFI.TY_=PN?<*:S#;SEO\ 4R9/^R:]>_L32?\ H%V7_@.G^%']B:3_
M - NR_\  =/\*.<:Q370\[T[PK-?8>XU&QLT/_/2=2WY9KL-.\->&-/4-<ZK
M%=OZ&9=OY UJ?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X5$FY:,B6(G(;=1
M>&+R 0E[15' 99%5A^.:Y'4O#\-J3+8ZE:7"#^'SE#C]>:[#^Q-)_P"@79?^
M Z?X4?V)I/\ T"[+_P !T_PK/V<7N*-><=F>4W2S,2!%(?HI-5[33YKJ]A@=
M6B61P&=QM51W))KU[^Q-)_Z!=E_X#I_A1_8FD_\ 0+LO_ =/\*WYRUB&EHC4
ML+O1[&QAM8M0LU2) H'GK_C4TFL:9@ :C:<GG]^O^-8O]B:3_P! NR_\!T_P
MH_L32?\ H%V7_@.G^%9<IAS,V_[7TO;_ ,A&S_[_ *_XU7EU73L<:A:'Z3+_
M (UF?V)I/_0+LO\ P'3_  H_L32?^@79?^ Z?X5+IIAS%A]5L.U[;'_MJO\
MC67>7UL)A+%=0'/7$@JY_8FD_P#0+LO_  '3_"C^Q-)_Z!=E_P" Z?X4>S0<
MQ1&J6WE_Z^(,/]L5>LM5LBGSW<"GWD H_L32?^@79?\ @.G^%']B:3_T"[+_
M ,!T_P *I1L%R6XU#3RI*WML?82K_C7/:I>Q30LD4\9;J,,"*W/[$TG_ *!=
ME_X#I_A1_8FD_P#0+LO_  '3_"AQ$V>9SB65B A#>O8U 895CQ,C.JMP8L[E
M_P 17J?]B:3_ - NR_\  =/\*/[$TG_H%V7_ (#I_A3:N0H)'EOV4-@^?*5)
MZ-"014LZ,[-"!)Y(XSC[Q]:]-_L32?\ H%V7_@.G^%']B:3_ - NR_\  =/\
M*+:6!02=SR^/3Q!\YD9QC  '-1.TZRGRXYMV?E(3@"O5?[$TG_H%V7_@.G^%
M']B:3_T"[+_P'3_"FM <4U8\\29YUAN9$9;B)PK9XW+_ /6K66:,-_K%Z^M=
M;_8FD_\ 0+LO_ =/\*/[$TG_ *!=E_X#I_A1+WAP7(<]%<PCK-&/JPJ['>6P
MZW$7_?8K4_L32?\ H%V7_@.G^%']B:3_ - NR_\  =/\*GE-.8I'4+7_ )^8
M?^_@I?[1M?\ GZA_[^"KG]B:3_T"[+_P'3_"C^Q-)_Z!=E_X#I_A1RH.8@.I
M6FS_ (^X/^_@K/N[Z!@0L\1^CBM?^Q-)_P"@79?^ Z?X4?V)I/\ T"[+_P !
MT_PHY4+F.*N9@SDA@?H:[?P3_P BC9?67_T8U-_L32?^@79?^ Z?X5U6G6\-
6MIT$4$,<4:KPB*% SR>!1:R'>Y__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gbkyd1brmfwp000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'Q!.,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  @GAO\ Z!O_ )'D_P#BJZ.BCZK0_D7W(/KF)_Y^2^]G.?\ "">&_P#H&_\
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MCR?_ !5='11]5H?R+[D'US$_\_)?>SG/^$$\-_\ 0-_\CR?_ !5'_"">&_\
MH&_^1Y/_ (JNCHH^JT/Y%]R#ZYB?^?DOO9SG_"">&_\ H&_^1Y/_ (JC_A!/
M#?\ T#?_ "/)_P#%5T=%'U6A_(ON0?7,3_S\E][.<_X03PW_ - W_P CR?\
MQ5'_  @GAO\ Z!O_ )'D_P#BJZ.BCZK0_D7W(/KF)_Y^2^]G.?\ "">&_P#H
M&_\ D>3_ .*H_P"$$\-_] W_ ,CR?_%5T=%'U6A_(ON0?7,3_P _)?>SG/\
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M49<E3?H^_P#P15*4)0]I2VZKJO\ ->9L4445N<P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4456U
M"Z%CIMU=MTAB:3'K@9I-I*['%.3LCGX1_P )#XKEG?+Z?I3>7$/X7G_B/OMK
MJ:Q/"-FUIX:M-_,LZ^?(?4O\W\B*VZQP\7R<SWEJ_P"O+8Z,5)>TY([1T7RZ
M_-ZA1116YS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<QXFA;3+NV\1VP^>W(CNE _P!9"3@_
MB/\ /2NGJ&[MTN[.:VD *2QLA!]",5E6I\\&EOT]3:A4]G43>W7TZDB.LD:N
MA#*P!!'<&BN0\.Z_':Z#:VURW[V -$V>HVL0/T HJ(8JG**DWN:5,'5C-Q2O
M8[&BBBN@Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %87C'_D4=1_ZYC_T(
M5NUA>,?^11U'_KF/_0A6.(_@S]'^1OA?X\/5?F:UC_QX6W_7)?Y"IZ@L?^/"
MV_ZY+_(5/6D?A1E/XF%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >#>(/^1DU3_K
M\E_]#-%'B#_D9-4_Z_)?_0S17Q%7^)+U9^AT?X<?1'O-%%%?;GYX%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5A>,?^11U'_KF/_0A6[6%XQ_Y%'4?^N8_]"%8XC^#/T?Y&^%_CP]5^9K6
M/_'A;?\ 7)?Y"IZ@L?\ CPMO^N2_R%3UI'X493^)A1115$A1110 4444 %%%
M% !3)F*02,IP0I(_*GU%<?\ 'M+_ +A_E0A/8\5_X3_Q/_T$_P#R!%_\31_P
MG_B?_H)_^0(O_B:YJBO;]E3_ )5]Q\+]<Q'_ #\E][.E_P"$_P#$_P#T$_\
MR!%_\31_PG_B?_H)_P#D"+_XFN:HH]E3_E7W!]<Q'_/R7WLZ7_A/_$__ $$_
M_($7_P 31_PG_B?_ *"?_D"+_P")KFJ*/94_Y5]P?7,1_P _)?>SI?\ A/\
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M9_PG_B?_ *"?_D"+_P")H_X3_P 3_P#03_\ ($7_ ,37.R^6)G$)=HMQV%P
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MH<:/9"53&.S<Y6=NKZDO_"?^)_\ H)_^0(O_ (FC_A/_ !/_ -!/_P @1?\
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M1_;.E_\ 01M/^_Z_XT<LNP>UAW1=HJE_;.E_]!&T_P"_Z_XT?VSI?_01M/\
MO^O^-'++L'M8=T7:*I?VSI?_ $$;3_O^O^-']LZ7_P!!&T_[_K_C1RR[![6'
M=%VBJ7]LZ7_T$;3_ +_K_C1_;.E_]!&T_P"_Z_XT<LNP>UAW1=HJE_;.E_\
M01M/^_Z_XT?VSI?_ $$;3_O^O^-'++L'M8=T7:*J)J>GR'"7ULQ/82J?ZU:#
M!AE2"#W%)IK<I23V8M%%%(84444 %%%% !1110 4444 %%%% !1110 4444
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MRU-%X8TQ#OFB>YE/WI)W+$ULT4W4?V="5AX;S]Y^?^6Q1&BZ6O33K3\85/\
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M2_L?3/\ H'6?_?A?\*/['TS_ *!UG_WX7_"KM%'-+N'LX=D4O['TS_H'6?\
MWX7_  H_L?3/^@=9_P#?A?\ "KM%'-+N'LX=D4O['TS_ *!UG_WX7_"C^Q],
M_P"@=9_]^%_PJ[11S2[A[.'9%+^Q],_Z!UG_ -^%_P */['TS_H'6?\ WX7_
M  J[11S2[A[.'9%+^Q],_P"@=9_]^%_PH_L?3/\ H'6?_?A?\*NT4<TNX>SA
MV12_L?3/^@=9_P#?A?\ "C^Q],_Z!UG_ -^%_P *NT4<TNX>SAV12_L?3/\
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MSV4QQ:RL<[#_ '"?Y?YP[*:TW(YI4G:3O'OV]?\ ,Z"BBBLSH"BBB@ HHHH
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M"I_A1]>CV#^PJG\Z/GZBOH'_ (1W0_\ H#:?_P" J?X4?\([H?\ T!M/_P#
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M<-M/H<=*XKP"P;7O%#*05-X2"#P?F>M;PK%HD=WJQTBXFED:?-T) <*^6X'
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MQV^?&55O1NH/Y@4KA8\]\(>(M$T+1T5]-OI+R4$S3I;AM_/ !STQ1IFI6_\
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MEJEX5'E6JD0>[2?<Q^!KG]LEY>$11EI)7)5!R<GM6YK]U-%I>GZ;-@3I&&G
MZ\<*#]!52C9J*ZF<*CE&4Y=-5Z[?Y/Y#[K4)]/T/26M=D<KQONDV M@-TYJ:
M2UAO_$>CF6- +JV2:8*,!FPQ/'OBL&[O_M5E96WE[?LRLN[/WLG-65OYKW4=
M,$!2":WC2!'=N"03R>.^:7(TK^HU7C*5GJO=T]+7-31=:N;WQ##!.D;6[,P2
M+RQB/ .,<<8Q4.B6ZII-W>I-;PW/FB*.6?H@QDXX/)K4T_S(-8:YGT5;/8':
M>Y+-MZ'[N>.3Z5R]AJ8M(Y[>:!;BUGY>-B1R.A![&I2YK\J[&CER<KJ._P 7
M?LOF:FI^7<:.S75]9W-]'(/+>!OG=3P0>!GUJZKZA;W$"O<V.GP?*/L9(9L>
MA !))K#GU>,6J6UA:BVB602L2V]G8=,GT]JFFUNTEO/MQTQ3>$ABS2DIN'?;
M_P#7I\DK6L2JT.:_-KIW_P"'?X&A<0QV_P#PDT42A47R\*.@^;-<I6O<:YYS
M:FPM]OVX+GYON8_#FLBM*<6EK_6ASXB<9-<OG^;-JT C\*:A*OWY)HXB?]D<
MU9TM[5/"EV;R*22+[4ORQMM.<>M4](;[39WVF$X:=!)%_OISC\1D4W3]6@M=
M.ELKFR%S')()/]85P0,=JF2;NO,UA.*Y6WI9KYZ_YC;B?1FMW%O9W*3$?*S3
M @'Z8K3$EC'X3T_[=!+*IEDVB-]N#FJ$FH:2T3JFC!'*D*WVAC@^M.M]8M5T
MN&QN].%PL3,RMYI7J?:AIM+1[_UU%"<5)WDM5VTW7D7)C:7?AJX72UD@2!UD
MN(Y.2^> =WMZ55S_ &AX6 ',VGR9/_7-_P#Z]176LQO8O9V5E':0R$&3#%F?
M'09/:H-)U,Z9=-(8A-$Z%)(V. P__70H22OYA*K!S2;T:L[;?=]Q;UHBTMK'
M2AQY*>;,!WD;G]!6E8?V)_9.I^5]M\G;'YN[;G&[C'XUS-W<O>7<US)]Z5RQ
M]LTU+B6**2))&6.4 .HZ-CIFFZ;<4KD+$*-1RMILONLO^"2W36J70;3S,(UP
M09<;@?PK0\4(JZY(ZC'FHDA'N5&:S]/M?MM_# 3M5F^=O[JCDG\!FI=7O1?Z
MK<7"_<9L(/\ 9' _055O?7H3?]TV^K7Z_P"91HHHK0YPHHHH ]1\+_\ (MV?
M^Z?_ $(UKUD>%_\ D6[/_=/_ *$:UZ\>I\;]3Z[#_P &/HOR"BBBH-@HHHH
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M]5J]OR#^UL'_ #_@_P#(]*HKS7_A;/\ U!/_ ";_ /L*/^%L_P#4$_\ )O\
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M_F%%%%0;B$X&:PV'V_6(XB,QQ_.P^G3]:UKN3RX&/M5#0XR8IKINLK\?0?\
MU\T 9'CC4S#9Q:?$?WDYW.!UVCH/Q/\ *MK0--&EZ1# 1^\8;Y/]X_X=/PKD
M[0GQ!X[:<?-;V[;LG^ZO _,\UW]<.&_>U95GZ(]'%_N:,*"WW?JPKA_$W@ :
MI>27VG3)#-(=TD<GW6;U!'2NVD7?&R9(W C([5Y!9ZOJ7A/Q0XU!IYPF8Y%=
MR=R'H5S] :G,)TDHQK1O%O?L7ED*SE*="5I);=QCZ;XK\-DRHMW%''R6B?>F
M/4@9&/J*[#P9XNEUQY-/U +]I"%ED48#KW!'KSVI+OXD:0+-S;Q3RS%2%1T
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M/G_[YH_X1_5_^@?/_P!\T<\>X>QJ?RO[C-HK2_X1_5_^@?/_ -\T?\(_J_\
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MML2/K1G@U43H3+?&,@CHNULX_+BH(+](='N[(HQ:=T8,.@VFG_\ "/ZO_P!
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MG'-LOTJY5+3?^/5?I5VNLX@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR3XI_P#(R6O_ %Z+_P"AO7#5W/Q3_P"1DM?^O1?_ $-ZX:O9P_\ "1\1F/\
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M"AL_5_F%%%%0;F'>GR]7M'_Z: ?GQ61\1XR='M)0.$GVG\5/^%;&MC9Y<O\
M<8-^1JOXYA\[PK<$#/ELK\?7']:YL9'FP\UY'7@)<N)@_/\ ,T]"E$^@:?(#
MG-NF?J% -:%<YX&N!/X5MQG)B9HS[<Y_D:Z.M*$N>E&7DC/$PY*TX]FPHHHK
M4P"LKQ-_R+&I_P#7L_\ *M6LOQ(K/X:U)5!+&W<  <GBLZW\.7HS6A_%CZK\
MS@O >FPZOI>M6,_W)1& P'*GYL$?0UE:=?W/A;4-1TV[5A'+&\,B^^#M8?G^
M1KI?AC#+"-2\V)TR8\;E(S]ZK7Q!\.F^M%U2UC+7$ VRJHY=/7'J/Y5X<:$G
MA(5J?Q1O]UV?12Q,%C:E"I\$K?)V1C?##_D+7W_7 ?\ H0J[?_$""TU*ZMCH
M44AAF>,N90-V"1G[E5OAI!-#JMZ98I$!@&"RD?Q"O0FTRP=V=[&V9F.23$I)
M/Y5O@Z56>%BJ<N75]+G-CZU"&,DZL>9676WY'GO_  LB#_H7X?\ O\/_ (BN
MF\(^)(_$/VS9IZ6GD;,[7W;MV[V'3'ZUM_V5IW_/A:_]^5_PJ6"TMK7=]GMX
MHMWWO+0+GZXKKHT,3&:<ZEUVLCBKXC"SIN-.FT^]VR5_N-]*\K^&?_(P7'_7
ML?\ T):]4?[C?2O+_AO;S1:_<-)#(@-N1EE(_B%9XQ/ZS1]7^AK@6OJE?T7Z
MG=^(]$37](>S9]C@AXWQ]UA_3J/QKAK&Q\<:/$^F6<)\DL=KY5E7/<$]!7;>
M*+2_N]#E73)I(KI"'7RW*E@.J\5Y_8>-]:TFR;3YK8S7 )V23[MZD]B.]98U
MTHUDYWCINNOD;9>JTZ#C3Y9*_P +Z>9FZ%:R0^.+6U+B22*[VLPZ$J3D_H:]
MKKSSP'X<NUOVUO4(F1B&\E7&&+'JV.W?\Z]#K7*Z3A2;:M=_@8YQ6C4K*,7?
ME5GZA1117I'DA1110!QWBD^=KME;CD[5_5O_ *U;NOG_ (EFW^](H_7/]*P+
MH_;/'<:+\PC=1_WR,FMO76R+2'NTF[\A_P#7KDPVLZDO/\CNQ?NTZ4/*_P!Y
M=L!BV7Z5;J&V7;"H]JFKK.$***1FVHS'L,T +17+?\)WI_\ S[77Y+_C1_PG
M>G_\^UU^2_XUK["IV.7Z[A_YCJ:*Y;_A.]/_ .?:Z_)?\:/^$[T__GVNOR7_
M !H]A4[!]=P_\QU-%<M_PG>G_P#/M=?DO^-'_"=Z?_S[77Y+_C1["IV#Z[A_
MYCJ:*Y;_ (3O3_\ GVNOR7_&C_A.]/\ ^?:Z_)?\:/85.P?7</\ S'4T5RW_
M  G>G_\ /M=?DO\ C1_PG>G_ //M=?DO^-'L*G8/KN'_ )CJ:*Y;_A.]/_Y]
MKK\E_P :/^$[T_\ Y]KK\E_QH]A4[!]=P_\ ,=317+?\)WI__/M=?DO^-'_"
M=Z?_ ,^UU^2_XT>PJ=@^NX?^8ZFBN6_X3O3_ /GVNOR7_&C_ (3O3_\ GVNO
MR7_&CV%3L'UW#_S'4T5RW_"=Z?\ \^UU^2_XT?\ "=Z?_P ^UU^2_P"-'L*G
M8/KN'_F.IHKEO^$[T_\ Y]KK\E_QH_X3O3_^?:Z_)?\ &CV%3L'UW#_S'4T5
MRW_"=Z?_ ,^UU^2_XT?\)WI__/M=?DO^-'L*G8/KN'_F.IHKEO\ A.]/_P"?
M:Z_)?\:/^$[T_P#Y]KK\E_QH]A4[!]=P_P#,=317+?\ "=Z?_P ^UU^2_P"-
M'_"=Z?\ \^UU^2_XT>PJ=@^NX?\ F.IHKEO^$[T__GVNOR7_ !H_X3O3_P#G
MVNOR7_&CV%3L'UW#_P QU-%<M_PG>G_\^UU^2_XT?\)WI_\ S[77Y+_C1["I
MV#Z[A_YCJ:*Y;_A.]/\ ^?:Z_)?\:/\ A.]/_P"?:Z_)?\:/85.P?7</_,=3
M17+?\)WI_P#S[77Y+_C1_P )WI__ #[77Y+_ (T>PJ=@^NX?^8ZFBN6_X3O3
M_P#GVNOR7_&C_A.]/_Y]KK\E_P :/85.P?7</_,=317+?\)WI_\ S[77Y+_C
M1_PG>G_\^UU^2_XT>PJ=@^NX?^8ZFBN6_P"$[T__ )]KK\E_QH_X3O3_ /GV
MNOR7_&CV%3L'UW#_ ,QU-%5M/O8]1L8KN)65) 2 W4<XJS6;5G9G3%J2N@HH
MHI#"BBB@#P;Q!_R,FJ?]?DO_ *&:*/$'_(R:I_U^2_\ H9HKXBK_ !)>K/T.
MC_#CZ(]X894BL6T/V;76C/W9D(_$<_XUMUB:NK02QW2#YHV#?6OMS\\/-_B)
M:?9?%<D@7"W$:R#Z_=/\J]0\.WPU+P]8W0;<S1 ,?]H<']0:YKXD:?\ ;O#\
M&HQ+N-LV21_<; _GBJ7POU56ANM*D;YU/G1 ]P>&_I^==L_WF'3['A4?]FS&
M4'M/7]?\ST6BBBN(]T**** .2N_!*W7BT:[]N*D2I)Y/E_W0!C.?:NL(!!!&
M0>H-+152G*5K]#*G0ITFW!6N[LX*;X96QU5KNWOC#%YOF+"(LA><XSGI7>T4
M4YU)3MS/8FCAJ5"_LU:X4445!N%<CXE\#KXBU5+XWQ@VQA-@CW="3Z^]==15
M0G*#O$RK4*=:/)45T%<EXF\!VFOW7VR*<VMT1AV"[E?TR,CFNMHHA.4'>(5J
M%.M'DJ*Z.#T3X:6VGWT=U?7?VKRSN6,1[5SVSR<UWE%%.=24W>3)H8:E0CRT
MU8****@W"F2RI#"\LC!412S,>P'6GUS7C;419Z$T"G][<G8!_L]2?Z?C5TX.
M<E%=3'$5E1I2J/HCB-,1M6\30Y&?.N/,8>V=Q_2N_NS]IUX(.D* 'ZGG_"N;
M\!6862[U.48CA38I]^I_3'YUTFD(T\LETXPTK%OI73C9ISY5T/,R2BXT'4EO
M)W-M!A0*=117&>R%%%% '.Z_X,T[Q'>QW=Y-=)(D8C A=0, D]U//-97_"K-
M#_Y^M0_[^)_\17;T5JJU2*LF<L\%AYR<I03;.(_X59H?_/UJ'_?Q/_B*/^%6
M:'_S]:A_W\3_ .(KMZ*?UBKW(_L["_R(XC_A5FA_\_6H?]_$_P#B*/\ A5FA
M_P#/UJ'_ '\3_P"(KMZ*/K%7N']G87^1'$?\*LT/_GZU#_OXG_Q%'_"K-#_Y
M^M0_[^)_\17;T4?6*O</[.PO\B.(_P"%6:'_ ,_6H?\ ?Q/_ (BC_A5FA_\
M/UJ'_?Q/_B*[>BCZQ5[A_9V%_D1Q'_"K-#_Y^M0_[^)_\11_PJS0_P#GZU#_
M +^)_P#$5V]%'UBKW#^SL+_(CB/^%6:'_P _6H?]_$_^(H_X59H?_/UJ'_?Q
M/_B*[>BCZQ5[A_9V%_D1Q'_"K-#_ .?K4/\ OXG_ ,11_P *LT/_ )^M0_[^
M)_\ $5V]%'UBKW#^SL+_ "(XC_A5FA_\_6H?]_$_^(H_X59H?_/UJ'_?Q/\
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M,UJ/-7'\2_Q#\N?PI_@;6?[4T)(9'!N+7]VPSR5_A/Y<?A6EHUQF)K*7[\/
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MZ+\@HHHJ#8**** /!O$'_(R:I_U^2_\ H9HH\0?\C)JG_7Y+_P"AFBOB*O\
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M*W_Y_I?^^!1_P@5O_P _TO\ WP*Z^BCZQ4[A]0P_\OYG(?\ "!6__/\ 2_\
M? H_X0*W_P"?Z7_O@5U]%'UBIW#ZAA_Y?S.0_P"$"M_^?Z7_ +X%'_"!6_\
MS_2_]\"NOHH^L5.X?4,/_+^9R'_"!6__ #_2_P#? H_X0*W_ .?Z7_O@5U]%
M'UBIW#ZAA_Y?S.0_X0*W_P"?Z7_O@4?\(%;_ //]+_WP*Z^BCZQ4[A]0P_\
M+^9R'_"!6_\ S_2_]\"C_A K?_G^E_[X%=?11]8J=P^H8?\ E_,Y#_A K?\
MY_I?^^!1_P (%;_\_P!+_P!\"NOHH^L5.X?4,/\ R_F<A_P@5O\ \_TO_? H
M_P"$"M_^?Z7_ +X%=?11]8J=P^H8?^7\SD/^$"M_^?Z7_O@4?\(%;_\ /]+_
M -\"NOHH^L5.X?4,/_+^9R'_  @5O_S_ $O_ 'P*/^$"M_\ G^E_[X%=?11]
M8J=P^H8?^7\SD/\ A K?_G^E_P"^!1_P@5O_ ,_TO_? KKZ*/K%3N'U##_R_
MF<A_P@5O_P _TO\ WP*/^$"M_P#G^E_[X%=?11]8J=P^H8?^7\SD/^$"M_\
MG^E_[X%'_"!6_P#S_2_]\"NOHH^L5.X?4,/_ "_F<A_P@5O_ ,_TO_? H_X0
M*W_Y_I?^^!77T4?6*G</J&'_ )?S.0_X0*W_ .?Z7_O@4?\ "!6__/\ 2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[1DQJ?TK72-4& *[XVMH>=*]W<IVFG1VZC"BKP %+13)"BBB@ HHHH ****
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M9338$Z(*N44 1K!&O116-XQ 'A'4>/\ EF/_ $(5NUA>,?\ D4=1_P"N8_\
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MLV]C2&_N(HQA$E95&>@!-"PU)NR;*EF.)C'FE%+Y/_,]'_X2S1/^?W_R$_\
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MT:^F%M-IZV:/PDZ3,2A[;L\$4:3:67D:I-=0+=BU4% )&4-R1G(I/#P2UO\
M@6L?7DTHN/7OTU]3LO\ A+-$_P"?W_R$_P#A1_PEFB?\_O\ Y"?_  KD]/71
M]8NUL5TUK220'9*D[/@@$\@]N*J06,)T'49Y(\W$$J(K;CQDX/L:/84]G?\
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MO>+:]/\ +8Q/[6UC_H7W_P# E?\ "C^UM8_Z%^3_ ,"5_P *VZ*?/'^7\_\
M,7LI_P [_#_(Q/[6UC_H7Y/_  )7_"C^UM8_Z%^3_P "5_PK;HHYX_R_G_F'
MLI_SO\/\C$_M;6/^A?D_\"5_PH_M;6/^A?D_\"5_PK;HHYX_R_G_ )A[*?\
M._P_R,3^UM8_Z%^3_P "5_PH_M;6/^A?D_\  E?\*VZ*.>/\OY_YA[*?\[_#
M_(Q/[6UC_H7Y/_ E?\*/[6UC_H7Y/_ E?\*VZ*.>/\OY_P"8>RG_ #O\/\C$
M_M;6/^A?D_\  E?\*/[6UC_H7Y/_  )7_"MNBCGC_+^?^8>RG_._P_R,3^UM
M8_Z%^3_P)7_"C^UM8_Z%^3_P)7_"MNBCGC_+^?\ F'LI_P [_#_(Q/[6UC_H
M7Y/_  )7_"C^UM8_Z%^3_P "5_PK;HHYX_R_G_F'LI_SO\/\C$_M;6/^A?D_
M\"5_PH_M;6/^A?D_\"5_PK;HHYX_R_G_ )A[*?\ ._P_R,3^UM8_Z%^3_P "
M5_PH_M;6/^A?D_\  E?\*VZ*.>/\OY_YA[*?\[_#_(Q/[6UC_H7Y/_ E?\*/
M[6UC_H7Y/_ E?\*VZ*.>/\OY_P"8>RG_ #O\/\C$_M;6/^A?D_\  E?\*/[6
MUC_H7Y/_  )7_"MNBCGC_+^?^8>RG_._P_R,3^UM8_Z%^3_P)7_"C^UM8_Z%
M^3_P)7_"MNBCGC_+^?\ F'LI_P [_#_(Q/[6UC_H7Y/_  )7_"C^UM8_Z%^3
M_P "5_PK;HHYX_R_G_F'LI_SO\/\C$_M;6/^A?D_\"5_PH_M;6/^A?D_\"5_
MPK;HHYX_R_G_ )A[*?\ ._P_R,3^UM8_Z%^3_P "5_PH_M;6/^A?D_\  E?\
M*VZ*.>/\OY_YA[*?\[_#_(Q/[6UC_H7Y/_ E?\*/[6UC_H7Y/_ E?\*VZ*.>
M/\OY_P"8>RG_ #O\/\C$_M;6/^A?D_\  E?\*/[6UC_H7Y/_  )7_"MNBCGC
M_+^?^8>RG_._P_R,3^UM8_Z%^3_P)7_"C^UM8_Z%^3_P)7_"MNBCGC_+^?\
MF'LI_P [_#_(Q/[6UC_H7Y/_  )7_"C^UM8_Z%^3_P "5_PK;HHYX_R_G_F'
MLI_SO\/\C$_M;6/^A?D_\"5_PH_M;6/^A?D_\"5_PK;HHYX_R_G_ )A[*?\
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M:"8(\RM]^5SEW^IJ]114-MN[-8QC%6BK(****104444 %%%% !1110 4444
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MJ2EHF5414SNR>?RK=\SR]<@%WK$INQ(B&WMHSL7H-N<XQZTR\EEALO$(BD=
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MW^%'_""7_P#S]6WYM_A1[>GW#ZCB/Y3E:*ZK_A!+_P#Y^K;\V_PH_P"$$O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \&\0?\ (R:I_P!?DO\ Z&:*/$'_ ",FJ?\ 7Y+_ .AFBOB*O\27
MJS]#H_PX^B/>:***^W/SP**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K"\8_P#(HZC_ -<Q_P"A"MVL/Q@"
MWA+40/\ GEG]16.(_@S]'^1OA?X\/5?F:MC_ ,>%M_UR7^0J>J]@=VG6I'>)
M#^@JQ6D?A1E/XF%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >#>(/^1DU3_K\E_]
M#-%.UY6;Q%JC*"0;N7!_X&:*^(JK]Y+U/T*B_P!W'T1[O1117VY^>A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,K7M'&L62JDAANX6\RWF'5'']*AT/73>LUA
M?H+?5(.)83QO_P!I?4&MNLO6-!M-81&D+0W47,-S$</&?8^GM6$Z<E+VE/?J
MN_\ P3IIU(RA[*KMT?;_ (!J45S"ZAKVB?N]1LSJ5JO NK4?O,>K)_A5JW\8
MZ%<-M-\L+]UG4QD?GQ0L33VD[/L]/Z^02PM6UXKF7=:_\-\S=HK._P"$@T7_
M *"]A_X$I_C1_P )!HO_ $%[#_P)3_&K]K3_ )E]YE[&I_*_N-&BL[_A(-%_
MZ"]A_P"!*?XT?\)!HO\ T%[#_P "4_QH]K3_ )E]X>QJ?RO[C1HK._X2#1?^
M@O8?^!*?XT?\)!HO_07L/_ E/\:/:T_YE]X>QJ?RO[C1HK._X2#1?^@O8?\
M@2G^-'_"0:+_ -!>P_\  E/\:/:T_P"9?>'L:G\K^XT:*SO^$@T7_H+V'_@2
MG^-'_"0:+_T%[#_P)3_&CVM/^9?>'L:G\K^XT:*SO^$@T7_H+V'_ ($I_C1_
MPD&B_P#07L/_  )3_&CVM/\ F7WA[&I_*_N-&BL[_A(-%_Z"]A_X$I_C1_PD
M&B_]!>P_\"4_QH]K3_F7WA[&I_*_N-&BL[_A(-%_Z"]A_P"!*?XT?\)!HO\
MT%[#_P "4_QH]K3_ )E]X>QJ?RO[C1HK._X2#1?^@O8?^!*?XT?\)!HO_07L
M/_ E/\:/:T_YE]X>QJ?RO[C1HK._X2#1?^@O8?\ @2G^-'_"0:+_ -!>P_\
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M@O8?^!*?XT?\)!HO_07L/_ E/\:/:T_YE]X>QJ?RO[C1HK._X2#1?^@O8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "N&\>?\ 'FWT-%%<>._@2._+?]YB>74445\@?<!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
H %%%% ':^ _]>?K7J@Z"BBOJ<K_@'QV<_P"\,6BBBO2/)"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gbkyd1brmfwp000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '1 DD# 2(  A$! Q$!_\0
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M$<;OO4$.Y4;=PW'(!Y"Y(&.2 ,C.1)4<TRP('<2$%U3Y(V<Y9@HX4$XR>3T
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MEM[B*.:"5"DD<BAE=2,$$'@@CM0!)1110 4444 %%%% !1110 4444 %%%%
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MN8GT35[?QC)K.FS6;07*)'<17&X,%&,[2!UP._K73TF"/,H/^01X^_Z^I?\
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M"YC9O48!Q^7<\]J:/#6N:Q>6\GB74;:2TMW$BVMHI"NPZ;B0/\YZ4 1^)/\
MDH7AG_MI7:USVKZ#=7_BG1]4BDA$%EN\Q6)W'/IQC]170TF-!1112&%%%% $
M<T;2H%2:2$AU;<@4D@,"5^8$8(&#WP3@@X(DJ.8S*@,$<;OO4$.Y4;=PW'(!
MY"Y(&.2 ,C.1)0 4444 %%%% !1110 4444 %%%% !1110 5'/&TUO+$DTD#
MNA598PI9"1]X;@1D=>01Z@U)4<YF6WE:WCCDG"$QI(Y16;' + $@9[X./0T
M24444 %%%% !1110 4444 %%%% !1110 5&)E:X> "3>B*Y)C8+AB0,-C!/R
MG(!R.,XR,R44 %%%% !6/JWA;1=<NEN=1L_.F5!&&\UUPH).,*1W)K8HH YC
M_A7OA;_H%_\ DQ+_ /%4?\*]\+?] O\ \F)?_BJZ>BG=BLCF/^%>^%O^@7_Y
M,2__ !5'_"O?"W_0+_\ )B7_ .*KIZ*+L+(YC_A7OA;_ *!?_DQ+_P#%4?\
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M;_H%_P#DQ+_\51_PKWPM_P! O_R8E_\ BJZ>BB["R.8_X5[X6_Z!?_DQ+_\
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M".$S,A,\<:/O8 (Y8;=QVG) Y*X)&."2,G&2 S?:'5HXQ $4HX<EBV3N!7&
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MS_[%T_\ YX'_ +[;_&C^Q=/_ .>!_P"^V_QK0HHN%C/_ +%T_P#YX'_OMO\
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MRH_^>:?]\BCRH_\ GFG_ 'R*?10 SRH_^>:?]\BCRH_^>:?]\BGT4 ,\J/\
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M>,YP,3U&!-]H=FDC,!10B!"&#9.XELX((VX&!C!Y.> !?,7T?_O@T>8OH_\
MWP:?10 SS%]'_P"^#1YB^C_]\&GT4 ,\Q?1_^^#1YB^C_P#?!I]% #/,7T?_
M +X-'F+Z/_WP:?10 SS%]'_[X-'F+Z/_ -\&GT4 ,\Q?1_\ O@T>8OH__?!I
M]% #/,7T?_O@T>8OH_\ WP:?10! 5C:X2<^=O1&0 %PN&()RO0GY1@D9'.,9
M.9/,7T?_ +X-(1-]H1EDC$ 1@Z%"6+9&TALX  W9&#G(Y&.9* &>8OH__?!H
M\Q?1_P#O@T^B@!GF+Z/_ -\&CS%]'_[X-/HH 9YB^C_]\&CS%]'_ .^#3Z*
M&>8OH_\ WP:/,7T?_O@T^B@!GF+Z/_WP:/,7T?\ [X-/HH 9YB^C_P#?!H\Q
M?1_^^#3Z* &>8OH__?!J.18Y7A=O.!B?>NTNH)VE?F X888\'(S@]0")ZCD$
MQ>$Q21J@?,H9"Q9=IX4Y&T[MIR0> 1CG( %\Q?1_^^#1YB^C_P#?!I]% #/,
M7T?_ +X-'F+Z/_WP:?10 SS%]'_[X-'F+Z/_ -\&GT4 ,\Q?1_\ O@T>8OH_
M_?!I]% #/,7T?_O@T>8OH_\ WP:?10 SS%]'_P"^#1YB^C_]\&GT4 ,\Q?1_
M^^#1YB^C_P#?!I]% $$RQSH$?S@ ZO\ (70Y5@PY7!QD<CH1D'()%2>8OH__
M 'P:9<LZP[HYHH=K*6>5=R[0PW#J,$KD YX)!P<8//ZAXCDFD^RZ4C/(W'F;
M<_D/ZFN;$XNEAXWF]>BZLVHX>=9VBOGT-:_UFTT]/WK$R$?+&!R?\*YX_P!I
M^(Y 7W06>>RDK_\ 9&KVG>&OWGVG4V\Z9CDQDY&?<]ZZ( *H50  , #M7%["
MOC-:_NP_E6[]7^AT^UI8;2E[TN_1>A0T_3[/38]L$;%R/FD9#N/Z55_MF;_A
M,?[(V+]F_L_[3NV-OW^9MQ],>WXUM5C>9J/_  FGEXD_LS^SMV=GR>=YGKZ[
M>U>I3IPIQY8*R1Q3G*;YI.[-;S%]'_[X-'F+Z/\ ]\&GT51(SS%]'_[X-'F+
MZ/\ ]\&GT4 ,\Q?1_P#O@TY6#=,_B"*6B@ HHHH *CGA6YMY8',@21"C&.1D
M8 C'#*05/N"".U25'.)FMY5MY(XYRA$;R(756QP2H()&>V1GU% $E%%% !11
M10 4444 %%%% !1110 4444 %1B1C</$89 BHK"4E=K$DY4<YR, G( ^88)Y
MQ)48GA:X>W66,SQHKO&&&Y58D*2.H!*M@]]I]* )**** "BBB@ HHHH ****
M "BBB@ HHHH **** (S(PN$B$,A1D9C*"NU2",*><Y.21@$?*<D<9DJ,SPK<
M);M+&)Y$9TC+#<RJ0&('4@%ER>VX>M24 %%%% !1110 4444 %%%% !1110
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M 'R?\:<N[^(@_08H 6BBB@ HHJ.>%;FWE@<R!)$*,8Y&1@",<,I!4^X(([4
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MW#Q&&0(J*PE)7:Q).5'.<C )R /F&"><$DC(\*K#)()'VLRE<1C:3N;)!QD
M<9.6'&,D $E%1SR-#;RRI#).Z(66*,J&<@?=&X@9/3D@>I%24 %%1PR-*A9X
M9(2'9=KE22 Q ;Y21@@9'?!&0#D $C&X>(PR!%16$I*[6))RHYSD8!.0!\PP
M3S@ DHJ.21D>%5ADD$C[692N(QM)W-D@XR .,G+#C&2&7ER+.RFN3&TGE(7\
MM2H9R!]T%B!D]!D@>XI-I*[!*^B'W$\=K \\S;8T&2:Q'\6V/E.R13%Q]U6
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M,K0R1B-]JLQ7$@V@[EP2<9)'.#E3QC!(9&%PD0AD*,C,905VJ01A3SG)R2,
MCY3DCC( 3"9D @DC1]ZDET+#;N&X8!')7(!SP2#@XP9*CFD:) R0R3$NJ[4*
M@@%@"WS$# !R>^ < G ,E !14<$C36\4KPR0.Z!FBD*ED)'W3M)&1TX)'H31
M'(SO,K0R1B-]JLQ7$@V@[EP2<9)'.#E3QC!(!)6+YU]_PF_D^6W]G_V;OW^4
M,>;YF,;\9SCMGWQ6L9&%PD0AD*,C,905VJ01A3SG)R2, CY3DCC.),+^+QJ+
MA%DFLC8+'Y*3*,.9AE]C,. IR3Z @9. 6@-^BBHX)&FMXI7AD@=T#-%(5+(2
M/NG:2,CIP2/0FD!)148D8W#Q&&0(J*PE)7:Q).5'.<C )R /F&"><$DC(\*K
M#)()'VLRE<1C:3N;)!QD <9.6'&,D $E%1SR-#;RRI#).Z(66*,J&<@?=&X@
M9/3D@>I%24 %%1PR-*A9X9(2'9=KE22 Q ;Y21@@9'?!&0#D $C&X>(PR!%1
M6$I*[6))RHYSD8!.0!\PP3S@ DJ.<3-;RK;R1QSE"(WD0NJMC@E002,]LC/J
M*))&1X56&202/M9E*XC&TG<V2#C( XR<L.,9()Y&AMY94ADG=$++%&5#.0/N
MC<0,GIR0/4B@"2BBB@ HHJKJ%V]E9O-%;2W,N0J11@DLQ.!D]AZGL* +5%8#
M^)&MEO8KJRVWMLT2+##+O64R\1@,5!Y((.1QCO3I/$+646HC4;017%E"+C9%
M+YBRH<X*L57N"#D<>].P7-VBL)/$$WESPRV*IJ$4\=N+=9MRNSJ&&'V] I)/
M'&T]:W:0!1110 4444 %1B>%KA[=98S/&BN\88;E5B0I(Z@$JV#WVGTJ2B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH C,\*W"6[2QB>1&=(RPW,JD!
MB!U(!9<GMN'K4E%% !1110 4444 %%%% !1110 4444 %%%% !4<D\,+PI++
M&CS/LB5F +MM+87U.U6.!V!/:I** "BBB@ HIKND2,\C!449+,< 5S5_XBFN
M9?LFDQL[MQY@')^@_J:YL3BZ6'5YO5[+JS:CAYUG:/W]#6U/6;73%PYWS8XB
M4\_CZ5@QVVI^))1+<,8;0'*C''X#O]35[3/#2QO]HU!O.F)SL)R ??U-="
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M+^]*&R"5STQ@8ST%;M%*X6,S3[-=%M)6FE>>:YN?,E>.$\NY"C"KDA1QR<X
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MYB^C_P#?!I]% #/,7T?_ +X-'F+Z/_WP:?10 SS%]'_[X-'F+Z/_ -\&GT4
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MOF[1IU_'TK.K5A2CSU'9%PIRJ2Y8*[)=3U&/3+,SR*6YVJH[FLVR\4V<ZO\
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MJ'ZDG^=3I9VL?W+:%?H@H Q3XF9CB*S)/N^?Z4G]L:K+_JK'\?+8UT( 48
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M6(1001QH.RM_]:I<R?W$_P"^C_A12R_FE[3$OGE^"]$*>+M'DHKE7XOU8X
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MT?\ "D ^BF9D_N)_WT?\*,R?W$_[Z/\ A0 ^BF9D_N)_WT?\*,R?W$_[Z/\
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MB%VJ03EAQG)R <DCY1@#G,E1@S?:'5HXQ $4HX<EBV3N!7&  -N#DYR>!CD
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M PHPIY.!G ZD D\RVUO+.XD*1H781QL[$ 9X502Q]@"3VJ2B@ HHHH ****
M,KQ):3WN@7,-LGF3#9(B XW%'#8_';6>L">(-=:>:QN%L%L6@87,31%V=E;
M!P> O4=^AXKI:*=PL<;-ITL2_:[>"\AM1=")EC,IG,&[,CYSYA9W"9QSM1>V
M:Z#P_P#;/[!M/M_F?:-GS>;]_&3MW>^W&<\YZ\UI447%8*9L;_GHWY#_  I]
M%(8S8W_/5_R'^%&QO^>K_D/\*?10 S8W_/5_R'^%1BUC6X>X4 3R(J/($7<R
MJ25!.,D LV!VW'UJ>N7LO$-[)9P:U=6B1Z9<K&A5+D.8,L1O*^6I.2R@_,<
M @?>R 6O$6DW-_%"UN?,:(G*$@9SCI^55=(\,85I-10AL_)&&''UQ6_)J5C#
M=I:2WMO'<OC9"TJAVSTPN<FG)>6L@A,=S"PGSY6V0'S,==OKC!Z5PRR^C+$?
M6)*[_ ZEC*L:/L5M^(0VL<";8?D7T55']*DV-_SU?\A_A69X@UV+0=/>Y>"6
MXD"EDBC4\XQDEL84#(Y/KWK6KN.49L;_ )ZO^0_PHV-_SU?\A_A3Z* &;&_Y
MZO\ D/\ "C8W_/5_R'^%/HH 9L;_ )ZO^0_PHV-_SU?\A_A3Z* &;&_YZO\
MD/\ "C8W_/5_R'^%/KFX_$MXVEMJTFF0C3T=UD9+HM*JJY0MM* =B<;NE '0
M[&_YZO\ D/\ "C8W_/5_R'^%5Y]3T^VDBCGOK:*24 QK),JE\], GFI!>VK*
MK"YA*O)Y2D2#!?D;1[\'CVH #:QM<)<, 9XT9$D*+N56(+ '&0"57([[1Z5)
ML;_GJ_Y#_"LS5]0FL;W3TMU,LMRSPI"\BQQ$X#;F;:6! 4@ ==QR#QBSI&HK
MJVEP7JQF/S <H3G!!(//<9!P>XH M;&_YZO^0_PHV-_SU?\ (?X4^B@!FQO^
M>K_D/\*-C?\ /5_R'^%/HH 9L;_GJ_Y#_"C8W_/5_P A_A3Z* &;&_YZO^0_
MPHV-_P ]7_(?X51UG4Y-,M[=XK=9Y)[B.W57DV %S@$G!X_"F6FJ3MJ;:=?V
ML=O<&+SHS%-YB2+G!P2JG()'&.] &CL;_GJ_Y#_"C8W_ #U?\A_A56+6-,G+
M"'4;20JRH0DZG#$X X/4G@"K2312221I*C21D"10P)7(R,CMQS0 ;&_YZO\
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MFC&HVA>#_6KYZYCYQ\PSQSQSWJTLT33/"LB&6, N@8;E!S@D=LX/Y4 &QO\
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MPL%1R2,CPJL,D@D?:S*5Q&-I.YLD'&0!QDY8<8R1)4<D\,+PI++&CS/LB5F
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MG1KF#X;E%VD0E8Q,C,9@@VJ01A2-V<G)(P"/E.2.,S?\(O\ ]/G_ )"_^O3
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MHHH **** "BBB@ HHHH C,\*W"6[2QB>1&=(RPW,JD!B!U(!9<GMN'K4E%%
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M-'F?9$K, 7;:6POJ=JL<#L">U $E%1SSPVMO+<7$L<,$2%Y))&"JB@9))/
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MC$\B,Z1EAN95(#$#J0"RY/;</6B:>&V0//+'$A=4#.P4%F8*HY[EB !W) H
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M>#D9P>H! !)1110 4444 %%%% !1110 4444 %%%% !1110 45'-"LZ!',@
M=7^21D.58,.5(.,CD=",@Y!(J2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHJ.>%;FWE@<R!)$*,8Y&1@",<,I!4^X(([4 24444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gbkyd1brmfwp000018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )' \D# 2(  A$! Q$!_\0
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M4 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\
M>:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1
MM/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I
M_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU%
M #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_W
MFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U
M&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -V
MG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G4
M4 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\
M>:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1
MM/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I
M_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_WFIU%
M #=I_O-1M/\ >:G44 -VG^\U&T_WFIU% #=I_O-1M/\ >:G44 -VG^\U&T_W
MFIU% #=I_O-1M/\ >:G44 (!CN3]:6BB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6'BCQ6\VLZ7>3S3(UU;:<CJD$WS9X/'/L>H- 'J-%%% !1110 4444 %%%%
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MC_\ B:ZZBAT8/=!'&UX-N,M]]C&E\.6\NAQZ49Y1'&00^%R><],8[^E97_"
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M"[BA0PE=IB!&<YZY/M7-2QE&K+D@[OYG;6R_$4(>TJ1LO5'5T445TG$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7(?\U?/_8"_]KUU]<A_S5\_]@+_ -KT =?6/XEF
MU>#26?1HA)=;QD8!(7N0#UK8HJ9QYHN-[%TY\DU)J]NC/-/[4^('_/K)_P"
MRUPTS2M/*TXQ,78R#&/FSS7T)7)3_#O1;BXEG:2\#2.7(648!)SZ5YF(R^I.
M%E-OU9[6%S6E3FY2IJ.GV4>;Z#/JMOJJOHR%[KRV& @;Y>_!KJAJGQ R/]$D
M/UMUKJM&\&Z9H=_]LM6N6EV%/WD@(P?PKH:JC@)Q@HN;7H]#/$9I3G4<HTD[
M]UJ16QF:UB:X55F* R*IX#8YJ6BBO31X[=W<\F\!H+OXU>.[RZ(:Z@:."+<.
M5C]O;"K7I6M:9I>KZ5+9ZQ;PSV+8,B3?=X.0?SKA/%/A/Q'IGC7_ (3/P:+>
M>ZFB$-_I\[[%N%'0@] >!Z=/J*RM:L_B+\1K9-#O]%@\.:/(ZF\F-RLLDB@@
M[5 ]_P#]= BKX_OCH/Q:\&W&G:7-?BWL9$AM+3[S+\P 7Z#^53^*M<\8^.]
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MF]T+P#I&F:C"(;RWA*RQA@VT[B>HX[UTU '(>!/^/CQ5_P!AZX_]!2NOKD/
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M8'@[_H:-'_\  R/_ !H_X6!X._Z&C1__  ,C_P : .CHKG/^%@>#O^AHT?\
M\#(_\:/^%@>#O^AHT?\ \#(_\: .CK$U?PO8:WK6D:K=-,+C2I6EMPCX4D@9
MW#'/2J__  L#P=_T-&C_ /@9'_C1_P + \'?]#1H_P#X&1_XT ='17.?\+ \
M'?\ 0T:/_P"!D?\ C1_PL#P=_P!#1H__ (&1_P"- '1T5SG_  L#P=_T-&C_
M /@9'_C1_P + \'?]#1H_P#X&1_XT ='17.?\+ \'?\ 0T:/_P"!D?\ C1_P
ML#P=_P!#1H__ (&1_P"- '1T5SG_  L#P=_T-&C_ /@9'_C1_P + \'?]#1H
M_P#X&1_XT ='17.?\+ \'?\ 0T:/_P"!D?\ C1_PL#P=_P!#1H__ (&1_P"-
M '1T5SG_  L#P=_T-&C_ /@9'_C1_P + \'?]#1H_P#X&1_XT ='17.?\+ \
M'?\ 0T:/_P"!D?\ C1_PL#P=_P!#1H__ (&1_P"- %/P)_Q\>*O^P]<?^@I7
M7UQ7PYN[>^3Q-=6D\<]O+KD[1RQL&5QM3D$=17:T %%%% !1110 5EZ]K,>B
M:>+AH'GDDD$44*=7<]!6I6%XL.D?V.$UII$M7E $D8.8VY(/'2F@9S$*+>:]
M%#+I5UX<U.X5F@GMY0R2E>2&4  UOVU]KNF7,5MJE@MY#(X1;VS&",\9=.WN
M1Q57P_I7AV"]74+;67U"X1,(]Q=!S&#UP.,?C717.L:99KFYU"UB'^W*H_K3
M8D7:*H:5K%EK4$D]A*98D<QE]I ) '3/UJ_4C"BBB@ KG/$GCSPSX1D2+6M5
MBMYI!N6(*SN1Z[5!('O71UXU\*=/M?%'BKQ;XJU2".ZN?M[6MN9E#")!V /M
MM'X>] 'J&@>)-(\3Z?\ ;M&OH[NWSM)3(*GT(/(/UK5KQVQMH/!_[0XT[3(E
MM[#7+ RR0(,()%#'(';[A_[Z->PY'J* ./'_ "64_P#8OC_TH-=C7' C_A<K
M<_\ ,OC_ -*#78T %%%>5:CX^UVVU2\MXFM?+BG=%S%DX#$#O5PA*;M$QK5X
M45S3/5:*\PT;XAW[:K$NK2VZV1#;V2(@CCCOZXKH)OB/H<8_=BYF/^S%C^9%
M8UZD*#Y:C29T82G/%QYZ$6T=?17 3?%"$<6^ER-Z%Y /T -4C\0=<NLBSTJ/
MV*H[G]*Y'F.'6SO\F>A'*<6]7&WJT>F45YE_:OCV^'[JVEB![K J_P#H5+_8
M7CF]_P!??21J?[USC]%I?7F_@IR?R*_LQ1_B58KYGI3ND8R[JH]6.*I3ZYI5
ML,S:C:I]917!I\.-4G.;O5H\GKC<_P#/%78/A?9K@S:C,WJ$15_QH]OBI?#3
MMZL/JV"C\5:_HC=G\;^'H/\ F("0^D:,W]*S9_B5H\>?*@NI3_N!1^IJQ#\/
M-!BP72>4_P"W*<?I6C!X3T"W^YI=N?\ ?&[^>:+8V76*^\+Y=#I*7W(Y2;XH
M9XMM+Y[>9+_@*@/CCQ->'%GI:KGIM@=OUKT.&PL[<8AM8(Q_L1@58X'2CZMB
M)?%5^Y!]<PD?@H?>VSS3[3\0+_[L<T0/^PD?\Z/^$6\9WW_'UJ)4'KON3_[+
M7IE%'U"+^.<G\P_M24?X=.,?D>;)\,[R5MUWJJ'_ '4+'\R:T(/ACIR?Z^^N
M9/\ ="K_ (UW-%7'+\.OLD2S7%R^W;T2.8@\ >'X<;K:24C_ )Z2G^F*TH/#
M.B6QS%I=L#ZF,$_K6K16T</2CM%?<<T\77G\4V_FR**VMX/]5!''_N(!4M%%
M;)6V,&V]PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !5>XL+.[8-<VD$S*, R1AB!^-6** */\ 8NE?] RR_P# =?\
M"C^Q=*_Z!EE_X#K_ (5>HH H_P!BZ5_T#++_ ,!U_P */[%TK_H&67_@.O\
MA5ZB@"C_ &+I7_0,LO\ P'7_  H_L72O^@99?^ Z_P"%7J* */\ 8NE?] RR
M_P# =?\ "C^Q=*_Z!EE_X#K_ (5>HH H_P!BZ5_T#++_ ,!U_P */[%TK_H&
M67_@.O\ A5ZB@"C_ &+I7_0,LO\ P'7_  H_L72O^@99?^ Z_P"%7J* */\
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MU):Z?9+# ^A"1DWLV6\_&>2>U=Y_9EG_ ,\!^9KF1_R64_\ 8OC_ -*#78T
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M ,\!^9JW10!4_LRS_P"> _,T?V99_P#/ ?F:MT4 5/[,L_\ G@/S-']F6?\
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MXFQT^-I+@J?XR/\ ZZC_ +ZII"9V-M:Z==VL5S!&KPRH'1@3R",BI?[,L_\
MG@/S-<K\/KV6&"]\/79_TG392JY[H2>GX_H17:T-6!%3^S+/_G@/S-']F6?_
M #P'YFK=%(94_LRS_P"> _,T?V99_P#/ ?F:MT4 5/[,L_\ G@/S-']F6?\
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M %3^S+/_ )X#\S1_9EG_ ,\!^9JW10!4_LRS_P"> _,T?V99_P#/ ?F:MT4
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ME^(X/^/C0HYAWS:J_P#Z#5&21(FQ>>'53UV^;&?YXH]A3>WYA]=Q$?B_%/\
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MHK$_X2_P_P#]!2#]?\*/^$O\/_\ 04@_7_"CDGV#V]+^9?>;=%8G_"7^'_\
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M\:L?J14U8W.P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M61U!1110 4444 %%%% !1110 4444 %5KW3[/4H1#>V\<\8;<%D7(SZU9HH
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MD>HI#%HI,CU%&1ZB@!:*3(]11D>HH 6BDR/449'J* %HHR** "BBB@ HHHH
MXK7/$FIVVLWXM3$EAI< >XW?>D=U.P#\<52\+:IKT6HZ6VJ7GVFVU=)&C0CF
M,J,Y]@1VJWXM\.:9?:D+BYUU--\]5$T3N )@IX/)'(_&K&F6NB#Q-'=PZU!<
MLL0@LK2.4,(@% .,$]@?2JTL3K<Z^LW7["\U/0KRRT_4'T^[FCVQ72#)B.>H
M&1_.M*BI*/-=!\ ^,],UVSO=0^(-W?VD,FZ6U:$@2CT)WG^5<[XG\7ZA\1/$
M=SX0\-ZA#IVCVYV:EJDD@4N,X*ISR.HXZ^PZ^U2()(VC;.U@0<''6O-S\"/
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MC:O]T?E2T4 )M7^Z/RHVK_='Y4M% ";5_NC\J-J_W1^5+10 FU?[H_*C:O\
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MM7^Z/RHVK_='Y5!9WUIJ$ FM+B.:,_Q(V?\ ]56*PV.Q--70FU?[H_*C:O\
M='Y4M% Q-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_ '1^5&U?[H_*
MEHH 3:O]T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3
M:O\ ='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_=
M'Y4;5_NC\J6B@!-J_P!T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&
MU?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_ '1^5&U?[H_*EHH 3:O]T?E1M7^Z
M/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O\ ='Y4;5_NC\J6
MB@!-J_W1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J
M_P!T?E1M7^Z/RI:* $VK_='Y4;5_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O]T?
ME1M7^Z/RI:* $VK_ '1^5&U?[H_*EHH 3:O]T?E1M7^Z/RI:* $VK_='Y4;5
M_NC\J6B@!-J_W1^5&U?[H_*EHH 3:O\ ='Y4;5_NC\J6B@!-J_W1^5&U?[H_
M*EHH 3:O]T?E4<P989&BC5Y I**3C<>PS4M% '*^#?#MUI"7UWJGEMJ%Y,7<
MJ=P"]>OU)_2F1^'[[3_'LFJV21G3[R/%RA;!5O4#OR ?Q-=;13N*PFU?[H_*
MC:O]T?E2T4AB;5_NC\J-J_W1^5+10 FU?[H_*C:O]T?E2T4 )M7^Z/RHVK_=
M'Y4M% "  = !2T44 %%%% !116;KNM6V@:5)?7(9E4A51>K,>@H X+Q3IT%[
MXGU:&]28W4EJKZ:1G:=JDL/KP:9X:;0CXMTB3187,DD#_:D?<1"VWJ">_4>G
M-:1^(\/D;KS0YXKO >T1AD29XX) (Z]A4_A?78VUZ33[W0(=+U"9"ZM''M\P
M=<'BKUL1I<[FBBBH+"BBB@ HHHH **** ..'_)93_P!B^/\ TH-=C7"W6HV=
MA\8RUU<)$O\ 8 7+'O\ :":ZJVUS3+R=8+>]BDE;HH/)K-UJ:ERN2OVN3S1O
M:YH45G7&O:5:SM#/?0I(APRD\BI+/5]/OY&CM+N.5U&2%/(%)5Z3ERJ2OZAS
MQO:Y=HK+;Q'HZ.5;4(0RG!&:L6^J6-W!)-!=1R1Q??8'A?K1&O2D[*2;]04X
MO1,N45E?\)+HO_01A_,U9&J6)L3>BZC^S X,F>*(UZ4MI)_,%.+V9<HK*_X2
M;1?^@C#^9JS/JEC;6T=S-=1I#+]QR>&^E"KTFFU):>:#GB^I<HK*'B31B0!J
M,.2<=:LWFK6%@R+=W4<3.,J&/44*O2:<E)67F'/&U[ERBLV'7])N)DABOH7D
M<X50>II]UK>F64Y@N;R*.4#)5CR*/;TN7FYE;U#GC:]RY+#'/"\4R*\;C#*P
MR"*\SU[PO?>&+S^V-#DD^SH<LJ\M$/0_WEKT"TUK3;Z?R;:\BED(R%4\U'-X
M@TB*1X9;Z$,I*LI/0]Q6D,73@N;F5GYJQSXBE3K1U=GT9G>&/%EKXA@\F4+%
M>JOSPD\./5?4>U8_B3P$LKM?:)B&X!W& ' )]5/\)_2LS7/#]K-/)JWA>Z5I
M(#YDL$+8*?[2?X5L^&O'MM>0"#5I$@N4'$IX63_ ^U="G'E]M1=XG)SQJ?N<
M3OT?<H^'_'<UI-_9OB!71T.SSV7#*?1Q_6O0HY$EC62-U=&&593D$5S6MZ9H
M7B?3I+LW$:M",?:TZI[-ZCVKAM+U_4/"-Z;831WMCG[J-E2/53V/M4\U&M;D
M:N^E]_0M5YX9J-5\T>C_ ,SV"BLBR\3Z3>Z=]N2[1(@0'#G#(?0BG?\ "2Z+
M_P!!&'\ZYJE6G3ERSDD_-G>JL&KIHU:*IW6JV-E'')<W4<:2C*$G[WTJNGB+
M1Y)%1-0A+,< 9ZFE*O2B^5R5_4;G%.S9J5D:MX:TK6@3=VJ^;VE3Y7'X]_QJ
MU>:QI]A*(KJ[CBD(R%8\XIEOKNEW<ZP07L4DK?=4'DTUB*<9<JDD_4F?LY>[
M*S.#O/ NLZ+.;O0KUY,<[5;9)_@U2:?\0KZPF^RZ[9.67AG5=CCZJ>#^&*[>
MXUW2[6=H)[Z))4X92>15>1M \2!K9S;795<X_B4>H/45NL;2G+DFTWZZG$\-
MR.^'G9]MT6-,US3=8CW65TDAQRF<,/J#S6C7E&J^&M+MKAI=&UV*.6,\12N0
M01Z./ZTNF^/-7TIA%J""\A4XW,<-^#=#^-$?8U7:C--]KJX1QS@^6NK>:U1Z
MM17.V'C?0KZ(,;L6[]XYAM(_H:UUU2Q:Q:]%U&;93@R9X%9SE&$N63LSMA5A
M-7BTRW165_PDVB_]!&'\S5F;5;"WM8[J6ZC2"3[CD\-]*S5>DTVI+3S17/%]
M2Y164/$NC$X_M&'GWJS>:K86!075U'$7&5W'J*%7I--J2LO-!SQWN7**S8?$
M&DSS)%%?PM(YPJ@]33[K6M-LIS#<WD44H&2K'D4>WI<O-S*WJ@YXVO<OT50M
M=:TV]G$%M>12RD9"J>33)O$&DV\SPRW\*R(<,I/0T>WI<O-S*WJ@YXVO<TJ*
MIV>JV%^7%K=1RE!E@IZ"JQ\2Z,#C^T8./>AUZ22;DK/S0<\;7N:M%4X=5L+B
MUDNHKJ)X(_ON#POUJM_PDVB_]!&'\S0Z]))-R6OF@<XKJ:M%4VU6Q6Q6]:ZC
M%LQP),\$U6_X271?^@C#^9HE7I1WDE\P<XK=FK15.YU6QLX8Y;BZCCCEY1B?
MO?2JZ>(]'=U1=0A+,< 9[T2KTHNSDD_4'.*T;-2BJ5YJ^GV$BQW5W'$[#(5C
MSBH[?7=+NIU@@OHGE?A5!Y-#KTE+E<E?U#GC>US1HK/N-=TNTG:">]BCE7[R
MD\BGV>L:??RF*UNXY9 ,E5/.*%7I.7*I*_:X<\;VN7:*RW\1:/'(R/J$(93@
MC/0U8M=5L;V.22VNHY$B&7(/W?K1&O2D^525_4%.+=DRY165_P )+HO_ $$8
M?SJRFJ6+V+7JW49ME.&DSP*(UZ4OADG\P4XO9ERBLK_A)M%_Z",/YFK,NJV,
M%I'=RW4:V\GW)">&^E"KTI)M26GF"G%]2Y165_PDNC$X_M&'\ZLW>JV%AY?V
MJZCB\P93<>HH5>DTVI*R\T'/'>Y<HK,B\0Z1/*D4=_"SN<*,]34EWK6FV,_D
MW-Y%%)C.UCSBCV]*W-S*WJ@YXVO<OT50M=;TR]G$%M>Q22D9"@\FF3:_I-O,
M\,U]"DB'#*3T-'MZ7+S<RMZASQM>YI453L]6L-09UM+J.5D&6"GH*K'Q)HP)
M!U&#(XZT.O224G)6?F'/&U[FK15.#5;"YMI+F&ZC>&+[[@\+]:K?\)-HO_01
MA_,T.O223<EKYH.>*ZFK15,ZK8"Q%Z;J/[,3@29XS5;_ (271?\ H(P_F:)5
MZ4=Y)?- YQ6[-6BJ=QJEC:01S3W4<<<OW&)X;Z577Q)HSL%74(22<#FB5>E%
MV<DGZ@YQ6[-2BJ5YJ^GZ?(L=W=QQ.PR QY(J.#7M*NITA@OHGD<X50>30Z])
M2Y7)7]0YXWM<T:*S[G7-,LYV@N+V*.5>JD\BG6FL:=?S&*UNXI9 ,[5/.*/;
MTN;EYE?M<.>-[7+U%9DGB+2(I&C?4(0ZG##/0U/:ZK8WR2/;74<JQC+E3]WZ
MT*O2D^525_4%.+=DRY165_PDNB_]!&'\ZLIJMC)9/>)=1FW3AI,\"B->E+X9
M)_,%.+V9<HK*_P"$FT7_ *",/YFK,FJ6,-FEY)=1K;R?<D)X-"KTI7:DM/,%
M.+ZERBLK_A)=%_Z",/YU9N]5L+$1FZNHXA(,IN/WA0J])IM25EYH.>.]RY16
M9'XATB:58X[^%G<X49ZFI;O6=.L9O)NKR**3&=K'G%'MZ5N;F5O5!SQM>Y>H
MK/MM;TR\G6"WO8I)6Z*#R:2?7]*MIWAFOH4D0X92>0:/;TN7FYE;U0<\;7N:
M-%4K/5K#4'9+2ZCE91E@IZ"JY\2:,K%3J,.0<'FAUZ27,Y*S\PYXVO<U:*IV
M^JV-U;R7$%U&\47WW!X7ZU6_X2;1?^@C#^9H=>DDFY+7S#GBNIJT53_M6P^P
M_;?M4?V;./,SQGI5;_A)=%_Z",/YFB5>E'>27S0.<5NS5HJI<:I8VMO'<3W4
M:12_<<GAOI55?$FC,P4:C#DG YHE7I1=G)+Y@YQ6[-6BJ5YJUAI[JEW=1Q,P
MRH8]14<&OZ5<SI##?0O(YPJ@]30Z])2Y7)7]0YXWM<T:*S[G6],LYV@N+V*.
M5>JD\BG6FLZ=?3>3:WD4LF,[5/.*/;TN;EYE?M<.>-[7+U%9DGB'2(96BDOX
M5=#AAGH:GM-5L+Y9#:W4<HC&7VG[HH5>E)\JDK^H*<6[)ERBLK_A)=%_Z",/
MYU9CU6QFLWO([J-K=/O2 \"B->E+2,D_F"G%[,N45E?\)-HO_01A_,U9DU2Q
MBLDO'NHQ;N<+)G@T*O2E>TEIY@IQ>S+E%9UOKNEW<ZP07T3RO]U0>36C50J0
MFKP=_0:DGL%%%%6,*XCXHD#PU;D]/M2_^@M7;U6O=/M-2A$-[;QSQAMP61<C
M/K36C$SS;Q3XCT:_U7P]+:W2R1VLP:8A#\BY7V]C5Q]7L=8^*&D3V%P)HU@9
M"P!&#A^.?K76_P#")^'_ /H$6G_?L5-:^'M'L;A;BUTZWAF3[KHF"*=T*S-.
MBBBI*"BBB@ HHHH **** .&N;"TO?C&5N;>.4?V #AAW^T&NKM]&TVUG6:"R
MACD7HP7D5S@_Y+*?^Q?'_I0:[&LW2IN7,XJ_H3RQO>Q0GT33+F9IIK*%Y&.6
M8KR:DM=+L;%V>UM8HF88)4<D5;HH5&FI<RBK^@<D;WL9K>'])9BS:? 23DG;
M5BWTVRM89(8+6*..3[ZA>&^M6J*%1IQ=U%?<"A%;(S/^$=T?_H'P?]\U9&FV
M0LC9BUB^SGDQ[>*M44E1I1VBON!0BMD9G_".Z/\ ] ^#_OFK,VFV5Q;QV\UK
M$\,?W$*\+]*M44*C22:45KY!R170S1X>T@$$:?!D'/W:GN],L;YE:ZM8Y2@P
MI9>@JW10J-)*RBK>@<D=K&?#H>EP3++%8PK(ARK!>AI]SH^G7DQFN+.*20C!
M9EY-7:*/8TK<O*K>@<D;6L4K;2-/LYO.MK2*.3&-RKS4<NA:5-*TLEC"SN<L
M2O4UHT4>QI6Y>56] Y(VM8J6NF65CO\ LUK%%O&&VKU%<EXH\!P7<1NM(C6&
MY49:$<+)]/0UW%%:TK4G[BL9U:%.K'DDCS7PGXEMK='T+6K=(=S%=[IC)]']
M_>NTD\-:+-&4;3H"K#TK/\4^$+;7HC/#MAOU'RR8X?V;_&N8\/>*[SP[=_V/
MKJ2"%#M5VY:+T^JUJZ%*I:<(JZZ?Y'%&3H-4ZZO'H_T9!K_@N\T.4W^E;KBU
M4[F0C<R#W'\0K5\,ZMX=UG9;7>GVUM>G@#'R2?[I]?:N]CD2:)9(G5XV&593
MD$5QWB;P);ZD6N],VV]YU*=$D/\ 0^]*4:5;2M%-][#GAI47[2@KKM_D=3<Z
M;97<<<=Q:Q2+'P@9?N_2H$T#28W5UL( RG(.WH:X70_&=]HES_9?B".4JGRB
M1A\\?U_O#WKT:WN(;N!)[>598G&5=#D&LJN%@I7E%/SL=-&M2KJZ6O;J076E
M6%]*)+FTBE<# 9EYQ3+?1=-M9EF@LH4D7[K!>15^BH=&FY<W*K^AOR1O>Q0G
MT73+F9IIK*%Y&^\Q7DT^UTJPL9#):VL43D8+*O.*N44*C34N915_0.2-[V,U
MM TEW9VL("S').VI$T;34MY+=;*#R9/OH4!!J]11&E3B^:,4GZ!R1['#ZO\
M#>RN=TFF3&UDZ^6WS)_B*YPR>(O"<+6E[9K<:<QY21=\9^C#D'ZUZW2,JNI5
ME#*1@@C(-=/M;KEFKKS.2I@8-\U-\K\O\C@]'USPCJ6V.XL8;.<_PRCY3]&Z
M?GBNR?3["ZM(X'MX9+=.8UQE1]*P-8\ Z3J6Z2W4V<YYW1#Y2?=>GY8KE)=-
M\6>$%=[29Y;, Y:/YT ]2I^[4K"X>2?LTE?I8S4ZM'2K"Z[K]4>A#P]I .?[
M/@X_V:L76F6-\4-S:Q2E!A=R]!7CO_"8>(,?\A27\A_A7;_#[6-0U5;_ .W7
M33^64V;@.,YI2P4:<7[JMZ%T<70JS]G%?@=-%H6EP2K+'8PJZ'*L%Z&GW.D:
M=>3&:XLXI)",%F7FKM%8>QI6Y>56]#LY(VM8I6VD:=9S":WLXHY ,!E7D4R7
M0]+GE:66QA:1SEF*]36A11[&E;EY5;T#DC:UBI:Z98V)<VMK%$7&&*KU%5SX
M>T@G/]GP<_[-:=%#HTFK.*LO(.2.UBK%IME!;26T5K$L,GWT"\-]:K?\([H_
M_0/@_P"^:TZ*'1I-).*T\@Y(OH53IMDUD+,VL1MQR(]O JM_PCNC_P#0/@_[
MYK3HH=&E+>*^X'"+W15N--LKN*.*>UBD2/[BE?N_2JZZ!I*.KK80!E.0=M:5
M%-T:<G=Q5_0'"+U:*=UI5A?2"2ZM8I7 P&9><4R#1=-MIEFALH4D7[K!>15^
MBAT:;ES.*OZ!R1O>Q0N-%TVZF::>RA>1NK%>33[72K"QE,EM:11.1@LJ\XJY
M10J--2YN57] Y(WO8SGT#29'9VL("S').WJ:GMM-LK..1+>UCC63APJ_>^M6
MJ*%1IQ=U%7] 4(K5(S/^$=T?_H'P?]\U973;)+-K1;6(6[<F/;P:M44E1I1V
MBON!0BMD9G_".Z/_ - ^#_OFK,NFV4UJEK):Q-!']Q"O"_2K5%"HTEHHK7R!
M0BNAF?\ "/:1G_D'P?\ ?-6+K3+*]V?:;6*78,+N7H*MT4*C22:459^0<D=K
M&=%H6E0RK+'8PJZ'*D+T-27.D:?>3>=<VD4LF,;F7FKM%'L:5N7E5O0.2-K6
M*5MH^G6<PFM[.*.0# 95Y%,FT/2YYFEEL87D<Y9BO)-:%%'L:5N7E5O0.2-K
M6*EIIEC8LS6MK'$SC#%5ZBJY\/:022=/@R>?NUIT4.C2:LXJWH')':Q5ATVR
MM[>2WAM8DAD^^@7AOK5;_A'='_Z!\'_?-:=%#HTFDG%:>0<D>Q5.FV1LA9FU
MB^SCD1[>*K?\([H__0/@_P"^:TZ*'1I2WBON!PB]T5;C3;*ZACAGM8GCC^XI
M7A?I5=?#^DJP9=/@!!R/EK2HINC3D[N*^X'"+W14N]+L;YU>ZM8I648!8<@5
M'!HFF6TRS0V4*2(<JP7D5?HH=&FY<SBK^@<D;WL4;C1M-NIFFGLX9)&ZL5Y-
M.M=)L+*4RVUI%%(1C<J\XJY11[&GS<W*K^@<L;WL9SZ#I4DC2/80%F.2=O4U
M/;:;96:R+;VL<:R##A5^]]:M44*C33NHJ_H"A%.]C,_X1[2/^@?!_P!\U933
M;*.S:T2UB%N_WHPO!JU125&G':*^X%"*V1F?\([H_P#T#X/^^:LR:;92VB6L
MEK$T"?=C*\#Z5:HH5&DMHK7R#DBNAF?\(]I'_0/@_P"^:L76F65Z(Q<VL4HC
M&$W+]T>U6Z*%1I)-**U\@Y(]C.CT'2HI%D2P@5U.5.WH:DNM)T^]F\VYM(I9
M,8W,O.*NT4>QI6Y>56] Y(VM8HV^CZ=:3":WLXHY%Z,J\BDFT33+B9II;&%Y
M'.68KR35^BCV-*W+RJWH')&UK%2TTNQL79[6UCB9AABHZBH#X?TAF).GP9)R
M?EK2HH=&DU9Q5O0.2.UBK!IME;0200VL212??4+PWUJM_P ([H__ $#X/^^:
MTZ*'1I-).*T\@Y(]BK_9ME]B^Q_98OLW7R]O%5O^$=T?_H'P?]\UIT4.C2EO
M%?<#A%[HJSZ;97,$<$UK$\4?W%*\+]*KCP_I"L&&GP9!R/EK2HINC3D[N*^X
M'"+W14N]+L;YU>ZM8I648!9>@J.'1-,MYEFAL84D0Y5@O(J_10Z--RYG%7]
MY(WO8HW&C:==S&:XLXI)&ZLR\FEM=)T^RE\VVM(HI,8W*O.*NT4>QI\W-RJ_
MH')&][&=)H.E2R-(]A SL<L=O4U-:Z9960<6UK'$)!A]J]:MT4*C33YE%7]
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M?B&TV3#9<(/W4ZCE?;W'M6QO7^\/SHWK_>'YTU)Q=T3.$9QY9*Z/*],UC5/
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M[P_.C>O]X?G6)V"T5%/(!;RD. 0AP0?:N+^&^H7=[X?O9+V\GN)%G(5II2Y
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MM[;XQLMO!%$I\/@D1H%!/V@^E=K@>E<</^2RG_L7Q_Z4&NQH ,#THP/2BB@
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M;RKH#+P.>?J/45NUSRBXNS.Z%2-2/-%W08'I1@>E%%(L,#THP/2BB@ P/2C
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^-<OH'BF]\-7AT?74D$"':K-RT7I]5KTVL?Q!X<L_$%IY<XV3H/W4RCYD/\
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M^58'?<EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\?3-5T)ZG8T445)04444 %%%% !1110!QP_Y+*?^Q?'_ *4&NQKCA_R64_\
M8OC_ -*#78T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_BGPC9Z+;6U]H/GW<<>V23[)$VX^NXG-;OPXTV]LY=3O)K.:SM+EE\B&0'.
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MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ''#_DLI_[%\?\ I0:[
M&N.'_)93_P!B^/\ TH-=C0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!G:IH.F:PFV]M$D;M(!AQ]".:XC4/A[?6$WVK0KUBR\JC-L<?1AP?QQ7I%
M%:0JRAL<];"TJNLEKWZGF5IXYUK1)Q:ZY9O*!QEEV2?GT:NUTGQ/I.L@"UNE
M$I_Y8R?*_P"7?\*T;NRM;^ PW=O'-&?X77-<5JWPVMY29M)N#;R=1%(25_ ]
M1^M:7I3WT9S\F)H_"^=>>YWE%>6)K7BOPDXBU"%[BU' ,OS+^#CI^-=9I'CO
M1]3VQRR&SG/\$Q^4_1NG\JF5&25UJC6GC:<WRR]U]F=/12 AE#*00>01WI:Q
M.L**** "BBB@ K(\3ZP-#\/75[D>:%VQ ]W/ _Q_"M>N;\3^&Y_$=UIZ-<HE
MA;R>9-$0<R'/^&1^)IK<3.&72I_">GZ#XF&\RM)F]&>2K\C_ ,=R/J17K44B
M31)+&P:-U#*PZ$'H:IZSI<6L:-=:=)A5FCVJ<?=;JI_ @5#X<TZ[TC1(+"[N
M$G>#*JZ CY>PY].GX4-W!*QJT444AA1110 4444 %%%% !1110 4444 %%%%
M !1110 454U2Z>QTB\NX@ID@@>10PX)"DC-<'IOBKQSK%E]LL-&TZ: DKNSM
MY'7@R TTA7/1Z*Y7PEXNDU^2ZL[VU%M?VOWT&<$9P>#R"#U%<_I?C#QIK:S/
MINDZ=.D3[6/*X/\ P*04687/2J*XG1?&&J'Q&FAZ_IL5K=2KE&B/'3([G(.#
MR#UKMJ&K#3"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 <</^2RG_L7Q_P"E!KL:XX?\EE/_ &+X_P#2@UV- !1110 4444
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MAJ]DMY8^"-;FMV=T#K)  2K%6',@Z$$?A5O_ (3+6_\ H0M=_P"_EO\ _'*
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M:W_T(6N_]_+?_P".4 =C17'?\)EK?_0A:[_W\M__ (Y1_P )EK?_ $(6N_\
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M% !1110 4444 9,>AK'XLN->^T,6FLTM?)V\ *Q;=G\:UJ** "BBB@ HHHH
M*R-(T-=)U#6+M;AI3J5T+@J5QY>$5<#U^[G\:UZ* "BBB@ HHHH ***0$$D
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MV*]CHH YWP1X1M?!/AB#1[:0RLI,DTQ&#+(>K8_(#V KHJ** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!U).>>N/P-=-5#1=-32-%M+!,?N8PK$=VZL?Q.35^DQH****0!1110 4444
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9%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gbkyd1brmfwp000017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '?!.T# 2(  A$! Q$!_\0
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M47"S+M%4_P"UM._Y_K?_ +^"C^UM._Y_K?\ [^"BX69<HJG_ &MIW_/];_\
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MUKJX$*E2.])FR-*+I@U=@'KS56'@9(J_;J/O'O32*>P,B8)%9ERI4,<UK3L
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M ':L8+N(.:WM+91PH_&KW0D]3L-/E78!FM9>5S5+P]H-[JKJ8XV2#/S3,/E
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MR!6PK<$#O7O?PL4+X)A &/WS_P ZV4M+$*/O7.UHHHIEA1110 4444 %%%%
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ML*O6$1EEW8^4525<'%;MI$([?/<BA(B3LATIY7%7;%-TOTK-W9D..M;.EP%
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MRSQIH<L5Y]KC3=&WWL"E%:EMZ'B,@*-@C!]*6-RA)!K4U6R*WC/CY:R2X+'
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MR(W9)$/F'J:Z.T7;"-_3%8NFPB63S#T%:\K'A%H6B)EJ[$HE+OM0X7-6=HB
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MMB;5[TFR4NQ<5WCD+(NY3P:N0F-X]H[U5LY]T/EXP.].QY4F1P#3O835R65
M@(!JAM=7]C5TDR'VJ-V"L*EZE1=AD./,^8<4^90IP#E:5 -VXBFE<EAFI>P^
MH@7(W+TI[C='E>HI(0T38<?*:&;RY3C[IHZ">Y&WS1U .M6Y4PFY._6JF2.W
M![T,:V(9X]XSTQ5(H3D-5]LYQVJM(-K<"D(J>6$SFHG'>K,OS\TS;E>E,EE!
MUS4+PDC)K0,6!DTW9GMQ2$9GDY/3BH)HAYZX[5J,ISA1^-1- JG<>6IB,>YC
M:0A1TSS7KOP\C\KPI&O_ $U?^=>5RCYRW:O5_ )SX80_]-7_ )UI3>HF=111
M16Q(4444 %%%% !1110!5OSBV_X$/YUA9RQSZUO7V/LW/]X?SK!<C<?K6<MS
MHI?"-8CM4#G/%/;(Z5"ZN>:@T1"QP:C)8FI2I[U&PQT.318=Q1(1TJ&9SGYJ
M1WV<U0N;HC))IMDV*][<;01NKF+R<LYYXJY?WA9C@\5A7$X.<5DW=FT(V1'<
M2J:QIL%B:LRN2:IRMDU2"3(&ZT[H*,4$X%,@:.33U7/%,49JPHVC'>@H?&NW
MZU, W>F(<5.@+<FI&.521Z58MXM[C/04V.,EN1Q5XA((,#[QH$WT()3\W!X%
M1<NX6I"N%W-3]/C$EP7QD#I2W87LKFK:QM#" .]7D_=J7)R:BC9%'S'IVJ&]
MO$1/EZGM5/1$+5DLDY?Y%.6-;>G6OD1 EN2.:RM&LI)!YSKG-;Z0;!R<>U**
MZA)]"S',5(VKS4VYF<-)^55PVU>M2Q,7Q@9IMDV+,CAEQZ5&IX..M-D0KWZU
M(D;!<DT!LAT:;?G8Y/I3D3?+FFOG;@4L18)R"*0="R00::58GBDC+=3S3V8G
MVH)%7 '7FFE]W:G*A*YH (.<4!< .,&D*X-2G##CBHMV&YI,$(VW.!UJ%@0>
ME38YS2[2>32'<KK&2<DT,N[Z5.R\<&HF7O2&,V$,,#BG.@7YN]*6VGKFG#YN
M6I 1KN9\]JFR?NBF_P"[TH)/84"(W1,Y/)JO*K;OE'%6R,]:801T%2-.QX/8
MP'[:K#UKK';]VJCTKG[08N W3%:ZN6D&:FY;W)E7Y@35N%_WF!4! W YJ6/
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M@I/)[U<DB/F*F?NTM]17Z#47,RTYP&E"YQBGA<RX]*:VQI&QU[4.U@0Y3OE
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MGK2!:F5*9(JKQ3@V#0!2XYH%8<"2<FD?GBEZ=*502P%,1:@AV(".2:V[&#Y
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MSINYZUIV=]]D(E(!]J%JB)MK8YR\#V]T+>X3Y@.M([[(-H.5%:&M>7-="[#
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M2*S \T@9(<[ASQFMVQ_U!_WS6",9%;MAQ;G_ 'S_ #JX;DO8M4445H2%%%%
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MZ4L.7^X.!VK(O[&[>8O;L2O=:)-I:"BKO4V<D@",Y458#8&>QZUFZ7YL46)
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MSS43L,X!ITN0 %J+R^,FI92'!N.M)NYJ/;WIX7C-( 89IF12MP*8* /-8G<
M@FK<.54 'K5/:T<V".*O(!M#>E8+0ZF6-W'3%1[MZ-'BG%7)#?PTK#D;>M7<
MDIR1 C;T(IA0,NTCFK[H-X8_C4<D'5THL,I*C1 YY%2"-2F[/-3)N"$L,TW
M:,A1B@H2.(2?>J2./]YL%.1&C5>^:G("CC[Q%7$#&O8 ;E$SR36G"HC&WVQ5
M&-6FOM[?PU=4Y=O:A:ZFCV!AY8/.33D#.,GIZ4QO4U)TBRIHV*0A(/'\Z<W
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M3+1EB:I 64V 9(XK+U)P)!MP5I_VQA'^\X Z50?_ $C<X;@=*94-):BO<+/
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M1BK)E>QH!7OH0J_E)C&32VZF6X / 9A484/)Z9-7;=/LTX+?,:5[ERV.BN=
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M<TXN&IW$1D4#K2GFD%(8K'B@&D-,SB@"8OCBFDBH\Y/-2;<TP&E@!FH6F#'
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MQ%- R;)W;EZ=Z?YG''6H5([=Z1GPV*8BVDA*Y'XTPOB3)J-7*'(Z&C[S4@+
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MAL"1V&_Y>*5,LI/>HY'$@XX]Z16"$$-TI=1V(+J)G/<&I$@_<A7;!JT\L4B
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ML=C7;>'QC3 /]MOYUPXSD>QKN= .[3 ?]MOYU4=R9;&I1116A 4444 %%%%
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MBEL+<L.6 &>5J-0C.#GY:?DF/=V]*18U<C'%,!)%59..13#C.,<5(Z;?PH;
M7<10(@1O,<J.U3@!D*/U'2HPH.63@TL62V">:!CXE8'CM5B1@RCCI4!) XJ0
M99,4P)8Y%'!J8[<BJ2P,PR3TJP&R@5QR.AIE%A<*^X#BK"O\I(Z52CD9<KV-
M2Q[O6A#)3-S\OXU+]\ ]A51B%?)%6(ASG^$T6*Z%R,@IP,5.BX4-5:)B3M%6
M%D)&T]J1);0KD$T]Y% ''-58R=V>U6F=2/F7GM02P+GM4ZOF/K@U BAR!^5.
M9BK[32'N3X= ,<@]:E18BO"X)ZFH(WRA]:EB1BN[-,3)4&W.*4-\^<8/K3E
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?"K4#-DFD!'DGK2]J <T#K2 8"12$\T\CFHRO- '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gbkyd1brmfwp000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '> V(# 2(  A$! Q$!_\0
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M6.)"ZH&=@H+,P51SW+$ #N2!4E% !1110 4444 %%%% !1110 4444 %%%%
M!1110!'//#:V\MQ<2QPP1(7DDD8*J*!DDD\  =ZDHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (X)X;JWBN+>6.:"5 \<D;!E=2,@@C@@CO4E%% !
M1110 4444 %%%% !1110 4444 %%%% !4<,\-RA>"6.5 [(61@P#*Q5AQW#
M@CL014E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%075Y:V
M,7FWES#;QD[=\T@09],FJ8\1Z&2 -9TXD]!]J3_&@"^(56X><&3>Z*A!D8KA
M22,+G /S') R>,YP,25#$SRRM*DT4EJZ+Y81>=V3N.[.""-N!@8P>3GB:@ H
MHHH **** "BBB@ HI&944LQ"J!DDG@"H9[ZTM8%GN+J"&%R LDD@56)Z8)H
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M6W$MWHWA2YG&)IKB&208QABH)_6A >@UQWQ*NEA\++;M)L%U<1QMZ[1\Q/\
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MH/#?Q$LX+%1!9ZI PDA7[@=<D$#MV'XFI]#?[)\1/$5I(5!N4BGCSU8 =O\
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MD].2!ZD4 2445'#(TJ%GADA(=EVN5)(#$!OE)&"!D=\$9 .0   F^T.S21F
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MD$84\YR<DC (^4Y(XR 245'-(T2!DADF)=5VH5! + %OF(& #D]\ X!. 9*
M"BHX)&FMXI7AD@=T#-%(5+(2/NG:2,CIP2/0FB.1G>96ADC$;[59BN)!M!W+
M@DXR2.<'*GC&"0"2BHS(PN$B$,A1D9C*"NU2",*><Y.21@$?*<D<9)I&B0,D
M,DQ+JNU"H(!8 M\Q P <GO@' )P" 2445'#(TJ%GADA(=EVN5)(#$!OE)&"!
MD=\$9 .0 "2BHQ(QN'B,,@145A*2NUB2<J.<Y& 3D ?,,$\X))&1X56&202/
MM9E*XC&TG<V2#C( XR<L.,9( )**CGD:&WEE2&2=T0LL494,Y ^Z-Q R>G)
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M8!'RG)'&2:1HD#)#),2ZKM0J" 6 +?,0, ')[X!P"< @$E%%1P2--;Q2O#)
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MD@8Y( R,Y !)1110 4444 %%%% !1110 4444 %%%% !1110!'/"MS;RP.9
MDB%&,<C(P!&.&4@J?<$$=JDJ.<S+;RM;QQR3A"8TD<HK-C@%@"0,]\''H:DH
M **** "BBB@ HHHH **** "BBB@ HHHH **** (X(5MK>*!#(4C0(IDD9V(
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M!+147V:#_GC'_P!\"C[-!_SQC_[X% $M%1?9H/\ GC'_ -\"C[-!_P \8_\
MO@4 >=_VGJ'_ #_7/_?UO\:/[3U#_G^N?^_K?XU5HK\Z]M5_F?WGV/LH=D6O
M[3U#_G^N?^_K?XU:T[4;Y]3M$>\N&5ID!!E8@C(]ZRZM:: =4LP0"#.@(/\
MO"M*-:I[2/O/==2*E.'(]%L>DT5%]F@_YXQ_]\"C[-!_SQC_ .^!7Z"?(BR3
M+$\*,)"97V+MC9@#M+?,0,*,*>3@9P.I ,E1?9H/^>,?_? H^S0?\\8_^^!0
M!+147V:#_GC'_P!\"C[-!_SQC_[X% $M%1?9H/\ GC'_ -\"C[-!_P \8_\
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M .!WP!DDY) )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHI8A('9L#T !)/L.:=YZ?W9/^_;?X4 2T5%YZ?W9/^_;?X4>>G]V3_OVW^%
M$M%1>>G]V3_OVW^%'GI_=D_[]M_A0!+147GI_=D_[]M_A1YZ?W9/^_;?X4 2
MT5%YZ?W9/^_;?X4>>G]V3_OVW^% $M%1>>G]V3_OVW^%'GI_=D_[]M_A0!+1
M47GI_=D_[]M_A1YZ?W9/^_;?X4 2T5%YZ?W9/^_;?X4>>G]V3_OVW^% "P&9
MK>)KB...<H#(D;EU5L<@,0"1GO@9]!4E017D4T*2JLX5U# / ZM@^H(!!]CS
M3O/3^[)_W[;_  H EHJ+ST_NR?\ ?MO\*//3^[)_W[;_  H EHJ+ST_NR?\
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M HHHH **** "BBHX8(;9"D$4<2%V<JBA069BS'CN6))/<DF@"2BBB@ HHHH
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M\RVUO+.XD*1H781QL[$ 9X502Q]@"3VJ2B@ J.&99T+H)  [)\\;(<JQ4\,
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MF11(#$^QMT;*"=H;Y21AAAAR,C.1U! 9)=;+I+?R9F9T9PRI\F 0#EN@/S#
M)R><9P<3T4 5IKOR$#O;7!!=4^1-YRS!1PI)QD\GH!DG !-2>:__ #[R?FO^
M-2T4 5H+O[3;Q3I;7 21 ZB1-C $9Y5B"I]B 1WHCN_->9%MK@&)]C;DV@G:
M&^4DX888<C(SD=00+-% %8W>VX2 VUQO=&<$)E<*0#ELX!^88!.3SC.#@FN_
M(0.]M<$%U3Y$WG+,%'"DG&3R>@&2< $U9HH B\U_^?>3\U_QJ.&[\]"Z6UP
M'9/G38<JQ4\,0<9'!Z$8(R"#5FB@#RO<"Y7G( /0XY]_PH+!2H.?F.!@$]L\
M^G2EHK\VTN?::B,P1&8YPHR< D_D.M6]-.-4LR 3^_3@=_F%5:M:9_R%K/\
MZ[I_Z$*THV]I'U1%3X)>AZ!#=^>A=+:X #LGSIL.58J>&(.,C@]",$9!!H%W
MNN'@%M<;T17)*87#$@8;."?E.0#D<9QD9LT5^BGQQ6DN_*>%&MK@F5]B[4W
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MP<6:* *TUWY"!WMK@@NJ?(F\Y9@HX4DXR>3T R3@ FI/-?\ Y]Y/S7_&I:*
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M44 %%%% !1110 4444 %%%% !1110!'!!#:V\5O;Q1PP1($CCC4*J*!@  <
M =JDJ."-H;>*)YI)W1 K2R!0SD#[QV@#)Z\ #T J2@ HHHH **** "BBB@ H
MHHH **** "BBB@ J.&"&V0I!%'$A=G*HH4%F8LQX[EB23W))J2HX8VB0J\TD
MQ+LVYPH(!8D+\H P <#O@#))R2 24444 %%%% !1110 4444 %%%% !1110
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M9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\
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M +]G_&C;/_STC_[]G_&@"6JVH65IJ%FT%Z@>WR'92Q .TY&<'ID=#Q4FV?\
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M226P !WJ3;/_ ,](_P#OV?\ &@"6BHML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&@"6BHML_P#STC_[]G_&C;/_ ,](_P#OV?\ &@"6BHML_P#STC_[]G_&C;/_
M ,](_P#OV?\ &@"6BHML_P#STC_[]G_&C;/_ ,](_P#OV?\ &@"6BHML_P#S
MTC_[]G_&C;/_ ,](_P#OV?\ &@"6BHML_P#STC_[]G_&C;/_ ,](_P#OV?\
M&@"6BHML_P#STC_[]G_&C;/_ ,](_P#OV?\ &@!8)&FMXI7AD@=T#-%(5+(2
M/NG:2,CIP2/0FI*K03&ZMXKBWNK>:"5 \<D:[E=2,@@AL$$=ZDVS_P#/2/\
M[]G_ !H EHJ+;/\ \](_^_9_QHVS_P#/2/\ []G_ !H EHJ+;/\ \](_^_9_
MQJ1<[1N()[D#% "T444 %%%% !1110 4444 %1PR-*A9X9(2'9=KE22 Q ;Y
M21@@9'?!&0#D"2HX9X;E"\$L<J!V0LC!@&5BK#CN&!!'8@B@"2BBB@ HHHH
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M@?H>DT445^BGQP45')"LKPNQD!B?>NV1E!.TK\P!PPPQX.1G!Z@$24 %%%%
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MVI(RC*+T!^E=;7"7_P#R$KK_ *[/_,TT!9_MW4O^?G_QQ?\ "C^W=2_Y^?\
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M?\*EHH B\I_^?B3\E_PH\I_^?B3\E_PJ6B@"M.R6MO+<7%Z88(D+R22%%5%
MR221@ #O4GE/_P _$GY+_A4M% $7E/\ \_$GY+_A1Y3_ //Q)^2_X5+10!%Y
M3_\ /Q)^2_X4>4__ #\2?DO^%2T4 1>4_P#S\2?DO^%'E/\ \_$GY+_A4M%
M$7E/_P _$GY+_A1Y3_\ /Q)^2_X5+10!%Y3_ //Q)^2_X4>4_P#S\2?DO^%2
MT4 1>4__ #\2?DO^%'E/_P _$GY+_A27:3RVDL=K.L$[+A)6CWA#Z[<C-<SX
M7FCTK3-=EO+IWCMM1F,DTIRS85>3[GT%,#I_*?\ Y^)/R7_"CRG_ .?B3\E_
MPKD=&^VR>.VNK_<DMSIAD6W;_E@GF@*GUP,GW)KI-4TZ'48HQ<K+-#$WF&U4
MKMG('"L#U&>0"0,@9Z46$30,EU;Q7%O>F:"5 \<D91E=2,@@@8(([U)Y3_\
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M#KSRO0Z3&>64445^:'V@5:TS_D+6?_7=/_0A56K6F?\ (6L_^NZ?^A"M:/\
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M\**** "BBB@ HHHH **** "BBB@ J.&%8$*(9""[/\\C.<LQ8\L2<9/ Z 8
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M= 0?]X5I13]I%^:(J/W)+R/2:*K0BRN4+P"WE0.R%DVL RL58<=PP(([$$4
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M[U^\U6\M/L\,ELMHEO(59G4$LS/M)7J< 9/ YQ6'_P )1,7*"UL-P )7RSD
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M6-'F?9$K, 7;:6POJ=JL<#L">U $E%1SSPVMO+<7$L<,$2%Y))&"JB@9))/
M '>I* "BHX9X;E"\$L<J!V0LC!@&5BK#CN&!!'8@B@3PM</;K+&9XT5WC##<
MJL2%)'4 E6P>^T^E $E%1S3PVR!YY8XD+J@9V"@LS!5'/<L0 .Y(%24 %%1P
M3PW5O%<6\L<T$J!XY(V#*ZD9!!'!!'>B.>&9YDBEC=X7V2JK E&VAL-Z':RG
M![$'O0!)1110 4444 %%%% !1110 45&(56X><&3>Z*A!D8KA22,+G /S')
MR>,YP,24 %%%% !1110 4444 %%%% !1110 4444 %%%1F%6N$G)DWHC( )&
M"X8@G*YP3\HP2,CG&,G(!)1110 5PE__ ,A*Z_Z[/_,UW=<)?_\ (2NO^NS_
M ,S30%>BBBF(*]#KSRO0Z3&>64445^:'V@5:TS_D+6?_ %W3_P!"%5:M:9_R
M%K/_ *[I_P"A"M:/\6/JB*GP/T/2:***_13XX**CDA65X78R Q/O7;(R@G:5
M^8 X888\'(S@]0")* "BBB@ HHHH **** "BBB@#EO&7_+E_VT_]EKE:ZKQE
M_P N7_;3_P!EKE:^(SC_ 'V?R_)'T^7?[M'Y_FPHHHKS#M.^\.?\@"V_X%_Z
M$:U:RO#G_( MO^!?^A&M&:%9T".9  ZO\DC(<JP8<J0<9'(Z$9!R"17Z#@O]
MVI_X5^1\EB?XT_5_F24445TF 4444 %%%% !1110 4444 %>65ZG7EE?-<0_
M\N_G^A[63_;^7ZA1117S1[1J^'/^0_;?\"_]!-=]7GNAPK<ZM% YD"2)(C&.
M1D8 HPX92"I]P01VKT*OKL@_W:7^)_DCY_-OXR]/U84445[AY84444 %%%%
M!1110 4444 %<7XN_P"0M%_UP'_H35VE<7XN_P"0M%_UP'_H35Y&=_[H_5'H
M99_O'R9@4445\8?2!7?>'/\ D 6W_ O_ $(UP"J$15&<*,#))/YGK7?^'/\
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M +=1D3?:$99(Q $8.A0EBV1M(;.  -V1@YR.1CF2H)+R"*Z2W=RLCHSCY3M
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MF#_GM'_WV*/M,'_/:/\ [[%?H)\B+()B\)BDC5 ^90R%BR[3PIR-IW;3D@\
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MWW2.".*V%T'5M:\4OJ\L]_H,%I9I:V,</V9W(?#RE@RR*O(1./[AY((KM:*
M. TK1_$/A[3-0T==/BUC24OW98[EH@]W:3*6=5&50.LC-E6"JRG QUJ"'PI*
M9=<NM(\.G0;>[TB6S:PW0I]IG/W'V1.T:[1N7<2"=YR !D^C44 8.E:-?P6V
MF/+J]] (+:*.2P18#$65 ""WEE^OH_TK!OM+U?4;2307\.VUL&U1;H:I:M$E
MN$642B4)N\WSB!M/RX+$G=MKO** //#H6M_V0_A(:839/J9G&I>;'Y0MC/\
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M!$F]T9P1&Q7"D Y;& ?F& 3D\XS@XDHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %%%% $<$RW-O%.@D"2('421LC $9Y5@"I]B
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M2HX8VB0J\TDQ+LVYPH(!8D+\H P <#O@#))R2 24444 %%%% !1110 4444
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M<(3&DCE%9L< L 2!GO@X]#4E1SS+;6\L[B0I&A=A'&SL0!GA5!+'V )/:I*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@". S-;Q-<1QQSE 9$C<NJMC
MD!B 2,]\#/H*DJ."9;FWBG02!)$#J)(V1@",\JP!4^Q ([U)0 4444 %%%%
M!1110 4444 %%%% !1110 5'"9F0F>.-'WL $<L-NX[3D@<E<$C'!)&3C)DJ
M.&99T+H)  [)\\;(<JQ4\, <9'!Z$8(R"#0!)1110 4444 %%%% !1110 44
M44 %%%% !14<,$-LA2"*.)"[.510H+,Q9CQW+$DGN230((5N'N%BC$\B*CR!
M1N95)*@GJ0"S8';<?6@"2BHY((9GA>6*-WA??$S*"4;:5ROH=K,,CL2.]$\$
M-U;RV]Q%'-!*A22.10RNI&""#P01VH DHHJ.&"&V0I!%'$A=G*HH4%F8LQX[
MEB23W))H DHJ,00K</<+%&)Y$5'D"C<RJ25!/4@%FP.VX^M$D$,SPO+%&[PO
MOB9E!*-M*Y7T.UF&1V)'>@"2BHYX(;JWEM[B*.:"5"DD<BAE=2,$$'@@CM4E
M !14<,$-LA2"*.)"[.510H+,Q9CQW+$DGN230((5N'N%BC$\B*CR!1N95)*@
MGJ0"S8';<?6@"2BHY((9GA>6*-WA??$S*"4;:5ROH=K,,CL2.]24 %%1P00V
MMO%;V\4<,$2!(XXU"JB@8  '  ':B."&%YGBBC1YGWRLJ@%VVA<MZG:JC)[
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MGD14>0*-S*I)4$]2 6; [;CZT200S/"\L4;O"^^)F4$HVTKE?0[689'8D=Z
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M!)XHY4#JX5U# ,K!E//<, 0>Q - $E%%1P00VMO%;V\4<,$2!(XXU"JB@8
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MXP9* "BBB@ HHHH **** "BBB@ HHHH X?P7HNEWF@WLES:PS//<RI(TB@D
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MWR6,DGF/8I/B!CG.,8SCVS0!C:9IFDZCIOA>RU66?[6MLTD%NI*JZD9.3CT
MXR/RJW!:1>'_ !W96&F;HK.]MW>:V#$HI7.& /3/2M_5=!L]6BMUE\R&2V;=
M!-;ML>(_[)_ 4S2_#UKIEW+>>;<75Y*NUKBZDWOM_NC@ #Z"G<+&M1114C"B
MBB@ HHHH **** (YXVFMY8DFD@=T*K+&%+(2/O#<",CKR"/4&I*CG,RV\K6\
M<<DX0F-)'**S8X!8 D#/?!QZ&I* "BBB@ HHHH **** "BBB@ HHHH ****
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gbkyd1brmfwp000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W N4# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *K:A_P @VZ_ZXO\ R-6:K:A_R#;K
M_KB_\C0!Y9^SM_R3RY_["$G_ * E>N5Y'^SM_P D\N?^PA)_Z E>N4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%Y>VNGVSW-Y<Q6\"
M?>DE<*H_$T 3T5E:5XET/76=-*U>RO63EE@G5R/P!J?4-9TO23&-1U&UM#)G
M9Y\RINQUQD\T 7J*S++Q'HFHW(MK'5[&YG8$B.&X5V('7@&M.@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JVH?\ (-NO
M^N+_ ,C5FJVH?\@VZ_ZXO_(T >6?L[?\D\N?^PA)_P"@)7KE>1_L[?\ )/+G
M_L(2?^@)7KE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9VJ:U::1Y7VE;@^9G;Y,#2=/7:#BM&B@#FU\<Z,SLBB]
M+IC<HLY,KGID8XK<L;V+4+..Z@$@CDZ"1"C?B#S6/I'_ "-WB/ZVW_HLUT%
M!1110 4444 %%%% !15+4M*LM6A6&]A,B(VY0'*X/X$5F'P9X? )-D<#D_OI
M/_BJ (_%OB;_ (1Z&V$2J\\L@)0_\\Q]X_T%;]M<17=M%<0L&BE4.I'<&O#=
M45)M3N'LK26.UWD1*0Q^4=^?7K74>!],TS55N+34;*0W$?SHY=URO3'! X/\
MZ /3Z*P!X+T $$63<<_ZZ3_XJM\# P.U !7#>,_ EQXR\3Z'+>W43>'[$M)<
M6)+!II.<'CC'3OTSZUW-<-\1?B O@ZUMK*Q@6[UW4#LL[<G"CG&]CZ9_/\Z
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M_D;/#?\ OW'_ **-=!7/ZQ_R-GAO_?N/_11H Z"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y[1_P#D;O$?UMO_ $6:Z&N>T?\ Y&[Q'];;_P!%
MFNAH **** "BBB@ HHHH *9+((H7D()"*6('M4=TMTT8%K)'&^>3(A88_,5G
MW46K_8Y]UU:D>6V<0GT^M92J.+MRM_=_F7&":O=(SAXVMV4$6%S@C/WD_P :
MNZ7XEAU2^^RK:S1,4+AG*D<8]#[UP<?^J3_='\JU?#RW#:Y&+:2-)/)?EUW#
M'%>%A<VKU:ZIR2MKMO\ F>M7R^E"DYIN_P#7D>A45G>5K&?^/NT_[\G_ .*K
M1KWX3<MTUZGDRBH[.X5YY\5M>UK2X-!TSP_>?9-1U74%MUEV!L+CG@CU9:]#
MKS[Q[X"A\;>(]$>;Q U@MD'/V:' FD#8R4.<C[N,X-601:9X5^(MOJEK/>>/
M(;JTCF5IH19*/,4'E<]LBJWBC7?$?B'XA#P5X8U%=+2UMQ<ZC?>6'=0<850?
M8K^?MSS7B[PT/A+?:-XB\,:A>I!+>):WEE/,9%F5N?Z']",5O^$/D^/7C=).
M)&MX'0'KMPG^(H E\-:WXC\-?$)?!OB?4UU2"^MS/IU\8PCDC.48#V!_(>M>
MF3SPVMO)<7$BQ0Q*7>1S@*HY))]*\L\;_/\ ''P$D?\ K%2=FQ_=P?\  UWG
MC+_D2-=_Z\)__0#0!!<^/?"5F;<7'B+38_M""2+,Z_,IZ'Z>]2ZEXT\,Z//%
M!J.NV%M+*H=%DG7)4]#]#ZUY;X,\!>'9_@=/J%UIL%Q?7=E/.US(@:1"N[;M
M/5<;1TH\ ^!_#]]\%)M0OM-@NKV[MIY&N)5W2)MW! K'E<!1TH ]I:[MEL_M
M;7$0M@GF><7&S;UW;NF/>L*W\?>$;M)W@\1Z:ZVZ[I3]H4;5R!GZ9(YKP^2[
MN=1^$/P_T*6>1+/4]3-M<NIQF-92 N?3G/\ P$5V7Q?\ ^&;+X:W-Y8:7:V-
MQIWEF&2",*S L%*L1RV0>^>E 'KT,T=Q!'-"ZR12*'1U.0P(R"/:GUE>&/\
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MA"3_ - 2O7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N?UC_D;/#?^_<?^BC705S^L?\C9
MX;_W[C_T4: .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>T?_
M )&[Q'];;_T6:Z&N>T?_ )&[Q'];;_T6:Z&@ HHHH **** "BBB@ ILB+)&T
M;?=8$'Z&G44 8 \'Z4  /M&!_P!-VJU8>'K#3;K[3;B7S-I7+R%A@_\ ZJU:
M*RC0I1?-&*3]$:.K4:LY/[PHHHK4S"N$\=^!+W7]6TOQ%H&H1V&OZ9D0R2KF
M.1#GY6Q]3V/!(KNZ* /+4\#>+O%>OZ=?>.M0TW[!ILOG0V&G*VV20="Q;_Z_
MIQFM+Q9X(UF7Q9!XN\):A;6FL)#Y%Q#=*3#<Q]@<<YZ?D.1BO0** //?"O@G
M7!XNE\7>+[^VNM5\GR+6WM%(AMD/7&><]?S/)[=CK]A)JOA[4M.A=$ENK:2%
M&?.T%E(!..W-:-% ')>'O"MYI'PQC\,330/>+92VYD0GR]S;L'D9Q\P[4WPI
MX4O=!^&L?AJXG@DNUMYHC)&3LRY;'49Q\P[5U]% 'C6K>#]*\/\ PCTCPWXJ
MU:.SNH[P_9-0MT9TBG+,R]@<8R#G%8/Q0TWQ?!X$8^*/%FGW-K&R"UM[2'#W
MCY&"YXZ#)XR.*]SUK1--\0Z7+INJVD=U:2XW1OZCH0>H/N*Y72_A!X,TG48;
MZ+3I)Y8#F$7,[RK&1TPI./SH ZG0(7MO#FEP2 AXK2)&![$( :T:** "BBB@
M HHHH *\!T;P59?$;XD^+Y/%5Y=--I]UY4%FDNTB/)"G_=P!T]:]^KYZ_P"$
M;U[XH?$OQ#J5KJRZ(FDS_8DE@0K*P!(&2I!/3J3Z#M0!VO\ PH'P-_SPO_\
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M .@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>T?_D;O$?UMO\
MT6:Z&N>T?_D;O$?UMO\ T6:Z&@ HHHH **** "BBB@""ZLK6]0)=VT,Z*<A9
M4# '\:J'P]HQ!']E67/I O\ A6E14N$6[M%JI.*LFSQK5_!FKZ=?/'!:2W5N
M6_=R1+NR.V0.AKJ/!O@QK99;O6;2)FD7;'!*H?:.Y/;-=[17+3P%&%3VB7^1
MW5<TQ%2DJ3>G?J9W]@:-_P! FQ_\!U_PK1HHKJ48QV1P2G*7Q.X5S/Q"UE_#
M_@#6M2C;;+';%8SZ.WRJ?S85TU4=7T?3]>TV33M4M4NK.4@O$Y.#@Y'3W JB
M3E_A+HB:'\-=(B"XEN8OM<Q/4M)S_+:/PJ)?&&AVWQ3N]"U#2K?3]1^SJT&I
MS% ;I2 =H;&?7C/\)KM[>WBM+:*V@C$<,*".-!T50, ?E63X@\):!XIBC36]
M+@O/+SY;."&7/HPP?PH \V\17%GKOQ\\+)H<D<]U81.^H30$,$3!PK$=\$C_
M ($*](\9?\B1KO\ UX3_ /H!I?#_ (1T'PK%)'HFF06GF?ZQD!+/]6.2:U+J
MU@OK.:TN8Q+!.ACD1NC*1@C\J /.O!"A?V?H< #.EW)/_D2F?#@ ? 6#  S9
M7)/YO7?6FB:;8Z(-&M;1(].$;1"W&=NQLY'KSDT6.AZ9IFBC1[*S2'3PC((%
MSMVMG(]><F@#YX$<EK\(? .NM$\ECI>K-+=!1G"F4\D?\!Q^-=W\8?&OARZ^
M&5U:VFJ6EY/J(C%O'#('; 8,6('0 #OWKH_%6EZCX;\%0V?@O1;2XMX)OW^F
M2)O$T#9+JH)ZY.?SKS'5=/MO$^G2:'X1^&E[H]]?.BW5[>VOE) @8$A6/T'3
M'':@#W+PQ_R*>C?]>,'_ *+6M6J]A:K8:=:V:G*V\*1 ^H4 ?TJQ0 4444 %
M%%% !7SX= \3>.?B9XCAT/Q9J=GI%E<E99FG<!7).8XT5N0,$=N!7T'7BFH6
MOB_X8>,]8U?1-&;6] U>7[1+!""7B<G)Z9(Y)YP01[B@#)\:?#CQIX:T"YUC
M3O'.JWT=JADFB>>2-P@ZE?G(..N*C@U#Q=X%TO0_&">*+G7?#=^T8N(+PL7C
M#_[Q.",$9!ZCWK1UGQGXZ^(FFS>']%\&W6F0WB^5<7=WN 5#]X9*@#]3Z"K/
MB?PCXCO;'P]\.M,T\G0[5(9+W57X5B"VX#^>!D\@<4 >U*P= RG((R*6D10B
M*B]%&!2T 0W5W;V-K+=7<\<%O$NZ261@JJ/4D]*X;QIX(@^).FQ75GXEO(;5
M[?$,=M*&MICDD,RC[WI7;:A86VJ:=<V%Y&)+:YB:*5#_ !*PP17F%K\./&VB
MZ;+H6A^-8X=$8L(Q-:[IX5;JJM^?0C\* .$U37;C6?@'Y-S;00MHVKQ6DGV=
M-J,B]#@<9^;GUZ]Z]Q\5W,*?#O6+AB/)_LR5L]B#&<50T_X;:'8> )O"&));
M2X4F>9B/,>0X._V((&/H*Y63X7^,+W28?#6H>-%E\.1D*42VQ.\:GA"WIT[G
MI0!R%@K6FE?!R:?*Q?:Y1D]BT@V_S%>B?'.1$^%6HJ_626%4'J?,!_H:V?%/
M@#3/$?A&WT&-FLELMC6,T7WH&084^XQUKFQ\-O$VO7^G#QGXHCU+3-/D$J6L
M%OY?GN.AD/?]>_K0!=U^R^(#:/H$?@^\L[=8[-5NQ<A<EMJXQE3[US5SI_QP
M%K,9=6T<Q^6V\!4Z8Y_@KVFJVH?\@VZ_ZXO_ "- 'E/[.F__ (5_>;B-O]HO
MM_[X2O7Z\C_9V_Y)Y<_]A"3_ - 2O7* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HKB_$NAG3= OK^WUC6!-$NY<WKE021V_&MG3_#L=I<0W0U/596
M49V37C.AR.X/6@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y_6/\
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MJ2< 4 +16)-XITU93#:-+?SCCR[-#)^9' _.H_.\2:A_JK>VTN(_Q3'SI?\
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MP/=;D'-S: A&]^A7\FKU7PYK<7B3P]9:Q#!+!'=1[UCE^\O)&#^5 &I1110
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MX4X:3IHZ:?:?]^5_PH_>^0?N//\  B/B#1AUU6R_[_K_ (TP^(]$'_,6L_\
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M: -.BBB@ HHHH **** "BBB@ JMJ'_(-NO\ KB_\C5FJVH?\@VZ_ZXO_ "-
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M@D(^C'&?3-9OB?0M7^%5K9>*=-\2ZKJ$$5Q''J5M?2^8LR,<$@=CV]LCGCD
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M^TYKGC3[1Y1_SVE^1/\ $_A1_9DUSSJ%V\H_YXQ?(G^)_&L?;\W\-7_!??\
MY7-/9<OQNWY_=_G8\\ &6Z?>;^9JYI!E36[,P1H\F]L*S;1]T]ZLZEX;O-*T
MZXNS-;/%#E@@# XSP/UK5TKPS>VFIVUW+<6[1QDL50-DY4CO]:^?I9;B8XI5
M&K*][W1Z]3&T'0Y$];>9M;=9DZR6< _V59S_ $H_LZ[D_P!=JDY]HD5/_KUI
M45]!]7B_B;?S9Y'MI=$E\D9W]B6C<S&><_\ 369C_6IHM,L8?]7:0K[[!5NB
MJC0I1=U%?<)UJCT<F( %&  !Z"EHHK4S"BBB@ HHHH **** "BBB@"*XN8;2
M!I[B5(HD^\[G %4/^$DT3_H*VG_?T5I.B2(4=593U##(-8&IVEL/$>AJ+>$*
MS3Y 08/[N@#7L]3L=0W_ &.[AGV8W>6X.,U:J.*"&'/E1)'GKL4#-24 %%%%
M !1110 4444 %%%% !1110 4444 %%%,>6.,9=U4>K'% &'I'_(TZ_\ [T'_
M * :WZX7PYXDMKOQEJL?"QW9'DN3][8,?J.:[D$$9!!'J* %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /&?&M_9Z7^T)X5O+^YBMK6.QDWRRMM5<K*!D_4@51^,WBK0-7M_#0T[6;*
MZ,&J))*(9@VQ<=3CH*]+\3?#KPSXOOXKW6K!KB>*/RD83.F%R3C"D=R:Q/\
MA1W@#_H#R?\ @7+_ /%4 ;__  L+P=_T,VE?^!2_XUO65[:ZC9Q7EE<1W%M*
M-T<L;;E8>H-<%_PH[P!_T!Y/_ N7_P"*KMM'TBRT'2;;2].B,5I;+LB0L6P,
MYZGGO0!>HHHH **** "BBB@ HHHH *K:A_R#;K_KB_\ (U9JMJ'_ "#;K_KB
M_P#(T >6?L[?\D\N?^PA)_Z E>H:G#//9E+>_-B^0?."*V!Z8;CFO+_V=O\
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MXZ@\CG_ZU=5'IFGQ?ZNQMD_W85']*>@M3,/C3PZ#@:K"Q]$!;^0II\::,?\
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MH **** "BBB@ HHJCJ%[=6GE_9M-EO-V=WER*NW_ +Z(H I:7_R,^N_6#_T
MUMUREI<ZO;ZMJ%X?#]R5NO+VJ)H\KM7'/-=):32W%JDLUL]M(W6)V!*_B.*
M)Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3_&O8Z* /'/^%9_$C_HI5Q^4G^-9?B3P7\1/#_AO4-7F^(EU-':0-*T:EP6
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ME\0_#'A:_P!9G^(=W<1VJ!FB1G4ME@.N?>O?:XCXO_\ )*-?_P"N*?\ HQ:
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M7L'A/]GM;-%GG[.5*Y_#O5JO%M<T*Q^%GC[PSJGAX2VNG:K<_8+VS$C-&V[
M5N3U&<_\!]S7M- !1110 4444 %%%% !1110 5'-)#&F)WC56X^<@ ^W-25X
MK\9+G2;WQQX3T77;L6VD(LUU>.7*_+C ''.3M(XYYH ]AMY+&,"&V>W4$\)$
M5'Z"K->1^ _#OPKN]>AO_"MX\VHV9,BHUQ(&'!&=CXR.:]<H **** "BBB@
MHHHH **** "HA+;W)F@$D4I3Y98P0VW/9A_C7,^.+_Q5;6EK:>$M.CN+V[=D
M>YF.([50!\Q]>O'TZ&N*^!UO=VFI>-;>_NC=WD6HK'/<$G]XXW@MSZF@#UEF
MM-.MLLT%K O<D(H_I4D4T4\2RPR))&WW71@0?Q%>/MI</Q*^+VMV>MF6;1=
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MM:S='4?$M_S=7;'(0'^!/;IS[#H!5?7?@YX?\0>(KK7+J_UB.]N2"Q@N54*
M ,#Y20,#UI^B?"'0]!UJUU2VU/6Y9K9]Z)/=AD)P1R-HSUH R/@ZPL=;\;Z-
M,0MW#JSS%">2C$@-CTX'YBC1V74_VC=;NK=@\-AI:6\CJ<@.2OR_7[WY5T?B
M7X9Z-XCU<:PMS?Z7JFS8]UIT_E/(OHW'/'%:GA+P;I'@S3Y+32HY"TS^9//,
M^^29O5C0!T%%%% !1110 4444 %%%% 'GWCOQ[>:=J4/A;PM:_;_ !-=KE5Q
ME+53_&_;IS@\=SV!N> ? $?A*.XU"_N6U#7[\[[R]?DDGG:N>V?S_(#.U?X+
M^'=9U^\UJ>_UF.\NY"\AAN54#/8?)G' XSVJSX?^$VB^&]<MM6M=2UF:>W+%
M4N+L.ARI'(VC/6@"+P/8^ =7O=;OM"TQ&O!=,EZ;N,LX<Y)P')P"<],9P?2L
M#P+;6NF?'/Q9I^A!4TD6R/-%'_JXYOEX Z<$OQVY':NEUOX3Z+JVM3ZO9WVI
MZ/?7/_'P^FW'E";U+#'4^U;GA/P;H_@S3Y+3287!F;?//*VZ29O5C_D4 =!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZVA@%MIUO,I#=,%N0,X!;G'5N.E &Y\1-;3P)X4TNW70(-2T'<EI=I*-PBC
M 'RXP<@'KWQZUY?X\L/A0?#LFK>&=1%OJYVM;06<CG+9'#(?N_7BOI&>"&Y@
M>"XB26)QAXY%#*P]"#UK#M/ WA2PO1>6OAW3(;A3E9%MERI]1QQ^% ">!'U.
M3P+HKZR9#J#6JF8R_?/IN]\8S70T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !29HHH ,T9HHH ,T9HHH ,T444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>gbkyd1brmfwp000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )W I0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM1WT/0:Y;Q[K5]H6APW-A(L<K7 C)*AN-K'O]!7#:E:_\(S!#J6D>*DN[E7
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M_H+5CZ!\1M-TK0K.QFM;EY((]K,NW!_6O2YH(;A-D\22*#G#J",U!_9>G_\
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M2W0O]Z+_ - :O2WM+:2%87@B:)?NHR @?04/:6TD*PO!$T2_=1D! ^@HN%C
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MA1_PTIJ/_0O6O_?YO\* /HNBOG3_ (:4U'_H7K7_ +_-_A1_PTIJ/_0O6O\
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M?K0![Y112,<(Q]!F@!:*^;6_:&\3AB/[,TC@_P#/.3_XND_X:'\4?] S2/\
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M](_[]R?_ != 'TG17S9_PT/XG_Z!FD?]^Y/_ (NC_AH?Q1_T#-(_[]R?_%T
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M?KH/ O\ R4#P[_V$K?\ ]&+0!]OTV3_5M]#3J;)_JV^AH ^$G_UC?4TVG/\
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M=:/ 7A=-5U6&"2/,*D%_>OHS^S4TZSCAMT"H@X %?-YIF%;EDJ"^'?R/>M#
MI12O-]>QY;#\([ 0R?:+V5IL?+MZ5&/A+8-:L?M<WG8XYXS7I0^:7=C&>U6$
MM=\@*C'M7R4,RQ]1VA.XGC:RU<CPO7?AA=V%GYL7^DC'( Y%>::AHODEM@96
M'56K[*2T61765>,5Y=XZ\&6]U;2WEG$%F0$MCO7T&$S2OAW%8G:6S_S1<*]+
M%?NZRU[GS65(.".:;6OJUF(F+@8(/(K(KZ^$N97/&Q.'E0J.#"BBBJ.<****
M "BBB@ HHHH ^W_ O_)/_#O_ &#;?_T6M=!7/^!?^2?^'?\ L&V__HM:Z"@
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ML<+%K?=GMYC25/#QIKH4J***[CYX**** "BBB@ HHHH **** /O&OC[XT_\
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MBB@ HHHH **** "BBB@#[QKX^^-/_)6-:^L7_HM:^P:^/OC3_P E8UKZQ?\
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M=_["5O\ ^C%H ^WZ;)_JV^AIU-D_U;?0T ?"3_ZQOJ:;3G_UC?4TV@ HHHH
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ML>A2FF^86=B\Q('RYIA"=^#36D'13Q32<GWII:"E-7;)F(C 7;R:DCF!.&'
MJNK,>#S1G82*5BE4:U6QI B2+:.G8T)!Y?)8&J\3$1@>M30HTDF,_6LFK'9&
M2E9DLRE8U;D'M51CEMS5M&)&7:QSBLZ]ME0;USCT-1":;L.HG:Z*[3MM^44P
M3@CU/K41+8(-1,2, 5NHHY)5I+4>REF]:?%(T$@;MWJ$.PY%*)<G##K5-&2G
M%.^S+<NV0[U;KVJN[ 9%(2-I J$#/6A(=2I?9 ?453O8LH'QS5QAQQ4,PS&0
M?2M(NS.'$1YH-,RJ*#P:*Z3P HHHH ^\:^/OC3_R5C6OK%_Z+6OL&OC[XT_\
ME8UKZQ?^BUH X$5:M(]S[B.E516A:C$(/K43=D=.%@I5->A9!YJ42E0,5".1
M3\<<5S-+J>Y"4EL7X9@4SCYA2LP8%I3D]LTR",%-N<>IJK._S[<Y [UDHIO0
M]"=5PIIR DYXIY;"]>:9'R#S1QZ5;.9-I7[DL98<@G-6XKJ15&3D>]4U9MIJ
M:($J%]:SDEU.FD[:(L;FD.[)YK2L[7?&P(R>U)!9AHT4C-:)7:@QQBN&K56T
M3HYC$N;"2/D<CO6?SFNI616W;UX KG)_]?)M4XSQ6U"HY:,EZE=LCI3,YZ]:
M<=Q7%-Z=>M=1S2>H]65@0?O=JT;/4_*M7M9T#QGIGM60^592#Q4JL'7Y?QJ9
MTU)680J.]GNB2:9#G8N,U3)-3D=L5&^-O%7%)$U6Y;C<EQM;H:R+B/RY2*U"
M352]3]V&[YK>GHSR<='GIWZHH44M)70>*?;_ (%_Y)_X=_[!MO\ ^BUKH*Y_
MP+_R3_P[_P!@VW_]%K704 '>OD/XW_\ )6-6_P!V'_T6M?7G>OD/XW_\E8U;
M_=A_]%K0!YY3D7<P [TVK%HN9<^@I-V5RZ<>::B7441Q@ <U+$<=:C[THXKF
M>I[L/=:MT+.-Q^6KENXM48GEF&!6?$27XJSR/F;MTK&<>AZ%&5US#'R#N?J:
M%DYSBF%S,V:<0 HS3MW%S:WCL2;B_&>*<I:+!#8J$'I3C\W2I:-%+2_4TX-1
M94/8_2IH;@S-@C<,_E6;;HQ8 #-;EM;_ ">9MQ7+54(G3%^[=B7-GYD(D0?,
M.*Q)EEC;!4J174](P,5CZPNU5<+@]*SP]5\W*Q2U1DDL3EC^=-$H P#@T;BW
M:HV&*]!;6.64FM4/5N<'O5BVD%G<JS\J>M4R/ER#3DD!&UN32E&Z%&IK9[FO
MJ!MI'$UO("K#D'L:RY#@X7FD).-O2F;2IS2A#E5BJE1M60WHU9]_%MEWKT:M
M%^M5[I=T/TK>#M(\[%4U.DUV,FN@\"_\E \._P#82M__ $8M<^>M=!X%_P"2
M@>'?^PE;_P#HQ:ZCYX^WZ;)_JV^AIU-D_P!6WT- 'PD_^L;ZFFTY_P#6-]33
M: "K=L/DS52KEO\ ZNIGL=&&7OE@<T\= *:@&:D'+5@SUHHF@CW$FDG<(-JT
M^,[(R?6HITZ-GK4+5ZG7+W:7N[D:Y)S5AAP,=:KQYS5C!S@=:;W(I?"(@.[F
MIEVACGFF8/KS1M.<U+-X^Z78DW*"!FM&UAPV_.,]JJVL0\M?F^8]JU HC7^\
M,5R59]$>C'X40]'(7EJ;>1AK0Y^^>@J1%+,3TQ2S1R*,*N<]ZR3LT-ZZ'/R1
M-$ 6[U"0?O8J]>AMV#50$D5W1=U<XJD$I6(B.V*A/#?2K)RU57&UN:TB<=56
MU+,7S#=22(,%A4T9#1J%%0R$JV*E;F\DE#4@)XIAY6GD=:8.AK1'%+S,N3[Y
M^M-I\O\ K#3*Z%L>#/XF%%%%,D^\:^/OC3_R5C6OK%_Z+6OL&OC[XT_\E8UK
MZQ?^BUH X&M&W_U K.K0MO\ 4BLZFQV8)^^RPHJ5.#]*B3K4S'G%<[W/:IVM
M<MHX%LVT?,:SR#G!'-7"N(%([U5?ANM13W-L3=I7) ,1BG*0331EE'I3QM44
M%1W%/7 JQ;QO+*JJ,D574C/-7K1]C?*.6XJ*C:6AT4E=W.@MN%&X88"I)'4Q
MD=S4<*R"/! Z5(D)*_,#R:\B5KW-6,6-?+YK.O41(G 7#]ZZ?3-(%W-\[E8U
MY-9VM:8C7+"U8N.G-%*O#VG+<2FKV.,0E6I9,%LXJ>YLY;64K(N"*B615.''
M%>PI)ZHRV7*RM+QC%2VNW:3WIDP].E1PG;6F\3F4N2K=EL]#55CE<8Z5.6P!
M4!Q@U,4:5G<A/6H+UOW>*G/7-5KP_)^-;PW/*Q#_ '<BE24M)70>(?;_ (%_
MY)_X=_[!MO\ ^BUKH*Y_P+_R3_P[_P!@VW_]%K704 '>OD/XW_\ )6-6_P!V
M'_T6M?7G>OD/XW_\E8U;_=A_]%K0!YY5RR'4U3JY9=ZF>QT87^*BT#S4BINX
MJ,<&K'1<]ZYF^Q[=**>X^WCP_/:BYD).T#Y121DX)HF8-#VSFL_M7.O3V-EH
M1P_>XJ4C-10@YJ< #DGFG+<BDKQ!OEQQ0 3[4%LFIH@I=0QPN>:ENQT1CS/0
MTM-1=F2I+>M;:Q!(< Y)Z^U9]F1(Y$ P@XS6D%VC !+=Z\JO)N1T/16'!!'!
MGKFL_4(%FB7>W0YK2\K(&).>X-27&C7$UKYBKE!W%81JJ$DVQ)I;G&W:1QR@
M1#C'-57 !Z5I7UC*DIPI(]JSSQPPKV*<N9*S(FD1$ C@U!DAN*M%%SE3VYJJ
MW$F:WB<=9-69<5=ZYQ@CK3'!V4JR948-1R2$_+4J]S>4H\I%(W;TI#\T7/I2
M/0/N&M$<#;;:9D.,.1[UO>!?^2@>'?\ L)6__HQ:PI/]8WUK=\#?\E \._\
M82M__1BUUK8^=EN?;]-D_P!6WT-.ILG^K;Z&@1\)/_K&^IIM.?\ UC?4TV@
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MP_6M\.[H\?.(VDNPRBBBND\0^W_ O_)/_#O_ &#;?_T6M=!7/^!?^2?^'?\
ML&V__HM:Z"@ [U\A_&__ )*QJW^[#_Z+6OKSO7R'\;_^2L:M_NP_^BUH \\I
MT?WA]:;3D^^OUH>PX[HVHU)1<#J*4KAN:G4;+96]JA7+\FN)/<^J<%%174DY
M:W?%4XCG.:O8VPL#U:J48QGZT0>C(KIJ4?0ZWPW&QB8A2172@A5.W[WI6#X>
M<QV)(/4XK65G8GYN37@XI.55GH):(=+,0<A>HYS4]DLTPD*0EU YXZ5>TC17
MO+V)95)1CC@9KUJR\(Z;IFFR1R,JF8<N:PC&52,E25[;MZ+[SDQ.,IT+)[L\
M7ACCCN"UP^._-1W>O01S>5"I.!P1WJ]XMT:1=1D2R(:&/OFLS3=)M;J+]]*$
MF4X(-*'LG'VDW?R.F+BX\[*TMTLL+,[$,?6H;;3A*!+$-V#S6OJT.F1P"UB5
MFD Y85J_#C3;2?4I([IR8EZ9K1UE&BYQT]0G54*;GV,Z.QO+1!<*&AC/!85O
M>#IVE\20!I=[9X)KT:_T31+G2VM8Y4! )!SWKR>VE'A_6GD)_P!7)E<=ZYY)
M[2:;_NNYQT\0L3"22LS0\?V5T/$4T; NTRY3CK7D&JV,UA>-%<)L?KBOJ%[_
M $3Q#I U0L@>)<$OP0:^=?'5Y%>:]))$VY1QFO2P4I1Q#I+6+5[D4*KE1Y)*
MSB<JG-TH[59N!^]-5TQYX(JS*#NR.:]F6C"DFZ<O4C$;8SBHKM!L(]JM0EC+
MM/ J*_0KGZ4HOWBJT%[%M&$>M=!X%_Y*!X=_["5O_P"C%K /4UO^!?\ DH'A
MW_L)6_\ Z,6NT^6/M^FR?ZMOH:=39/\ 5M]#0!\)/_K&^IIM.?\ UC?4TV@
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M)^%9=CT;MMV,"?B9OK6WX%_Y*!X=_P"PE;_^C%K%N/\ 7-]:VO O_)0/#O\
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M>SDZR5T]S92]VYB:I ^I2JX/W#C K-U72EMKBW4NJ^8N2?2KC3HNHN%<A"W
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MH:B[XJDS&<;:%9NIJM<#H:MR@[JK7'W5K6.YYM=>ZRM1116IYP4444 %%%%
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MCA@#5ZPACO P*D%1GBJ<^579C[.$Y:,PY%_>8J];)\F3ZU%<1;;EAZ&A'96
M'3/-7)\T=#"DE3J-LTYBGRK&O0<GUJE.?EJ>.7SGXX XXJ&[.,CL*R@FG8[J
MLDZ;:.?N?]<U;7@7_DH'AW_L)6__ *,6L2<[IF(K<\"#_BO_  [_ -A*W_\
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M6HH/6BNT^8"BBB@#[?\  O\ R3_P[_V#;?\ ]%K705S_ (%_Y)_X=_[!MO\
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M,]*S:4E8Z=8G:F**6U,L. O7BDW10Q><R@E1R*YB#69;. Q)\RGJ#4,FLS3
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MF4]17-'1M'KU7SQC+R*S^U9LW^L-:<HXK+D.7-==,\+'::#****U/-"BBB@
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M+/[L"J=\",>E7,';TZ55U Y5*FG\1MBU^Y=S/HHHKI/""BBB@ HHHH ****
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M?^P;;_\ HM:Z"N?\"_\ )/\ P[_V#;?_ -%K704 '>OD/XW_ /)6-6_W8?\
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M2:/^%">!O^?6\_\  DT44 '_  H3P-_SZWG_ ($FC_A0G@;_ )];S_P)-%%
M!_PH3P-_SZWG_@2:/^%">!O^?6\_\"3110 ?\*$\#?\ /K>?^!)H_P"%">!O
M^?6\_P# DT44 '_"A/ W_/K>?^!)H_X4)X&_Y];S_P "3110 ?\ "A/ W_/K
M>?\ @2:TM%^#W@S0[R*\MM->2YAE66*2:9F,;*<@CGUHHH [RD<$HP'<444
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, ,"X?_BZ*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gbkyd1brmfwp000021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^ BT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSW4OB[HMGXZL_"U
MK!-?SS2B&::W(*PN3@#_ &L=_2@#T*BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+74CP3)ZKGH>X]NO6N&T76]<^"'B;^P=>\R[\-7+EH)U!(49^^OH?[R_B/<
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M;WP? 'P\M<#K-+G_ +Z-=Y12<[JQ4*/*T[]_Q"BBBH-@HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX0U;7+O19I/$]@+"YMG*M*Q"I(HZOC/&.YZ'J/:WS+5O8Q7).Z2M?K8HZ?\
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MTZQ2_:_6RMUO&78UP(E$A7T+8SC@<>U);Z;86CW#VUE;0O<-NG:.)5,IYY;
MY/)Z^M4YZ6,E1M*_FW]YX-*2?@+;@GIJA _6NM\<V-J/$O@&V%M$(/-$?E[!
MMV@QX7'I[5Z-_8.CFP%@=)L/L8?>+?[,GEAO7;C&?>II]-L+J:WFN+*VFEMC
MF!Y(E9HCQRI(^7H.GI3]IK<E8=\MK]OP."D18_CW"4 4OI>7Q_$>1S^0_*L;
MP;KNFZ+:^,K34KR&VN/MLS)#(V'DR",*O5CD=!ZUZN=/LC?B_-G;F\";!<>4
M/,"^F[&<>U12:-I4M\;Z33+-[LC!G:!3(1C'WL9Z4N=6LRO8RO=/J_Q/$D_Y
M-]D_Z_\ _P!G%=#X_MH+?P]X*\F)(_+N850JN"HV@X'X@5Z7_8>D?V?_ &?_
M &58_8BV[[-]G3R\^NW&,U)<Z7I]Y'#'=6-M.D!#1++"K",CH5!''X4_::W)
M^KOEM?HE]QY/K7VRU^,.H22>(8]!,UHOV:[N+=)49,+E07("\AN?4$=ZWOA3
M;1K#K5W;WUQ>6]Q=_P"MDLUMT=QG<R!78$'([+_AW=]IEAJ<:QZA8VUW&IR%
MN(ED /T(J:&"*VA2&")(HD&%1%"JH] !TI.=XV*C1M/FOW_$DHHHK,Z HHHH
M **** "BBB@ HIDTT=O$TLKA$7J33Z OT"BBB@ HHHH **9++'!$TDKJB*,E
MF. *YC4?%9R8[!!C_GJX_D/\:Y<3C*.&C>H_EU-Z&&J5W:".GDECA0O*ZHHZ
MLQP*R[CQ)ID!P)FE/I&N?UZ5Q$]S/=2;YY7D;U8YJ*O K9_4;M2BEZZGK4\I
M@OXDK^AU[^,+<']W:RL/]I@/\:9_PF,?_/DW_?S_ .M7)T5Q/.<9_-^".G^S
M<-_+^+.TB\6V+\2131^^ 1_.M.VU6QO"!!<QLQZ*3@_D:\XHKHI9]B(OWTG^
M']?<93RJB_A;1ZG17G]CKU]8D 2F6,?P2<C\.XKK-,URUU(! ?*G[QL>OT/>
MO;PF:T,2^7:79_H>7B,!5HZ[HU****],X@HHHH **** "BH+:\ANC(L;_/&Q
M5T/52/6IZ "BBB@ HHHH **** "BBB@ JAK=D^I:%J%C&VU[FVDB4GL64@?S
MJ_10)JZL>3>!_'^C>&O#:Z%X@>:PO]/=XVC>!VW98GC:#SSWQ5K6O%$_C;X8
M:]<Z;IMY;I$P568@^:@<%B,?[/4?ADUZ!>Z)I.I3+-?:7974JC"O/;H[ >Q(
MJY'%'#$L42*D:C"HHP /0"M')7O;4P5*?+R-Z6L>#2*FI:+X;M/^$P-Z[21B
MTL+/2X3+;.!_$1(K #IDGGKSUK:U/_DIGC;/_0 D_P#14=>J6VC:59W;W=KI
MMG!<O]Z:*!5=OJ0,TYM(TU[J>Y?3[1KBXC,4TIA4O(A &UCC)& .#Z4_:$K#
MNVYR_P */^2;Z7]9?_1K5VE06EG:V%LMM9VT-M F=L4*!%7)R< <=:GK.3N[
MG1"/+%1[!1112*"BBB@ HHHH **** "BBN:\>ZX- \&:A=JVV9X_)AQUWOP#
M^')_"FE=V)E)13;/,[[Q5KI\2W7BRVO[EO#UGJ:6C6ZS-Y3)C!;;G!XY^K"O
M6/$'B:Q\.:"=8NEFFM<H!Y !8[NA&2!C\:\HL? 'CQ_!HTV'4=,CTNY03M9N
MOSY.&P3Y>=V0/XNU-O=;?5O@4]O<%OM>GW,=K*&&#A6^7_QW _ ULXIVL<4*
MDX)WZJ^O<[^/XF:(^HV-J]MJ<$5\0MO=S6I2&0G' 8G)Y(&0,>^*S]5^(EW8
M^/XM#CT:_DM8U8RB*WWS3'!PR#/^K'7/L?3G,^(@ \.^#0  !=0  ?[@J7Q+
M>V^@?&72]7U)GAL7L3$)O+9EW_.,< \\C\Z2BNQ<JD]F^J_$Z75/B#ING:E<
MV$-AJNI36@S<_8+7S%@XS\QR,?\ ZZNP^,]$F\*GQ&+DKIRCYF9#N#9QMQZY
MX_\ K5YGJ6I)?>)?$%EXJNM8:56*:9I=MY@BN%.[;\J=2?EY)&<]^U&TTZ[U
M3X%R0V2/)-9ZBTD\*+EBHZC'MN!_"CV:LA>WG=V\_P #T _%31DCM&GT[6+=
MKN54@2>U"&13_&I+8*].0<\CBMGQ!XQTSP]=06<R75W?W S%9V47FRL/7''O
MW['TKS;QKXKTWQ-IOAHZ9#,5COXO-=H2BPMC_5Y(P3_NY'R_2MO5[@>$_BO)
MXAU:*;^R;RR$"W21%U@8;>&P,C[I_P"^OK2Y$5[:6NO;4Z_1/&&F:[:WDEL+
MB*>S!-Q:7$>R:/ SRN?;UK!3XMZ')I?]HQ:?K,ENK[9G2U!6'GC>V[:,^F2?
M:LK1!)KWC3Q#XJLH)8M(DL&MXI70I]I;:/F /4?*>?I6=X9 'P#U<@#E9R??
MI3Y(A[6;V\_P.L\0Z_I,M[X5N/[0UF.._G!M?[/D"1S9*8$P."5Y''7EJL:A
M\1=+LM3NK&WL-5U*2S.+I["U\Q(3W#'(QT/Y&O/;K_D&?"W_ *^!_P"C(ZM>
M(6T#3/%&HW,.LZYX6U1I-[[H#)#='D[E"$[@3SR<<].M'(B76EJUY?D=?XD^
M(<%AX+CU[1;>2]6X.R*0QGRXFS@^9T(YX [FM[PKK4FO:#;WDUG>6TI55<74
M/EF0[02ZC/*G/!KS[4[KQ!XC^"M]/JUJYNUE5D*PE6EB5U.\J.G?H,8&:[OP
M7K%CK/A6QDL)O-6"%()/D*[75%R.1^HXJ912B:4YN4]7I8Z"BBBLSI"BBB@
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MFAW\UX6;^*,8,?'N3G_@=>YU,XJ)I1G*=V_Z?4****@V"BBB@ HHHH ****
M"BBB@ HHHH *S];TQ]8TJ:RCO[NQD?!6XM9"CH0<]1V]16A5*;5].MSB6\A4
MCMNR?THO;4?*Y:)'))X U&\NM/;Q!XHGU6UL)!+#;FU6++#H78$EOQYZ\\UW
M59J>(-*<X%]%^.1_.K\4T4Z;HI$D7U5@11S\Q*H^SZ6'T444#"BBB@ HHHH
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M_A5CPIK#$C3IVS@9A8_JO^%;QDT^5G!5HQE#VD-.Z.LHHHK4XPHHHH ****
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M1W=L'.DW.$F3)/EMZ_U_,>E=E&Z2QK)&P9& 96'0@U'=VL-]:26UP@>*1=K
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M^=8!J7UBFM'O_F>YEN+37L9[]/\ (QZ***^=/8"BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYO\ 5JV,KNX/0#T/WQ6-KUEXR\*Z]I/BWQ#?VE\MO,L#O:K@B,YR" BC!!8
M^IKW&BM%4LK6.>6'YFY7U/)M5UFUTOXT1ZG.DDEF-,#/+%&9/*0@_/@<XZ9(
M[&I?#;G7?&/BOQ/912+I,UF8(I60J)F"J"1D?[!_,9KL?^$5_P"*]/B?[;UM
M/LWV;RO_ ![=G],5O7,/VBUF@W;?,1DSC.,C%#FN@HTI7;?>YX?X:\5:=IOP
MHO-'NK><7EXL\=J@@8K<E_ER& QD$X.>>!5C6],NM*\)> ;&^1EG2^!>-QRN
MYPVT_0'%>G^$/#@\)^'8M*-W]J$;N_F^7Y><G/3)_G5ZVU[1[RZ-K:ZM8SW
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BR22L@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gbkyd1brmfwp000022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )_!88# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM[#HUU)IR>9>*F8EQG)^E%@+]%9N@3:A<:';2ZK'Y=\P;S4VXQ\QQQ],5I4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9@EH9.DZ'_9,LDG]JZG>;UQMO+CS ON.!@UK445)05YSX$_Y'CQ+_P!=7_\
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MK)TWXAV<<4MOXBS8:C Y62-87*GTQC)Z>M+X1D?6O$FK>(T@>&SG58(-XP9
MN,G]!^>.U#!':T445)0$@#)X IGFQ_\ /1/^^A3R 1@C(-,\J/\ YYI_WR*
M#S8_^>B?]]"CS8_^>B?]]"CRH_\ GFG_ 'R*/*C_ .>:?]\B@ \V/_GHG_?0
MH\V/_GHG_?0H\J/_ )YI_P!\BCRH_P#GFG_?(H /-C_YZ)_WT*/-C_YZ)_WT
M*/*C_P">:?\ ?(H\J/\ YYI_WR* #S8_^>B?]]"CS8_^>B?]]"CRH_\ GFG_
M 'R*/*C_ .>:?]\B@ \V/_GHG_?5'FQ_\]$_[Z%'E1_\\T_[Y%'E1_\ /-/^
M^10 >;'_ ,]$_P"^A1YL?_/1/^^A1Y4?_/-/^^11Y4?_ #S3_OD4 'FQ_P#/
M1/\ OH4>;'_ST3_OH4>5'_SS3_OD4>5'_P \T_[Y% !YL?\ ST3_ +Z%'FQ_
M\]$_[Z%'E1_\\T_[Y%'E1_\ /-/^^10 >;'_ ,]$_P"^A1YL?_/1/^^A1Y4?
M_/-/^^11Y4?_ #S3_OD4 'FQ_P#/1/\ OH4>;'_ST3_OH4>5'_SS3_OD4>5'
M_P \T_[Y% !YL?\ ST3_ +Z%'FQ_\]$_[Z%'E1_\\T_[Y%'E1_\ /-/^^10
M>;'_ ,]$_P"^A1YL?_/1/^^A1Y4?_/-/^^11Y4?_ #S3_OD4 'FQ_P#/1/\
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M '<GH*Z/0XFC\Q3R(XXXB<_Q '/\Q^=;872;2V,<6KP3>YL4445Z!YP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!.T%M \T\OEQ(,
ML[2$ #\Z!HGHKB+_ ,<+O9-,M6=1TEG=@#]%!SCZD5GCQCK(8%EM3ZKL<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%%( H/(Q110!5O+FUT^U>YNIC%$O5BY_(>I]JXV\\<3.Q73K/:O9[AV)/\
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M$+_]>FI)["G3E!VEH/HH&<<]:*9F%%%% !1110 4444 %%%% !1110 4444
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M5'D?]-9?^^JFHH A\C_IK+_WU1Y'_367_OJIJ* (?(_Z:R_]]4>1_P!-9?\
MOJIJ* (?(_Z:R_\ ?5'D?]-9?^^JFHH A\C_ *:R_P#?5'D?]-9?^^JFHH A
M\C_IK+_WU1Y'_367_OJIJ* (?(_Z:R_]]4>1_P!-9?\ OJIJ* (?(_Z:R_\
M?5'D?]-9?^^JFHH A\C_ *:R_P#?5'D?]-9?^^JFHH A\C_IK+_WU1Y'_367
M_OJIJ* (?(_Z:R_]]4>1_P!-9?\ OJIJ* (?(_Z:R_\ ?5'D?]-9?^^JFHH
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M 'U1Y'_367_OJIJ*\D^D(?(_Z:R_]]4>1_TUE_[ZJ:B@"'R/^FLO_?5'D?\
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M>2Q/J35ZBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYKKZ4KYKKT,#
M]KY'SN?_ /+OY_H%>E?";_F,?]L?_9Z\UKTKX3?\QC_MC_[/6^*_A/\ KJ>=
ME/\ OD/G^3/2J***\@^S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "H;J<6UK+-@'8N0#W/8?G4U4=84OI<P4=-K'Z!@3^@I-V5QI
M7=C#FG-E9O<N/,F9L*&_B<^OMW^@K,BM'NI/.N&,LIZLW;Z>@]A5S6 ?L5LX
M^ZDPW?B"!^O\ZDL9%VBO*?O347L>K#W8N2W*D^F*5R4&1T/<5)87<XE,+L6N
M(1YD,C=6 ZJ?7_ ^U:-Q(FRL>W.[6(V'1$=F^F,?S(IM*G-<H7]I!\QW$4BS
M0I*GW74,/H:S-90^;:2_P@LA^IP1_P"@U>L 5T^V!!!$2Y![<4^YMTNK=X7R
M W0CJ#V->E./-%H\R$N629QNJ QZK'*?NRQ *?=2<C]16A:SJ$%%W:AT^QWR
ME3G,<B\<^JGU]JSC8:A <1F*=>S!]A_$'_&O.:E"=TCTHN$X<K9=O)U*FJVB
MHSS.ZC(EN(U7WV\L?PY_*HO[/NI"/M<BP1G^&-MSM[#M_.NFTO3Q;JLC1B,*
MNV*/^X/4^Y_SWJZ,)5*G,S.M4C"GRHTZQKFQEM)6EMT+P,<E%&2A]AW'M6S1
M7?."DK,X(R<7='%OID3N7L;A8<GF)AE0?;NOTJ,Z=<_\M[V"-<XR@)/ZXKLY
M;6WG_P!=!%)_OH#216EM <PV\49]40"N5X.+=SJ6,DE9&+IFCJ$ \MD@)W.9
M/OS'W]!_G%=!1175""@K(Y9S<W=A1115$A1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\K\8_$C5(+;4]-T6S^SZA#
M,8HKKS5?&V0 G:RXY4'J>,UZI7S]XB_Y&?5O^OR;_P!#-=>$IQG)\R/)S7%5
M</"+INUV9?\ PG_Q0_Z"?_D"V_\ B:]G\+>./^$EU.2R_L[[-LA,N_S]^<,H
MQC:/[WZ5XS7;_"S_ )&>Y_Z\V_\ 0TKJQ%&G[-M+8\["9GB*N(A!O1O^M[GK
MM%%%>4?3A1110 5\UU]*5\UUZ&!^U\CYW/\ _EW\_P! KTKX3?\ ,8_[8_\
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M-1>$8&T7Q3K&@0S/+8Q(DT08Y\LG&1^OZ4WJ)';T445)044ASM.,9QQFHO\
M2?\ IE^M $U%0_Z3_P!,OUH_TG_IE^M $U%0_P"D_P#3+]:/])_Z9?K0!-14
M/^D_],OUH_TG_IE^M $U%0_Z3_TR_6C_ $G_ *9?K0!-14/^D_\ 3+]:/])_
MZ9?K0!-14/\ I/\ TR_6C_2?^F7ZT 345#_I/_3+]:/])_Z9?K0!-14/^D_]
M,OUH_P!)_P"F7ZT 345#_I/_ $R_6C_2?^F7ZT 345#_ *3_ -,OUH_TG_IE
M^M $U%0_Z3_TR_6C_2?^F7ZT 345#_I/_3+]:/\ 2?\ IE^M $U%0_Z3_P!,
MOUH_TG_IE^M $U%0_P"D_P#3+]:/])_Z9?K0!-14/^D_],OUH_TG_IE^M $U
M%0_Z3_TR_6C_ $G_ *9?K0!-14/^D_\ 3+]:/])_Z9?K0!-14/\ I/\ TR_6
MC_2?^F7ZT 345#_I/_3+]:/])_Z9?K0!-14/^D_],OUH_P!)_P"F7ZT 35\_
M>(O^1GU;_K\F_P#0S7O?^D_],OUKP/Q#G_A)=5SC/VR;./\ ?-=V!^)G@Y[_
M  X>IFUV_P +/^1GN?\ KS;_ -#2N(KM?AAO_P"$EN?+VY^QM][_ 'TKKQ'\
M)GC9=_O4/4]?HJ'_ $G_ *9?K1_I/_3+]:\8^W)J*A_TG_IE^M'^D_\ 3+]:
M )J^:Z^CO])_Z9?K7SC7H8'[7R/G<_\ ^7?S_0*]*^$W_,8_[8_^SUYK7H_P
MI\S_ (F_E[/^6.=V?]NM\5_"?]=3SLI_WR'S_)GIM%0_Z3_TR_6C_2?^F7ZU
MY!]F345#_I/_ $R_6C_2?^F7ZT 345#_ *3_ -,OUH_TG_IE^M $U%0_Z3_T
MR_6C_2?^F7ZT 345#_I/_3+]:/\ 2?\ IE^M $U%(,[1G&<<XI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHHH RO$FF3:QX?O-/MVC6690%,A(4<@\X!]*N65L;?2[:UEVL8X5C?'(.%
M/X59HH X3_A$?$FCRRQ>&];BAL)&+"&X7)CSV'RM_2MWPSX;&@0SR37+W=]=
M-ON)V_B/8#VY/U_2MZBG<5@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**@O;R#3K"XO;J3R[>VB::5\$[44$DX')X':@">BN'_X7!X$_P"@[_Y*3_\
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M8NWN9+99I)B6(VHK'! QR>M)\4;N&?PVGA^*0-J6JW,,%O"C?/\ ZQ6+8[
M=:S;_2=.\8_$S4-'\2$RVNFVD36%GYAC\W>,R294AB00!UQ51LUS-=^GIT$[
MIV1T7@C6M1U2VU*TU.:WNKG3;QK4WEN,)/@ YQT##."!WK6AUZUG\2W6A+',
M+JVMTN'<@;"K$@ '.<\>E<5X0T])O^$J\)V&I7D>BV4\:V=W:S!982PW21K)
MC^%N.<GG%9]K\.[H^/=0B;Q!XLCM5LHBFH"\(>5MQRADVX8#KCMFDX0<G=V!
M2E9'K->:^-8?&F@:5J&MVOC7_1XY5,=I_94/R*\@4+O.2<!NI'.*]$M+?[)9
MP6WG2S>5&J>;,VYWP,98]R>YKE/BE_R3O4_]Z#_T<E12=II%3^$N:!HWB>PO
MS/K'BW^U;8QD"W_LV.##<8;<ISQSQ[UKZOK.G:#I[W^J7<=K;)P7<]3Z #DG
MV'-75^Z/I7#>,_)_X3KP5]OV?8/M$_\ K,;/.V#R\YXSG./>E'WY:C?NK0Z3
M0?$VC>)[1[K1K^.ZB1MK[0593[JP!'XBLU_B+X1CU@Z2^NVPO ^P@AM@;T+X
MVY_&H-4;2(;[Q(-'Q_PDTFF,\PBWY("D1[OX0V>G\6/:N TC1;Z]^%L5Q+X^
MM;;0#:XN+<Z/"XB/\2DYW%@>_P!XG!')K2-.#U>B_KR)<I+0['Q+XCU73_%F
MIV5K=>7;P>&YKZ-/+4[9U<@/DC/3MT]JNV_CK2='\(:'J'B358X;F]LXI22A
M+2,4!8A$!XR>PQ7':I'Y.M7$8NGNPG@611<.A1I>?O%3R">N#5JRT2^NK/PM
MJGAS7-/M?$$.APQ-9W8#B6 @'.!EE&<C('MD=[<(<JN3S.^AZ/HVN:9X@TY;
M_2KR.ZMF)&],C!'8@\@^Q%,\177V+P[?W/\ :/\ 9OE0EOMGD>=Y/^UL_BQZ
M5SW@369[V_US3-0TBPL=4LID-W+I^/*N&<$AO7=@<Y)/\JN_$7_DG>O?]>;U
MCR6J*)=[QN3:GXQT'PWIME-K6KQI]HC4QN8V+2\#Y@B@D#\.,UH:3KVE:[I@
MU+3+V*XL^<R XVXZA@<%3['%<1?:)?76HZ+JGAS7-/M?$$.E)$UG=@.)8#@Y
MP,LHSD9 ]LCOCZCK.HWO@?QOIDND65CK%D$-[+IO^KN YRS<<YV YR2?7TJU
M2BUIN+G:W.UM_B7X-NM4&G0Z];-<%M@RK!"?:0C8?;!YIS:Q?CXJ)HWG_P#$
MO.CFZ,.Q?]9YNW=G&>G&,XK.\3GPT/A)=;!9'2_L)^QXV[?,VG9M_P!K=Z<Y
MS7/07+6?B:UNM6669H?!/F72AB'?# L,C!!//-.,(M-I=Q.3ZG7R?$WP9%J?
M]GOK]L+C?L)VOY8/O)C8/KFL_P 1_$2RT'QWI>CSWL<5H\;M>'R'9@Q \H @
M'@DGI^.*XK6X]:_X5,TTMYH&DZ#+;*UK8VT1FDD!Y5"[G[_JPR<@FNM=MWCO
MP$Y;(;3+C#9ZGRDI^S@M?7\O07-)_@='KWCCPUX9NH[;5]5BMYW&X1A&=@/4
MA0<#ZUI'6]+&B_VP;^W_ +-">9]I#C9M^OUXQZ\5YAHNGZ]J?C'Q<MCXLCT>
M[34&\VW?3HIW>' \MMSG.W;QCH/QJE+96=AX4TY'UR/5M'_X2=7OYQ:_9X4'
M\2[<[2F_G(^7GVI>QCHKZ_UY?J/G9U-U\1+#5]7\.P^&]8CFBN-0\B\C$>&*
M;">CKN R.H_.O0J\^\:#3/\ A-?!+)Y']H->_*4QN,.P^G\.<8_&O0:SJ)65
MD5&]W<****R+"BBB@ HHHH **** "BBB@ IK[A&Q0 M@[0>YIU07L=Q+87$=
MI,(+EXF6*4J#L<C@X/!P: /&=%M?!.L>8OCJ\E3Q2DC_ &D:C=RP>2=QVB,[
M@FW&",9KMK:ZU'P3X)U6^N[M-9L[1VET]OM!,CP$C:KOMY(R>1GBL=/'&@_V
M9%I7Q%L1#J]O^[E2[L#,D[#CS(RJ$8/7C'/3BL8VLD7PS\;75M8SV&AW3"33
M;2<$,J\;F"G[JL>0*[9)R?O;77I\C!-+;^O4ZE?B1=0_9;_4/"]Y9^'[IT2+
M4FF5L;L!6:+&Y4)[GMCCG%,TW4K72/'_ (_U&\D\NVMX;*21O81'IZFLG7_%
MMMXL\)IX3TNUNSKUXD,,MH]LZ_91E2SNQ&-H X()ZBH-8T:[UG4_B3IEB#)=
M/;:?Y:YY<JF[;]3MQ^-2H*SNK?Y76HW)]-?^&9T\?CS5+=H;K6?"5YINC3.J
MK?/<QR%-Q 4R1CE!DC/7%+J?CO48/%-_X>TGPQ/JEW:Q1RADNEB0JPR=Q887
M&1CKGVKSZVM/AK?16MIIGA.[N_$$K(DNFM-=1& Y <NY) 5?7GMT[>@Z H'Q
M7\5\#BULP/\ OEJ)0A&[M_5UY@I2?4L6OQ!T^3P;+XANK6YMS#,;:6SQNE\\
M-M\M>FXDD?\ UJIQ^/M4LKBU;Q'X2NM(T^ZD6..\^U),$9C\OF* #&.>_>N5
M2QO+KPSK%W96TEU)IOBV2^:VB&6E1'&Y0.YP<X]JT/%/C+2_'N@'PUX;6ZO;
M^^DB65!;N@M5#JS-(6  QC'&>:/9QOHM/R#G=MSJ=<\8WEGK;:+H6@3ZUJ$,
M0FN56=8(X5/W<NV1N/9?2HG\?V__  BMCX@BL9#;2W:6MVDK['M,OL8L,'.U
ML<<=:QY]:L_ GC_7+S7?.@T_5HK=[:\$+2)NC4J8R5!(/<#'2NBMY'\=>"[Y
M+O3I+""_26*!9FR[1GA)",#:3U Y[<U#C%)-K334I-MO4L:UXCDTW6=,TFTL
M/MMW?+*X7SO+"(BYR3@]3@#IUKCOA_XGU&#2?$-]KU@]O86UY<SR7<EVLI5P
MP!A"]3M' /0]!4OPV:]UW6K[6]30B;3[:/2$S_?3F9OQ;%8EO'_:_A'QMX0M
M6?\ MP7]Q="U*,I>/S588)P/FQCKW]*M0BKP?E<ER;]XZZ/QYJENT-UK/A*\
MTW1IG55OGN8Y"FX@*9(QR@R1GKBI]6\9ZC%K]UH_A_PW+K-Q9(CW;?:TMUCW
MC*@%L[B1Z5YQ;6GPUOHK6TTSPG=W?B"5D2736FNHC <@.7<D@*OKSVZ=NC\<
M_P#"&)XE:76KC6?#^J11H(=3M%=5N%QT5D#9V]#D ].:/9PYK<K_ *^=PYG;
M?^ON/1=$U-]7TF&\EL+JPE?(>VNHRCHP."/<>A[BM"N0^'%UK%WX9DDU>:>X
M47+K9W%S%Y<LUN,!'9>N3SUY^M=?7--<LFC6+NKA1114C"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .8U&_U74]?DT72+F.S6VC62ZNVC
M#L"WW553QT[G^G*-X>UVW'FV7BBY:8<E+J)7C<^F/X1]*H-JDFA>,M<GETG5
M+F*Z$'EO:VV\?*G/.1ZU>_X3B/\ Z%[Q!_X!?_956I)J>'M6?5],,L\0BNH9
M&@N(U.0LBG!Q[=_QK5KE_!7G/;ZM<2VMQ;"XU&69$N(RC;6"XXKJ*3W&@HHH
MI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **\K_X7[X5_Z!^L_P#?F+_XY7I.
MF:A%JVDV>I0*ZPW<"3QK( &"NH8 X)&<'UJYTIP^)6)C.,MBW1114%!1110
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M[HW6DZ1#!<8P)69I&7L<%R2/PI-?\!>&?$]^M[K&F_:;A(Q&K^?(F%!) PK
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ME?Y@<=_\B_9R:N+F6QV=%<_I6N7-]XK\0Z5+'"(---OY+*#N;S(]QW<X//3
M%<]-XYU9?A*OBJ*VM&U%B (MC>429O+Z;L]/?K0J<F[>GXAS(]!HK'\,>(;?
MQ-H4.HPJ8Y#F.>!OO0RKPR'W!_3%<I<^.M73X:R^(88++[>+PVR(Z/Y6//\
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MW(.Y(F^7>O/\+%2>.F:V00RAE(((R".]39VN.XM%%%(84444 %%%% !1110
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MO-O_ $-*Z\1_"9XV7?[U#U/7:***\8^W"BBB@ KYKKZ4KYKKT,#]KY'SN?\
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M(G7159YOLB7&Y?-/R[6.!S@Y]J],KE=>\"6NNZXNKC6=:TZ[%N+<MIUT(=R
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M1)$9)%5D88*L,@BJEOH^EVDWG6VFV<,O]^.!5;\P*=J.J66DVZW%_<+!$S;
MS9QGDX_0URMCXXTX^(-56YU:+[ !%]DRO'W3OQ@9Z^M.S%=':T5'!/%=6\=Q
M X>*50Z,.A!Y!J2D,**** .6\965M:^#M8>"".-Y@'E95P7;<.2>]:5N67PA
M$4SN%@",>OEU#XRMYKKPEJ$-O#)-*Z *D:EF/S#H!6AI<171;**5"K"W165A
M@CY1D&GT%U,7X?!1X)T_;W\PGZ[VJMI6!\3]<"YP;6(MQWPO]*RK.?Q'X+-Q
MID6ARZG8&5FM9(2<J#V. ?R('.>2*W/"&E:C#)?ZQK"+'J&H."8A_P LT'0=
M3^7L.],2.IHHHJ2A"<*3@G Z"HO/_P"F4O\ WS4U% $/G_\ 3*7_ +YH\_\
MZ92_]\U-10!#Y_\ TRE_[YH\_P#Z92_]\U-10!#Y_P#TRE_[YH\__IE+_P!\
MU-10!#Y__3*7_OFCS_\ IE+_ -\U-10!#Y__ $RE_P"^://_ .F4O_?-344
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M[HSS_P"UDN6VM^E]OP/H7S_^F4O_ 'S1Y_\ TRE_[YJ:BO+/;(?/_P"F4O\
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M@#G_ %;5S==+X _Y'?3O^VG_ *+:N^K_  Y>C/G<'_O%/_$OS/:?/_Z92_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9=Q>6QX!R!D\<UH5)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>1?%/_D9[;_KS7_T-Z]=KR+XI_\ (SVW
M_7FO_H;UU8/^*>5G/^ZOU1Q%:?AW_D9])_Z_(?\ T,5F5I^'?^1GTG_K\A_]
M#%>G/X6?*T?XD?5'T#1117A'WX4444 %>1?%/_D9[;_KS7_T-Z]=KR+XI_\
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M+G_K\;_T!*UQ?\(X\F_WI>C.WHHHKRCZX**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .'\/W]Y-KEO'+=SR(=V5>0D'Y3VKN*\^\-?\C!:_\  _\ T UZ#7B9#*4L
M-)R=_>?Y(]/-8J-9)+I^K"BBBO;/,"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,'49?%*WT@TVVTQ[3C8T[N'Z<YQQUS6/J>O>*M'
MMO/O8=$C4\(OF2%G/HHZDU)XF\<PZ3J)TFW*1W0 \RXG5C'$",CA02QQCMBJ
M&EZ]X/L;DWUWK3W^I,/FNI[>3*^R+MP@]A56)N=5X;O=6U#2_M&L626<S/\
M)&H(.S P2"20<YX-:]4-)UG3]<MFN=.N/.B1]C-L9<-@''S >HJ_4LH****
M"BB@G S0!Q=]XYOH=7O+&P\.7.H+:R>6TL+L><=P$.._?M6WX=UF]UFWFDO=
M'N--:-@JI-G+C'4945Q>B7'B^SM[U].\/EI+F[>>62].PG/0!2RG\>>M=;X8
M\2G75N;>YM6M-0M&"SPGW[C\JIHE,Z"BBBI*"B@D 9/ %,\V/_GHG_?0H ?1
M3/-C_P">B?\ ?0H\V/\ YZ)_WT* 'T4SS8_^>B?]]"CS8_\ GHG_ 'T* 'T4
MSS8_^>B?]]"CS8_^>B?]]"@!]%,\V/\ YZ)_WT*/-C_YZ)_WT* 'T4SS8_\
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MF_\ '7I^K"BBBO</+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** ,2PU"6\\3ZS82I$8;,0^60OS?.I)R:V/*C_ .>:_E7&?\(Q8:UX
MTUV75;%Y8U$'D.6= ?D^;!!&>@J__P *]\+?] O_ ,F)?_BJ>@M3I@H484 #
MV%+5#2=&T_0[9K;3K?R8G?>R[V;+8 S\Q/H*OTAA1110 4V3?Y3^5M\S:=N[
MIGMGVIU% '$Z;\0[..*6W\19L-1@<K)&L+E3Z8QD]/6E\(R/K7B35O$:0/#9
MSJL$&\8,@7&3^@_/':NJNM+T^^D62[L+6X=>%::%7(^F15I55%"HH55&  ,
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M+%S_ -?C?^@)6N+_ (1QY-_O2]&=IY4?_/-/^^11Y4?_ #S3_OD4^BO*/K@
M & , 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >?>&O^1@M?^!_^@&O0:\^\-?\
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M=@PS@'*L/O#GK5RD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &Q_]GKS6O2OA-_S&/\ MC_[/6^*_A/^NIYV4_[Y#Y_DSTJBBBO(/LPHHHH
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M ",]M_UYK_Z&]>NUY%\4_P#D9[;_ *\U_P#0WKJP?\4\K.?]U?JCB*T_#O\
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M_P"BVKOJ_P .7HSYW!_[Q3_Q+\SV^BBBO$/NPHHHH *^?O$7_(SZM_U^3?\
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M_P */^$5T/\ Z!EI_P" Z?X5W?7H]CR9Y3B9QY95-#8HJ'R/^FLO_?5'D?\
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M +ZJI=:%IU]*);RUBN) NT/-&KD#TR1TY-;4:BISYF<>.PSQ-'V:=CY\KI?
M'_([Z=_VT_\ 1;5ZO_PBNA_] RT_\!T_PJ2W\/:5:3K/;64$,RYVR1Q*K#(P
M<$#TKIGC(RBXVW/*H9+4IU8S<EHT_N-2BH?(_P"FLO\ WU1Y'_367_OJN ^A
M)J*A\C_IK+_WU1Y'_367_OJ@":O$/'__ ".^H_\ ;/\ ]%K7M/D?]-9?^^JH
MW'A[2KN=I[FR@FF;&Z22)68X&!DD>E;T*JI2YF<.8826*I*$7;6_YGS_ %TO
M@#_D=]._[:?^BVKU?_A%=#_Z!EI_X#I_A4EOX>TJTG6>VLH(9ESMDCB56&1@
MX('I71/&1E%QMN>90R6I3JQFY+1I_<:E%0^1_P!-9?\ OJCR/^FLO_?5<!]"
M345#Y'_367_OJCR/^FLO_?5 $U?/WB+_ )&?5O\ K\F_]#->]^1_TUE_[ZK/
MD\-:/-*\LNGVSR.Q9G:%"6)ZDG')KHP]94FVSSLQP4L7&,8NUCP&NW^%G_(S
MW/\ UYM_Z&E>B_\ "*Z'_P! RT_\!T_PJ>UT+3K&4RV=K%;R%=I>&-4)'ID#
MIP*VJ8N,X.-CAPV3SHUHU'):&C14/D?]-9?^^J/(_P"FLO\ WU7">^345#Y'
M_367_OJCR/\ IK+_ -]4 35\UU]'>1_TUE_[ZK-_X170_P#H&6G_ (#I_A73
MAZZI7NMSS,QP$L7R\KM:_P"-CP.O2OA-_P QC_MC_P"SUV7_  BNA_\ 0,M/
M_ =/\*LVFC6-AO\ L4"6V_&_R45-V.F<#GJ?SK2MBHU(.*1RX/*9X>O&JY)V
M_P B_14/D?\ 367_ +ZH\C_IK+_WU7$>Z345#Y'_ $UE_P"^J/(_Z:R_]]4
M35\UU]'>1_TUE_[ZK-_X170_^@9:?^ Z?X5TX>NJ5[K<\S,<!+%\O*[6O^-C
MP.O7?A9_R+%S_P!?C?\ H"5O_P#"*Z'_ - RT_\  =/\*MVNEVMC$8K.,6\9
M;<4A4("?7 '7@5=;$JI#E2,,#E<\-6]HY)EVBH?(_P"FLO\ WU1Y'_367_OJ
MN,]HFHI ,*!DG ZFEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?%NG^9"E]&/FC^23Z=C^
M?\ZZ:F31)/"\,@RCJ58>QKFQF'6)HRI/K^9OAZSHU%-'EE>B:%I_]G:9&C#$
MK_/)]3V_"N<TG1'_ .$@DBF7,=JVXG'#?W?SZ_A7:UXN1X)P<JU1:[+]?\OO
M/2S3$J25.#TW_P @HHHKZ,\8**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .6U?X?Z'K%\UY(L\$TAW2&!
MP Y]2"#^F*W-*TFRT6Q6SL(?+A4YZY+$]23W-7:*=V%@HHHI %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV^<.1ZJ?XO6MFUU;3M:ADM=^UW4H\$HVO[_Y%59K45TRCI>I_:&_LC68XVN
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M50 !T I:&-!1112 9)+'$ 9)$3/3<V,T_J,BN6TNPMM=DO;O45,THG:)8RQ
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M],DG'ZUI444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP'%.XK%7PF'71,'=Y7FOY.[^YGC]<UNTBJJ*%4 *!@ #@4M)C04444 %%%%
M',7$<_AJ_DO;>-I=,G;=-$O6(^H_S[>E:5WJ&EWNCS.]S"]N\9SEAGIZ=<UJ
M$ @@C(/4&LW_ (1[2?M'G_88M^<]]O\ WST_2G<5AOAM91X>M!.#NV' ;^[D
MX_3%:M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[U8HI7'8****0PHHHH **** "BBB@ HHHH **** "L;4]#,]T+_3YOLM\O\
M'CY7_P!X5LT4 <\VGZQJOEP:JUK':(P9U@SNEQV.>U=#113N%@HHHI %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5;O3;*^(-
MU;12L.C,O(_&IH+>&VB$4$21QCHJ+@5)10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT<JWLA1BS$%<%1Q_WU7,>/Y(+[Q;HEI9,KWR/MD,?)7++M!QZ88_C5GXC?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gbkyd1brmfwp000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N!94# 2(  A$! Q$!_\0
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M_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H&?\
MD>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC_H&?
M^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H
M&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC
M_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'
MAC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P
M@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_
M  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\
M51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\
MQ5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R
M/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P C
MR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?]
M S_R/)_\51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S
M_P CR?\ Q5'_  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$
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M_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H&?\
MD>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC_H&?
M^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'AC_H
M&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P@'AC
M_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_  @'
MAC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\51_P
M@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\ Q5'_
M  @'AC_H&?\ D>3_ .*KI:*/:U/YG]X?4\/_ ,^X_<CFO^$ \,?] S_R/)_\
M51_P@'AC_H&?^1Y/_BJZ6BCVM3^9_>'U/#_\^X_<CFO^$ \,?] S_P CR?\
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M*3^XGZU2HHL!=_M*3^XGZT?VE)_<3]:I446 N_VE)_<3]:/[2D_N)^M4J*+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %!( R3@"BL#QG>O8^%KMHB?.F @C ZDL<<>^,U48
M\TDB*M14X.;Z%'PTK:UK5]XCF7,1)MK+/:->K#ZG^M=;5+2+!=,TBTLEQ^YC
M"G'<]_US5VG4ES2TV(P]-PII2W>K]7N%%%%0;!1110 4444 %4]2_P"/=?\
M?_H:N53U+_CW7_?_ *&@#+HHHJB0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** +^F?>D^@K1K.TS[TGT%:-2RD%%%% !1110 4444 %96H_\
M?/\ P$5JUE:C_P ?/_ 130F5****8@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** -BQ_X\X_Q_F:L57L?^/./\?YFK%24%%%% !1110 4444
M 97B/2%UK1)[3(6;&^%_[KCD?X?C3/#&K'6-#AN)!MN$S%.I[.O!_/K^-;%<
MII6-*\<ZGIJC;!>QB\C'H_1P/KU_"M8^]!KMJ<M3]W6C/OH_T_R^9U=%%%9'
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>*6^T:[X=L.
MJO=F=A_N#C^9KJ:Y35_G^(.@IZ13-^AK2E\5_)_D<V+_ (:7=I?BCJZ***S.
MD**** "BBB@ HHHH *IZE_Q[K_O_ -#5RJ>I?\>Z_P"__0T 9=%%%42%%%%
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MXRL42Y8BF:1XFT_696@A\R*X49,4R[6_"N=N)HM.^)#W&HL$ADC'DR/]U?E
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M,C8..F<?K6/)&LGQ0C#@';"&Y'<)5OQ1JTEGJ=A90+:PO*<_:IT!$7/;TI6
MO:9XJL=2OOL7E7%M<D9$<Z;<]_7TJ.X\8Z9;SW%N5N&GA?9Y:QY+G_9YKFXS
M_P 5_8!M3&H2 8>8*% .&^48X_\ UU-HE_96/C75S>2QPEV8))(< ?-R,]O_
M *U%@N=+8^*-/U"PN+J 2YMUW2PE1O ^F<'\ZM66LV=_I3:E$S"W4,6W#!&.
MM<OH)BOO'.JW-KA[-HBK,!\K$E?YX-8EU/<:(-6\/1!B+B91#[*?\1M%%@N>
MBZ3JL&LV7VNV258MQ4>8H!./QJ]5/2K!=,TNWLUY\I "?4]S^=7*0PHHHH *
M*** +^F?>D^@K1K.TS[TGT%:-2RD%%%% !1110 4444 %96H_P#'S_P$5JUE
M:C_Q\_\  130F5****8CR[0-/MM5^UM?:O+:F.0!!YP7<#GUKIDTNWTKP[JL
MUEJ4MUOA/SF0-M('8COS6%X0T'3M96_>]A:1HY %PY7&<^E=5?:7::1X5U&W
MLXRD31NY!8GDC'?Z53$AG@J62;PS"\LC.Q=\LQR?O5<\0Z4=6TMX8Y&CN$^:
M)E..?0^QKG_".O:78>'H;>ZO8XI5=R5;.>36W>^)M/M]&EU&"=)E4F- O\3X
MZ4NH=#CV\3W\^A1Z(JRC5&D^SLW\6WI^?;\*[?2[*/0M%"33%O+4R32N>_4G
MZ5Y\+'5K2UB\5EB9FF,C*1_ >_T.2/H172Z[)>>)M M&T=/,AE;,Z;@",?PG
M\?Y4V",>+6+O5?&NGW#>9':R.1 F>"@R,_B0:Z/6/#T]W>3WW]MW-I#M#%$8
MA4 7D]?;-<I>2:S%XCTL/80174486WA0_*0,X[_6NE\9WLT'A>.-ODGNF6-P
MO;C+#],4 4_!=M>SW4^H27]S+9H6CA65R?,_VL$UBQ7::CJ%]+=^(;BQ7SSY
M2*[$$9/H>!7HMA:KIVE06R)Q#$!M7J3CG\2:Y%+WPI-HNH".TCM7 8>7, )2
MV.-O)/7TH ZK1K?[+I4,0O&O!@L)V.2X)SU_&FZOK5MHD$<UVLICD?8&1<X.
M,\\^QK*\")<+X:7S\[6E8PY_N<?US6AXEL?[0\/W< 7+A-Z?5>?\_6EU'T%U
M3Q#8:1-;Q7)<FX^Z4 ( XY//3FGWFMVMEJEKISB1[BYY0(H( SU//L?RKSJ"
M*7Q);W4TNX_8+!4CY_B4Y_4!JUO#5T^I:M=:W=#(LK14!/\ >V\G]&_.G85S
M;TDM>^,=7NLDQVZK;KZ9[_RJUXO=D\*WS(Q5@$P0<'[ZU%X,B== %S)S)=2O
M.Q/<DX_I4GC+_D4[[Z)_Z&M+J'0YG2O#C7GAQ-3_ +8NK>1D=C\_RC:2/7VK
M3\)Z^W_"/7%QJEP2EM)M$K\D@@8'N:H>'_!UAJFA6UY//<AI-VY4<!>&(]/:
MK7C#2XM.\)PV]C%L@CG5GQR3P>3Z\XI^0&G9^,]-N[J* QW,'G'$3S1@*_;@
MYJSJ'B?3M,U#[%<^<)=F\%4R#Z#KG-<GJ/D7UA9077B:&5&*F*.&S!9#C&#M
M;(]*O7,8_P"%DV*O\Y6!>2.I"GFE9!<TX?&^E2"4.MS%+&<"%X_G<^@ /6KN
MC>(K+6WEB@66*:+[T4R@-CUX)KGXXT;XJ3$J#MC##COY8J31P!\2=7 X_<$_
MK'18+F9X3\20Z7IMR+D75Q*9-P6)=Y"@#).3P*[&V\06%WI$VIPN[0PJ3(N/
MF7 SC%<CX#U/3["VO4NYXH)&8,&D(&Y0.@]?I[U'I"^9I/BFY@0K:2*XBXP/
MXB!^ (IM CIK/QEIM_?V]G;1W+R3]#L&%^O/H.U)?>--,LKM[95N+AXR?,,"
M A<=>213/"$('A&'R@!(X<@X_BR1FL?P7J.GZ7:WUM?R1VUVLQ+^;\I9< 8_
M YX]Z5@.CFU:UU7PQ?W5E*646\@/9E.P\'WKF[.6%OAXCWMQ<HGGG,D/+_>X
MZFHM"0R6OBB[@0I8RQ2B(8P#PQ&/H#^M0'_DEZ_]?'_LU,#J+CQ/IVB6EC#/
M]I<26Z.C! 25QCGGK4FF>+M.U6_6RMX[A96!/SH !C\:RM7\2?V1X?L+2U/^
MFS6T>&/2-=HY^M2>$?[&L@(X[^*YU.XYD89)]2 ?3^=*V@7-W2];M=6EN8[9
M90ULVQ]Z@<\].?:HK?Q'97*Z@T:S8L<^;E1SC/3GGI7->%-0L]-U36DO;F.W
M8S9'F-MS@MG&:K:%*L]EXIF3[CHS+GT.ZBP7-]_'6E"W29([J13]_9&/W?./
MFYP*6?QQI,(1D%Q/&<;I(X_E3/8Y(Y]JR-'C0?#6^8*,N)"QQU_SBG01HOPL
MDPH^9"QXZG?3L@U.FOO$&G6&FQ7\LI:&8?NM@R7^@JG8>+["]OTLG@NK6:3_
M %8GC"[O3O7/R:L^G>%M"BCBMR\X($TZ[EBPW7]?TJK?,?\ A+]'\W5EU&42
MQEG1554^88 QQ18+FCJ.IIIOQ!\ZXED$"P?<7)R2O  ]<UOZ5XGL-5NVM$2>
M"Y7GRITVDC\S7.ZC=6UG\2HI[LA8EC WL.%)4@$_C3KNX@U+XAZ>^G2)*(D'
MFR1G(XSGGZ$"BP'=4445(S8L?^/./\?YFK%5['_CSC_'^9JQ4E!1110 4444
M %%%% !7+:^OV;QCX=O0,!VDMW/U'R_KFNIKF?%_RS^'W'4:M"OYYK2E\7WG
M-B_X5^S3_%'34445F=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%%PL9=%:G]FP_WI/S'^%']FP_WI/S'^%%PL9=%:G]FP_P!Z3\Q_A1_9L/\
M>D_,?X47"QET5J?V;#_>D_,?X4?V;#_>D_,?X47"QET5J?V;#_>D_,?X4?V;
M#_>D_,?X47"QET5J?V;#_>D_,?X4?V;#_>D_,?X47"QET5J?V;#_ 'I/S'^%
M']FP_P!Z3\Q_A1<+&716I_9L/]Z3\Q_A1_9L/]Z3\Q_A1<+&716I_9L/]Z3\
MQ_A1_9L/]Z3\Q_A1<+&716I_9L/]Z3\Q_A1_9L/]Z3\Q_A1<+&716I_9L/\
M>D_,?X4?V;#_ 'I/S'^%%PL9=%:G]FP_WI/S'^%']FP_WI/S'^%%PL9=%:G]
MFP_WI/S'^%']FP_WI/S'^%%PL9=%:G]FP_WI/S'^%']FP_WI/S'^%%PL26/_
M !YQ_C_,U8ID48AC$:DD#UI](84444 %%%% !1110 5S/C'[_A__ +#%O_6N
MFKF?&/W_  __ -ABW_K6E+XT<V+_ (+^7YG34445F=(4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<KJ?_)1M#_Z]YOY&NJKE=3_ .2C:'_U
M[S?R-:4MWZ/\CEQ?PQ_Q1_-'54445F=04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$JC_N3_ /?7_P!>CVN/_P"@9_>@^LY;_P!!"^YGM=%>*?\ "51_W)_^^O\
MZ]'_  E4?]R?_OK_ .O1[7'_ /0,_O0?6<M_Z"%]S/:Z*\4_X2J/^Y/_ -]?
M_7H_X2J/^Y/_ -]?_7H]KC_^@9_>@^LY;_T$+[F>UT5XI_PE4?\ <G_[Z_\
MKT?\)5'_ ')_^^O_ *]'M<?_ - S^]!]9RW_ *"%]S/:Z*\4_P"$JC_N3_\
M?7_UZ/\ A*H_[D__ 'U_]>CVN/\ ^@9_>@^LY;_T$+[F>UT5XI_PE4?]R?\
M[Z_^O1_PE4?]R?\ [Z_^O1[7'_\ 0,_O0?6<M_Z"%]S/:Z*\4_X2J/\ N3_]
M]?\ UZ/^$JC_ +D__?7_ ->CVN/_ .@9_>@^LY;_ -!"^YGM=%>*?\)5'_<G
M_P"^O_KT?\)5'_<G_P"^O_KT>UQ__0,_O0?6<M_Z"%]S/:Z*\4_X2J/^Y/\
M]]?_ %Z/^$JC_N3_ /?7_P!>CVN/_P"@9_>@^LY;_P!!"^YGM=%>*?\ "51_
MW)_^^O\ Z]'_  E4?]R?_OK_ .O1[7'_ /0,_O0?6<M_Z"%]S/:Z*\4_X2J/
M^Y/_ -]?_7H_X2J/^Y/_ -]?_7H]KC_^@9_>@^LY;_T$+[F>UT5XI_PE4?\
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M&I_]!&\_[_M_C1_;&I_]!&\_[_M_C1]3EW#^UH?RL];HKR3^V-3_ .@C>?\
M?]O\:/[8U/\ Z"-Y_P!_V_QH^IR[A_:T/Y6>MT5Y)_;&I_\ 01O/^_[?XT?V
MQJ?_ $$;S_O^W^-'U.7</[6A_*SUNBO)/[8U/_H(WG_?]O\ &C^V-3_Z"-Y_
MW_;_ !H^IR[A_:T/Y6>MT5Y)_;&I_P#01O/^_P"W^-']L:G_ -!&\_[_ +?X
MT?4Y=P_M:'\K/6Z*\D_MC4_^@C>?]_V_QH_MC4_^@C>?]_V_QH^IR[A_:T/Y
M6>MT5Y)_;&I_]!&\_P"_[?XT?VQJ?_01O/\ O^W^-'U.7</[6A_*SUNBO)/[
M8U/_ *"-Y_W_ &_QH_MC4_\ H(WG_?\ ;_&CZG+N']K0_E9ZW17DG]L:G_T$
M;S_O^W^-']L:G_T$;S_O^W^-'U.7</[6A_*SUNBO)/[8U/\ Z"-Y_P!_V_QH
M_MC4_P#H(WG_ '_;_&CZG+N']K0_E9ZW17DG]L:G_P!!&\_[_M_C1_;&I_\
M01O/^_[?XT?4Y=P_M:'\K/6Z*\D_MC4_^@C>?]_V_P :/[8U/_H(WG_?]O\
M&CZG+N']K0_E9ZW17DG]L:G_ -!&\_[_ +?XT?VQJ?\ T$;S_O\ M_C1]3EW
M#^UH?RL];HKR3^V-3_Z"-Y_W_;_&C^V-3_Z"-Y_W_;_&CZG+N']K0_E9ZW17
MDG]L:G_T$;S_ +_M_C1_;&I_]!&\_P"_[?XT?4Y=P_M:'\K/6Z*\D_MC4_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFQ?\%_+\SIJ***S.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N5U/_ )*-H?\ U[S?R-=57*ZG_P E&T/_ *]YOY&M*6[]'^1RXOX8_P"*
M/YHZJBBBLSJ"BBB@ HHHH **** "O)O&G74/^N__ +-7K->3>-.NH?\ 7?\
M]FKSL9_O&'_QHU_Y@\1_@?Y'"4445]@?FP4444 %=WK?ABQE\.V5QI<86_AL
MHKFYB4DF1&'+\^A!Z?X5PE=MK.K3Z+K'A^]@YVZ3 '0]'4YRIK&KS<RY3MPO
ML^2?M%II\O-&1H-C;7>C:[-/"'DM[97B8D_*<]:H:;H>IZN&-A92SJAPS*.
M?J>*[<Z7;VVC:_J6G'=IM]9AX<?P-N^9#]#6)!:QIX6L3K6K2VUC,[O;6MO
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M_P"=_P!#IM$U^W@T^6UOL[DC86\F"2-PY7^54K&\L[C2&TN^D: "7S8I@NX
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M_P /_P#88M_ZUTU<SXQ^_P"'_P#L,6_]:TI?&CFQ?\%_+\SIJ***S.D****
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M$_WD(JU#K$$G\0H TZ*B2XCD'#"I 0>E "T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2,P49)JO<7<<"DL163]HN]3?;:KB/.#(WW1_C0!H7.I
MPP Y850^U7U\<6T#;#_&W"TZ2#2])03:A.KR=09.<_1:P]1\;2OF/3XA$O\
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M_P!5KN:X;P/_ ,?8_P"O7^JUW-?&Y3_ ?^)_F?J&-^./HOR"BBBO3.,****
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M *]=711_8^#_ )/Q?^8?VCB?YOP1RG_"'/\ \_J_]^__ *]'_"'/_P _J_\
M?O\ ^O75T4?V/@_Y/Q?^8?VCB?YOP1RG_"'/_P _J_\ ?O\ ^O1_PAS_ //Z
MO_?O_P"O75T4?V/@_P"3\7_F']HXG^;\$<I_PAS_ //ZO_?O_P"O1_PAS_\
M/ZO_ '[_ /KUU=%']CX/^3\7_F']HXG^;\$<I_PAS_\ /ZO_ '[_ /KT?\(<
M_P#S^K_W[_\ KUU=%']CX/\ D_%_YA_:.)_F_!'*?\(<_P#S^K_W[_\ KT?\
M(<__ #^K_P!^_P#Z]=711_8^#_D_%_YA_:.)_F_!'*?\(<__ #^K_P!^_P#Z
M]'_"'/\ \_J_]^__ *]=711_8^#_ )/Q?^8?VCB?YOP1RG_"'/\ \_J_]^__
M *]'_"'/_P _J_\ ?O\ ^O75T4?V/@_Y/Q?^8?VCB?YOP1RG_"'/_P _J_\
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M-/L>!];K_P [.B_X375O6#_OW_\ 7H_X375O6#_OW_\ 7KG:*/8T^P?6Z_\
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MPFNK>L'_ '[_ /KT?\)KJWK!_P!^_P#Z]<[11[&GV#ZW7_G9T7_":ZMZP?\
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MC*KJ58!E(P0>]+4)N[97V-<1!_[I<9I-KJ-)O8YO4M-ETF=;RR+"('I_=_\
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M7XGHA/#.CMKFK!9,F"/YYF]1Z?C_ (UZVB+&BH@"JHP .PK'\,:2-(T6*)E
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M_KU_JM=S7#>!_P#C['_7K_5:[FOC<I_@/_$_S/U#&_''T7Y!1117IG&%%%%
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MZ+<S$B*'5(9'(&<* Q-:4?C1S8QI4)-_UJ=717+_ /"P?#O_ #]2?]^FI/\
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MG4Q-9*[A-+5)Z:6.F\5ZS9V7AR[W3QL]Q"T<2!@2^X8R/;G-<=\,/^0U>?\
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M8?\ QH^F_P"8/$?X'^1PE%%%?8'YL%%%% !1110 4444 =%X%_Y'/3_]YO\
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MQ,(SC.\G9]3IM.O?&YU"%5&ION8 K/&Q0CONW#&*H>+#;6/C"=],*1B)T?\
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M_DG"[8^%C7^ZHX JE5P34=3&M)2FVMO\@HHHJS(**** "BBB@ HHHH ****
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MAO\ H)_\D?\ F>,45[/_ ,(=+_S^)_WP?\:/^$.E_P"?Q/\ O@_XT?VUC/\
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M^@G_ ,D?^9XQ17L__"'2_P#/XG_?!_QH_P"$.E_Y_$_[X/\ C1_;6,_Z!?\
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M!?\ R=?Y!_JQAO\ H)_\D?\ F>,45[/_ ,(=+_S^)_WP?\:/^$.E_P"?Q/\
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M*KF_@;LSZW'8>.)HJ$?C237I_7Z%CXC_ /(T#_KW3^9KU-[JWM+:-[F>.%2
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M?ZY_[[-'US$?] \_N#EPO_/^'WGIM%>9?\)!>?\ /]<_]]FC_A(+S_G^N?\
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M]HE:0H^ 6Y/2MVNO#UXUZ2JQV9%:DZ4W!] HHHK8R"BBB@ HHHH *XCXH?\
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MRK7_ "/GN:XEN!$)7+>4@C3/9020/UKV'Q7H-UX@T>WMK22%'1PY,I(&,8[
MUA7_ ,,UN+Z::UOD@A=MRQ&(G;[9STKT!!M15]!BL\#@IQ52%9:.WZFF8YA3
MFZ53#O6-^FU['E7_  K+6O\ GZL/^_C_ /Q%'_"LM:_Y^K#_ +^/_P#$5ZM1
M6_\ 9.&[/[SG_MK%]U]QGZ'8RZ9HEI93,C20QA6*$D$^V:R_'?\ R*-W]4_]
M"%=)69X@TIM:T::P681&0CYRN<8.>E=5:F_8.G#M9?<<5"JOK,:L^]W]YRGP
MO_X\-0_ZZK_*NG\0:QIFE6:KJB,\,^4VB/<&]C57PIX:?PW;W$3W2S^<X;(3
M;C ^M:.M:/;:YISV=T"%)W*Z]4;U%8T*56GA%!+WK=3HQ-:C4QKJ-^XVMO0Y
MFP\-^$;^T&L11LMKRS))*0J8Z[AGCZ9KD-"A75?'<36L>V 7!E 48"HIR/IV
MK9;X97XE*1ZG#]G)Y)5@?^^>GZUV'AWPQ9^'87$+-+/)P\S#!(] .PKBCA:E
M6<5*FH):O;4]">,I4*<W&JYN2LKWT1N4445[9\\%%%% !6/XHE\K09QG&\JO
MZUL5RGC:ZVVUM:CJ[%S]!P/Y_I7/BI<M&3.G!PYZ\5Y_D7O",6S1 _\ STD9
MOZ?TI(CYVO73]@P4?@ *T=)@%GH]M$>-L8+?4\G]36=HP\V66?\ ON6_,U="
M/+3C'R(Q$^>K*7F;HZ44M%:F('D5@WO^BZI;W'0!\'Z'C^M;U9FKVWG6S<=J
M .2^*-B9+&ROU7_5.8W(]&Y'ZC]:3X8:H)+.ZTQ_O1-YJ>X/!'X$?K72SVPU
M_P *SVDGS2/&4R?[XZ'\P#7DWAC56T#Q+!-*"J!C%.IXP#P?R//X5W4OWE!P
MZH\#%_[+CX5^DM_R_P F>ZT4@(8 @Y!&0:6N$]\**** (YH(;F%H9XDEB<89
M)%#*?J#45IIUC8;OL=G;VV_[WDQ*F?K@59HIW=K"Y5>]M1KHLB,CJ&1AAE89
M!%5+?1M+LYA-:Z;9P2KT>*!58?B!5VBB[0G&+=V@HHHI%!1110!4N]+T^_=7
MO+&VN&484S0JY ]LBK,<:0Q+%$BI&@"JJC 4#H *=13N]A**3NEJ1S017$31
M3Q)+&W#(ZA@?P-9<'A30;:X\^+2K829R"5R ?8'@5L44*36S)E3A)WDDPZ#
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MM%>Q3P\U%.VMVK>EO\S.HHHJSG"BBB@ HHHH **** "BBB@ HHHH ];\#_\
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M96D4MQ(B2R\K!SO"^I]*%--V"5&2BGY7]-6OT*-%%%68A1110 4444 %%%%
M!1110 4^+_6I_O"F4^+_ %J?[PK#$_P9^C_(WPW\:'JOS/0?!_\ QYW/_70?
MRKI*YOP?_P >=S_UT'\JZ2OF\J_W.']=3[C'_P"\2"BBBO0.0**** "BBB@
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M-L(Y&>>2#U[5;\ PHWB#Q%*4!83E 2.Q=LC]!4&IW$%C\7;6YNI4AA$.2[G
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M?_QYW/\ UT'\JZ2N;\'_ /'G<_\ 70?RKI*^;RK_ '.']=3[C'_[Q(****]
MY HHHH **** "N9\8_?\/_\ 88M_ZUTU<SXQ^_X?_P"PQ;_UK2E\:.;%_P %
M_+\SIJ***S.D**** "BBB@ HHHH *\JT'X=/J.L76I:RC1VAN':.W/#2_,<$
M^B_SKU6BKA4E!-+J85L/"M*+GK89%%'!"D42*D:*%55&  .@%/HHJ#<****
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M:W((5B0 #I7)5J.I+F9[&%PT,-25.'_#DBJ%7 IU%%9G2%>3>-.NH?\ 7?\
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M#Z[)I^H*QLY&^;'(QV=?ZC_"O4H9H[B%)H7#QNH964\$&L76-'L?%6D@9 D
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M/ADK))_IVI8XXX0^P[?4\UU*-+#ZO61Y$JF+S+W8+EI_G_F9/ASP:(T74]<
MC@4;D@;JW^\/Z5U+--JTJJ%,5HA^5,8S]:6.UN=2F$UVW ^Z@^ZM;<-NL*@
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M.-HU=$[/L]&<N(P%>CJU==UJC8HHHKK.(**** "BBB@ HHI&=44L[!5'4DX
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M\-/_ .^?_L:[VBC^S:?\TO\ P)A]9_N1_P# 4<%_P@<G_/#3_P#OG_[&C_A
MY/\ GAI__?/_ -C7>T4?V;3_ )I?^!,/K/\ <C_X"C@O^$#D_P">&G_]\_\
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MZS_<C_X"C@O^$#D_YX:?_P!\_P#V-'_"!R?\\-/_ .^?_L:[VBC^S:?\TO\
MP)A]9_N1_P# 4<%_P@<G_/#3_P#OG_[&C_A Y/\ GAI__?/_ -C7>T4?V;3_
M )I?^!,/K/\ <C_X"C@O^$#D_P">&G_]\_\ V-'_  @<G_/#3_\ OG_[&N]H
MH_LVG_-+_P "8?6?[D?_  %'!?\ "!R?\\-/_P"^?_L:/^$#D_YX:?\ ]\__
M &-=[11_9M/^:7_@3#ZS_<C_ . HX+_A Y/^>&G_ /?/_P!C1_P@<G_/#3_^
M^?\ [&N]HH_LVG_-+_P)A]9_N1_\!1P7_"!R?\\-/_[Y_P#L:/\ A Y/^>&G
M_P#?/_V-=[11_9M/^:7_ ($P^L_W(_\ @*."_P"$#D_YX:?_ -\__8T?\(')
M_P \-/\ ^^?_ +&N]HH_LVG_ #2_\"8?6?[D?_ 4<%_P@<G_ #PT_P#[Y_\
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MB_\ H#UI2BIS46<^+JRHT95([HN_\+$\-_\ /W)_WX;_  H_X6)X;_Y^Y/\
MOPW^%>*T5Z'U*GYGSG]MXGLON?\ F>U?\+$\-_\ /W)_WX;_  H_X6)X;_Y^
MY/\ OPW^%>*T4?4J?F']MXGLON?^9[5_PL3PW_S]R?\ ?AO\*/\ A8GAO_G[
MD_[\-_A7BM%'U*GYA_;>)[+[G_F>U?\ "Q/#?_/W)_WX;_"C_A8GAO\ Y^Y/
M^_#?X5XK11]2I^8?VWB>R^Y_YGM7_"Q/#?\ S]R?]^&_PH_X6)X;_P"?N3_O
MPW^%>*T4?4J?F']MXGLON?\ F>U?\+$\-_\ /W)_WX;_  H_X6)X;_Y^Y/\
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M*7QHYL7_  7\OS.FHHHK,Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ9%9^M27?_"4SE"XF6;$6/\ QW'Z52G)NQG*C3BN;5K3;_AAEC:Q/H6L2RQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+D[(H45>2Q6;2'NX2QD@?$RD\;3]UA_(U1H33"47&U^H4444R0HHHH ****
M"BBB@#T/P1_R G_Z[M_):Z6N:\$?\@)_^N[?R6NEKR:W\1GU>#_@0] HHHK(
MZ0HHHH **** "N9\8_?\/_\ 88M_ZUTU<SXQ^_X?_P"PQ;_UK2E\:.;%_P %
M_+\SIJ***S.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKIJYGQC]_P /_P#88M_ZUI2^-'-B_P""_E^9TU%%%9G2%%%% !1110 4444
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M ,31[>G_ #"_L_%?R,XRBNS_ .%8Z]_STLO^_I_^)H_X5CKW_/2R_P"_I_\
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M^_X?_P"PQ;_UK2E\:.;%_P %_+\SIJ***S.D**** "BBB@ K&U;Q#'IEP(!
M99,9/S;0/YULUPOBC_D-R?[B_P J\W-<34P^'YZ;L[V.W 485JO+/:QH_P#"
M9?\ 3A_Y&_\ L:/^$R_Z</\ R-_]C5FR\.:=/86\SHY>2)6;#GJ0#4__  B^
MF?\ /.3_ +[-<4:>;2BI*HM?3_Y$Z93R].S@_P ?\S/_ .$R_P"G#_R-_P#8
MT?\ "9?].'_D;_[&M#_A%],_YYR?]]FC_A%],_YYR?\ ?9I^QS?_ )^+\/\
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M +&C_A,O^G#_ ,C?_8UH?\(OIG_/.3_OLT?\(OIG_/.3_OLT>QS?_GXOP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ^_X?_[#%O\ UKIJYGQC]_P__P!ABW_K6E+XT<V+_@OY?F=-11169TA1110
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MV,I@A2,RN9)-HQN8]2?>HSIUDU\M\;6(W2C FV#=CIUK*D\66OG3I:65_>I
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MV?\ UR7^5%&D?\@>S_ZY+_*BO2P_\&'HOR.*M_$EZLNT445L9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<KK/R>/?#\G]Y)D_3_Z]=57*^,0
M+:ZT/4SPEM>JDC?W5?@G]*TI?%;U_(YL7_"YNS3^YHZJBBBLSI"BBB@ HHHH
M **** "DI:2@!**\^^*-Q/ FDB&XEA#R2!C&Y7^[Z5%_PBNG?]#I/_X$K_\
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M&]17/Z7XPTW5+_["$N+:Z(RL=Q'M+?2K8\06;>(6T0++]J";R=HVXQGKG^E
M&K24M<7KUPMUXLBTO4KZ2STTV_F($D\L3/GH6_I0!V5)7+P:%/IM_9W6A7TD
MMFTFVZ@FG+H4_O+[BM/4O$%IIMVMIY5Q<W3+O$%M&78+ZGT%,1JTE<\?%EM-
MI][)!;7@N;8?/;M#^\7(X./2LWP6]JNFR:K<F\6X\LM<7%TQ\M@3DE><8XH
M[.DKGT\8:>S([V][%:NV$NY("L1]#GL*IW7B*:/QM%9"&\:U$!!1(LAF+??]
MU [T".LI*I:;JMOJBSF .K03-#(D@PRL*6QU*#47NA 'VV\QA9R.&8=<>N*
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M2G8GF,CP@ZMX;ME# LN[(!Y'S&MVJEIIEE82226MND32??V\9JW0A2=W<*4
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M-_C1_P (WI/_ #ZG_OXW^-'U?-O^?J_K_MT/;8#^1_U\S)_X3%_^?%?^_O\
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MK6_X1O2?^?4_]_&_QH_X1O2?^?4_]_&_QH^KYM_S]7]?]NA[; ?R/^OF9/\
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M)_Y]3_W\;_&CZOFW_/U?U_VZ'ML!_(_Z^9D_\)B__/BO_?W_ .M1_P )B_\
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M_P"_'^9_PI/[*G_OQ_F?\*.9![*?8H4E:']DS_WX_P S_A2?V3/_ 'X_S/\
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M:K37[R/S3_1V_4ZNBN N_'.KZ0YCO["QF9>28)74'\P:J?\ "V?^H)_Y-?\
MV%7]6JO9&3S3"K24K?)GI5%>:_\ "V?^H)_Y-?\ V%'_  MG_J"?^37_ -A1
M]5J]OR%_:V#_ )_P?^1Z517FO_"V?^H)_P"37_V%'_"V?^H)_P"37_V%'U6K
MV_(/[6P?\_X/_(]*HKS7_A;/_4$_\FO_ +"C_A;/_4$_\FO_ +"CZK5[?D']
MK8/^?\'_ )'I5%>:_P#"V?\ J"?^37_V%'_"V?\ J"?^37_V%'U6KV_(/[6P
M?\_X/_(]*HKS7_A;/_4$_P#)K_["C_A;/_4$_P#)K_["CZK5[?D']K8/^?\
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MFO\ ["C_ (6S_P!03_R:_P#L*/JM7M^0?VM@_P"?\'_D>E45YK_PMG_J"?\
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M_@_\CTJBO-?^%L_]03_R:_\ L*/^%L_]03_R:_\ L*/JM7M^0?VM@_Y_P?\
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MG_J"?^37_P!A1]5J]OR#^UL'_/\ @_\ (]*HKS7_ (6S_P!03_R:_P#L*/\
MA;/_ %!/_)K_ .PH^JU>WY!_:V#_ )_P?^1Z517G,7Q.N+L[;?2(D;IF2Y)'
M/T6M>&7Q?JB@I=Z79QMR#'&[L!_P+BD\/-?%H5',:$]*=Y?UYV.M>1(D+R.J
M*.K,< 5S=YXPA>=K+1+>34[S.W]T/W2'U9^F*:G@R.[99-<U*[U.0=%=MD0^
MBC_&NAM;.VL8%@M8(X8EZ)&H J?<CY_D:_OZG]U?>_\ )?B<]8^&+B\O$U+Q
M'<+=W*\Q6ZC]S#]!W/O74=!@445$IN6YM2I1IJT?^"PHHHJ30**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>gbkyd1brmfwp000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbkyd1brmfwp000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'H!?L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQXZN;/2I4MVDTY$>=N3&F[M[G@5K>"[B%-,?2V@6VO[)MES$.K-_?SWW>O\
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MQIR:@@QQO5 K@>YX-=7J=BNIZ9<V3.46>,H6 R1FLW4_"UKJMOIL,TK@6)4
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MQT^E=)'X806&I17%[-<76H1E)[EP,XQ@84< #/2I[_08[_PXFCM.Z(B1IY@
MS\A!Z>^*=Q6.=U70TT[5M(2TO;V.2^E:&[E\]BTPQDDYZ'KTQC-6]/MDT?Q?
M>:99O*MG)I_VCRGD9PK[R,C))Z5O:AI27][I]RTK(;.4R*H&=V1C%-;1T;7G
MU7SFWO:?9?+QQC=NS]:+CL<1 UU=>$O"<:WEQ$]Q>E'E20ARI+@\_2MN*QBT
M'QEIUK8/,MO>PRF:)Y6<%E (;YB>:O6_A6&WT[2+,74A739_.1BHRYR3@^GW
MJOW.E)<ZW8ZF965[1)%" <-O&/Z47%8XZZCL+Z6^<0ZQK-UYCE;J M'%"1T5
M3N"\?0U)%=37NF>#;BXD,DK77S,W4X!'/OQ6S%X4EMX9+*#6+F+3)&8FV5%W
M ,<E0^,@&I;?PM';V>DVWVN1QILQE1BHR^2>#^=%T%F=!1114E!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM^-+J"R\1^%[FY8+"D\A9FZ+]P9_#K0@98N]=\2Z'$M_K%A8/IY8"7[&[>9
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MO1LT5C?\)9X?_P"@Q9_]_11_PEGA_P#Z#%G_ -_11R3[![>E_,OO1LT5C?\
M"6>'_P#H,6?_ ']%'_"6>'_^@Q9_]_11R3[![>E_,OO1LT5C?\)9X?\ ^@Q9
M_P#?T4?\)9X?_P"@Q9_]_11R3[![>E_,OO1LT5C?\)9X?_Z#%G_W]%'_  EG
MA_\ Z#%G_P!_11R3[![>E_,OO1LT5C?\)9X?_P"@Q9_]_11_PEGA_P#Z#%G_
M -_11R3[![>E_,OO1LT5C?\ "6>'_P#H,6?_ ']%'_"6>'_^@Q9_]_11R3[!
M[>E_,OO1LT5C?\)9X?\ ^@Q9_P#?T4?\)9X?_P"@Q9_]_11R3[![>E_,OO1L
MT5C?\)9X?_Z#%G_W]%'_  EGA_\ Z#%G_P!_11R3[![>E_,OO1LT5C?\)9X?
M_P"@Q9_]_11_PEGA_P#Z#%G_ -_11R3[![>E_,OO1LT5C?\ "6>'_P#H,6?_
M ']%'_"6>'_^@Q9_]_11R3[![>E_,OO1LT5C?\)9X?\ ^@Q9_P#?T4?\)9X?
M_P"@Q9_]_11R3[![>E_,OO1LT5C?\)9X?_Z#%G_W]%'_  EGA_\ Z#%G_P!_
M11R3[![>E_,OO1LT5C?\)9X?_P"@Q9_]_11_PEGA_P#Z#%G_ -_11R3[![>E
M_,OO1LT5C?\ "6>'_P#H,6?_ ']%:4=[:RQK)'/&R. RL&X(/0U+BUNBHU(3
M^%ID]%1?:H/^>J?G1]J@_P">J?G2+):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0
M?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_S
MU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0
M?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_S
MU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0?\]4_.C[5!_SU3\Z ):*B^U0
M?\]4_.GI(D@RC!A[4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#OBS1?%5M+/I%ZLXA;;-&RE'B/HRL 16*WQ6\&IJ#6AU;Y5E\EKD0N8 _\
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M1S/)->WLD3E@G!B ;#-[?2O0/"+,W@W168[F-C"2<YS\@[T :ES;QW=K-;3
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M '_QKJJ*/;5/YF'U+#?\^U]R.5_X5UX;_P"?27_O^_\ C1_PKKPW_P ^DO\
MW_?_ !KJJ*/;5/YF'U+#?\^U]R.5_P"%=>&_^?27_O\ O_C1_P *Z\-_\^DO
M_?\ ?_&NJHH]M4_F8?4L-_S[7W(Y7_A77AO_ )])?^_[_P"-'_"NO#?_ #Z2
M_P#?]_\ &NJHH]M4_F8?4L-_S[7W(Y7_ (5UX;_Y])?^_P"_^-'_  KKPW_S
MZ2_]_P!_\:ZJBCVU3^9A]2PW_/M?<CE?^%=>&_\ GTE_[_O_ (T?\*Z\-_\
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M/\S0!V7@;_D0?#__ &#X/_0!6_6!X&_Y$'P__P!@^#_T 5OT %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -D#F)Q&0)"IVD]
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M?]\"@#:HI&944LQ  [FHOM=OG'G)GTS0!-134=9%W(P8>HIU !1110 4444
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MER;V23$<!<;3C'(^E?0%Y_QY7'_7-OY5Y+\%/#^FWG@ZZDU'2;>6;[?* UQ
M"V.,=1TH TO^%^>!?^?J]_\  5JUO#?Q9\*^*M:BTG2Y[E[N5691) 5& ,GF
MN@_X1/P[_P! /3__  &7_"I[30-'L+A;BSTNS@F4$"2*%58 ]>0* -&N0N/A
MQHFI>*)]>UD2ZI,Q'D073;H;=0!PJ=.V>:Z^B@"*"V@M8EBMX(X8U&%2- H'
MT K,\2:SHFAZ:+C7IH8[2600CS4WAF.<#&#Z&MBO*?C_ /\ (BV1_P"HG%_)
MJ .D@^&^A67B6T\0:()-+G1LS16IVQ7"D'Y63IWSQZ5V516__'K#_N#^52T
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M/>"-S$?>![8[&L2^UOQ'IU]-:7&I72R1-@@O^1H ]HHKB?">KFUT\W&NZO\
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M(PRK*<@CU%>!Z<?#/BOQ+XJ\9>)UB?PS9JNGZ<9PVT@#J@Z[N,COEZ[_ .#
MNQ\,=-^U"4)OE^SB7[PAWG9^&.GMB@#OZ*** /-;3_DXN_\ ^Q?7_P!&K5/^
MT;/P/\9=;N];E^R:?KEK"]M>2C$7F1C!0MT!ZGGV]:]3\J/S3+Y:^81M+[><
M>F:;/;0747E7$$<T9_@D0,/R- 'CD-HWQ \0^.]7TA6?3KC2?[+M+@@JMQ*!
MD[<]1D8S[BG6/Q$T2S^#_P#9$\[)KL-@=..F%")S-M\L#;C..AS_ %KV..*.
M&-8XD5(U&%51@#\*C-C:-="Z-K ;@=)3&-X_'K0!Y?IOP9T/5_"^@_\ "10W
M0U&UL$A=8IM@7DM@C'4%B*X[XK?"CPQX0\$2:KI4=TMTMQ'&#+/N&#G/&*^B
M*\N^/_\ R2^7_K[A_F: .P\!J$^'_A]1T_L^'_T 5T-8'@;_ )$'P_\ ]@^#
M_P! %;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%96K^(M,
MT3:+VX"R,,K&HW,1ZX%0Z3XKTC69O(M;@B8\B.1=K'Z>M3S1ORWU+]G/EYK:
M=S;HJ.2XAB8+)-&C'H&8 FGY&,YX]:H@6BH8[NVF<I%<12..JJX)J:@ HHHH
M **** ([@E;:4@X(0D$?2O#O[>UC/_(5O?\ O\W^->XW +6TJ@9)0@#\*\2_
MX1K7,G_B4W?_ '[-=%#DN^8X,?[7EC[*_P B?2=;U:36;%'U.[9&N$#*9F((
MW#BO:J\9TKP[K,6L64DFEW2HDZ,S&,X ##FO9JFOR\WNE8#VOLW[6][]1-RC
MJ1^=&Y?[P_.O&?&;N/%VH .P&Y> Q_NBL+S)/^>C_P#?1JHX=RBG<SJYC"G-
MP<7H?0E%97ADD^&-,)))^SIU^E8GCO7=1T1+ V$RQF4N'R@;.,8Z_6L(IR=D
M=TYJ$7*6R.PHKQW_ (3WQ%_S^1_]^$_PKMO NMW^MV=Y)?S+(T<@52$"X&/:
MKG2E!79C1Q=*M+E@]3K****S.D*P_$NEW^K06\%I+ L*OOE60D;B/N]!TSS^
M5;E%3**E%Q>S'&3B[HX7_A$=7(P9+$Y_VV_PKIM LKS3M*2TO9(Y&B)$9C).
M$[ Y].GY5%;>(K:YU^;2E4@Q@A)<\.P^\H^G^/I4VOO?+H\RZ="TMS)A%VD
MJ#U;GT%<]##4*%W25OO>QM6KU:ME49RVJ>([C_A(!=6LCFTLV\ORU/$P_C/O
M[?3WKN()H[F".>%@\<BAE8=P:\X31=5C1472KD*HP.4_^*KJ/"4>HVMK-9WE
MI)##&VZ N1T/5>">A_G6&#K8B=2:K1:6Z_R_KS-L32HQA%TY)OK_ )G1T5Q7
MBS5IY+]+&RG:(VQ$LCJ>LG55^@ZD>XKI]'U)-6TR*[4;68;9$_N..H_.NR%>
M$ZDJ:>JW.:5*<8*;6C,WQ7JKV-BMK;2%+JY)564\QH/O-_0>YJ7PQJK:EIOE
MSMFZMCY<I/5O1OQ'ZYKE=1@U:_U6XNY=,O/F;9& F0J#IW[]?QJ71X=5T_6K
M>X73;L1N?*F!3 *'OU['G\ZXEB*_UOEY'R;7MU[_ *'2Z-+ZOS<RYM]_P/0*
M***](X@HHI#G''6@"*[M+>^M9+:ZB66&08=&Z&I418T5$4*JC  Z 5Y?J/C?
MQ)IFHSV4ZV@DB<J?W1Y'8CGH15[PUXM\0:YK<5J5M?)'SS,(B,(/QZGI0!Z'
M7&_$'0OM^F#48$S<6@^; Y:/O^77\Z[*D90RE6 *D8(/>@#QWP7H?]LZVKRK
MFUML229Z,?X5_'^E>QUGZ1HUGH=J]O9(51Y#(Q8Y))_H.E:% &)XEUZ7P_8Q
MW:V1N8V?8Y#[=GIV/6O-XO$EE%XIDUL:4=S#*P^;PLAZMG'^<UZW?V4.HV$U
MG<+NBF0JW^->-6_AN[E\4?V(X(=9,.X'1!SN_+^= 'J_AW6)==TP7TEF;96<
MB,%]VX#OT'?/Y5K5%;V\5I;1V\*!(HE"*H[ 5+0 4444 %%%% ",P1&9CA0,
MFO!-/_X3OXK:GJ=_INOG1-%M;@PVZ1@C<5]EP2>F23WKW6\_X\;C_KFW\J\4
M^#WC?PSX>\)W5GJVLVUI<F^E?RY"<[3C!Z4 =!\+_$OB'^W]9\'>*9Q=7^FX
M>.Y[R(?4]^H(->I5X-IGC;PS!\==6UE]9METV:P6-+C)VL_R\=.O!KU;2?'O
MA77=02PTO6[6ZNW!*Q1DY( R>U '1UYKXM^&.J^)/$4^IVWBZ_T^*15 MX2V
MU<#'9A7I5,F+B"0Q &0*=H/<XXH \6F^#^IV[;9OB1?QGT>5A_-ZJW'P;-Z(
MTO/B'+=1HX<1S2;QD>Q?K5/X?_#G3/B#8:CK?B74K^XU0WLD<L23;3%@]#P3
MS78K\ O!JNK!]3RI!'^E?_6H ]/C79$B YVJ!GUIU(BA$5!T48%+0 4444 %
M%%% !1110!A>-/\ D1M>_P"P?/\ ^@&I?"?_ ")^B_\ 7C#_ .@"LGXCVVJ7
M'@W4VT[48[2..SG:X5X!)YJ;#\H.?E[\UJ^$<CP;HFXY/V&')_X * -ARP4E
M5W-V&<5SUU;"Y\4PRR0 2QVAVL),8RU=%7%:_JKP:Y/'"5^:#R2V>F>365>O
M"C#GGL:4J4JLN6)I:0]K?O>!7D4QR$XWDY'K^E9'BK08=:U*QN;=B/F$=R=I
M^X._]*SM.OY--O$GBV_W65NA!]:W-7ULQ7=K&EN(VA822KP0P/0 CJ,5PX;,
MH3H.K5TL[/Y['57P4HU?9T];F=XP\/Q7&C+=6,CN+%<>4PSA/8]>/2N4\,Z>
M]S=2WBD)]E0O$SQED,G\(->P "YMPT"0M!,G.[N#]*HZ)HW]AV!M8/)9#(SL
MQSDY/]!Q7IG">=GX@^(!D&2W!'7]U7H?A>YU*]T6.[U,IYLQW(JIMPO:N2UO
MPA]I\:0"%0+*[)DE*]$Q]X?C_6NW73%1%6WN[F)%& JN" /Q!H =JVJ0:/8-
M>7*R&%2 WEKDC-<__P +&T+_ *>O^_7_ ->MNZTRYNK26V>]WQ2J5821 Y!_
M*O)8/#ES)XH&B.#N63#L/[@YW?E0![%IFHPZK81WL"R+%)ROF+@D?2K=1P0Q
MV\$<,2A8XU"J!V J2@ HHHH **** "JNHV,6I:=/9S#*2H5/MZ&K512O*F2J
M*5 R26Q0!B^$O#Y\/Z6T4I5KF1RTC+^@_*M^J5E?-?VZ3PHIC8D9W<C!J[23
M35T#36C"BBBF 4444 %!Z444 9\LN0N^64#<,?NN]68'9BV6<X_O)MKF?%.J
M.MU#:V[X:(B1R#_%V%='IUXE_817*?QCD>A[BN>GB:<ZLJ2WB;3H3A3C4>S+
M5%%%=!B%%%% !1110 R1F5<JF\YZ9Q5=;TO<20+%F6,!F7<. >E37-PEK;23
MR'"1J6-<'8ZO)#KGVZ4\2MB0?[)_PKDQ.,AAY0C+[3_IG10PTJT9./0] 4DJ
M"R[3Z4M("& (.0>0:6NLYPHHHH **** "H97E3<51"@&22V*FK!\4ZA]ET_[
M.C8EGX^B]ZSK58TJ;J2V1=.FZDU!=34M;F2ZABF5$\MQG(;-6JY;PCJ&4DL'
M/W?GC^G<5U-1AJ\:])5(]2J])TJC@^@4445N9!1110 4A&012T4 <7X@^TVT
M0:XLK3,C[482L6^N*G\)*)$<-#"?+<GS-QWDGGI7/^*M;BN=4D9LO# ?+0*>
M_<UE:9XBM]/U'SS'.867:Z(>37!"IB*F)]R+=-:7\SHJ/#4:-JDTI[V\CV!U
M#H5/0^E5_P"SX2P;+Y'0YKCK/Q]IQ\F)OMBL6"XV@CK79?;[;('F\GH-IKT9
M1E'=')"K"I\#N<OXD^T23K:003M!%\[-L)!8_P" JKH;7]I=X'G00R+EF:(E
M..A/^-=H%AN075F8=#AB*JZAIZ3V+0+-+"K8!*DMQZ8KS98'_:/K*D[]NGH=
M\<5^Z]BXJW?]3D8M=F77?[0E.5/R,J=-GM_.NRCU:R?&9A&3T$@*Y_.N<_X1
M>WWX^US[<=?*KI+&U6+3XX)',X0;0TBX)%+ 0Q,.95^KON/%RH2Y72Z:$TL2
M72 "5@ <YC:LJU-M=:A=VJ3S;X2,G?U]?RHUB*RTW3Y+E$,4G2/RF*Y8^PKC
MK&^FL;U+F-QO!^8MR"#US3Q>/AAZL(/KOY(6'PDJT)373;U/2D78BJ"3@8R3
MS3JSTO+P(KO:++&1D/ ^<CZ'FGKJMJ6VR,T+?W95*_\ UJ] XR[6'K6@VNJ:
MGIMU,!NMY.1C[XQG!_&MD.)8R8G5LCA@<BLB\FN+>ZLXY;F,-+)A1CVI-I:L
M:3>QJS6L%P,30H_H2.157^S3%_QZ74T/HI.]?R-6;=9U#><ZL<\8J:F(H>;J
M,'^L@CN%_O1-M;\C_C7 ^+]8UG3]4WVU[=PVTZY$;IC8>XZ5Z;6+XJT<:SH,
M\ '[Y!YD1_VA_CTH Y#P5?Z[K.KYGU&=K.W&Z0<88]EKTFN9\->&H].T2 2&
M2.[<;Y'1R"">WIQ6QY&H0_ZJZ291_#,N#^8_PH O451^W3Q?\?-E*!_>B(<?
MXBI8=0M)SA)TW?W6^4_D: +-%%% !1110 44F]?[P_.@$'H0: %HHHH ****
M "BBB@ HHHH **** "N'\;?"_1/&3B^*BRUA,&.]C0-DCH'4\./KS[UW%>6^
M)->\8Z_\0KKPEX3O+73(M/MTFN[V:,.26 ( !!]1V]>: .&\<*?#_@_4]'\2
M>#].M]0DC"V6M:;:*(9B'7K@9C8@'Z^E>S>$/#^C:?HFF7MEI5E;W4EE$'FB
M@57;*J3D@9Y-><1_%'6_#TFI^%?%.F+K'B.&1$L4M(LK=AAD%@!QC@],\]."
M:ZGP/HOC:?6V\1>+]12$- T5OI%O_JX0Q4Y.#C(QCN>>O:@#NM0-X--N3IXB
M-[Y3>0)L["^/EW8YQG%>;W47Q;O;=K>[TWPA<0O]Z.7S'4_4'BO2-0LHM2TV
MYL9FD6*XB:)VC;:P##!P>QYZUY+XH\ >!O!^E"_U75_$"H[B.**.^9I)7/15
M7')H M2:7\3YM/73Y="\$O8J0RVS1OY8(.0=O3K7HGAO^VAH< U^.RCU$;@Z
M66?* R=N,\],5X)9VW@ZYTO6;^6Q\:P+I,D"W$+W?[T"3=\Q7L %R<^M>W^!
MX=(A\(6/]A7D]WILBF2&:XD+N<DD@D\Y!R,=L4 =#1110 445RWB/QWI_A_5
M8-(2SO\ 4]6GC,JV5A#YD@3^\V2 !U[T =317.^&O&>E^)[>\:W$]K<6+[+R
MUO(_+E@.,_,/3@\Y[5@'XOZ)M>[73=9?14E\IM76TS;9SC.<YVY[XH ]!KR[
MX_\ _)+Y?^ON'^9KTZ&:.X@CGA=9(I%#HZG(8$9!%>8_'_\ Y)?+_P!?</\
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MJ^FZA\-?[#UV#7=3ODFNXK;5(;R<R)*).KJ#]T@],4 >@^-/^1&U[_L'S_\
MH!J7PG_R)^B_]>,/_H J#QI(G_"$:\N]=W]GS\9_V#4_A/\ Y$_1?^O&'_T
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M_>-=S\,?^0E?_P#7)?YUV5*$8PYD>1AL=5J5E"5K'IE%%%<9ZX4444 %%%%
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M_0!6_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBZB42PPA6P2<C(H ]+\",&\ >'RIR/[/@_\ 0!70US_@4!? /A\ 8']GP?\
MH KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7R_]?</\S0!V7@;_ )$'P_\ ]@^#_P! %;]8'@;_ )$'P_\ ]@^#_P! %;]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5#6
M=8L= TBYU349A#:6Z;W;&3] .Y/2K]<%\9=/;4?ACJ4:SQ1&-HY?WL@17VL#
MMR>Y[>^* .=7X_Z9,-]MX9UN>$GY9%C7#?K6YX4^+%OXJ\00Z3'X?U6S:56;
MSKB,!!@9YI/"?Q/\#OX:L(X]5M-/,4"(UK+\AC(&"/0\]Q73Z9XT\-:S?+9:
M;K5G=73@E8HI,L0.30!NT44$@#)X H CD@BF&)8D<?[2@TL<,4(Q%$B#_94"
MO']5^/<%M<WQTSPW>7^GV<GE27P?;'G./[IP#VR:JS_'363=VMA!X*N8;Z\*
MBV6YD($F>A'RC- 'MM%-0L8U+C#$#(]#3J "BBB@ HHHH **** .0^)%KJES
MX-U)M.U-+...SG:X1K<2><FP_*"3\O?GWK6\(@CP;H@8Y/V&')_X *C\:?\
M(C:]_P!@^?\ ] -2^$_^1/T7_KQA_P#0!0!Q7Q+C=]8LRL;L/(/W5)_BKB[=
M)6FC(C<CS!R%/K7OS>7GY]N?>N>\&^5_8;D[,FZF/./[YK55(JS<4VNIRSP]
M27,E4:4MUT_,Z*/_ %:_04ZBBLCJ"F3()87C9%=6!!5NAI]% '!S_#:VDNS)
M%<-%"3DQ YQ[ UU^G:;;Z?I\=E% BPQ\!?O9]SGO5VBLX4:<&W%6-ZN)K5DH
MU)-I'+^,=$6Y\/7!LK<"=2'(08+ =17D0!+[ I+DXVXYS]*^@W#,N%?:?7&:
MHC2(%NC<A8Q,1C?Y*Y_EUKFQ.#5:2E>QW8#,WA(.'+>^I5\)V4^G^&K.WN01
M*%R5/\.3G%;5-0,J@,VX^N,4ZNN,5&*BNAYM2;G-S?4****H@**** "HI+=)
M6W,7S[,14M% %=+*&/&W>,'(&\U8HHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "LN^L-.N;JWEFMK>1]_+,H)Z&M,@$8/
M(-1?9+?_ )XI^5#2>XTVMB1-@4*FT*. %Z"E90PPP!![$4V.*.($(@7/7%/H
M$4WTNT=BZQF)S_%$Q0_I7DWC9+B/Q/,D\DCA57RF?^[C_&O9:R=9T#3-6B9[
MRV#R*I*N#AA^-<^*HNM3Y4[';E^*CAJWM)*ZV/+/!TTL'B>UDB#E1GS=@)^3
M'.?:O8X+J"Y7,,J/]#R/PK.T;P]IFDQ+):6P61E!,A.6/XU>GL+:X;>\0$G9
MU^5OS%+"T71I\K8\PQ<<56YXJRM8LT50^SWUO_J+D3*/X)QS_P!]#^M']I>5
MQ>6\D'^UC<GYC^M=)PE^BF131S('BD5U/=3FGT %1SP1W5O)!,NZ.12K+ZBI
M** .:E\': DUNBZ<F&8@_,?0^]:^FZ/8:0DBV-NL*R'+ $G)J6<C[3:\C[Y_
M]!-6:;E)[LA4X1=TD%%%%(L**** "BBB@ HHHH **** "LSQ'97.I>&-5L;.
M3R[JXM)8HFSC#,I _6M.J&N:FFB:#J&J.A=;.WDG*C^+:I./TH \G\!_$CPG
MX1\,6V@:U#+H>J62>7=0R6K9D<'E\J#G/7G^57/!]U!XM^+=SXIT#3Y;71(M
M.-M+=/%Y8O)2V00.^!WZ_*,]17.7?B'XB7EGX<U6]GT&"WUZY6"U62S$GD;^
M4W$@G!^IKK/!>I>,X?B+<Z!XLU*UQ#8F>VM[6W58[A2P&\, "-O3:?6@#M_&
M,$USX*UR"WB>6:2PF5(T7+,Q0X '<UQ/@3X8^&9_ ^D2ZSX9@_M)H ;C[1&R
MR;LG[P/0UZC5/4]6T_1;)KS4[V"SME.#+.X5<GH.>_M0!S?_  JOP-_T+-C_
M -\G_&NCTG2-/T/3H]/TNTCM;2,DI%&, 9.3^IKGO^%H^!_^AFT__OY70Z5J
MVGZWI\=_IEW%=6DA(26(Y4X.#^HH NT444 %9GB#7K'PUHEQJNH2;8(5X4?>
MD8]%4=V)X K3KQS7=8O[WXD-<:UX3\17FCZ-)C38+*R\R.:8=9W)(!Q_".?7
MUR =AX&\<MXG\&7/B+4K9+!+>682("3L2,9).>^.OTK!7XC>*IM"?Q7!X3A;
MPVN7 -UBZ:$'!D"XVXZG&?TYKD_!NISZE\(_&&DP:9J,<A2]N!<R0XB;/6,-
MG[X[C%=UI%]9K\ 8;GS$%NNA,C'/ 81%2/KNX^M '<Z9J-MJ^EVNHV<GF6US
M$LL3>JD9%><?'_\ Y)?+_P!?</\ ,UA:)X.\<:KX*\-3Z'XK;2+9=.0-;D-R
MQ9FW<>H*_E7,?$WPAXXT7P=)=Z]XP.J6(GC4VWS<L<X//I0![MX&_P"1!\/_
M /8/@_\ 0!6_7/> PR_#_P /AFR?[/AY_P" "NAH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#^27R_]?</\S0!V7@;_D0?#_\ V#X/_0!6_6!X&_Y$'P__ -@^#_T 5OT
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M#&FL5B*^5D_+SU- '14444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %'48-%(Q(4D8R!WH X[5/!&CS
MZK;NJ21"XD;S$C; /!/'I74V-A;:;:):VD0CA3HH_G5.YDF>[LFV1?(['_6#
M^Z:T(9'D!+A1@_PMFHC3A%MQ5KFLZ]6I%1G)M(EHHHJS(**** "BBB@ HHHH
M **** "J6L>4=$OQ/'-)#]GDWI!GS&7:<A<?Q>E7:@O;@V=C<7(ADF,,;2>5
M&,L^!G 'J: /G%=.^'Z,77P-XX5CU81N/_9JZ_X4R^#9_%ETOA[1]?M;R"W9
M9GOG)C0$CY2-QPQQQGT-;?\ PMV;_H0_%?\ X!__ %ZI^$1K7B7XKW'BR30+
MO1-,33OLA6Z78]R^[()'?'KVVCF@#U>N*^('A35-;;2M8\/W$,&N:/,TMMYX
M^256&&0^F<#_ #R.MOKVWTVPN+Z[D\NWMXVEE?!.U5&2<#VKB/\ A=?@#_H.
M_P#DM+_\30!FSZ]\6KZ![&#PCIUA<,-IO7O5=$S_ !!<YX_'\:Z_P-X77P=X
M3M-'\_[1-'N>:;&-\C'+$>W.!["L+_A=?@#_ *#O_DM+_P#$UUVAZ[IWB328
MM4TJX\^SE+!)-I7."0>" >HH T:*** "LC7/%.A>&DC;6=5MK+S/N+*_S-]!
MU-:]<I?>'O#^D^(K[QKJ]POF?9EB+W94QVZ+_<R."?US[T ;>D:YI6OV?VO2
M;^WO8,[2\+AL'T/H?K6:_CWPG'J_]E/X@L!>A]AB,PX;IMSTS[9KS#39[@VG
MC_QYI%DVF:1=6#)8KM\LSNJG,^WMSR#[GWK>TOPIHTGP"2WDL8&\W23=O(4&
MXS%"^_/7(/?TXH ]3KR[X_\ _)+Y?^ON'^9K(TSXR6WAGPCX<M]5T[4;ZZFT
MY)6F@52" 609R1S\M<G\3?B[IGC/P<^D6NDZC;2M/'())U4+A<\<&@#W7P-_
MR(/A_P#[!\'_ * *WZY[P&X?X?\ A]@"/^)?#U_W!70T %%%% !1110 445S
MVLZY<6]TUM:)LBAV_;+PIO%N&&1\N03ZD] "": .AHKE[C4]0T^ZC2VNQK!*
M>;+ L2J4BZ[PZ\?0'KVKH[:XBN[6*XA;=%*@=&]01D4 9NMW%YFVT[3Y5@NK
MLN!.R[A$JC)..YZ ?6N?Q;L?[/2VO!XBQR/M<GRC_GJ7SC9^'MBNCUG3[F[C
MBN-/F2*_MBS0M(,H<C!5AZ'^8%8?V&3['Y2:/J U0/Y@O3+'N\S^\7S]WMC&
M,<8IH3-K1+F[87-A?R+-=V;*C3*NT2J5!#8['J#]*UJS='L+BSAEFO94FOKE
M@\[H,+D  !1Z "M*DQA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7?AU+I-Z=9N=2'V=5B)5T+ [L_A^M>_#3Y-+^')TY_FDMM*,+;><L(L''XT
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M;IQ^.<=.E3>'/$WBGPQ\1(?!OBR]CU**^C+V5\J!6)P>#^1'UK"FOM0^$_Q
M\27EQIL\^F:RIEM+F-"R)+R0&QVR2#^&*Q]"\7R^.OB]X9O]=@CTHVD)$*D,
M!/)S]W([DC\J -7PC+\1_&UMJUY8>,A:_8[QX$AEMU(;'(YQQUQ7=_"WQGJ/
MBG3=0LM:C1-7TJX-O<,@P).O./7@UYI\./B!8>![/7;/4-.U.:YGU"26)(+<
MD,.F,GIR*[CX-Z%J=M%KGB'5;5[2;6+LS102 AE3)(R/QX^E 'J5%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:203!B7R4/&/]P_G7H- 'CG_  SMH7_0>UC_ +[3_P")H_X9VT+_ *#VL?\
M?:?_ !->QT4 >.?\,[:%_P!![6/^^T_^)H_X9VT+_H/:Q_WVG_Q->QT4 >.?
M\,[:%_T'M8_[[3_XFC_AG;0O^@]K'_?:?_$U['10!XY_PSMH7_0>UC_OM/\
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M?$NE>-=+\.Z)H-[#>WFHW\$ICA;<8HU.YF<#[N/>O6TBCCA6%(U6-5VJBC
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M6 ,H(.WT^4_I7TOM7G@<]>.M<QXR\&KXLL[5(=4O-+NK5R\,]JV.O4$=QP*
M/+M'UVW\2_M"6&IVFGW%K;26+"-KB'RWF 4_/CT[ ^U=A\9_#>I:[X7L[O28
M3/>:7=+="!1DR #G [D<'%7_  S\.GTCQ._B35]=NM9U4P^1'),@18U]@*[J
M@#YW\7?&N\U;1KS2K/1)?)N]/,4_FHRR02GASTP5QTK,O+JRT;1?AG>Q2F\M
M;,O+<26J%L-O!9?J,XQ[5]+M!$X8-$A#C#94<CWJ*ST^RT^U6UL[2&"W0DK'
M&@51GD\"@#Q'Q#K4GQ>\3>']-T+3;Z/3[&Z^TW5W<P[%4#'] ?Q->[T@4*,
M ?04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\4B&.2(^C*P!'2L1_BSX/2]: ZC(85E\EKP6[FW#^GF8V_CT]Z .VKR[X_\
M_)+Y?^ON'^9KU!65T5T8,K#((.017E_Q_P#^27R_]?</\S0!V7@;_D0?#_\
MV#X/_0!6_6!X&_Y$'P__ -@^#_T 5OT %%%% !1110 57O+&UU"'RKN!)4!R
M PZ'U!Z@_2K%([K&A=V"J!DDG % &?;Z'IUK<+.D!:9/N/+(TA7Z;B<?A6C4
M$%Y:W6?L]S#-MZ^6X;'Y5/0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXT =:K!E#*<@C(-+2* JA5& !@"EH **** "BBB@ HHHH X#XM?V'_PBD_\
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M+XR\=:;X,\-Q:)X5;6+=M.0M<L6)#!F7;P>P"_G7+_$WQ=XXUGP=)::_X/\
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M#U3.  I]\X[8KH88H[>&.&) D<:A44= !P!0P0^BBBD,**** "BBB@ HHHH
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M1<6MS*7 .0,C_OK(/M7N= !1110 4444 %%%% !1110 4444 %%%% !1110
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M'!:)PPS^%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXX[.=KA&@$GG)L/R@G[O?GWK5\(Y'@W1 3D_88><?[ J/QI_R(VO?]@^?_T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M-XCAT35;!M UB>$+J2F%(6D"NYZ_+WR,9_"M2ZG6UM)KAAE8HV<_0#->+?"_
MPQ_PFNJS?$37[F:XNC>,;&(.0L80\<>@Z >U !=> O&?@O39O[+^("6>A0<Y
MO 1Y"$_0COVQ73_#GP%:Z7=2>*+O7?[?U:[3:+T-N15/4+UKN-8T>PU_2I],
MU. 3VDXP\9)&><CI[UY'X6TZ?X:?&!?#%K=2RZ%J\#301RMDQN,_KQC/<$4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 R:))X)(9!E)%*L/8C%>%>%?%A^$.JW_A+Q3!.FFFX:>QO
M8T+*5;V]/IT.:]XJEJFCZ;K5J;74[&WNX3_!-&&'Z]* ./N/C+X$M[/[1_;:
M2\9\N.-B_P"6*Y/P7/J/Q&^*)\:264MKHFGP&"R\T<R$YY]SR2<>PKO8/AEX
M)MIQ-%X;L X.03'D _0UU,44<$2Q0QK'&HPJ(N !["@!]%%% !1110 4444
M%%%% !1110 4FQ=^_:-Q&,XYI:* "BBB@ HK*\1Z_:>&-%FU6^69H(BJE84W
M.Q9@H '?DBL'_A8MO_T+?B7_ ,%CT =G17&?\+%M_P#H6_$O_@L>C_A8MO\
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M?_!8] '9T5QG_"Q;?_H6_$O_ (+'H_X6+;_]"WXE_P#!8] '9T5QG_"Q;?\
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M[K-GI<FE:Q9S7A986O+,Q(Q49(R?:NMH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N2\0^.!I6N0Z!I.DW&LZU+%YQM876-8H^
MFYW;A1G_ #TJ#5?'.I:=J\]C#X)UZ]CB?:MS!$ICD]P<]*X>VTS6]9^-WBVS
MM=:ETB(P022RPHIG>,(NU4+?=&3DGV% '?\ AOQU!K,VJ6>I:?/HVI:6H>[M
MKE@P5",[U<<,OO6$/BQ</IS:[%X1U)_#*N0=2$B!BH."XB^]M]\US]]J&O6,
M'CKP??ZB=5:VT9KNUO7C"S;".4<CJ>?T]^.JTA[8? 2%LJ(!H!SGI_J3G]:
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MI/-"VKK)'%,/E0$#D%\_*3GBNAK-USP_I/B2P-CK%C%=V^=P60=#Z@CD'Z4
M>:^']/M/!OQ?30_#]RUQ9:C9-<7T4C^:\+K]UMYYY]":]<K$\/\ A'0?"R2C
M1M-BM6E_UCC+._U8DG'M6W0 4444 %%%% !1VHHH \(U1/&5I'XOU?5?"+W%
MQ?6TL"WOVV,+:VH4X54Y/N?6O0_A7>7]U\/]*6^TTV2PVT<<#&4/Y\848?C[
MN?0UUMY9V^H64]G=Q"6WG0QRQGHRD8(I+&QMM,L(+&SB6&VMT$<4:]%4# %
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH7>N:787]M8W>H6\%U=?ZB*20!I.W [U9NKJ"RM9;JZF2&")2TDDC850.Y-
M$U%5K&_M-3LX[RQN([BVD&4EC;*M]#5F@ HHHH **** "BBB@ HHHH ****
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MM3?%O69=,:$L2)T;>"/NA<\L>F.M=5\'[/3;/P##_9$U_+833R21-?1+&_.
M<!21C(//UJ5?@_X"6[%R/#L&X'.PR.4S_N[L?ATKM888K>%(88TCBC4*B(N%
M4#H !T% #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.@-9M<&ZOKB4SW=R1_K)#_0444 =71110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>32
<FILENAME>rapt-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T12:44:34.2890823+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:rapt="http://www.rapt.com/20211231" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.rapt.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.rapt.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapt-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" id="Role_StatementCONSOLIDATEDBALANCESHEETS">
        <link:definition>100010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" id="Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100060 - Disclosure - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100080 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100090 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments" id="Role_DisclosureCommitments">
        <link:definition>100110 - Disclosure - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100120 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100130 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100140 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100150 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100160 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100180 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100190 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100200 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables" id="Role_DisclosureCommitmentsTables">
        <link:definition>100210 - Disclosure - Commitments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100220 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100230 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100240 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100250 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100280 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
        <link:definition>100290 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
        <link:definition>100300 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100310 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100320 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" id="Role_DisclosureCommitmentsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails" id="Role_DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails">
        <link:definition>100340 - Disclosure - Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100350 - Disclosure - Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" id="Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
        <link:definition>100370 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
        <link:definition>100400 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" id="Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
        <link:definition>100410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>100430 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
        <link:definition>100440 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100490 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>100500 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" name="StockIssuedDuringPeriodSharesEmployeeStockPlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" name="StockIssuedDuringPeriodValueEmployeeStockPlans" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_AtTheMarketMember" name="AtTheMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_IncreaseDecreaseInDeferredRentNoncurrent" name="IncreaseDecreaseInDeferredRentNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" name="OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" name="ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_TwoThousandTwentyOnePublicOfferingMember" name="TwoThousandTwentyOnePublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_SecuritiesReservedForFutureIssuance" name="SecuritiesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_CommonStockCapitalValueReservedForFutureIssuance" name="CommonStockCapitalValueReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_WorkingCapital" name="WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_NumberOfFinancialInstitution" name="NumberOfFinancialInstitution" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rapt_OperatingLeaseExpirationYear" name="OperatingLeaseExpirationYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" name="AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rapt_IncreasedAreaOfLeasedPremises" name="IncreasedAreaOfLeasedPremises" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rapt_LesseeOperatingLeaseExtendedLeaseTerm" name="LesseeOperatingLeaseExtendedLeaseTerm" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_SouthSanFranciscoAndCaliforniaMember" name="SouthSanFranciscoAndCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_LeaseTerminationMonthAndYear" name="LeaseTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_UpfrontMilestonePayment" name="UpfrontMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_UpfrontFees" name="UpfrontFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_DevelopmentMilestonePayment" name="DevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" name="ContingentPaymentsUponAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_HanmiPharmaceuticalCompanyLimitedMember" name="HanmiPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_UnconstrainedDevelopmentMilestonePayment" name="UnconstrainedDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_CommonStockNumberOfVotesPerShare" name="CommonStockNumberOfVotesPerShare" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_OptionsIssuedAndOutstandingMember" name="OptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" name="RestrictedStockUnitsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_OptionsAvailableForFutureGrantMember" name="OptionsAvailableForFutureGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_PercentageOfIncreaseInSharesReservedForIssuance" name="PercentageOfIncreaseInSharesReservedForIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_TwoThousandNineteenStockPlanMember" name="TwoThousandNineteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_TwoThousandFifteenStockPlanMember" name="TwoThousandFifteenStockPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" name="EffectiveIncomeTaxRateReconciliationWithholdingTaxes" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" name="DeferredTaxLiabilitiesGrossDepreciationAndAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_IncomeTaxDisclosureLineItems" name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" name="CoronavirusAidReliefAndEconomicSecurityActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="rapt_UncertainTaxPositionsReserves" name="UncertainTaxPositionsReserves" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="rapt_UncertainTaxPositions" name="UncertainTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_EmployeeRetentionTaxCredits" name="EmployeeRetentionTaxCredits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="rapt_EarlyExercisedStockMember" name="EarlyExercisedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_CommonStockOptionsIssuedAndOutstandingMember" name="CommonStockOptionsIssuedAndOutstandingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" name="EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" name="RestrictedStockUnitsRSUsSubjectToFutureVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>33
<FILENAME>rapt-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T12:44:34.2890823+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="rapt-20211231.xsd#TemplateLink" roleURI="http://www.rapt.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:type="locator" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" xlink:type="locator" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:type="locator" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:type="locator" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>34
<FILENAME>rapt-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T12:44:34.2890823+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="rapt-20211231.xsd#TemplateLink" roleURI="http://www.rapt.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:type="locator" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PublicOfferingMember" xlink:type="locator" xlink:label="rapt_PublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="11860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_WorkingCapital" xlink:type="locator" xlink:label="rapt_WorkingCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockCapitalValueReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SecuritiesReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_SecuritiesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SalesAgreementMember" xlink:type="locator" xlink:label="rapt_SalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:type="locator" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="rapt_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_FollowOnPublicOfferingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_SecuritiesReservedForFutureIssuance" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockCapitalValueReservedForFutureIssuance" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_WorkingCapital" order="11480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_NumberOfFinancialInstitution" xlink:type="locator" xlink:label="rapt_NumberOfFinancialInstitution" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11310.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:type="locator" xlink:label="rapt_LeaseTerminationMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:type="locator" xlink:label="rapt_IncreasedAreaOfLeasedPremises" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLeaseExpirationYear" xlink:type="locator" xlink:label="rapt_OperatingLeaseExpirationYear" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:type="locator" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" order="10570.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_DevelopmentMilestonePayment" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontFees" xlink:type="locator" xlink:label="rapt_UpfrontFees" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontMilestonePayment" xlink:type="locator" xlink:label="rapt_UpfrontMilestonePayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="rapt_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontMilestonePayment" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontFees" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_DevelopmentMilestonePayment" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="11040.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:href="rapt-20211231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:type="locator" xlink:label="rapt_OptionsAvailableForFutureGrantMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_OptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenStockPlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11970.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12730.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10810.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="11030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EmployeeRetentionTaxCredits" xlink:type="locator" xlink:label="rapt_EmployeeRetentionTaxCredits" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositions" xlink:type="locator" xlink:label="rapt_UncertainTaxPositions" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositionsReserves" xlink:type="locator" xlink:label="rapt_UncertainTaxPositionsReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositions" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_EmployeeRetentionTaxCredits" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11030.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EarlyExercisedStockMember" xlink:type="locator" xlink:label="rapt_EarlyExercisedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EarlyExercisedStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>35
<FILENAME>rapt-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T12:44:34.2900818+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments (see note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized; 29,555,119 and 24,773,361 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Per Basic And Diluted Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average number of shares used in computing net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" />
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares employee stock plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" />
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value employee stock plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_AtTheMarketMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AtTheMarketMember" xlink:to="rapt_AtTheMarketMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_AtTheMarketMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_AtTheMarketMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock from employee stock plans</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock from employee stock plans, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the employee stock purchase plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the employee stock purchase plan, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain (loss) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:type="locator" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in deferred rent non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering costs included in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PublicOfferingMember" xlink:type="locator" xlink:label="rapt_PublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PublicOfferingMember" xlink:to="rapt_PublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_PublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of premium on marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Amortization Of Premium</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of capital equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain (loss) on foreign currency translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable, accrued expenses, and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Rent Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock under employee stock plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Plans</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of non-cash investing and financing information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Offering Costs Included In Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="rapt_CollaborationAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="rapt_CollaborationAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements not yet adopted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Remaining Contractual Maturities of Marketable Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified By Contractual Maturity Date Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Non-Cancelable Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reserved shares of common stock for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reserved Shares Of Common Stock For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grantee Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GranteeStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grantee Status [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Employee and Non-employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Payment Arrangement Employee [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used to Value Under Stock Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially Dilutive Securities not Included in Diluted per Share Calculations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="rapt_FollowOnPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_FollowOnPublicOfferingMember" xlink:to="rapt_FollowOnPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:type="locator" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Public Offering [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SalesAgreementMember" xlink:type="locator" xlink:label="rapt_SalesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SalesAgreementMember" xlink:to="rapt_SalesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SalesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued during period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds received after deducting underwriting discounts and other offering related costs</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SecuritiesReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_SecuritiesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="rapt_SecuritiesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SecuritiesReservedForFutureIssuance" xlink:to="rapt_SecuritiesReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockCapitalValueReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital value reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockCapitalValueReservedForFutureIssuance" xlink:to="rapt_CommonStockCapitalValueReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_SecuritiesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities that may be offered and sold</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SecuritiesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock that may be offered and sold, value</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Value Reserved For Future Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_WorkingCapital" xlink:type="locator" xlink:label="rapt_WorkingCapital" />
    <link:label xml:lang="en-US" xlink:label="rapt_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Working capital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_WorkingCapital" xlink:to="rapt_WorkingCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash used in operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents and marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Working capital</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_WorkingCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Working Capital</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_NumberOfFinancialInstitution" xlink:type="locator" xlink:label="rapt_NumberOfFinancialInstitution" />
    <link:label xml:lang="en-US" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of financial institution.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_NumberOfFinancialInstitution" xlink:to="rapt_NumberOfFinancialInstitution_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies line items.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of financial institutions</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_NumberOfFinancialInstitution_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Financial Institution</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses on long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets To Be Disposed Of</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset-backed Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Backed Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in less than one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due in more than one year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities After One Through Five Years Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AccruedResearchAndDevelopmentExpenses" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WorkersCompensationLiabilityCurrent" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Workers Compensation Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and consulting services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:label xml:lang="en-US" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Square feet area of laboratory and office facilities under lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLeaseExpirationYear" xlink:type="locator" xlink:label="rapt_OperatingLeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLeaseExpirationYear" xlink:to="rapt_OperatingLeaseExpirationYear_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:label xml:lang="en-US" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional square feet area of laboratory and office facilities under lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:type="locator" xlink:label="rapt_IncreasedAreaOfLeasedPremises" />
    <link:label xml:lang="en-US" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increased area of leased premises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncreasedAreaOfLeasedPremises" xlink:to="rapt_IncreasedAreaOfLeasedPremises_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease extended lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:type="locator" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">South san francisco and california.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_SouthSanFranciscoAndCaliforniaMember" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South San Francisco and California</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">South San Francisco And California [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory and office facilities under lease</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration period</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional laboratory and office facilities under lease</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Square Feet Area Of Laboratory And Office Facilities Under Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increased of leased premises</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncreasedAreaOfLeasedPremises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increased Area Of Leased Premises</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Extended Lease Term</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease existence of option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:type="locator" xlink:label="rapt_LeaseTerminationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_LeaseTerminationMonthAndYear" xlink:to="rapt_LeaseTerminationMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination term</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_LeaseTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Month And Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingency losses, accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualPayments" xlink:to="us-gaap_LossContingencyAccrualPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual Payments</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontMilestonePayment" xlink:type="locator" xlink:label="rapt_UpfrontMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UpfrontMilestonePayment" xlink:to="rapt_UpfrontMilestonePayment_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontFees" xlink:type="locator" xlink:label="rapt_UpfrontFees" />
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UpfrontFees" xlink:to="rapt_UpfrontFees_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_DevelopmentMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DevelopmentMilestonePayment" xlink:to="rapt_DevelopmentMilestonePayment_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" />
    <link:label xml:lang="en-US" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments upon achievement of specified milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="rapt_CollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CollaborationAndLicenseAgreementMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Hanmi Pharmaceutical Company Limited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Hanmi Pharmaceutical Co., LTD</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Hanmi Pharmaceutical Company Limited [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront and near-term milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments upon achievement of specified milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Upon Achievement Of Specified Milestones</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unconstrained development milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UnconstrainedDevelopmentMilestonePayment" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unconstrained development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unconstrained Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:type="locator" xlink:label="rapt_CommonStockNumberOfVotesPerShare" />
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock number of votes per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockNumberOfVotesPerShare" xlink:to="rapt_CommonStockNumberOfVotesPerShare_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes for each share of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of votes per share</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockNumberOfVotesPerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Number Of Votes Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan and 2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_OptionsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsIssuedAndOutstandingMember" xlink:to="rapt_OptionsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:type="locator" xlink:label="rapt_OptionsAvailableForFutureGrantMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options available for future grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OptionsAvailableForFutureGrantMember" xlink:to="rapt_OptionsAvailableForFutureGrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Future Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OptionsAvailableForFutureGrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Available For Future Grant [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in shares reserved for issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandNineteenStockPlanMember" xlink:to="rapt_TwoThousandNineteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees, Officers, Directors, Advisors, and Consultants</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandFifteenStockPlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_TwoThousandFifteenStockPlanMember" xlink:to="rapt_TwoThousandFifteenStockPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandFifteenStockPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock available for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in shares reserved for issuance on common stock outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Shares Reserved For Issuance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" />
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award increase in shares amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in shares at the beginning of each calendar year</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award offering period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" />
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee subscription rate on salary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase period</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock as percentage of fair market value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, employee purchased shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, shares at weighted average exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, Stock options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price Per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Stock options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price Per Share, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Per Share, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term (Years), Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, options, grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock options, exercises intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option vested aggregate fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Unit ("RSU")</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Outstanding, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Outstanding, RSUs awarded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, RSUs released</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Outstanding, RSUs forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Outstanding, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value Per Share, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs awarded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs released</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value Per Share, RSUs forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value Per Share, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares not vested and subject to repurchase</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received from early exercise of unvested options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost, expected period to be recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total provision for income taxes</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" xlink:type="locator" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" />
    <link:label xml:lang="en-US" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation withholding taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" xlink:to="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign losses not benefited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Foreign</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Withholding taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Withholding Taxes</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:type="locator" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" />
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:type="locator" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities gross depreciation and amortization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Gross Depreciation And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Gross deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_IncomeTaxDisclosureLineItems_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk Or Uncertainty By Nature [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk Or Uncertainty Nature [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Coronavirus aid relief and economic security act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="rapt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Coronavirus Aid Relief And Economic Security Act [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_IncomeTaxDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositionsReserves" xlink:type="locator" xlink:label="rapt_UncertainTaxPositionsReserves" />
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncertain tax positions reserves.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UncertainTaxPositionsReserves" xlink:to="rapt_UncertainTaxPositionsReserves_lbl" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositions" xlink:type="locator" xlink:label="rapt_UncertainTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Uncertain tax positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_UncertainTaxPositions" xlink:to="rapt_UncertainTaxPositions_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositionsReserves_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions Reserves</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_UncertainTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Uncertain Tax Positions</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EmployeeRetentionTaxCredits" xlink:type="locator" xlink:label="rapt_EmployeeRetentionTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="rapt_EmployeeRetentionTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee retention tax credits.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EmployeeRetentionTaxCredits" xlink:to="rapt_EmployeeRetentionTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_EmployeeRetentionTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee retention tax credits amount</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_EmployeeRetentionTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Retention Tax Credits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to prior years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions on tax positions related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense or penalties related to unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EarlyExercisedStockMember" xlink:type="locator" xlink:label="rapt_EarlyExercisedStockMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_EarlyExercisedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercised stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EarlyExercisedStockMember" xlink:to="rapt_EarlyExercisedStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_EarlyExercisedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercised Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_EarlyExercisedStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercised Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Issued Basic</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: weighted-average unvested common stock subject to repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used to compute net loss per share, basic and diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated shares issuable under employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Shares Issuable Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" />
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units (RSUs) subject to future vesting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Subject to Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S Us Subject To Future Vesting [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>rapt-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-10T12:44:34.2900818+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : f743394adaf745ebadcea8e7806ae039 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.rapt.com/20211231/role/TemplateLink" xlink:href="rapt-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rapt-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" xlink:type="locator" xlink:label="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodValueEmployeeStockPlans" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:href="rapt-20211231.xsd#Role_StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:type="locator" xlink:label="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreaseDecreaseInDeferredRentNoncurrent" xlink:type="locator" xlink:label="rapt_IncreaseDecreaseInDeferredRentNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfPremium" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PublicOfferingMember" xlink:type="locator" xlink:label="rapt_PublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_PublicOfferingMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeAmortizationOfPremium" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="rapt_IncreaseDecreaseInDeferredRentNoncurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization" xlink:href="rapt-20211231.xsd#Role_DisclosureOrganization" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="rapt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses" xlink:href="rapt-20211231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements" xlink:href="rapt-20211231.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="rapt_CollaborationAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock" xlink:href="rapt-20211231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rapt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:type="locator" xlink:label="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables" xlink:href="rapt-20211231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables" xlink:href="rapt-20211231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GranteeStatusAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:href="rapt-20211231.xsd#rapt_WorkingCapital" xlink:type="locator" xlink:label="rapt_WorkingCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockCapitalValueReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_CommonStockCapitalValueReservedForFutureIssuance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SecuritiesReservedForFutureIssuance" xlink:type="locator" xlink:label="rapt_SecuritiesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AtTheMarketMember" xlink:type="locator" xlink:label="rapt_AtTheMarketMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SalesAgreementMember" xlink:type="locator" xlink:label="rapt_SalesAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandTwentyOnePublicOfferingMember" xlink:type="locator" xlink:label="rapt_TwoThousandTwentyOnePublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="rapt_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_FollowOnPublicOfferingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandTwentyOnePublicOfferingMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_SalesAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="rapt_AtTheMarketMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_SecuritiesReservedForFutureIssuance" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_CommonStockCapitalValueReservedForFutureIssuance" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="rapt_WorkingCapital" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_NumberOfFinancialInstitution" xlink:type="locator" xlink:label="rapt_NumberOfFinancialInstitution" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="rapt_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="rapt_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember_li0l2" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember_li0l2" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesTable" xlink:to="rapt_SignificantAccountingPoliciesLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="rapt_NumberOfFinancialInstitution" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AssetBackedSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WorkersCompensationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_WorkersCompensationLiabilityCurrent" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="rapt_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="rapt_AccruedResearchAndDevelopmentExpenses" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_WorkersCompensationLiabilityCurrent" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualPayments" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LeaseTerminationMonthAndYear" xlink:type="locator" xlink:label="rapt_LeaseTerminationMonthAndYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_LesseeOperatingLeaseExtendedLeaseTerm" xlink:type="locator" xlink:label="rapt_LesseeOperatingLeaseExtendedLeaseTerm" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncreasedAreaOfLeasedPremises" xlink:type="locator" xlink:label="rapt_IncreasedAreaOfLeasedPremises" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLeaseExpirationYear" xlink:type="locator" xlink:label="rapt_OperatingLeaseExpirationYear" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" xlink:type="locator" xlink:label="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_SouthSanFranciscoAndCaliforniaMember" xlink:type="locator" xlink:label="rapt_SouthSanFranciscoAndCaliforniaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="rapt_SouthSanFranciscoAndCaliforniaMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_OperatingLeaseExpirationYear" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_IncreasedAreaOfLeasedPremises" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LesseeOperatingLeaseExtendedLeaseTerm" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="rapt_LeaseTerminationMonthAndYear" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LossContingencyAccrualPayments" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UnconstrainedDevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_UnconstrainedDevelopmentMilestonePayment" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" xlink:type="locator" xlink:label="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DevelopmentMilestonePayment" xlink:type="locator" xlink:label="rapt_DevelopmentMilestonePayment" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontFees" xlink:type="locator" xlink:label="rapt_UpfrontFees" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UpfrontMilestonePayment" xlink:type="locator" xlink:label="rapt_UpfrontMilestonePayment" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_HanmiPharmaceuticalCompanyLimitedMember" xlink:type="locator" xlink:label="rapt_HanmiPharmaceuticalCompanyLimitedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="rapt_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="rapt_CollaborationAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_CollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="rapt_CollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="rapt_HanmiPharmaceuticalCompanyLimitedMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontMilestonePayment" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UpfrontFees" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_DevelopmentMilestonePayment" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="rapt_UnconstrainedDevelopmentMilestonePayment" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockNumberOfVotesPerShare" xlink:type="locator" xlink:label="rapt_CommonStockNumberOfVotesPerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:type="locator" xlink:label="us-gaap_CommonStockVotingRights" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="rapt_CommonStockNumberOfVotesPerShare" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_DividendsCommonStock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:href="rapt-20211231.xsd#Role_DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsAvailableForFutureGrantMember" xlink:type="locator" xlink:label="rapt_OptionsAvailableForFutureGrantMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_OptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsIssuedAndOutstandingMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_RestrictedStockUnitsIssuedAndOutstandingMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="rapt_OptionsAvailableForFutureGrantMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" xlink:type="locator" xlink:label="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_PercentageOfIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="rapt_PercentageOfIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenStockPlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenStockPlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandFifteenStockPlanMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_PercentageOfIncreaseInSharesReservedForIssuance" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfOptionPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfRSUActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenEquityIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" xlink:type="locator" xlink:label="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:type="locator" xlink:label="us-gaap_GranteeStatusDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:type="locator" xlink:label="us-gaap_GranteeStatusAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" xlink:type="locator" xlink:label="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" xlink:type="locator" xlink:label="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" xlink:type="locator" xlink:label="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EmployeeRetentionTaxCredits" xlink:type="locator" xlink:label="rapt_EmployeeRetentionTaxCredits" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositions" xlink:type="locator" xlink:label="rapt_UncertainTaxPositions" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_UncertainTaxPositionsReserves" xlink:type="locator" xlink:label="rapt_UncertainTaxPositionsReserves" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_OperatingLossCarryforwardsExpirationBeginningYear" xlink:type="locator" xlink:label="rapt_OperatingLossCarryforwardsExpirationBeginningYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureLineItems" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:type="locator" xlink:label="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:type="locator" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_IncomeTaxDisclosureTable" xlink:type="locator" xlink:label="rapt_IncomeTaxDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="rapt_IncomeTaxDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="rapt_CoronavirusAidReliefAndEconomicSecurityActMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureTable" xlink:to="rapt_IncomeTaxDisclosureLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_OperatingLossCarryforwardsExpirationBeginningYear" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositionsReserves" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_UncertainTaxPositions" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="rapt_EmployeeRetentionTaxCredits" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rapt_IncomeTaxDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EarlyExercisedStockMember" xlink:type="locator" xlink:label="rapt_EarlyExercisedStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EarlyExercisedStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesIssuedBasic" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="rapt-20211231.xsd#Role_DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" xlink:type="locator" xlink:label="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="rapt-20211231.xsd#rapt_CommonStockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="rapt_CommonStockOptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_CommonStockOptionsIssuedAndOutstandingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952545688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 04, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RAPT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RAPT THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001673772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-3313701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">561 Eccles Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">489-9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,573,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Redwood City, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant&#8217;s Definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956649096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 24,027<span></span>
</td>
<td class="nump">$ 24,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">165,627<span></span>
</td>
<td class="nump">86,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,319<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">192,973<span></span>
</td>
<td class="nump">115,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">198,636<span></span>
</td>
<td class="nump">118,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,016<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,595<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="nump">2,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,256<span></span>
</td>
<td class="nump">14,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (see note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 29,555,119 and 24,773,361 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">470,629<span></span>
</td>
<td class="nump">319,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(284,046)<span></span>
</td>
<td class="num">(214,842)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">186,380<span></span>
</td>
<td class="nump">104,179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 198,636<span></span>
</td>
<td class="nump">$ 118,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952475576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">29,555,119<span></span>
</td>
<td class="nump">24,773,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">29,555,119<span></span>
</td>
<td class="nump">24,773,361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952417720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,813<span></span>
</td>
<td class="nump">$ 5,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">56,985<span></span>
</td>
<td class="nump">45,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,037<span></span>
</td>
<td class="nump">12,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">73,022<span></span>
</td>
<td class="nump">58,256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(69,209)<span></span>
</td>
<td class="num">(53,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">(69,204)<span></span>
</td>
<td class="num">(51,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,204)<span></span>
</td>
<td class="num">(52,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(287)<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (69,233)<span></span>
</td>
<td class="num">$ (53,089)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.53)<span></span>
</td>
<td class="num">$ (2.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares used in computing net loss per share, basic and diluted</a></td>
<td class="nump">27,390,326<span></span>
</td>
<td class="nump">24,134,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950774040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At The Market</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>At The Market</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>At The Market</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 73,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (161,950)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,833,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">69,842<span></span>
</td>
<td class="nump">$ 3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,842<span></span>
</td>
<td class="nump">$ 3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock from employee stock plans</a></td>
<td class="nump">1,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock from employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(52,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 104,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214,842)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">24,773,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,773,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 134,770<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,769<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,356,060<span></span>
</td>
<td class="nump">214,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans', window );">Issuances of common stock from employee stock plans</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans', window );">Issuances of common stock from employee stock plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation gain (loss)</a></td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(287)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(69,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,204)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 186,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (284,046)<span></span>
</td>
<td class="num">$ (206)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2021</a></td>
<td class="nump">29,555,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,555,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_StockIssuedDuringPeriodValueEmployeeStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value employee stock plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_StockIssuedDuringPeriodValueEmployeeStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950784936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (69,204)<span></span>
</td>
<td class="num">$ (52,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premium on marketable securities</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">996<span></span>
</td>
<td class="nump">1,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">8,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of capital equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign currency translation</a></td>
<td class="nump">258<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,764)<span></span>
</td>
<td class="num">(965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses, and other current liabilities</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">2,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(3,432)<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncreaseDecreaseInDeferredRentNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(61,026)<span></span>
</td>
<td class="num">(40,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(164,977)<span></span>
</td>
<td class="num">(139,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">84,385<span></span>
</td>
<td class="nump">52,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(755)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(81,347)<span></span>
</td>
<td class="num">(87,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuances of common stock under employee stock plans</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">1,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">141,482<span></span>
</td>
<td class="nump">75,461<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="num">(891)<span></span>
</td>
<td class="num">(52,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">24,918<span></span>
</td>
<td class="nump">77,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">24,027<span></span>
</td>
<td class="nump">24,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Offering costs included in accounts payable and accrued expenses</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">134,770<span></span>
</td>
<td class="nump">73,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreaseDecreaseInDeferredRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deferred rent non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreaseDecreaseInDeferredRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956397192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of the Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc. (<span style="color:#000000;">&#8220;</span>RAPT<span style="color:#000000;">&#8221;</span> or the <span style="color:#000000;">&#8220;</span>Company<span style="color:#000000;">&#8221;</span>) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Equity Financings</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In June 2021, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 16, 2020, the Company completed an underwritten public offering (&#8220;2021 Public Offering&#8221;) of&#160;4,356,060&#160;shares of common stock, including&#160;568,181&#160;shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $33.00&#160;per share. The Company received approximately $134.8&#160;million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.</span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company completed an underwritten follow-on public offering (&#8220;Follow&#8209;on Offering&#8221;) of 2,500,000 shares of its common stock issued at an offering price of $30.00 per share. The Follow-on Offering generated approximately $69.8 million in net proceeds after deducting underwriting discounts and other offering related costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering (a) up to $350&#160;million of the Company&#8217;s securities, including up to $100 million of shares of common stock that may be offered and sold from time to time in one or more &#8220;at-the-market&#8221; offerings pursuant to a Controlled Equity Offering<sup style="font-size:85%;line-height:120%;vertical-align:top">SM</sup>&#160;Sales Agreement (&#8220;ATM Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and Stifel, Nicolaus &amp; Company, Incorporated, and (b) up to an aggregate of 1,000,000 shares of common stock that certain selling stockholders may offer and sell from time to time. During the year ended December 31, 2021, the Company sold 214,971 shares under the ATM Sales Agreement resulting in net proceeds of $4.7 million after deducting underwriting discounts and commissions and other offering related costs. During the year ended December 31, 2020, the Company sold 188,700 shares under the ATM Sales Agreement resulting in net proceeds of $3.8 million after deducting underwriting discounts and commissions and other offering related costs. As of December 31, 2021, there was up to $90.9 million of shares of common stock available for future issuance under the ATM Sales Agreement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Management Plans </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2021, the Company incurred a net loss of $69.2 million and used $61.0 million of cash in operations. At December 31, 2021, the Company had cash and cash equivalents and marketable securities of $189.7&#160;million and working capital of $183.4 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#8217;s current cash and cash equivalents and marketable securities </p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will provide sufficient funds to enable the Company to meet its obligations for at least </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">months from the filing date of this report.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952322648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Summary of Significant Accounting Policies </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by two financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities primarily consist of commercial paper, corporate bonds and <span style="Background-color:#FFFFFF;color:#000000;">U.S. government agency securities</span>. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2021 and 2020, the Company did not record any impairment losses on long-lived assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space and laboratory facilities under non-cancelable operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the lease. Funding of leasehold improvements by the Company&#8217;s landlord is accounted for as a tenant improvement allowance and recorded as current and non-current deferred rent liabilities and amortized on a straight-line basis as a reduction of rent expense over the term of the lease.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaborative agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Licenses<span style="font-style:normal;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments<span style="font-style:normal;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<span style="font-style:normal;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant for the period prior to the IPO. The fair value of restricted stock awards granted after the IPO is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#8217;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU&#160;No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases</span>. ASU&#160;2016-02&#160;requires lessees to record most leases on their balance sheet while recognizing expense in a manner similar to the accounting under the original lease guidance (Topic 840). ASU&#160;2016&#8209;02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a&#160;right-to-use&#160;asset for the right to use the underlying asset for the lease term. ASU&#160;2016-02 is effective for the Company&#8217;s fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company intends to adopt the new standard as of January 1, 2022. <span style="color:#000000;">The adoption of the new standard will have a material impact on the Company&#8217;s consolidated balance sheet as of January 1, 2022, as we will recognize the right-of-use assets and liabilities for our operating leases. We expect to record lease liabilities of approximately&#160;$8 - $9 million&#160;based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We also expect to record corresponding right-of-use assets of approximately&#160;$6 - 7 million, based on the operating lease liabilities adjusted for unamortized deferred rent and lease incentives. The Company, however, does not expect a material impact to its consolidated statements of operations and consolidated statements of cash flow.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. ASU 2016-13 amended guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span>, to increase awareness of the amendments and to expedite improvements to Topic 326. In May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses, Topic 326</span>, providing companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU&#160;No.&#160;2019-10, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</span> and ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses</span>, which defer the effective date of the new credit loss standard. ASU&#160;2016-13 and its related amendments are effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company is currently assessing the timing of adoption of ASU 2016-13 and the impact that adoption will have on its consolidated financial statements and related disclosures<span style="color:#000000;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956457400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Fair Value Measurements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash </p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equivalents, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketable securities, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accounts payable and accrued </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that approximate fair value due to their relatively short maturities. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-size:10pt;font-family:Calibri;">To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#8217;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimates the fair values of investments in corporate debt securities, commercial paper and <span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;">U.S. government agency securities </span>using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.<span style="font-family:Times New Roman;"> </span></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,658</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,658</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,704</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,565</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,882</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,669</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,285</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,164</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,212</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,368</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,047</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December&#160;31, 2021 were temporary in nature.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of December 31, 2021 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than one year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in more than one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,481</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,285</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956439208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Property and Equipment </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,684</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,082</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,741</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,982</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expenses were $1.0 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952297480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Accrued Expenses </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,576</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,967</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956463128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Commitments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, the Company entered into an operating lease for 30,376 square feet of laboratory and office facilities in South San Francisco, California, which expires in May 2022. In April 2018, the Company amended the lease agreement to include an additional 6,378 square feet of laboratory and office space increasing the total leased premises to 36,754 square feet. The lease amendment extended the lease term to November 2026 and contained scheduled rent increases over the lease term and an option for the Company to extend the lease for an additional <span style="-sec-ix-hidden:F_000377">five-year</span> term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2019, the Company entered into an agreement to sublease its facility lease of 6,378 square feet of laboratory and office space, which terminated in July 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum non-cancelable lease payments, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the lease agreement provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. Rent expense includes certain monthly charges that do not represent non-cancelable obligations, as defined. These costs are determined based on actual charges incurred. In addition, <span style="color:#000000;">tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $2.3 million and $2.1 million in the years ended December 31, 2021 and 2020, respectively. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and no contingency losses were accrued at either December 31, 2021 or 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956485096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Collaboration Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Hanmi</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (&#8220;Hanmi Agreement&#8221;),<span style="Background-color:#FFFFFF;"> pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#8217;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#8220;Hanmi Territory&#8221;), and certain sublicense</span> rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $10.0&#160;million, which consisted of an upfront payment of $4.0&#160;million and a development milestone payment of $6.0&#160;million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $108.0 million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) </span>the exclusive development, manufacturing and commercialization license in the Hanmi Territory; (2) the transfer of know-how, technology, research data and information, and any improvements in technology; (3) the obligation to participate in the joint steering committee and appoint an alliance manager; (4) <span style="color:#000000;">the responsibility to complete certain Phase 2 clinical trials; and (5) the supply of FLX475 for use in Hanmi&#8217;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the transaction price as of December 31, 2019 was $10.0&#160;million, which consisted of the upfront fee of $4.0&#160;million and an unconstrained development milestone payment of $6.0&#160;million. In December 2020, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $0.4 million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#8217;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, $3.8 million and $5.0 million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of December 31, 2021, deferred revenue related to the Hanmi Agreement was $1.5 million and is expected to be recognized over the over the remaining period of the Company&#8217;s Phase&#160;1/2 clinical trial of FLX475.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trial Collaboration and Supply Agreement with Merck</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>), Merck&#8217;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952344248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Common Stock </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holders of the Company&#8217;s common stock have one vote for each share of common stock held by them. Holders of shares of the Company&#8217;s common stock are entitled to dividends when, as and if declared by the board of directors. No dividends had been declared as of December 31, 2021 or December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,688,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,415,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the 2019 Employee Stock Purchase Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,070,476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,106,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956431256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Option Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#8220;2015 Plan&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the consummation of the IPO in November 2019, the Company&#8217;s board of directors adopted the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221; and collectively with the 2015 Plan, the &#8220;Option Plans&#8221;). Upon the effectiveness of the 2019 Plan, the Company&#8217;s 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2021, the Company had 2,688,372 shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the Company&#8217;s 2019 Plan will automatically increase on January 1 of each year beginning January 1, 2020 by a number equal to (i) 4% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#8217;s board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s Option Plans provided for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over four years and expire no later than ten years from the date of grant. As a private company, the estimated fair value of the Company&#8217;s underlying common stock was determined by the board of directors. Following the Company&#8217;s IPO in November 2019 the fair value of the Company&#8217;s common stock is based on the closing price of its common stock on the date of grant.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#8220;2019 ESPP&#8221;). The Company reserved 240,336 shares of common stock pursuant to purchase rights to be granted to the Company&#8217;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) 240,336 shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, 2021, an additional 240,336 shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed 15% of each employee&#8217;s compensation. The 2019 ESPP generally provides for a 24-month offering period, which includes four <span style="-sec-ix-hidden:F_000426">six-month</span> purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at 85% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended December 31, 2021 and 2020, employees purchased 76,424 shares at weighted average price of $10.80 and 87,325 shares at a weighted average exercise price of $10.27, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $2.5 million and $2.7 million for the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the Options Plan is set forth below for the year ended December 31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000448">8.36</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,336</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000449">8.04</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000450">8.04</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,417</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000451">7.41</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#8217;s common stock, as determined by the board of directors, as of December 31, 2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options granted in the years ended December 31, 2021 and 2020 had a weighted average per share grant-date fair value of $15.04 and $24.57, respectively, and a total grant date fair value of $11.9 million and $8.7 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2021 and 2020 was $2.4 million and $2.4 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate fair value of options that vested in the years ended December 31, 2021 and 2020 was $6.8&#160;million and $5.4&#160;million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted <span style="color:#000000;">Stock Units</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Employee stock option valuation </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s IPO, the grant date fair value of the shares of common stock underlying stock options was determined by the Company&#8217;s board of directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of common stock was determined using valuation methodologies by considering a number of objective and subjective factors including important developments in the Company&#8217;s operations, valuations performed by independent third parties, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies and the lack of liquidity of the Company&#8217;s common stock, among other factors. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term represents the period that the Company&#8217;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended December 31, 2021 and 2020, using the Black-Scholes option pricing model, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">3.93 - 6.05</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.19 - 6.07</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000477">81.0%&#160;-&#160;86.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">84.0%&#160;-&#160;87.0%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000481">0.55% - 1.26%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">0.28% - 1.43%</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;<span style="font-style:italic;color:#000000;">Employee stock purchase plan</span></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000485">0.25 - 2.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000486">0.25 - 2.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.3% - 92.9%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000492">0.05% - 1.55%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000493">0.11% - 1.57%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Early exercise of stock options </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the 2015 Plan permitted option holders to exercise stock options before they are vested, subject to certain limitations. Such unvested shares were subject to repurchase by the Company at the original exercise price in the event the option holder&#8217;s service to the Company was terminated either voluntarily or involuntarily. As a result of early exercises under the 2015 Plan, approximately 0 and 3,000 shares were subject to repurchase as of December 31, 2021 and 2020, respectively. The Company treats cash received from the exercise of unvested options as a refundable deposit and classifies such amounts as a liability in its balance sheet. As of December 31, 2021 and 2020, the Company included cash received for the early exercise of unvested options of $0 and $6,000, respectively, in other current liabilities. Amounts included in liabilities were transferred into common stock and additional paid-in capital as the shares vested, which was generally over a period of 48 months.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,637</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,642</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:2pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $15.7 million. This unrecognized stock-based compensation cost is expected to be recognized over <span><span style="color:#000000;">2.6</span> years</span>.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956441400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,740</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the provision for income taxes related to Korean withholding taxes on the near-term milestone payment the Company received pursuant to the Hanmi Agreement are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign losses not benefited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding taxes, net of federal benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,665</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,089</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,331</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $14.4 million and $12.5 million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is mainly related to the increase in net operating loss carryforwards incurred during the respective taxable years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had federal net operating loss carryforwards of approximately $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">233.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span>177.2<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are carried forward indefinitely, while all others</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> along with the federal tax credit carryforwards, expire in years beginning in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> state net operating loss carryforwards of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> approximately </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.1</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, which begin to expire in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and are available to offset future taxable income. As of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company had </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research and development tax credit carryforwards of approximately</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and 20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Company had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state research and development tax credit carryforwards of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Moreover, as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company recorded federal and state reserves of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approximately </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and </span><span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.4</span></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The tax relief measures under the CARES Act for businesses include a five-year net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act did not have a material effect on the realizability of deferred income tax assets or tax expense in 2021. The Company claimed employee retention tax credits in the amount of $0.4 million for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#8217;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#8217;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#8220;SB 113&#8221; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#8217;s expected loss position in the current year, the new legislations will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods..</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50&#160;percent likely of being realized upon effective settlement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed for both US and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,747</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,434</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#8217;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits through December&#160;31,&#160;2021. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956485096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended December 31, 2021 and 2020 (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,390,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,164,828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested early</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; exercised common shares subject to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,523</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,390,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,134,305</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding under the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Equity Incentive Plan and 2015 Stock Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated shares issuable under the 2019 ESPP</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,592</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs subject to future vesting</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,071,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553,590</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956729016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#8217;s cash is held by two financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amount of the Company&#8217;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Equivalents </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities primarily consist of commercial paper, corporate bonds and <span style="Background-color:#FFFFFF;color:#000000;">U.S. government agency securities</span>. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#8217;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the consolidated statements of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2021 and 2020, the Company did not record any impairment losses on long-lived assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space and laboratory facilities under non-cancelable operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the lease. Funding of leasehold improvements by the Company&#8217;s landlord is accounted for as a tenant improvement allowance and recorded as current and non-current deferred rent liabilities and amortized on a straight-line basis as a reduction of rent expense over the term of the lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaborative agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Licenses<span style="font-style:normal;">: If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Milestone payments<span style="font-style:normal;">: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Royalties<span style="font-style:normal;">: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#8220;CROs&#8221;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to restricted stock awards is determined using the estimated fair value of the Company&#8217;s common stock on the date of grant for the period prior to the IPO. The fair value of restricted stock awards granted after the IPO is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#8217;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and certain changes in stockholders&#8217; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#8220;JOBS Act&#8221;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU&#160;No.&#160;2016-02,&#160;<span style="font-style:italic;">Leases</span>. ASU&#160;2016-02&#160;requires lessees to record most leases on their balance sheet while recognizing expense in a manner similar to the accounting under the original lease guidance (Topic 840). ASU&#160;2016&#8209;02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a&#160;right-to-use&#160;asset for the right to use the underlying asset for the lease term. ASU&#160;2016-02 is effective for the Company&#8217;s fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company intends to adopt the new standard as of January 1, 2022. <span style="color:#000000;">The adoption of the new standard will have a material impact on the Company&#8217;s consolidated balance sheet as of January 1, 2022, as we will recognize the right-of-use assets and liabilities for our operating leases. We expect to record lease liabilities of approximately&#160;$8 - $9 million&#160;based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We also expect to record corresponding right-of-use assets of approximately&#160;$6 - 7 million, based on the operating lease liabilities adjusted for unamortized deferred rent and lease incentives. The Company, however, does not expect a material impact to its consolidated statements of operations and consolidated statements of cash flow.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13,&#160;<span style="font-style:italic;">Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. ASU 2016-13 amended guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</span>, to increase awareness of the amendments and to expedite improvements to Topic 326. In May 2019, the FASB issued ASU No. 2019-05, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses, Topic 326</span>, providing companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU&#160;No.&#160;2019-10, <span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</span> and ASU No. 2019-11, <span style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses</span>, which defer the effective date of the new credit loss standard. ASU&#160;2016-13 and its related amendments are effective for the Company&#8217;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company is currently assessing the timing of adoption of ASU 2016-13 and the impact that adoption will have on its consolidated financial statements and related disclosures<span style="color:#000000;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781955623208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,658</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,658</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,704</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,565</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,882</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,532</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,669</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,520</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,285</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds&#8212;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; classified as cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,333</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,164</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,212</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Asset-backed securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,367</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,368</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,962</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,047</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,873</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,925</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Remaining Contractual Maturities of Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the remaining contractual maturities of the Company&#8217;s marketable securities as of December 31, 2021 (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in less than one year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,804</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due in more than one year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,481</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,285</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952326408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,966</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,295</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,294</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">482</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total property and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,064</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,684</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,082</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,741</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,982</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956488152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses consisted of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,205</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,576</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,967</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and consulting services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,326</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,935</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956764760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Non-Cancelable Lease Payments</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, future minimum non-cancelable lease payments, are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,037</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,259</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956436072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock', window );">Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows: </p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding under the 2019 Equity Incentive Plan and 2015</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Stock Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options available for future grants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,688,372</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,415,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares reserved under the 2019 Employee Stock Purchase Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,070,476</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,106,321</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reserved shares of common stock for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781953597272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Plans</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity under the Options Plan is set forth below for the year ended December 31, 2021: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term&#160;(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000448">8.36</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,123</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">794,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.62</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(120,178</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(130,336</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.33</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000449">8.04</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,417</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and expected to vest at December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000450">8.04</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,417</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,028,650</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000451">7.41</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,142</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted Stock Units (&#8220;RSU&#8221;) activity under the 2019 Plan is set forth below for the year ended December 31, 2021:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Fair Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,125</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.66</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text">
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.2%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000485">0.25 - 2.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000486">0.25 - 2.00</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71.3% - 92.9%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84.0%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000492">0.05% - 1.55%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000493">0.11% - 1.57%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,637</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,642</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,952</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,686</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employee and Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used to Value Under Stock Option Plans</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended December 31, 2021 and 2020, using the Black-Scholes option pricing model, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000473">3.93 - 6.05</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000474">5.19 - 6.07</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000477">81.0%&#160;-&#160;86.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000478">84.0%&#160;-&#160;87.0%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000481">0.55% - 1.26%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000482">0.28% - 1.43%</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956537240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,464</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,961</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,740</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,941</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,902</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for Income Taxes</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the provision for income taxes related to Korean withholding taxes on the near-term milestone payment the Company received pursuant to the Hanmi Agreement are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total provision for income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal tax</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.76</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.55</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.83</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign losses not benefited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.14</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding taxes, net of federal benefit</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23.99</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.91</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,791</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,665</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal and state research and development tax credits</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,103</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,644</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,089</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,331</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,522</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,488</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,060</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed for both US and foreign operations on the Company&#8217;s annual tax returns were as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,747</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">807</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions on tax positions related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,336</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">544</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,434</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,291</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956416504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share of the years ended December 31, 2021 and 2020 (in thousands, except share and per share data): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69,204</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average common shares outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,390,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,164,828</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted-average unvested early</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; exercised common shares subject to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,523</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares used to compute net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; loss per share, basic and diluted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,390,326</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,134,305</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.53</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Securities not Included in Diluted per Share Calculations</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding as of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding under the 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Equity Incentive Plan and 2015 Stock Plan</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,024,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,481,100</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Estimated shares issuable under the 2019 ESPP</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,592</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs subject to future vesting</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,071,773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,553,590</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950267576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,070,476<span></span>
</td>
<td class="nump">4,106,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,204<span></span>
</td>
<td class="nump">$ 52,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,026<span></span>
</td>
<td class="nump">40,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember', window );">2021 Public Offering | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="nump">4,356,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 33.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and other offering related costs</a></td>
<td class="nump">$ 134,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_FollowOnPublicOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and other offering related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters | 2021 Public Offering | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="nump">568,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and other offering related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,971<span></span>
</td>
<td class="nump">188,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds received after deducting underwriting discounts and other offering related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember', window );">At The Market | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_SecuritiesReservedForFutureIssuance', window );">Securities that may be offered and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_CommonStockCapitalValueReservedForFutureIssuance', window );">Common stock that may be offered and sold, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CommonStockCapitalValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CommonStockCapitalValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SecuritiesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SecuritiesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandTwentyOnePublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rapt_AtTheMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956589448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Institution</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_NumberOfFinancialInstitution', window );">Number of financial institutions | Institution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment losses on long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease, right-of-use asset</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Lease, right-of-use asset</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">us-gaap:OtherAssets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_NumberOfFinancialInstitution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of financial institution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_NumberOfFinancialInstitution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952934872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 188,520<span></span>
</td>
<td class="nump">$ 107,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">188,285<span></span>
</td>
<td class="nump">107,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">22,658<span></span>
</td>
<td class="nump">21,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,658<span></span>
</td>
<td class="nump">21,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">52,704<span></span>
</td>
<td class="nump">32,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">52,565<span></span>
</td>
<td class="nump">32,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">23,882<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">23,861<span></span>
</td>
<td class="nump">12,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">59,532<span></span>
</td>
<td class="nump">28,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">59,532<span></span>
</td>
<td class="nump">28,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,744<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 29,669<span></span>
</td>
<td class="nump">$ 13,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956685128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in less than one year</a></td>
<td class="nump">$ 132,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in more than one year</a></td>
<td class="nump">55,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 188,285<span></span>
</td>
<td class="nump">$ 107,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950158536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 10,425<span></span>
</td>
<td class="nump">$ 10,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(7,684)<span></span>
</td>
<td class="num">(7,082)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,741<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,291<span></span>
</td>
<td class="nump">5,966<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,295<span></span>
</td>
<td class="nump">3,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952286664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 996<span></span>
</td>
<td class="nump">$ 1,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950361672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 2,205<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WorkersCompensationLiabilityCurrent', window );">Accrued compensation</a></td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting services</a></td>
<td class="nump">415<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 6,326<span></span>
</td>
<td class="nump">$ 4,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WorkersCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WorkersCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950125384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_OperatingLeaseExpirationYear', window );">Lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022-05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Additional laboratory and office facilities under lease</a></td>
<td class="nump">6,378<span></span>
</td>
<td class="nump">6,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncreasedAreaOfLeasedPremises', window );">Increased of leased premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm', window );">Lessee operating lease extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lease existence of option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee operating lease option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_LeaseTerminationMonthAndYear', window );">Lease termination term</a></td>
<td class="text">2020-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Contingency losses, accrued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember', window );">South San Francisco and California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease', window );">Laboratory and office facilities under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncreasedAreaOfLeasedPremises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased area of leased premises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncreasedAreaOfLeasedPremises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LeaseTerminationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LeaseTerminationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_LesseeOperatingLeaseExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease extended lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_LesseeOperatingLeaseExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Square feet area of laboratory and office facilities under lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rapt_SouthSanFranciscoAndCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952671560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 10,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950092792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">$ 3,813,000<span></span>
</td>
<td class="nump">$ 5,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Hanmi Pharmaceutical Co., LTD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UpfrontMilestonePayment', window );">Upfront and near-term milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UpfrontFees', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_DevelopmentMilestonePayment', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UnconstrainedDevelopmentMilestonePayment', window );">Unconstrained development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Hanmi Pharmaceutical Co., LTD | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones', window );">Contingent payments upon achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments upon achievement of specified milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UnconstrainedDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unconstrained development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UnconstrainedDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UpfrontMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UpfrontMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rapt_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rapt_HanmiPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rapt_HanmiPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956701096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>vote</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Number of votes for each share of common stock</a></td>
<td class="text">The holders of the Company&#8217;s common stock have one vote for each share of common stock held by them<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends declared | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956594376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">5,070,476<span></span>
</td>
<td class="nump">4,106,321<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember', window );">Options Available for Future Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">2,688,372<span></span>
</td>
<td class="nump">2,415,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember', window );">2019 Equity Incentive Plan and 2015 Stock Plan | Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">2,024,681<span></span>
</td>
<td class="nump">1,481,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Restricted Stock Units Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved</a></td>
<td class="nump">316,923<span></span>
</td>
<td class="nump">153,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_OptionsAvailableForFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_OptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rapt_RestrictedStockUnitsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781949998360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,952<span></span>
</td>
<td class="nump">$ 8,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.04<span></span>
</td>
<td class="nump">$ 24.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue', window );">Stock options grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Number of stock options, exercises intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Stock option vested aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, expected period to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total shares reserved</a></td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount', window );">Increase in shares at the beginning of each calendar year</a></td>
<td class="nump">240,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate on salary</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Purchase period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock as percentage of fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Share-based compensation, employee purchased shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,424<span></span>
</td>
<td class="nump">87,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased', window );">Share-based compensation, shares at weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 10.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,688,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember', window );">Option Plans | Maximum | Employees, Officers, Directors, Advisors, and Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember', window );">2019 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance', window );">Percentage of increase in shares reserved for issuance on common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rapt_TwoThousandFifteenStockPlanMember', window );">2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Shares not vested and subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Cash received from early exercise of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_PercentageOfIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_PercentageOfIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase in shares amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, options, grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956567336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Option Plans (Details) - Option Plans - Share-based Payment Arrangement, Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Beginning Balance</a></td>
<td class="nump">1,481,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Outstanding, Stock options granted</a></td>
<td class="nump">794,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Outstanding, Stock options exercised</a></td>
<td class="num">(120,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Outstanding, Stock options forfeited</a></td>
<td class="num">(130,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Outstanding, Ending Balance</a></td>
<td class="nump">2,024,681<span></span>
</td>
<td class="nump">1,481,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Outstanding, Vested and expected to vest</a></td>
<td class="nump">2,024,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Outstanding, Exercisable</a></td>
<td class="nump">1,028,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance</a></td>
<td class="nump">$ 16.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options granted</a></td>
<td class="nump">21.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options exercised</a></td>
<td class="nump">9.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Stock options forfeited</a></td>
<td class="nump">21.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance</a></td>
<td class="nump">18.33<span></span>
</td>
<td class="nump">$ 16.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">18.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 14.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years), Balance</a></td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Vested and expected to vest</a></td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">7 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 38,417<span></span>
</td>
<td class="nump">$ 11,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">38,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 23,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950845704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - 2019 Plan - Restricted Stock Unit ("RSU")<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Beginning Balance | shares</a></td>
<td class="nump">56,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares Outstanding, RSUs released | shares</a></td>
<td class="num">(14,125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares Outstanding, RSUs forfeited | shares</a></td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares Outstanding, Ending Balance | shares</a></td>
<td class="nump">40,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 44.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, RSUs released | $ / shares</a></td>
<td class="nump">44.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, RSUs forfeited | $ / shares</a></td>
<td class="nump">44.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 44.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950628024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details) - Employee and Non-employees - Share-based Payment Arrangement, Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">71.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">92.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.55%<span></span>
</td>
<td class="nump">1.57%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">86.90%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.26%<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">3 years 11 months 4 days<span></span>
</td>
<td class="text">5 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952638600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,952<span></span>
</td>
<td class="nump">$ 8,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,310<span></span>
</td>
<td class="nump">4,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,642<span></span>
</td>
<td class="nump">$ 4,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781955728584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (66,464)<span></span>
</td>
<td class="num">$ (49,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(2,740)<span></span>
</td>
<td class="num">(1,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before taxes</a></td>
<td class="num">$ (69,204)<span></span>
</td>
<td class="num">$ (51,902)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956743448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision for Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 990<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781950804904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(0.76%)<span></span>
</td>
<td class="num">(0.55%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="nump">2.39%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Foreign losses not benefited</a></td>
<td class="num">(2.14%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes', window );">Withholding taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.51%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.86%)<span></span>
</td>
<td class="num">(23.99%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.91%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation withholding taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781949936024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 49,791<span></span>
</td>
<td class="nump">$ 38,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal and state research and development tax credits</a></td>
<td class="nump">7,756<span></span>
</td>
<td class="nump">6,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves', window );">Accrued liabilities and reserves</a></td>
<td class="nump">1,644<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">61,522<span></span>
</td>
<td class="nump">47,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(61,488)<span></span>
</td>
<td class="num">(47,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities gross depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781952878632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest expense or penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=rapt_CoronavirusAidReliefAndEconomicSecurityActMember', window );">CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_EmployeeRetentionTaxCredits', window );">Employee retention tax credits amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 233,100,000<span></span>
</td>
<td class="nump">177,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear', window );">Operating loss carryforwards expiration beginning year</a></td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UncertainTaxPositionsReserves', window );">Uncertain tax positions reserves</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rapt_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards amount</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_EmployeeRetentionTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee retention tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_EmployeeRetentionTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rapt_UncertainTaxPositionsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain tax positions reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rapt_UncertainTaxPositionsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rapt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=rapt_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=rapt_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956684712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 2,291<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions on tax positions related to prior years</a></td>
<td class="nump">807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions on tax positions related to current year</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 4,434<span></span>
</td>
<td class="nump">$ 2,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781949954920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (69,204)<span></span>
</td>
<td class="num">$ (52,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Weighted average common shares outstanding</a></td>
<td class="nump">27,390,326<span></span>
</td>
<td class="nump">24,164,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">27,390,326<span></span>
</td>
<td class="nump">24,134,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (2.53)<span></span>
</td>
<td class="num">$ (2.19)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EarlyExercisedStockMember', window );">Early Exercised Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Less: weighted-average unvested common stock subject to repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,523)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EarlyExercisedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EarlyExercisedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139781956562232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,071,773<span></span>
</td>
<td class="nump">1,553,590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">2,024,681<span></span>
</td>
<td class="nump">1,481,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember', window );">Estimated Shares Issuable Under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">6,592<span></span>
</td>
<td class="nump">15,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember', window );">RSUs Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_CommonStockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>rapt-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rapt="http://www.rapt.com/20211231"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rapt-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001673772_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_20220304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2022-03-04</instant>
        </period>
    </context>
    <context id="C_0001673772_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001673772_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandTwentyOnePublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rapt:AtTheMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_srtStatementGeographicalAxis_raptSouthSanFranciscoAndCaliforniaMember_20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rapt:SouthSanFranciscoAndCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_0001673772_20150501_20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="C_0001673772_20180401_20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="C_0001673772_20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="C_0001673772_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="C_0001673772_20190201_20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rapt:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rapt:HanmiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:RestrictedStockUnitsIssuedAndOutstandingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rapt:OptionsAvailableForFutureGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenStockPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandNineteenAndTwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rapt:TwoThousandFifteenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001673772_us-gaapUnusualRiskOrUncertaintyByNatureAxis_raptCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">rapt:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEarlyExercisedStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EarlyExercisedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:CommonStockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001673772</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_raptInstitution">
        <measure>rapt:Institution</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_raptvote">
        <measure>rapt:vote</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001673772_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001673772_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001673772_20210101_20211231" id="F_000007">0001673772</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001673772_20210101_20211231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231"
      id="F_000305">http://fasb.org/us-gaap/2021-01-31#OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231"
      id="F_000307">http://fasb.org/us-gaap/2021-01-31#OtherAssets</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="C_0001673772_20150501_20150531" id="F_000376">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="C_0001673772_20150531" id="F_000377">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031"
      id="F_000426">P6M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001673772_20211231"
      id="F_000067"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001673772_20201231"
      id="F_000068"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001673772_20211231"
      id="F_000069"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001673772_20201231"
      id="F_000070"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      id="F_000448">P8Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000449">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000450">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000451">P7Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000473">P3Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      id="F_000474">P5Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000477"
      unitRef="U_xbrlipure">0.810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      decimals="INF"
      id="F_000478"
      unitRef="U_xbrlipure">0.840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000481"
      unitRef="U_xbrlipure">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      decimals="INF"
      id="F_000482"
      unitRef="U_xbrlipure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000475">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      id="F_000476">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000479"
      unitRef="U_xbrlipure">0.869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      decimals="INF"
      id="F_000480"
      unitRef="U_xbrlipure">0.870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000483"
      unitRef="U_xbrlipure">0.0126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20200101_20201231"
      decimals="INF"
      id="F_000484"
      unitRef="U_xbrlipure">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      id="F_000485">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      id="F_000486">P3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="INF"
      id="F_000492"
      unitRef="U_xbrlipure">0.0005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000493"
      unitRef="U_xbrlipure">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      id="F_000487">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      id="F_000488">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="INF"
      id="F_000490"
      unitRef="U_xbrlipure">0.713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="INF"
      id="F_000491"
      unitRef="U_xbrlipure">0.929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="INF"
      id="F_000494"
      unitRef="U_xbrlipure">0.0155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000495"
      unitRef="U_xbrlipure">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <dei:DocumentType contextRef="C_0001673772_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001673772_20210101_20211231" id="F_000028">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001673772_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001673772_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001673772_20210101_20211231" id="F_000029">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001673772_20210101_20211231" id="F_000015">001-38997</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001673772_20210101_20211231" id="F_000006">RAPT THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001673772_20210101_20211231" id="F_000027">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001673772_20210101_20211231" id="F_000016">47-3313701</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001673772_20210101_20211231" id="F_000017">561 Eccles Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001673772_20210101_20211231" id="F_000018">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001673772_20210101_20211231" id="F_000019">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001673772_20210101_20211231" id="F_000020">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001673772_20210101_20211231" id="F_000021">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001673772_20210101_20211231" id="F_000022">489-9000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001673772_20210101_20211231" id="F_000025">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001673772_20210101_20211231" id="F_000005">RAPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001673772_20210101_20211231" id="F_000026">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001673772_20210101_20211231" id="F_000030">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001673772_20210101_20211231" id="F_000031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001673772_20210101_20211231" id="F_000013">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001673772_20210101_20211231" id="F_000024">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001673772_20210101_20211231" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001673772_20210101_20211231" id="F_000010">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001673772_20210101_20211231" id="F_000011">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="C_0001673772_20210101_20211231" id="F_000012">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001673772_20210101_20211231" id="F_000032">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001673772_20210101_20211231" id="F_000014">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001673772_20210630"
      decimals="-6"
      id="F_000033"
      unitRef="U_iso4217USD">622000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001673772_20220304"
      decimals="INF"
      id="F_000023"
      unitRef="U_xbrlishares">29573318</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000229">
&lt;p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant&#x2019;s Definitive Proxy Statement for the 2022 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference in Part III, Items 10-14 of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001673772_20210101_20211231" id="F_000034">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001673772_20210101_20211231" id="F_000035">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001673772_20210101_20211231" id="F_000036">Redwood City, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">24027000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">24918000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">165627000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">86592000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">3319000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">4088000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">192973000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">115598000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">2741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">2982000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">2922000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">389000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">198636000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">118969000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">1999000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2383000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">6326000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">4935000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">1016000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">4096000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">254000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">328000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">9595000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">11742000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">511000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">863000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">2150000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">2185000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">12256000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">14790000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000083"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000084"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000085"
      unitRef="U_xbrlishares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000086"
      unitRef="U_xbrlishares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000087"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000088"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000091"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000092"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">29555119</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">29555119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">24773361</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">24773361</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">470629000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">319196000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">-206000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">-177000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">-284046000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">-214842000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">186380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">104179000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">198636000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">118969000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000099"
      unitRef="U_iso4217USD">3813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000100"
      unitRef="U_iso4217USD">5042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">56985000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">45485000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">16037000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">12771000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">73022000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">58256000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">-69209000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-53214000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">1312000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-69204000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-51902000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">990000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-52892000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-249000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">52000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-69233000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-53089000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="C_0001673772_20210101_20211231"
      decimals="2"
      id="F_000122"
      unitRef="U_iso4217USD_xbrlishares">-2.53</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="C_0001673772_20200101_20201231"
      decimals="2"
      id="F_000123"
      unitRef="U_iso4217USD_xbrlishares">-2.19</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001673772_20210101_20211231"
      decimals="0"
      id="F_000124"
      unitRef="U_xbrlishares">27390326</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001673772_20200101_20201231"
      decimals="0"
      id="F_000125"
      unitRef="U_xbrlishares">24134305</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000126"
      unitRef="U_xbrlishares">21833037</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">235049000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-161950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_20191231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">73121000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000132"
      unitRef="U_xbrlishares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">69842000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">69842000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231"
      decimals="INF"
      id="F_000135"
      unitRef="U_xbrlishares">188700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">3768000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">3768000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">251624</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">1851000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">1851000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">8686000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">8686000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-249000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">-249000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">52000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">52000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-52892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-52892000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000149"
      unitRef="U_xbrlishares">24773361</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">319196000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-214842000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">104179000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000155"
      unitRef="U_xbrlishares">4356060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">134769000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">134770000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">214971</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">4690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">4690000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">210727</rapt:StockIssuedDuringPeriodSharesEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">2022000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <rapt:StockIssuedDuringPeriodValueEmployeeStockPlans
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">2022000</rapt:StockIssuedDuringPeriodValueEmployeeStockPlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">9952000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">9952000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000173"
      unitRef="U_xbrlishares">29555119</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">470629000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-284046000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20211231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-206000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">186380000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">-69204000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-52892000</us-gaap:ProfitLoss>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">1270000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">497000</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">996000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">1123000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">9952000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">8686000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">-258000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">249000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">1764000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">965000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">933000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">2390000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-3432000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">959000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <rapt:IncreaseDecreaseInDeferredRentNoncurrent
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-35000</rapt:IncreaseDecreaseInDeferredRentNoncurrent>
    <rapt:IncreaseDecreaseInDeferredRentNoncurrent
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-40000</rapt:IncreaseDecreaseInDeferredRentNoncurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-61026000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">-40491000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">164977000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">139334000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">84385000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">52297000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">755000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">398000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">-81347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-87435000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20210101_20211231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">134770000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptPublicOfferingMember_20200101_20201231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">73610000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20210101_20211231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">4690000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">2022000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">1851000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">141482000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">75461000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">-52465000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">24918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001673772_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">77383000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">24027000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">24918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">990000</us-gaap:IncomeTaxesPaidNet>
    <rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">20000</rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">208000</rapt:OfferingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:NatureOfOperations contextRef="C_0001673772_20210101_20211231" id="F_000230">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Organization&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Description of the Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RAPT Therapeutics, Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;RAPT&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt; or the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Company&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. The Company is located in South San Francisco, California. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Equity Financings&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In June 2021, pursuant to the shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on November 16, 2020, the Company completed an underwritten public offering (&#x201c;2021 Public Offering&#x201d;) of&#160;4,356,060&#160;shares of common stock, including&#160;568,181&#160;shares of common stock issued in connection with the exercise of the over-allotment option by the underwriters, at a public offering price of $33.00&#160;per share. The Company received approximately $134.8&#160;million in net proceeds from the 2021 Public Offering, after deducting underwriting discounts and other offering-related costs.&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company completed an underwritten follow-on public offering (&#x201c;Follow&#x2011;on Offering&#x201d;) of 2,500,000 shares of its common stock issued at an offering price of $30.00 per share. The Follow-on Offering generated approximately $69.8 million in net proceeds after deducting underwriting discounts and other offering related costs.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company filed a shelf registration statement on Form S-3 with the SEC covering (a) up to $350&#160;million of the Company&#x2019;s securities, including up to $100 million of shares of common stock that may be offered and sold from time to time in one or more &#x201c;at-the-market&#x201d; offerings pursuant to a Controlled Equity Offering&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;SM&lt;/sup&gt;&#160;Sales Agreement (&#x201c;ATM Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and Stifel, Nicolaus &amp;amp; Company, Incorporated, and (b) up to an aggregate of 1,000,000 shares of common stock that certain selling stockholders may offer and sell from time to time. During the year ended December 31, 2021, the Company sold 214,971 shares under the ATM Sales Agreement resulting in net proceeds of $4.7 million after deducting underwriting discounts and commissions and other offering related costs. During the year ended December 31, 2020, the Company sold 188,700 shares under the ATM Sales Agreement resulting in net proceeds of $3.8 million after deducting underwriting discounts and commissions and other offering related costs. As of December 31, 2021, there was up to $90.9 million of shares of common stock available for future issuance under the ATM Sales Agreement. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Management Plans &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has incurred net losses and negative cash flows from operations. During the year ended December 31, 2021, the Company incurred a net loss of $69.2 million and used $61.0 million of cash in operations. At December 31, 2021, the Company had cash and cash equivalents and marketable securities of $189.7&#160;million and working capital of $183.4 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management plans to continue to incur substantial costs in order to conduct research and development activities and additional capital will be needed to undertake these activities. The Company intends to raise such capital through the issuance of additional equity, borrowings and strategic alliances with other companies. However, if such arrangements are not available at adequate levels or on acceptable terms, the Company would be required to significantly reduce operating expenses and delay or reduce the scope of or eliminate some of its development programs. Management believes that the Company&#x2019;s current cash and cash equivalents and marketable securities &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;will provide sufficient funds to enable the Company to meet its obligations for at least &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12 &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;months from the filing date of this report.&lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630"
      decimals="INF"
      id="F_000279"
      unitRef="U_xbrlishares">4356060</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630"
      decimals="INF"
      id="F_000280"
      unitRef="U_xbrlishares">568181</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210630"
      decimals="2"
      id="F_000282"
      unitRef="U_iso4217USD_xbrlishares">33.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandTwentyOnePublicOfferingMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210601_20210630"
      decimals="-5"
      id="F_000284"
      unitRef="U_iso4217USD">134800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229"
      decimals="INF"
      id="F_000278"
      unitRef="U_xbrlishares">2500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200229"
      decimals="2"
      id="F_000281"
      unitRef="U_iso4217USD_xbrlishares">30.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptFollowOnPublicOfferingMember_20200201_20200229"
      decimals="-5"
      id="F_000283"
      unitRef="U_iso4217USD">69800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <rapt:SecuritiesReservedForFutureIssuance
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130"
      decimals="-6"
      id="F_000285"
      unitRef="U_iso4217USD">350000000</rapt:SecuritiesReservedForFutureIssuance>
    <rapt:CommonStockCapitalValueReservedForFutureIssuance
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130"
      decimals="-6"
      id="F_000286"
      unitRef="U_iso4217USD">100000000</rapt:CommonStockCapitalValueReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20201130"
      decimals="INF"
      id="F_000287"
      unitRef="U_xbrlishares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231"
      decimals="INF"
      id="F_000288"
      unitRef="U_xbrlishares">214971</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000290"
      unitRef="U_iso4217USD">4700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231"
      decimals="INF"
      id="F_000289"
      unitRef="U_xbrlishares">188700</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000291"
      unitRef="U_iso4217USD">3800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_raptAtTheMarketMember_us-gaapTypeOfArrangementAxis_raptSalesAgreementMember_20211231"
      decimals="-5"
      id="F_000292"
      unitRef="U_xbrlishares">90900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000293"
      unitRef="U_iso4217USD">-69200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000294"
      unitRef="U_iso4217USD">-61000000.0</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001673772_20211231"
      decimals="-5"
      id="F_000295"
      unitRef="U_iso4217USD">189700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <rapt:WorkingCapital
      contextRef="C_0001673772_20211231"
      decimals="-5"
      id="F_000296"
      unitRef="U_iso4217USD">183400000</rapt:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by two financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities primarily consist of commercial paper, corporate bonds and &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;U.S. government agency securities&lt;/span&gt;. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2021 and 2020, the Company did not record any impairment losses on long-lived assets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space and laboratory facilities under non-cancelable operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the lease. Funding of leasehold improvements by the Company&#x2019;s landlord is accounted for as a tenant improvement allowance and recorded as current and non-current deferred rent liabilities and amortized on a straight-line basis as a reduction of rent expense over the term of the lease.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaborative agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Licenses&lt;span style="font-style:normal;"&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone payments&lt;span style="font-style:normal;"&gt;: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties&lt;span style="font-style:normal;"&gt;: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense related to restricted stock awards is determined using the estimated fair value of the Company&#x2019;s common stock on the date of grant for the period prior to the IPO. The fair value of restricted stock awards granted after the IPO is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign Currency Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#x2019;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU&#160;No.&#160;2016-02,&#160;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;. ASU&#160;2016-02&#160;requires lessees to record most leases on their balance sheet while recognizing expense in a manner similar to the accounting under the original lease guidance (Topic 840). ASU&#160;2016&#x2011;02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a&#160;right-to-use&#160;asset for the right to use the underlying asset for the lease term. ASU&#160;2016-02 is effective for the Company&#x2019;s fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company intends to adopt the new standard as of January 1, 2022. &lt;span style="color:#000000;"&gt;The adoption of the new standard will have a material impact on the Company&#x2019;s consolidated balance sheet as of January 1, 2022, as we will recognize the right-of-use assets and liabilities for our operating leases. We expect to record lease liabilities of approximately&#160;$8 - $9 million&#160;based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We also expect to record corresponding right-of-use assets of approximately&#160;$6 - 7 million, based on the operating lease liabilities adjusted for unamortized deferred rent and lease incentives. The Company, however, does not expect a material impact to its consolidated statements of operations and consolidated statements of cash flow.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. ASU 2016-13 amended guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/span&gt;, to increase awareness of the amendments and to expedite improvements to Topic 326. In May 2019, the FASB issued ASU No. 2019-05, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses, Topic 326&lt;/span&gt;, providing companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU&#160;No.&#160;2019-10, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/span&gt; and ASU No. 2019-11, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses&lt;/span&gt;, which defer the effective date of the new credit loss standard. ASU&#160;2016-13 and its related amendments are effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company is currently assessing the timing of adoption of ASU 2016-13 and the impact that adoption will have on its consolidated financial statements and related disclosures&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000241">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and include the consolidated accounts of the Company and its wholly-owned subsidiary, RAPT Therapeutics Australia Pty Ltd., which was established in 2018. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001673772_20210101_20211231" id="F_000242">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities and stock-based compensation. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses and revenue reported for each of the periods presented are affected by estimates and assumptions. Actual results could differ from such estimates or assumptions. &lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001673772_20210101_20211231" id="F_000243">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and marketable securities. Substantially all the Company&#x2019;s cash is held by two financial institutions. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds and short-term marketable securities comprising commercial paper, corporate bonds and U.S. government agency securities.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <rapt:NumberOfFinancialInstitution
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000297"
      unitRef="U_raptInstitution">2</rapt:NumberOfFinancialInstitution>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000244">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its President and Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001673772_20210101_20211231" id="F_000245">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amount of the Company&#x2019;s financial instruments, including certain prepaid and accrued expenses, approximates fair value due to their short-term maturities.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000246">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash Equivalents &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001673772_20210101_20211231" id="F_000247">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities primarily consist of commercial paper, corporate bonds and &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;U.S. government agency securities&lt;/span&gt;. The Company has classified its marketable securities as available-for-sale and may sell these securities prior to their stated maturities. The Company views these marketable securities as available to support current operations and classifies marketable securities with maturities beyond 12 months as current assets. The Company&#x2019;s marketable securities are stated at estimated fair value, which is derived from independent pricing sources based on quoted prices in active markets for similar securities. Unrealized gains and losses are reported as a component of accumulated other comprehensive income (loss), net of tax. The amortized cost of marketable securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in other income, net on the consolidated statements of operations.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000248">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consist of computer equipment, laboratory equipment, leasehold improvements and furniture and fixtures, and is recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the improvements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense as incurred. Upon sale or retirement of assets, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in the results of operations.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20210101_20211231"
      id="F_000298">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000299">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000249">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company evaluates its long-lived assets for impairment annually or more frequently whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount of each asset to the future undiscounted cash flows the asset is expected to generate over its remaining life. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. For the years ended December 31, 2021 and 2020, the Company did not record any impairment losses on long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000300"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="C_0001673772_20200101_20201231"
      decimals="INF"
      id="F_000301"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000250">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space and laboratory facilities under non-cancelable operating lease agreements and recognizes related rent expense on a straight-line basis over the term of the lease. Funding of leasehold improvements by the Company&#x2019;s landlord is accounted for as a tenant improvement allowance and recorded as current and non-current deferred rent liabilities and amortized on a straight-line basis as a reduction of rent expense over the term of the lease.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000251">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License and collaborative agreements consist of license, milestone and royalty payments generated through agreements with strategic partners for the development and commercialization of certain product candidates. The terms of an agreement may include a non-refundable upfront fee, payments based upon achievement of milestones and royalties on net product sales. If a portion of the nonrefundable upfront fee or other payments received is allocated to continuing performance obligations under the terms of an agreement, such portion is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers or counterparties in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized, the Company performs the following steps: (i) identification of the promised goods or services in the agreement; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the agreement; (iii) measurement of the transaction price, including any constraint on variable consideration; (iv) allocation of the transaction price to performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Licenses&lt;span style="font-style:normal;"&gt;: If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an agreement, the Company will recognize revenue from the nonrefundable, upfront fee allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If a license is bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligations to determine whether the combined performance obligations are satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Milestone payments&lt;span style="font-style:normal;"&gt;: If an agreement includes event-based or milestone payments, the Company evaluates whether the events or milestones are considered likely to be achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is unlikely that a significant revenue reversal of cumulative revenue recognized would occur, the value of the associated event-based or milestone payments is included in the transaction price. Event-based or milestone payments that are not within the control of the Company are not included in the transaction price until they become likely to be achieved.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Royalties&lt;span style="font-style:normal;"&gt;: If an agreement includes sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001673772_20210101_20211231" id="F_000252">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, clinical trials, drug manufacturing and allocated overhead and facility-related expenses. The Company accounts for non-refundable advance payments for goods or services that will be used in future research and development activities as expenses when the goods have been received or when the service has been performed rather than when the payment is made. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trial costs are a component of research and development expenses. The Company expenses costs for its clinical trial activities performed by third parties, including clinical research organizations (&#x201c;CROs&#x201d;) and other service providers, as they are incurred, based upon estimates of the work completed over the life of the individual study in accordance with associated agreements. The Company uses information it receives from internal personnel and outside service providers to estimate the clinical trial costs incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001673772_20210101_20211231" id="F_000253">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for nonemployee stock-based awards is measured at fair value using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense for the estimated fair value of the vested portion of nonemployee awards in its consolidated statements of operations and comprehensive loss. Stock-based compensation expense related to stock-based awards to nonemployees is subject to re-measurement over the service period, which approximates the vesting period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense related to restricted stock awards is determined using the estimated fair value of the Company&#x2019;s common stock on the date of grant for the period prior to the IPO. The fair value of restricted stock awards granted after the IPO is determined based on the stock price on the date of grant. The estimated fair value is amortized as compensation expense over the service period of the award.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000254">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign Currency Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of RAPT Therapeutics Australia Pty Ltd., the Company&#x2019;s wholly-owned subsidiary, is the Australian dollar. Accordingly, all monetary assets and liabilities of the subsidiary are translated into U.S. dollars at the current period-end exchange rates and non-monetary assets are translated using historical exchange rates. Income and expense elements are remeasured to U.S. dollars using the average exchange rates in effect during the period. Remeasurement gains and losses are recorded as other income (expense), net.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to foreign currency risk with respect to its clinical contracts denominated in currencies other than the U.S. dollar. Payments on contracts denominated in foreign currencies are made at the spot rate on the day of payment. The cumulative adjustment resulting from the translation of financial statements to the reporting currency is recorded in other comprehensive income (loss).&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000255">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period such tax rate changes are enacted. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the effect of income tax positions only if those positions are more likely than not to be sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely to be realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Valuation allowances are established when necessary to reduce deferred tax assets to amounts more likely than not to be realized. Interest and penalties related to unrecognized tax benefits are recognized as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000256">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss includes net loss and certain changes in stockholders&#x2019; deficit that are excluded from net loss, primarily unrealized gains and losses from marketable securities and foreign currency translation adjustments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000257">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive securities outstanding during the period calculated in accordance with the treasury stock method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000258">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) or other standard setting bodies and adopted by the Company as of the specified effective date. Under the Jumpstart Our Business Startups Act of 2012, as amended (the &#x201c;JOBS Act&#x201d;), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000259">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU&#160;No.&#160;2016-02,&#160;&lt;span style="font-style:italic;"&gt;Leases&lt;/span&gt;. ASU&#160;2016-02&#160;requires lessees to record most leases on their balance sheet while recognizing expense in a manner similar to the accounting under the original lease guidance (Topic 840). ASU&#160;2016&#x2011;02 states that a lessee would recognize a lease liability for the obligation to make lease payments and a&#160;right-to-use&#160;asset for the right to use the underlying asset for the lease term. ASU&#160;2016-02 is effective for the Company&#x2019;s fiscal year beginning after December 15, 2021 and early adoption is permitted. The Company intends to adopt the new standard as of January 1, 2022. &lt;span style="color:#000000;"&gt;The adoption of the new standard will have a material impact on the Company&#x2019;s consolidated balance sheet as of January 1, 2022, as we will recognize the right-of-use assets and liabilities for our operating leases. We expect to record lease liabilities of approximately&#160;$8 - $9 million&#160;based on the present value of the remaining minimum rental payments using discount rates as of the effective date. We also expect to record corresponding right-of-use assets of approximately&#160;$6 - 7 million, based on the operating lease liabilities adjusted for unamortized deferred rent and lease incentives. The Company, however, does not expect a material impact to its consolidated statements of operations and consolidated statements of cash flow.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. ASU 2016-13 amended guidance on reporting credit losses for assets held at amortized cost basis and available-for-sale debt securities. For available-for-sale debt securities, credit losses will be presented as an allowance rather than as a write-down. In April 2019, the FASB issued ASU No. 2019-04, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/span&gt;, to increase awareness of the amendments and to expedite improvements to Topic 326. In May 2019, the FASB issued ASU No. 2019-05, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses, Topic 326&lt;/span&gt;, providing companies with an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. These ASUs do not change the core principle of the guidance in ASU 2016-13; instead, these amendments are intended to clarify and improve operability of certain topics. In November 2019, the FASB issued ASU&#160;No.&#160;2019-10, &lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/span&gt; and ASU No. 2019-11, &lt;span style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses&lt;/span&gt;, which defer the effective date of the new credit loss standard. ASU&#160;2016-13 and its related amendments are effective for the Company&#x2019;s fiscal year beginning after December 15, 2022 and early adoption is permitted. The Company is currently assessing the timing of adoption of ASU 2016-13 and the impact that adoption will have on its consolidated financial statements and related disclosures&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;</rapt:RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231"
      decimals="-6"
      id="F_000302"
      unitRef="U_iso4217USD">8000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231"
      decimals="-6"
      id="F_000303"
      unitRef="U_iso4217USD">9000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001673772_srtRangeAxis_srtMinimumMember_20211231"
      decimals="-6"
      id="F_000304"
      unitRef="U_iso4217USD">6000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_20211231"
      decimals="-6"
      id="F_000306"
      unitRef="U_iso4217USD">7000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000232">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Financial instruments include cash and cash &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;equivalents, &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;marketable securities, &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;accounts payable and accrued &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; that approximate fair value due to their relatively short maturities. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets and liabilities recorded at fair value on a recurring basis in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&#x2014;Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&#x2014;Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&#x2014;Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;span style="font-size:10pt;font-family:Calibri;"&gt;To date, the Company has not recorded any impairment charges on its marketable securities due to other-than-temporary declines in market value. In determining whether a decline is other than temporary, the Company considers various factors, including the length of time and extent to which the market value has been less than amortized cost, the financial condition and near-term prospects of the issuer and the Company&#x2019;s intent and ability to retain its investment in the issuer for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimates the fair values of investments in corporate debt securities, commercial paper and &lt;span style="Background-color:#FFFFFF;color:#000000;font-family:Times New Roman;"&gt;U.S. government agency securities &lt;/span&gt;using valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of, and broker/dealer quotes on, the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;span style="font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&#x2014;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&#x2014;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,212&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-size:10pt;"&gt;The Company does not intend to sell the securities that are in an unrealized loss position and the Company believes it is more likely than not that the investments will be held until recovery of the amortized cost bases. The Company has determined that the gross unrealized losses on marketable securities as of December&#160;31, 2021 were temporary in nature.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of December 31, 2021 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in less than one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in more than one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000260">
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and marketable securities, all of which are classified as available-for-sale securities and measured at fair value on a recurring basis, consisted of the following (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&#x2014;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,658&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,532&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,669&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,520&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.86%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&#x2014;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; classified as cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,164&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,212&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Asset-backed securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,367&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,368&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.06%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.08%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,962&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,047&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.06%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,925&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">22658000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">22658000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">52704000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">52565000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">23882000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">23861000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">59532000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">59532000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">29744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20211231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">29669000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">188520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">188285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">21333000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">21333000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">32164000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">48000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">32212000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">12367000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapAssetBackedSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">12368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">28962000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapCommercialPaperMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">28962000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">13047000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">13050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">107873000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">107925000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000261">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the remaining contractual maturities of the Company&#x2019;s marketable securities as of December 31, 2021 (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.48%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.36%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in less than one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132,804&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due in more than one year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,285&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">132804000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">55481000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">188285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000233">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Property and Equipment &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,082&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,741&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expenses were $1.0 million and $1.1 million for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000262">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,966&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;482&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;447&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,064&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,684&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,082&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,741&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20211231"
      decimals="-3"
      id="F_000345"
      unitRef="U_iso4217USD">6291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000346"
      unitRef="U_iso4217USD">5966000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20211231"
      decimals="-3"
      id="F_000347"
      unitRef="U_iso4217USD">3295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000348"
      unitRef="U_iso4217USD">3294000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20211231"
      decimals="-3"
      id="F_000349"
      unitRef="U_iso4217USD">482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20201231"
      decimals="-3"
      id="F_000350"
      unitRef="U_iso4217USD">447000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20211231"
      decimals="-3"
      id="F_000351"
      unitRef="U_iso4217USD">357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000352"
      unitRef="U_iso4217USD">357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">10425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">10064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">7684000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">7082000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">2741000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">2982000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000359"
      unitRef="U_iso4217USD">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0001673772_20200101_20201231"
      decimals="-5"
      id="F_000360"
      unitRef="U_iso4217USD">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000234">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Accrued Expenses &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;415&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000263">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses consisted of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;415&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,935&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">2205000</rapt:AccruedResearchAndDevelopmentExpenses>
    <rapt:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">1576000</rapt:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">3652000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:WorkersCompensationLiabilityCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">2967000</us-gaap:WorkersCompensationLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">415000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">129000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">54000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000368"
      unitRef="U_iso4217USD">263000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">6326000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">4935000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000235">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Commitments &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into contracts in the normal course of business with CROs for preclinical studies and clinical trials. These agreements provide for notice of termination by either party and are, therefore, cancelable contracts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2015, the Company entered into an operating lease for 30,376 square feet of laboratory and office facilities in South San Francisco, California, which expires in May 2022. In April 2018, the Company amended the lease agreement to include an additional 6,378 square feet of laboratory and office space increasing the total leased premises to 36,754 square feet. The lease amendment extended the lease term to November 2026 and contained scheduled rent increases over the lease term and an option for the Company to extend the lease for an additional &lt;span style="-sec-ix-hidden:F_000377"&gt;five-year&lt;/span&gt; term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2019, the Company entered into an agreement to sublease its facility lease of 6,378 square feet of laboratory and office space, which terminated in July 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, future minimum non-cancelable lease payments, are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the lease agreement provide for rental payments on a monthly basis and on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period and has accrued for rent expense incurred but not paid. Rent expense includes certain monthly charges that do not represent non-cancelable obligations, as defined. These costs are determined based on actual charges incurred. In addition, &lt;span style="color:#000000;"&gt;tenant improvement allowances recorded are amortized as a reduction to rent expense on a straight-line basis over the lease term. Rent expense was $2.3 million and $2.1 million in the years ended December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. An estimated loss contingency is accrued in the financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company is not subject to any current pending legal matters or claims and no contingency losses were accrued at either December 31, 2021 or 2020.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_0001673772_srtStatementGeographicalAxis_raptSouthSanFranciscoAndCaliforniaMember_20150531"
      decimals="INF"
      id="F_000371"
      unitRef="U_utrsqft">30376</rapt:SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:OperatingLeaseExpirationYear contextRef="C_0001673772_20150501_20150531" id="F_000372">2022-05</rapt:OperatingLeaseExpirationYear>
    <rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_0001673772_20180430"
      decimals="INF"
      id="F_000373"
      unitRef="U_utrsqft">6378</rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:IncreasedAreaOfLeasedPremises
      contextRef="C_0001673772_20180430"
      decimals="INF"
      id="F_000374"
      unitRef="U_utrsqft">36754</rapt:IncreasedAreaOfLeasedPremises>
    <rapt:LesseeOperatingLeaseExtendedLeaseTerm contextRef="C_0001673772_20180401_20180430" id="F_000375">2026-11</rapt:LesseeOperatingLeaseExtendedLeaseTerm>
    <rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
      contextRef="C_0001673772_20190228"
      decimals="INF"
      id="F_000378"
      unitRef="U_utrsqft">6378</rapt:AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease>
    <rapt:LeaseTerminationMonthAndYear contextRef="C_0001673772_20190201_20190228" id="F_000379">2020-07</rapt:LeaseTerminationMonthAndYear>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000264">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, future minimum non-cancelable lease payments, are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #FFFFFF;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,037&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,259&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.04%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000380"
      unitRef="U_iso4217USD">2037000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000381"
      unitRef="U_iso4217USD">2109000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000382"
      unitRef="U_iso4217USD">2183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000383"
      unitRef="U_iso4217USD">2259000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000384"
      unitRef="U_iso4217USD">2137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">10725000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000386"
      unitRef="U_iso4217USD">2300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001673772_20200101_20201231"
      decimals="-5"
      id="F_000387"
      unitRef="U_iso4217USD">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000388"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="C_0001673772_20200101_20201231"
      decimals="INF"
      id="F_000389"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000236">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Collaboration Agreements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Hanmi&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company entered into a Collaboration and License Agreement with Hanmi (&#x201c;Hanmi Agreement&#x201d;),&lt;span style="Background-color:#FFFFFF;"&gt; pursuant to which the Company granted Hanmi an exclusive license to develop, manufacture and commercialize FLX475 and related compounds and products with respect to human cancers in the Republic of Korea, the Republic of China (Taiwan) and the People&#x2019;s Republic of China, including the special administrative regions of Macau and Hong Kong (the &#x201c;Hanmi Territory&#x201d;), and certain sublicense&lt;/span&gt; rights.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration of such rights, under the Hanmi Agreement, the Company was entitled to $10.0&#160;million, which consisted of an upfront payment of $4.0&#160;million and a development milestone payment of $6.0&#160;million that were received in December 2019 and April 2020, respectively. Additionally, the Company is eligible to receive contingent payments of up to $108.0 million upon the achievement of specified milestones, as well as double-digit royalties on future net sales of FLX475 in the Hanmi Territory.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;The Company identified the following promised goods and services at the inception of the Hanmi Agreement, including (1) &lt;/span&gt;the exclusive development, manufacturing and commercialization license in the Hanmi Territory; (2) the transfer of know-how, technology, research data and information, and any improvements in technology; (3) the obligation to participate in the joint steering committee and appoint an alliance manager; (4) &lt;span style="color:#000000;"&gt;the responsibility to complete certain Phase 2 clinical trials; and (5) the supply of FLX475 for use in Hanmi&#x2019;s Phase 2 clinical trials for which Hanmi will reimburse the Company for the supply of FLX475.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the identified performance obligations, except for the supply of FLX475, are not distinct and should be combined into one distinct performance obligation. The Company considered factors such as the novelty of the drug candidate and that the promised goods and services are highly interdependent and are expected to significantly modify one another.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the transaction price as of December 31, 2019 was $10.0&#160;million, which consisted of the upfront fee of $4.0&#160;million and an unconstrained development milestone payment of $6.0&#160;million. In December 2020, Hanmi requested the Company to supply FLX475, and as a result, the Company increased the transaction price by $0.4 million. Other future development milestones were constrained as their achievement was highly dependent on factors outside the Company&#x2019;s control. The Company expects that the revenue from sales milestone and royalty payments will be recognized when the sales occur or the milestone is achieved. The Company will re-evaluate the transaction price at each reporting period. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue for the performance obligation by applying the cost-based input method over the estimated service period. The Company determined that this method most faithfully depicts the transfer of its performance obligations to Hanmi as it reflects the progress made towards providing Hanmi with the necessary know-how to continue developing FLX475 in the Hanmi Territory.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2021 and 2020, $3.8 million and $5.0 million of revenue was recognized pursuant to the Hanmi Agreement, respectively. As of December 31, 2021, deferred revenue related to the Hanmi Agreement was $1.5 million and is expected to be recognized over the over the remaining period of the Company&#x2019;s Phase&#160;1/2 clinical trial of FLX475.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical Trial Collaboration and Supply Agreement with Merck&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the Company entered into a clinical trial collaboration and supply agreement with an affiliate of Merck (known as MSD outside the United States and Canada) under which the Company will conduct a clinical trial evaluating FLX475 in combination with pembrolizumab (KEYTRUDA&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;&#xae;&lt;/sup&gt;), Merck&#x2019;s anti-PD-1 therapy, in patients with advanced cancers. The Company is the sponsor of the clinical trial, and Merck will supply pembrolizumab for use in the clinical trial. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <rapt:UpfrontMilestonePayment
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">10000000.0</rapt:UpfrontMilestonePayment>
    <rapt:UpfrontFees
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">4000000.0</rapt:UpfrontFees>
    <rapt:DevelopmentMilestonePayment
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200430"
      decimals="-5"
      id="F_000392"
      unitRef="U_iso4217USD">6000000.0</rapt:DevelopmentMilestonePayment>
    <rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="INF"
      id="F_000393"
      unitRef="U_iso4217USD">108000000.0</rapt:ContingentPaymentsUponAchievementOfSpecifiedMilestones>
    <rapt:UpfrontMilestonePayment
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000394"
      unitRef="U_iso4217USD">10000000.0</rapt:UpfrontMilestonePayment>
    <rapt:UpfrontFees
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000395"
      unitRef="U_iso4217USD">4000000.0</rapt:UpfrontFees>
    <rapt:UnconstrainedDevelopmentMilestonePayment
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000396"
      unitRef="U_iso4217USD">6000000.0</rapt:UnconstrainedDevelopmentMilestonePayment>
    <rapt:UnconstrainedDevelopmentMilestonePayment
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000397"
      unitRef="U_iso4217USD">400000</rapt:UnconstrainedDevelopmentMilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20210101_20211231"
      decimals="-5"
      id="F_000398"
      unitRef="U_iso4217USD">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000399"
      unitRef="U_iso4217USD">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000400"
      unitRef="U_iso4217USD">1500000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20211231"
      decimals="-5"
      id="F_000401"
      unitRef="U_iso4217USD">1500000</us-gaap:DeferredRevenue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000237">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Common Stock &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The holders of the Company&#x2019;s common stock have one vote for each share of common stock held by them. Holders of shares of the Company&#x2019;s common stock are entitled to dividends when, as and if declared by the board of directors. No dividends had been declared as of December 31, 2021 or December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and 2015&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Stock Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options available for future grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,688,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,415,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,070,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,106,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockVotingRights contextRef="C_0001673772_20210101_20211231" id="F_000402">The holders of the Company&#x2019;s common stock have one vote for each share of common stock held by them</us-gaap:CommonStockVotingRights>
    <rapt:CommonStockNumberOfVotesPerShare
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000403"
      unitRef="U_raptvote">1</rapt:CommonStockNumberOfVotesPerShare>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000404"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001673772_20200101_20201231"
      decimals="INF"
      id="F_000405"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000265">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved the following shares of common stock, on an as-converted basis, for future issuance as follows: &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding under the 2019 Equity Incentive Plan and 2015&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Stock Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units issued and outstanding under the 2019 Equity Incentive Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:71.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options available for future grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,688,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,415,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares reserved under the 2019 Employee Stock Purchase Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;153,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:71.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,070,476&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,106,321&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000406"
      unitRef="U_xbrlishares">2024681</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember_20201231"
      decimals="INF"
      id="F_000407"
      unitRef="U_xbrlishares">1481100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000408"
      unitRef="U_xbrlishares">40500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptRestrictedStockUnitsIssuedAndOutstandingMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000409"
      unitRef="U_xbrlishares">56500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20211231"
      decimals="INF"
      id="F_000410"
      unitRef="U_xbrlishares">2688372</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20201231"
      decimals="INF"
      id="F_000411"
      unitRef="U_xbrlishares">2415710</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000412"
      unitRef="U_xbrlishares">316923</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000413"
      unitRef="U_xbrlishares">153011</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_20211231"
      decimals="INF"
      id="F_000414"
      unitRef="U_xbrlishares">5070476</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001673772_20201231"
      decimals="INF"
      id="F_000415"
      unitRef="U_xbrlishares">4106321</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000238">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Option Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2015, the Company adopted the FLX Bio, Inc. 2015 Stock Plan (the &#x201c;2015 Plan&#x201d;).&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the consummation of the IPO in November 2019, the Company&#x2019;s board of directors adopted the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d; and collectively with the 2015 Plan, the &#x201c;Option Plans&#x201d;). Upon the effectiveness of the 2019 Plan, the Company&#x2019;s 2015 Plan terminated and no further grants may be made thereunder. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted thereunder. As of December 31, 2021, the Company had 2,688,372 shares of common stock available for grant under the Option Plans. In addition, the number of shares reserved for issuance under the Company&#x2019;s 2019 Plan will automatically increase on January 1 of each year beginning January 1, 2020 by a number equal to (i) 4% of the shares of common stock outstanding on the last business day of the prior fiscal year or (ii) the number of shares determined by the Company&#x2019;s board of directors.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s Option Plans provided for the granting of incentive and non-statutory stock options and restricted shares of common stock options to eligible employees, officers, directors, advisors and consultants. Terms of the stock option agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the Options Plans. Options granted generally vest over four years and expire no later than ten years from the date of grant. As a private company, the estimated fair value of the Company&#x2019;s underlying common stock was determined by the board of directors. Following the Company&#x2019;s IPO in November 2019 the fair value of the Company&#x2019;s common stock is based on the closing price of its common stock on the date of grant.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2019, the Company adopted the 2019 Employee Stock Purchase Plan (the &#x201c;2019 ESPP&#x201d;). The Company reserved 240,336 shares of common stock pursuant to purchase rights to be granted to the Company&#x2019;s employees. The 2019 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1 of each calendar year, beginning January 1, 2020, by the lesser of (1) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (2) 240,336 shares or (3) a number determined by the board of directors that is less than (1) and (2). As of January 1, 2021, an additional 240,336 shares of common stock were authorized for issuance pursuant to the annual automatic increase to the authorized shares under the 2019 ESPP. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the 2019 ESPP, eligible employees are granted rights to purchase shares of common stock, which can be funded through payroll deductions that cannot exceed 15% of each employee&#x2019;s compensation. The 2019 ESPP generally provides for a 24-month offering period, which includes four &lt;span style="-sec-ix-hidden:F_000426"&gt;six-month&lt;/span&gt; purchase periods. At the end of each purchase period, eligible employees are permitted to purchase shares of common stock at 85% of the lower of fair market value at the beginning of the offering period or fair market value at the end of the purchase period. During the years ended December 31, 2021 and 2020, employees purchased 76,424 shares at weighted average price of $10.80 and 87,325 shares at a weighted average exercise price of $10.27, respectively. The 2019 ESPP is considered a compensatory plan and the Company recorded stock-based compensation expense of $2.5 million and $2.7 million for the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity under the Options Plan is set forth below for the year ended December 31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000448"&gt;8.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;794,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(120,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(130,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000449"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000450"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000451"&gt;7.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the Company&#x2019;s common stock, as determined by the board of directors, as of December 31, 2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The options granted in the years ended December 31, 2021 and 2020 had a weighted average per share grant-date fair value of $15.04 and $24.57, respectively, and a total grant date fair value of $11.9 million and $8.7 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options exercised in the years ended December 31, 2021 and 2020 was $2.4 million and $2.4 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate fair value of options that vested in the years ended December 31, 2021 and 2020 was $6.8&#160;million and $5.4&#160;million, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted &lt;span style="color:#000000;"&gt;Stock Units&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs awarded&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Employee stock option valuation &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&#x2019;s IPO, the grant date fair value of the shares of common stock underlying stock options was determined by the Company&#x2019;s board of directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of common stock was determined using valuation methodologies by considering a number of objective and subjective factors including important developments in the Company&#x2019;s operations, valuations performed by independent third parties, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies and the lack of liquidity of the Company&#x2019;s common stock, among other factors. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In determining the fair value of the options granted, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected term represents the period that the Company&#x2019;s options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term). The Company has very limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company recently became a public company and has only a limited trading history for its common stock, the expected volatility was estimated based on the average historical volatility for comparable publicly traded biopharmaceutical companies and our historical volatility over a period, where available, equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, life cycle stage or area of specialty. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.86%;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the options. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.86%;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended December 31, 2021 and 2020, using the Black-Scholes option pricing model, were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000473"&gt;3.93 - 6.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000474"&gt;5.19 - 6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000477"&gt;81.0%&#160;-&#160;86.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000478"&gt;84.0%&#160;-&#160;87.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000481"&gt;0.55% - 1.26%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000482"&gt;0.28% - 1.43%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;span style="font-style:italic;color:#000000;"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000485"&gt;0.25 - 2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000486"&gt;0.25 - 2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71.3% - 92.9%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000492"&gt;0.05% - 1.55%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000493"&gt;0.11% - 1.57%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Early exercise of stock options &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the 2015 Plan permitted option holders to exercise stock options before they are vested, subject to certain limitations. Such unvested shares were subject to repurchase by the Company at the original exercise price in the event the option holder&#x2019;s service to the Company was terminated either voluntarily or involuntarily. As a result of early exercises under the 2015 Plan, approximately 0 and 3,000 shares were subject to repurchase as of December 31, 2021 and 2020, respectively. The Company treats cash received from the exercise of unvested options as a refundable deposit and classifies such amounts as a liability in its balance sheet. As of December 31, 2021 and 2020, the Company included cash received for the early exercise of unvested options of $0 and $6,000, respectively, in other current liabilities. Amounts included in liabilities were transferred into common stock and additional paid-in capital as the shares vested, which was generally over a period of 48 months.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,637&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:2pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest was $15.7 million. This unrecognized stock-based compensation cost is expected to be recognized over &lt;span&gt;&lt;span style="color:#000000;"&gt;2.6&lt;/span&gt; years&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000416"
      unitRef="U_xbrlishares">2688372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandNineteenStockPlanMember_20211231"
      decimals="2"
      id="F_000417"
      unitRef="U_xbrlipure">0.04</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000418">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001673772_srtRangeAxis_srtMaximumMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000419">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031"
      decimals="INF"
      id="F_000420"
      unitRef="U_xbrlishares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <rapt:PercentageOfIncreaseInSharesReservedForIssuance
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031"
      decimals="3"
      id="F_000422"
      unitRef="U_xbrlipure">0.010</rapt:PercentageOfIncreaseInSharesReservedForIssuance>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031"
      decimals="INF"
      id="F_000423"
      unitRef="U_xbrlishares">240336</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101"
      decimals="INF"
      id="F_000421"
      unitRef="U_xbrlishares">240336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191031"
      decimals="INF"
      id="F_000424"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031"
      id="F_000425">P24M</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20191001_20191031"
      decimals="INF"
      id="F_000427"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="INF"
      id="F_000430"
      unitRef="U_xbrlishares">76424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20211231"
      decimals="2"
      id="F_000432"
      unitRef="U_iso4217USD_xbrlishares">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000431"
      unitRef="U_xbrlishares">87325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20201231"
      decimals="2"
      id="F_000433"
      unitRef="U_iso4217USD_xbrlishares">10.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20210101_20211231"
      decimals="-5"
      id="F_000428"
      unitRef="U_iso4217USD">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="-5"
      id="F_000429"
      unitRef="U_iso4217USD">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000266">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock option activity under the Options Plan is set forth below for the year ended December 31, 2021: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&#160;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000448"&gt;8.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,123&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;794,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.62&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(120,178&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(130,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000449"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000450"&gt;8.04&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,417&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,028,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000451"&gt;7.41&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">1481100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231"
      decimals="2"
      id="F_000441"
      unitRef="U_iso4217USD_xbrlishares">16.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">11123000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000435"
      unitRef="U_xbrlishares">794095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="2"
      id="F_000442"
      unitRef="U_iso4217USD_xbrlishares">21.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000436"
      unitRef="U_xbrlishares">120178</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="2"
      id="F_000443"
      unitRef="U_iso4217USD_xbrlishares">9.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="INF"
      id="F_000437"
      unitRef="U_xbrlishares">130336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231"
      decimals="2"
      id="F_000444"
      unitRef="U_iso4217USD_xbrlishares">21.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000438"
      unitRef="U_xbrlishares">2024681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="2"
      id="F_000445"
      unitRef="U_iso4217USD_xbrlishares">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">38417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlishares">2024681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="2"
      id="F_000446"
      unitRef="U_iso4217USD_xbrlishares">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">38417000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlishares">1028650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="2"
      id="F_000447"
      unitRef="U_iso4217USD_xbrlishares">14.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20211231"
      decimals="-3"
      id="F_000455"
      unitRef="U_iso4217USD">23142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_20210101_20211231"
      decimals="2"
      id="F_000456"
      unitRef="U_iso4217USD_xbrlishares">15.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_20200101_20201231"
      decimals="2"
      id="F_000457"
      unitRef="U_iso4217USD_xbrlishares">24.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_0001673772_20211231"
      decimals="-5"
      id="F_000458"
      unitRef="U_iso4217USD">11900000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue
      contextRef="C_0001673772_20201231"
      decimals="-5"
      id="F_000459"
      unitRef="U_iso4217USD">8700000</rapt:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000460"
      unitRef="U_iso4217USD">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001673772_20200101_20201231"
      decimals="-5"
      id="F_000461"
      unitRef="U_iso4217USD">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000462"
      unitRef="U_iso4217USD">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001673772_20200101_20201231"
      decimals="-5"
      id="F_000463"
      unitRef="U_iso4217USD">5400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000267">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units (&#x201c;RSU&#x201d;) activity under the 2019 Plan is set forth below for the year ended December 31, 2021:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Fair Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs awarded&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,125&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.66%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000464"
      unitRef="U_xbrlishares">56500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231"
      decimals="2"
      id="F_000468"
      unitRef="U_iso4217USD_xbrlishares">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000465"
      unitRef="U_xbrlishares">14125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000469"
      unitRef="U_iso4217USD_xbrlishares">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000466"
      unitRef="U_xbrlishares">1875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20210101_20211231"
      decimals="2"
      id="F_000470"
      unitRef="U_iso4217USD_xbrlishares">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231"
      decimals="INF"
      id="F_000467"
      unitRef="U_xbrlishares">40500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20211231"
      decimals="2"
      id="F_000471"
      unitRef="U_iso4217USD_xbrlishares">44.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001673772_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_20210101_20211231"
      id="F_000268">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value employee and non-employee stock option awards granted under the Option Plans during the years ended December 31, 2021 and 2020, using the Black-Scholes option pricing model, were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000473"&gt;3.93 - 6.05&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000474"&gt;5.19 - 6.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000477"&gt;81.0%&#160;-&#160;86.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000478"&gt;84.0%&#160;-&#160;87.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000481"&gt;0.55% - 1.26%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000482"&gt;0.28% - 1.43%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000269">
&lt;p style="margin-bottom:12pt;margin-top:6pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the rights granted to employees under the 2019 ESPP was estimated using a Black-Scholes option-pricing model with the following valuation assumptions:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000485"&gt;0.25 - 2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000486"&gt;0.25 - 2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71.3% - 92.9%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84.0%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000492"&gt;0.05% - 1.55%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000493"&gt;0.11% - 1.57%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231"
      decimals="INF"
      id="F_000489"
      unitRef="U_xbrlipure">0.840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231"
      decimals="INF"
      id="F_000496"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231"
      decimals="INF"
      id="F_000497"
      unitRef="U_xbrlishares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20211231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20201231"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">6000000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001673772_us-gaapPlanNameAxis_raptTwoThousandFifteenStockPlanMember_20210101_20211231"
      id="F_000500">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000270">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense recognized for stock options and RSUs granted to both employees and non-employees and for the employee stock purchase plan was as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,637&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,642&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,952&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.84%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,686&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">5310000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">4637000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">4642000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">4049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">9952000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">8686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001673772_20211231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">15700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_0001673772_20210101_20211231" id="F_000508">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000239">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the provision for income taxes related to Korean withholding taxes on the near-term milestone payment the Company received pursuant to the Hanmi Agreement are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign losses not benefited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Withholding taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred net operating losses for all periods since inception. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,665&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,089&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realization of deferred tax assets is dependent upon future taxable income, if any. The Company has established a valuation allowance to offset deferred tax assets as of December 31, 2021 and 2020, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. The valuation allowance increased by approximately $14.4 million and $12.5 million during the years ended December&#160;31, 2021 and 2020, respectively. The increase in the valuation allowance is mainly related to the increase in net operating loss carryforwards incurred during the respective taxable years. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;233.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;177.2&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively. The federal net operating loss carryforwards generated during and after fiscal 2018 &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;are carried forward indefinitely, while all others&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; along with the federal tax credit carryforwards, expire in years beginning in &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2035&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. As of December 31, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; state net operating loss carryforwards of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; approximately &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, which begin to expire in &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2035&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and are available to offset future taxable income. As of December 31, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;federal &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;research and development tax credit carryforwards of approximately&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million and&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and 20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, t&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he Company had&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;state research and development tax credit carryforwards of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.5&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.3&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Moreover, as of December 31, &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;202&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company recorded federal and state reserves of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.5&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million and &lt;/span&gt;&lt;span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, respectively, as uncertain tax positions. If not utilized, the federal credit carryforwards will begin expiring in 2035. The state credits carry forward indefinitely.&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted in response to the COVID-19 pandemic. The tax relief measures under the CARES Act for businesses include a five-year net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property. The CARES Act did not have a material effect on the realizability of deferred income tax assets or tax expense in 2021. The Company claimed employee retention tax credits in the amount of $0.4 million for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state laws impose substantial restrictions on the utilization of net operating loss and tax credit carryforwards in the event of an ownership change for tax purposes, as defined in Section 382 of the Internal Revenue Code. As a result of such ownership changes, the Company&#x2019;s ability to realize the potential future benefit of tax losses and tax credits that existed at the time of the ownership change may be significantly reduced. The Company&#x2019;s deferred tax asset and related valuation allowance would be reduced as a result. The Company has not yet performed a Section 382 study to determine the amount of reduction, if any. The annual limitation may result in the expiration of net operating losses and credits before utilization. Under the new enacted law, the carryforward period of net operating losses generated from 2018 forward is indefinite; however, the carryforward period for net operating losses generated prior to 2018 remains the same. Therefore, the annual limitation may still result in the expiration of certain net operating losses and tax credit carryforwards before their utilization. On February 9, 2022, California Senate Bill 113 &#x201c;SB 113&#x201d; was signed into law. SB 113 lifted the limitation for California NOL and Credit utilization disallowed by California Assembly Bill 85. Given the Company&#x2019;s expected loss position in the current year, the new legislations will not impact the current year provision. The Company will continue to monitor possible California net operating loss and credit limitation in future periods..&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. The amount recognized is measured as the largest amount of tax benefit that is greater than 50&#160;percent likely of being realized upon effective settlement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed for both US and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions on tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company does not expect that its uncertain tax positions will materially change in the next 12 months. The reversal of uncertain tax benefits would not impact the Company&#x2019;s effective tax rate as the Company continues to maintain a full valuation allowance against its deferred tax assets. In accordance with ASC 740, the Company would classify interest and penalties related to uncertain tax positions in income tax expense, if applicable. There was no interest expense or penalties related to unrecognized tax benefits through December&#160;31,&#160;2021. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns with varying statutes of limitations in the United States, various states and foreign jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. All tax returns remain open for examination by federal and state authorities. The tax years from inception in 2015 forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000271">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents domestic and foreign components of income (loss) before income taxes for the periods presented (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(66,464&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,941&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(51,902&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">-66464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">-49961000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">-2740000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">-1941000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">-69204000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">-51902000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000272">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the provision for income taxes related to Korean withholding taxes on the near-term milestone payment the Company received pursuant to the Hanmi Agreement are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000515"
      unitRef="U_iso4217USD">990000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000516"
      unitRef="U_iso4217USD">990000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000273">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the statutory U.S. federal rate and effective rate is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.76&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.83&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign losses not benefited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.14&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Withholding taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23.99&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.44%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000517"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001673772_20200101_20201231"
      decimals="INF"
      id="F_000518"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001673772_20210101_20211231"
      decimals="4"
      id="F_000519"
      unitRef="U_xbrlipure">-0.0076</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000520"
      unitRef="U_xbrlipure">-0.0055</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001673772_20210101_20211231"
      decimals="4"
      id="F_000521"
      unitRef="U_xbrlipure">0.0239</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000522"
      unitRef="U_xbrlipure">0.0283</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="C_0001673772_20210101_20211231"
      decimals="4"
      id="F_000523"
      unitRef="U_xbrlipure">-0.0214</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <rapt:EffectiveIncomeTaxRateReconciliationWithholdingTaxes
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000524"
      unitRef="U_xbrlipure">-0.0151</rapt:EffectiveIncomeTaxRateReconciliationWithholdingTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001673772_20210101_20211231"
      decimals="4"
      id="F_000525"
      unitRef="U_xbrlipure">-0.2086</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000526"
      unitRef="U_xbrlipure">-0.2399</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001673772_20210101_20211231"
      decimals="4"
      id="F_000527"
      unitRef="U_xbrlipure">0.0037</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000528"
      unitRef="U_xbrlipure">0.0031</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001673772_20200101_20201231"
      decimals="4"
      id="F_000529"
      unitRef="U_xbrlipure">-0.0191</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000274">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;49,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,665&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal and state research and development tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,644&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,089&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,331&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,522&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,488&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(47,060&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.64%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.64%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">49791000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">38665000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">7756000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">6103000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">1644000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">1089000</rapt:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">2331000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">1273000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">61522000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">47130000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">61488000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">47060000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">34000</rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization>
    <rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">70000</rapt:DeferredTaxLiabilitiesGrossDepreciationAndAmortization>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">34000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">70000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001673772_20210101_20211231"
      decimals="-5"
      id="F_000548"
      unitRef="U_iso4217USD">14400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001673772_20200101_20201231"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">12500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000550"
      unitRef="U_iso4217USD">233100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000551"
      unitRef="U_iso4217USD">177200000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000552">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000553"
      unitRef="U_iso4217USD">12100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000554"
      unitRef="U_iso4217USD">12100000</us-gaap:OperatingLossCarryforwards>
    <rapt:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000555">2035</rapt:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-5"
      id="F_000556"
      unitRef="U_iso4217USD">6100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000557"
      unitRef="U_iso4217USD">4800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20211231"
      decimals="-5"
      id="F_000558"
      unitRef="U_iso4217USD">5500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000559"
      unitRef="U_iso4217USD">4300000</us-gaap:TaxCreditCarryforwardAmount>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000560"
      unitRef="U_iso4217USD">1500000</rapt:UncertainTaxPositionsReserves>
    <rapt:UncertainTaxPositionsReserves
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000561"
      unitRef="U_iso4217USD">1500000</rapt:UncertainTaxPositionsReserves>
    <rapt:UncertainTaxPositions
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000562"
      unitRef="U_iso4217USD">1400000</rapt:UncertainTaxPositions>
    <rapt:UncertainTaxPositions
      contextRef="C_0001673772_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000563"
      unitRef="U_iso4217USD">1400000</rapt:UncertainTaxPositions>
    <rapt:EmployeeRetentionTaxCredits
      contextRef="C_0001673772_us-gaapUnusualRiskOrUncertaintyByNatureAxis_raptCoronavirusAidReliefAndEconomicSecurityActMember_20200101_20201231"
      decimals="-5"
      id="F_000564"
      unitRef="U_iso4217USD">400000</rapt:EmployeeRetentionTaxCredits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000275">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending amounts of unrecognized tax benefits for the years ended December 31, 2021 and 2020 resulting primarily from research and development tax credits claimed for both US and foreign operations on the Company&#x2019;s annual tax returns were as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,747&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;807&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions on tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,336&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;544&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,434&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">2291000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001673772_20191231"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">1747000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">807000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">1336000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">544000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001673772_20211231"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">4434000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001673772_20201231"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">2291000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_0001673772_20210101_20211231"
      decimals="INF"
      id="F_000572"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000240">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended December 31, 2021 and 2020 (in thousands, except share and per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,390,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,164,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: weighted-average unvested early&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; exercised common shares subject to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used to compute net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,390,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,134,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding under the 2019&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Equity Incentive Plan and 2015 Stock Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs subject to future vesting&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,071,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,553,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000276">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share of the years ended December 31, 2021 and 2020 (in thousands, except share and per share data): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(52,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average common shares outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,390,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,164,828&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.84%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: weighted-average unvested early&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; exercised common shares subject to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(30,523&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares used to compute net&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,390,326&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,134,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.84%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.53&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20210101_20211231"
      decimals="-3"
      id="F_000573"
      unitRef="U_iso4217USD">-69204000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001673772_20200101_20201231"
      decimals="-3"
      id="F_000574"
      unitRef="U_iso4217USD">-52892000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_0001673772_20210101_20211231"
      decimals="0"
      id="F_000575"
      unitRef="U_xbrlishares">27390326</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="C_0001673772_20200101_20201231"
      decimals="0"
      id="F_000576"
      unitRef="U_xbrlishares">24164828</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEarlyExercisedStockMember_20200101_20201231"
      decimals="0"
      id="F_000577"
      unitRef="U_xbrlishares">30523</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001673772_20210101_20211231"
      decimals="0"
      id="F_000578"
      unitRef="U_xbrlishares">27390326</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001673772_20200101_20201231"
      decimals="0"
      id="F_000579"
      unitRef="U_xbrlishares">24134305</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001673772_20210101_20211231"
      decimals="2"
      id="F_000580"
      unitRef="U_iso4217USD_xbrlishares">-2.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001673772_20200101_20201231"
      decimals="2"
      id="F_000581"
      unitRef="U_iso4217USD_xbrlishares">-2.19</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001673772_20210101_20211231" id="F_000277">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding as of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding under the 2019&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Equity Incentive Plan and 2015 Stock Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,024,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,481,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated shares issuable under the 2019 ESPP&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,592&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs subject to future vesting&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;40,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,071,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,553,590&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20210101_20211231"
      decimals="0"
      id="F_000582"
      unitRef="U_xbrlishares">2024681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptCommonStockOptionsIssuedAndOutstandingMember_20200101_20201231"
      decimals="0"
      id="F_000583"
      unitRef="U_xbrlishares">1481100</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="0"
      id="F_000584"
      unitRef="U_xbrlishares">6592</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptEstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="0"
      id="F_000585"
      unitRef="U_xbrlishares">15990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20210101_20211231"
      decimals="0"
      id="F_000586"
      unitRef="U_xbrlishares">40500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_raptRestrictedStockUnitsRSUsSubjectToFutureVestingMember_20200101_20201231"
      decimals="0"
      id="F_000587"
      unitRef="U_xbrlishares">56500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_20210101_20211231"
      decimals="0"
      id="F_000588"
      unitRef="U_xbrlishares">2071773</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001673772_20200101_20201231"
      decimals="0"
      id="F_000589"
      unitRef="U_xbrlishares">1553590</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*:QI7<@?[/$S["?DZW@)*T3S/WK<VSH3E-1"LG+OK C*O-K]I4_[1!PX8&_
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M=7'<PS:-/"<:2&W04@>CU+=,TN((P,#,;$SBT.TA6LRP[\<#D&$+&;Z16B4
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M;@*K95F6W+3-[GZ=#*N@MDO4]GFH^?U&>"UBRLA?B.J0<T]OA\6S\L\>=(/
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M8P#_WTBI7T[,#;I/4*?_ U!+ P04    " !;0VI4XB]1SH4&  "$#P  &
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MZNCB[/F;I[2>%_S:ZEN7?59$R<R8;_3E??/JZ)00TIVN/4&H\,^-OM1=1X"
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M%5O*EZ6&M=1FM:[Z#:VO3>^PI:F\;M2\[:N^;JM..:S7,%#OU+*ZT6JF=:^
MRKJR6-?V#,0V6*VAU7ZIODZOIVJA>VVKKMO0SWI-(*L1M;5M 7S= ;E'__%O
MS\[/3U_PKO^\N+CB[V<O'JNJ)_!U-S1:>2!;X!> ,5GTXZ70(9OP^'9I</BQ
MN>VQV TSUS8MV#51GR^NOA#MMEKKP;>U4Q<#:4+75NK*;]0'WTPGV-[62W5;
M.:5!_ZQK87M,[/GIV;.INN@Z?/':!O;!973$ ,?G UKO*O9'.<]TU\*T&7L
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MJU@4L(E;(04&81>2]@0S)Q<-OS!81";4D&L<24&>Z+#(JZQ44BG+GX02TOD
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M'*T9:KU7.4AI@Q'>P=^1UO=4&^HP^H1 4K306%.'/E,B-M#8W-DM.;;Z 9G
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M283!7'C'RQ@0 3;I)!BEL1LOT?OV%#>!#:JD!DW6@(F=Q;T(FY7SO2\:XLZ
M2NH.9PM4:0*V7<CA<;@+[V#V2 *4/EV#$R^^[1V[GN%!^U>@5D[D--Z&1IA6
M"3IKIZ/S5C[>W5L1?J1JQ80F' J$1KW1P">J%;9V863MQ&0I#4J3FY;X+P!E
M'?![(:79+^P&W=]E]A=02P,$%     @ 6T-J5"BR$)*% @  ; 4  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&ULI51+;]LP#+[[5PC&#AL0Q+;\Z -)
M@*3ML!V*!>T>AV$'Q:9CH;+D27+3_OM2<N)EQ9K++I9(D1\_4OXTVRG]8!H
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M%).4%KAFDXLT_]=U14<*:$%OO<[=O'II!S&,WO$I60X*^A,^O$.W3&^Y-$1
MC:GQ]"P/B1ZT/1A6=5Y/&V51G7[;X',(V@7@>:V4/1BNP/C +EX 4$L#!!0
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M^'R(PQK?:^1X =Y7%K3H'MC!\ 5X\0]02P,$%     @ 6T-J5$@YPDM%!P
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M.-Z(19]E6_2X F\(;&BH)_-F2R84$K@$D)&UC) ]!G0?]E'O=>649DZ9#%L
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MJ5O[84V?1]0N@/;WBB[J,'$)Q@_N]A]02P,$%     @ 6T-J5%LY>"SL#@
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M=?FY]2&HL8Y?AB.(3]C;.&KGO:U#CXL4LON])(\IT-&WR &&HE;U;L]*?M"
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M8]EXPP7IV]2Y+K5DE@N86;BF=8W9BL^3JXE8J4(9G&R %H>.6JT4\Z%_I.W
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MB"Q)SYA@::-6W,S27D"&6-+48);;6-RNT:QQ&>0XLU!+E@T.I#Z/L5CMFI+
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MOJI)LJ(M=Q/M77$VWCOM=:Y%@'E?*W^SU+!;("D4TL' S&.$3[$Q!A9;I4,
M:,MSMK\^<G!XI_\]#"I)LS@F^.L:H9O#(=Q7(JY5,8J<!\;3,+CY7G1?QWK;
MM&5!8L+!A'.'U_[+@BU.A;?I9I^'D*$KK&L+QJM0=&D&;]V)5=.EY7C$">PV
MX#0R/GBMBQ<J)P\$78"\@SM<80YB=2(^]SQ=J]N>^Q'ZWO_#, T7* =%[0B4
M298;T[Z,V4$E>RG6S:WBJG](!@7[(T(V6&@(6!9D%$T9UM_92>K= *)A@[V4
M_7A:1\7Y(52[-N @N@>3.L"-([49@_ZQ!MTL32M1Z,^9@+)87!(=-Z;6%#\U
M$=!;TBU-IR+4ZZNW]"X4:Z[5E B<_8 !/IL(OP16KGC2@C4#@PG4@91?/OZ3
M#;CTR@\IK-"6\\%/EH,]%S"[6B+I6+<S-# _H735>[F"F-U'$_%?UT)U*.?^
M_I99.>X#L$2QM:7TW,J-$^472!AQ>6_;[GYWG):\#YT//.4G]ZI!V,%XZ& U
M-0,#BPY0=?#H #W=WTR$B\3)A+\-&8_[!_I&'CRH=P5QH6O$I +0<#Y-QQ0D
MI?Y"C2H(L6:+F1D]LP;80A=)/1 =CS/XLD1]E> 4&?B#.RJR Q'=E&TH4<PJ
M/>6A-09S<_VEBYUK;QV@S+DMBX6_N0J%;==>5+"ZNXP([#4PB SQO1_S)4>>
M-*@C;D!U@]L1;R%V7:...*8@F'Z:$+@Y.3@@@EU+Y2WB<M.9W5^[@]%=R;T+
M"MN!2_Q!"T=7]O[ZTZO%\+3UP)+Q%<Z@=WC\CB00"9T.=JJDT;" P^);;AS[
M;H?[9(SIXO/5Z.NI$*:#MN->>?8DY[M$Q"HED?JNR]>WLO3WS&Z 'J B(*(G
M419G?,6:QHO9(KHH"KW3:Q3W@TL?3]B,9'26+/I+PF_;/4Q\B)U.Y]'I;#;4
M4]7%0,-9/)O.>DV']% TX0L03U A$MW!F<^G7M?QPJ-Y_R6'IZVO3J09D8Q;
MA_PP5-U H3ZXAJ?VD>6[C#OL=H]"^S!GE_*73G8T#W<T9YGGZ&)2\OCRO5\<
M\(Q)7UN8PC=#=#UT<74I%K-D/(E[ Q"SX-35MI]Q.&+1TF.RT>,O%@_!J^OA
M=!#F =\,;38EN >,'<HY%[VZV0GKI@<B]_TR#V6V6YNFO5[?S^9Q+5G1=YQ#
M_?J\(F!N4,$I,?RWA/[J85<R^KY^]#5O3+LT$M"/&7:4XO_!E&Z+,%R,-=$^
M:$,>( S]B#TH %2KAW-6BSPW_LL**EY^P(G#= /$_(WS'9$7Y9@_?&-%W.,;
MB#OR[E_##,3NK@<\?_H+\>Z+-S_RI:=]DS@4Q==W.TF#*WANLNC.R"=7:P]]
M[W=GVICL^X7"R> ''RAPU_RS%C QE0;_VX_^:?_+F0O_@Y'=<O^SFP\H=]2!
MEFJ%K<ED<7HDC/\IBW_CF@W_? 34[IJ*7ZZ5!'RT )^O&DQ1X0T)Z']/].:_
M4$L#!!0    ( %M#:E2T\$@6\ ,  &$(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;*6676_;-A2&[_4K"'48$D"U),IR;,\QD#095J#-C+A=, R[
MH*5CBPM%JB05)_]^AY2B.&F3F]Y8)'7.P_/QBO1BK_2MJ0 LN:^%-*=A96TS
MCV-35% S,U(-2'RS5;IF%J=Z%YM& RN]4RUBFB23N&9<ALN%7UOIY4*U5G )
M*TU,6]=,/YR#4/O3, T?%Z[YKK)N(5XN&K:#-=BOS4KC+!XH):]!&JXDT; ]
M#<_2^?G8V7N#OSCLS<&8N$PV2MVZR<?R-$Q<0""@L([ \'$''T (!\(POO7,
M<-C2.1Z.'^F_^]PQEPTS\$&)&U[:ZC2<AJ2$+6N%O5;[/Z#/)W>\0@GC?\F^
ML\V2D!2ML:KNG3&"FLONR>[[.APX3%]SH+T#]7%W&_DH+YAERX56>Z*=-=+<
MP*?JO3$X+EU3UE;C6XY^=GF%??^DC"$KT&1=,0V+V"+7O8V+GG'>,>@KC)22
MSTK:RI!+64+Y'!!C0$-4]#&J<_HF\0**$<G2B-"$IF_PLB'+S/.R5WB73$LN
M=P=9DG_.-L9J%,6_;_#' W_L^>.?JN+;C#0=D>\YY$L%9*L$?CR8 +%L(X 8
ML 87M:V(Q=>%JIO6,J]RM?5+*%1>$"9+4G+16BB)1+1PZ ;1QJ-[VP=@VA!P
MK2-8>*@W:/%8?,_ 04*.N$1SU1I<,1&!^P(:VY.<T1.W1"$>SX._D=LIXA ;
M.*K[28*KM@;-K-+SX*J/+O@E.)K,(IJ,@V,WSFDTG5$<7X!4*/_.^L9_:\AE
M=PC8^0K4F+S?WA \>XS%D+!@ 3V)LED29702T'&43L;1E$Z#3V#,G.Q[S/M'
M3"OOP#@N1BX>,$70!3<X?\XW[>8_/%2(57@L-:TN*CP6@E_?36E*?PN.LB3*
M:88QW[SD]_ZM0Z)SUS?X06NB[QOX,I-L'&5)/A3N;5^L)!WE65=3.DIGP3%9
M*0O2<B8P4V^'IR,JJV@UMQRCM!6S6"+LIU26<%F(UK72JP &63UUO6"B:(57
MH2$;*!BFZ4P?\%QN18E+&)+E[X>]/)N97MUF'OSYU#>WKK;!H1P/A+.VJK@E
MJNGVXL:T3@N8[T'GL9DE.KI8:9+.R.6WEML'\E$6+FO<?B68[-6=YJ1#NK6
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MK;J&K15J$^V:! WW "GW;=T.[B5F1PNR[;8Q-[05EI+AXF/1@2U(O IVN8#
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M#4A/^D'T]$B8IF)Z(#.'TRPJ$EII?3?9-22Y@N,@T*:0N!"Z32*##^W0;HH
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M-2?85\C7579XNQLXX"4>Q(,!AEWQR"4>6R</N"\OJEP\<CC?9^RYFL]F9,-
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MCJ#?P(8'P[YMMX,;5. &1G#?8!.-TB5@6T? Q;; @Y; CML5>%@%'AH#:W5
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M;$FS6#^*W1^L2"BTX\U%K/)?M"ML@PZ:9TJ+I' V"A*>[O_I]Z(0!PZXU^
MA0.<ZD *!Y(GNE>6IW5+-1V/I-@A::W-:/8@KTWN;;+AJ6WC5$MSEQL_/?Y$
MN41?:9PQ=,^HRB0S/=(*7:"IF3&++&9(+-&$JC7Z_5O&MS3.;]-T@>ZI?&::
MSHS)E,TSR35G"DUBJA1?<K9 5*'K+>6Q-;DP,^YB2H]MBXC&4J,#(::[C]9(
M\G2%;JCB"KV_-9%XK#X884_36_3^W0?T#O$4_;46F3)JU*BK33EL4MUYD?K-
M/G5H2/V6S2\1P;\A" ![W">GNP?'[EW3A+(34'8"\O%(PWAEO?]<NK(A,U=1
MM6S_W!E7]$6S1/W;$IB4@4D>N-<0^#H14O,?I@T3H;2OCGO_*/>W7-B.\6 0
MVJRWA_7RF 7]09^49D?R>J6\7JN\I]3@*<[U?398\C5ZLA\A/(@<-D0-RZCA
MJ5'OA%+,.[_"6M@+(&&E*AXC[-<6E=JB5FUNJ?A$1;5XIEDPJ,KRF 7](81^
M:?U26K]5VAW;LAAA]!^Z%RE[*1B!/F5FA9J+58ZTS-Y!&7'PMLMF6 8>GKEL
MAK42 T3AH-((CQ4FI&'ZXL!Q/3ACDA3./]/F,VL1=_#0P2=,$[ S0LB-D%0S
M=,MFNJ4MV'$4OS%(L2,I/A>EQ0!'J()^T*L6OFY& $>]AL([EN+S88KK-.T-
M&@([G.)?P%/L8R49-L1VN,3G\!+721A"&%5YZ3$C !@:Q#E@XE.(:9?"M2F+
MOIC1^;,IDINE;1/301*_,26QPR0^EY/8@T!BGEG5#M3-,)"H[^\ .%)".RE/
M61/@ 6%#7 =!:(?@24NB&./X'0-7*N,S:GC'@(/743ACU13.E9Y%-65U,]NS
M!IR  RVT@_;P 9(D3,XYC=$#W3#9]B;N, F]MUTNX$ )[:#\^7*!.B7#84BJ
MR\5C!H-AU#1M'4WA')J"AZ8^<76S-G&.IG J39\NIY?HL]@RF=HO6G2]8NG\
MY32N@N,JO#%7P7$5SN4J>+@Z[/>J[QH>,TR"7@-7B>,J.9^KI,[5AI=+XKA*
M?@%7B0>9_8:/'^*82<YA9N$<'?4CBH;5S^BZF>E'&%3$=0\V?>R.F_G46IDJ
MHY@MC5]PV3>YR?TFUOY$BTV^#S036HLD/UPSNF#2&IC[2R'TZXG=6BJW$L?_
M U!+ P04    " !;0VI4"9Q5QVX"  "^!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6R-5$U/XS 0_2M6Q &D7?+1!KHHC03MHN6 A"BPA]4>W&3:
M6#AVL2<M_'O&3AIU=UN62^*QY[UY\_R1;;1YMA4 LM=:*CL.*L3511C:HH*:
MVU.] D4K"VUJCA2:96A7!GCI0;4,DR@Z"VLN5)!G?N[.Y)EN4 H%=X;9IJZY
M>;L"J3?C( ZV$_=B6:&;"/-LQ9<P WQ<W1F*PIZE%#4H*[1B!A;CX#*^F*0N
MWR<\"=C8G3%SG<RU?G;!33D.(B<()!3H&#C]UC !*1T1R7CI.(.^I /NCK?L
MU[YWZF7.+4RT_"E*K,;!*& E+'@C\5YO?D#7CQ=8:&G]EVVZW"A@16-1UQV8
M%-1"M7_^VOFP XB'!P!)!T@^"QAT@(%OM%7FVYIRY'EF](89ETUL;N"]\6CJ
M1BBWBS,TM"H(A_DU%X8]<=D NP5N&P.T16C95S:C U,V$IA>L'MP!T*H)9MH
MA8:\;[ADMQP;(U" =3FWW#P#\CDA9E!L%XZG-">D/2'&Q]F4'1^=L",F%'NH
M=&.Y*FT6(O7AU(1%I_FJU9P<T#R%XI0-XB\LB9)X#WSR>7CT)SPD]WH+D]["
MQ/,-#O#=J#58;&V;PAS9I2K9]Y=&X-NN$[\NY]9;]_N#FH.^YL#7'![J@?:+
M3)1@+<.**Z85L#?@9I^;+=69IW*W>IW'@V04#;-PO4?"L)<P_(R$6AOXOX26
M*MV1D*;#4;Q?0=HK2#]4\*"1RWW5TG\;'HV24=J7:X_)GK3H_%N2_J4JW+E=
M[F6C@[X4RI+Y"P)&I^?$8]K7H@U0K_R%FVNDZ^N'%3VP8%P"K2^TQFW@[G#_
M9.?O4$L#!!0    ( %M#:E0#/_[#*@,  ,P+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;+5646^;,!#^*Q;J0RNU!0.!I$HBM<FJ5>JDJ&FWAVD/
M#CC!JL'4-DF[7S\;"-"$T$YJ7A+;?'?WW<?YN.&&\6<182S!:TP3,3(B*=,K
MTQ1!A&,D+EF*$_5DR7B,I-KRE2E2CE&8&\74M"W+,V-$$F,\S,]F?#QDF:0D
MP3,.1!;'B+_=8,HV(P,:VX,'LHJD/C#'PQ2M\!S+IW3&U<ZLO(0DQHD@+ $<
M+T?&-;R:0%\;Y(B?!&]$8PUT*@O&GO7F+AP9EF:$*0ZD=H'4WQI/,*7:D^+Q
M4CHUJIC:L+G>>K_-DU?)+)# $T9_D5!&(Z-O@! O44;E ]M\QV5"/>TO8%3D
MOV!38BT#!)F0+"Z-%8.8),4_>BV%:!A ]X"!71K8GS5P2@,G3[1@EJ<U11*-
MAYQM -=HY4TO<FUR:Y4-2?1KG$NNGA)E)\<SKBJ"RS> DA!\>\E(JMZ1!!=@
MK@HFS"@&; D.@$ZG6")"Q9F"/\VGX/3D#)P DH#'B&5"8<70E(JCCF0&)9^;
M@H]]@,\4!Y? @>? MFS88C[YO+GUWMQ4RE3RV)4\=N[/^4B>&44JX^MW^?^^
M5VAP)W$L_G3$<JI83A[+/1#KD4E$0=K4&F]CM0E9>/-R;_JVKL?0<NW>T%PW
M]6I#69Y;H=Y1=2NJ;B?5>RR$NH%!%F<421RJBZ.:2$!0<345<Q0S+LG?_*"-
M?.&_UZ!UX7M]=X=\&\KJV^WD>Q7Y7B?Y6:O"YR#!K3+W]CC8O@MWB+: !H=X
M>A5/KUMDM& <2<;?ZIKK*#._<NL?O:3[5:S^EY9T?T]&SQ[L:KT/Z@T\KUWK
M045T\$%!JT]!Q&@([F)%=XTU0]&A +3J!FL=76_8:.?P2Q4OW375=.S!;A-I
M1QUH(K!NKM#N)#MA<9I)S#]5W[#NH] YON)U*X3=O?"_%=]O:FZC592"MX!<
M_X#>=>.#W9WO-N,)D1G'.<M;\JK7G55>]RKH'5_SNH5!_VLU]_>^@D[/W]6\
M&U10-1NCEIYS?R"^(HD %"^5E77IJS? B]&QV$B6YM/7@DDUR^7+2(W;F&N
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M]<A4*)L;N>EH4;E+;2VTN2)=LS"/&$@;8.8W0NC7CKTGNV=Q^@]02P,$%
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M-'9;\ZZ(<*\5N*YZ1_6628/Y-ZB++L9H0C>=JIE85?GNL%86>XT?EMC<0;L
M7-\H9=\FKN%T?Q>SOU!+ P04    " !;0VI4,Y;QIIP#  "D#   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6S-5U%OXS8,_BN"L8<[X*ZV["1-BR1
MFG2X NU0M-?M8=B#:M.Q<+;D27+2&_;C1\FNDS2.FP$;<'E())D?^9$4:6:R
MD>J;S@ ,>2ERH:=>9DQYZ?LZSJ!@^DR6(/!)*E7!#&[5RM>E I8X4)'[81",
M_()QX<TF[NQ>S2:R,CD7<*^(KHJ"J>]7D,O-U*/>Z\$#7V7&'OBS2<E6\ CF
MJ;Q7N/-;+0DO0&@N!5&03KTYO;RF0PMP$K]RV.B=-;&N/$OYS6YNDJD76$:0
M0VRL"H8_:UA GEM-R.//1JG7VK3 W?6K]I^=\^C,,].PD/EO/#'9U!M[)(&4
M5;EYD)LOT#CD",8RU^Z;;!K9P"-QI8TL&C R*+BH?]E+$X@= !T= 80-('P+
M&!P!1 T@.A4P: "#4RD-&X!SW:]]=X%;,L-F$R4W1%EIU&87+OH.C?'BPEZ4
M1Z/P*4><F6& <_8L%7-IFZ\4 %X#H\EG,D\2;D]93FY$?26MS(<E&,9S_1%%
MGAZ7Y,-/'R>^02I6H1\W9J]JL^$1LS0D=U*83)-KD4"RK\!''UI'PE='KL)>
MC4N(STA$/Y$P"&D'H<7I\* #ONR'STN%\. H_/IDZ_2B)QA1F]7(Z8O>S^H:
MR%PI)E9-7N<B(;]($1^3(%]QJ9DK8TU^OT7-Y,9 H?_HX35H>0T<K\$17@^P
M!E$!=IA8K@3_ZVWFZT37.D9.AVUTZUDTIE$08&#7NQD]E!L&@W!7;H_DL"4Y
M["6Y7Q(,XW7+8VR-L"T/\C?YPD3!R7W&L"YBJ R/L4X6\NP3N?VZ[ G5J&4Q
M^J%2>-[R.N^-SE.9*JQ<%Q<!3'TVH KL3#E@KT)#)?MN.735P/E!OFA0?[H3
M-FXIC4^BE )TF:W!PQVS@SZK%ZW5BUZK2[S+N2Q=P$]Q?WEQX/ZHCP<-MBT\
MZ/<?KX+01N%8  F^)?\=KT6C_3! ^^5VW2'7[\#..XC^!VVA43+<ZPL=1!>-
MX'YCZ",:;HF&[^0\!:4PR*IFW$DS/+SFPS[KVZ9.H_^[,>'S._;"BZKH:05T
MV\[IX(=J4G3;P^E[35P8CJ;04'/U-:E*-YEF')/G*,B4Z!)BGG),:5LKNJN)
M-.;VF]>X\U;Y.]-8 6KEQF!-8ED)4\\S[6D[:L_=@/GF_(I>+NJ!>:NFGM_O
MF%IQ#%L.*:H,SLZ1G:I'XGIC9.EFOF=I<()TRPS_1H"R O@\E=*\;JR!]H_)
M[!]02P,$%     @ 6T-J5,/A@LRD @  E08  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&ULE57;;MLP#/T5P2N&%MCJ2RXMMB1 +AW6APY%LVX/PQX4
MFXF%ZN)*2M( ^_A1DNNE1>)M+[9(D><<4C(]V"K]8$H 2YX$EV88E=96'^+8
MY"4(:LY5!1)WEDH+:M'4J]A4&FCADP2/LR3IQX(R&8T&WG>K1P.UMIQ)N-7$
MK(6@>C<!KK;#*(V>'7=L55KGB$>#BJY@#O:^NM5HQ0U*P01(PY0D&I;#:)Q^
MF/9=O _XQF!K]M;$5;)0ZL$9U\4P2IP@X)!;AT#QM8$I<.Z 4,9CC1DUE"YQ
M?_V,_LG7CK4LJ(&IXM]98<MA=!F1 I9TS>V=VGZ&NIZ>P\L5-_Y)MB&VB\'Y
MVE@EZF14()@,;_I4]V$OX3(YDI#5"=FKA"P]DM"I$SJ^T*#,ES6CEHX&6FV)
M=M&(YA:^-SX;JV'2G>+<:MQEF&='4R4$=G-N5?Y WI-Q43#77LK)M0QWQ#7[
M= :6,F[.!K%%4I<:YS7!)!!D1PC2C-PH:4M#KF0!Q4N &-4VDK-GR9.L%7$&
M^3GII.](EF3I_7Q&3D_.-LK" 6W3?T=*:J06@9VFIQT/VSD">_6X9G9'?HP7
MQFJ\IS];,+L-9M=C=H]@?EF+!6BBEL25:@B>#0&:E\245(/SY^$DC3O)0\?4
MCO^U!%(J7H V#LRBB5>CHG+W]LUEEEY\-"\(2$DWR"K!R_F+&E("+\ABYU!%
M2R]Z32]Z_]6+"HU _(L<N0B3@-CSB&ZR;4;I(-X<$-%O1/1;1<S8AA4@"X-#
M(^=(7B#[R2'J@-/?HTX:ZG!+VR*"N'CO"Q>@5W[PN2-92QN^G,;;S-:Q'RFO
M_!.<N6%$_H$) _N&ZA63AG!8(F1R?H'-TF$(!L.JRL^1A;(XE?RRQ/\&:!>
M^TN%O:\-1]#\B4:_ 5!+ P04    " !;0VI40A2R)2T#  "Q"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6RU5EMOVC 4_BM6GC9I:^S<@ J05KI+
MI4VMRKH]3'MPPP&L.C&S'5BE_?@=.R'0<E%5M2_$EW.^?/X^?'+Z*Z7OS!S
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M\HA3WSN>R\8MF9O%BT-,>7S7^73Y-"0:A&\D$8:& W?M_[\<929'0(1'2I[
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M+96_#O*!D3-W(X^DH?O==:?THD)E!>C_6$JS&5@'Q1NM\P=02P,$%     @
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M+XP^,,XT0_^S)6C*N'J/D>Y72W+V[CUY1UA![K9BK]!:35V-T&9I-ZT KTO
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M*[2NKGU?90661%V*"KDY60I9$FVV<N6K2B+)':AD?A0$?;\DE'NC@;/=R=%
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M ZBIZ(=&4#=T-&X"_+MLCGN7=O BWJ!A]U)_7IKM"#N'9J'7BI9L9>>KLA>
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MAL#3B".8 M" (4EBS\&#\RC:G%/1]E>2R6]02P,$%     @ 6T-J5)>*NQS
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MQ[9L(>XE3=NO&MHO,K[_ 5!+ P04    " !;0VI4H9?JE,D!  "@'@  &@
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !;0VI4RLSKZNX    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !;0VI4
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( %M#:E0(^2<>00<  -@<   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !;0VI4
MU<03B6(%   L%0  &               @(&$#P  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ 6T-J5"=#K>K( @  2PD  !@
M     ("!'!4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M %M#:E3L<WV5@00  *H.   8              " @1H8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !;0VI4("^$4E(%  #Y%P  &
M            @('1'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ 6T-J5&-?#:VC!@  CAH  !@              ("!62(  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( %M#:E3B+U'.A08  (0/
M   8              " @3(I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !;0VI4R3MR^!@7  ![10  &               @('M+P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 6T-J5)_VKKCO
M!P  [!0  !@              ("!.T<  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( %M#:E1:P*CWZ (  &D&   9              "
M@6!/  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 6T-J
M5"BR$)*% @  ; 4  !D              ("!?U(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !;0VI4/<N9-@T&   -#@  &0
M        @($[50  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( %M#:E1(.<)+10<  )X2   9              " @7];  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 6T-J5(%@_1]@ P  ? <
M !D              ("!^V(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !;0VI46SEX+.P.  "%*P  &0              @(&29@
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %M#:E0-$H8V
MW P  %LD   9              " @;5U  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ 6T-J5+3P2!;P P  80@  !D
M ("!R((  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !;
M0VI45^C225L8  !<3P  &0              @('OA@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %M#:E1 W6K>4 0  #H+   9
M          " @8&?  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#
M%     @ 6T-J5.^QZ?*] @  W 4  !D              ("!"*0  'AL+W=O
M<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !;0VI4)KR^JY("  !M
M!0  &0              @('\I@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;%!+ 0(4 Q0    ( %M#:E2G=ZY)E (  '$%   9              " @<6I
M  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 6T-J5*5X
M.QH# P  ?@8  !D              ("!D*P  'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q02P$"% ,4    " !;0VI4CE<S.;X%  "A#P  &0
M    @('*KP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M %M#:E2]H)<_TP4  &D/   9              " @;^U  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ 6T-J5&/"JZLB!   -@D  !D
M             ("!R;L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !;0VI4L''S(D<%  !Q%@  &0              @($BP   >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %M#:E2E#JOTH ,
M (L,   9              " @:#%  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ 6T-J5*;]X5^$!   5A0  !D              ("!
M=\D  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !;0VI4
M"9Q5QVX"  "^!0  &0              @($RS@  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( %M#:E0#/_[#*@,  ,P+   9
M      " @=?0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ 6T-J5.V=YZQ/ @  0 4  !D              ("!.-0  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !;0VI4FYV-3:("   B!P
M&0              @(&^U@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( %M#:E33Y[M+XP,  %8-   9              " @9?9  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 6T-J5.0?H;AQ
M @  .@8  !D              ("!L=T  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !;0VI4,Y;QIIP#  "D#   &0
M@(%9X   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %M#
M:E3#X8+,I (  )4&   9              " @2SD  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ 6T-J5$(4LB4M P  L0H  !D
M         ("!!^<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " !;0VI4!</V':<&   O'0  &0              @(%KZ@  >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %M#:E2U]NJXFP0  .<2
M   9              " @4GQ  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ 6T-J5,#7<-43 P  KPD  !D              ("!&_8
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !;0VI4'\1:
MJ!<$  #G$P  &0              @(%E^0  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( %M#:E1FHWA"Y@(  .X(   9
M  " @;/]  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M6T-J5!885!>B @  D08  !D              ("!T  ! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !;0VI4B/;XIST"   %!0  &0
M            @(&I P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( %M#:E2MA0AQ-@,  #X*   9              " @1T& 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 6T-J5#1A7AY3 P
M5@H  !D              ("!B@D! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !;0VI4-?W5DA4$  !J$   &0              @($4
M#0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( %M#:E0Q
M*?GRQ0(  $ '   9              " @6 1 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ 6T-J5$R*Y=\\ P  -0D  !D
M     ("!7!0! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %M#:E2AE^J4R0$  * >   :
M          "  =PC 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %M#:E0HM&@3PP$  (D>   3              "  =TE 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     [ #L %!   -$G 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>144</ContextCount>
  <ElementCount>377</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails</Role>
      <ShortName>Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails</Role>
      <ShortName>Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail</Role>
      <ShortName>Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="rapt-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="rapt-10k_20211231.htm">rapt-10k_20211231.htm</File>
    <File>rapt-20211231.xsd</File>
    <File>rapt-20211231_cal.xml</File>
    <File>rapt-20211231_def.xml</File>
    <File>rapt-20211231_lab.xml</File>
    <File>rapt-20211231_pre.xml</File>
    <File>rapt-ex211_234.htm</File>
    <File>rapt-ex231_8.htm</File>
    <File>rapt-ex311_9.htm</File>
    <File>rapt-ex312_6.htm</File>
    <File>rapt-ex321_7.htm</File>
    <File>rapt-ex322_10.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gbkyd1brmfwp000001.jpg</File>
    <File>gbkyd1brmfwp000002.jpg</File>
    <File>gbkyd1brmfwp000003.jpg</File>
    <File>gbkyd1brmfwp000004.jpg</File>
    <File>gbkyd1brmfwp000005.jpg</File>
    <File>gbkyd1brmfwp000006.jpg</File>
    <File>gbkyd1brmfwp000007.jpg</File>
    <File>gbkyd1brmfwp000008.jpg</File>
    <File>gbkyd1brmfwp000009.jpg</File>
    <File>gbkyd1brmfwp000010.jpg</File>
    <File>gbkyd1brmfwp000011.jpg</File>
    <File>gbkyd1brmfwp000012.jpg</File>
    <File>gbkyd1brmfwp000013.jpg</File>
    <File>gbkyd1brmfwp000014.jpg</File>
    <File>gbkyd1brmfwp000015.jpg</File>
    <File>gbkyd1brmfwp000016.jpg</File>
    <File>gbkyd1brmfwp000017.jpg</File>
    <File>gbkyd1brmfwp000018.jpg</File>
    <File>gbkyd1brmfwp000019.jpg</File>
    <File>gbkyd1brmfwp000020.jpg</File>
    <File>gbkyd1brmfwp000021.jpg</File>
    <File>gbkyd1brmfwp000022.jpg</File>
    <File>gbkyd1brmfwp000023.jpg</File>
    <File>gbkyd1brmfwp000024.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="499">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rapt-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 144,
   "dts": {
    "calculationLink": {
     "local": [
      "rapt-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rapt-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rapt-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rapt-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rapt-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rapt-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 444,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 34,
    "http://www.rapt.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 39
   },
   "keyCustom": 35,
   "keyStandard": 342,
   "memberCustom": 22,
   "memberStandard": 28,
   "nsprefix": "rapt",
   "nsuri": "http://www.rapt.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Property and Equipment",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Accrued Expenses",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Commitments",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Collaboration Agreements",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Common Stock",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Income Taxes",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Net Loss Per Share",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Common Stock (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Organization - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rapt:NumberOfFinancialInstitution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_raptInstitution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "rapt:NumberOfFinancialInstitution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_raptInstitution",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Remaining Contractual Maturities of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "rapt:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20150501_20150531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:OperatingLeaseExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Commitments - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails",
     "shortName": "Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20150501_20150531",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rapt:OperatingLeaseExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails",
     "shortName": "Commitments - Schedule of Future Minimum Non-Cancelable Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_deiLegalEntityAxis_raptHanmiPharmaceuticalCompanyLimitedMember_us-gaapTypeOfArrangementAxis_raptCollaborationAndLicenseAgreementMember_20191231",
      "decimals": "-5",
      "lang": null,
      "name": "rapt:UpfrontMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
     "shortName": "Common Stock - Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "rapt:ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_raptOptionsAvailableForFutureGrantMember_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Stock-Based Compensation - Summary of Option Plans (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_raptTwoThousandNineteenAndTwoThousandFifteenStockPlanMember_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_raptTwoThousandNineteenEquityIncentivePlanMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
     "shortName": "Stock-Based Compensation - Summary of Assumptions Used to Value Under Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapGranteeStatusAxis_us-gaapShareBasedPaymentArrangementEmployeeMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapEmployeeStockMember_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Income Taxes - Schedule of Components of Provision for Income Taxes (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfSharesIssuedBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "shortName": "Net Loss Per Share - Potentially Dilutive Securities not Included in Diluted per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Organization",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Fair Value Measurements",
     "role": "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rapt-10k_20211231.htm",
      "contextRef": "C_0001673772_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "verboseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "verboseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "verboseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rapt_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional square feet area of laboratory and office facilities under lease.",
        "label": "Additional Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Additional laboratory and office facilities under lease"
       }
      }
     },
     "localname": "AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_AtTheMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market.",
        "label": "At The Market [Member]",
        "terseLabel": "At The Market"
       }
      }
     },
     "localname": "AtTheMarketMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.rapt.com/20211231",
     "xbrltype": "stringItemType"
    },
    "rapt_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_CommonStockCapitalValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock capital value reserved for future issuance.",
        "label": "Common Stock Capital Value Reserved For Future Issuance",
        "terseLabel": "Common stock that may be offered and sold, value"
       }
      }
     },
     "localname": "CommonStockCapitalValueReservedForFutureIssuance",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_CommonStockNumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock number of votes per share.",
        "label": "Common Stock Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "CommonStockNumberOfVotesPerShare",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rapt_CommonStockOptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding.",
        "label": "Common Stock Options Issued And Outstanding [Member]",
        "terseLabel": "Stock Options Issued And Outstanding Equity Incentive Plan And Under 2019 Equity Incentive Plan And 2015 Stock Plan"
       }
      }
     },
     "localname": "CommonStockOptionsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_ContingentPaymentsUponAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments upon achievement of specified milestones.",
        "label": "Contingent Payments Upon Achievement Of Specified Milestones",
        "terseLabel": "Contingent payments upon achievement of specified milestones"
       }
      }
     },
     "localname": "ContingentPaymentsUponAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_CoronavirusAidReliefAndEconomicSecurityActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus aid relief and economic security act.",
        "label": "Coronavirus Aid Relief And Economic Security Act [Member]",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax, deferred expense reserves and accruals, accrued liabilities and reserves.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities And Reserves",
        "terseLabel": "Accrued liabilities and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndReserves",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DeferredTaxLiabilitiesGrossDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities gross depreciation and amortization.",
        "label": "Deferred Tax Liabilities Gross Depreciation And Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGrossDepreciationAndAmortization",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_DevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payment.",
        "label": "Development Milestone Payment",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "DevelopmentMilestonePayment",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_EarlyExercisedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercised stock.",
        "label": "Early Exercised Stock [Member]",
        "terseLabel": "Early Exercised Stock"
       }
      }
     },
     "localname": "EarlyExercisedStockMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_EffectiveIncomeTaxRateReconciliationWithholdingTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation withholding taxes.",
        "label": "Effective Income Tax Rate Reconciliation Withholding Taxes",
        "terseLabel": "Withholding taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxes",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rapt_EmployeeRetentionTaxCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee retention tax credits.",
        "label": "Employee Retention Tax Credits",
        "terseLabel": "Employee retention tax credits amount"
       }
      }
     },
     "localname": "EmployeeRetentionTaxCredits",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated shares issuable under employee stock purchase plan.",
        "label": "Estimated Shares Issuable Under Employee Stock Purchase Plan [Member]",
        "terseLabel": "Estimated Shares Issuable Under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on public offering.",
        "label": "Follow On Public Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_HanmiPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hanmi Pharmaceutical Company Limited.",
        "label": "Hanmi Pharmaceutical Company Limited [Member]",
        "terseLabel": "Hanmi Pharmaceutical Co., LTD"
       }
      }
     },
     "localname": "HanmiPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_IncreaseDecreaseInDeferredRentNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deferred rent non-current.",
        "label": "Increase Decrease In Deferred Rent Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRentNoncurrent",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_IncreasedAreaOfLeasedPremises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased area of leased premises.",
        "label": "Increased Area Of Leased Premises",
        "terseLabel": "Increased of leased premises"
       }
      }
     },
     "localname": "IncreasedAreaOfLeasedPremises",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_LeaseTerminationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination month and year.",
        "label": "Lease Termination Month And Year",
        "terseLabel": "Lease termination term"
       }
      }
     },
     "localname": "LeaseTerminationMonthAndYear",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_LesseeOperatingLeaseExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease extended lease term.",
        "label": "Lessee Operating Lease Extended Lease Term",
        "terseLabel": "Lessee operating lease extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtendedLeaseTerm",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_NumberOfFinancialInstitution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of financial institution.",
        "label": "Number Of Financial Institution",
        "terseLabel": "Number of financial institutions"
       }
      }
     },
     "localname": "NumberOfFinancialInstitution",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rapt_OfferingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs included in accounts payable and accrued expenses.",
        "label": "Offering Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Offering costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_OperatingLeaseExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease expiration year.",
        "label": "Operating Lease Expiration Year",
        "terseLabel": "Lease expiration period"
       }
      }
     },
     "localname": "OperatingLeaseExpirationYear",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "rapt_OperatingLossCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "terseLabel": "Operating loss carryforwards expiration beginning year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "rapt_OptionsAvailableForFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options available for future grant.",
        "label": "Options Available For Future Grant [Member]",
        "terseLabel": "Options Available for Future Grants"
       }
      }
     },
     "localname": "OptionsAvailableForFutureGrantMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_OptionsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options issued and outstanding.",
        "label": "Options Issued And Outstanding [Member]",
        "terseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "OptionsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_PercentageOfIncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in shares reserved for issuance.",
        "label": "Percentage Of Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of increase in shares reserved for issuance on common stock outstanding"
       }
      }
     },
     "localname": "PercentageOfIncreaseInSharesReservedForIssuance",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rapt_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently issued accounting pronouncements not yet adopted.",
        "label": "Recently Issued Accounting Pronouncements Not Yet Adopted Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserved shares of common stock for future issuance.",
        "label": "Reserved Shares Of Common Stock For Future Issuance Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock on Converted Basis for Future Issuance"
       }
      }
     },
     "localname": "ReservedSharesOfCommonStockForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rapt_RestrictedStockUnitsIssuedAndOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units issued and outstanding.",
        "label": "Restricted Stock Units Issued And Outstanding [Member]",
        "terseLabel": "Restricted Stock Units Issued and Outstanding"
       }
      }
     },
     "localname": "RestrictedStockUnitsIssuedAndOutstandingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_RestrictedStockUnitsRSUsSubjectToFutureVestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units (RSUs) subject to future vesting.",
        "label": "Restricted Stock Units R S Us Subject To Future Vesting [Member]",
        "terseLabel": "RSUs Subject to Future Vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsSubjectToFutureVestingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_SecuritiesReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities reserved for future issuance.",
        "label": "Securities Reserved For Future Issuance",
        "terseLabel": "Securities that may be offered and sold"
       }
      }
     },
     "localname": "SecuritiesReservedForFutureIssuance",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase in shares amount.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Amount",
        "terseLabel": "Increase in shares at the beginning of each calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAmount",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, options, grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant Date Fair Value",
        "terseLabel": "Stock options grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantDateFairValue",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Period",
        "terseLabel": "Purchase period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rapt_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies line items.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies table.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rapt_SouthSanFranciscoAndCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "South san francisco and california.",
        "label": "South San Francisco And California [Member]",
        "terseLabel": "South San Francisco and California"
       }
      }
     },
     "localname": "SouthSanFranciscoAndCaliforniaMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Square feet area of laboratory and office facilities under lease.",
        "label": "Square Feet Area Of Laboratory And Office Facilities Under Lease",
        "terseLabel": "Laboratory and office facilities under lease"
       }
      }
     },
     "localname": "SquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "rapt_StockIssuedDuringPeriodSharesEmployeeStockPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares employee stock plans.",
        "label": "Stock Issued During Period Shares Employee Stock Plans",
        "terseLabel": "Issuances of common stock from employee stock plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlans",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "rapt_StockIssuedDuringPeriodValueEmployeeStockPlans": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value employee stock plans.",
        "label": "Stock Issued During Period Value Employee Stock Plans",
        "terseLabel": "Issuances of common stock from employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPlans",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_TwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock plan.",
        "label": "Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2015 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenAndTwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "Option Plans"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan and two thousand fifteen stock plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan And Two Thousand Fifteen Stock Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan and 2015 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Plan",
        "verboseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandNineteenStockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock plan.",
        "label": "Two Thousand Nineteen Stock Plan [Member]",
        "terseLabel": "2019 Stock Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockPlanMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_TwoThousandTwentyOnePublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one public offering.",
        "label": "Two Thousand Twenty One Public Offering [Member]",
        "terseLabel": "2021 Public Offering"
       }
      }
     },
     "localname": "TwoThousandTwentyOnePublicOfferingMember",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rapt_UncertainTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions.",
        "label": "Uncertain Tax Positions",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositions",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UncertainTaxPositionsReserves": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain tax positions reserves.",
        "label": "Uncertain Tax Positions Reserves",
        "terseLabel": "Uncertain tax positions reserves"
       }
      }
     },
     "localname": "UncertainTaxPositionsReserves",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UnconstrainedDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unconstrained development milestone payment.",
        "label": "Unconstrained Development Milestone Payment",
        "terseLabel": "Unconstrained development milestone payment"
       }
      }
     },
     "localname": "UnconstrainedDevelopmentMilestonePayment",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees.",
        "label": "Upfront Fees",
        "terseLabel": "Upfront fee"
       }
      }
     },
     "localname": "UpfrontFees",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_UpfrontMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront milestone payment.",
        "label": "Upfront Milestone Payment",
        "terseLabel": "Upfront and near-term milestone payment"
       }
      }
     },
     "localname": "UpfrontMilestonePayment",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rapt_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.rapt.com/20211231",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r190",
      "r199",
      "r234",
      "r235",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r407",
      "r409",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r190",
      "r199",
      "r234",
      "r235",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r407",
      "r409",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r190",
      "r199",
      "r225",
      "r234",
      "r235",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r407",
      "r409",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r190",
      "r199",
      "r225",
      "r234",
      "r235",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r407",
      "r409",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r145",
      "r146",
      "r223",
      "r224",
      "r408",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r145",
      "r146",
      "r223",
      "r224",
      "r408",
      "r417",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional and consulting services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r167"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r46",
      "r47",
      "r48",
      "r398",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r45",
      "r48",
      "r55",
      "r56",
      "r57",
      "r90",
      "r91",
      "r92",
      "r327",
      "r410",
      "r411",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r272",
      "r273",
      "r274",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r239",
      "r269",
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r158",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset Backed Securities [Member]",
        "terseLabel": "Asset-backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r127",
      "r136",
      "r142",
      "r160",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r323",
      "r328",
      "r341",
      "r364",
      "r366",
      "r380",
      "r397"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42",
      "r83",
      "r160",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r323",
      "r328",
      "r341",
      "r364",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r162"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r155",
      "r157",
      "r391"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Five Years Fair Value",
        "terseLabel": "Due in more than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r155",
      "r156",
      "r390"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "terseLabel": "Due in less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r149",
      "r152",
      "r162",
      "r383"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfRemainingContractualMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r74"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r69",
      "r74",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r346"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r176",
      "r384",
      "r402"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments (see note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r177",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Total shares reserved"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 29,555,119 and 24,773,361 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Number of votes for each share of common stock"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r52",
      "r53",
      "r60",
      "r387",
      "r404"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r117",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r226",
      "r233",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r304"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense Benefit",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Schedule of Cash Equivalents and Marketable Securities Classified as Available-for-Sale Securities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent",
        "terseLabel": "Cash received from early exercise of unvested options"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r294",
      "r381",
      "r396"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r15",
      "r354",
      "r363"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue, current"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r297"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r300",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Federal and state research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r296"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r72",
      "r165"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r220",
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r86",
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal tax"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Foreign",
        "terseLabel": "Foreign losses not benefited"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized stock-based compensation cost, expected period to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized stock-based compensation cost related to outstanding unvested stock options and RSUs that are expected to vest"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2019 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r55",
      "r56",
      "r57",
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r111",
      "r161",
      "r213",
      "r220",
      "r272",
      "r273",
      "r274",
      "r307",
      "r308",
      "r332",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r410",
      "r411",
      "r412",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r335",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r191",
      "r226",
      "r227",
      "r232",
      "r233",
      "r335",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r227",
      "r232",
      "r233",
      "r335",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain Loss Before Tax",
        "negatedLabel": "Gain (loss) on foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions And Translations Policy [Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain Loss On Sale Of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of capital equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r72",
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment Of Long Lived Assets To Be Disposed Of",
        "terseLabel": "Impairment losses on long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r85",
      "r311"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r127",
      "r135",
      "r138",
      "r141",
      "r143",
      "r379",
      "r385",
      "r388",
      "r405"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Net loss before taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r85",
      "r311"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDomesticAndForeignComponentsOfIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income Loss From Continuing Operations Per Basic And Diluted Share",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r285",
      "r292",
      "r299",
      "r309",
      "r313",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r87",
      "r100",
      "r101",
      "r126",
      "r283",
      "r310",
      "r314",
      "r406"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForIncomeTaxesDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r54",
      "r281",
      "r282",
      "r292",
      "r293",
      "r298",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses, and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income Amortization Of Premium",
        "terseLabel": "Amortization of premium on marketable securities"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified By Contractual Maturity Date Table [Text Block]",
        "terseLabel": "Schedule of Remaining Contractual Maturities of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lease existence of option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Future Minimum Non-Cancelable Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsScheduleOfFutureMinimumNonCancelableLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lessee operating lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r83",
      "r137",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r324",
      "r328",
      "r329",
      "r341",
      "r364",
      "r365"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r83",
      "r160",
      "r341",
      "r366",
      "r382",
      "r400"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r83",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r324",
      "r328",
      "r329",
      "r341",
      "r364",
      "r365",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual Payments",
        "terseLabel": "Contingency losses, accrued"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r35"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r114",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "negatedLabel": "Cash used in operations",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r49",
      "r51",
      "r57",
      "r59",
      "r73",
      "r83",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r100",
      "r101",
      "r104",
      "r127",
      "r135",
      "r138",
      "r141",
      "r143",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r333",
      "r341",
      "r386",
      "r403"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing information"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r127",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r46"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities",
        "verboseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r150"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.0001 par value: 50,000,000 shares authorized; no shares issued and outstanding at December 31, 2021 and 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Net proceeds received after deducting underwriting discounts and other offering related costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds From Sale Of Property Plant And Equipment",
        "terseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds From Stock Plans",
        "terseLabel": "Proceeds from issuances of common stock under employee stock plans"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r49",
      "r51",
      "r57",
      "r68",
      "r83",
      "r93",
      "r100",
      "r101",
      "r127",
      "r135",
      "r138",
      "r141",
      "r143",
      "r160",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r322",
      "r325",
      "r326",
      "r330",
      "r331",
      "r333",
      "r341",
      "r388"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r171",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r166"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r168",
      "r366",
      "r393",
      "r401"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r168",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, plant and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r279",
      "r377",
      "r433"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Unit (\"RSU\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r220",
      "r275",
      "r366",
      "r399",
      "r413",
      "r415"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r161",
      "r272",
      "r273",
      "r274",
      "r307",
      "r308",
      "r332",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r124",
      "r125",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r147",
      "r222",
      "r223",
      "r378"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Potentially Dilutive Securities not Included in Diluted per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Components of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r239",
      "r268",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r239",
      "r268",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]",
        "terseLabel": "Schedule of Domestic and Foreign Components of Income (Loss) before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r241",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r248",
      "r258",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Assumptions Used to Value Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r39",
      "r81",
      "r112",
      "r113",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r206",
      "r211",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r291",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Shares Outstanding, RSUs forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of Shares Outstanding, RSUs awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs awarded"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance",
        "terseLabel": "Shares not vested and subject to repurchase"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Shares Outstanding, RSUs released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share, RSUs released"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate on salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Total shares reserved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "verboseLabel": "Common stock available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Number of stock options, exercises intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares Outstanding, Stock options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares Outstanding, Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r250",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares Outstanding, Ending Balance",
        "periodStartLabel": "Number of Shares Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Number of Shares Outstanding, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r238",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased",
        "terseLabel": "Share-based compensation, shares at weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": {
     "auth_ref": [
      "r238",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award",
        "terseLabel": "Share-based compensation, employee purchased shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r238",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStockSummaryOfReservedSharesOfCommonStockOnConvertedBasisForFutureIssuanceDetail",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r241",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r237",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share Based Payment Arrangement Employee [Member]",
        "terseLabel": "Employees, Officers, Directors, Advisors, and Consultants",
        "verboseLabel": "Employee and Non-employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options granted, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r264",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years), Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Stock option vested aggregate fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Purchase price of common stock as percentage of fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r55",
      "r56",
      "r57",
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r111",
      "r161",
      "r213",
      "r220",
      "r272",
      "r273",
      "r274",
      "r307",
      "r308",
      "r332",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r410",
      "r411",
      "r412",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r111",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r213",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs, shares",
        "verboseLabel": "Shares issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r213",
      "r220",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Shares Outstanding, Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r213",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r213",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r220",
      "r240",
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r83",
      "r148",
      "r160",
      "r341",
      "r366"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfAssumptionsUsedToValueUnderStockOptionPlansDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r179",
      "r183",
      "r184",
      "r185",
      "r188",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r88",
      "r226",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfCashEquivalentsAndMarketableSecuritiesClassifiedAsAvailableForSaleSecuritiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r280",
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Expense",
        "terseLabel": "Interest expense or penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk Or Uncertainty By Nature [Axis]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyNatureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk Or Uncertainty Nature [Domain]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted average number of shares used in computing net loss per share, basic and diluted",
        "totalLabel": "Weighted-average shares used to compute net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.rapt.com/20211231/taxonomy/role/StatementCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation",
        "negatedLabel": "Less: weighted-average unvested common stock subject to repurchase"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r102",
      "r103"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number Of Shares Issued Basic",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WorkersCompensationLiabilityCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Workers Compensation Liability Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "WorkersCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.rapt.com/20211231/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r434": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r436": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r437": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r438": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r439": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r441": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r442": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r443": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r444": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001564590-22-009488-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-009488-xbrl.zip
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M,PC6_?OWB1X041,34PLPTS,+_#\^T-T *0$V$:X3#M83 )L4"X<4"_T3  $
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MH&?5>QC"T?516$Z_ &T: >KQ=FYWNY/6KRY$0;I*SSV^S(=XNTV!9U.$:Z[
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MT3JH)]38%#/%]'E:Q7XP_6QVR\1M[*!.J6),3(#J8G>TKDJ\K("-VZ<L",M
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M#.H*"^'Q2G;6M+BCTZ6^QW0^O,-1.LY&XK/C(@.%W)"/&:]&[3>BG!0A RC
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MH*S@2BX3(,G*H<H/-7)WTBQK 'NP63CB]HUF?C;>>0)#M#:CR=JLPQ%[D70
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MKLP@3:L]YC[RS'$D,'3]HEO\;/ML5[.*DZBS0.D^HZ#CB\N'Y<S8KYOWJ2@
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M6U#Z]_B)W$O2ER^+>EF=48"WL S+*=<NAD\=/<,_1!6MX/$I1C,_"=OP^V:
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M;#HOYT8"2<2\&DB4<]$[+FOV@XXK/'R ROFAS!BWU#2 WN_,':R_AJG'L*Q
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M!O8_!@-QH]=/+OF"'[XQ"5_P 8;.^,+7<&_LY-,0(7$RYLZ4P::ZY;X&8TW
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MEJW7I>3V%9"R?F@DYA9KTX1>@)Q'XBRCT>HVMHCS5-YTTM1YX,Z'Y"(/4(J
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M1\AR_>M<J),G0)\%5OCZG?I,BV*1>_Q1/+"?RAKAA?/2^%=N(7YG@)=&[UB
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MX-OAVP& ER6 U-^M_Z7G;R;_JSS@7CH .,B WE?J\' X@%<X</ X<"\] $H
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MO&>$: N2H=:19!>SFRJ/Y+>2+P"QV[Y>L C49VP(UD*@^9\^N8H*NPM>)Q^
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M_C3,]].\NW\J%FM[:"6LMA2>E^MDZ_9A[,=%^JTY(SDOQ",-0V\"2S8B.*5
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MEI!KQ%C]IMXW +=U;2+#,-'U"$3'F>Y\?GZ:<(-[O50%TZXRO"]X[D"DW[P
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MQZ=J=?99XI<9%<FA(6'LZU1SV@A&;A#:6XS0T(N;4#^,6W=G:OP#<=%S'9S
M_9F3TO^3J$:Y<K,$O/OCZJ_H^\:!+'Y?ENCC+^J^5;HO@*2A*K.CC\\KOU\
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M%)_\)1ZDF6JQ!H9A:6N]!\:H(F,0!N.BQM-B2&XA#?J!_24! )0D=K@ITQP
MB .@!%!10 ?:?Y]"G=D,1DJ=3@W+T+U*19/>98(2T^.4A,1L==RS<J06Z4LN
M:IE2V8+Y'6H""!?UCO C@@,?\F&VZ5/GTQPDV&>GXV_R6V.]%W=4]BJUFM3K
M\GXMZK54<:HU#] $Y%"9_TP#^/I]GX])B$V/[7?NLZ]8"(/,BBY#U\67<V1S
M5?1.D14!1&X553!_%%)!>D"$LZ&04:@M"B8USN@IH2U5:+;_%I *U,:-I/,:
M>4=>RNV]<3'=IYVRQ#D-F1C,9@# +D?& 162^^%P@C8FOV!AQ7#B/6RV%H((
M5M9$DWW3NT$#- 6PF3R<@%P<6[ZG07N:%2T:EZP%D5@P[/,+ZO_!)@8: B4A
M8+S7:&G#_R>(WJ"A_,%W#JDOR;2?I>U+H1 F*"5RE"^>=@M<=H?\:7N)F1Q.
M.S(0\SJJ(WID^_16AW7_)MJW8^.).HIMZ,!ZL:"B_F]>SN%<V-+T4!&# /6K
M\XSV?%BOHI*(P2;BFJ-$DE<34=@?',^.EKB)I3+4*!7.HSG,OB\2OC_14T6?
MLTZ5?[=+C8MM#2A&F33?C7%'C4 ([J*<;LU/&G#HW =Y!_5EF@B3D8FE-0N,
MYV<PAK/PF(:MM!H]QS1+:CFD6FH\#7\Y KA&#PKAD'R6+?B.X&DB+D!ELF)B
M95H7O#6/4MBPL>]F:!&IW1V+Q!%Y4]%7,L=0MYH#+#\!$@#&CZZH?9P/Y9^*
M?W,ZJI;[R*B[?0E*@6W?ZX25J2@KAH^5S>TUNZ_3F#!Q[?>8,4^5GL#SN*8)
MQR=5^N7>9M7*N.HZ3#2\R?RS.G;=.I^E".UM-'&Q1XEX1Y -Z&2A*I04%]SY
M_5'1EYESW"4J+[[@F"#C!S]]%,_,#-P^-&XVH'HWI\H#2'540FME5VS/@AZ^
MS\8W>(Q<'E#"&1 @1^"T"M5G0,D"IX<7RZ"+9VN%O=G4W!T1#"!,).1@8%7C
M(>3RH$),;")5.8("\V"0X"*:G/Y0%@BN!MB#=#WB0I"O6 $A7KAF&Z\K5K"8
M%NN3+AS;4"(B7PY+_=DC3,Q,8K7_<>#+?8&;A2#E'8LMBN(%E<<PL#)W4Q]-
M-RM) I>J#>,V_$Y_\WRL^LA0P:HB5_?:YG(UR9CWPTZ^4-74W!T&/RS8G/G(
MY<U'IS2EZ]K!GW] ?UU2FUQG*\,X]MBI63*SZ!<D,CNBH+K$OPUX;8NU5G0I
M%>JMJ^/>\NV%DH0PS]DY\V+HF?"9)BP][^B7XSOAE1/!G ?;ZY1ZD;]%KF3+
MK8E'FI]KJ+WR1"#.$;$W'E$=Y!>/6MK+]D+&1A\>6@X&QMH+>>H%.%05]9^"
MR67Y!TTBWY 55+!9;VN7,.85QCG:VMFJ ]^2U!<&;X;B6^B8K(%.0H\G2&U<
MY^L^%8/ QU4LKJ"GR%4UI96O".;!,)<88 7CB%VE^$G*6(W<@=V.KC,1>T+$
MAUSVK60A.SD)B:R)3+8/_Y,E_^^S"L/<F![TE!^:_L$PR.+?G8EM[J?R_=.K
M@Q? Q1W?D<^/_T@S9%T9^C[-\)4Y2 #N<&?$&9U[3N]U9U3<O_7I+^Q]Y+ZS
MY&DI&_2>,7SU^.VTPB#QT>S\+LJ,K0KQ B HO;O^=OD"Z&1=:=+RP!UUQO1!
MSYJ<5Z:BKH$4=."] (X>(U.O+A^BQ_BJ%1[7GN&-0@?B<G<[!"\ P^OV!KW]
MF[(=&WC5^FW:"\"=%VF\].(>8B"6<_,8:3#[^.IBS/F9VFV^3NL_=8X,WNTY
M[M_3)__X+TQ.?B Z<Z%J0+CG*%'Y26+CQL>6@VKRX5F^XM"%FNO.$B4#-Z[=
MIGSV/[+,D#ZQ+.I"VXPGQ]9]W0XCCZQ;+<B5+^#QFTSJKC#;Q*&^ZJ5ZUGP%
MV[?W^R>ONYV77@!7CX="E+A9DSH4?:7[_W<DDG$.(N;;AHLY%:H14(MO^TB+
M21&B1O<FR=2D[41R_T>2PMO\85;14L;?OT<&]UP_?ZE]$_IMM\X'Q>.85V_I
MTB<25:E9_'6)C?3/OEKX^#OQ;2;43\D1%DI28)60V5'(A/>#M6ACW=S/U;=%
MG,+A>]GZ0?,D480$1_N5%MRTW#&PK1"GN.S$5ZDX[36K];7""IWCD<ZN-6QM
M#GB%D9\A8[DN5RY#K9OS!^PX-9N+"4]!,_H7NTZ;$/M[Q2;VB@"0@9&&DL*N
M2D?SO0)(OYXSN<Z:0X)ZJL)5SRJ,DLG:9=M".98'-)T0PC :4V0!<D/Y'?/W
M!Z8B+?W%@L9:I4'E':QC]<][M69%HY $WIIJIY]FM8E$A H1PX:?OE^X\L#?
MQGD()46/:36YA^MJGOWC''L:KL:>5T\AYO8+-R4/:.\_MD<5#S"]4<S]7;]@
MTR3PW!1?OZ35W/C#%K"U@T7N8L0^55JH)SQ8R3_A?C KW0DBQT0"H2FP0J;S
M(U"+')2H%D@K/;4<Q%;K@_+S&-0<&%BZG0@RNEB%@"< W+G=\/D@-@I[@X8"
M2):9KJ>F?:IOX G0AB#:I?=RY;5:UR:NUA(KGC!/?_^G%E5C_;B.3AZ#*?PA
M1JE/: 4(:CIWA)*"4%L+CQ$KY73<UG=M 3\0F1-S"\:N0\]!UID[/3J1K5TB
M+8O8@?8R3GX"LU^1!I@<XFOHA!KM2W,;WH;]AV=','J!0"W;;44,2CJLC=-G
M?NZQ;VPMIIR\,0?-RI!F%)@3/O@=?52]S?_^<^0;ZT7\1N+*@BQXF1-C5!4;
M]>Q&XNMZG6!"4T!U]EXG</O+[!9% 2H%0)U/8@YM-EWXU3HQ)@,:6J8BRAQU
M_OI900"/-A)RS4FV;:]#<\)Z7G#_3Q&73XU;T_=JAI]U(\4M(<;$T6^P(P,=
MN1PI?OC'EW*OQ( 3;.@#@0%6K3\_- __8MT?)&L220Q[CQ=G".T,-J.=/NOY
M(H9I%\PV$.'-^KUGD'MQ)></_Q(8QK, @ZT?QE"@L?QES.L(1?@<^1(2)7YR
M6QTC#3]J+1W=KF![S3-JQ^$VIC]+06A/)N]Y4UE@\BOW/7^^3HB<OEG)GO8&
MB#AUQI;\>L>>- *;%2T_1EY:D29J7U_$3[H3NU\FN[CXOI3EH#==-(Y2@WY.
M<P5#[$ 1";6$B64<VQP(_"0#K<B9[>I[[4;1!#RR=V.(5U/1<\U.59LO"*]2
M+9QO(TV#$T"A]*;-!\KE9-'D!=@:/K)\[ZSH5O\N&6=@_\F]BM%W;N:.D[+G
M!$2]#691R+UP2B* #@<TT=-??DE/VSL-BH_9L$N\*"]@4==>=]"R(=U@$'D7
MI2T<?B#_"6+Q/[PCJ5/UJA6M=A,W*M]+I\F)4SQ =?15$-\^R N@HDJWHG\@
M?W!P8$%CHR+B,_-(BY0AZY%NM#6=4@H+X_1;G@CI]W-+P:KUF4>"!X3IP<_^
M><VR6^8WO6<X*UMGKP!"XR2@55UW#?AT10&IQR08'3UJ#P>:[C6T%:$+<L:I
M8_D_:!Q7#;T D'Y[?%/Z[1$*.Z.F^K1)T;:Q235*@8CXTB/&NY'UW7,2@2XF
M"EV@=N,+OS99S3L()6+BY!W;C$6-@HR-9[,^W?>]YU+Z09<\3L$JVM/(0!.+
M'.V]M9>+G&WE</^=,D.$"BN>*QH"M&/I8[Y$DB"0I#J*7"2J;H07K*Q@1,1\
MOT#.\F6QKE9GA8[[(0T=Y")U,I%N,Q&FH=N?I(ZIEB>HN#;.SX^LJ(C9->GV
MX#(QEXYEE?,K,3Z-#!'/[?5'&K/N3S;:^6/LUZ0&E:)K'GXS?E<VRR(QSB&;
M/$\I[A=#!X)?_O'M5N,/QH\/BH\2/*^2J=U;MK\J&\4F^_+1H1&C<)M.Q9P#
MK[!E"M#9>,1ZBM?PWHH@IOVRT2F]R/ZSVML/?2U#U=2Z9':Z1#:K@8;OQ6R2
M%CB[;&D1RW!P));2$8AVL4A)^8=4 FS[A]MT61^ ],=B#R<K2[OJ)F-A!@\J
M"\_G4@*L_!NVQ2+D)XW$V/A?N^GWBT,D9QUV364RUKLNQ@=36.<NL7R0$=/T
MA2>U!(;$]\?RN6S(1_E?0:O8YN6>2UU$*Y30,BN#%DS6.;H:<A029,YW;%]%
MU-9:=>-^#((&.5D[$N-@57S&@XK-KE?#_43$1CTCPB35B&XK =+")7D8&"X-
M:X<UF)4. >-@'N,>52)M-MB5.9DE"_J.RC%@<N6H\ICO,0D%C:D*F-8)M"PR
M]CDL((T$/\%=()9ULD<8%OT2P=]MQ!)5SI:0+]/:^</353$ Y==K*J%SDOUH
MM]6/N0GYS(39:"R2@ + %@!I'?"/LG#K$"@!+Y2&Q"]LR5>NJ%H7U<DEFN>6
MU%O,9>.MRIIPAYGQT:*V_\V&C";%$+FNT5I0@*4.'WJCC+\?*BLV6 I3$W %
M0(B[J D-KB,"-]G@W=+]NG1Z73U\;"2_9I'J&(,T+4 !:-P1J&@4S*4#6XSX
MQ\PYHW1B'K#7123[YQ)A0T]7P/@A(?&_=X^W<_^AZ=H)>]\L"?SPA#!5:$3O
MHCF-VAZ;O0:V41U(4 .\%?SN'OZ^ -JD! ]GJ-#1Q3<>O5EGTU-!G&_\^L_?
M(TZQD)%1!@$>U UP ;^0T%"_!X5D"P8E"G0-;4&XNA"BUY2Z=56K9A/ITII%
M:F_?KD#T2Z$\U'\AB\(_O!5/A<[!1X(I*32ZVN,OTAENR$<';0'G=&_NF\<2
M'1[K_\%EYIZ,LKQZJ8F!N#BSA<DX/J@ EQ]J/K&X> *<@:?;FY12&O*>S[X2
MF0WB>3WU+I_7(+\RQSY<@S+[,)CS_&)+UN8-!@Q3XWBF:T')\[K1YO:EBPP6
MJXE\'\?ZY7[S:L])R?V,4UJ/O[N;1?5SCN[8CY[H61&C.MZX 9^6SH12IBD%
MU05 I\OI@-2U4AZ**"I-JF5-U=$ZM+.F#[5Q6(P;7/AT%5."_JT4(3Q$T_8E
MLX-!A\4&Q(E']K)HZY<:E/*8P&\(H^O\:6%?W6X8VO,2V>8T'%K/<AW31 J>
MB3I/+": =X$4P1ZHT/ M7=R.SVV\!B?@/_QR3U&SN9WB[A6>H1>-D+[$=U;L
M2QUK M@BL+D-^L&B;V_TZ^C>?P3^B$_)(2 ^],S,/G;=<*U5:.C[I+'*P5"T
M55]11L. ),< I')=/]E%[].O2KY4N-"HMAXS9M/XPXG9WFDIO=8(-[+%7U8S
M7DPIUBT]DX:D Y&Q9A*IM<U^\=ED.,1^C"K5IC4K2QQT[9QF)*:MM4,@E@%A
M_L05<<R,<:;.))W@I"1>C(OS"7J7!2J##!<;:!]%B8V0)M,?=<;VAF "=I*Q
MOJ >S3P>+(-/":C\<.>,$L5.2F\VI++N*SF1#Q;7#*XUY 1,MNIVWQ=^3N+3
MB^_P+#XYPZW T2!9XZ'Y0EI*#AQU)9<U!4%[7,[%@!W24LLF?>#7O_???';C
M(]P],P1ZVBNG:]CCRK1*QXZVPDA*TLH,1ME=4GOE*(B6&QC,E_A4E_W<]S^\
M^QJ[@N5 [! P0CA<*$.DXGOZ F@4NP*9R?8K[Q-^S8V/CHN6BJ#G42.J<Q;;
MQ18<MF (KDXG]_]Y2=>H44 U",P9-?D"V,DAO?F[/?#\ J!8\&MP*B"U7RE<
M/JU (GG*$Z*M?%HNTJ(]CM&J_1!&1N;,:L?34V:>8H_]CH.!_F-0PCOVI?'R
MJ9$"*M[(*,LQE6]'^+OCOD5KJ8-P7;6V.?F6017#:.>:CY:+X^HC3$9!Q=R:
ML^9L&,3#356Z<2#!Z(P&4]UX\ BI!Z8^6@1KN3R'60J/UMKN[;.O^/VX>\G_
M4LZNX:#VMLY(%'ZNDEE*.%2-XT-WR.R25?T 98^'X&)3W2V9]6[#6N75Q],$
MHM(*RUPK=92(9E7EM%A.*I(,%<'+8# T&+]?<9!T#Y/"SPFJS= _#P+7%T=L
MH2&["S*A=%)AG@&]#KF2_E,4F$.GST7\R^Y_5VCY_9\[^#(,N[MAN0#7]^IL
M3<^;1R)L=$.R\^N599#CZ?)8-55M(SY;BJ?\@#X>[CJ;>F9 1C=^/%8#:]C
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ML01MVDY\BJJK/+CY??/:X 2) *G8CSVZX;SP/JB)CM'P(:'$MH_A4/:-T.0
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M;1#]LPB2D*$D?PRK?X NKG?69!?2+&L 4B<YB\?@T'^ '"$W:2S)OD?)1]?
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M,G%A$>"P;.FC.D*]PUZUQ.^@WJ//7A5,J"_7))88U(IG=;KI)F:TZJ?+[-)
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M:1A^7&"="[_7Y( -9D26D0*09H!EF]4NG(E$@?%U06,,,[9Y@6Y_QR@/_3]
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M0#& \30"4P'TG]4'  #N 1)8XVD\6J9FBZ@ZBRH0!TA_;+\R0_,A$P)5Y5C
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M(^]"F:2N\-03<4O.4H&^U!K&UU@]*:MSXL%ANZ<0-DB[UYDQ^;16+4DHV,E
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ME==_)DS];S!37!WJ8J^HI!M(J@95(7MH!)W@),)'M[0F[&2BS^1.&?@$(^(
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MRP'8O ^A=3[L-#"E;UMC7Q/1)+33Y^4SLU$&4_W&A-FZFD3NY\S0YPI^2C#
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M>, 5.WS5$#&0KV%E=(7HS7\"!QGP6W_./9$ZGX#G):T,TI%# =Q *"XP_9X
M$;P))1@)W/]!X"%L+VO@.^@I+'T.EF/-0!;/M/?YUN0MNQN%SM<R-:Z9-JWS
MN)#.FUAI[U=CFO$$>)_=WL[E,C!D&%,6H_GRAW1C!N?K_5^LO6547,VZ+=Q
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M1D((:,@9092;AKSE>[// -E+OMQ"*5M7,\'X]MC83)7SG5* :TO'$C9H?ZA
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M5:DJ8T\4#G^\D]]OJ?W_,]%==R37 \(9.]DLFW1<(-0I*&^F-8%+I*"@V)4
M.'!HO"E]U#L-2LS679[?OW8+.*.A!;_J\$CU];W;.2W-P'#9Z%C^R"J1MY\P
M 1* -ZN601 P"M_95:!!R"K8J0V:QDE>-U\+\;KH;5/UE"FD[_=B0>6>>J3
M:1Q.QP?WH5_ MSDCDFA:.0U[:P,NY>4Z^;C"1R'Y17-:22U3(3NJ*Y=]I:\<
M8X!C_A1HQ;2]%),:OGL]'4+T9\RAC2;KCB&/[*;%^7O=WQ:D$8K>-M3VGB1"
MG@&KK0VD: XK56_$;!,/U_4;/RP[>>'M'84"3G9?1GRAHWC'T_ BCG!GG@&2
MI2JPL8I3X6X]FQ.=Q,-DKSHPZ@)(EA4W":]-; ENW_7Z"JIRGGWQN5G[+L":
MN2;5S31%L!)7R57CG12'V2VE2,<Y!]Q&]#QW)\:[VQ.-<6"&0NVX]Y\CIM=T
M-5B^<36"DI+LQ[33PI@<<L(OTFON_7 ?I,/ 82,/F]R>:X4!O7:8C^@9H'W-
MLQZ)-\T3H\R)IZ;D(XP2/CO/.5K/54;H.ZZ"MRQ,4@FW=6_;EH:A<=K\TLH;
M;&YQI:HR:3W#% .0G$&X(^(/"/]Z37L4FHMX&Y9EO:JSG$,-9C=:Q3$>[P@>
M-(M^H/DE:/<Q)\*:UV"F/OP8< 6*P3!2I8D'(=(G@(:X)@G2,R &N>,9</T?
M^K#EOYB9_X<+&%]\&_9YC"MLP></2W]WMCWF@>^7/2'Z<<ZDQC =OX\"/S;U
M2KS2JP3&6ABOF.=&$I/GG;EV"S9K@SZB4HYED_C^@K>XPQMVN2HBTZ;#.S[*
M^QZC*T$1601Y4UCPCS(">'X_]7GEMZ_%1$EE3T^.CHR$SX%-SX"6(1CG,3>@
MJK((248,\$C?V;)&,,/FO:[B_ SP&G+XLMFPS<,*FTD0ZG\1#I[4.E,YTU9*
M5_S5DK4B_::&KQ=YH)90_/%&_I*N$BV9CXD.!7'9['C# #1>J&DA=&#H.-[G
MNGGH06?YZ=-B=B%I&F'B0\<%%/\LI?;,Z3="&6&B3\]#5EECG_!.]C-@1;*(
MQYDFWYZO+IQVJ*UKU_.-A(F+<=Q:!$NLS .?X[TZ=>35DM0G.82O;-TF3*0T
MA#S=?$_@U_G4QLX*EIC?$WH/::#$SX" FT[]BSO2IUO%4\A":_T2K,;,E>IQ
M@$**3.T#_*K1/,0A%]')2 I7MK+.X(JOGR:K@D^L[%$N=V5_5*?-@@$5I?E.
M74QR7>A$=$( IE8G\3DK%Q>W@LAX_3@2%X9)K!N.SZ#@O6!["DD1^=,X49E3
MV13+2T#^R91-X7T9[^7>G:KZ,GEUW<SV>+PTJQ^6[NFAT'E4_NV]ZOS#"E,4
MV]YH90W;5UP+0(&@3H:H[B7+)(W>N/K#<O=4\52QB5)J=>$Z?]2M-.)42:0U
MP\+ ^>09"XS]Y.CR!K+^)KO.CW?-X*PW,S[X&WCXO<24D83$.$2LH'5+^+9H
M7X"*)!L,YDS;RHGN(+3QJ2/&4%M-#[Z;QN.;#9E,+L5).'AL@;);R=.Q!NCQ
M?KQ_!B2-C>EJA'%:;+;($=+.4UA]^L.7_L=1[?YMCGOHWJ6G#*<U&WT5H5;0
MW/N'2+ZHX88/H/>%=!;[-;RYLG9^*=KLW%UNQ;.SI:65@4P0&343@6[_$^Y+
MDNW<T^ZB^824K>&Y^FHAW9PK6\E'J8/D+4<\3O"3^OJQ'MO%MG6,3Q**?[[7
MDS=!HE2PVL15L7O@A$VGC4>A[V?XX!903\9P;0)YR_2=*^G'F1K0,R!S?'?\
MOH6;;7O%N_7R14LT4?R@R8K>(7+\_1IRQ'A2:EQ='V(2)!HLN6NI*A$!Q!0K
M"@?PP8'T"VY7.I--LP5_'IA3AO1G+)%(&?+N2H!.9\(\1"%@.^WXJG.I$?;7
M/]HQ>@KW1$B"=6T[B5&/[@TF#3XO:F.D("1$M6S-7$#Z8WZRQ1N@Q/AAN '.
M5A!WO1?XYAN+4W2L9#ZZL<* C]ZY[L1F>P2<Z<&6U]?2:B3B%#B\E!F[?.J!
M $.71%!BQS7K4FE,742&4?2#DYN3('AH_8SJ)X@V3H= :;&#'B.EO=>MV@YF
M#ZKQ-GF;_94SK?TXU)AN90/$:;O64.>A]/1C-5B+Y1CY$]'Q8TL:P*TEV#'$
M<8E%7\;4.C[U1YOG@L_)J//(EO84L*E1/6%LH=V7/$2,+K)5M?*?>W;A;9A)
MD=AHR:?RPK#W+:'SZ?G>>0<[G\:L;="X]O H[/1-VJCS9 0/EFS_Z8>P;P4W
MO-%NW=N=U=VJ*ZPMOMOF>C.)V5=N(.<"'$A1'^7628^>S-J6:5/U]/=J78[=
M>X,G;_9?<^ZKK<Z;132R(_?HZ6AYFLXYS)7@<-3VS8^<GTU D9IT9,Y. AV7
M1!DXFFRF]X_:Z+&--WW8W+\@2X' ZRM!?- 0 0FA?.OU@R<A6J!(34#U5&N/
M*7!/M2_L!R4KP!C%R7]Q(Q1P9M&,L>]T5&T;@GN6(14??.%6;'=JM?QC_&*=
MJ$8I.QASZ.-9S*%^J<JM]^G.YUO_KP4'7E23T&-.<7?*[YUQUJP&EP+OAYSH
M3U';BO;;K@0*7WGG>E\5($QLZ,60(Z05(7E:3/[(Q/SBH.0K]V]LC0?B>"%X
MPA=0EGD\ ^[A"CVH7ZC1ZZ]S8UB> ;OP?[PH%BP32= G%Q0FC2HC^7GGUT!P
MU,DI&/UOO4"/T]" [P*$63:\PE^#J6$ &H2O XA4&O9.^%WV,^KM.UTL Y0
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M=#H3E#U1*?TJ2/IXT39FK)<L?3E5O2>F0!Q6M/=1Z9&="6-;N-V'64G5:TE
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MB91!%?N/K8W6;7.Q;CM1LAF#,\^ RFS]"HN5KZW+,/<[GXU4]%\'$^GQQ1(
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MY3;GO#5'&&BF=]$7KQJ'5GWZ,XYUOT^;KF4+R8F8\[/;\OFFL["G]PSP+Q,
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MRTG%.I;O]$PX=6,SY?PC.M_9]^()'NS5[S3:?0Q&#F#>.2.BYTK""J'\\0S
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M5G-^YO&BZAG0C'$[ UX]^GX"FOA8VX 9+".+[H^ !Z5X0-]1_*.8<;\-'O.
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MQ!T]V5(E.7IMW5=92V-?D]YE-.$IEHL:,4*ZU#EG+UB1BA8G726!2>;@\<K
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M(L8X2.$5[-S3M:;XOV_^^U^QOA=;2\N..N.]Z38EC1\'E3K;Y"L#7[?HT#+
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ME>""B%?=-N][+D8?4PO+S+U@/ANV^L[?UDBXFO+0L*+%8V"O 8=HU69PVK+
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MX\+MZSSJY#P=?^[/ +E)DK@Q W*^TE[ZGX2&1O\8+IK$\*@;IA+4W^#+(N6
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M4M=65[\;$*K;#&4.?8%9Z^05[93(&<OLT1X[X./I3T'&U$?D:TU46$4N-:G
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MG5\]8T$2,=QHD;B G UDS)8W@]4ZJ?8%<EV @ZM6HSGS^Z9!%@8^V R7R"Q
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MF,=VWO[^-E[!)_P=V-UQJ8)0#C7HKC*1/>6Q"DD9DU1R=?.F** CRV<ZN-<
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MS%34(@A^>R,M]ICE!\HM981K(3YV[4LVV2+Q.J6--,TXO'A5Y37BG>+0VY"
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MP4_]TP"_ ]Z;&(!&]IASDMBO]^SR.@L&F,G+3G_QO@0>^5.[_C(&2#,ZO:^
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MI-='-6ZS##9IM[ZGATG^X_;TA?8(0K5'5*AB:]Q  <)S+V@.)4.4DV:.4@9
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M55/$IPC7:'\E22:>1M$IE(QLD!881BD^9,$9TM;O(20GW(&-3'X_"V;&DN>
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M!3,TIC>ZNBI_>5BN,^<#/^ZY45$3R]'A^\4?NI4YZ&;'P ZU0Q]_Y*UH>Z/
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MJ/T)X4SAA&]]VZS6@,#(&HO5>UJA)ET]V8C[L<S\E%X-S%3#PGF37_G1F1C
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MU8C5G4&[D+X,!-&ZA1;S>QP2?_E"6=^,_M1:HYKO)!R^@1A@]_M[!D)FDI@
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M0OW2\E(B\S8W.3BWR+*D-_WQ%7^=U![=MOI-A"E!76LN1N5:60TZK]W:H%:
M)-U*G+/"A8([/3@%$K(.N3X6+72_SRKC*W62B3I"/POBKA6'"4"A[W\&7:)-
M/D$:>PC>;!2-DM?\'%<>+U&K+R'M*SR*9H'R>+8PT]P&_'KGB)5@Q&3?"C<=
MPV%$I,6"K=#, JIK>LR*.QZ(+3)=6EOHV2>0<KR0+WNKR'[-.5R4#@,,Q?.K
M0O5;#>AX=2C[;RZEF\26MLTN*9O4_"-22N2#J@1XDHYP[\,.@=T'1!0W&.R1
MR%T#Y__LB!,6:O^DBN#% XIAR"/)HP'BAT*Z<V_584^Y.\OJJ)GJ-D&1-?(&
M>KV31V 0:4I,3$I4.DZ,ETXPT71:1%1WE3AU>VC7TQ^J5Y.N%Q=/<0"#:)U/
ML>MMJQ[3)6^8.)C?4S8KX'$#OI(8[<;\2(&,-;HG]<R+17%7(D33.L_36=T?
M,[;"B^SGM%S7NK'DK'CE?&\-"\#1MMY"]2@T7JN'VKD%<(<BF8_'<#S[T#R_
M%1,\OE'N:,4S[TOWY+[\V I;M\^GF<HE>MK[+,PA<S*O]4'DL^91(6FPD^M]
M7)C N;;Z;K 1W2XU@89/-B#&:P!RZRS/\.(!A&,7(Z/GS?.G;RA2IS["0'9<
MCGL0EBH YBFW9:P0(X6'24A ?!X%S+FGV%W9I;G0;E$\$5LTG]H4!M-\"XM,
MO<V@(A%J_@W K!B.3XP.-2]8ML.,W)"RL1_Y$GUG IFMQAD$YU1YZ64^]9QN
M+):(%/J&$7-]OGH\5[-(/_1HLM2;??P^K%DD\RG6Q6/7C83K(I'R"9K-)\OV
MI\_B^K<"@ESV+KPS&+Q"U\'7T\'#<+?CJ>.PG\_[>PM-K $)*FGU9IP5338#
M^5(Z(;+C7X_U+V]XN7T'FG[)&<:NV^M,A9ZIBC6OC5E@+;11U]/H9GI7.[29
MOCM$T^A!>[JC7K4\!+V!D;#2!I3BE-=R2)&3A5]P-T20X>SDBM=F@2XWS""/
M\%")48!O&-_01WGD[OR+JX_G8)-QT7M592_4_(M/0C/[OBXZ;J]ZA!RL+Q@)
MCL_=(B-NX;77N92V,@3-Z67;I1GU2P6%WY@27DN+$HQ]$N3,+HM5RB\-HWWP
M7S "UG@HD3CG#6*4E1B#@S!/7Z1P"_$U1G-8"( 7!$!SZ\2IF=VY>&#.I1S!
M+)7_ =WMT<GKEIYB]R& CN1&=_S'!)^MDG^O%ZI.$O'F05/KN<DF-R2";H-\
M,U$)9HF\.A#]TBIT.\N(T#S<&B_@@92-Z>>"[ZPCFBU.)=GC&*JC0Y?3X%<7
M)1NT65E:],73!<6!/;MA9-J@#D]7WB4XBRC8$'Z52"<X;TZ?.W1#.V!7#VFW
MR$ ;>;T;3D>[Q1U[!.E0XM<0H1L^X3?,84(@"S 0HS@UI=$:3#B:ZV47O4";
M7<)#>[T QC37B_/.3/P?7Z$_)A#:@>@DP)G$AT:S[$$K[!](TA0(2E"0NLS,
M8ZC.G1A_C8<>ODN?BR1,ZX"/$AG6(?0>_BUN;KK(>MR8CH:W/DG>,\$J*PPT
M*Q[;"XF]P?(#*47++.]RBVBW2$?3+._VI8MVB_^*/P+:O',"(*%XR"+9+U=#
M!,.E% &SLV+ND:CG.]%$K]P?9P"RL7<)O\&BD(D@V5I5VZA3;$&;N2+0*%DB
MD72V5.5PHZ9]T)U*>2N.ODD9!E;IW%A<"D<VPTY??G(UDLX\G>B@N00'E,5[
MA ZVEYZC .XQ#4MH9JI([R'3:C\@-D#TR2%Y-CP<(B^MW^Y!1YU5I';N],6#
M9HOT^LA1BP[E"%9TV)"VD#(7DY\)J'0#B/USL"NR#N.DNHKS9"_SCV4GB3)$
M-D/EU80KR"7BMX\/DEV$PDHL]N+".G6Y?7Q,Z\'@&T^U@\,)KQUSW4I;NG+/
M\&P53[!1L5J]$0FR1U(::I$G/!?V^K*D>%;P5[JD[VRZ1M5*L"<F%X*R'+H6
MMC;M5L;?50GVH-YT.1EJ-5L]N.KZ96DR>F=7$<2+E[4-Z3';#/]L6/I\L6#[
MY.9NR+6\PN:G$&I(&/JHK45XM0%HEPG/_9=+COFW=2<#Q5+V#0QD:C^P+'0T
MD3IY']GDBIC/1TFF;[8"]. )*N,C;B<%A?>:@XN=CA'M/$R>46GQ)GTJ,F%.
MQWD/EG] "[A_:G9MRS>G^"20)D9;/3X/LYW.&%65?M*6*S9?&+I'N%-2O">^
M4OUZI_?H&^+^>(KD,V+I 7-2[29'#K%@WXEF[.=;\J7UR=9?^%^8:'_,_[W?
M5_QN7KRC\7)B?BIA1CV'=+A_G6B7T,(+B=)_%#!8/!MWI>4[0'[TA7,MZ[?!
M[P9?[PAE^3NP*Y7?JSE! /ZK7SZIWCSC-V+AW.<4':DJ/(@^D]GWL"#NZ.-T
MX8B6U3BZWK=_^XE9VKF7*]D$U+NB3)(!Q 7>GK/^$B [:P0ZMQ=*64M\\#]]
MZB;C%R'MY^"[S@![(=;M'H2.+&>'896:W]FY@P6!>,NH;]HYF-^F#2%KUG^H
M].G+OO&S96/EC=%U=Z"GIN07L#DX.AW >VS'\RW/=D84.+E=*KRB)@W-0#6
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MN/TQN7JV<^]KQ?BR$T8-/N_[/ZHB)%JU2,(V+1:Z(DZAXSG?SC::N+L5O=
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M1^>C',74W[<),9D9(9EAH<SO3GE29#MCS@C5'2LS,05E8=GQ'Y7/ZW':< 8
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MZQ? ':/6W:K3Y_X:9UY5%\# 57SH@&,J6XQ*?9A&97GB!:"=XJQJA^+__"&
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M-]V7D\%FG<  %L< -F_S?-\;_'@V5![-IZ:^S4A\8DV6[;=I@+3).ZHZ5[P
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MA7-F?K8<KRR4-)^$7'%TO '?L:GDO=)7+!B8^%#XB0XY<=R7%5*JF<LE"EP
M1$3-<P=8FNST"SI*SGWO6]5DU!LV,6=&P.3LMJQ"F-I*7T^[^35+#@MEXS10
MDQ=D?Z/JYYRM1(1D"7=VD/Q'O:*R11>(XUB42T!>%68J*XXIX8'0>JZ3#R56
MEC6C!X7S@3<USP=NS:RLS)M&22]VLS!^"]DCO/E8?R&_WC9GO62=G"H4RI+0
MHU&.0S* .[W&$UCR(.QOWE9@A^WY!Z\M$[E)X2NF,R*\,?'#[VDB.919)T+M
M@[K,#D>@I$7=>XX!D?\,FP L; J.BQG'73Y8IYWY?&DM>2$TSO)PX\$KA>OR
MEB^&I.[/1Y-T;U:*G5!()B')$SW6U2<S%F2ICAP5AHL*TS31PHXU\.?*%&6/
MQ %T 3)%/W-08<!@A7UW[JFSTW*HTUTI;4ZE^RY\^-)*,T4/C1L9>=2*'31L
M"JL-2UYUGE;:_BC6SHP*1]UVH?457&S[8/U)L<)JKT=QTK0N4&;+XV-#L"6:
M0<QTA,]IP6G0J'^U'!'X"OL=K<OO6)Y37P]O^,IY :#W+H!=D9@BQU2\\62H
MLXC]0G78F<GAK@JJ =5B>D9IBIO[2N4<]%;(K=B!8OJ9WO7[!#?D41.<R"=4
MQ>Q8)[SY/&-L2O_-EH#\,A>^U1=]^)ZHK:S =]-1)6'N6Q /1M#HN3*41#>,
M1"<,B5*Z+4@BSXR=GUT+ZR5>TJKJG]_H)UE_]/8-O<.HK2Y4QWF.^1996.!P
MCC?JDG@!G-BL]_U0'':S0;=O2I-B' <NXT6?IY-&8RUU]L_#Y+;N>SNOTWI1
MBE<3B0U.D_KDOL<X3+]9O!F1%3[+O<^=AT'>8>3=)#"QW3#5I11S*X2N3'9$
M/N8N<*B<1'YS'S9$2,76\[PG>>*J\Q,/_'D!+3$5H+]['O+^VZM$\J@8+A-&
M#M$R/G<-+E??>8^4(L2:2\;@?1?9C6WAP[ASA:,+(*G1^/'=@4>>RR7A-HET
MG@B+68DX2DO>#CQP[IVXX;?5%.NS%*HO5H=S1ST/;1<>Y=HE=$B(7X[FN>+O
M436>ESD;-#X-V_UO8ZT8N3Q_S) UW>T%N2ZF_["].RJ1;[-^^: Y5;QQC1N[
M-LM[NS$1!\:%*JL316O)>VXL4C,&'JF1 G/@U +LQ]_*M5S$SAZ'I<IB&ACV
MQ:_>660+";3TL^5Q[Z1,;\?%YWEZ34.=%.:U7H_R[D[W[6BN54<G<N9/XV?8
MD)UELME.I5P A);0/NF2 _I1RH$<^%B<ZO<+0"AXS&L.XNC>(C59OF,J?UZT
M.BFAK7 C:4(YVS$5?_#)P.&O3ZVO],'DIAJP8LY3;\N#8KG,MSV;;OY*4?7T
MF=]BOQBM%UE$B=LS8B.4,CPV+-7^UROD*<M[^RIJH?6^$O5PFFQR7."7]56O
MLN8JT;W&53DTDZ( !M-(AH(BN *;(-[Y'+57U16[V\_)/WZL*HO2M:2O5R6G
M#KT7FPY*BR^FDC@*6]#&O_6:\0?N[!\$C/56J2GL7G:@7#XH5S7H_.DK7%7E
MQ_DD6C532"O+:9_\BFBS1O_>H9GN_%X7WRR<Q4D)K=T?$[W^])0F/'X5T1=
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M%:A=W< -&:OQNT1#$Y( 8[:^S8X6"]R4O\LENBVI2" 5WL@N%:N.ZPK_FZ4
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M_'M%E,'N$XU_0HG:+IUPV/08GWZK")\O?X]M_[)J!_^S:I<O-7X!I/G)BEP
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M)<'%[U5MNED.<>OAY[>YL.ZF13-J!SR9_*P@[O'1=U?9+%/JU= G1Z]/VJY
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MJGY! \WYJ]]=3H'*E!_<+A7;U&T_UDZ,$=(I/*> 1U3OKBGRWL\]7AT^N;:
M9G\*H)\"?1'6W:SFZ+@0Q:G,9W)-#K/5)B0=!OZN#8PS\]@232D[0.4I$."W
MHE!N&9,NTT$02[I:JYK#2 E4=<O48[.]1ZMG TX"X<B?SSZA^'Z9)?1$\*?Q
M$@QY'YC_N5U>_R&Q\J+XL)Y5WRMA3FDAB9%4TEI-MZ0##\9H57E'ZC9,K0%R
MVY&\F"!:(M4R3"XK.N;PSH""XAU<AL=#%[5OA\;C)"M-'I9@$N>,5Z^#H3M4
M0-*.K"AU/2(C6"$>7Y)?[GKINDMF--A_^@H$1!#Y#<)(Y_]G=L-YSQHZ:_>D
M2M=,H#5L$VSZ5C,43VD5C>.SU$'*3<1_"::+[)JI#A'&K/'H1N-C=0^*'$W*
M$7?1YLT?:/@W^U$Y%KJ5JV*S'AP<:(_Q9&3K3.+CWT",*(V,R:P48-&:TH:T
MBXFR)0T7BMRA"3\:'E[/YRY*8^:XSA]_+R3-DZ3!(":F+U)<6UX><-8^@DBG
M>#O;VUU#L&D2"Q\DZ%3E)D:NE5BV2MW,V6^Q][+$9:QX][.KP?K012CS*K5<
MS/8Q6SQF%3&O^(^12>1PD<(NCR$P/$A1\==$;:*&?S<:-2.E0?+XDT*5?X,0
MY'*HUYI&N+#-TC"&X ]/W\/^8FCO].P4V"&M0<92O<<]@I@IZY/*)X_\MEM.
M ;QK5>Y7OW\_!=JHCCG%P^X)^OWRN? W7@YG0/'US-9_9'<N6U/8W:8>YJJ'
M/OHI1O_>5-/V5U,MM#X%**5SPE(P]J3(_H9OA>KOXE3JP&]$3,5YIYC?;$'S
M&-/';V.S+:E?PUW_;W)\_C]QZCJ^O;OY,XI?8-EOJNVR9Y\VGZ'V+[;?;'5Y
ML^S[(Z6CA[4_QZY=ZT%NQ$:F8YZ/&")>RE4R6ZGM.@$GVP?YN_SZC-Z;MY0,
M507B5'6?<T0JWFT&)!"8ZEO+Q_[<'V:,CT@*]7YB8YZLJQQS[D@KDQW;''WH
M_CLB6E'L_QH"UEH"ZJ@;H^<FH?@=T" *-9D.:(P_\-\E8/W?)3S^<3GY,QO)
M2D2;G7B#! ^I5I37]:]5$*'N;T;6>X4"A@D[7Z8D[!7,H -)9:;:L1N^F+SB
M?G\S&&_I:==+O=:+B@^A5>*F,?;C)SIL+]"S/V&P3;SX(G1;G%Z!O:6S2Y!/
MY+F]1M%H.QTGQI!5-"X&HU46)8G@OR:L-7Y7AV7;:?'JP] 5O0DBLM@G^L<1
M60<!;;W!$AHQ0^ZBV2R=X[)2CQ,&>5ZQ;,=S:W%'WK-$%X4+"V]&\S6T=18F
MF:N9O)WXN\$B>I73DBNSHX!0Z&_OA]'Y.RBJPXEP+\= 7E0IF?\""TJI00#"
MMX?[[_"YE["3"JZS*+,6%!,(=+;H.$_P,D8VD_R+,Y'^2$>??YB0 FC:VL,&
MPDNN&D(<3!A;G?#'64(79!0%\"H:[]QZV4\-D/(:\($67>&/U. *BJ*M=\PO
M$"[Q/VOE,6 Y!8X?%WWXBHS9! PG_POR^;"G/X>_(ZK;>4<42[V(=,8>6?NF
M:A8*G,B-^.U/7MMC.A_-6,/84> %05#$SWKP8Y!M&I;RPSWBO_N+F@9+TH7/
M[ .A'&*@EED^&$WJPTYJ?$K#[" QVCOKV5 &-/ R\U]?=['.XA3@,3X8/ 4L
MBK1JBJG]NI[]+#\%1NWBBT,^7INVVCF.V?ON^:/\D=]+9"Q7UU2^^>\%$U9>
MKB<RE--;5W_BC(0W6LHP(@1]5V%N7,(;M,%H=/'MV)*D1$2\?K(-?K7(]8%W
M'(5H1L8UCXIWH>EAG)GU?YF2/)_">9LQ^<75MB5!XKH 7R70"+GG463R"Y;A
MD;2#BB$+G:R@#'D<0\\K4=;8&&")T':IW,\\[H):;&'N5\HGA2^5=?;U.+N3
MXS,KOHLCBPUJZ*B7-!G&+S08L];+ZGE=Z.[JZD"B>Y519PR]V33,V]HY,-E+
M]*C?U.!+=I"#_6) =P!4+MPL)L8?0L<?K?$#CK-^5YO5_667Y]#>O$^I"OE7
M<JI8#B#,;&KM6^-Q(%OJ";'/)V4;5\SA4F5[5_INQ0 N!S ?'8,B>0&_S]]5
M/SI+^V:JGJ@&+W?5!A^L;^B),6,JK#W,I%L&?]6K:/E6>R+7[_<)[11($W(Q
M<_;3S%CG]JM?:9S]^>Z.\N?/3QK'W*M"R#3@(R,L2I)9P1+NJI<]'M8K/G0>
MW,[7%A8Y))'YFA/B,!M=6N=,0A9X?)7:\;G9S[3 ]K:;NZN<K:> SH<OT_.G
M +#WH0094W[S:Y#H(;M^TNF]_.++1M%K#868LD;&QN+N[K;(K.<(;]9$Z8#E
MT9J7!485 Y-/HZXRBL>4V_=. IBM=D&&#>1BF"4=&$!*EN<)'=)AQJPZQC\%
MY(0F_7L>56D.+E;$;SXXV%'DX43;][%]^.E3U3&I/=OMDQZXTTZH9?6K#1:G
ME[*6>]2B "">'/\HC'-$<NMOZ:JS029R(>:,M==Z(6)=?&9=I,ZQ]2M80#V@
M<8$* @ ]M\R1$>SEH%I'VL:!;<X5#L;2XFB*G T >3"&@;8JFL8+2A+GY3W#
M>2?RFH.@[D#\?88?*ED 3%X1NM6XE5G:&B6P%JKKC\K=^OXS=1NZ'(QB08>:
M!>-$UR&4&C3)"1"P&4"B#QE^G4O^!<Y7A2#5N.>E-[L^HM.]G5[;"G;0O">'
M$/>_67G)-WL@E"V8*H@E01#ES'2?.3.K'OET1/7)0RB%AMTF.T?NEN:2)I"2
M$0QJDA>&!8-N ?2K9_H4R;1Q5T$EG0&C^! LM/BP-_/5)K+T(<P!DMQ.!U^Y
M++WZ#><)1#A*F&#T,BSZV.\'OZ!$9CHD>>NN<)6<4>Q-4!1[8_4*G1D/T$$N
M.U!PE6)5+R$Q0T7XY?V"+C(! XF(-P'3CEJ.LN$^1_3/V8)7ISB?>IN]P%65
M=%%HB!\*A^/,P"5&C#Y0#[L1:K6V9"2O, 5E:%-K<X Y71O&.KW79#=E*(K<
M:3LVW S%\6-!5='E@Q]SLN!Y@?6,13#I)VEYSRYD+ I-EH^,10:Y$M@(+;ZK
MS4R :^@:23):&C9C5(0M)SUL2I;7>5.Y QW:)S0TK3)4, ^7%;B"YL0L;Y9$
M>4^FGBT!L/1G?_W6'>?]X$(=ELY&-]]4)XE<*[E K0EF)T;D\PZ#R(K!<8/K
M[@ZQ^KUTV[S?S2,"L=KH%2FZC;Q\=._SF%>61E*#^I]S#=H6(R+!Q9=Y#.#3
M88$#Y0\%:%\JYZ\5Q^885$S@E7(&T&*.>5[A<(V8(!5+):RY0',JTLO2&W'%
MS#/HX&9>?9Q]VINI)W97&I#C="MZC#83?AVW.H9Z0+CU0).1#R,7*(4_<& H
M1Y.BT#.UN!^P3+G-Y"[36R%K:9(GMG&F+)#["]7K3UN5ARH^9[Y7$7=+7=_-
M@'F$5$%1ICFQ(HADJKJV-7Q5.R0\NRLQ/EYE4NSCI6S0([<^XO[;/'#Y\)HG
M)CH\WHQF;)=#CEN(OM!L>&J"@KKH7.X QS#TYT^TTSXE:[OCE+Z5V\+W5I5@
M,A^KYR_1HO,DP(&4@.Z:28Z$W5XU2#6M!FXN1U]26?#CP,^+)ZBG%%5540_?
M_H9A_&*G]O,/Y;0_[9%YX:LA']<H-,Q+1 '-=X(8>;IP-"PWT.7#(!OY:S94
M2R$Y/SNN0@:L\_J><L9=!:I0AG>[X%?#TQ5J&L^I.@OAQO\4POTD_S:G>[Z0
M#S1O )_=B#Q._\P8QGXUAG1G"Y3AU5>=(0"LXG<$P'SQ*VU0\9RA4$5>]H;R
MMM/!*O>9R0MO_,GD,>.NXMWD[E_RC>&TQQRWN7\U=ZS 20+] >K?RN<Z4=@3
MX'BFP!!KBU)@B*T'/'^=:0H]/@N![AA\3R]C\[Q:F,(8+>&*1VD20S/#'HEY
M%:Y#XX0*LT"FE</2/U?1PL&$E#5&RO:SX[=^XRH_$][J?:F[]Z:>*P07S-+J
MA 7CP%ZU2T3Z#&1'"]/9"U'972D_!+6+EQK#Y-W=M!4("OC!='!VH@(=3G2-
M67\I(H'>&7GONF)C2.7*YO&O'L6Y<D)$UY[TI T4S$0W'(22*NJ,TXYJ;C43
M9:)WXJY7^XPD-7:.8GSD1IVIF6+[RYF:QJDF'R9SD;[G(\6.>WX1U[2_)_Q"
M.*1#[T3!D;.C(&FJUT*4'6<N-8BD >2)#(1Z_J,!0OW;OV%F%'IH%NZ.%"W5
M56<XJ%CQ&P[V8<8:2-4\=455E"-J?ZTHI^(+:MJ<-^EJHJ6HBLJ,_C\P?NPW
MC%]!5XZ/6;=4>FRI($=\D__Q?$13]7[1S4]-.[VN65@#F27Z8C=VRI])VSK0
M4U),C6O$QC9N8>M]??3;^+1<#6-UCJ]X8XK@A[!%.STX^L3#2:N,%YL[-!5,
MZ3Z^L.).]4S\>97N_0(1_MNAC(EQ@C&'[-=-&.8]))8I[G0VSFT:UPT[<DOW
M$B1T62?L4%BZ@\H$UEE\DM!BZY<IGIP"N#=:.O'U">O1M;O$@+W--3^.2V&L
M=],*[Z.9!6$)=+1Z+??1+)R,-:X73[CY66I/J]1]>##;EMRD1CGBI,]GH:SO
MAO=T,3-L_="K.^C!P7CR?E::[D2#<):[,YG^TZX4(>[1N#@TN85UJ/F\)-E8
M*9>D'$LM^@$G#K<F_6+\,VMY32X8= 8M$E94_#MCU;#ZOJ&D!MV7]0=TPUN[
M:3RZ&\KR6H]U#=*\,.MRZ*-+[4VH=?*))()!))_A[.@=10R3\F^3!;6]6B<[
M"Y3N*JKB:C5LEA]IRX9:AA4RE@;-PN1K)'M+6>Q3:^VY@_;_*47#1JF%BF_Q
MO<[BVY>:J/@V&<!X!^C^P9'5<#H7K-+SSU^"SW7U&;U;ZE#I@/6S=,"#!$:T
MB6AVY-+\A<>;X:]KJ-_B[,#]CS-AUW\[$W8/S;+Z Y5?N][5HYEK>ZQ%1><9
MP7[[MS?R#,4$MB3*,F#V^H_@A?EMBH5EFSI(E9L/M5DEDP_8[:Y 'D$9)C4&
M=![A=$U/[UN7A,&1\AX)S%R+0R,&D4W-,*'M-]O['=#WJ_^P!S% KZGAS,#2
MHB8@DJ68\#(?,UAISS-)4#)$J/*VT$KX.UZOB)LY8#PL=F4^!7P2$OI/K'=V
MC6<4/^U9+E+H/&6I5O:@G/,F>061\.3/10NA_Z<"THWSD$'OX7?+7WC:\N5]
M!GHM4@4Q78X<V&%*S\G_.2(N* *:Z'*P52)S@@AJ& IP?\4"V'F^4"I*'"R9
M5M_;@8<E\JS0"<%$%3K94&D,E(H5P=9$FA=+I 91NRZ8EZ! \PE]$SK.FBPY
M[KGIQ#-%O?..'";K)2RLJZ(B;3L#_1CX;Z"?BGN!GASIN8$WRL\[/[$)308;
MD2?HG"$1[Y^V'U"<ANLY3Y+[G[O9@EOCC-Z+D5">'.K/[%S=%(I27<3 AA**
MV:OAI$(X7*=-N=-V!N*H\TW^ >+I8K.)2TI9$5-4HQSYZ&J5P4T^] 79V"78
M[_Y&BN0"/9V+J% *IEK5L(Y8'P@CN@)^,&-2D9-*)Z]2^S*XXY]EED;C4Z#]
MYM>3VFN[0I.?</V0/@MG\=':*= ]**.='G8EA+/O:R]GWQ>^9%UY<NVE)V.8
M>H/7%KBM3@%#9$PN1Z'UYPZ47YFKZ6%(WV0F/>."9,!?XAR,A%\V\-4_!?_O
M(:*G@&]*UX[BX.+T1O_WD_O(P'N7:/#]KVG$SE\^4*?I]D$2 :+B':5VEP*P
M2R:=N8LX2;0++L41$?[/L91OV@L/$]B^#>[[);*0JQFR_J6D9Z1KE&VD:RS4
M?&UG<_F(843EX,0X1TV>8E>QW/:;Z\GU U3Z /3)U^A!6F.5>+FJ6#0TE)DO
M4D$!R"#ZISQ,L5QQ4?NUR:P3MN^0Y5W'^:LJPZ@LZ>SB7XJ6SH]XD-%HN?%^
MO=_*;<.L/WTT4O \6?FIMF*1LGF9U03Y!-M/!C ]IWX-7^LY'LNK);'7=T!/
MK K_'-ENF L?#14>%^\J/GMQ"J 9?UCIT6-/?U_]_6\#U_2P\X^"O5 BYW>I
M')/;!T\L$0)H\C@!.":C$J'W9^#",R9FV+')T)SFSD^7 %+'&]K0U@:GYH#@
M5MSO=V3$Z*RHJ?^F\Y(SY5-][4CY;7[3]P-S,/,7D$/SG4\<M$/FR_2B!?JU
M5I&;Z@.%A9-[70_RE4.YF>_6*_P(#\L3+]*@SQC:EJ$?IFC0-_A.POUX9/!G
MB#$UI ('H[0VA96[0 :830H,YPC?+^JZ,\0T5(C9S/%EEU_2A8"?'T&M@[1U
MH$HM1F2,)$&I&0TL3L[RU-R>J<P?F(P)3(I4$$.D(G9PBA"3$P61X?.+$C(@
MC(25WUJAZT%[&L8V@2</%)%+-4QZ$/OX(.KDQU_BENG?+YF_>B]F<T-7+?%6
M@2P&G-\FE4/MKC?I*=#+AG2];S/<^+#;@<3^V%LWW%?<Z__XPO./F]RR>MZO
M[ILP?^*[B/R&\+)%-:J;W&\ST#CI!\V'SI/Y-=\"B72:7]I+.:Z53OCUUGTX
M;,@7=Z_KR!V3:&+.ZWZ,R 3X.6\*VCY0^E'LWA<6S]2^K\\0*B]_\/S:<KG?
MX>>,=5Z_7FODTY2<2;; [VT]SXQ0E;8@"'K*,]B8%)'M,8BX!(2[QK!H(4Y&
MV()H5%&-^/ S7HFH6I!D$L&,.R/U+V-"035F@MSN^Y';_;VH\H930"H#^08M
M9XH@_[SG:V5?>](-&UG0_,+WJ 5V##2N0O=>LJ]JMJHLW5JA!+S00&;>+V_#
MCOB@#YM2XEQU (-5'_F(EI\5+<=^)M5P5J7P3 -LC@+G]GM4FPQ/JHN"%]B'
MLM\/NE\M578ECG1F>=D)+IYT7S#UAWIB1XKFS@D+^]!\\:!2EZ&\QLW"6\O;
MJ[4B[0#K+788UJ8(?VEX_[HK?<^Q"-5=/3UB B8=YB)*FTBEC_H<?+%!9N$T
M:QDQ+!'(Z!KBWZGH9)<PQ,55A$.I76@=W/VYAE;;>6';_QVO(H1-RD=K_U4/
M8CR3&%8IJLK\!-,+ Z-(8" 69/JMZ\3@PWKV29=!H;L1%];RVB.978_-C[TO
M+WL.O/WPVZ05A_7DWM'IJ* :1"*AQ6Y8D[S(]*ZYH,;T[S.O..IP;7G*^,?,
MIU=KMJ< YX_(7CNBE0W)7\,84P%&8AB-]#ZTAI+6D[ )B+RY@)&,BXT-%GL!
M"B4*=:0KRIGWT(S$^1YE^T[H9P$._2*(2N,[VIG$3<=OO"MC[\#;IKG9Q_D[
MTNJDFWKVGGZ)2(_E]W6B^,?\UMR"(<.:W^;>]_6E[^N7?QZ<4>?_F/G+OR]J
M(&L._RW70XF<23FE!$Y/<TA)&_;65QVLUFF%J*9G"7PA16S)HCQT[J_,Y?2]
M3R#1.&Q9;E3/7OCV5+1D;JS3Y?2+DI2T0["3M+@K"NQ8_-\/TZQ.JT@4SNN+
MR.F#M5QCJW/:P1A%MP59S4?Q>WB6!LQ+$H7HJT@,RV/B]1-?G0)N^'N/'MV'
M.[W],E!SB6@U@2=&I[Z*-E,QD8=5$WV3\$FT26S',C8VR".?U$"W*T_>FZ6I
MM(%:)V/G\J+9X4O1Y7"T-KJC[9>9GW5MJCQVWNWV4&2J$*;[Q@^U%HQ*1$E$
M M3U1^H8^<5<Q7=^W+J\.W;MQYKVRY^_&_'#$3]<Y=&=_$WDIJ/.WI:\6;5Z
M7?[V@7[4]\-G)]\$_[#VAYLE^<?%&U)1R/FM2@M]J15Z5N96@G@3U^3?O_];
MG5L[31LM(^'-T'QM=9A%,+FG2XD '4B*'!VV!Y#ZX&W\-B\4^][D%G2"<?'O
M-OL9L.Q8.#JR!_?-R_\&T2C6&6S^'?O] S-D2#_Q)FC5+(?NYU2PDRYQW@@&
MD\K&@-TF6GS!"&G3WDZQPN^.A>F&/>R,20]3^(Z#3 V":.(.QQRR#F .]T@^
M0LN\KU/\**H+YP5%SFRWD?<E]J*YYGZA%*$Z^$2U_1,^AY/(S!_C1)=7TL84
M8ESGPS!77NA>0MCM*;(U80BSL9;A#3()J]9]+081NY_3>H<BDM=.#V)FE5;T
MS-1=$,UL9T =OXQ@WR%P:2'IZ&!=HP(?GQ..&?]5CZE,F"=X>,);TN3J+9+V
MCEZCN U*\><+,#-=B$G[#'_,!,W\0T.DTV3]X:O_*=#WHN:!Q$N6*B7&V/M.
MJ?)$>%M8V 966:Y&[(K50_->FEEJ.*#4]H_Z W7AJSPZ6NG%>5($%5E&FR6]
M:G^/X9?_8<!1Z0=O-D*HG.2)9.^[R-2S?4'>\M>>"J=\1Z>5 NZE)H+PUOJ3
M&\Z&K0',U]/UVSCS1"?CS>#29F/OZA"OE.8RERG+?;F'&2RM1&_"%SV1D<F[
M<V;15VT&T:_VFZ%RR)MTXD7+KLBF8OXUT4W&02(94[MY#X])K<IYC!>VP(,F
MM@!W$@A@423H$J>2940;E?8:/>,F8OS&3?0_/]']IZ0WL5S5):<2!;88"@:9
M#%<.A ;9D+_N&PD'Z8J_:N98V;[0_?! =S9E[= #X1W=J>ZU8!K_#,(8*1ZX
MJ9#X6BBN2EO@(\]5GB3!@<>?J]6"- V2 *D.:.R+_G1_/HL^@@2UG!KT?9Z6
MY62SSO+W7U-JJQ9;?=!Z# ;<^E_KEBL8"^NR>+]^YC"YL08371/[LJZ=@](,
M$  A-W="<DNO_A@HAPA'"::_E R+-N1]/RH3_9L?;N 1D^.5;T03?G 4&6&'
M^3[#U8;.Q0;1.7XO/IJT<5862K!'8=;R8JDLXTLE9<TMX:J:_7F*" 9A$N'V
MT07[M%+LKO*';9B?"@%W06U(@=<(K1_>RM%P7&5_0UX7@8VGFTJL;>D5^QV3
M2"SA><Y=8ESR[?RO(SYWLAXXN?7(C4B)%=_?IQ7D:V'"4[I.'=,!,@W$:L"N
M% -65_)\;@\]&Y.*6$B[$3O>QHE)A]Z)VU8EU&GSGO/M<)V*M^GE$,EK]]\8
MOROW<8M^5IL(:=VYE,P+(\)N=P[?[0$\]K2)'VH7^#[_VBAQ=8UBZ'9,%9_(
MF&2)2+3EKLCZCU- >#+%S7?MD^-O#7GG:T+]XO:]VKY3F/OED(;E=<)!3$^N
ML6]B5DU EH8QAV*[IAMT$?@Z5?SEC5W,K66-(;>O.6''^78F6[S2F>6],>L!
M^ZF$XISA6Q_"'?8+'\V-;. PE]1$PO9"U9FRP\1N.>BS@7ZV@=LZYU(KM^^4
M%1K9YF9,6N>[9_=RF2E4*XC<+;"O<O;CQ6DZ!7#9ZQT,8E%>9*!]H6'//-8
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M^EVDMZ%$*YH6X5?,H;ZSU20QGZ(5<X18%,42[1?MO.813H];$6+REFW &U!
M\C?1/:$_.YD4+5Z;36.5N=Q9K<'H$P8*1Q9?OP?@Z?5$#!#LFW-&BQ^W48SU
MR]!E30>_\*/4MZ\<S2@*<LX6@+!_-IP;2V5XM%HEVD81[_[:5N";S[3,L"2M
M8Z'!F$+ER.&.T(=1'TS25PL=U&U<E,(+)@XSGU+59!C\LKTD='YXQ(*.(CZF
M.*9^X1W5FQCSYG)@X0 55M[P307)\*,M'!0:8UO7/'M2+/1.?';Q[6#RUW4/
M3Y?G36)QEAH<_FA/0%NI#X^UM>4![\6-P$+ZJSI;Y>+&B1:YTS#^572=9K7K
M@LGF 7&5/^=Y #S9SAVQ-MW9<<ZGRM0+=5%=M;4U+Y8TVR4\^3Z_I2,E9EX>
MJUA))?)KT+.?BIG5?\"Y4I?_^,5LHB?6[&L/]6CG=A,_FA4.48(>1S(#13K7
M.*P;$5UYE6)H(:#PP_K>U L4PG)F(]+EB@5C2=?&D]@9*:%7.X%Z;(SW0 <;
MM$.MT=*<U6M><:H>Y-+D,%^^$-!A0,K7 #6?AUZL'O;//P@9IX$D 'M'8A!+
MBXF2(0'_KH-R\P)*1H8 QP04!'O7GT1"2]$83:0/QEX"@Q9VPV?F+I9T11=C
MU4DF-V7B?]\R3LN+;>/X/" (K-Y1_Q'[+MJ?&ZXCO><K@UXG5K:^NX.+JL?D
MD7P5)FTOR6K5;=>DI47XX?4.54C)/[QME?GY78&R4%GW@ J^DNQ=+(#H?3G:
M!WGGL:K0?2G2VW(C"[J]DI0EDRW\"NU!M^#\U,IDR=D2^:DEG]S6%>;7#G:O
MO3 CS8/AMQI>JZOUGY!JE0>L^PWVDW/S[#[85 \D?YQJO4+#;K1$&9]M,?L2
M[9GM<L!0$EG;S;?I=MB:8;.LCV6];?C@<XSC_J:3*NZ0&!F:B@LX_&46G_;:
M+;PRWS9E4)@N5H'<UW6'"N\@WL%85M<,KGSTD159L5'3I:DL.S F,+(=86'A
MD^MEV)> T;F("KWRR_U:8QGPLPQZY+:M$,H5S9W?VG*''\,[(C"PC<(9@:@9
MYM>S&7TE3]$38:S^89MNS#>\,EJ6/M,3+;O2!KS)%@DU4"^HH+]W< K<'3C^
M"BXJ8) :_)DXRJ)X5QMW"3W3+.7Y($F_FL&GX'UN.]TPY<0-+E)V!_. C,C^
M0U[U\&!^YY2T7)9MPMYCE@2]6Q[\+ 6O-1^$1A<=W"#\43(4$+-+$OA1W-)?
MG(;SN:^K9K6AWDZK!)_5Z\YM\&LM_CMFBUOU_DE.H@X*MU6$L_,FQU^N2^J.
M?9GK=[C[H.7JTH;AY\;JS\#J'9\MT50B>%A6YC1R0["A?+9$&;A.PI6L[VX0
M930__<[P%S&R1/O"Q5?-02@9GHA7*.$0^)EPR-U_<?Z"(JC+U9%\!8J2;X'>
M#T>C7M1!S_[LCPRT+O#.+A3F^E=Y_S.7X1Z.UNP&)7OS#G-&.[F#Q=V;<)]H
M?&%L^[:1S)SF^SP,ZH)!U!0W;O ,,R:]F1=#6F',3CC:1_,+K)!7[A.N4[^"
M500UJ5R&2SZQ#L80NJ:+Q#I#/(N"F9D3(C03)Z?S'II'"=0TBKJ] 0-TZ?D"
M ^^%Q B2\S4,.<0@5EZZE@@^V@T+U>IH>XB=.5EXM%=#9Z1S]"]/F6/'5U=S
MZPN-0,EXD!KBD:DV$A7Y.SO7KZXG%EIIDN9"6YVPY/6'W=K>;[]/WJ3OJU06
MNZX,0BA@.( Q^Z*ZA(;49.BR0P5I'_@1V-YK[+1[FA]U]=&R=U8<MI$('W<X
MT2O,V^]OVS77: Y1/G-JNH>HZW7%D.\JZ@MTHHUR49"I7XXQY"9'Z[)&P&:?
M4KN]'%>N4F+QJ'PQ-KJDFV'))3TCH4,J2QCYN5>O8K90>A57B%MA!P(:B^A]
MP0@EHT$+(HP4,8N-TIM&XN/NNLJMNI=W:ZZ9)M\0*+NR \->:H=$I17+YBQ%
M9,GD"D9'KXY'7X%B@8J[<1HPL-_C-F"#G.:=E"G3DPK-\@E#O3S&M-]V&XT9
M5#6]K-6LBIL0JO._0;P)+4$ZN+EY7BXZY1'21V,274W6I+I[XT\3S6'U&(P0
MON]/5,6=PQGBQ]4,-6SR-.9ON\%\6RG8>D5$AB<6& =/@8J'%NX/N&C"*0=T
MKI<T]=SW-%^\,U 7==V0)3C1ZC7TJ0V)BM!A^]K:QOIJ=W/LMQ=5\M:R'[UX
MQN8^*=<IAT"#7IQX:L;@(;*J)0^$6/,=)9-YMO:^$$20RRUWQVC$WTK%8*NT
M>Q0&S DI:_/;:?7KK6YU>31S5Y1N5M5R51.9C_ZH.P6()^JN^M3,X=,+$U+I
M]%N\JZBL"+_.I=7C4EKZ>H"7:L%1SCEIGV)8389:FKKJ?<76>I)XJ*M;WGC@
M^R55G7C0(9/3-;R17U7VO)AJJA*FYMB7X!I7H"[L%NX0$+$78^0PBZ*DO5!=
M"71 9B-(2Z<Q04YQBC: FMX;Y!-X$>,0I4 G2UA8IW6PK4A PJ@T'R&7QPX&
MT.H!CUP.48BU_5SH$L+S!MY .[E M/3V&-#QM1ZC#^\"C9-(,%.E7+0\G9)A
M4AZ[JN[S,@:)!&CL!,+V9B1X#,JQ"^/CZ7G;"$>[)W><2@ X2<P0(%R4_J)P
M\K?GP1!,6[M;SQ.#[D;2)7#'5E.T A@.1'=<O,!+-\-O%3IMH;'NR;O<ND]%
MH 2^;Y(2MX 1T^H<<]%Y,.?K5<+4$N,=2-&A*/&OB#"46%#X[V)!%P/#!4&-
MQD5:@!?H=[=:R)A$BOBNXGAR"&_01LI(!G5@T$5C*;A <Y82360VH(PUV1VT
M8EV\:HUPY]B.%2Q8/:COPB&]P%T]7ZWG8@_)OWMD6ZC9N4U,QEQIHB;?+!KL
MK]3[D. (#Y$!MWA;%>9&BM+20P@KH/2:T,[TFB[@QYVO0)EXODB1X/DS<ZX(
M>A]CD /#[+UP%68.R0"%)4UH#ELN4&;B,>%KC3JDC3'8*F@Q3,3+^.&M3ER%
M,6W.%8\R@LCFR#T5D(C6SOB$/%W?S2!HI#Q!4:8)_!*(9.SL9,=S3 #UB^=K
M]-\X-[&)ZHDYU^Y1W2$-A*7D</8YN;5%-3EX=\OS[8D2:/)"K R<HOI!4!B?
M9$C.#B9MH@8B-3D3O2=@W'D?U;ASOAY0W 7BMR$SP52)<V&"WBD/"_+0/,:H
MN%<]\L*3ZXE0?=C4<,IJY> P 4GK=@0%;;P.O)XAE30_9MIZ+_T"\=Z<\_3N
MSP[[!/'6]9*K973_6+10Q:_L>^NH7J%A?@!XI)ZKI736GW..:M!95Q*(>&R\
MQ=&1W*F!%!0I.L21'N /T '8MA XV,@JC+U_R7>G- =SW-J@*G<LC_\!(('Z
M14L<O5D>&O;N[0QF)0T'S7OX@(__S2)%WXR!T'/.%$")#&0$X]A'9Y(HDE)9
M<8214UIRM44NAD(/H:@#&<-E\2:D&EO R3<TO-$CNO-@JBIWT2SKUZN/^J'$
MW5MU)0J;^)NAB;+LXS<7?8E&3&,^QTRACK&\(#GY_^ME[MQ <%6@A=QZ5_J[
MK@;Z>CF/_M"Z)K64/WW.N0Y>'!J+/&8WE5*OHZ0K1XD"7[4)V!V;_JM(\PCK
M*2"72+5..V?QBG+BBH>;29>_U\<9G$/TM\78-C23"7FGP-C=R3:P<?GC6SB&
MF9?YWV!LHOO=&5I/+?*,TS+7>_W$PA&S3N3(C9@Y)"V"55Z5:A$OE<[$#$S/
MIST'!R?K,H<)VGR&<3+[F]NG>9)-_.-)<PF0TW[NPM54>#>P6?Q2V<9^@P>"
M[N'O_P-//+KM#5-ES 0Q(6"<7GHL6T!(=M,NC>J5@'@+@6[KH0-0\-)>4;VO
MJ+SGFGKY8$9)=4O%VS=:\@'^W]5MYL%@<-M-#XJ/>6%/+"I2JZM)VBAWESZN
MIE(QR4Q,9=OF=*RE>A3)V/D,]T0=0_N^O'#5;8Q:S C^ 0N$/*)-_5CO'#7+
M ']*M&PG[TIS4#ZH8_WU=8.-*VN6I#U.;7@I^V51%[1VC@:E/8B4O/67P&;F
MQ0\5+V\)_R":+N4*J#(WDXCD"S^)T]$6RCG?PL]%J$S^_U>6Y?\P^O9+$D_J
M=SDZD[O*<I CQ,CY:V+@.)+$BK9G![R>KRZ>TTU<T6@@J)8XKW C.F<BKYD2
MV ?B#2)_*&:1G0.&,F='+9\#AJC7%F4*6O)*CV"PFN;D\#>L#.KR>967P?8&
MHP+K7#!$ =0+' =5Z+8B![8VWBH82XL@.WG6G_& D>;L?'+&X)$IS@=>2&",
MACJWIFF2$P# #""A1D?<N"NIIA EL!D?+\,S+K?X[LZP6NQG--2<GA_!Q=T&
MB;"3>F7$8^0'N1-@<&*I]SK5$S] F@M,GH*.^+J=(\6[.K4FD!*IZ+QJ7A@6
M #@!]#G(E2!Z[CX&.R^R.^MVA=/F>]MO,$=:L\@A%)F#M>_RRF*CF')GW:[$
MXTQ*S)%0GH^:Y.Q<W;I1]%VDL V8(,ZY.H*H059B2ISUOA<Q135-Q@]7JXSO
M/*(O:(*40-Z1-1 .UU4>DB@*DJ;!(#'7.7/!C($-((__A_:5\T[;0=7EX3CV
M]G-556&B)J'HBG2V%&HR]0 1@%%!<B[,_R55![E A3$#R[%<O-PY!/V*(I$R
M9<<$WCR 5H7-)B9)X'J!KWV^"F-S/+6 ;QJ%67B]VM.W+F!AA3XJ,&/$J!BX
M?F;9_T(YH?]9S?K98ZKT+YXO"->>";_IWIWH1 B&X0*D '95,4-%]LR5I91&
MRO=V H^M(D4<"@)"Z [WCCEIFXS(["+X5R9[\W0$/_'C,D5>I^E\.Q.MZ-RJ
MP,]975X!;QW@U+=.8&=6S7G:A_<:ZF+$\=3XV5W5?*\CAOXEUJ1.-K-IL84H
M4ZUC$9$GEOZC*W?N;Q#G=R;KD,WJD-)ZB6%OQ*Y,$#LIJFDN/;D/G\.W9ECF
M")I8E]8UK5T"DK$9W:!H,4.<*Y2\DK9RU],Z)Q0IBQTVIB>-7[YPC'CO5:Y#
M4B+XHD#:.*?5Q0]O>LCMJ[U6HSYG>W-T)V]3]1ZD+ZSGS=:[PE=[(HC)::,>
M]'C_R9ZZ&Y>PK0'7R*7']>\*(; T6QS_,J%R?[2)=:&@S![28[Y(!1,S0ZG#
M1WBR%!\HGL3GJ?@>U&;OJEZ-WK&$MKD;-<^5C#>(VTR33DRSA".\H^[%SF&)
M?>0+GQ\71(MX;?/B3L;K;T9=F@E^%85E,,P:1-ZJPIT[4L \9"??24]^]A2@
M']6Q>9E>]J[*\\5G/O8LUV!@K_?F]+ ;K90>I_NS[F!ERTG0R'K)W+6UE'IU
MP0^7]+X\<YGRKJ+21A2-5-?$/E@_69D!I.&O&ELKR-7N\OXI]SMO4[@8RHK
M=N,H;24O)97>FL!I_]H.&:)!9"1U5^Y4U#EWB,J9P>C2R\S\==!E>A_2^=#\
MB^@,+AP\Q9YLP^8F4\@5<%T,8Y,^E2"Y#I "<O\7YMH;/UUR*&VUBJ"8XFUR
MR2<ECT&"_9L'Z]+Q+!>D#M429_4?5]F8D;6'?Z$V?1NO1""#1-FW4E67]! 7
MRWR=SS> 72"<J>&J0EB*G:R#(EV\@O]"NO@7='Z27DEA%"]&&1E9!2T@%)"1
ME3E"!4";ROP7:F21N+-GDFHZ_Z"SO/F-SK)_X:C\!V?P^IV._A]02P,$%
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M^S^X4 "H*/^G_#_B(OR'ZP4:&BH:YG]PH;SP^X\"(1HZ(S\&D;0VIJ4',9-
M.!:)3&)!_7=L9D&="U(KSVD<,A:A3=;+_T#['\C^WP'[^/\+V?\&]G_A6@;@
MHJ+\"QXJ(> =8&5.F-9HVWR^!RE,D<0U;"T'W4T%83#@OH)\=A66I;2NA?3L
M/X4LI^UZ53G9/Q7JQC\&%GX8),/P,F*>+E' QVYB-CL*LW%J;S%_^ -I+#59
M7UMG$?P58:#GBF(\0(.4ND:D2^[!/Q=_M$W$'LF!PJG_&B6#ZU=&K7VH+?PC
M3![=-'^!!&0]=N/?F"_XW:\%*CWI@2#'P2[4!0\]#^F= M2W]H#?R..D%8*Z
MFV4D6TE49J@?+[4Y\D?X,'E4;5<DG]W++:#_]D>IU= ?7YOFK8Q'';2C4%;W
M'W"FH5MO,W/>KENITW<D3U.J?")>+!426_*4E*_U&7P,R;\H+YT^TXO1)#A>
MI&LI>^3R4;#N 5Z]3G>4C(.D6 ;'W+EW#4IY9]>U/0,^19NRU_UQ? ;@E".S
M8-9[2,0>^U?RXI /^KI-V[Y2&>6\7G4O0JS\2U/>..$IY)Z.Q%GR^(B,2G56
M#72&?[-R3+N$O"D/SC,G<*(6#!OU[T%6_^V0J##$25[T*RN).LXH8:?&,,#?
M:[KS?G"S*M%(K;7FW9H%??3#[*,:3),Z_VU,_&O.\:[S"92UU]E=<_M-PL.4
M>X6%W?UX 5H0SZO /WC?";&F<G$B1J<0KL^6]-,JS/^E)#P^.1VR&!@X3[1<
MFP5R6FY\?<:[W&3W_IIV)_.5>0GHRH@Z]["GFEDARYA*(87'#D'Y#" &1RE0
MW=708BBXKF T8%14-Q7R5Q\%L,??M#P#J(ZV>.X"R+SI3^Y8P#Q5![9>M# +
M[Z&=N7+I[D_C U0'1J!Y,O0 GU.+QE#?R["O>/+Q5'N-\>;-"(>WYSS)N\S,
M84%Z#A$"2?Z,]3H%&,V,"B*+8;S%QO0KRX-/&,(<QK?'M<?O?E',6Q 88Q1E
M^TJ9.0:)MM1YRGT.61U[OW";]^[P$H[_QWC>Y8Q.%#$.JLSYL."6OV\\]$=6
M9$H$EFPBUTC=T<9JB^IECUHBKZ0@P5CIT59$UE8[]I.WL0+]]JWFDW"UBQ]<
MK;BYLW('?\'%()$&( $N"6>R9<ZYA"T E?[$K7PJ()TR],&SDMPVF?>_[0B]
MK!1PRCJB"76!F/\B>09L&Z<3ODE#H;V<J7.MGM@.#P,Z20(-YHTAD<,$IJ'&
M;@^Q1_]33_-I%7G]#&#LU'P&O/CY"(F;CU^KB.S(6A\JT0!^V3=#1C\.W+Y[
M?!EZ6>P2:HSY)!N8_H3^[A?2SH^**I^31R?>6LUI>?.P^G^]5LGGU)_^ >]_
MW1E>BN&=RL6]W(O3<_<N6&Q?9UJ0?@8D((N> >&:3T+P+5KW9\"8F\XSH*?L
M7]P*PH*\- W&<;CJI2: 7[;-D).F;CKT=S?_+*GXK'DUMU30_PG\A_0C=U:J
MMGZ+T(-6D.@=^S\ OT-=(8;/@-K_&#$_'7>COZ*:>P9<\#P#!N I>/..!2IY
M"O(TY>E8::'-MVO%L6XZ$Z+/ )5_IHKZVI].:.VU_]<.,JUO2(V,+<P]XYH>
MK!?S#))"?ZC6VC_)&L7_!_0,/=%Q3^C0_]8NM?S.&LE?-#F3SQU$.DS7/[T5
M&_04(?X_=.<.MWA<6EV<="?_!O]SEPP;_O0H57H + >6;Q1-.OTJ"1B;?WIJ
M@.\SKOL_'2]R25;S;D^LXAFP8?P,B+62J <^I0SHOTQ. !YHF<HN]:U^Z3,:
M2SJE6B^)Z[Z\^T_H7+Q,UR*1"*9WQX?_D-:[Z$,R7X6@J]6,+!G5&$2S!%$S
M&RR(1/W;P^#?X.Y?R#[!GZHO5'S^6F#07_^:'U643"8)>V$8A\%5'D7R<8EI
M8H]6LZ*T@.R.R3WNTX@PFZ1_A/[*,\ \5CT1@35@W$?5)?@,>.>B7:A*\GTZ
M:NR*<[6^*I%P7MVXC&0L2SG5R%3.>\$G_Q$74L&Z5X\;$=)6^6!S2^[V)&S!
MU2=RMA:762FX+A;*NL65M^:E3Z45C"?&I Y$-B6]2:V!5%/?L)W^PU!=!($3
M!MR>FM#UF"($-:$>5]]".S 9L^!FI@'I/!2A*30>B@T1'YK94]_:*+.>E28^
MY*\$]NCXCV][@58,Y[TBD;=N _\Q5#+W75&KC*/)JE$#R.6@73I_0E.^@/@V
M7R8J?@?/E^\(S-O;NYM7S-SB,>$_O6L6:@<Q49ONX(V/6YH+ E=A??G9G3)%
MV.K%33(-;25_:WW'R(!^1G;LJ']Y*HT[97Y/OW<),G#4O'@YL-5096-P!E:0
M63Q 5_6R[[)+97TPV=^?W%6?*LVM(I/)-3?A'&M'5C2%SOYS9JSBW[;JT"FW
M?S'O^4^E:G&&H]FR]^B([PMK! G'4MEDB<3DIV-FA8SD6S3P&D ".U=/B8^-
M6E#%C <+U<VUC--C??X:5,)LUEK8X)_!@YJLKW[+]3X]D&95)&>I?*+N_#@T
MXV)OB"]SG%5@]O/PWQGK7A&?_(MQJ_F?$UP9, *+4PPU:G.D\6RFL<"_U8B5
M<!8F$?.)M<CSZ=0*7?G/#@-#(\[/SC[PV//T]R6K?.BQ23BSCK80T#1##YA]
MZ:WU(AH3!CV7)'X&,,6F_YEY!AP,U'"K624UU/,8;-M;" <[TW4OZ^8_!E:N
M[H^.Y#6U>))>DC5T4%3,L0_38HXYVE)0WI!.Q-M%-6T?V&=X8IPA2*9Y18<J
MEKH"$]YCO6)?.P%"[L1UZF46)J,VS4BYI8=1.PVR)*)RBPT6&<4& O7Z,0MY
MY^\JWEO>=Z>J)N3>UZ-_Z])Z-1TI\4=!EAU? 8@'+(S3CJ*X)U5PD3+8?44=
M\.5P:D8I:E8<_HXP8PH#UG8>T>^XZ%3Z^]8J@UNZZY!^: &K?O7MB WVJ6YP
M@856-:]F15&>XX&:I8J^.B30(YERGVO*JJ#UDS(%/I;U!,JIB6E:\Y0\-<O@
M[A"SL*VDGN="]B?IS</$[[^1JX<L$P&6):%>ND5I9$1$6,R_-.\AK_>8= G0
MT/\,E _#^Z"UK#_0);>%&G_*(/>M(UI]2!N2( ,FL4:[V5]B7")&F9.*ODYX
M:=@9DMK$4]-*CWNJLSW$L"1G'7A/MPN;_)W6'&N? S$'?6K^ 1906/2EV*\H
MC@)0YJ:GT 1#;NHM!OYB 2%B $7V7P;:I[15GM?-53K>=LDLM\=J<4O,%LSO
M*X&<O?B.!(^+)&W?.W&NQQ:76S&__M91Z-!-SKDO5:5[4!S_J+FO0FQAY_7C
M.D*_\/V,4C@+2Q[6]P.G]$MJD\-EZ)K1)(NJZ#"._RJP@O>;<N /]<\DUAXX
M[X?[+<=]A,Z[]A13X^_C54:*9Q?GY4L=G@$_Y,M-ECN_E>!?1C"8"(-CG+=G
M*HHC0MYOU50,H8$@]U1@;BX")R<U6-OU*ZQ<)RQAHY9.?T%$?6*$X9Q."E7<
M5HJKC\ZI1 ":L-T1?V7IT^!L)SC8UH@4[15?D(?A/?FIQ.,@Q6%<:F]4K]ZG
MA[R8B3Z=%DD]OXKI#]\[A.*QF2/,/CM$>D 5ME)*UV]^X+_FW'(]X3AJVYFU
MCJD?AB?VKLZ^3,0:/M1E>_]=F U 2LSW%4R:$7<S^39/7>X$@K</=(Q9G[52
MS12IE\2=7VCXDK-C@31+]$Y4OTX@@=FUT-G@4-# ;.@&OHWIJ4R5M]%%!9WI
M.PFMBWCD&Y4%H[3@# +H ^ON(\0P*:K4=>Z#!WZLD4./"G .>?W*_O$4&CM-
M+4=!0EHN[N%)(VTN9I\:.*FUFB(1[7K3.:?DV02DTB0:E<&NE'WJPJ$.M9C7
M74KW6&\OK(!Z5#PO#!1)F1\.]OLDG?0:$7X CL6-D% I/]2P>9%W'<8IL&XQ
MX8#F=.CF?)'Z"2W[5^,<,K8[@S+MO8:8[K&)TYD^;I7TB71-46^#V=K[<PG7
MSQHDB<.W<)UZP7C.-CBA@,]6&28]1\]-*0U7&.:+/.8-A,B8H=&FM F7B*9/
MV>)R(=ZNP.*?R5&0I]RTJT7?6=FR#<>$.Z:P>E [WJ,XZ;FP<%@BXO.I@9VG
MJ@B 9?;V981P+XVE?KC6RD-0M[][:1/,I=X#+/]++5W$^16K.%6I.W9UIY3H
MA\+$5HEHFFLMUA3I.*T<NM(:P<8ZV.(9>TP\QZ+%!>=> <XXFI]2MFKP[8UP
M<7U?C)2\^8_R(T&NRL*\W/>E)>,\! 8C<5[$WEO5H8Z?&*ILZFXE]13,L]%T
M8GJ.C0R!_=8Z[X7Q^.WYN3TQOC-XDSSP;)M*O=Y2VWH_&*<NCU%8/[BCE/D)
M1O0NU[PA:RPL<3SM -7#0.62;("W+MN'[5X+THZ?ZJ7-!3RN>Z)/"=KZ"J5D
M"XX1]U0^0'>B9:H14F%"><FW@5.[UR:*&;$(;A+YPD(MN3%(6]ERIUJ<R5O(
M/Y>5J0S$&'*>RUZ<L_])>AB"_0Q(5!C]>QAZ8ZV/2KN6PGDY@-VS&QUX_NV_
M5UG3&R;C'."<_.V:PW7\Z;^G;CAK68J3WG%.I=3>U;2W/70WV3\#IBJ;?#-=
MKBXZP\]-$F=UEWL/5:0^B2#W--?K'H)0UZN",X;^%#,[''"<C<=6] OZ1V+[
M[D6=N041;9)_+5]2I9EWY!U$";HO[YK:+_(^?9^5S'/"&3C;A= \Y<:BK !O
M<^7-4;8VB:NW/40I5NMF:WZT0_L6L2AL>*W]4"K:@QZH*^ALXXM$_O05&/Q;
ME*5\CK6I,,71H-1CPS=9HH?;F";;JZ63)?>6W#@C05V9K(A/JTVT.(@YCE.0
M$':%4()7G!D9/^BUN$QNFXID5LKOG N@H]:H>P(KC67R(?%CHN][A<L$97)?
M#T,"]>96JI4U6B<@Q;J9I_/U)]*5BB#^/HVUWGK:2/V.^3$1)JTB#PN L(L1
M%9UGF:VU=)DFSVIN933ZO^HT+RS?T,Q!'-6:78 IH5AMO7:L3ZXMA":7V&):
M5&U[:CTTN*\=Y&SB>"]4?9N='9J:H9*_YMH=7G'^X7V#49/'P)]5RR]TJ5"4
M"N:8NK46H;G,J@*\$?I.(ENKGW%]NGN&9QA4I-)QX4Y&7(J6R5=0_1B&;?;U
MXO&.#)DE0G<_UWM23K8Y>,-P_"9]JIR-['VJ@W2%N9!=V1_QU@=JQQO)6;RF
M+Q.HH1V@2,^.>C@8?.HUZEYT6^YO_9'?F"KP0Q'L#82:)*-TWLHL5P*$KN Q
MI5=UXEET=O,[J^I@G'TTQZ_*44^//&.?'&^(BN5=OYK(X^T07 'W?@\>D$WO
M*%QL%$1T!B3@D:S3[JDL-;RG3P?0M14SKNS9,P3B%";<)\;*F.?@-_TJS-I]
M+&=*T@>2DM3#:[\ZD1WO#9>LH:&*70V7N+M07@&(DZ^I*@-G=YU'%#0VW*5I
M7V-=*Q$)V7M-@VSR?]1PJ88ECFC-[\ZQ<-2U<1VJ?'A;'?/86V)Z<IS/C?0:
M9.'5FT^,UK/\R''5GS1C!]4PB7-BU[%[FG+^NXK7K3+[!_U$Y-"+IVD8==L9
MUJJ;ER$LJTO?"7L&-(+4$9P8YRHF60YPD>7@TR.)Y65U@<'[)8*$;J//)$/;
MSE3=:-G?S>:SJ$GKG8J/&OH:^LM6&_A&&@:4F/(^-;$DG:CA%,\F!%1+Y!(;
M3(Z6KN7$/^PX\9Z-7/75+I_:182N79/ _G(X>BIDJM+L%4.MRO)2B?IC>EO6
MA*P]'C0P.]&9@GO>,3.+]?N*VY6AW158FI9@4+T[6R!M4'-'^:WWE_>AZ6%4
M&56\;MEC3K<=)V%/T3ZWE[F34ZE7\O+ ,>'ICF$$]O7.%4^HES]][T$K!.&G
M@#,I,\2D&U8&_,N1U!K&-WB1H^=8"T:R*5U=T94V3N^F>7!8U8CST^@-D*-C
MZ'=\6GV;2XD)E-=-6O:6' C%66S_XE.D-O)17O)$% W\-E^@63;Q-&O>H-YE
M.WT"3)U2,20\UWW.1,QP)*!88K6(Z.\-6UPYALZVIE9;Z\77ZC@D=2B[<CD5
M$$N="69-M$NI;<0)#L&GU^1._QR$/0,<.81?$K.V^G=YBM&KE#YXVTI05NWY
MK8ZG 0]GV.@!ON56'S4E,< F0>"Z!E&B&DUZ/J&Y1!%!I64QDB_C#E_T$S;*
M:(<KBF:V =<=4E&?E1GL!*60&\@QE2)U7U3T* TN@1U9-V9F7@,Z)Y49O:0%
M6G*2DCJ8&.^.PG(^C^K=Y[T8;)K$E?5JDZ6>TPYWC&ST@A78CCT4?FLMRSRS
MGT8PRH2WNG%7JW:A^0@5,3]7?0844;52=TX91DTR6%#]WRHIKMEPYMCV6;K+
M7;U ? YDMB:X43MLQKWO2=A_&;@VT%3!]-74;#-.T4P>W*;K0CB\%M=:HY"W
M7Q_I5T*BGP5JT= 4CO0+3I?<L<LN-SNS0V6KI]VQ3A*M$"^BIK8ZR6@ 3*K-
MGNZ@]U@%G(,V\>Z$UOF4-P+G,ZI=,QX3W^ZJS1OU9Q*FQDP$'R9V8*[,^947
MI_E_CEV,6-6S9D;M!^D21T5!TQ2&F0^SFI->]=Q5"2>VV,POFFPSS)=GM#N>
M.8PZLYJ4&4'Q^#+?TG=F)2'=<G"6V=ZQ*FU^/C6<#YF0')2L>,N2J'AR2(^+
M<BML=C0O8N,-GQR4\,B[53E2PRNJJ%$1YE0)S%+)L6KB6Z58O2?Q'5>[Z%#2
MF!U7XC%V$&46/F#3NZ&FG?_1'^D</BM4J,R+Y4C3TF*I9+6()Y.$]3NOZ<QS
MKGE'XTL:ZJX%A. $7U!G+,_I(7$__QN"F^P/N5?BN(HZ83L+(F:HMU:XE-D@
M?9>2:T "'+C.HHX0O85;V;;*?I2U+JOVLFI[")XY-,Y>)RU.+.;4'(9128<5
MOV7 YS_44N6+L6QSO=6NS8C]F@#DX@1QJJ[OU7OEA)!$KT7J#G")9>?@Y"D&
MB &/,"+K6Z$W3%55ME]W,\,WY@[%2#4=3SCEB;X.R2C.9.2H#G-*P,K9%T@+
M"+6R6\(P(3U_="H>DC&7:XU^#HZTK &]M-_RZKN,Y>C=OFGA;PY@+Q Z*$'A
M;^$6GW,=;:&.FIV $/N1*,;)NVO'JOXI4]?'0+!9J=J$@\ZX4[KV4F!W+_+O
M%B\\].PZ5CVY:B(YI)M_9X*R<I/D^AA0LQJM[98C=T1\MP75OH.H1HG_+.A?
MG":94QB?#>C1U"Z03MWH"R8UM"V9FQZ&OO(>^MJ$,*S=,TD*;('SW]S5F+V#
M&LV8!"1).[&([?&5:.YK^]^!W2A6BS-_#(0K-G.E)J' PK]7Q K-+T$_(I;J
MMW*-!ON64ZNR7+/O'%==$B[;]8&8-"%2MZN*;B4?1*>8VK-632#)>&U/;,Z>
M*">%K>^P9>*W.H5$'^1ZKH_$]=4OWTMFG1:V8#4_F/\YF+]:*_>F.U4L4'O4
M69#K<ELZE:QZ!L"70_.<W@[0O9Y]5'9ROCC,DS_8<XP3#\3UH3?J3261CX 6
M:FSW.YX4YDX7?G+S#NS^K/\.YR;Q(.T9\!L]0*2D;PA(U.G5E_/AS8RB9_/V
M,X"FEF7.PK<=5[ I?J2QK%AMP]'_7:]]/]7WIK?8:/RUF5S$UZ23%_%&=[%L
MZE2T L\ U6F]#_#7(T.C4_68W5Z#;-\XQ_'JUN.&?@V -A9*'H48FW*=7YW%
M_T6'BV<=J=W.76%W&>:$-H7F^E&9]^5Z]FI^'&%%\,N$DS39B]+'NB]4#DOL
M/ ,(G[P3E"?9H?,L]V\4VT[,*"_+8C[(5JTL<RY7&?X4Q(K'$K]_?$>U'\+M
M]+G<_R-0BHB2FR3ZW6E>T<56^[N7?5VO+O"0G>Y?35=+#U+;MW]A;B\<FKT5
MNM*43![9W4G]TD$\ES7..NYM7W)#OT_V([GG5)<YK%,#DG!;H7TLJ]2HPCX$
M]W#U!6FIO@6 G=\8__Z@P'+]ZJ?EX!^FHK2S@<?'RGUINR<Y_N\LD3FX=C7#
M4?&NCS06^N](XI+=S(PI]IH*6@6&8A19D!-4#IXCR=W\U$OMNY]7!;6'G@P6
M2<ZJ.6@M94YZW3KU'$^O*)Q_[]5DVPYX!A42O_S&7>PN#VJN@SK>#5/V' $A
MFYT?M@2BI_3@ E>\AR\^:E*0%K7KL^DTS!-86K1:%-%XTU9RE#QX*F(BJU8?
M%"S&$^05)1V%K-VT-=ZT;N\I.KX8>P9XH],D@^WTB9X.Z)UU%G]TV]FZRQ)/
M3H%^@!B*;5SI>U=!(VX9GY6O':3?Y)+6>Z(JK\1!RE:6J<WY>\ET(Q*'RUUK
M>*F.'=CCYDS/TM;%@/@4J*"TK+2OMJM';_59:O[&:,K#VTEJ>&'..SL>R=I8
M"_#7CQ6$:1QZVP"^?UT14?7&;O1W9^7?8B5WTFCAO'18=]MG >6>ZL\Z0)T5
MYL_DM4*CH);FQ$(0G9W4Y1'$FDNAC^74FM^R+35#R*5E@=3US0UH=7(68=3:
MZ62CY3ZV%@V93-:^IA8P*AB4@3QD&Z74+F;K)HP6545T0&_>H#T#AHILGVZZ
M?_/#Q]DRSWHV.&O7Y _-TC?R'TB<N]?3GP$*PAY6L\J4XT8#> 5N+4Y?O9_F
M6Y^L&GVLC.:7141I_8__,3LNT^/^#D@+30A3HX]RU&DQ71#.H(_U_ ^)[\PP
M'\%6@P%UN;NQ)&<?AKAOX+M\1_*[3,\#<K%__-QU[-WR%=_KRW.*57_F8X,5
M8SJHOFWMR\/$(_)8EE\<%!M41ZX%2BXE%N'Z- 3\!L>,<6LZ'*=R?I2Q?3BJ
MN'<85;Q9:=DJ93E69I+WW![*F<I''EE?TMKM6&CRYI62(*9Z6U&7,_QQ@:@Y
M>@ZK+1]"2*M,$QL"B2NVLP+)= <@?>"V3Q*)R=JIO1;>E7K$B]%6I]]:O[OB
M.0C_,EB@521-WWW\.DN14"940@H<RT\,N$5+V/TL]6U6K;XQG8B&;A!ATU$#
MQ--(9OA">ZB\.#%,/OX#7<(<[WRF4MF+^QMSOC-(C,6J#*N>[>3#V@&QC8#(
MD)+?ZM^AJCN_]\9BI*YJHPRH)40K6[PI(M:O4S?:T!X',86Y[^4N\'07VX[7
MRPS4JO E]"A.1O[DBYWK]KN/KM=*Y9 ",-DIA;5/,S55M).2VH6NK(3&_AY>
M?/4M]ST]XG1@ ;FI%+0N41,:P >PZ54^[C%2G0PH5FMDP50QQK<];BL;5\MI
ME/ #9P21.VEW#!O;/LZL3:H !:VJ^?&2QP//ZE^$.L"_<_U^*OZ'4#C)UA)9
MO4V=B@PL:*N^)<45S\E<XXI^O<TZ[C9A.\N1V'7GQV[]W,RYW;G6:S@.L'(&
M+1)M>KBD7QDW: =P(9'E:!)$<'9J]$0U9S.#.#;>0?]6]I ^KXEY(YPV'97[
MT;,0T13$EA>"]1 @5L).4;I;G[-;<"C%?_']DD7+25R")=FYMS04^<8Y"+I=
M=-'5PH7UKM&>R![3O8<^UME@W>Q0,+2ORQ?&_Y 8M>OV ?RIZPTRB_*%I(HB
M]6/[1IQ(;E7F1$Y2_>3/7[[W/_33R),T<9/(B-!E1Q*\XCW.34L[2^2WU8F6
MGP&:WG] UHP&3P[!>.ZZB/';49.UL6N5P$::6<9Y83RR[?'9?8>,O[M'U;>D
M!Y[-R9H@H%FG2DL>V4+_4*0W/&E\X,7EPTW%K1O:SP,JO:Z"("&)8I?J%_F9
MFK>/7-[^?\S]-2>=8^.H1R8/LW9K:\\1$E%M<S5YFX,O\R(6\>>> 0%!0UV.
M/D!J\Z;VKE]N)?WVJ..\_Q8H&9R/37#SJ)&/M0_H)HWX$;9.AK]6^D32/(S[
M>5JA+%B9T3DHX>NY[_K,"?I1A_=6/A2].WKW^Q:J8\3,Z@6#C;..&@?G:8KR
MZU)5\"3.6>B7/HHA6EMF;A-YFJ;)M)N4*75"P(=95\=N).N&3M$&+5?]FW8?
M&FP]U_P?G9P?C2ZU_S0LAVZ\>P:8I12Q54%3E\5RS2;.<$<]'"4Y3<)F%$9>
M;<F;7BB$/3%?\B R=>^\I9QW?*6?@!R_SV,1/XD->?)*6#MD:FBP-I<]@=<Z
M_DY]5+51R-"3;1QJF)M]C*#'09!>":\Y'W+0\?*-'CGYU*'("3JB\'&D\ZUU
MV<:[W #F%]BHR'9EHZ!/>0$YWQILDC19\A"?[DZZ57RUP7*=6*0QY] T$;P5
MC&R8>T!9)>R"__TL;P^&] 2_\=VZ<UV-HM&^];AY5  (T,!W\[WPL72U1E6V
MM#F"WO_I18W12D8+'[W8!M@EM:G(:5BH>D!I MT!N%6^D= [TZ3>9/=04CBG
MNKB?.O^"-LROLMLB.XF<?0:Q$7QG6<R2<YG76M#PBI8SY:.P32K,GR?7GLXJ
M=;#::9+)T'@@,$&T_&X7FN>E=_NZ.,F'O@< T U<PGNZ4MG)B-LYG\ ^!>-:
M4;P, KONAM5HAGQLVN=$GM!L4OB0:*KB%!LY>K,VCRI4O3\W$'S(=_%LNT;U
M@"*;0UD]Z;UMO)G1=-]'GPJHQ+6A)N>EI,4V6#RPG('SEFH(31*I21_BQ$J-
MA!C-YL((?+R.=;H*W!A%K3P&(%6"*Y2Y9)(<.UT!PH4="M W:6/5H30)JHBN
MPUVE<VUYYZL*MW8)XO7V"!I/8T_2 0%LT@G3(<,[U*LX#@7]#NLR*5LK%S&V
MJ%O%BSJ&Q"GD1_O3FAU 9=@+Q< R"$X*<XMP@2@O='CHKHS53JZ+F1E$T3FQ
M:BL]60T:)"TI9[O&H3E#S0F::L;]1 ;XBR?DD*4]!UTBM)'OX0Z,5[EY]U\;
M420B2K2,,?4^#]8+/?OO(Y")<6<<I/IM0:QU:KYYB$HL>#O\EC2B8GUH6IE3
MCF"@]Z_%T:L2UT4ELC]F"IB.\[SO,FHD#%6S51<0CCM)N.<PL0F4*NHF36-T
MZN^D<K )@SSE8_#+5,05M!QMA\8+)'LJ">IR$C-(1U_Y>E,UJ=Q!BVO%_[7O
M*,!0ZH(F0K/C4M)C.;;5=P _:$'@R5-A.F"\*>^]I!Y9^'5$#FAQ_'L#=9OZ
MVDDR>H]U'J<<(SEJ?J![!&J)<$)DJ81!+F\\((_3-H%P0-V&WQ;H +TRR-X5
M*VD>\%14=6-2*O#S!%;8F!"\QWWE8>BN84=GXV](7DY[K$#=_S*I%=@/LO>V
M6J']FTL3NX</E.=;BED)_SV7[X*:XU,Z[$^I@2?([LFF33F:P'^L_:WZ+8 6
MH1*P$\ WN O76F5Z,^$AZX(-5"7X 1BN;&G@DY#U4!6^D&17*9<<7H'$CNM3
M_ 0[Z#M'& 5^< LSA]V4]EM5RJIM/ ,:$,XJE?[P9%/\@"-'K/M3KT<N:*2>
MN;NS_5>*LI6QFFB/#9S8AJJ??)B4%.=FIHHGD* .JEFS&:HS6=8&^P3.%&1]
MO%M!-;9)RL.DL!*<?]SOA\FTCF"'QECIM/PB_4 "Y^LA4H<?0?-^VCEZI2_L
MV84V_E +$^/2IR<J]40>ZWFLNO2>6T'@/A64E8+'H!BK\ '(?.5#/,S^6*M/
MH"JX$IGS*JO/$V37!)W+3A0_24V?FL]61O.TC28E2A3>'\/'WB>U/QFE)O,:
MM-2XL_*<BF/YR=+@LG&!J"]2;-A4S0$'?E@312UQD$%3;LUIN8#=5G$AALY.
MK&:3&]X:_ACSO9+9\$!6!G2+4'HD7W-(XL#QOTXSLBJ<!")#"OP-/Z.%.0T6
M1>[G<P;B:*6\5:AHCV--)L*-^#?W$5UKISEB/X2B@![OG<\D=0L)&ZU9\DL"
MF_CJ"Q_2=DJ5::X2KVG>7%>K\XJDA?*5<Q91W%1E-I3%?:Q:-!/B20@I0C95
ME8B[\/0M38WC9%R&B4W.U-W&2'90_CI"5-PM+O,][-,@@U<WY^,$Q"T6\'&$
M+9;3>EV\17,C1-?BRRN(<)\!!-5X"DN6FDT*978AMC>5VA/8/?2I@0XO^8P
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MA!_*8#77D=?;<X-KN(7++OCQ:,P3U>,Z>,;IZVQ3>>T92WA=%<KW^U+537M
M911XD/)</D&DQG9RMY*HL_(+3=RW.<%O"4.78KL:6.62 Z[HCE@']JQ?']@8
M*[)'Z0+@ONTV"QK8U/H=5,G:45CV!++3&-BWPE6.':89/"-3TCS?F80GQ//"
MP$TBQVB<)5%GU7$WHS97F]BS;?="6]B2J,I'3J.>8M3<'C.%N%\?U[AD@"*.
M^B&KKXRJ?2!UM>Q91D0SZ'-,GSZD#,Z'#9!Z8F B[$:ZHBKYQ"J\"^\5>'F<
MQSF$14)>[>M\YTMX,29OC;M7JDSACEWID%+EPD?Q9_^ZG(+M9(>JO)J1]@@T
MX"[/2I3(U4U!:AI17_T%^.Z4^\7-63#G_9T(24)/?HE<Y>RG-IM;P90DL=#&
M^E.E"X&XU(650\(Z_80</XK2R:)^ ?K7)VY>_:H#.K V8\%]L6PGOR1V!F]2
MGI@EU"'%,6.W3?T6GA+X .:Y@'1EVM$X';Y'UAFXP<%DX:7<2^8NL0J;HY<W
M]X6"-!@*OBC_DF&YWKXC[6G;<T<!G]3AB$."JL*'6KW>AH(.48 WIMN=4B81
M] R(M%!\R0TU"$F59-UNLVJC0>I93I(364M(9,](=P8?Y8Y]H.VC 4VO!GQ]
MC?<MSW'V->@[:M;NCRDXI6DUGA,(5E3PF>'[=HFR4[Y 50;)3EXJFJCR'?2&
MI2K.8S;M9[R1M[O8KKR$99ISF%*U* .K.SJO0[]I))0S"742%9FC<OK=&0EK
MMD49FN 2VTQ2EM-6,%S<U%-0K@HN3"MO+3:NFV:?3Y+&>9-\;[KC_+K2+P2]
M\Q_M":1EBWX7H.%AVN2;3N6;:>L<QL6PNGC8>EM=RZ2OEV9!)Q&YPE2^0759
MECFG9P3]IG_KA; D+BT+-MPW D<+KQ[B,.!J* -) K-N.J5&-1L;5.5;?2RD
M[&^E$#G+SE*T=7X_VP.4AV_,YC_F,3GDR<E4=T>TVK7QMV;.I[93;=:-0"Y]
M[?58YW[[3,'J+7]*PE\99>T6_>$:=<)Y'$V*_J597NF;SK]ZF(B=\@WJSUQ.
MOVGD(4]S,6!IN<=LC[;-/--*.ML@E/MUUDFOV\Z#"-)HHKD[-%B#A8EZ5?.9
MN^K,N6LTZ*6F:XA%/];W6U+:\9*X6 _A&8%1+V9;/WSFWZ^,E'QV^.L#2J\E
M_.A3";^QC@=)[>OIGVY"/*:V;Y\!.*9+ZZ]GMM/.D-HIMI1<)S^WM:4W3%7T
M\+Q\7)P'?V%S]QY#SS=:H4=K^ZO6'$]U'#V6QR"W;S()#-"!-]SXM2TL"R5_
M*_0371Y:KD0+(I+3.9\!4:*FFC]^Y\5CM[VBN:A=]X_GNL5H4"C@C&_'\\,$
M^7T\VSK-+"+D<_G9G]A3*[$J7:N+$E-AEITR7V4?4UBAFG;/EG5D>,$BAOIU
MD+31I;Q B304^784YETE%-CAPCG(V85)NER3.\;JR&5PD'<D^QH$Y#P:4S8)
M,[@]-4A<E^WPU0A)#123'YR(+M.$+&327*FLD"_+O,(H_MS<?!(,*:0W@VB^
MM?^ENW<@NSSPE;$KJBB+Y>KJ_5:A:LH$-F6I.I>*3$3D&83TS"JYC9@I"B^!
M__><EX(KX/M*2VX>@I\3 ["/+/K\0TDO*! YHG#8.94&F7Z;$/Z10$.SVG[=
M5/TNCJ)"%KJD3$"S\42JJM6LJ)^KESHTA/'ER%2,-]0_:OERCYN2@(^&0*S"
M93-1%S7-.@^2^I&L];B'!MD$LZ)G][BO3)ZJ_"R_S*3J,*%YCH7F72H/ -NH
MP7!=;\NP=UPI7I67&$+I7;?22O53JP1/1KJ]K\]-\S^&[F@W_,MX\[\4\T."
M&";0X\?_3O]E79@Y.A8W;\78D[;-FJ"^8;0J?JO1:+EK4CE@X9Q:8#/+NTY9
M1.>Q:E\:L3)98RB*"_)W9T_"JS,BL4<N:E4/JE9/+_; ?3]@%;'9L$$CFX9[
MH$[$GZYOOT$"_#]G21;2K=P]SI6.&?.V*77$*M7Y,87V67\"Y<&I#>[BNIP[
M>1[6JEUP_*:"MKUJ1I/31U9Q1;29YNG&TJ"L;/T.0E-LZ;56KU,3EY+5NEVM
M!,%D_;R+L2^=;:?:+FKMZ2ZW'#QGCP=Q^%Y&@P-Y)O9CGP2W/TKH\REI!8SK
M^:Q"'G2Q^P4Z_PXNN^YDX+J)P:E$/ZW2-Q$VX=\21LS951LO;^R3%@<CO2;
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M>[&3!QN*+RLDTK^!>J%?_<A;Z^0(4/6*&->70**VI#-]2?9=+R1=H6=Y38?
MG)QX"KN$?A2S=<09Z=OPQ-,)5F].;-R['6>7(+4SS?.#H5);_W/?J__:$'8Q
MS@RIQ:B#N>;_>U,PFFF7TP/73Q0GPG\EVE.VB,=.7!X)FG KIZ-(XX@'X2PC
MS:[_Z!M^-HS,ANCNX$>V^#WRZUFV?,=5+G<]N.-SY%1.Z/"*U#%&5F:LFXY)
MXR"JIC$IUNK\4"O@G/58=R[4(:F8^F^MT[Q3K7E)3B8$];".G"JS!C@2"L7T
M@-$J?9VS=LT\J2.A_MZ5\1E>S*(V-#/;.5-O\0O#.V::7A:,]&N2W*R:=_+I
M:VX:N+R<N%>)WNU9>Y2Z?:,N=S/7]]!* =<R:HHN4>=4] C9(OQ3YX[H<+'?
MD<_!^QLIKS)50N=(<,[ND%(P_;$\R95\RD?8_D3;FB-.M-\PP""5YE7&5C;1
MGNS5X\XIQ;D)B4<JIUZ+C),6S/%:U4O<V-?W:@  =!(QY4^XJ9E840.E?-L1
M&WQYJ#OL\J)\C8I T<0;#L^<UMF-ZXK&6]H7-!+(N]6>BT,L'34WRQ!=JH1'
M7^Q7>Y([5^YPK#JU1\J#):<?56!#<GO"7 B5O(%*9='#QDN,8G_;%#) XJF>
M361R>?6#VK^D,*%K(X5P^XI577&@O/8LCI"1T:EOX%"W9ST._XBJFW4[]".L
MZU:9*DC.T)-D(T%P"F3F8/Y-[!2T-"S&DGRLW9BW+W1BR]$,*1F3/;>AAZ2?
M,L0G-AI4#M08&HX'L1$01)R_L]24<1W]+'&.4\8=A(\H3EP5?\47.:@^*/2+
MQQ*A7L\.7+P5^I349]?H>6+.L!/U>D"9-]CQG7MMQ[",IJ> 8Q'-V5ZJNU'I
MR8?B+OM2P!W)@A=L+S7$6B.)J?=%6+V*<HRD[G8[@\]>L8.<T]#P;65-6 X4
MT\:(/#9O+_>N$5INETRQBCFE4Q7=-MG\NLXS>8C5$R=/JDD>-W) Z9V*12Z)
M=UEQ6Z+RAK8E,%9/I[(2]$3J.B,7V3*T.,@0B#1I<<  W1P:SASA=82;0*.!
MJTVMZAV>19Z_=S2PT/81ZL4#%RJL7 GB?_Z T7-F5M6D=)OT#=VN%."S;>4U
MVRKYC3':97Z^CD=\PWZV$.>]6$J%M08:U\=@R'A-).MNVM+VS_!K$K%^6YYA
MDR*F8<HCF*APR&O4EER[:V-)U32Y$+P @<BX,FIFUJH;+HY%^)K&D;NU7@_F
M:A9[5M -5B*6A6QJ'&\H\;&VJ=#]O<WR-[737@43+M2_D&_8H?B%=21])?61
MKHK(MC+*49=X&=BA#,?PD6%X#=E[8L]323[X[[P"EU>IE"!N\B1%HQFE0B(L
M;$J:-M1DD[-:6\).^Y;5X_SVK09H_/+4LH9.DKM^??:[5.Z5(G3EZB].GQE;
MEKI?KKX><.3Q-D"P7S6XY&+(UC)?5CO1XS0Q_^72^=Q"PUG&_3,2LLE63>E@
M=SP#RY?T$> 5'C;@K$KB_-JCM8J3KC97?&VTI?.A?, P.QQ:%UO\#'!\J4KM
MX7[TQR9-L^,\7M?03"@S9(TVA85)H5O2\<=^"QT"@<M9(4PV!M]ZL'08],*_
M!V5KM]M;H5DD4KWNT59J&WQ7K6>W*,-.5];)$-S=IWPK?%.OS,7<!SG7E=8B
M3)H3,8ZDJ*P;,;T[J_YW-!^+7XC/S95_K1FD6%LBZ9K@3V=)7H:;R.G^4OJ-
M[))LQFUE!FI"*KR_%SK3_-ZKCV)4468Q+MVJ64J@B>I7::"JW-\OB]KJ2")T
M%E$TF5JMEHGM5ZNB\-+HE3/V,+I+KDHHGU"B8&J,FY5S97(?1999:KQ5N*$F
MC<#UT)\?6.>BPP;[C%ST>'(ZE"9J"%[%(2 */"*0IE9YS+:JE<-=XDA]B];3
M8W6G/=<7%^)VL1W# :_,YHG2PBE6P/I)>U9+ !L8$3K(81B(9YYP*OHR_!14
M9J<[TQ KSQ,K9D19AX]=:_!?OUKZEFD.=$)^^*^5N:*B?M)0:+KOR"BRB?BX
MN?&,^W?.28$BP]FQR<H1ON@$E[YABX!3>\=E_"EE#]V?6.LC[-W"W1?;W=5V
MN]7QYECI#9]=J1/KR"2SZN_JC[.&&IO;VBT88<V!>DM"?Q8)FA+J4*N!^$-7
MA?L9I&^KPGY#$WF)=M4\ 7I16%7@!/RHLI;0=7S()D$*L?QB$V:>;Q2+/8LM
M%JV\<?[W%CX6_Q<*MJ.<M[('3@47@^>N13L?ON;_:.?*43CEY'S(/)^0]U^*
ML]3',Y0A6]SPA( E?<\UG:RC=+".\/1CUU!P^NQKN!"7K$7J'LQ18)X)3,C.
M> 68L57X6"L+KB%XYCV;BBQN#]EODS,K7M"PP1F+\U34X6)65#KM:U02Z+&$
M*-AS:FAHLK7 H\MTL-5-/D]H^WWA,34;J$Y!]:O6;^Q^&43)$]'J9;!PWA*>
MDW>;W^PC 6N[04W6/MFD:.TWVF=9"6I$LMA>&U@ ,(WV;^&?R?C\4*AQ872:
MR+JFE>-XGC1E5HX%W* Y_>O\;)9M1$"K2<?B9&['(ZQX!?S:U"P):S)P\DU;
MI+CN6L=\\ ;?/O1VBW#J1.@EQ3I[@$<C[6%63:RKCC)CEF3\YKAE<RVW[X_7
M/W$4\'2\^#^[,AM:@R64_2:VCS MY7//5#G'LDWB \-F,X<E<V:IA7U??LXR
MF9.;B5#3IU,7@KICY#9_=.7YQB,T3.1C#3W>C.79,F"F0(VON*W*??&3A_4[
MO;>+>;4S3$&5?[^N:N^VOIB0,1YFE[D[4#8W:^322TJF++I/BH'TQ7Z/"HU@
MR5=)C,#8%RW:/5>+U0:VKKZ']W"B)DZZ!9:Y#F'UP&'DU#&2"R),7E -1G4.
ME1FF5-+O%/UV&I$:Z(X$+\A=EDX-D\5\&?2T4E;=&(=9N>0BPM7QWX(*B6$M
MI(:KS,CAR.$?F<5R&R\\\E5X45IR!CM$#R#?!),]J<O$ +IG*P)G$YJ!!28>
MOLS53"[G]Y5M*3<5+H5)AN&HHA5IWYURZ3*=8U##9Q^0$Z?P. $GWGF8 WR6
MU%-,E=[D@FNP:K7$JS+'N<HXS#5X<<.[FL+>R6\5P_\ANKS2??/]#2GS.PG%
M$,2X#EBA'IK<R"]<36=@I[IB]Y.:S\=\2S;G&NR&%:W3,I\$ J3ZF6]AMMY7
M=SAY!7B1<"JNO5ZZ.<(3/U>):60QIAXQ.7.]_9);)=J;9=(0%*) 5A1R8>[*
M^K%[G#IN8RXM'>-,\YLR>QPGI4\3F&QFJ=\'L-'7BQZZ!JS<"9S(MZ7_S98S
M-108$"U:M<;Z)H!6NUJ45[$VT\DLS?2M6M3R[&>[AQ++N4"<+[T\'JQ'JAQ6
M(-J=.U+:S^G@SE=,$AN[7:D=]L&N):>L2G-2^J,121'U[,@<?2_.^#1).'C"
MQXR6=2>WY'.,E3:S&,N"(/.PEU Z$=%87Y+RD9.^:5VR9A<?_WKLF"OF.D9]
MS4](#&B;UL,,29=C7>73M@_*3MLUY*/FW= +J+$V(\Z"NZO4C]K![=DZT6J\
MTOJGP4/5+TT5'1B2)S\@V87"8X1VT>8SG,_BUB526V-%:)X!_GHO1S/F:35_
M'L+ -&]UV->LI*+R9H2BN979VC:CM'-_4WFU4*.*&.64%O8# TY-8W*_O%8F
MV? OWXX=9  -O$D7ZR=_&>5_K%*6!^$6E:29B\$68WD%48_F#V$B%! 5*MR\
M_*A,:LSN)N, MA,%9'WB*I+!Q%V%-MBL2IF/E,>OR;T_7H?_+9C++8;YE5>0
MOUZ2P):0:)3U6,4/ I'S5B(,5J4$'RLP#N/V:'RK*G3<_6Q'/O3ZV>SHU_ZW
M/]@U=S?TJ_S_RR]&H,6]FEO%;*>%@14#Y#9MR$\)U,/KK-W]CC1/7)@&EV9_
M7&]_8,/^[A^;0?H+D:H/^'-MX/WJ3T\D&ODR';[RZ/,R3X4(GV< \?*@]9V2
M5$ \^*:&1)G%<%EI7#_9BR:OJ4U8V .YN^W5>:5NW)*-CX!E-Z []*%!*%?*
M(#/HUX?6TS>J38T&.V@$.UR\ AZGIF1E_"U-CDMW(JN<_XK0S^A;"7\WRZ2=
M[J1H9KK.RKWNK= 65YROO"<1>4[#@Y92]5\^%=&2G=^(V9+M*):;/\S8=(\;
M9O=V YU85E6%\MD"D;FQU6/Q(W2O)/6KL<KA+#J0UYTDZ@,H#+<5=@^Z#C3W
MU7 \X&[8I@#("W1^LB/ODL-7M-P_FO0[8Z1DC(-Q-=H3-["^W];4J9G*;T@I
M36VC6'+[LA3B,6$KY>@KNYB7FLA"4-AR]AT8J"=DS>;3W-)\G[9E[$DE(+:-
M%BS/TX<R"W3*F3VC!\BMF_2>Y9M;GQK?I4?M8MF^9/)@"M5603(J]7?$PCY9
MAQLFN>*91O9GV*YB&O5U-(%8MK/*ZTT&7!;W<NX%FIC8/+5\X7B$W[>AD.4S
M,2#GF:JMC:1N?1["LN#E#^@'\( LC(I7?82-9Q5%0XG"$]U9L:QNWT7SCFS3
M-^<OA\F7C$-L]D2-JX851=U^9\VR432Y!D)ER]*.UBR3*HN=0 2.,KPPR65Q
MJB72^60[/CQ\LJVR0<WP.JO1T_"WGB;+V82'ME<#AURBWJIMP-?BI0/_,NDN
MYE3.X)B*IUDIY:7O-U_A#06)@[@<8#GV1,T &W8VR;_R8.?DW-;"(862;PZ:
M(X%S5]UC[UG0_SJQ8><)\'&IL#K&]-#SGQN RL9F@BA_)IU7T$P82:+ ;BJ[
MP)C,&,W+@]@YL+AY!0/H-=0]Q:;S!PEL>)@F$ R*;=?-0K:AV;]HV(&E25HU
M*5',/X3XB#*5&H(MKR^"(=UIBKHP;0KJGDE26;E^F69%IF:A&0+,9<'EAC%;
M8Q='X]P8(*8*-!\OE@DA?+TW%/;J_Z#:+!NB8+NN#2(B2(B"@'3'T#!T2'?#
MT$AW#QTB($@W PPM/</0-91T=[=T=TKZ7N^WY_X#Y[=SKWVLM7:K+]S54' D
MBANU3Y2E/N2^V_5DU+9PI)93=8MP;^C-7;5( *X?5A+O\"?>SHYW][/IW\U1
M*KGA+1.'Q>7U]/YA5=.6:04\3FS[+,E'XDZ15-JQDG&*=P_S$MQV<\V&T>OD
M]/?RHH9_EJIWZJ9XZY4R#0$M3=N=7UE#"@[]0>QI_.KA-%Q^_1,%'+=>P7BW
MJ2\K"CUNP6D)#ZC/]K&-$<?U3J,,X8=#/IA,G81E8IDE#FF_'9+F;AHJ\-*_
MR*=X4<S4YH7@_T-YN\VE\/G\U-?Q&6!;F!J9@LQ>B^F=E87[.OYFKIY.N4Q(
MX@\T;&// &,K--!^3C$Z87S]#^7FR$3\Q/"XN\SFN)QS, ;]'XH]$OX;;Y1^
M[X'@?)A8W(?S=: $S&U7@N12"6*LFO,\==6MN<(_8DI=8#%C$P(8WTL!0!AW
M@96(P\UII7C9Q@0QTH"Q$JJ<CL\[A5Y6*T&?;\X)K#Z;7.QM6A=I7!Z+^7X
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M<VG$_H<"81DGIG?EF@"ENB5$U\SL[=E0>E4V[DJ*8\$)EDEQC*U6^!I1(L5
MM&=X!CNG3G21D625"!?97] VZ(?48;.GGJVJS40O>53:W3.=$Y+@W:)NNER/
MK:5F_C<>S<;EDBN*%?KIIA?32RUG_U-CKVN3_L76(MVSMXW%K9<S>R#V?P]5
M<XE'M3/3AB\$81XBRT8D%V\JXWXO_3?)]ZU+=\!UIE5P"MH,JOF;D'[([RPF
MBI91BVZ>CY=97(>K1\VD%.V$WPX9LO)8P@-J<UR%L,;:D^]> 8E9W1W SQ1_
MY"W#6A>)G1,CG@%I&=M@R&:% :DG@-=?CO&<$'.A]63P#F@6+A057&#N@W%!
M&!U1& YP=N;2S8M-OWK0YM2O*VD7#7,R7)1Q((;827*X^-'( 7]^^? 6JB^[
M,&%9S1OI"BV'-YW$J@WDSA_I^[5MK0Q5ERZ^HDR5 Q_:/2A;CA2([I?F] P:
MDWM"XO#H-N2.#+KP&#@38K(\[=N*%C&IPM!L ,DW\"N]>],'C]U6Q;^_URX5
M05)1)6]7X0,['#1NX>BJ&%0@MV&N/BE48]Q\,Y8>ZQ>RK;CZJ"^KRZZ5!C&_
MMDZ%"]VO^$Y[:Y9IOUU\,QL<%;O4>FO'*2_JNXY5R?7"NT7NP&>8H>4UW82_
M%CFAPU#$EO8E5D$"2-&F$%=#6)7_[1=\_-O\:[-FKW+A$MN](8ZAE:V)V>S-
MI?>CP_PR\%@FB4=8E[N[04O:Y*F4>X[IPQ6H$4,YE<4_= ;$A&3-;)W_\SS!
MB;&E&J=/'#:X?8L@D!G(\+.5>J5[#7,D$=JCJ$MRCE/N.\O]Q@S:3UUF]<5X
M_ 7K<\;+@^W\'/I6#S=O&< 0%*N7I*3_YKCN'[4PC?U&AZYAY%*^++D&F:R\
ME-11)\ 6PT%\9K2S4P @BSK^+&/98R%(F5#^.!NY:;J^'3CUJ[5<C+L@EW7T
MU[%;>::*GI+DI/.SG;,V[0O0^73C0^<G=F[!2HW,!BNFYPVT:G@B,Q#T)WG4
M3C;[(-322D9V".]54<J/3;BS^4Q$+1D-VE^8-$@K@;DTQOZ8$])/@'F I.-W
MS-*.#W#[TH@"5I?GRT+_-9AL*4/?D^1!IA-X3"HRFQW6G*7M+BW$P8M[\%XD
M+-Z/ )N\8S:="K6FJW[31UGYMPT9]BN[A30Z< '3-RW-@I^D>M^ ]H:FQ.MN
MZKZ,5%B%H9+RB'3RC1IA$"+' BW'/HO,3$VQZ:?=P!,@KM5YU/0X+EB>ZV>_
M\TVJ+T<&M=$Z5@Z@/)C$>46'.2.@^Z:2G<")+V,2\\.H*]0ZGN[/Y510"GC2
M(23K_NJ,]2U#2Z!JEXJ::CB3L?1DC)-%3+Q]EQK&'SRH^GL_"''Y;O9:B8H@
M_04I@/]),_/7_9<4#+0X+CWK -PV^[4";W1(>K,C#UW-)QQFJ82F$VCWE80@
M8[!)\8=,[>=M=Q 4[,7/EN5K,QO.W&Q5E;23F!YN(HOAIEU^RC^$868P<=CL
M"1_XQ:<??!])LGI= 6V=++XG7!8H =3:RYF'9KU"5H@;S-+E:!'3FI.Q Q3/
M-(E@']ZN?CD$CUH'62FY]YQ'KT*1YSZ>2G_*D #CF+#LU:YC5H5UU$%$IH/.
M=PQ/+>9MO-.9:CTY2W&OEMR61@/C?%6][9SZM1VP7L46)5U.">_^AL!@B6^I
M*'.L!Z>;)FB[%\(U2 +C7DWZNQJLG*39CU!S*&P[U6M8PK!,U#@5"P DX7RM
MCXW$R=JM.75<&]NR('L /2>Q>B6.9O?VJRE&CDJ*C&0*"M."IN;OT%?E1'F4
MFQI1]H@'8-5&/$K$J>.0<H%KA'[%R3O+(:PXKJB-V[7'Y%DO!NV2-^46O.&T
M"YO0- RQW5@E:S"%9&(B--_YWMEOWL/)(;]?IVP:8P0S3@$-B#X<3.ID%E8.
M]AKP"I&ASO2YC]RK.C.J[C((N*/O_5'+TXX*))$#FJGC+I2E@B=T;>^5SVH3
M!XI(3# 1GXQP4R!\W(?-*7R<_1GTCC:4'MZ\1J#JV2?129F><?@*@T7$R7>*
MDY47PHG_:UT80AK4#Z !?%Y'#4QI:']FYBC_;](WMC.R.,SO#1ZM/Z'9_(=B
M/+OWX\V[4M46\/B?(VV:B8J4D"&BBXK^XTK@*9*&#^LP#27XAC"1K1-W\O<:
M^4$7S%O#GZ*!T 3*?7KB$M9BL&BX/=#D:]P5]N W*] J5D7E\-@G!G\_?F0P
M*BS[U!#(H@,6&*H:.,3S:V08BS,D1(SE.F8Z;>(<CG#;+PUB#[\@WOY#\8*]
MIG#3^C1]R+*MGO=5,?R/>GWW\<0>#<$3.JA]FOIWK,9POE8WA\$D=IXIWE@&
MK1FX&9H"Z7(5S(S'5FF\(V)Y"9&(*ODP7CP&%W&,S2ET_1;>G%M?*L"[2!=E
M5B.MJ[405>%U1U_L^-?&(,*,3BNMX[57!>3T%. "V9C5S@KI)ZD4-R3 :<?,
M$;_U"U:W3_K#2P+1354/:!+L]6W*:B".@A6=K'26?&QK:J]](["=)")P+^\6
M H!<X#Q#_F[4X@<4L$[.YS:4;J<REA"7(>@@UJQMGQJ[=MSR@?0,3\WXM'F&
ML9,VE:6PFBI615=_;9D(]>YX@W"%_O2B;ZD'[AE\?!K8"]1>BK]3-1+3+]>S
M*&[*T"N7TFNV*38KR#_8S:1OV:"5H14I0Q6/4VESKGP/-/O%%M$L\A'QQRXT
M>X,Y(OQS)6T3ZXT-5XWHXXY3FBK&1"-6HR+./S%6U=QTZP;*S\P$S!E,2H.*
MP,EF=-2& L7=[N>*-?G=6/7DJ-F:=';4(&*J:R!.'ZR*O)I9X)HP%%RNPB]*
M.M>FM+X>I89WE/:QDVR4;"/\!N.7#>&'2>/TP46RW=1R)?H,>K*-*MFW\(_V
M(PD5%JB#AW(&^VS?&%BKTOZA_'"?%?V1^QP+7N.X\)D_S@_C'4!\)F)#DM(]
M>A".LXH**I[2=YWEQ_KSYU('AH$/N:!E5PJ726XFN1=\2_23'D'L3+,98XJE
M)/<ROC.@CJI#@&U+@:V"(C^YBWTW!@9%$[Q3$NL:#]UD\=# $4KXY%;[@X:/
MA7OX(%?#R+JE:,7N<\O!<?FI(;YI4#E&,9/F7$^9B5'Y4+KE.>8#]FQ P&:;
MPM1\1SO^'Q$-)9BQ!W;>T\*+9.N(%.OI%.<P%UV6)P/4F_='2G(@YCJ(SM0&
M&% 0<2EPL]DR_OJO,SG#DO"J@NZ)=Q K5]/8Y'Q)6:_["[.5VL<U.@M;?4$4
M4UV@7=&GB!](F+X'MR32BM[H$55F*!N)WZ!6[\7Y]_9MOG0@!67JEP&S\0.#
M9HPH(I.9WD(_$69BS7$&B25Q#@-MT_4*&0/$M4B? !TXY.U#U$3CM!)^&*M:
MO8<)((>T\KV0X2_8EW9]%D[,,^, M4_Q!7K]MY:)4=C;V->C'HI&U<@?)?F[
M>ZI,;CN)?]6=,HG1HJY)8XUM&I.HK3Z?:2*OQS?T@LQBXE(V-$1'D(M#HF7]
MBL&(AIC-9E_'/A]"34-V(="H\:=BLVY[2SK<68:^>*;NG%DGQ(@-36)$@I/;
ME1<P:QU:76YO;^,;4Z'JIY7/H,#/+Z' RTI6Z9?LDI09*#1/KG=94)."S* =
M1#;LK<R+PO^<NL/ZT;[S&/ GISLMYV; 4Y#NI[9=D_,9:0;%$&E9K19>V''_
MW(]&FQ-07B/70&$<NG=AA1N2"&'JDVH<CGJ@K\NO\IS/1-)WN(\]S$)3VK>T
MN[WK;8Y*'P\L4'P@4<AF2*:R-?X=X?F@,Y+C-E?K@?EZ8CBYPU0 8:>AFX Q
MO=2:I2,(1GH(<UX9M182O3X>#_ J+Z,S50.6<#U/D <"6)SKEU5/,:O=#_M\
M2^QV\Z[B7.UJ/HTJN3A./2VK: A_6.Z;^JUXP!K1^#WF!N;%9_6%WE]G4-?>
MU(N<F=ORU-+^YY@@L8 (Q36$_]'\TE(6"U=BP:?B9[=F[Z?B85:-NI'?2/:\
M];C?L5X7#M8B;+UURC^1,9_[RN>[)I/+!L8%Y8?[6E"%Q]"-X[IM.5R1.GOV
M.:G[N]-2L^]]YS28^]^(IU&F@EK./8M&T%DKUCXN"*P XM2C'1)*(E-2X]EF
MZ*^VA?VQ=2R_1"<)5A3_0^EH7H77TBFYYZY%7-V#N*;9J9.=>KBENVO+"/=E
M /J.VE:DMB-_:EMCFVR@U815D>Y^CW/;G[@B:IXHNF FD@.9?Y>SL,8$HIP#
M(@_9'6J28D>CJO08)M[\AX,^\H-[>7 ^2".1<V+WQX'MIWQ=('"'[Y[& 5?G
M3#["&=</8E&'=?T'XZ^'':CX=E>T$1SW$\91,O?K?#YT;DBGO<WXSEA';57M
MI<TSIE/.*->@#[.3=S',;\A/.DJU?NS_>N^&4T.HFU7_8Q;!0]O&0."N>\>@
MQC^Q_: F8L8*^0KVRRN/Q5&E35)(= ^TZY7;[4'\BY@#KIP-W72!).\.,]OV
MJ;^/P,L!CP;C2C>CR&S&QR'7BVKR(TQZ*UI@ ?V"C\7;>RK3N:2V:R$H[U:6
MO)C%J$HJ8.89K'>>QI8U>Q-8\"8:4R8YXN]@$G0/#64WSX;NW-XV!/\*ZB*)
M)-%)L&&$NJP^%KX /7\ #70D!H B/4!S>>.'4T)3,0?RBE=9N*N'/NS#N XR
M93&S YZ!'][ML'TNUQ75Z>APL= 3\IRLSC[9C7>,\JH2JU_\]*$[<=:7,!AV
MT.5D,K9MZEMB$>\V,7>=J=K/)F,I3#KOQ2G*(CT=,/#4BR9X:J]O_LJ7-F9'
M[D"91E9JL.NZ$\&>;)=U/#U%%6PCP4RMMD;3(O69#K!302CW16@>4&#(F$F9
MFYOYG<<8," M_\XBNY6B_NJ^M5( _GN")F=/?/.M^&3[Q$_G[N^!#J&_9]CI
MGI?E%>,6*\9-<FRTW@?T82AN5)A:NZL1[J\7,&DHFCL9%4'5,>$0/Z-Y=W03
MHA:*D$:S*3:VBX0I?OCGXUUYO[8XKS^JR&:75;G+?RB^380GE)B\NXWG+PBT
M9@C$%%<(+YFP"Z(WCQ-&GH)UK?83F_3+[%"(6-!S4DWI:639.]D=X%\SC^BP
MWXUHBRIN8DR3]!- *2NZ01[B[E.)CG'[%!X8F#7W;K'\L4C_LG?9&SE*[W\X
M:D;"MG@@_E&//;K YG'O'XH$84=O??@.<#\(?TINBM>-3/DO. M[:X>P2\:&
M2;@UDFA^AS?_/%$5%$5KN%C.H%1*5CC):4D[UY8S-/?',%1ICL/QUD2.XAKG
MB2[^*NKJ#^9?AT<;'?U3HF>LQ5 Q/V&OKQ>%%QP]@B=/7YV7_#^6+#3TRQSP
M^;B\-$X5&[30V)RU2/==L)=YE__-V3N)F+AG-X_[](*.\7!3T=CY0ADY_RA[
MCFJ'-\+O82Z>5^RS)?<3-)UW(9OZ$X>8Q^F%[OB/QEIVL<^C\LM0X[3S]3Q+
M]0]GV3[:-N&&.M),USJ%_+GMV:<@<W"TSS K\TG=U0UPW"<[]&^ENO+Z_>^I
MYC;&KQ/L 7(.#@X%Y=[LJH/?*3G>E/E SI2:9RJ.\Z=2.2 :[4=HC.1V=)75
MS$N&9&1EU1=)#E,>\AAAK>3TUZ%$:::$&)7B'M^,YMCC-VYF;@82Y^^X<KF_
MN@I_ Q9MMOQ#:3P<ML-_[JT<[I=<_8?"GNJR%E XI#O14QOM,71IN5/3/Y_C
M,&'=/N4L;=@]6.W:]-H<"0!(]NIH0T11$*EU/H:.$4-K/T!)(9!=GL02ODPG
M8%E3C:@@BP-K/W1UNH#O5DLX!N".6KX:4@Q5J+,07*2)-@Q=RD^:CTLMJ]+2
M!R@EP [!M8MQ/N4'"+<Q0"D$7__NTV'WF_ IV4/E79$:2W;??H3D8%NDN >H
M;03UF\Z!_IW2CE2=IZA#.&)/F/S:9I@T:[>P3XX*]"648]392%HO60>$+:YX
M$N-K84XOYJ3 QO9>HJUZGAAHVHV_109-Q#C]3MZB:[R1^S;(;IGM)9\CV1R3
MR@:]?[ZJ BNY%+;O1&E=MB:'S\K 9&G5YY5EC63>I77?2W)8.65_0G/\-C:!
M&7)NK%Y%&>LFQG=>$OY1[O-I,$QNIQ;]D2OP<5"\>X6RLLA;MNA.CA12(KY1
M0FE&1Q'0#?V3$4I%1N%;VD[FPWUF"'5 TEWR]@@;M[3@#C^K>-]]\"%23E@6
M^6KK*6"M;MGY,*>3E-;LH%H"F*1P 5,-HM5;#RPRM-$:G9^%GWG8>1I3W)AQ
MQ:1'6_(WX%%-_>7I]@/NA9^>U2N) _-3!QVS3K#PU,9RN:LKZT'(W7>U(Q0V
MJV?&#!FW=EI#\1BOFIMT-T:OX:@-T!5DAS=VJ+C1G$V4" ]E:$5^6VUB85TN
M"QJ%Q%'\4/3J@M%!RWL5.E#B^DVOS;NF;;9<A.7*(8_)<+TVA!$+9?M1M\2V
M_55=W?G(].&D+S2T:RIU12ZU'^U(JLZ; !HULZ%I:JVP)9#$AUV_)"DS@^GY
M=DB>>_AL13=]^?"UV!P9FDGPAG!A@BB<[W6W^ZN@"&V=L,ELO0.P/JH$$K/7
MH'&6/O+[:N*9C@%?G,4\1@CS@;TR_-2G@AC.@U91_SO.-OQJ\)1%GR9\YZU[
M7'M<??QK# $R)C*HODM78QJE?;OU3_,AVV9)52N^H;% OV\ZUD["RDWJ-8M=
M'1[HZ.KAOF1QF/"!T3@[9D-3VFC)25.GR8.YC38OK*:0-?R(7]*W*%C!.TN8
MC$4VY/KJS%ZQJ9FD$COV60O.#B*+A_9U239MG*E<]U%@DGW[UF04%N*?OX'_
M<]ZEEZ3KC-JK^W^+0?4EM1]%:GO@N?CV)_]0U*;QG@)F/@>&*NONC!I?8.V9
MS(X_2S/^_UA$Z9=Q_WL7SN Z-\/:Y:X_"[^*7K((8*E]PCIHSC3)SD*>%9"-
M@ER/C)-DO6#O:O#*1%P3@Q@94R'4D:+NDH]!C5"?YFH5V7&B/+G/U%02&6^A
M\[9G&?5 DTJXBDE24SE]H+^-*S.G;AU7D) @2\N6KHX6PM,()*S;H.L$L@R1
M*"9KN^VLY$KI]QY9NXU+%=8E\#C=E-:_ML"FEQNAN[<'D+Q%A:F8W["NZQ,[
MNW^3N0%.D^CMY<!ZW)4<+-X<9:3R#-)=.I _2<;U.M$N?\[RC1-D7 #13XN.
MC+H)G[G[Q7WWUT9Q<M>E\M-PWO87V_MEF\,8OK9 =[M1W/E\+LYU>XO O(D$
M"K2F;^B,BWA6\H6OLZ-2\LGY'?.2S&8$DRI\A30=FAU(WB!=Z"LUF!CI/TS+
M>*QP?JC,%Z"]@+F4]+/KSZ8P]^'YS5M 1.+D=C2&RL^_X[JM:)M=:)8!%#[K
M=O=!=V4#DEA9:"*_])LM%23I$Q+(H@D>G:A=?G/$?H2F4K\[53,X129111%9
MM&LE'QCSA6[:B8A;>#J1E[LCNBUK!8FW""-<A6=]B_[3[L+9[K1<V8]*?>@R
M!(9Q*ERJ>]NS/2A8FA-+<W(^N?CL(O6R4^M.,)21GT_,)9MT_>[9-"M>XJWB
M&T8<R_AD'%^UU PC0AH=Y^GU=-HVJE.8)Y76Y+37.'P\^*<=3S17]5VGX&17
M,R_ O;L)F$+GJ!.7Q-N V$)7 .ZEY+BAA@Y_.C3$*WCJKT-?H]^;#/8<IU\M
M]>Z*A16R*S>44GKN*V@\=1H1B>DUO[+"*%(-4.B(1;X1.AP7]KW5,J2KD$GR
M9M]OKH."$"ZEA0Z +H6W_2C;^/,7"![X8"!")8C.7%RTD4 K 8!.376-()6/
M--,QMW$:&U>[(&@.^-#KY$0JTGI?WD\['14^MU+KX@AAI,O9A>L9[I'I2CFY
M?!> *= FN6O0U<J&S4D+6&U_7E%1&8KG)C 7GK-G0%=&9Y81'5/0\9ZH%EU)
M0[/KJKR3D= WN"U?D@F&,D'LXE<D%YZ.LL_OXK=F3/1N>,,7$[;<JY?42D2/
M8!"L\@.AA+B(23/ S,\ZQ?V3 \04$JY&;J?K5U;UCM=&0)_<M=RA:#TF3L8&
M%*NH.DL84R);Q&@')]PF5+0:D[&M@M706\Z%3UA+)V(GR5@:]RB(Z$JQ@*.*
M1)3BLN8(?B$KQB('BRS=IY:J_Z'<Z#";ZO59!J >.N0UQ382[N,I@\AGN/KZ
M1X91SXQI8F(6ZK_RW0(,]4BB!S[ZNPH*')AD7C!<7)^\ZE:N%S/2(A/X>EI*
M%HCC&\"/;[!66+U<.;31IY9?:7"1W7A[%NYXHT2Y5B@U0BVKH"GX!*,G'">-
MN[-)'.3Z=!G("<!)L D>O$9$?\<Z&==*UK%JS&;#&3(<W'ZSO(LN##[(-2CN
M&S>^P*[<J PW<$J-?#_HMB/9*R?.N;)W&(1P50H3>4;WHQ]1VL(+G_NXM*EP
M,DNW('0F$?YUS\1^RC&@JAOM3LV^C_3SI 'W<DBA6QPW8**5H$9E/5N35W-L
MG 56J:F(=55JH)1>F&J>.,5U-0"35ZLL\E,+8; -("E5(0W8O^04^T$%[#\N
M(FFXY4?P'A3-;+.U4I:O-?<L!20ZK[=&U[$Y!*BU-8;*3]=9)BBXX6/_?7E/
M1/9@W1# MCD_RQC(KYGB6U-Y6O@U)5?CYKJ"ML?@\_X:4Y2H2B%D2$$J0X&N
MU7<OUV I6F5_9'MG_.S _"Z8]YT#J:"(/@*/?6[E4R.(TN<?BO\#GM_2>5H$
MNX@*?R2'C7'D-GHDS]U'G.";LIO'?R@8/B%=:WV!UGIL9COFC>@2_6CBS >@
M .IB'^NA>4UC2O6<3?Z(=R%[IQ5XM,%GVCN!^EG9TXX7'G$"1ED0P<UZWNA%
MQ(V286*6'!6C6,9NY=^?<I-LIR?SDJV0349-*U^U5<&M*IC$ECKM3^POG8YN
MAB;[?V3C#9H:<!@N[M1HBNI^!F2Z#5W_&I/@B[?A$O<C%"^2K_%]#_G:WE]9
M[ZI@(/>^,>T5\)+F'THP4#>$%P<9K@*@ C=YEVF\FN'WXCY6?K6'@N6O%)=J
MZ"U 7@:^"F0B[#<6-+01'>AU3V9??'L /:BXN@5#NUNB=U>8Z_,F_65:J#)]
M535^DL"O%IL_#/!S-&KH>36]_D0XK3]@ B1MM,@_96:<C(6+8D]D;1'J=HI?
M,BT&M7&\Q-@?Y'!][WN_A>P'COR/6=FI_WYQ3ZB'P2E('\N7Z.K_IT4UTA^D
M%P0)B\H5)__"=;'<,@]^7_-H5'N3.(*:5Q[("(+ 'PBYFU-6.\EF!O)E\>SU
MTMJ9M[$*JJ5#U/5F^-_.35@&[A[H4H<5ISB1]&K,1%XI)D\ETSCD0V*4GW+:
M' QFB%Q1#A[FQ&41_A+43,,3WH4C)N$%!F] K@+]8K.)KNETH/&E(68J&]=.
MPC2/7=FQ%2T9F96^%.ZL.!;,U:BRVR.##W+)4S 5"C_<\")XK5 B,D@QUSW,
M>5:MIZ@OGT2<F_C%Q,]O9HZE^[OP])/"Y\"HI9TQ++[Q4F"-' !D(_25*N3-
MVT-TZ6\''6)]"&?C[U248=1+'T_7YZ*$#G$(-+#X[NCE7,"&S2:E<_V8,S%D
M4</)Z&]% ^UWTPI75H4$[JE/]QZT!QF@UIK36G7530XMFF,%.P(X9Z"/Z49Q
M/UXHP_B(D^;5WI>M>XL^'R)&-S"KWQ*3M\QC,RW5)AD0[.XH,#85@I]M!71&
M;0*+N@.O-".A.K2TGEZT]%9-JMOG+/3*V,E2IE3C)C?$YOWD95#I(-(7$V8;
M]RBQE,A@1H2,ET* 5]&,XT\O53O^JLW,>+"*=<=N'344=#IN$W.) _(A&156
M3B4IC/=F3 !8S[+5**_Z]!=9";K#EW:=%D;J@V=_$DXMZ#%+7E5J=(B/%39&
M31GWT:NOW\!_HG(+TIE"K^!;9&FL6K+NJ2,'U]LZ=N^_(]<U[-ZNL3P]RK1S
MN@II@Z+3WK2XUJ8<K,FJ9,Z]C\$%V--UE!]17T;-J*;.N,XY^A#4:?/K<ND;
M*'D*.X93(Q=N">B6:P2/EVNX;Y;AHF)+^F<TD8GSSO>DI("1^E5^U<:JCTN'
MG")7Y.O4!_L W9[FV-\QUSM"'C6JL!T-K&/,TT"'B,3-*/0IS8V21/I=710F
ML9#V2K:NH2S"9<W#^" \XZD843C( 5P@1#:O'F3;URE2^MV+%97MQ)@RW,73
M4!P+<\WTA#;Q0X.A*?E+ZAY7T<Y"<V.2)H)X0",W_4'79CT7?T5_W[M9902_
M;Y+,?.LGU8-US%"J@ADTKN*H1&KB>3K%0EB<<6;_"; I_*RXZZ]TC7O1(-)C
M9-Y<\M7^*A[G3]%+I=NG[-U(!DG)+=*(\KI93[9WO6I[XU2:Y5.L<?)B"Y4?
MPO5!A48VA4EM.<?C/!V3J=\"@$D- S>TN+Y T"9^W6;>^3^4"+8G*;.]GA:R
MP.TQ-]W=#BWH%4PKF_E20;^@.\N*R,X9/(^?/1L,ZZ@.T<OQPSIBC X'CME_
M:9 "1]6;T2;DLBZ\:N' \&D_ZFZ .W&31C.82UL^#>84!74AMQSU']QR[)S3
M#9<A D-Q&&U:46[>P+B20+Z6=<!CPJ4=MVAWUK'2-[UGU-V,RD.BYH;4Y_CB
M@X8'$T@W'MUQ?O7^>X\*&YEW#H4RKAV!L/VLYAN=:\*9O]93PAG=BB%>&*?5
M Y1A+-I4ZWN,U=L68*PZ. OOUF^0]GF+R5_#.SYOT)W7J;<2YM"I&$S-;Z+]
M@BCDS,9ZI@ZI>23>^H:,[UO>E8$8W;2WDX,/7^(32[WF&.9VK;6#-K]"A]U[
MR^G4MZHL;EXT<7:@;#G55A<GZ/2VA?V::%6T<K+2^4M6P[D\5DLS:N=1V,T=
MD"BL5;_$+H>H?=I9>G?3*Z&X9^AI"&5P'&'_.WQ9/W;N88DX@DRH@LS_PFCV
M+J3^G0BB_$+9+8LR-=9"Z-.=MZ@RG]E/!)[?^3<KXLC8.7DC.#.ZO$BHL5?)
MIBA'C\EG0V-5YJ07<22=76*K]P/%3<];9\=MVQ+-."$XKMUCWP0::BATPZ-(
MT6ABX<8P5AO9?AF36/.A? @\'7702EYAL ]Z*-2UX^+7>!T_K+*R?K.WACRP
MQ'X.^@SA(U[7-4Z6%EC53Q7KZ:?+PO/+>-6CHVV9.Z ^Y9(0.N%!D!>VFWZZ
M>-@L-[[A3_L/11FV)CY9\* 3R/R9 UM/=@O;_'4\PLCML9XB!$G?(I"S1;TO
M 6=IU<:/:B0>FG-"_1R'>5>&S\EMKQ/=P&+V5B/-M&"M>#2JE_0_19 3+)^+
M'C%8;L:O$]9RNZ.-ZO>=XTAKNH;70_(#%5C9:!\E(V75S^VONEAW%RJXEJ%#
M_)J-F)?QSO5T^"WM>^9JR#(O')69UJYS=X?L_T&E\(5I_RIM<H7RW/_;:%#T
MQY)#"RI0"ZP\TE5X00 Q9W*5N<3G:BZJARP3<#S5W"=5*J7;5,M<U78!^+S_
M4(344FYN$%IB/_][!$R:0(O2JG-$3G&F<5^@S'@7K_C;(=^*'Q_Y?8"@D=^O
M+22D.J) JN, ZGWLJ>AG:R)D9&!5YOTU"U?-?O,TCXA?=4" H5GA">1\0D'"
MELS:9*[J>PMKUF8A&)[Y[LJU5ENFH1F:U4Q<87TRT_72[\Y3]:)3XF!MWF!E
MM?TMM9I:4)TKRRH^'Z8+ ,B28Y*0\Q@U!=@TIK&5"\UDT?HGVMU.<B862JZ[
MH@#)UW+X=F3TIX+U7;NI@U];(X9C.\A2:5]/:K84F$S-BG>HQ_,Z-\IQ0WS3
M,/*.M,_,=)*QN P_%Q7.=7][B]$&/N/ZD^30SG*ZO7:XDTFWM"C*(OXQ[Z5+
M714#BJLF 3H^'^+&T6]-8*=!U9=\&I*50*S]!*J,H9+UY1&1C+_V++I22*=F
M!+MR\T#WV>L PI5KAO*FXJM]H/(# QJ# 6MON1370ERB?RB56N,S0\?AW?+O
M7Q[VWYB+Z;E-KSS.;3*FH#J^Z4?QT%!]F_C4 W&>-?'UNE0U* GL>G_8Y5\P
M+0K@]B5!'F@*8XCZSRIE<"^0HVNHT-@N*%PF:Y6<9KW9]_L\(F-QQ0R?/+-<
MZGC47M9B2'3W0)?^ON,?57J)VG4+][IGL?CVP[R6<14[EA17X@@TD5QM32+N
M.ZKBFK$-AN;C#PX*P"]42(S+[4WB=G^0BH8)#V @ .])0T$("QZA4A*Z=9VO
M2LEL^%"G)R1(FE2/+ 2@*!BP<,?QVI.PA"^N\PVGJB#LJRE4])+F>?(*Q%6I
M^O4=I[NT'9B.#:D7(LHRXI>%)'%W!0_"%A0$:!TTV9!X_80%,2;[D;R.1<?)
MV#P?H;,UDO(B(/IR/5J&1B>!7B/S7^5QON3HE2A@)=C1^P.^#ZH=PRPQY4JS
M,&%K%*R1>4]CFJ6Y'?:-IB13 9]Y:@<XCM*2MD+Q,X9LMN#X72;9662K7-E7
M.\A#:DS-TO)62AB2L5U%B@(F(E=$"I@4[9V1)R%HF!4_0[V+M?;1U9NN/+6<
M9L?>4TTR?\1RQ\N#>Q-]@KP(-#BQ%:K_9I9,'_(FO&[O^N^+>.3;D&O]0PE%
M'O416*:Q>AB^UULR^*NZ39IWA^/= _^-WZ>FUE?KPOK?6OJCAC!GDFQ@O>PQ
MST_79LN6E</C'\JUCTH+T^M:"KPVRX,'7/@F\?&>7JKY%X(5>5>O> G5.&H!
M?[^X^<D_YYC-VEMG=(GU+NM<OO2S1R:^.$*;O-_=2&[&_?:^;OR)$%N9/N2O
M&G<A7K)F54J])3XRJ;=SAD"J.S)8HF-R;FA_#<3$<)=SROA4C5Z\3ZYMOC[8
M#KCJ&9S3:H\\V/>5&3:Q!;GR)A1*,HM/%GX/&!'%O$,HP0WM/.1FG)WT<PZX
M&U5]- Z,">=^L%D2O9=LQ,KU(A%\=Z;G@MU@X"!66O$ EM=G[=QS<3L&- ND
MSRIJK/U#X=]YM@U$9YF 5;ZQ^,NA'RIW><+PNE,X.PFU+ZBKC7Q"Z-1$8K=5
MKL_Z<&YSZ7!!FHU.?+^+)Z&]>ZWM7;<)BT-F>MW@+V^=2,41]3)&LNW/^CF8
M,U$]TT?(W;G=2KXM\M:QV(TMXG+21YIC;>PD5T!>^XQI;41#)^TMR9$VN\&+
M@^O%LD1]N#?UWH$)F=V0XEZL(5>1PF7=\B6W4UA]L*5\ 53C;MMS &,!E (Q
ML*Y\WXB<[E9H!$?H9H%>#4W*_Q$?4L7**8 &W=:/9J^D?9I*M1)P]":<9I*2
MI_-)[-G\"O156'KDF%@RIE3*^*$Q#,9+X(N(0$,[D"E9<#P-E0(.<ZTG7L;W
M5;$!,2DU/GYRR4;2[4$/6NM:9Z@;&[EZ>:.1&;^CPE1YM^?!@O/PB.+B&[O;
MLVH$&"!"V=KL,X.[E7P, 'K:;;HP$'<Z!N$/]K<10=) C8ERGNXU)YKWXZN$
M&>RO=RT#JGFU2HAVPR(J!>!+XQ:JI/7M:[5PWXAW3+HT$#;9I9,D/DURV4G(
MD?;U_N>KT:3E;>1W9ZJ<MW!0PSQ_;2U]6&2R>) 7SS4LQ3SS\@G[0#LKQ;DR
M"/#G!5-)=XIVUA%*EVG1MRAKEO2S26RV]U (.)>&D>&^'N):Y(MQ42G=ZM\F
MVI-\,-G7'\]E* @[-IW)]PK3L>H??8==\$+XH_3*?^#6U;>NZA\*TO[V !8$
M>)'+Z W98@2"LUO=#(3Z$IVP:6Y'/P/Q:FSCSRGM1U8D@Z$[*4;&&3<"?N<]
M6CK4M50)*6-^T(D)5D/0[,D)AEQ0YJ(<0ZE*EB76:?MGNY_\?G71WS&2B:XL
M] <OX7&%2(UEY2B^O@*L/!31,-E9P&7/C,I<4V79  NN_8I4G ]LGPOT2W#[
MFA#T*H#,,@#^ '6]['@L;"P#8F9"7<VYXO2N"?D#4:P&N_A%T2U( T>3#;5D
M/W&L":#!N<H=L@WF/BVB7.7.US,[OX4*F[YQZY7P+#-<+'OWV']MDBKIWQ*=
M>(7LOY-[!2-^]]FH"+NIK>5WVIXC@X_&!*C__[93-$G54381_Q<0#:2LI1L%
MD$/_4!P=)#+1'A7!_U#BM76)_#%.];"]8=#:Q$UR,W#_\I[XWWO8CQU?8'U\
M06?_';[U37QDIEID=Q^#NYC) C :=J0+S0HK"6"T-$&!N7_4D"W:Q@++AH_*
M",=\2/!!9//][>G.18 ,;?O7(K)F#IR(MP%8D&F0;89^IJ2TER:GQ$[U$G2J
MU+B-X*IV8D[O P=*0L%<8H6.>#0#DCJDA 3,T,^2E%1=^5ZOP.[MN".6?E5A
MP/8;HV<WO>$R)W'_>#_#6"?#UZB):[4]ZX<Z92.Y3R@E&EJQ4+9#;W^//^Q:
MR-\_1=V,I.,?UP"2MR^&??=2_,Y"6,40;J[A;/A*G(KWY,^:D)B<?I$BN$/9
M;RLZ]T79_"#?'+5Z(JX">;TLYS,=A$WX)!^*O.@5J"-JXYL")YZ+XIK6+N<-
M"WVHRTHM^Q^#;&6O^^WJN^(:$9QQU3ZHML @S:_;%3L:P;,WJG_&RNIZ(RCJ
M[L*R+SXG:TF5I COB,2MI=J%VE8R+"0_%^A?)L\3PGF5QL#0,2AW?\P4,MFR
MV>.;1U1[">%$.;[<YSQUO<!- *5:9('K04R\P;+:&DZ/6?5XF_NFL9)_:-%@
MD$^(7DCV$$8#@%\S="S"B&--E<PO:@&0ZJ[*=Z$C&;\FNTIFWMBMO1>6LZT=
M6PB:1B"*OD)Y6E9FHX^(:>/=J[!9A-$O,6/_6AV!G.<$B>AN$4()A2.B"XXV
MP.K"X0^J"':ON/2;<AM4.IJB\, 2A'92BI$2I/340/V- KJ>JST#4UD(+FG^
M386GI_YG:M)V;:]"_]'A[_UQBY7TIFPMG&ZVLRWA4TPD#5;C4M!AA0Q#,OQ]
M^]JAT2?I:8($,/2T@$+&^E0F=MBW3XX2X6"HZLX5;#3:V@]L-+]W:]ILULCZ
M%9<SD1QB!]3P\;AW<CJASL%\>=FX0M,TY/;]$C75^ U@KR-(/^J0=>ED[]M>
MO3&L@J?4**3=<DKKQAHC1_WX0FB<US3G&6UXPK<D)9*./?2;AF(/>) &%<LM
M+3.$NZ[?D/0Y"*O_-F;AJ-:GZ8EHTI:8:O.QCNT%F/@=/OU#X;&_KV/2;-6:
MZ$;.0(;5^;RYY,#;3#@?K\5NS#G>&W9ZU>@SQ_$]GN^QB*6._HW[<$)PAWN;
MIG?/8';96 LRSE[M;5NZWWB'\H7%Q_[JN3G:K>P?"LH]--U^H1BN"3E].,W5
M6N@K<KHU$Q:;I14H+9AC6TW@U9*M<(W;"J^@E?W]1T1]Y!\*G=RWZ2>YJ0;V
M&R7X2?ZO"+-V&9,9R1C+BA@N@:$ZFZ%5Q+:'MU]J6R8+%[?\*KX@,-4GZ8^>
M&AL"3H(QHO]0>MUK*9OC4#\[4TD2VY#T,RD0]I04'2VR##P;O"NB!?S=K"M2
MD8 [^^F;.!V[L<T%5"5-/_TQ>9'+V;_J 3Y& )DL/"+.XOT^O=V+>?SL!?=T
M*_E;,3/H^@I"&D6Y ?P/6I03;-5$4_#A8LHU:%<#@6KUKI\U#0X_Z;YZXE&S
M8?][B[=^*I9ZIE6I:J^3,RSW8K.D:L\)%H8O(I)6\!FS =CQMW)_)^W<R&H*
MO?ESK=%.(8/]4U5O2K"#7QG);=^@Y0.S?2NE=@E8W[[H;%QIA=38[.J4S?:"
M4NZ=%GTI?C@6S*XWA:C59D;H>G@K]:T+4QIL52!.$:>6*ZB2@OV\J_PZEL:3
M(P$-6RX(3R&&T@L%FJ)6]T%&^NU._,<Y)W9GR^'0K/]0W/E9U5 %9+L+8B^O
M88YU&]:UADJ8$3[WQ)*RQ+"?M*CH50=75B@M=3J]/W/CO$]_"-;Z:BB!^B>H
M%#&VINS0)X[EK 2=GQD%^XO6/:;=/P^$V)E#,-DI !FTYD2C&F$=QP"QI55&
M?:\/?)?$MP^SQE][=(DTB//5(=4!\"I3/,6!:/5<EY0XW:#7-J&&6J$:QVX@
M6!$P4+<H+E,M:<*D-2FA?$!CHIVP[4IG;DU8 :<W=B+.RCS@U^+ 2=V<;<Z6
M! 3#,\Z")4DG?.=!R_G&]@:0-_FE*IR2N^1+H*T"OV>UYEZ41M)=\M/3:'0N
MT;L6-88-TA$RLFM@FIG/Y)H<%0B__8M8?238+)!M/,VQY8Y"BA/CD&4GRU'9
MM9\QTQ4UQJ)0:>41VJ5C1MPT+5>@AF[@2:W9FG1243P3OG0JB U;4QG"><03
M_AFTH]W_D_>>3B;N14_[7+EZM\[1:NE"?ZDT"9W4*W'FCM>A(0TRZ5O]AC/T
MBD%0ZH6 13TUY=JQ*-V<25!$N%7KY"\DOIN7I? PQAOW%=5N"RD.'SFC4G@?
M'O+#ENC@J8JUCQI(*9M/P)+Q!(MKW,WPXY!#7P^X2_6#&#2<WMP.%KE2<<AM
MS_G&UEQ-*UC'JFG+WN.FPL-1CSMD@=!.(&;.B Y"6)K5;\#VH]-OIL:(OESY
MV9"$ 1JAA+I<!DN#?=VAU-*\QAD1E;ST'U3P<FI+\2BE_KY79/].=+2C;&I6
MJ_[+D))+KQIY"1C499&LH>1>'8/UFI3PC<K_!(DPH[4/N#B&_P/,Q77F-M C
MRWC\(V+*R_]6UY=P>P&GG11L#L:Y\L-$WQSZ.=QU\>G=_Q\OZD>4VZ,(;M8C
MKXE!SS\TJ:-5H[C:W3&O3U1\+4 ]B@7D'<4FQA_[[%N])_N:%I,55@ZV3PVX
MD[CMJ3U\<7HEG2?[_'0$BQF#51@&MSD"B[2?3K_ &G4U!MP^9/E!*U]SKPSA
M$V;-#I:#,"Z[,9+)3O;>U,4"#GM'?EFW<&WQSC8D]MW16SRKV+,5NL9SFQC6
MS!J6+?XEPROZ8&<;Z0TI4BA^&VRQ[H=5OI0U2:T1HZGX9<R!>U<Y 4-Q]% Z
MB:/HW"VTSU[/A2XR7%5NKAKY#OK;_'!!7Q>0:V!M2$Y?OP 5 <3?492S5E-W
M=V$TE<OJ;06M)L=+@0JL77%5@*7ZGU_LMUA0"/'=)?J!.GI;;0**>>_5@+).
M[ZBT[N)8RH,Q7N4"]A+LQ3YG9%JHU^1"*CN]]CE7HF"E;HFJ2^ H5NA,J-IH
ME/3]-ZTL*(('YQ\*\R@(6_VZN'U3"F :-\M90JR4@99<GPZ-"2-D_RB^ZJA#
M&Z#OJH 0L%(@@)=2G4N<Z?G%YM<BG_]PB0-.3@S:MSTI+-?L]0JL2]DLV+N!
M"XNVB87XP\ST$8-&<SH.74FMX7L64-ML.2EETC8<S[L'L#'!Y<2K-^)8!7QQ
MD-OR2_$SG@Z3V1]NVKN0YO8?@EGW-AI)=E*"AZJBASV0+5&[>/PM<H!GT\?E
M]K>(9<%V=>)OP$B[=\)A: R-884)LD5IE27VDT/,A2-[%N9S6WFO-QM.2M;!
M1MFM+7C 2B?P-'26;$I7R'9[X,AH/.JX N4QL)"#!_7JE^?#7#D_F2><9MT"
MP>8M)W+ S) S<IEQPWPC<TDY9D5&D*$JP_;SAV=+:4Q$, T&$]E5O/W-&ZY/
MJSMRN<:_<NA@645:FSS=&W83*E*5&7M+UK&P@SO-E4/J@F M%RKWP%@//[E;
MH^KAV^5IM+RA!_R30P<YP_HTS<F]D#<]"T/^N8I7;[<N/AJQ94$MBX([Z?W\
M=RM2=5YO+O;&=RK6S6PFWPB1NVC5U[(TU+3.'?X)B+&$.F=O1A?*. C7P 2X
MQ+#FZN._KR=-R?Z&:O"6-9JZI ;A&6S6QV,>"K%-OTUOWF/9]XMW4SK"Y?;6
M559CURPA]%=@_VE'_V@_A9;:F-I'''[/HWY@0B%&/$OA\)M]ZT1JV^,QV %#
M51]Q;&Y8T* [[C>)G*M@IXDB,=JE0/<C<!CR0-(\SR/#.7CZU']6964N?YU,
M^!OZ96JC;>4VG-YK-9URIU=[QB/PTZ)%H]YVSP")%5L(H#CIS9QC2@?:P'?,
M]P\Z3EHR<:=S2_,.F!-6/!/Q:O:;'K_JJ@NY@)_=-2>/W2!SLFO[2R[F:*]B
M#P&PL-'4PJ;7)&0<8JFBJ6'9+6<YFVMV3GT@7L>4AX>YKQ'L['2UW(85^H9>
M7TJC'(R/[01E38ZF,W_+"I[9U&>E[UA=[_XR+/-\5Z2RC11IS#M5 7,=>B>]
M(M>8\1SLI,RV-:P9)/TEKSNR,6M8V>!0<N36D)GC/K@WZOO;.W!TO.X9AE<K
M2T"K])@GS+0.$;LI*=VOTEOHY5@"@9+S3/[$@ODJ(!>\\<A7YQAY<,Y#K-,I
MU5UY'??WE.W^6),J$L8M9+.<5Y5\^:2(Y/UHG-=7A<P$83V^3(4/-[!J.='6
MJUI)[9,%(J2Y?6_1D^)R@Z]I5MBX8FOIO,;80<NX3WI/3^!929NQ-)(]QG4Z
MK4$=VHQ\920C5H*B+6,E;+#%.$W\M%\5>5+/%R=!8R4?N$7,.+U4R[N?-+9=
M=#G0ZOX#G#/[>T^I?,$7O_D9)I89AQUY -W3+B)$[@\3*A;>Q"+N5JH=@&%M
M=XG Z>4>&*H'B;6+BWW@&&)[A3/D9$_YO#\KWF_GS+SY.Q^MF.UZX??0J%"%
MF<+Z&8L@5I&V3[0#P,+#+CQC57N!S[.;66R$W_ZAG*M)3%,'2DR=#ED%"\D3
MP2C-C"DSM]'CQ^RJ.[T/'0#=#TZCB)1&(GG:G)V[]+1?N%V5(MR6']Z^/G<8
MZ#4GU[6J$3W^A&,V^S+]IVIQU\99%:-(=S6YEW7,V\G%I)Z^OD7^6:"" 6H#
MQRQCPW1*@1!68B4G8/BQG7RB?QWGK_U7+V6K3) !81L<&T"S[GFF$^,K"&06
M%/R57YUXC/:=A7\I&@(4[" !IOJ[XGX1P?JBV_);<"D+:Z )&62@5/;-OK2G
MWD"FL/R->3_TX'\*H!469M<5N?\G89P2)AFY:M.HWE0Q]?LS^@\E'VJW*5;/
M4)CW-TW/\>KV_OL_E/91.6;C%HE!!%Y^9^5*#S)/;_G/6A.2BLIDMQK8&SYW
MOQ41@MK+YY 6K ;94;@&)G4I;+.Z*]S\6LI46%S)4F:6^B2*6=)I+C_,C%!2
M\ABPUBP5V&NSA<HZ(ZZE/\5STZ(/E1WZZ?Q-<!K*3;\!.CG^^.FFS&&F%6VI
M$8*QH<'<0(> <S-$>(O,?JTM"-R*6O4Q$_T"JS64EB5L@'X'"[;)CIL.!70\
M@%Y7D\\NF!BH5N^AILTZL*B(NX=KXB& 1$[RCKWR[DWP!J]UA7 RG=XJ3Y+E
M1,UR=%=7.X3,L+M-'/,K=",G<KO#8(P*YDFYM>)+7>'T=3\=>K/+A5CC]"#%
M**<\SSY[V2QG,8-IK_(A[XNC7HV4:QE\VH*$/ZY@:(:1/#)65>V" EW']/21
MYQ(M,7&IO/ [^WN+E2E!J&.&IC39^Y% >QE?[:?)RCUUG%6%LM?NXJLDQ8"/
MOEGKI03])+P[/X*'+1^THF+K->R./P'>W ^0\5^5O8W;Y2$83GP(U1CY7@$.
M$=)^)7N4(V,WA/-!!F^Q<&DEKG^N&2&TP4Z]M.TB$3:X1SC2S12T.CCFIQTU
M2FI1#$C#_ZE#.S1B62\T[?;:OE"^D$,3Q_30( )JT7CZ#T6H>*SSVYU!$<!&
MG$_%0@[CL^H=DF[7%3SZCLHM6!M+0/ &84PS/9:AU:@9""]: F2DK,:.L@R:
MQUJ;>R<FB,)U5'?0JD_TITW8D)<SSOU?A+7%EX,IT;5?@+N/0K-%XQ9\*AX?
M,+W@-C-^6O^OK[<*B_+[WH<'49 01!H&49JA8^CND&;HD&9FZ Z13@EA!&$D
M)(8:0F((">GN;NGN4D3D]7]=[X&_@\_W;!\\U]YKW^M>:Z^UXUE'QVX!,X*S
M85 "RGY6C&FM%[T $'F5[TT>-)2IF;;B&3I3@><A4D9U/ CDALM1.KU9(@ZH
M'<HHH&_!L0PHM@>\IGD8\B-O$ZG*B_V@K""_ DX_M+A2%+5*&J;XR&CRPK\"
MNV?/1]]"[KB&XW"AB/JR8BKGXXL9W!AK2AXGI@QK&0^!*:2FQ# U!/;4:>>D
M%EVSUE?D\-W[\3,58JI1V%!D0I>J$#$=/'?:5>%I>775<_BC_C^<DZM?HK46
MJ;U%@%F-O1/U'<*C=E6;]B6!'/TPFJ .UOFNW1X +X3V46LA!N,)=?9(7JA]
M!W=+]QY='LTMUR+V\^MO-8UYL/CE!DL"Z5+Z"VK,20'63ZC::0J:W&W%C(.2
M4S4A)5N3*)!72_XDYL?DI0.C#U<M6HN%0(M]\47?[YHDLUG^A98E_AM7/%N7
M=/)%F(^R;CTDT@)2K_NJH9=\]*M2U=&->N6K*3:UVZSJ+KV4KX:6,SW \P[<
M!=8:GZ1&[%QT78(S5[6$[%N+?#(4@<P:+8AX*-[MR>L7*;0?VY% 8,7T4@.*
M74R@=:N'I$<'TQAD/*U*Z$LB_I4/X*S=0D!OHM(,]O?&[K5Q>5/FR>U3_%O#
MKK=<"^H Q-$=%SCN?_4Z^VK!\2VS$>?$PC'SUVJ+.+$XVH3@@(5D<D,L<DW^
M\>.CV;.J;K/=KR,(WCCKLFBJ_E%+=],%A7H.3\=J@<<O^H ;]@'(Y>E*KWD7
M"G5N*ZL!DHE28_G"7J^WX]0(5A">1-SDG&/6]]RP(<XE,[U LR;O_#E+OH:F
M*4J1MFSIYN\ZBJU9#O ')NWL4(&&YEC,YO7SU#'3RNAC6\-8(56:NY[;QA\5
MIOHM:3L&0Z\Y."YQ7]A,E!+=33=E7B$F%8Y_F7^T\#O>H?&JCM6Y!TPW$?+7
MYU;DJXY+=<,>;5(,LTF_-.K1)PXV67,RQ_"0LG]T<KO98"Q4^5&I"V7LTQ+C
M#\!J,,QY5[:P&3=V_84*K'&KEGABMW?G)#?@J5,=XC;^!^(Z*#H,*B%NHAXU
MF\W,.!#)>+: -SK NXS6G)A2R.@%LZ9A;P($]'C[>MP/E(ZW9(U>6=73:SZ2
M9;1=+TB]3O*$7"0CTX:?VL=/JA9OIMJ8_8TQN%$+GY3UC.I9&2H&7R*8?I1Z
M%$(+'O=F\4-?1TO"SNI6 G1O: /P\U6:^-$]8OAS_R8HQ?X6F.!__'_#H:*R
M3Y+8=.QSAAGB.^G1_[<"Y#(U (5GBF8M76,Q;@%!7VWN 4G(48&B,S;I!%A2
M((&X=M+GTCR']H<;)6AV&E:-ST&@W 8LGZ(!2<?ZX>ZV1&&1_:-=]HPIA--4
M?4+1>Q#W7.^*S0J&(12/L'/+@BS8Q/9Q'AB?-Q]%NO20BJZ4EON#^C--RE!]
MUN9>I=+S97=CQ"M?!\%$M*-9"C1I!*\X[1[ 4XLL7@@]5_,MVTX_7B(65+K3
M]%?8ISC8/ @#"<$]"&I?/]]T-T[[837E'PXX0QY(D.9WEAV$VM]\KG\.K[1O
M7WWK7;B8>8X,<T8X_B&<NG)4[)(Q7:R7%WE1/V80^;U3_0S/D=MYTTV@_I$G
MY+?GAOBW(ZA7$QZ2P-2S6BZ3TFK*8<RKPD;KC"7?^H\=9G.0Q7/0EKX8+%'I
M876TW8A0[^/F=.'DIEDYIHC3WR_C,T$J1V#,/0282,K<?-+T0MYF8X2RGGR/
M?Z.%#2-U^3Z82H5%F4FLMG(V&[OS)<M+@^O/"&.\?T7X0X>\)$WI+/&69 AH
M9#_S+7>K4N!OSJEQ=>5@IY.DK[+TY9[""Y+;J7SUS:%Y'[Y EL=KEIY? 6D*
M\^&\:2N_UAQ8Q2,B9B*W425^X7IU".T/PHB0S]RXEFJ^=8?#/:B['2_%=>G'
M2W[.KX4%>GD6")SGL_F2SLH<#]^%GJ\&(*]<8]S\O\\O.4 1]P"["G;G5.7A
M&P/=LKS8O*7/GVAS_0Q.#)/3IK$2B$>9HO$Q$V9OQ%L3OWM1/E5G.-=+_JG_
M!;X'74--EC&D<(3_V#H:U05]BSKFH>PR0)-5"UUWA52]J'PS*X%F98K?.@('
M&FW^1;P^6P45W\OI &???^("E<*=NGH':1SR&>,=J&TQ"@C=,[$ A]'_5)<_
M'#B2YZ6[!_2ASNAC$M% H1EK(RX;RPR!A-YZS8ZZB,,C#V#!1!6B_(W4M->B
MP=>$C:9845>>$ZR#N,T=#&\=U17PUK#\)Y%I6M0^M3%R6>8%WPC>/># ,!O&
MAO;G9R&T5EJ\'"6?I3DS4='Y4#')_[IVZ*V]G\6'^26<'E&&VK!&F9@&N@.Q
M_0DMT2S-(+94QT&K8]F++^VXV"AA*>.;! TGUA1+MI=2!=?E"C6)?"FABU-Q
MHQE7CPC2$XUG07B_\*M@]=I9>PU Z]IYRR\ ?<*41$\M))=QP@3[J]FB+:-1
MR0OM\JP-X!?L_6GH\L:^?[%&STKYL"/*.7:K2L+@%?$H?]+G8<=V,C:^-->2
MLICC$%U/A&[!Y@5"<9&Y8T>9O*/H,0"MZB6.W)[8=$A1-+E5ZE[.KC4;T1]>
MXV4,5]])/4%VJH\%P;0P#KF%]GMS,[>FO@64?A(T [?*+: !K._9625AH6.*
MP2Q#]!V-WT@M2RT4KT,4G+XQ7N-.%)DN96.8JDV7>K>TGJE%_S32+EP_CC^P
M2C7R$'@V:Q+B5-<<B0KWT5781%DTS3#6-9UG-+CHYTP4UH][Q6Q^)Z]A/[G(
MA&@],VECBEL/5 J2QC+_3"_!.DO7S2RL:3:N#':BKT7U:T^'=RV4L=^BH[Q<
ML'J@)<7J= O]#&5E4G9$(BPY4#L'^)/FIV;/4+YX]K0^X4>&&"ZQB9EVAZAS
M\2C<;8AD"WKBG2;[X?QYS;M(X_8#\IUZU.#X0<IWN80'92[Y1#'-UM7>] 1#
M%.)5G"^9I1D$R%]K86RE"J\3TNT6(G;V3*#K@Y^FW_G7Y_1OR6<B@;IOCZ)0
MXL(<W_-W#2T)^=7!J,'*G/B0A/?SEU*8(?-.[N3B?NQ8Y*--:ARU68? =38,
MH,R9@B!B_RP;X\%4.^T\MB^TVQ7/.>23(IE4[@ B^KVCP1E07Q6 JM>:]!Q%
M#GLS 41(-H6TB@)J6#+<BWJXO0YR)1M6<_<YON1TUGU1^.[PSL\F-5A:(HC]
M"U=6,S_G:9C,*JGQ5,'"=>R^EW9WNZKV!R]VOV UL<A#=O%:V 97K>=/@\N%
M-P$&GZO$<!XOYCL 55I3$3A?9@S9?1]3 4D2PU!3OV4]UVEW24DZBIOTK_NO
MI*XF&H\K3^?."TOV\UIN][952XR.')HGCTEM/,9JK&87Z0Z$QKL_K/NW2X9(
MV-Y"F@)W"T,6[C)6+D1T\YEN#?W76BC6:9_\2FBV@(HF ''8)._V^<#D8@'?
M?K+<>.,95'I]=1T7R/F"9%%QM9V(G*&U HGN+#2Q"0Z#^!',\8[W #\[?YP*
MKB;6QZ7Y<]8?^UU^_CX81,=ZOMVO'_H%%'JD:]G\9J7$D0>9LT36\Q6RB[NE
M>0[8[T#8PJ?O 2_->C_+S.JJ=LC_S&;7\UD>:4/LC>G'&U;U2>B3"LV=2H6A
MOBAP+Z8C'9G8"TFUEY;+GJ9Q3<8EFYF^BXCT)37F\K'_B.BVURK^E"/\I -I
MJL041U,#9!ZJ<":"KI@S 3? 3FRE= ,=+_)9\MQP8=6;V6'I7(/QR(\,R5H/
MLU.%_SV&$WZ/JQ;][](J7LA^*='4I4#\;/_F'I#S_RYD&@UUSM1*Z&]):*!S
M?@5]N@?(@\/J068X$O9?]:J.URR/&4QOWEY^BF'%4@[8*W-^1N!MR0/O'R2Z
M!Z@E]DS@;=0W\CG9FOW%^,!8G[ 1)3S^9+]''=1.9ZOAW3R-SIL@W=.G82 F
M1XJQ=R4L82 ?R=USG1QPBI=L]00#R>G+>8F@JMN%M1%FYLHD3#@2R7.^Z+B9
M'OZYA"B;C7"+U-/8CN^6"G-+XSB6GR7^)@AKWHIUL:MAC^M"!X4.$5?H7]QH
MH=@RV4 GSRV@&/&&Q7KFADU4LW^NK7@W125N+)AM4^_;$>&\9+LH3M5Z[/2;
M,7ZL$XN6XCT3UBX"KY8O+;>2N^;EO<-)2I8'QM<Y3Q1+=_2F&2B*/;IQEI)*
M]G3WH39B?ND]0FGQ/3^=O8+7.!)%B;]'=MRY(QT2N2RDJ58$=IQ"S56/A>+R
MRY:A2,,XQIQ.S75Q#R)59G6BAE$=BY!>Q;.[",T:?\HS0L#;\^P-^BZ0:4T#
M2LHDKKS6\0)M1/;U%%#. 8<D:L\/"B3MF(._=3;F-WSW+%'>Y/EAB$N?I&:N
M.ZE6WQ3%)9+&$?IR1%;TZJI";"+%T.9Z'%$M^-LE\D\7[FWP1"-S'?4>PN)=
M.?1)Z8VXK?[Y169B8^]/ W4_ \?D=#/E\_B[A8%FF*A06I0@K(=7M>83!:&.
M7 EG+Y;,YJRZG8/K6B!%4R8>#XI*__+Z'D!J$B"5EG9:WKFV;7>C95?,78MW
MXD(XN<S!MRMTBONY. (D!]PS_]:F5T*MGMI"!#[:^M:4LK]5K\KH @;7)?[X
M8?&*($5K*)#M"ESI7S#H'/2D=*!H>'>9SYR)QG7.B9#""<T1M&=DBSA02RG1
MU5 OW"C19>?PYO4671N[S$?M_5T'E]Z>:[VZDC990_;K;R;TKC3U-[.Z"U#
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MUN^(D*.H!ZP_-]!J*F\8=>_;&T;QTFZ3MUAMFU2;/48J7EFX&W&P$.-@:JO
M1TL&=2/]G.4A^AO/+R$+)];VTTD&8RC5RV*4PN(WIGC?<FJC KN.3?S\_+UA
MU'P,S;9ZU+[Q;1"'_*-0G;%SQ3?<+WN\"]9/? []RRO@R7(4CH-4'UC?)&)(
M;WQ(Z$'D"< =?#Z$7E.IDIMLVY'9=E/YPVCH"V<RQ =$Y/(]H'*L01YIN.LB
M'^QTMK79/H(?EV::GI=@'#NG]!;3\_/M@+G.PN7 (&!C'ZZG&Y1V#[ +FN@1
M$W0@E$K5)'FWI92">@YGE-8](W0;&6QBE&H!B=,I[6C7-=R*'_,]Z62MQ-@L
MF4#KMK*.>)CZMS:3X6K+JS4$3Y Q^6U.I!<.2S,K(WR),7OA8R.(KDG!=S3H
MOIMV;5'Z2-]D,T&?IZ*Z90.TN!@'Q[0TEO6_C& WV!H=<A\)0O_-L>8'.6P;
M@#SR1I MA!JHYUE3:IE=/_,(VJ^XP<S;)14'X\?E_*3DM=H56$[#V?E8HQG6
MO?B9#BYV^VJ:6Z>21S9J*@!856Y#<66WFQ7G,^CKRSA(FK?8>Z$RY/?@4_'N
MK$GD5[.%4";BME1_\F!9PT;2RI1Q8Z4B3]X#H^O9C[VZ?H>;*2)T(S;TGL\+
M#!5,6Y%&GG$^-2^_-M!(?IRS$B]X:PNS:VG+46U8 2S&OW;3$-";9LR^UN;Z
MG/+4K8B*I7@P8$*)X7&R0A&#(-!AZM<L)G)POT?GPYW*AY6A]\[//_Q.0NE<
M-!9QI.W"E_BJ H=ZY=5<OH *:<DZ_#;'&PZCS31/SG?*Y9)M<@_4>'L??'C
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MH!(0!5T9R=(VD@W:+[#$EJ=-47\PI8=2G?&_NPS($J*IP&^T6H&DXXZD=O>
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MX#4L=)C!Z$0R='4RS9<5 <$#!VHF,']T"A>,=6;HXAEEJ<!KWQB#B!=KU&8
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M,RSMSX&3K\;;!NS7HM5J\?L&/>-=J"Q1Q!I.=L(E%J>U+M;RD3I)Y9 XC9:
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M.8@,ZXA9L%CY76S!/6",>_ >@#7YF^U/UT3P+J7=/2!D[P^YQ?3[,P^7:];
M(SZE\6(9T]M!T#3MLL'$RG0V1[J%M5L3$!@X=0^80VK=/3C\=DHGW9%TJ,'Z
M)]3'\B=1SAJ$YLB+<@8U3<;IK>*-E\IM'P;&W8;:$B3_G#AXSA2#;G=<O:@/
MR 9<H[__5P]7GP:NB<N:5GJ4$@*=26XUAKM@C(-D2_S?(^WVQ::[[];2!P9R
M6Q5&\3G0_PI.%OQ_4*DLEW*QC[R*#IRK0$;FM7TZ_LP5^IX)2#_R&;D^<.B<
MMDTD)HP4^!N"_X,>_3\BU4 6?%4LC8+BX>I]J:@H&Q?RIY%6O*!I06&#-)^R
M[]#(38F0"B(.K7_UI_-_8&5OE@_"FG7-W0F(')KU)3Q7&AU]/IW[N;4[V<$V
M$N^1?B;^D?1_#/ZIJWZ,SN<7,*WZG4]R-UV7*7F47$,[;KF$H-X (ZDR4"?>
M]@OY=/!_TH#@V:PL:)@K7KIN49Y $1C3IT1D66XWDO:T[SF'(\IS+,,SW#SZ
MF@5Q#Y!IXOF-JW6:_^\T#+G4O&"#R +2U^A^)T\<#^LGS$.R9_&,A,2?2WV=
M@>_Y3Y[Q46W..OP/$E763O23'ID?^S/-(!A?=PU)ZMN7##JXT7K(LU_/P>?_
M$_6/HD4SEC:]5G$'5([,]/I@L<57Y<FDM[\+6US_&VBV'>*RP:K-86?V3:6;
M>X#7E-)*\,T6Z]TY?/;;?XR3Z-&*X>Y]3Q"8!E18O2TA1Z&6EA;IN5:#BAK)
M][[]!S/5TS_&_E6G6#+2:Y4X[\+L=YKOPYRE@>!5G)9/_X,&)0^Z,&-G G9N
MP5LKEK>KDY$);69!V6;W@ ;XPG_)EU.+&^.:N\XR<B!]=B1\=PKM&-FA/SOA
MN3N%+_X7:3Z*!%E=2YB(PS^XO1WEH3^DV;T\Z+=)>B;W=X*52O_#5$3;UVEW
M_0L+CD3OEKB#.I!#0A=I]P ]%JU;EI; _P4[33=X[*)%O*/&TNH83$LK*'TQ
MX<UU8]_T1+S3@FIR"CR")E_\1?W1=?,)[+^YJO I+3[6FO5EO8Z?]3D67J"B
M3IM=,B1Z [GIS4/<"7M5)Y:*ZB!>N_@@<N=?T?G?XG!(.U VY%NXSV?K>=7P
MO5!\^8L=;#&IA=R_IJ(S84YN<W#'Z/LR(:]._M&H\K\V4'XS:!25%C/UI6G\
MT,D*\TZ[1C_V0>A.Y<^I"3B-/8 FH8@UYWOESQF>_S0< [-"X-#BG]F)ZWM
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M,V[2*9F4#72^/OKBT#[&.7&(=5(;RN!HW+_52%6:N^A+&M]:-^0FX[CO(/Q
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M" M,A'06)4-$P=AHEWF1H#!WN%32-WZN6^[!<#[?;)-+S;<.&9;P %T%F]I
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M/#!'.PA>J8!A#V<PJIR>:EBYF_:.CT%>\,;*&!HV[INSV"T<.JY @8$G4R#
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M@/==_N/SMP-(+S$>X :C*61+WN^CX;.DQX[@,O3(:7+@_XEM-(Z"&6.G\
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M?UM34CA-F)>JA/BZ;SD<EF\ZW>W+B6O/QJRD8F%/MKQ>RD8286W0;GYKN0_
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M=<X"[Q'>N<DNO&<(M[/OJ>&#SRZ^^#Y'1R(V;Y[;MLACSO$L\$7*9_&6ROF
M'PTT+:A?8^5MU9P4.I*L&@.B524%?M+L'7&3&QLXX&I,LGPWMM_,[(R8$-\M
MA::M3!1)/P:/L'+P]Z+  97@&OSP_O7@G^?[J=\O/;-7<L?XL#Y2>SPON93W
MI5$/U%THEV\RZ=6\I-(4[4YCNZ8O,R#P_BB'06GKN*A@2VEOFY=[E2[<:U($
M=2<$I>*R' *S:(]>=8S**/P,#Z73MU+:Y1CM\^+<52XGL'H#'2H_IQ_2P"XL
M'7>LF# (W,\)@9RH%V>=!5VCN'LA/0$Z:NND RN(H^WSK]Z)<"5_JB-\C[V"
MR[8PAR[DM<F]*;'5TGH&7VZ40$D=>"/1_=.8LW^3.Y;Y_@6]/]'(^NL?(4])
MV#.=J-+L $OPIM:&IA:>1FNF[8;X U0M?Y?>(7B^?JA78H42@.LMDJWL=X9*
MBB:YT+]<0H"':C>7_7S>3FW<Q0%'8UCP4,V!V>_(B7<XP#NX>-GC3F9)^V>2
MV_G$3SBFEAG,^R^*5+E+?E.J<G^]__IQWQI [F;\IY&M;C3+WOG6I'\.L?V<
M.LFO-/7M@+0B=Q:72B<SNS$?JY+JIGBC5G"(.K:% 3)4LU2XQ?A04LBK/>GE
MC#,\[C0<_U!0+91.#_F-YBHN:,&T3%XNV;-H6!384CT0?0S_6FQH+E .)=V8
M5*UH?05W-L-83>\T*H!-YX(<AF\)I.8VQ;!]2W_35WULH60E_>1MU2 \.W2A
MN81XF*W(&^,C.E&_!>:8_N;^^RKA6'61HD+-\.[=QU*MD96M/6C3<60QH42&
MIKKPW3S&/CW=&V+2W;%ET@W3@@IOUN=#MBM,;B#MOT5L3H9EVB4]UXWV?E7#
MQ@;S"Z .R_(*6)]1E)YF?:C0UZR@#W-6V?(;G#&&_K+W2PTSU%Y>+?(/=9,H
MWU1CW[)(-2-89PV<;G'Q7#J#\S+ CMI>3YTY/RO_':A<I@G^VJ4)?2QH^/!U
M_T'QHHOZ5<9@X>V95*MP437YN$6RTO7\O%MW9*^$6K#8G--O;X7OQZ$4RHIG
MPI]531&<O("B1L<1(O?TS>J@"1/A0\5\5M1GEP5LTI?^;PI,BD&N0W]XK;7=
M-1'M?$2(O0K!]IL,TEWU"5EXB0.>GK6]D;C9 ^XG@)Z%[/ZEJ3MJ7V[<^<-Q
M3(7ZP.8:_ZS]!IV3)$H+_6/.O\>7C.A!R-"/9!N>=7'A>PET2P^>W%IBBQX>
MRM8AX4\GV'E^Z>3QC!<X_(8Y-,8!%<.'>1(:\@!S: :YAC+='SM_V9S+G,E\
M,Z=_S 73D:.^G=#FC+CX-TO3PL8RTZ^I_LVJ)HP@O?4XTR=$J<_\*;8SG5C;
M$5LC_1O4G9D-1G7VUV 5WH'D-M1LM$$"5Y)J%2\*RGVJS+K?71^_?CL*(!$7
M\@YJ&LT#[S 2/;Z.Z-&<L&;HA<C>YO;-C/[C.!T8'IB3I0X0 B^U:#!N&&)D
MSL!5Z.&T;S$RCR,8XWIQJ20"\)]\H+70+)D,9^0@5HB ]<&+&5FPAJH\H+C<
M,>Z( ]P7$X0<'O@IS9";VOE8-FV:889E;UP,SMS;?QBV*]$*G6>A]]I0E;US
MWBESHK=Y/8>KP'^,>-UV9"SLWM[#M-ST:Y>Q!0>XH1#)7F-C2E*RPS\QT^M9
MY ,O84=;IE]6V).)N)OXK$]SG=W'/6ZZ$0U0M'L3=#"A/@@$ZM!8/X\97$*N
MFQ)61#$\L@^F-5CN)G]Q3=!@DB:XT*F"1]GJ8P]#5GOG8"9SN \*X?11(>3#
M77F-=U2W",YTU$UN?/2)&K'%UD*:X_I@8MS$%].:"G)13\@4% \+>V^946^X
MV=&_J"[KWKP+.?EJS:!*5G 6+G!<@!+)(ZO(-)IK:>ZNL<)NN3/OBQ<@NR:@
M;>)+-]P//3=0)8)3*):EO>)%<720S ?>EIS*Z$4316W;!1BD_LO- A%:E7I+
MLOB.37M-4LWV30COO=R9"UYOX;:M.%>3S3(G-LOG&C0#)'U7/UQGN=/)7.&'
M<=C4R%^B78=9Q^K1::EKCJ8FX  ^0DS_EG'O'EH)[6SO)V.D9B!?COU@]8]5
MV*+O,UV^%E1#*4-7.3M& L>2%DW8MR1(>_-=Q!@M;XEQ/3RL/UF#M3=,ZE K
M<10E+(\$?DPV71_[48J6S@^S?U+1(*744ZGS=^K6O(+S"XE#\!WQR^2AO&AH
M'O14#1"_=D<Q/>M'", ARB[&+;B1V'; F,43EJ](,,7=&C8S0E9]"N<N$W2R
M9H6Y>A=ST24JDFM-Y,X@I>^+F'$.K#EU'J..YFCM(TSM)X53OVFB#F?7?)^%
M'>XN 5408Y1N>Z"7!SNO4,&B58C29SHV5LA5FX-\T5J/%%B8G[B%A5/$4XJN
M1ZV,,\J[7IOV'E^"?$ALG8:J_FBOJX<_:#\I=<(!C\R^MM#XE!>X+=J7N,I-
MQ_);O81MS< 02'@B>\8'UA#V,;&!5QK7 ,;F-/FWQD=_9YR3'K2J^U,-YXLW
MC?Q$+KYC#+R>,:#+6WS1:Z\</*3@=F9>N46Q=)K*6VYVOD8HNI:XW&Y/Q+@+
M3I1X4ZO6V(55F*'2,+'A_T@X8IT1^?"9#7LZ.TN$@.8HJ1.T[+7H$=1UIA\K
M8:L\(:+-W,O*N"8Y?_WK>M@;@_>IJP9>,O-Z1J5R0UIGN<*!\_%^:3=MMT(I
MR?#TXHJY_8_"G]TCYO7AH0XU)8(!#G:['7UR,LTI\M0EW?\]<^;?->K^LY"]
MUK%A62%2B<E-$:W5A/@K.94R'O /(<"1&KA=1FC4"5Y46)XB85!DY-#3O2/.
MG!=A$^&CEVX;9=J3/=680?+4JR?!XFF,UDX7UJ,%+8,#(M-:YY!S.,#&YUC"
M08G];[C^#S<+IB O\WN^CQQ3^1+Q.[+#$W0A_58E),U#]A1^;U$4)=P1C&1,
MLZG?.BN ;E?,#/O><%($S45 *]*&,G,[*'\B7T!3E)5>/4_"J%[<&MZ@M5)"
MTJ83_4BX\T?)7UMK'<A=7&\9#%-^#D%&D;^!J@#^E[./'6-RV%%EC1R*KKU
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MR]IR]NMQ&!^V1W02_,RY=,O^MDP5J1O-<I0U,H'O#?B-57_8+^H;9^KY7]P
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M5DUT34>%& +F_N?$%V8#6AM?L960YC396\[(KF/\55YT;Y9VC%1)D97OP'&
MUXZ9K#=ZG:"TDS"=SGIFP)_4-56:DD%B,&110& F,-6E'6JXQ?#D(PD_(=FW
MJ2DQX9O*/' M/W5^Q9SJT^R4E-;141A=T1XQL<RC*DZR*XU[KV ';6IY9UK;
M$A4QR6]]HW:Z,QZ[QB.1\":5?0S\JQ,UV)?KYQ'KJZX3Q@_EWV)"EVC<[$)@
M71JGJGP#@Y5R0[+06</.D:A$'+ YM6Y;E\E@08P9P\<]A1C/E-]QX8OO0"!4
M!8K$0_%FP;/XEP$: _\0(1#0X0!8$ YX<ZEZT+;!RM!@6M!MRK+W$9_ RVS%
M4,3<V2CYW==C=_JMA%Y<7ZZIU5_F?'-=V@MY6H"EQ0$1J?CWQ RZI/@5>Q*)
M_Y2G=_+YXE%[2N:$K<:WLO<6,Z=)!:(CHYD7AY=Z8YD$T&PT9F^=\^;];@:2
MU(\O$2F;].Z3'CWRG"D)YZ#[_,7RA3-0T+C>LZ7=@_.0HS)N;ONA5:<^41M/
MPCN<.N*Z0R5KPQN/M^Z63C5__&FR<-!\IY,%839O?^"_$._J(L4[^*=IY@T4
M-8\5SGZGN+![#3SHC>>XUC4FC'3E)GJ0AD^BOM(Z4DE!\FR6Z2G%Q\R!9XG]
M!,':+'E5GL,!2;883SXZ@[&O*44VSG]V$!CWM*#_RIB-V4QU633E"M'WT\F[
M\9XHF[=F-R=G0W]T&\NRWQ#>0)XD\!INKE5IN15>S5P-EVPVO54^YL \XK3+
M(G >FDU$2QH8#C'<YWJ9[^NDCZR3J;N9J($J_7:\4@I%I(0G+6QKMBTH_4D/
MBM+S.L+@T;V^\+#J('B.JD3^_AT6C8>9KZ_DY_X"-)5/,T [T*>F,^R^8NR>
M,F9W]*9T8M2WW13"3B,A(UI^,5B*GF,+30U#VLCM"/<X+(JNT$30&U%A<*7@
M=G=.LB[2_+69\&X!VRE<X-RZAFO+,.H(&BWQ>D,]X] L41C=+'/L)).,8/NA
M5.IUT4HI^))3D98M? YCM\T5M9_*>D#\)6<KZ>>[BUNC8V.9-&GK/2T;*@6'
M9BA-B5]R=%=!63S\+718@K-;FM[Z%_"E@_XC>&!H5 C,(2,C#U5T[[^&)!"5
MX60#>0DYS.@EW.,J1A.#N^-9%*H7.FYN[<E2CK$%R[@WIF%]C*O.,?;F>A,W
MFTZU$[OVFR-_9##"M^>*7+41E&J>:EA5I(3MQA/G7K[>)*%+I/+;&/:U1*9A
MH0Z\9Y) Z\N+!Z4(O0?Y:>!%D3C:9:-)98X3-F8T5QIE(95OQ7E*/ .GN*<F
M-%"BLVF4 TF'WOIX $('[T+GP:CK<*3"*.& >37?'1S0&;"&);Q<ASW$\\+3
MUSC@2\#S]6YH* :L;:6+#-O2?_VF^]JRZ/-2-FO-^I#?!6%OZ0:'^DE7N5>?
MN+0+A)S7\YA9<2A+2MJ>,8[Z! RR5V3U^MJSEH_8>*EOV1:Q>!E-,<C\R#/L
M=\;$\PA?MU%B?,JBI2!Y+.T38B)H8*3*L6.CX&[ES)Y[]3LS\7YND?!-: DF
M!$L3!4QE>/4QD/OY(&PJ,EX?"L%385:^K]%UX*=)$R.(!-,Q1+&)OV]T$H2W
M?:-\1L[F8ZY@N\7DE&* O[2\8@%%K(\#%[9@>^'7MGYTHEY3245Y(H,$W>F?
M.D:#SDXS6:+'L]@Q5:'RD0>10X_]:AXR2=CDKGW@M.)4D[!3%JG?KFBH0)C5
MKB@(-DGJE1TVCC4A!W*NGMYI$7H1>[AL-LM.1\N ::R 7N9^*$3C &/\F'Z2
M&?>BK*HT:DKMD\Y1=93!YVG%] XJ'%!I^_;NW0B3HGDOJM!6&F(VZ<T'M.S=
M:1*.Q7&M*9&:KJY:*UM'$P6A P%&-2MFR$BCSH,#M'YA:6OEHK*Y6V+329W1
MO74GH3FI(!!_]51_%4.)UCF*4GE-N&BRRHS5P--F"T%]/S)%&)+"=A<C7)GE
M)M;;'U.7:3,#<7'ACUTNB<C];=6N:#<VX+#F:]]3YW7ZA[+[LR491*L_O;#G
M M%49SOS)-11FX%:44YS9K;C48JMS95J_?>V-PF.Q+'?-//4J;,TU>I,9^[Y
MFA7G:H>NJ,EQF07T'![S;8G0<&4;FA@_TWS=$<W&M$Q>ZY7=RUH93531-/ZR
MVMN<0N4P--678T>[_&*\:+ZVJD;OM<USOW<4M.Y2(XO8YM4QZJ8/GJE$XT64
M (.B[,3&F9YB1=:CM6O?$HVV*C$2!=)U&2 ;L8M2/>7C86B:XMJXV1UJQR<B
MLD]H;^?*Q!>&C#0VEC:-+"5JI_"TOC)X0?KK_924>>G%@;%7>Y:AUM=:AXV6
M''H['H</=7MDT,XK4UBBRX6B>?M_AD:J3#C .^[,;#6<>^J,"W%L742E86;L
MM__OZF;H:07N&.JL- JN_MJ Y4<:=[1PP21_#W:D(06[0%MU>&<,;Z^&?,(#
M_AWXQHQ,KY?7<1\>85KF#)BHSSHCO8^9L!6LCS7BDWT"U2\EL-81;3]"8+W$
MGW]?SB>D$_QGO0S=&.V=E:2+@J[<$T'(4161#Q\#>?&2%F=^*#O@^X)0@!DI
M29R^/.Q7H6S!Y*I\-34G)#$C+BQX, BXS*4B!&$L;:9A0VG/X\[(,TC\ :K?
MV(:&$:BAOR#6".8![GL'4FKA5,S-^O&.CD: [>)'FH;"9D3VTA3@,X0]A*"L
MF_ PV/#=[=K,WN@NC7<2J>75D2CTUW6)1'G9Z'V)8K::U:STZR'YM">A?G-I
MU[*R5=&@/?QM'IO5@F=!?6G/DS &*-@:))W,OC6-MVKA% ?D1(%CW#4QHWAH
M 958\],[G%F/@GH>0+/<M: %.. ]^2I'0T3LMO]E@4DE'_J<_,TW&Q)^<6Y7
MGNSG2Y0Q?JA'0>GL'W<;L"EII]ZQN$K>.LI>J1JEF-E!+R00^T)]L(_=4EMS
M:H): =+["[V5M-_TI2\;![RJ>U'%6:.HT?(>L6Z+93V0KDPM'5?X9!_\!$[0
MG,Y<@SS)ZMY[=<1EO%)A1KTI6L5WXIO 5*GYY.JY,F-FB% :]2:]?W?2E^6:
M2K8U93(EQO2QZ_/F*?<A4E^I5$P5)75DEZ.-#/3;=]=*>%J='XJQ<#V28V:,
M>?FX:H8)0^KBDQ:B#EO>.-'(',9#367FM==,M]X1F\;H=K0?8K(4OCO>?*)^
MLS7S\<7%F'$A(N&>Z=TU#81121UX#';WB#>\L:J@5W&!IW3:GD+^P3CB69ZI
M''$67TC@UY1[W/<P B[M')CO_M&YN4L70] F#-&]:?_U?O35U83[N?3/*Z>K
M#FYIWX48!#P4&W!J##P/&;YZ)T(.I:OW!8)6<I(^P>,AX[.F4V\4N'..%/W:
MI_A/K$552ZC;$ ('6.7SF^%'LI?ZY,OTSA><A--1=CM[/0L3_D4'*%VKT:3I
MLR>('J)$5@.1]UT,."#%!>$6FO1I$Y0W+*^@H>(K?G^Y"J'5:1FUJ-FZO/"Y
M:(YL2[!B:,*XTU(/5&<M]4'2NB9_;'^E,(Z^W)5=QA@L*.J43++_1B<?8RY5
M5#F'%M]:S!L^>;QJQ%S6X!A+0[I!"1I @/<QGF<2PYAL/$F#T4^.W;/^$M!1
M41^, QB$$^:#IN9G),-S.W  HS 2@EGP ?<RLK@WJZ)5#VWD-)I0G1TU6!W6
MOZHX2A-BNLO$0B)S+_O5JOJXBU-N>]OP$8MU0?U9&M !VPSFW* @*KLZT;[;
M[/LP1(4RP!XI4A"Y#^J_5OP&NE*$3LO! ?#:KGN6#AUG<L+=:"E\$+C>H^33
MX\:,;<+8U6P9WD0<\\;&V\'ZN(Z@W\<TY*D'7/[6;G\&V&9.$_PBC,3ZVQGV
M5X^6;Q$^J&^L#%S=8/D.D1L?(*P0#F=XO"E;_?#1NLODC\$'EH..LI%Q',DO
M[_0+]V^EB@SF##OQ%&8E[NK><[G*+;LV\H[37LVF5=#@]]VTA9QGVCH4L^HE
MX6DS6\;H**]4IQ!P$@YXY_PGYN9;: Z:,@^SOAMV=D?AE,$<O$]!ZI;V\B!H
M#^UG?U>$Q*<HJR8"ZZR(?J!["CJD'/50>RJM:?0A#T^(\5 *H1;NIKG7*B'_
MY>'>BZJ@X'W)L+DXPX6.+X6[4F[>4!NBV>^@"=WK086L7\3IMD+)ZA&V-@N.
M)"T@FZ$B[?#0KH;@Q0GAX(5OJC *KT]+KZ=.*H*\MM/Q72ODK#YZPM>TG# :
MK*F]J2R3EB2_7@&C,%5)50S6G21M<8][RRRV=Q@NE[TY>[^^:62U)D3IBLST
M-8M4*G*(W3HZ!N1>BJ$=CE%!FL\9)NO>3>4DH19IZ/QNZL[:2]HG^J\*P_^F
MAK,O_U$-+N%/29OU@-HN2C4N??U7>9P0])_%=3OL&1>4-RXK7^=\/KP(Y_O?
M71JV_9SMLJAV*G//KEC3ORH)%=$/)8+_EQ 2/A3RCWZ )KU@?-6+_ZIM_!>E
M8)T*.[:U^;*@]O^/>^R.4LN,I;<4&8KA32K5/NBAQ-CM4 \']>2^REY3/ZT(
MM5_B1,"X3_",NR[\Q;^KF0VG; &OIU'X*=L,]U[Q"\!'Z6WD#(*8UU&&OZ-\
M1[32WP5! CV;$7KTUN')WRP5 4DAE3L^MYR<B)1*V,7%K9%V#]=;!F%G0[2I
MNGO(4+.IJA7-2Z7@M"H=LA,'@&.4-;I^/UUOSDR_DB"**KVL^'!9<4H=/"$$
MH#@(N@,W.5X31$,+^K\3(W.&']$%=93DA"N\!K)%4>O8CUH),33<LM0WR^H4
MM!U-YKR0Z[XOKO[9#.1V>?X'-KQLIC468Z$COCDW*VU[3-#EE682K13&PXTU
M2G@JJ.+-6<-\)-P.K\AG^2&7.[U++/Z8 LP;4[7T59E2*WSO:MO#[?Z7+57+
M]K%%/V)"+6?ZU??[JB=[*ZT!XY;#KO"PY)=C&!=3PK)8L;5ZE\\K#RBE#Y+3
MLCPKOE4)A[?\9]:RY=SFE^/?&-OC3X^=D3S'.2-N,4;>=)]U2)19YDGR,-F%
MHFWV;MS25W,3B-<%HZ1_I9,Y=]!_TVA(*7=,RK6BC RG\NRUZE@*>ZZ:,'3C
M(8O5E1BQ$_%"_% 0B&X5U;R]8)QGLJF]!+A+G0A'&[$7T-9(IGY.E1JF:ZX7
M9<\IH+Y*WHE0=G8A';DA1<$=*=9=FDKJU? 61+X64;13P]*>9:+@0YF, S@3
MY%G=M2VGRGC/=NE8!I8BO956B; ?[Z![O4=]H*&.R]7[RUA]EO:>!X0#C/9_
M.%I>0=S,FN<.!0W\%@(L$$W=7OD^Q0F8$M_5M3]'<YX^R#RT]-4X1J82_4\&
M5F3^WUSMRPYH/@YKQ13S6.H[73]O(8_!8,)$ALR5R[U'E:\>3JE'_UIA?1KS
M:D2SHK[+D:%%8?;YQ_PFA_",+>6KE";J/XW:AU0Z"+0M1RE$%&TMO>^OS'P5
M0#Y*,FF;^S!OPDM1&@___JZ\\)I.YS(.^&17]<F/PQEJ?RW#0\!K/(J)$)A?
MBMYH@SPN,8:OS.$CU<&:/PXPT3O7Z:=V\_^>M^Y,?)RY'W]ESQ  B"8 LAE;
M/WPH>4!Z$]M$?)Q[(8^)SLI=P@&Q:7OT41E?SW# G#!1R*O0Y&T %<X%:LTK
MDX^^U7I7XX/;;.4631L;EJ50VE(#A> 5Q4P&A*XW0QD9<Z-UCBA;CI8+^*+#
MXX7&A25-!)^511W*4=!^XY#:7?IY?R1QC1%4 SK^0SZBEVB'<)V9 PF$CVL_
M^YI*11 .3J%:\M/#U#:)<'2/0R^\L8KJI[6/,N"3A43/7"6]Z[ZE6TS62?IZ
M.?ZX\YN^/; TY,#G& >0]"%05RG4HA]2TOG-5Y(3'Q9E!.6H:";K%O8NVFAR
M4OC>12M<2 GGB6:5X0= 8#-76;/A2QR0#6#]AJ4,;P50CG1&EBQ'!O8;)K44
M< ?<&];FC.")#IT_QH^^5>855 KXB!@'. =\:N#' <5FIY CJE1;D(\HZ!,T
MAE\ES*6%O&XN'#G@$CV(A^NDPXYE*0W,%BA=Z">$4Y#S7C4VNVBSJ$RYSAG_
MBG3_&$!8?WD-WH@'I[A*NZAV\QTIJ@R38?26NRHXI(HX#R&[O]8N 4;8O!BZ
MB5A_[2Q0=+6]V"L6PM4B@6=]PW6P/^8_]C--S3Z6CV->$A^MH48;7&YV@7OO
MEC>#Q?E^@X\>"SO?,>YR/3!HBB&Y[\1@-+>ALUTO[V_/+Z@RW):68 :7#K.&
MW)R:5KX52!:J'0)+?6>9^J%1W>N/8H6;JRU^M)![BAG*],?(Z^]X,.CI*#]4
M8U.XL%.EA4KOWA4R7@M,5=X8'LO#I+7K-6WQE<\(0R /F05A\%U!HUH''N?L
MJ2=X#\X,8%QT"[;SNJH?C>7T]'$H9Y7\@3;?1TAM^NSF>:?F/CK, .]37Q:@
MRCE3;#FQK^7AG$ER:5%I?+6U.5&T>5DD?%=0SU,M$K8HKW3\>3Y,AWI5GB3C
M2N6(XXN,=-I"$S_O. EC\%PU_K^N7<J"/\PX-BO>]- >"J4IP(!E?X1P%:[>
MCB!@2X<__<7\9Q@.K^OWY4Y !R/A<=I)VRBUY;FC/F+G+C5SK[L@KN9*\<W.
M/NC\<VASS4J1%[P+&VPES5_F/VF6)&''_J.6['^_W\S_IL$IV]+64\'[;6L0
M@3]T>.I!@ /*$&^-V5KGCGW5F%\0)MG_[A^QP</@["K*\=U-(1Q@Q(0"#>.
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M(7>^AM*3=W8JF7KVKG1'5DQFU&6LOCX*/>&*[[ XN(O.E+6TTE'"J#WTQ@
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M0=3!5!;F,++I\9C<RIX="UJQSM=$\0*_T*RHHK0BA[=Z=:1\Z">:@2F=NWZ
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M6O_D.(+Q]&6MA[T-CH&2>P=']%7:-F6/F9&,A]P?DQM<:]!%.P3&=N&I\C[
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MGG"B:1'<*+I;O31 <[!LG?1W3LO,IT2:C[ YZZX(.OH:GYA5> @=OJ;]);5
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M76D3PIUGEQ:$PM%\7\0:]F\<0+AS!9T!X:QQ_3%_SGK;U4FK>0^P]*6!,@[
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MEO^@ PU49/\1<P"T=<_I+2[I"D*G/SQ(R\B[3;%?3D)\1[J\ #P'1*=27%6
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M1OK9B+9U).4*Y,+E;W/;"W/"KP-A/&6L FGNOK3ZK/ N< 1?3_7CEWLBPR)
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M"_1>O<P-?'LZ6#M!SO.[C^-I**,9AS@]DI@_\'I:^C_LS+W/--T/;'BU?#4
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M]-=K6F4=\7XHTSX'?-AZKN%(1WI&(KX]SAQ= )XWP(0UZ/X9;0N#O_=8\YA
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M^K)R-V/@S4C:IV0=FU 4,[%5 N(B^VF;MUC!Z<X:VN=Q.*$JJ+QJ(B!BKBG
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MDPTL(7OB$H)RO^@A53H!L"DW-_+.Q0 D*FPE)O^]%5THW@>,IQ^#H-0$[F5
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M"%G(&XBW; J"VN(C@T]5BQ9,+#Z<#YOP1C^SMC'U'##2Y!$8CLA.!X-QO@0
M9J2J,AY&O'%^P'^);W?]"J$C0ZHB=[XC]I 3.K5FUN:WDD '<I(W&L\=([%;
MV-%78HQF7,!JXI\*_O$Y4>8/Z+)LK=\@<I83R46M@7$33/D4,T71(A!?@T!M
M%P*\GOM%APMQ X&^[XB%7\TQ9EVHD]B@ ],'L ?J3&UKK/"/I1*WX_NX.S\_
MP7%PX"N[RWL(HAB-4V?$'[E=R>HHZQA+](%6.33+"U"LJ7R@ :C&A!ID+3!V
M$%)A!=[:B_O-TIFE#C^OKXEY=>6X1#0(E&%\S!&%#-94\3A6<(%YG83:G3[_
MG;J!TQ*I#?XZ^+O7#C./29>^7^LIKWM=XWN]B7>SS*QLGS$GXCK06@5SS[@$
M%ULLU=0C3_A-[$@H\PZ@N:HL']8W<<GOR70N'L:78O0)3P21[F*D5*C*V9&N
M0AG?R*<-M'E'6]/WE@=M9)TB;8R_^E='7T5;=)<LN]=DKK?8]M3*!+[:!%Q8
M^<G-M)ITUC<U36_6>K+H 5$4'$E#^#C>2TBA/JFK(WF:QX;-4(OS*9!)H@2^
ME7AS$$X6"MP+]M;0J>7#U+.W\_8J:G>!<6/-?<34]S2SUM9N#.XP;?G(6?-S
M;W/XP?PMI6$EG\ !9+JJL-8)]-'>A&_J!1_0!T-+(2\K--<!@*J]<:#B$4WV
M &FW):+EJ=_31^P,_-YUW$ X)JEFOI8 &KV,4RD1^^10.,KP_7/=US"]0W:>
MN*"\@SBY]JRL"[EL:SAUA?H<I=FUYT ?YS=J.W[5,8.LE)]* !WWTLKOW2H,
MC5T?I%6V5WUH7N=7K0ZP@;#ZI[*\+20?X_^9H;+8)QX^K:;/\J-'!.^!^=SP
MJ^K-%C2<4H%5EF,OJ;II5Q5N^R,RR_QD;@JS$D%Z/[L.XNAL#CB6KM5>CJ_I
M. -F$G3K(I?XV=N:$41"=<J?\5QOZ%=F1'9MZ$I9R-\_=)YCB?#NZI,*:43R
M>JM";3ZRQAMT]*T3?4 ML? @K^D(]Q !!DDW=FN*#]HMA7<L'=Q3WE2L([Y4
MJ]_/_\].Q69+ S&MWA;Q'",C(\)4;^(D![\6JX1DO4 N*;$C^T(@G@8 65_L
M5Q=E^B9+3[,+VV%'6<,04>G0'Z?45F2:9_UN7&EO7Z&C'PTDS='T+<.8HV64
M56C9V*03PA6 LFWWG,G^.XLQ7U&SXR%KEO=;&4]LL.28,CS*5JI.#ME\^F*H
M8M&'"Z,RWHPN>9KI,=&W)EW/9MDOD[>91Q(* /F_X1<DZ)!U=5L_;D5?XU51
M7_E;)W-<M;5N,\C^Q'$=^,3:9Z%8PVZ0I2VUEHO\,T;[>]!M1?7Z.DV>@( @
M&]+K,':%M#!=KDJ%W6;^G*COH8_$(98+@K QP/6,G>9X^+/91UOQWU4Q=%HM
M/FQZ1;"3]281X*Q18J+@SM#3G'32S8&)W]2M/ =W%0V7FJDX)A,Q9[)#:PE5
M(6R,88&,[^>MMEH6H$>5FTW-S;%7>PQC$./9YVS^^&3\99+]\/-* <[Q(B=?
MTX#VO(E(X\Q0!XM"PG$MS)VPU%7.PYT296:D"VJY%\(LU&*G-ZZ(HOA2*7OQ
MD'/%9/ETR1K68NMDP$.F"Y^.O_[^<%",)R7/S[4HPO:+(,E#K6:G35^*""0!
MA^3HJVFOX91L'9<43RN72)M>-?W11!D84I9@4_[)J3.-[F)A3[//2==3<=6I
MT,ILQ8PG)@+[JTF2A6UAH&1&4]'0Q^.:I!<Q>(F;GYN2F2!./9:.BA12;O*G
M;D9 9@@. WQ4$59HX3_G:--^*XO.$5IHH-/%>]AP'<HH"$. ]QUQ@H_VU[,'
M E$T;F]\I@ 8XBRYC#MNN@,MUXH_LTVGF,6WPB)?!YZ7 ,=Y17[9E_6Z7P(O
M/@U_^-S[= I8HU'6AT^VGI9T2N36+B9*;D98F#13]I40B\BR;1XV%4K'WT9=
MM]CXO7 4E7G)%?S><7U+VG@%_M+">0+]L')R:&N>Q2HT:'$,7UAE+PJQVUOE
M4&?"2H;=SZI)Q "4[[5M2BP-?O\RW!AM$_0YK"=4M"0F8YN-! 'N9Q/%JDGK
M8;08-E<2*S>#GK%]QOXAL=0WI3 N3P NM>Y ZCT]D-NE,<24/QW/GG_4@[.O
M6F%=N*S*CR9\VOQ\8IC>]^5'1C7R.L^NE'?,6'/'%XN-+2B4_9FK79.NU-!/
M-;DNM?6]*$"E>\7'[32)VI8P*\DT$U/FVM]M+=U9/5[E7"7H85Y8ERC<W><Y
M)%%[*A_$",^V(G'0LO:<19\2ULV9M<>C@GZT/OSE*3W3-V38,D4,PXM:8##'
M!F@6$3!9J@/:J.\WV&MRBRY0EZ^_$S-?K'F )_=#J.FREK#T7BIK8\Q\]9$M
M )N(05N6ATFE.6MM3LVP[A32#!?*$#[P,(P$,(EK'WH2* X66O#_H8/**3U^
M<+EF9]OL^"EF-$[Y=[5.?W8EP,W"LAM:+'8\,O&.6"9#R", DL'8V3#?*.T_
M.YJ/&?8ABEXOPM<.)J.]^4Y9/" C=5G3_RSEZ(OM?GJ=)>SVBT"UNO4T?^[<
MJM]C<>)QGJ#N*WWA. ]9(N:3B>W94+'\SH:TS8.\UK!MS:./MGC)C/DE12JE
M\UH>T+7.)O](A1@[_6X&OS&_"AX&J;5):-+1P:)KMV!< Z.V3YRV_)F@9\#9
MGN'Y]S::6N63+=\:(9./K(8(A5!MCWT=M]R0C G\WS=;Z231R>&G1-;1!T_!
MABWG>W/HPB>)Y5H4O)/"0VWY<>KI9AD \.!O?!ZRVV?Z:0R&6=*1_@?KQN^Z
M7S"D:MB&'&TRJ%B.3XW^R8:78!K6\-_>)5P%+G@BWQ/GK&2M>.60?.0_R#4Q
M-?L0;].?8O*5*"OUO(AN#VYU5:M>+_]AO/4I,2&#1X!/A8GH\(*K-<H6*=W4
M=FLPV3-@F6L(:#)(I LXZ34)[[/<SU3RL;C+VP#S>-I@C(LF8P4V<<+D::#>
M'XH]$Q3$<D^#CAVX(K6WN7N(81GKE9K>LK+63FDW\R^J-^M3DQW=G\/GT"T7
M4]6FRW:18UL4LV2XX5NKML)@)D[+S*907U^<^/["O26Y'>U,OII,I08M(&)Q
MB+C@W0:1G+F'"F2<"JN<[RZ#9@<FAB'OO@\4IX#*+&6BE<G[BV1/M'QQW05N
M&OT! N?CICTN=#^AE>N-B'TVHJ"1:T;/>G$/^&="_['E #V\S+N*@#?Q[A[)
M&KA"VK?K@G$=BMB^L*1-E9!SK$J[L@5G"AV&AI.V;YO&!+AW?K*R=Z4USI_@
MK-?BR0)N!XUNSZNZCZ(/^SN%?L$U:R/]#L4("\.FP/;"H-QDX@=A>W'*9'IZ
M3D5_QJ9^Z 3B/Z4F#\X?L>3[3(S?YVM[\K^!B,=3?\:,4B%M86CZZUQ;W/[8
MHX 0T9IEM'G[1[P9X88WP?KRO2&H'?-]TY!R'FD=XIR[<&/QVK?,\&8L;'AS
M1$S_,^W+:M&/6Q\4<9TH,L$'9W$ 2#,. L/X&:LL+?%MTJDY^T&](K![H*[4
M\"9C1?\OP-$D.-4M9,%]0_SY\%;5=/0V@>3^&S83B:2YY!JS@2014]GV#[WD
M:\*26)&/P>;8"G0=-S!-"WXGDHH8DF&)Q=Z>;S][X]^R>1"=7BP>93GBY"!>
M)(DA)5ZI_ <>$=W]KZ^UBZ]&!7\ZJ&?A23H+!!*P711/*@&H_J,LG=(+O= R
M03RI__=)+>%;?5/GG&V-X1Y?O#1H78-%7G*_U2T#Z H"Z+$T_OU)D;CD%.>L
MY*0>E15W-);V_Y$@T]'Q+C&_?M%4X>&79<?U!V9[84;_?:6'_Y=2Q'\7_@=0
M2P,$%     @ 6T-J5.=_2M:^ 0$ 41$! !8   !G8FMY9#%B<FUF=W P,# P
M,#@N:G!G[+EU<)U!$!_VQ,Q@,<MBMLAB9F:6A18S,S,S6Q8SLRS6$S,SO"?)
M8F:JTZ1I,YVFF:1M_NG]\<WL=W>[O]V[6;K/U<]= +JLI(PD  (" JH/J@\
M^-P B/T'ZG]H_ <F_Z,\(#[[ !CP@ M( R@(#  D!@04!L3G$( 4  & A )
M_5L ^$\##AX&%@$*&A$2Z3\L,$ '0$!# 2 @(:%A4)#@X6#A8""AH&$!$'#P
M&)A8V @XN.1?*'BT/?#8N+A%W#S3,YM;VU;P*=E5M)R"6H87EZDT-'^XIK0O
MT7!PJKHG%5+3?C-)3A55,S7_7=[PCSWQ/[F0D%#_NW0   (*$AKV'PB$?]/&
M_Z!"0$%!_ON%@HJ(  4% _$/+30&#"8Y+!L6A0B<"C;[#R=X2@YN5767H*3D
ME(9YG&]<HFJN;NZ%C4TM<PNX>%2<FLYIS:W]7\0T3#R"4XL63=.O!I?VKL7-
M?P]\K@.0H?X!P(#"  @!7I^&Z:+5L$OIY%4S2]AD35+_,UG9FPW[$JE$PJSH
MI&?GG[,H,U,!7:'$9UZA3H6=J+M*0/?]C^*@M[6"LMO#-(R$J*HA!ZJ9G?:A
M\';F0J?=@T,KO(41AAS9IC:,11]@+TL-6441R?@!MB*W/?+)%F=,F5WT:)*]
M4B]PDOV+8&E'F_2-Z*LBG&.)GD./"K=3G1?UOH#7MN6ZJ4OVD?8OK<[SL4".
MQ4?#:I@V#1\6M@Z%"('EHL&*1;1X8D1/;.+P1E94MO;9*AQS;:Y,>]2GB4:V
M6#,_INAF^U_Q<CR\<"1IE4WLX9I6;0C&!LG0.MC2&UYNR+4U._L5?91"K56$
M>B\BS.P7&G;K3YG"_/%+&_Q!>ZRU%)WJ@ROB.CSZ<F.6:%V2!O#:[UK54.4W
M^\T;[H^R0XQGJ;44NT-A5,-?E]SS&K'(XNED4R&<Z%3B-L9&MPIB@ME.%)GT
MTAF[BB (9$Q0>IDRV_(VW(.:0RE!9J0I^.&7O=+<ED+#LLE2#%#C2ZO=WV^X
M1WN8O&O<)#;.6@IS+XH@_8PT9<]J_3'A3_7BB8(UY1PG,C'09&/P.]0LZE6I
M&##GV<ANFYY<AK&CY\Y5=2+Y%&]DKT\@GEE%. 4VP_E#U:_)TK57!0^58]+&
MSP'<9(]D[G<U'X5W4:LD?^\%#0A3L;J@H*7"7?P3/".XMKX>=04HEVA,)W6@
M5,$=@D\4YRLN5T<N=AB/1&H)]=AI<&!1?2%V;KH)9FTMKR$;,+^S9-@O6D X
MZW,]C&3 #\XF6O<[>YRM:M/%X8=[V+NAM -*W,LIG1C+.H!P?&CS/N"L? &9
M@[?6J-6@JYZXC9H2@J@%Q=$($ASVG)G^T69M&9Z[Y6+VP1&%DPJYJ&OM=;.O
M8YQ,+(ILW3&TXK$7<UF8U"0BTX?.V&B9*%.W09<EFZ6<XCK0=N2"+K'TO\8N
M1VBL$_)[]4]G3EET?CU%/5$<I?F'+'2''[7%A.539S\]\E<LYH'8!I&/0?.Z
M*(K'7"H5K?M(..HDB5/BFP:MQD-S((%:'A^-N M^*3-I'0W'H+5N47<S>WE
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M)9BK=]&D'<3X_3?PB&+,G0@?R1O;S^KWE1E=ER.$M*TI_3@>D4M(R.A8_[W
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M;@ULD%(E4KEN[ND]1GK&(#VG\XZ$!&:9K;%4A;RJ>XUIPK92I8S]M[2,$%S
M1E_L$*S>B26^X2> [*C]CC.084\KUJ(6)V>.Q #G%$61&!/^O,V\4P)1HM9X
M@M&ES6[I9RN7]>/8'="T?LDS;U,@,/)P]0?C^'*FY5[84+]LQ.X%3=CHSO5#
M*S?SI7(QE++='B->&:5#E?'94TX&GW9=H;$2U)9AFD]_ :[U0;JQ$J.#_5F
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MD>Z::3IF 9=KG"I[4Q/%F:HSMF5"2G( 6* /&<+,>CRZ>F,5&9?GZ& 7[;G
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MD/?XT6\G[F+LVO15EV6DX/7D/^\1@MB*\'E]F[K4_<<[.68__Q^DNA$ISD_
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M=Q-$+K%7K%*\I1HF)O13!TG.5;$82<F;E@#+V* 9WOV.X"F?"?>]'9,=""^
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MA2]XM!(B^@38":+!7;!]D'V,^Q>A80EQ,_.^B=0%M(/VL#[.:4 %YV7]N^]
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M;JMB&$12I2L^P ,]I/ ]'1Z9;-Q,(C&]F&LR\W3#9MXPABZ<>MB+63)UD)W
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M-#3V,I3X_4!A'(GN^+/=CB31BFV3JZMG\A0B2SRX5BFRE&$]Q:J-*O[$%2:
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M1PE$@_ER&."2_0Z%0C?-J%ON[/K)/)PN)"XG#K@,[/6PUCWXZ]2OXGGHC''
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M8B&IK"Z.4*!0B2?T"$U.QXX,A+G-DF,Y,7J0^*/L,K/RC&DPNMP&LFUP*C3
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M?\_J[I]*\X%;J/TY=O6$C,T+MQ,WYN8W89/KU._2OS:VTF.Z7OMM-VH-N#\
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M,\G8O[0"S;SK-+D E<" ^M5\-IZ <8MVE&+RTM%@+%=7=]XQ1".P66M<94=
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MH/B)FCD],>=3+9*'>BJP!LGX.0H.@QXI:%;A"PL$@!Z9A#GP0>B4\OC;VF+
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M@KA,H#2*BUSV"20HQ?#@YZS[I-3E4K[>Z'?%+F!%R.7(\"! /6Y V7NINE[
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M$F&PF=NE%MENJ!EZ)76)EV<-3NJAX)UKCPPJPOQJ-ZT)8H_1 (YTN@8]Z,/
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M=4F#'8WXR81$%-G%_EHF1V;!&LCXG$9A_](*MSI94G':J( Q3V]>;!IH2ZQ
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MIVX\D(Y!^#[,%UE46<@&SX<<W>U"@EOMYX9O,]U7R^PSZ*2@M1HEJ0.&:<\
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M-@&S/BL!^RGMM8)R/3=T5.#V  1>!G9H%LYR)EOS<]0;F2B,Y'U6^=#6EJ5
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M$;^2",0O"BK&P9IL%!$@O?K4/2B$VPE";@B%L"^8_ J%A1O88JZ3RN.14[8
MW((>/^@3_!MV_ <7794/=@P<#JI=$!>_P($%S C]9+HN/RUUTE#U=09/5^!T
M' 5SK1B#DECQ2_CY'9;%G%7U=)J+>13J))L2MKYFG/7\G'0#B#)\L'YW=N:(
MI[:GF GL>RR_O<S7W";Y(ULA8%3?@SY R$2.AR[GNJD814HU:*S<IKZ64ML=
MH#M?(K(U!^4<(FJAT$TO8?>O.3XV&[%U496<? ;D=LD"*\->Z'_ ^0FT[XH,
M?H2L20>T+5QFEUJ!\'Q=OP?YG]2PV_X?K#6#;V+,_-/)-/Y'>V\=&UGS9 N6
M&=MVF]UF9K>9F9F9V6UF9KO-S&RWF9F9F9FQ#&UFIN??SLSN?$\S3RL]K;1:
M[5]U2R7=FU$1<<[)FY&1 3.J[';7J'/X&>2RE9SVC\CSM*SCWSH)'S,U&PN8
M^V79*SV3"EX5*T_CG7+$G7_J6"9WLLUIBDPU5V[13-L:61F*,JP/S,O1)&A+
M?/M"&M&"CF44$212-9\C%3Z,$LX8X6,=*J#6":[HMY]230P5RXY/D;F'<4;A
MS-&H\>8%<2L0T9C[L9%-FV4#QB*)>%9.R'NF#-P&%!63_JR,=T#DO!%KNKI;
MB^73PE^JS<>=YA+;92H%Y5I+7;J5!2>:Z,6^>:?H2L=K52FN/-&Y1D[!7!%:
M[>8_*'>2W/N)2[' R^$9F2C!+\W7@I(KC<Q*CYOEMXX?'ZYU5C=[UG=;FK/
MXZ2PO2.HP0+ *,=JX*'Q/KQ>-JJ+IC!>)>PO9VWY/L+"IC>WC?4T8TSUGKQG
MNZ\NLO02MV9\S3IMWVQ/]$XSUI*8:DY#U<9\Y[F>=:/>$>8^ <LI\%>/L]]?
M>0.?.HM].RU87AKO,-Y_T75':RZ_!D=IITR%5FO]*R_^7[K>+,?=L_?.US!T
M?8)!W2QS-$3A(Q3^E^RR;V]Q%+UX:<]!MU<E7EM=ZK<@8$K*J;&!/BO:RVN9
M!3,Q;;(F)UYIXDQK).YI?=G-31*"R\_TFL@*N87 0&+*F^%460Y[A!AZ4'($
MLV8]"03'&!(<3QPWQK=;:QAC/RLB*Y5>J-"=S^T"&/K-!G,GN0R1ND0$A@4Y
M]F9L,(6_')!#^Z@NF4?%?;0=FKRQ'F8F1TJ]Q"B![8>,%AHXJNHR\F@0AG];
MD1\U$S_/[1=ID 3)J]"H]NRH^I.R_/]NJPQ#Y98_Q <8K)( >WE-I5L)U#0\
M<.C(XC=RX_%$H#3]5M>YM0U[XLNEYOW]EE>GD$+-G-4%"Z[BR[3,_#DQXZ:>
MWD:_F9DU\ILY>6N+VVXPP\D-9\GC\FQ#??L"G4%]36-+9WN+/0YZ4ZR$O3US
M2)T(.-6-^-&L@@3O2=$F6\M#.4UXUYM^GGCC\B95R3!=D^1=:F.\EJ\5$2A_
MBW JQ[P 2\&T4V<TC5XYCQ),[:!*8_OEK9KVJ_)#;J7VW:TG]#',5[9Y2_4N
M<>;HS)DUS%0GBX99*XG%WWP")#K:YY3AAA><Q[5,:R%H%8<^!"_PVUZT_K1A
M2X>HXRVVA3'KR-!TZ+ )S35"5[%HJ0H0MEA+T%:RP%EZ"X0U2?%0N2>?7615
M52)1?:\G'T1J)KJVVKPY,#PGV^.ZI1>*USWMN"+>]FT^D51WC>^7$G2]PDU@
MM&J&9OQM%8"GNWRZLGUGX+J +_,0M_@RK%9^\\Y5C,4IE[> YT4^ZY214&(Q
M2TF">D)KJQ[,C]K8ADAKUWVUM2[1=V<F:][)?7S-DK'9*;!0\'"-HKA @.[A
M%,EP--O0R:K",5#A7LX.#Z :.01;!H,%):/KK V&Q$<UAF0YKK3=%0Z>IR'V
MO%MN-Q=MJGQ_W7K,2BK\]2(;:(20EF>>[A-3K!4I8%"DL;ZBT8? M+NN.8Q*
M(0NY5P)G1)*@3?<)4%A@T2K]Z<QUVBEZ8Y1F<UEEVM:2T'H[R=41%9D).@!_
MK>'UPE+\ORY%DU;L1B"D([0NWSRWAQ7LC-"R>"C7DGVO8BUH^9JO7FBB)A7[
MA$LV=EJZ%:JR=LCE$D@C76J_,H]<F:=XL&8G+9Y;IE"(\9-<:X&75K-15HHS
MW,*&^A<\1'%STM?6 LTI3+9C?*.?R:V,:&(&+"/_]/D/@W7Q7R8H/\'XL4GT
MU;TY9C*,CMYSG'G3\[A71C3/R4I>!U;<EAE&J5O%LYML9:AJ4%8EUV0PGZ/&
MRH]E"PJ'5B/325KDERDW%XHZ: ]G.MO6-[,V +$1\=BL0/;*6=D!MN [CGY0
M-\IC!7U_TVAW8SMN9-GW7]X:T7JN'ZOD05><QVT[/AH91]QH;NXYT<"N9&1F
MY/?(>EQ(.?+F7^U>: O>5J6E&]:3E!O^;H 0#?8AZI",53P;)+,1>W"L%4"Z
M7F.31-H0".LHPU-=Z!3$2R'2&NVV!=;&.0A0E=;:0;)/AS5D,Z[+\@, [A4\
MZ)5NE2Y05@7'S21)_IR? ,XC"Z4,[LWR'%00Z8C)TJM)&]TD,S)(+^&&#;Z
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MH^51,%" &\EZM\J/U:B0XX XGY\<^E:EK*HS&K9#(/).Y)OJ2AS6YEM_]B?
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M5_T%N_ ;W8]J+U8LUUNS9(2,]+B&3#R0EU,C;/<[VMJ@_Q8COU(KR:]U/ZT
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M4B?O^;_V159:/OYK?_I_&&>PK NZ^T K!4WH$II[L)ROOL#Z(T8,C->*2"F
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MX#$\/;EA/%:\;"LHB5R15#08Z!',F@=9-1W)W5RW!A5]3%1:M+,NGLGBD/7
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MYUF3Q:] ;2#2$5'W4S"A,$>@$F+_V#$^28&*]O#3J2?WPM:[:0,ZLH?!HT'
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MNJI_]:OJ?E]\WP2@28M+B0.@H*!@NF&Z 8#W%8#(OTC_4\>_*/F?U0'UW@U
M1P"L0VO#0*$#H-&A8-"AWOL!1  H #0TS-]UP+\?\ @?$&'AD&"@H/^N:Z$!
MH&!A_GH "X. B(H CPB A8:!^P" @D= Q\#$PD;$(<7%(V/FY%)UPQ=2TW=)
M:@3-(Y%3L+#+VSNYQB4W-#7/4%)S"SO[ITRS&CC$)TXM4-&P*0:DUM;U_-7^
M!>K?=O\OFP/^2K!P'^ 1$/\NZ_TU% KF7T[ H" @0W^$AX*"A@' HL-AD'[
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M,&7> TJ>29EK@E&P4/N#&;ORXQ:&\,*(B5H/>7EU"!T5^HAL1'T[MRSZ%_4
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M8@%2BE/?CZ8(;P/KUV*+YRN0RTXL?]\JWR77)+NN/LI:5KS5Q%F;.++GT(T
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MGD$^VATL(VR:0G507#2R*6^G5^3!8*T^G_)5,V(Y7"B0=%PBH['>%@=,L:9
M)SH6] >>1+/=?62%8*:VJ2F"T7&J<\(OWJMWA,85B28D,\66&> 2$[0LN.I&
M=YJ3Y143V@WC+W^J#QOWV>@<]HPP^#YD;-VP>V$J!I?/F:B<4\(VTG% J2+6
MV6+U%OFN!@E:!2-6-,QI\X=5\KKB<#D^(X41S(AN?W^JX<"O&PHZ6?.5\68!
MLQ5_$W@NDAJH&&(O /SZAZ^+(@W5)AF2/\4_(.@:^3 R.DNQ,7B*[S6Z'<MQ
MEW9/6\@+H#<_O=JPF97TK'Z#(#-%?:2S+NR=^'80P07NV!)//"E(O*EN!F'#
MN\1%\.(8;JOM7MW,SF%_F/U9QN?7?0"^?IPWC"O]3P+$_^_%$L\&=5YLDP\(
MV8R3)*ULCTV+3%0[Q6<(Y8CH2BO/##TL\2K,!/11$@BB:O2UQ0A$*@H\(IN4
MHFC=7^K8H\+."'\C29*Z&K=CN<6P(#[ #%V5[9K^Y&5#D0($V &NJ+L/^F"V
M):)$561C]@YA[N#+U_FG]S/]#Y5[N&,GG*8"/4[&9H_3&D8^%_N+H',HO13T
M&JBQ_Q$WCI!A^8(A-O*XDE.KL)JX1@=0NCCW9'R1WQFY9O'>O&9AAKZ)>@B3
MQ;.Z>);:EQ7LLP=/\%FHYJI[RE0+'UZFO#EJE__1ZY3H]+8+;7HY+8\9#&L<
MR7U( I#*;]!1%F/<%#6@5@UA^RW%"4MR8S='DF$Y3#AV2._8\''?3.Y<#H/Q
MT_&_-SO_#"3 (SS?R>:K?0?TC11Y557\OQ$E6I#%Z^[YJS>?8^Z)3XXI:)<Q
MS_5YO617UE9WXVUAYG2T2>1Z_+'ZS:/8:X.L*^L=L%N\T$7C6ET/]G'(>GJC
MY@NCTVE]>VO:P'%]6;D=LP[9TWH'''8U24\<=4K!OZ4\DU=O5!,IV&HL>WGL
M/;V]I>Q:I;M6OTY@[(/>O/Y>K7LC DE<XQRF/I [/[DY 241=9G&9&;,G#XK
M[T:N@ZHOGHZ P.HKGWO(.^ Q;05^9/@Q[OEX\.A-6F"2>$WQI#@I8_VNFOAA
MOXNX:&ZW,4'C]4+7% QWH=/54>CA\\;1<UWG8^3SE%'\2/,.X/-U_*'E5;-1
M70R]+;7QUI6@LF;IN[G,9^3H:WIQHO8/[4FO=YQRU_)O;F_[&:!'TWM//MP@
MG[]FW\WQO@/:EJ[,QVU?GL;.0#?INF.,%P/_?FT7I_7UQH+.)/PF4<;MV\8(
M[[5KM2ZX\@A(U5)=#TGJTET>7/%-3KE!?GZRR=G-?[EZ'0<V/KJ>/")>;<R<
MW6YLR$UUG=\MK ?>>[QF=]F\"O@R-VWLF;ST^LXJ.H.'11[_^E]</%_-R,_Y
M#F#6X?%XFP?M24C>;KP^73[[Y.RO<ZR\5&RDRCV%VS0_TO@"WP&WMT\S>_=W
M]W8;A.A=NOW57Y\,.B?K9V:6+F]TNZ*:W@%TG/N8;WD954!IXLFN5X&7TKN,
MT=<G#WM& N?75]L1AIPNT O/%8SN.P!OQ?:ZWD=?X/AK1DQ"R,V$+P2ZRZ?.
MW?/D$>^J3>/M';#!/@/J\%V#%)QHO@. M?_%<DYB=]0#70C[8SENRO/=W4XG
M1_[I,V<U1:MGCFU5UV?7[0Q?T^+JE3,? ;EZ/-"C5,Q;$/S;RUO9A.DC5Q??
M.Z"Y>B/GT;O#1\K+1OS5UXE3SE%SX1W0A-/!^>9EL'&Q_S+M\U2;$=,><E/]
MG.X%&5T[T;U1WW%P??9X[G3:.[EZFW^[GW\'6+X#5*]V<-X!OIS["9#9<?"Z
MR./"WP"X[IU#'EFO6KX^\_L>C!8S>OQU9072GB_]>E$+[.J(U'Q]V4B76Y_Y
M-S>4'L$I*W=W!SZ<U%=/MN>C,PM'7<MW<JM?B+JZ'C3&#% [4V[,GT<F3)\7
MN[C^)DM1H5?GQD[NPVK6:W9VEF5QR\G#J\]D<[Y/3N/1_<7]VS_N>$1\'C'Q
M[8AXM'UN?7W,26F[?0><JD8=;IR=G.?.9+X#.-YVO[T#,I;> 5UX@1>%;\(^
MUVDY%P9OFF_G75E#[MX=KTG$!(K5]0N:AQW\G@N0MXT61X^-"Q\D7U_6"-_.
MC$?$UZ?!OR;Y)A^\ _240^%-3DD@%/Z:<8OYYT(UVLZ;&9S6Y,8DG*'F(6O8
MC,_]T2=C+"=1YDCV10N-Y$HY(2')%EM75S<##K7_VY!(079J7].+X]FJ>*5%
M:^6WV(TGW%L6.[%%9:SVQBZE@@$&PV9\([=:1%J#=FJYB/3H$*W\$0T!8N&\
MB!\1CX&<":\A+1U=-4-)=_#Y+O/5&S-26R@,'@FTK.!"_$Z]BXJ(7V'BN<X]
MQZ,O%L;B,/=F/*"'M1CS5-_Y..,&3M0BUR2TU8G(U:0D@8FBK;9IPM0FO5AM
M*3+Q2^P,-\96;(SD@#0;P 832W(2!P'.2S!2F<*$ X;77\END9SV&,_(G9!(
MW,MK7)TP0&R"(W8B2&H"'Z^TYP8?'YXPAC;MNK7N_P-U^%]%%8)W0&BF8\F2
M5;+E"B<OTFD<:]P&&<NKQ9I!LW$\$EDCJV&Q,)D4N;*5L4CW0,WJ+^"@&5DJ
MF1*46$I"$M=)\K8H$J[9LM#$P#"2%!*8L$IJ\^&!" "=',!)T;23>=51@PC
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M)H<1J6@,0#'(I]K[U1#R4L[A^]:.RK>K,GHC"_J'/Z/[U?OV>S''"ZM=&01
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M]7+,6NK[OP")1BTC<,HOD0,MM:[B3%'WU,^Q*M,WM0+\<4KQ)HU=?!*X+K^
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M2A" EJM![6W*>X)H^91>/TG*ZGFC5LL>WQV-U"B"=?DC-YY2N@??[OX".O]
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M7_\"Q*!!%CZJ8UXYKAP1V/$F(?*4C.\+PTQ*T6\[[SX4).B_U$AB+S6=;*<
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MZ_Z)[]B?*G"Y^'^7RM2V>9R6@& :%\MJ-Q_3SWT^/*L,\L+=&$S3:!!*.<M
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M/8Y^@,=4&LBRZ](EB:=-0T_6[Q!R5+D8DEVBQI'T\A$'Z?NIR"W8 A[@T0@
M)WCGB<YV_<DKT_\"SR[L0N=ED$7EU+@A3'8[6V$)<X8WH/5M9(5]("DVA61
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M6H?QF#097M)3GO@&(8Q*G6.*G<XWO\Z#<MYGPBVU5][,&QE_LQ#7*#C;;"H
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M+E+IK1T"<\X7K11CE18F2ZOHI[+'C7[EA"<4.LB6P$ ?[U80QN@\(L?)GD@
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MV\KJY,8DV20T?AKWENS*4\+-%I&#5LZ/*=2\(^1*X@+PH0V@9N;],%8+9[2
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MM6>*JPAL:!]SNA[UN%CJBO_A@WH+*3CBT3/O%':L MG@ ;/2RC/9SM=WO?5
M*_ (^A\8B&5PF9VJG&/.UOQ99V)H);+5A!;3Q".TC!68(WBA+7^  \@W%_R=
M$+V5=7>(7C,48CC3? \1-7K2VO?=R#@:&RO7\ZWL1))I;<V\ZK(YF#W;R]+N
M@7=+$A0TADORJID8]_@(;1JWW$#0^=X\[_[1)-8_8SOZW#SV _]Y ;WJ)4&R
ME;"^)KO<%='^PX'_;OP?DXY %KS\[(VD[J'7FC> T;'H#'&WHS_2&P"!/+9[
MZ0SK"5U3JZ%(N_Q?7UW#3I&H^%^>F6^ U762E\Y:JTWRX, 0 Y(7)NW7QK::
M8;:*Q4>7X\!;S.S7[[,GYIFG!#<6['+7=+>WKUZ-HO,+N7^WW?V>S*8.'FN\
M7SO:7D-*%O>QY@O_,EKGGY*GOOC/S1=UW$7_(?SW6?O_QA=B(7_&?6+Y2"@K
M%CV?\(Q<>33>>UFE1XNE/M7"M9 7U5>N#=1 ]H%G/ &_L4GZO)L.V]R[.B7>
M]UPCM"UWC'>9FGQ)@N=:+GR#\S1.'&F2,N0**MB_$2V(QXZ1 $^PVGM!"M_B
M;1RC)7IKZ#)6PU)Z]_&YB5$NQ3QEP.02+OFJ/?W2\Q9PJES\W=/X@ :85ULV
M+I*VEM\DWCLB=?9"%3XR5RZ*E;VH;<ZX6DL"5+B^&1+4]X\7V0-2#$PP3R>
M6N62M ']B5>364Z/#PG(?]T;?\U 5TQ3C82"KW[^V-7G8M;,ZG.I$$7,-E90
MG(X-0=6//GO]P2;9J3FJ&=UM&?]'L0#*8TR#R^4U6U<$PR]"Z%=(L$NM-,W\
M 0S3FIB-0(@I1%1?M^!'%WX40<#1E,<=!="DDX1K$U'-56**;Y6+?*3<"DE4
M24\U)+E^C?C5%EM0_ LI[9S];XD&N;FQ*RYEFD%2H;8[Z5,K;#23$&T+34"
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M&$4.I[?U6"7EB$'.5".EF&&Q0"WEZ 4"^B]YIL62IGL(/T&6IDK%GJ:8IB:
ML>PC / 90 K@@_^J9XF<D6:.D 2B R9Y Y-<0$))?I"G_TS;KZ?^3?KY^'_S
MEN^M'"WZ/2[PKT;WX^-=5)=J^?'EWZS%+S)!Y 3X-T6I.VR?@!$+I>24T1G*
M0C?1FQ4Y[HM<Q2U-CF=J:=!*WV?/C@7K'QY67I2>IO*<XGB<>-NZT;B@&^!^
M<V%'1Q0A7XTC=2P^HPS9^L]/]%N,%<,$&I@  -R>$<72XV7\ YOSY*V(Z!N
M5::V^0U "WL#>$8\N(M6$T?\^?D&>+D_>6B:6GR-[4:A1$R@"!!R+9^,S\O+
MG29$O37_2GGLH5&N*#'4\E5FZO)S&]->+:4]*S/RCS "<^P2V/6U23/?&Z#7
M7AI "I;@_!J3=Q!U1??K1N?#4]#D*_L<)DAHTX "+P>K_A$+(!3FN5EW]9OB
MW' G_] O\%5_R,3Q5='^]0+K_$14GQOK)NP-\'RV> %IQ>KMQJ&.$*M[%7%5
MD7*T74'$Q*#&C(6"]>[#==TQ2B&&]\6.H(4YZ!GX;N.A8RE..DI"*G+*/#16
M$]]\][<&@,-;R 6B9'*"2^2 -LEDS)4L.$:%^AG.T](L"$ D!/=UP*7K.A\_
M4)ST#?!8'GAU'5#'.\JM^6]*9O\3LLC_#0@;4B3K'17Y(5[^--A-9MG1IDVA
MPJ )Q:'6QEY,&-5H*DYI4^[4TY-;<[9QE)OA*B6$0N;E-L[C5;JB/ 8\G8F3
M<^M&#UOY$'[+$O7 BPBASN7+SISG@%Q+=?5E\2F]SPHR?[Z359EA^JRB&ZF_
MA:O$H>@D:C;4N[G6,/ &F&J9?/06K<Y*_^._>;#[>J=^%R+Q!N \RC_GV6RO
M#C4J5._]7=7 (]HYF958'NGS5[IR3\O4 /KE'-". DX-CYVR=N*/FJPB)NXQ
MC?;G>">NG25)?<X/H:/3FH.%W9U4H_#CC;4<D.*U)[ /M=-MZKP!D!J9D^\*
M%7?AXM5@/8/>\ U;.3<7/0_:_L_D(IBO>WELKV&#@7V__-WFNL?^00E1NH=*
M41TNMAN1S-<=^^>V,S,_S,MM$F5;ZB%R78("GHWA.7L[)[?7E?N7A8VI"LC&
M6;?70?O]2XW9JE'#T9GC0CE;#>T0Q)6KW;6Y,3'?P3G'@8ZH9T+(27B^P;'X
M:"'[16MP8;5QM7M^*X[LV;4YT+*RW6%_-6?'>2BJ>O(_T\7T[]6J-/NWQ)3^
M![0*FSJFV/K\@ZQ-UO7_>XB9L=';9+IJ;2QU2%&S=* 43W#>:QS1],G)V0IM
M\O@%K4S3YA[\+4:I\>\[PZB(#":Q5)%>[*#A+JKZ$'SL"]2[J4\=H9_7(W>=
M@A([DWB,.UQ'R/5W?I;G+F,3"'J"B E[!#77F'CYB0 YYL;DR@2KCS73S"]6
M0]6JTZQR!,\T!=73,VH Q(Q+*^&1L&":%,IL<$P,30Z<5&W,\)B*M:4B,=;S
MA[43=@%&^4]L]= @E!%R7]!#S=<_E9];O1)7!]*!<7"/\5])HVN)-,'_,R14
MD?MGXP<MK^Z<6E4@D^@N<:ZJ3>C:XD_!ZTX%1F$F879?P36_@)\2WZ;R'LQ*
M'7V)?\686_$-3P@Y'\1<Y7AI83HYQVSMB!!=3_ /^D$4GV_PAC]_\O-S,;P
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MRDK8]S)'GZ)HH*W@4AO\ZN'D(T+][+U%:EEYE_+^P9RQG9*2,VT)+A%6D42
MTBOT-21'F_'' 1)S[=VW&KHT4*W,@-NP@_-D5:'T*C-^5Z1F2,*"SRG3:KNT
M1D"QID5)P3ZM3# 4M Q*RB:$?:ERR9NN"MT@7A&+WLGYX:E?9MX?2W2>MM:#
MS=%C[ !X/FQF3S?G_^@?[30 /C49U,&HD%UOQ$OZ\*EU;7$\C]L7*059HZ]*
M7R!,.U]7!*P*=1N#BM0>*(% 15_-#D5=RY KVJ#F0;[<H9O!1:,*18[^9<Y)
M-PQ.]S-LUF+GA1Q[T4P\OQP8LZ/L6TE@:? ;$ 9GDGLSX0--.\9VQHM[EV>
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M=YW='+3--/7&?B%W!C8;VU[$!TN'+:0>839W6PS.-UX$C$5J=:86!D0KO0Y
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M630I\I24.)B 03OH\6-W"UJ])W\\O<'<19S@69_^_8B7X[Q)I N?%S[N3RU
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M%!Y] +B\T860'B'6#*V5-5(3BO56#%?WQY^A +F-M6N'>3KI2@RJJFR/X^G
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M'-UN9OYL7]+H7U+;$/*7P'_/;!86U@K(MGJE^."OP= 3WN19A[X&CVAH?=O
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M0U"*USO=$7EJ-+IA^L@;\<^8?/X3[\ F6_V3D:CHK.-D)NCB!');=/M*4*\
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MPLCC#4>?81R0Y]20YO>3+MA'$Q$L<\;H%OWR91#1XA@0D\HVB^19LWDK$#+
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MFQI\:U/Z^W3YJCS;Y<JA1\VU_;MLLI9#?D5:0W]RQ*<$7_=$0T].YW.,A^J
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M@7@]G""M)_S;#?$*2T#0N$JV27 PDL>V?!(%PD5NTCKJMY%CHX)IW"3/C6,
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MNCM565/ /5Q^W3+>^#XS\VYY0[X-C\&BTR\![R:GE9L^WW._T@5<@R)JB<<
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MYZ][ZEI/-'<>]Y$=]%G:#3IX%2BR^RLX6F%^!@61_)$GW=KX\$HZC9MZP6]
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M(GJ7N Y,7=XML[XB76+P;FN9Q"2;S=\&\6["C$5B%;,/[.PR5N2F^L+<ZDC
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M.L^QO'LFQ^D#?*O@\W_&N$'W9N-F.1AZ'A3KZ:7&T4VE8VF@DX+:VZF0]2\
MT:/(TQZ7&S?"]#A*4/ -7?W^H$=)YQQ@,+1"?=;FP)O:1CM$X@5,_/66S-M<
MI*/"ETGKS;67'IYL<0AT._]SBIZ@[%T+YV1-X;%)ZI9XKQX(H;_8IVA,E".3
M%BZT&\\XW>5$J0D?WS..D&5U"M=<19/W6UEUFT"R==J$ZKQ] DQ%LULK>*QA
M5.BIB0P_X,&%YD^;;MMT11@GF:L#&1?IBGD67$Z$%(@N94 O<5YX*8 E@KU2
M"2=EI2\ZA'?-^*A<\"\C- 'CM=J=>RVO5CAJ^UK8KRNT3+#*RE-?61G"'.GN
M@PP?RL/-)W"A]4*5D5=YM73A[,MEDK$*9#0UEEFD+P>[06LJ#\]QHBAUF7 0
MH],=,:/5!E_0LU)A1I\II](#W_M:<<42]#(43L8J;%^DMK"#T#/\GR[B4 69
MM+/*V3@4&"CV$A#_.%E%[PK8ILMA \.EQ73WI88R^ 9@%O.L\]A+/UG?_7I5
M9A)#<47;>CC6"3[ZC? ]PG+GSW<TXIW\+6?+RZA1U)@!0&6.(SK/S89^@?6M
M\"0S7U_<D6;9.3 ,*WR0^8USR^&H4;2J&\I-]J%3G+24]BO;]S/Q4P'?^2X/
M;FF+PAXU?3"2TXQBH,>G.UO#J.NT)@)?+*8F+$$W8CZB4&%=0N!"Z\]Z;LE=
M]/VAQX< T7:1\"BB2M>T\?QFPBMFFG7\0&YY_]&/G0-O=&]>L'*3JSP V_P8
MND0(% OQ#8]X_-W*5Z4&8MG-$&EGENHK@QFF0,$2RL,^ZOO^)G]-6$>8EQ]\
M"-&APU*C%1#C-[#OPT=Z<&?,HZ]^S/:14/SU!?U4'4V[\$J.?G^2(537#OWD
MZM#^OOC;56GK4]H'H>@1Q!,@)TR+?'&^+:T+>3*.KI0Q;Y9J<FTH&LSO*>:F
MP'-\?GAI9R(4)$.>C0^OE!NJ'/LF<1?O.]0PI("R'SAX\[)C6= J]?(EJ]K[
M[6K,8AJ&Q0.*JF OZRG'27R-<_]QU5O:<E.0+>..+7.1Q-I]U(_:I-#G=\.T
MT"LWB*!.T F&%]EP^:FNJ^]GYRGC.)TC[C&1]IW (Z"Y@EE./Y!OP=#YJ)9^
MU(8'_<&5_EC-WQ=%L:;TV_&Z7^8"SI380BHG@RANNG,N=!"!VZ%5!G<A8VPR
M&QL<G447=9V9@0^YB32-HO!:^=T1Z0V^NP)QUZQL=Z(E+'X$_]IY<W7"O>'9
M_6M$%XY*@^L+W+2#$5OY 1-'C>FT7Q^#O>([;4JT@J[UR-)K&_9CDT]:&0KE
M_?B7#ND<HGYOPZL2/G[@&O>F#/:/WW''WH'N&RUPBVC>J$4AJ\RD9L'WQ578
MY!TL[6(\"5R\2EZ-A))0"$EA2E5 KR+-]A@@&K_>?IK5BZA%Q\"BR\*+>H%U
M(4M-'CX!,DC+C,FC#_NF5\&6 "X#@SN1B6B?\WJO+0O]V&0D" V+!J> !5O9
M3TX<G:Q*<O<(/*7[[/YQ /&3D$<O\I.+>!KI&(2RW%FH+&[>:7)\]%RJ8D&N
M!]=Q"^T@-Z;5S*02J2J[:N.]8>_BFER4B5"_P#;2G*:G20JA.X6W1TEY;82Y
MB8P7US:,_O/[\J+M)[>A$O@7A(BN!X%'C*4'BVRD&&66NBAF1[J.M0MQ[_2=
MS17ZC>1">/$=8PCC& 8$2U[=SRZTI#MTU_5O7'RUIT#R.UQ_[0@]_D!-N%(V
MQ6:$J:#/LS'Z5V$*B+BKOVY N&\L3O0WZ-_Z'H[F3Z(*,<N5@WO(RF5TVUFS
M^9U]_<[Q0\"YF,#%X-6&Q(/]',GRM['VLN_NO@J6Z[RJF].!^<S'ACHG8'S-
MM',^1<[,V(,?'1'/";9?=7$IJXB/4)(8F>Q*"YJW)ZE'%*^$/3ZC1E-JOWNC
M=Z8PKAWC0LP7;?#U+7YY[289^>00\,DXOETH7,=N.(1DK>=LAT.=%"_]\)/D
M\Z,^('P7K4YF5\EE8ED,S/"#$PS$+*ZN;3MFU[SM.3Q?OW^4*!$9Z;6-_F@4
M."385ESGOD& S=+UV%5 OQ8<@Q'=A2;E(Q(R"-'V9LX^YQT"$X[(]+\.DVU.
MBT%\O@WB;%>DC1!0>PE&)8&$(7/_3E%J >R2Z"K6E)HHIYUQ[YWH1@2"=(.N
M2H-0,\F/X%+CXM?\E?R%"=]7<P(3;>E5^L_LG_6PRQ.3^8YAY@&,;;\ '\'E
M-\01)62'2^OW9=/H;0H;1G]))@9\URH3STC\:,J?_HVAP*9<T&=P_@8RXGG5
MF1E1#UNH8D#WJ;J1(ZD<ZD86#C8?N/]W6Y[TM?^@@6666"\6N+VGR8JIXV((
M$(DB75+'J'HC:BF0WM#0/;-W).\''HV2FE(*(Z"Y=[,U.<D8'_"S[)F39)<3
M%[K#SNA ,Z$<UW>HZ#^V'S09+Q*JV*'Z32GDC,'1ZK%$O5L KK+IZO+' QE)
MH:/+.;J^01?8N9-Q1KJ/Q4M&DL*(?O;=\',--0WYSIOR/KGS-;K/V+D,@DB;
MY:Q><HY"O(B,NC4;8HL%E<#M5S!D8R">WK7WV==)JF^B+%/_P<<U@# 6/%]=
M\^400#;#3D;=I!B65E2$I\Z_B[O=J/T21%>RO352H; M8&%[3N(Q\H,&[K+K
MEQR[8:Y4PZGDMCZ4_F?=8R7@%3?NX1T_JP87_*\^R0V+QQT!$+?&[V__JS?J
M?_,Y@F?\]YYC?1$%E@QYU&;Y<^@_6N*!_Y-1QOU'@E;YJH6O /_6FCZF9G5=
M,KZ;357:C](J/=(DO =#E>;=A9=6>V!M=&[XMUFNNAJ4;V1:G+!)%<,D6&DR
M;)I'P8]$L@?-E<_6XO[<LYM$GL+3KL2X_H._H;EINB,3:<^.I"-_#'<2X9P4
MV_:LXGYZFYG#&4LZ02M]G[0)5L@-+'7.(EYX^J'D&ZH>OWZ ?/]@1G0YCVIS
M<N!94;\,O@5G-,)(^[6NH^.G/^'GE^FKPBW_C[U8==1\:$,8 73TU]H>9ETV
M36FF^723FV&TH=:'ES:NEMAUFRSQC#*ED8_^%U3!9^%3"+(%,XSZC"+.,/A(
MF48E.C@..,TX."8A1-Q)X/OIZ4_ 6JQ?AX#:Y=3VTR"&-%R*O)@RI9D/*S51
MEI4?[+U&G&FD[+L):+[;N'*E%1KEBFKC,Y/%UBA+]49#.?0=)RHG]("935OH
MC3]N*G,X!C2PF %-(G"\OKRJ_W>Z^-#;^]B%=FVB)&[UM=6K%])GL\CL..^C
M?J3%^\Q'@8_TS$?K5?UF& 8,6XR\66^W"+B"QUQ_@CU?I/)UBY%Z->Z,[@>+
M33OJK@;V6MDU0D)GM;O-FPZU6M/^->HMSY\80<+;X9]N"?-(#=9/1*UE+_)9
M@Q*B-)SO3M.G[6<0-8/0#$LI<PAKZ! @SKK,L K?53E#DS_XWNOBEQW0@K@!
MUD1T6+!)>1$_39OY9WCI=D.;]X))6<:C"CL[,4G/9O:BDM5D"')BB78%AP#N
MOIY(F(9F=N#3XPW],]^,_\JGEF02BV(.!N-;:),_: <N?EV[0=B-QG'F(JD^
MAQ2=UA# KCU]@>;W)P@Q95KJ!.0]F1]5Y-8SCZN+@24P<WH0? !X''8,,C][
MFA9TN[&A>;S545 32^W='S:6B%^#D'@15JX7C1M'18'3_PQ]V>'$G$8\FIT$
M$["]EHD-+\VJIQPG5L6+$R"0DWV^K=9"?+':%+?OYJ\(JJ8HFU"S4&PR4?GR
M%W*A^.OUCN\V?C*MJ#!$'OT$&42%T)S)AO[*C&,E)OZX7%6U'([M-%2D.NS/
MM' 4L[HUBE)@-MK*1SFZ9=:OUI.J$]4OV=+_^O%4(#@<)^S^%!738YIB'-I<
MB.5;=G#[>V"5&+!:/E@TK5YT0T)KJ4 QO?CVB!_^@YGPAKS3',(G&NI&WNL@
M@6W(HX]P9O[SH<M_/WI4J%#X6J_$\-1RQ0N4I/Y96R>,//2W?@BS4E\=)EQ/
MH\R[:H/%?9+4J^LDIHVG1;@R>Z)#WD+$3[65=%6%A_X6(_F+!*O^@U% EZ.7
MP_IFE"AQ=<06DI?;V.^25N?5*S+?PI0EB5OH<31-&IFJRT:+L;@?X<,^"XE#
M[\VX\A(&_+"2D;A1+TD=R99CXC_?4#'83_M@KO!TYP35_CG?.U86OY7 9=M
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MS:'Q97U^1Y,5 W>$@@-[#-[:/(@3BYNX;W<(B BR>!]S7ECC1LEK\-[&W;>
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M:H'C =;U0_#M4:BIH2M=^9.ZP$^ORII+8YCI097S(R[:Y&Y=9YK4C:%S%_@
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M0[080WP)X^*=XD6<TZQ-E(#<>,SDYY%]B/'&XL?&=,T;69F?&]H(6PDAMA-
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M;@8DF!I)&:Z9H1I;G0NNG.'VW'F5S5H2P<=K,Y)X.S1C*=.;IZ-\9VC7(RS
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MJ@#/D21Y434192VHW. _?MO)WQGZUN;SKHDL> 2PSR->B8U EA0@O#M:=D[
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MZ:?:9^*?Q=USK>NAH%O1"HK#W^'[[6 UEP-NE+TZ]M8T,R*.X)7GP3G)"F7
M+S-OIE*_C02?H^,<LI\<F(TC)#L(RR#6S?34_-=TIKR4)"^S?!DMS<(^%.&X
MB_>'TB<7)[!GEWX7F?'_58];=V.@%U9*/(]XXOEZU1\-^*7PE-0]+WG!T>F$
MX8]7,4P[<FAAH13Z5"DL\$/SEU]WTZ[N1 S(S(,?GH OU;G1A,7!48O:)*>K
ML\Y#LK$HM<FM>ZA3M':; I!:AI=[UA8<&Y/8&DJ\!YQ<DSJZ*K:D(_*4GEB,
M&/XZ=[+@E-F&8F!?YH5=B/TOB9QB A=P2XPDBR <\EG];<XRN)H!;=+;K)]3
M5S9S?'[%+'Y_?LYF;=192-BT:LC[XC*==H9D>A^ZC]7"$3#9MF$E4UUK*?#P
M!N$B^&/M6!JO1;#KYLS^:7B]H\NI%]^M7FW,%?(.O1+T$U]&+Z1N7^,0N, 1
M4+!*+#.UL<8;G5=DF *[:^<0F']*;6Z!F7X[-B%.Z8S796BM^17QXWQBMV[N
M<P>RDQQ4I7+_X0V><8'Q0O*R'UB@8?[G'PKDRU+E7!Y5Y#3]C9K!8J+ XX7Y
M',U8"F0G>-<1Y\ 647NYP+>,'"[P^T^<6\%3>$7LUS0H!O 7.Q*>[EEY\]R%
M0]E)&7!/^UV >WYA_M\,CG7@UA\U:Y,)FA@P]T\(_4W>8C?(NWA>NDT/]?D#
MOY6)W$%JI+YT&R!V6^M!RJY"C^=_3),^P:_;[^<O!H)-6[G <(\-LR%6MJU&
M.,[A1M7C?8\2]=ONLHRVP<X(S<$S.O&0-J$"1T>SZD_N3.=T:]4(DX<'!6:V
M!N%NG6$')B%51]6:\F^?\>E6]]WZ!X:.O/Z=#S%DVLZ%@GGF(+IE%4^/-WSO
M:I(;O KJNW;HV;?ZR/V!B$9">WYC)0XO5<,LX@)2V/-+MS<O[<8Y,$!_6C80
M=7W+8?S*Y-!'QMQ0:%=^VH;(E*&H)<WIW7N9EO:YP*$>\R/2OGZ&%\X^'9Q"
M*>I@A&<-,%']#JQHA:A^S][B.N\&YOHP%X"PAC0ZH+%0";8^T]",Y<_ 6?9/
M50T4_TC#W_O@,E:':P4K(/4]R)(+H -,\V9CZ4PO;Z44,P>85/3&WUL<G;.-
M0P666>I>H5"'D /=5VT->Q+'SC-OH$7\,'N#0LU?4Q9I+M4WSX4[EL12,WVW
M80X,O9>KML_=_5)2_>(=4!)^:2!?*@G\,FO?4/&&A[O)8@VOM*(]%:1%+>9O
M&3L] +*D>7EJ^?NX#FTC?Q6!,T/%[BL6?LXM(]0ONNUB3]>Q*D9 83;,UY1Q
MW>@ZM:V#J./$;@T+(9B,0TF\S6,*K% ?RO#J:H)+S8EQ33^I-I]>Q(W!BBZR
M=!"J>>B6A5N!T]6'AE?I.?W2)3U4Q3@.#PM-^1D[3I*7]O(W.W/,O!/_7<G[
MV9'W(03,[3A/^R.Q'B2WRA<A<LA,_F><OT:)K, ;#&V#A/HO9F57;;LNC\;[
M;* $."I!H8Y57QE+T8M*,/U8=LZB9E9#;HAP./+0'%Z2->GOP\B!X*J=%.X\
M2IF;#5CE+W8J9R2^6N" 3K%O,87J) A/RCO7!=OT56=@_B_C]>T/S1'*![F
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M$Y/=WNEHTWJT(S%J2>LTN=1BOCMVV)HJWTV;+E%:E*E%7$F7:%==Q?)"G Y
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MCPZM[>P+FE^&.>BCQM:?C1]31A7('*^_V)MVM;I+5=+58:D"_04+)K@KOG*
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M;0MH+_<_&7!O+6>%#C74_RUU:4Z)C2B?SZ.JO5:%GY0:_6Y=EN[VA$\'33X
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MY#QB>:WET2HLSV:WM',CP<O553%5*B%!-*Z+H,Y48'Z%"#7S,RR)6H@"]'"
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M"G7/:WO$Y8)8G1,H;6I-IC0^6U^^XW.%7 F;,-AP"_$"_)DMM/D4ZL:8EE.
M=NF"1FZP8\V=?HN,I6N=OGIYJJ)B6P4*\)Q%\(2/V>#:WYWQT0)[F2-7OOGE
M38LE@J:J=32(^9A6R"-@GF=-)E"FU593N/&F7_3FVOBNM59M]!./GIWBV5.$
MN92LO\90L$(8P$'RR$KZN"HXZSI2U7/.7^FSS@>O+OCR[(O9$RK@EV">=13;
M_*_11Z&+_B8Q"YPU.K5YZMVI)GEZ2N;&.Q!IB*O, >AEIMHZAM++%)5IS^+
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M7-\ DM<;XU:MJFMMP_&OF[WB(H5V?Y>4#_ULO_.[UB%FU44EL\IDL[?OCUA
MZ^P+K*@*C\CX:M;Y4?E=4=UW5Z>B6Z5;UV17BK5[GC:\N=A]J8D5U4HQ[72
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M^;)?<BX8G18Q@[X,^K.7IKF5)3H')QRWZRV#,4RCU_8Z.PPM'<.J3=TE9']
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M/*Z_M,009A96P#\(=ZNN&)$@ZO%M?Y\CM?V#31@\[R#NL:;SQMTQ.Q@NU$U
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M(A/. >\=6:) F$W*I-TM:-V9QSQO,Q>^@0*IB%(G8=)_3!X:M?193:5ED[$
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ML4@JHKTFN(;N/8*VZ+S6%.);N0,BOYMD5S2$+X=)P;\:7!F[SC!F\^UAA$S
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MG6E(0T>UJG+G%2H4?@AIL&3-*=S^4KC\/G+,[!D\XU+ISXG+J;@ H5^B%]C
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M%-T5R;DMNB\"GW5A/LL/M/KOQ>G69J_\;KY_+G0@']2VN\'FDHRYBNBM/<G
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MW"=I3<FE+I?61^\">!D&3L:>-#5<>M;CH=DS08*)64 7FY= U!N( ==55A5
M%_TG)W"^Y_/,XH)DVG/6IFK+F2J%L%".ED<%=W6Q#2(IZ;JPP>RPD#<7*NU^
MX-G?A:ZY#)EJ&8]#!3!JS%- &ZD!B"!"#CE"[W1)JCE?G3XM\&"N41M+? ^I
MSB4@Q4DC$-%U^HA\CM%1/8P;PA1((-EU0P_"5.N!7")*V/F+3)97D-\5J?I!
M*68[B,<TPO!(L,\XG:L&Z)+YX.K2D#47,")F_-9>UM#WD<$;$WHUY#I; 18.
M.%(1'1R]RP'6>H[0I3QME/W4[H4LV$.Y$%XK$>!:\WX\6$ _P+/$R;%RZUW#
MXS2G&0TJM-=78A%[R)&(>PZ[%"2?'MH0@P_[/%E=V7<B\16\;M398QO1 0%.
MR<1D$_4"ABD:@HH6,5Z. 6.QQZNORWR3_=YGE6;B#RXHW<W2&3^>H5[W_?'_
MTH[D_]GG*)WC]-HYKO0M\Q[QF_'E5PA<SX=X[(JH-KJ_SPPRID7$O6!>8JC^
M9![&UQW0R,Y^+5O"I_CFA>UG[3-JSY4W+IL6G8TLF)A48?7F2M]H+4]LC1\2
M^7WBUIRA#? $*X)PQ?YR[=*UBV5++TKA*^BBCDN.YTK_, :<<IZ<GR#\D(7H
MXN+A^QZ=;7Y<%E8<_*SAE_:4?'"U=:5::OQR455-$_)K'O?#=?6Y""FPW-WQ
M8=^&0@N-WWZ]FK:&-SF*X@S3I@UTK0@O'0PF=&DYA/57;7D]*9A;&,[:'CD8
M>ENSWA9_MZ+UN#]![!SHF:BITU#C-?W2#B/1V__]_M5_?P03_:$<"M-QRU 6
M&"?S1,,4O8@#0DZ/A'TKY?KKB3()B_Y0&W!HS-S0T-+>Q8/CH>YUVBUZD:-'
MD>T&JK>&#$4\QGP*/7Y\$RN-.^'W67N;X)$?$6F>K$UV?OUQ\(_2B%;0$X=C
M[^.5_G//UK6P7<CAECA?^-\:(7!=$BW#:F+JH(.Q] >TH%BFUD>SD##_@L^O
M'#L-W7V4?R)O/I+,?_%L]</%KY-7K!.;'OJ9^"N#3S%Y &$R]B"[&T(M9QJ]
M_^8*>RS6&D>8FRB=\(.JC#FP!P=A\@VL5T7 H<JC2P05S;HJ_=<"42"_EB J
M83&MK55S8?;*09N%")OOD1^DL0UM47 $<[TBO*%U?>WX\)SV#NA7 FD2UXF.
M,)0&PH(A886>9?MRC744MPDP<5_3Q^&ZUF4B%]\GTO]KCOOONH-9_VVAI_(;
M8+AHZA%*4"-!T'#R8Y:C555OKOVVG=V-@.1+=:F!GCV_)H1?08@Y4-Y6?Q(R
M%G)8'2P!^"R9I]XFG&2<GCC%(M<^\)&@0 TF_T# $+>R%2F8U \,KY?#*.JE
M]YBRC&G_L:0[/U-"?!"G61?KZNIJ)^G!1PQP*LD;@OCH0NB-!JW 0U].Y)1=
M6*\0LPBI=U\FJ" 'VKSH4L!SQ/VWQ,AKF:V7=%XLFHDA-^._/K6344ZK&89X
M@,>0.%E!:M!+N*"7K@HJ>N.4?&-KBXW2"5S$+V0A//N,4D,?KB_1NY3>?#:C
MZ.OPSY_&TEI3#T1'O57NA9V<\(U5+UXWEQ(\>VBU2\*&6;K!%1&O+'+K?[2>
MNUB5R^##YX)R;V9IZ.4+YVR?&YYBO66+,B\.0AZS_+O'5J(J*>N_\+YG_QI)
M2ZML5.K-3,? +\#[=T!U>36TKO9I_@V+0_9+-0KWAT<OF1<<33&"/^\INF.D
MA9)I+ML!A;49(PH]MU_9UTE?S;RT=47%DZ+1A*JQK3'<Q\J"/+  PRX!X3/(
MH\'S74&Z1O2F<+\0=]?@R/ZNF&.P)AF6U]>*9]@Q7=\H6TC5^@Z(2Z/G4OB9
M(*FNTR&FR<&/?;]#^%CV#;4-]5&7]AV_+< M4UKVQ\%B'#Y-EV"N;"TT9*$?
M]RP7_ # ]'Q6&EL>D&[/ P&11#3?Q.)V;)1Z5&VV10UR,^5AA,$3GKWYP!XB
M*@%;2Z \@:L'$TCIA:1<-8LARF'ND1>H"_;50GQ5,LKK"G-X_D8!\4/*)8OE
MNJ-A,FKFP]9?:VOM,P(#BU>,ZUH#P37XW^5$2H]NUNV_WSU'X_+_W\KN'K#X
MOY>5W&_!S-SON\>>FH:T0VGC?^-7]2S&'8D5\\D^&+##TJ?Z=^YR\H.L_ <7
M-F;$%L=:W,VS66-,"BL:+@6 >Z"U03W._MV&1QN:6^MH8D/C$Z:&'KB,H=HB
MB:]GYYZF)J88%M/<F:)<= 35MDDALB*X=$KOY8C:-9_GO0@^/'"'X<Z4!#K*
M=T#W@"N<&.==6%_QM8$+?0F:[:"8@' 7YF*/RZJBZ''4Z,JRPGJ4E'U' '_C
M-:$MTG4*U)W]-71EV6YFR=O1F85B2WDV>U-R#LLY.8Y]3I0H\NX>_9KC.O%V
M)#5<& ;XT\9)FST&5O,FU.0FP1%\]87^*E-I3^O(/ .O?!HRX1E'>X!0WT./
M7#>/S/@S?Y(QPAR';J8,3G11560CT)!U?\(41I$ZET&N$)KIVA[-LO#UD[PC
ME_J._-[2,D/I28;Z35?2-(6+.DP.C P@JPHNT5>O/'"D\-7L_]50&4PN@QFP
M/AC*P"QH,M,Q,)D27)A&*G<N94Y ?!W=-ST6SI9G=Z-DZL Q"*& )FQUZXUD
M_>C7-I:%VD2X!GV3*;)$=(^!@YB"T#C=]<\!,J;"6I;- =)QBQ<>_3:_IM5T
MJ$3)%-?*O T,$J&1V[=#&Q(WBE5<4RRE>.7'4[P4NU&UV,X57N R 2<U_=*;
MLGQVI%;-1!L4 =C-"U,H-+W>Z=JYMAT0;UY2L;JAV.!&='5P0<;Y+Z>U7+PH
MX%^;1&27<!*DAB=V'?4R3[9F5(7X?#EY9@XW:Z1X\WQ\D]/$D*?T)T3'I1V0
M6UA?,<6;?<*S?/6SF)@OCY7?@C.J6WC,F&37!1:^ Z!ZV(H</XAY[&@B3[IR
M-' #':&A^LN.B.Q%C6T/M$/Y]/?<^[@@I0>F\)=I#VS_&=>[:;)>L0*<5HW=
MX.<0+$"8U!M''!VI92G?AE[HB5C]+7V@0PY?]NM2RXGP#TV.ANU48PJ:*D(6
MJN&0# LI^\E)=6_%5,$?*K4">:.*$9#'B$CL0::SZHMG*CY'L-&??FS-&%Q?
M0+I"E=@]4CN@92RX5QG!O3B][QE4$,CO.N%8?JC)TUH";F9K"HATL$$<M2A:
ME(*\J-569V@.+?]>51F)/MN_!4FRJ$:J*6>B"JZ'<VN_TLWRE#_5X[<#DH$%
MA5"G28%U,V;*?NK-@:@SM +-"U\_D*M,YY+&K3^-2<Q*V4ZBTK%ZK1P*R'V(
M5<8^R3R62HZ-,A2\C->%Z?VM/+*Q915*;D-V8*F6TM[&=.=F8!3MD4[?3&^X
M]MEAJ_S*Q%VB^Y)#F(YDZ6OWT:A&_5'H02_;/-FALQJYE\U?C7<.7>^I:I=$
M1RJPVB"<X21Y3_>RKA!SL72!KP[2D;"?25<">D)YXK&/*JS)X.47&,.1BO0A
M<ZM@"JSVJ?^<<*A!PB6*B&$Z8$.#=J'$89H8)6J-;]WK25OSCNK;Q#5G[0%7
M*(J JD4E8^]CH^'\5'!DJ]B1 K^R:1-&IH)R+B[(MT*KFP-2+5%C"))6MXS6
M1=I\QUL11B!8LU.A#7[ER>E<28/(,6,W>(3L30F"R Z(?Y-$8)ZYSA9'^%P,
M\&P("9P*ZO<CQ&^YMH,;&G"^PK"P*N A#4DJUX6%C@SB'L%'OB6QS@-VAQZ/
M8XEEH=*A%8,L;MDO%5UCX/>?+_T?O5UI-!MJNTVKK9:B-=>4GG):K=)2VBI)
M.AEZU#'5K'):'1"J45HEDM/!K&(X9A**QA2J$E%4$$&KJL8()1+4+(DATF;P
M^>ZZO^ZO;]US[OVQ_[W/6L]ZW[7VL_=:SWJWAE-93>2GT-N^_R5I(EC_X7?F
M19Q_LV0+Z'^SK_%_@4N C>V&*BH-QL_>AC1"=V\+0] .%!JH/"C1&V=@!=SH
MHDW\3+2,.'[$J5M6CQ7TG%'#7M[-B>&AN2I)!-O@54V@UU!Q0XX2>CJ *ZSU
M</*C9O> [\#)->RV,W@Q VS>R.W]<YA%7<]J[CU:B(N))66)SNV\X#HNQQ&T
MBA4XO-?-RASJJX1KL*/L&GIQ1-* : AOJ]YVX6SZ.5Z>RUY2\.4*X_C3;L_$
M)D6Z[F?4(X>!9WW3?_?S*NWHG E:>B&P0=//L&AQ54V!G(IV6LHWZ/C>B4Z[
M>Y(AE8\&2B*#F S^<:N7YD^8(">//J1R&*;?1K5KE7W2+4@'CL[XP$)%@7?4
MY^/2*%\S?#*"/! H:81<D+1G9\%5>;NF^D7G$W]-K_09OGQ-N/\],WH+<$=N
MVW0?K6;9)9'E;S43SE9<F.,M]2JL'-*%YZRCZ1$W^)U<A<G,.,B=4TIT;_J"
MLD.L\;+EG;#!-=KG28P>NP=H,6#L":WQ>YRP'S7N_;RB<[):YDIY_@.0H?),
MDH?#HE7=8V+4TO F1!_E)\<_QEX&<NXSC0J& MGX>T-*.=)'[P?/\F-[%Z&.
MXH](53Z>\X)G43\DM.S1;W^L,S:V^UXR<!.VL RS&C!IA/N5>U3V17\96+1N
M.)K5 .]/';\*F@+IAI;H=ZKYFP%UME_;0*SEG_%Q2DZ33[+&:%X6M,MW*]S\
M1888-X^!>T*)L\N:4ZAG0 5"8VYO].E%CUVT^%I;V?C:'K7)Z97#K.:\/F/0
MJ2M1A?W++DH^J177N7+1ZU!Y][I\O%OE5_*$Y9Q_),ZXZM,,(0#Y).P@$3I:
MQ)OA; &H<KO").V_KD<:]+/,XAZ<1.0O4:VG=V#2B:Q2S(!8JCI2 =&C%?='
M\WL*A!C9@=DWT*3/[*X 2M#U\U(M)Z!I])I6X>(T-@I20^YT%96SF\V%ML,K
M51Y,^?.CON%'S)1FYV#6@PF"Q!^F 1$Q;>S1-0M^'+?"BP^2?8$*@K]FY+I@
M8 B=8MV LA53_!9@=+1C80LP*1>O?_*/5+\[?55*VJ^NZ2R!RD]%,VK3L<^1
M1V%8>1/-FT%5)C9L\+B[(2]T1"6(?)U6#*6/,=J&20Y!21:C"^$'8(>,2T+\
MU,><)GOI$JT>O'\O[&\!!HT3&++?KH0>S6@LC C61/<WK;62=R$"6>P15^]^
MRUR3_"%THL?&K?K$LA0G>(<9;?XN-FI='V(G[JX=&#I\"VU07_T**AD*5$&<
M;^"0*.,/YTA&RJEFL4YP?70)3&UB0Y \+\#-DA,A 7IC[)'PM<F_R-+$BH@N
M_<^NF;5^);<D'K9*!OKQU6A0[F8+9)_0X.T +O5L$[$QI<BR0W&SBN$@>D4.
M0"GSPZ>8KK%"5.G'$@;0@+=BC717,.TPA'HA=HKRFO0X+UI&H=&CPV8)%>I7
MXZKJ_DB5]$X/SKMAG7BG-P,5!-P)<X4HBY4IQ;XJ"A18J<5L5N#J@4#-R!/8
MY>K)?)2+J @)]';C![-8>T-&VE.M=MR]KO625]U(!$KY>A1SO1@CE>A]G^^2
MHW,CF8'2]@U)*[Q6;^MH;9_1=\XR( RN=0M (+T0VD8([H2I.+[CB :3*:4>
MV<>2Y)TM&=Y#[<) ;G,91ULLM>,- CHDE,#[7[B9\^6=)K@G.VG2[$_8>LY4
MFX?,\G1X5 <&;WS,D%3B/(34Y)O=?"]P*2NR.(F=,/&FW6D= $?P[V_/3C '
MV(Y5HO/!G4R5!/S=QG0?]RH"[X87ICB]NO07^)$@Z<0UKXT8BMPN/YI-J$]A
M1^KQ3^]X55$7G5GO,D_1+:QRZQ>.-V8G':<<?N1H_P^F+OTM)(Z42&H;T\QO
MY^&TC?_C*D?#\ZR,>("_?/A Z;;KM;PY2+#?>6*9_=M%\Y3_>?0LG*JO"!C4
MV<#]M^%7OVBZ$]VV/0"+Q]8>E&R7R\*IBO8[#=BLXKL?>R[$ P 2)?]@*O'?
MP8[Y&P]"15(=4TNDAJ%B(Q^P%VDO_F=.PV? -*T=JHD7:\*@)*(XA6OG-)AI
MF]#VM@D^NF"[5X94K>2 /G/4<0;<7T<+\?R^ND2,<,\5O/VFA]*V;>8JQ^#J
MXP7NQ"ARHWY;F<@6 >7P!!2,)G^S^!NRES&:YFOH=4ZHXS@.-6E+;^V04W]*
M#87L LOYD8EWO[R?JDYHR"@\F1%.J,M(F=_LE:J\F'='%I=$].[-=+$SW0C,
M*'NSH-=H1X[>%HC7[\D(7[GIR!)7&<]N-8MRP>94SN(U<GWNE6'<@1$*W##5
MNN9C][8V]/AP?PK5"4._[+=,YGNO;@&"IW,1\!X;'%LG_OM*N/N7\^6;#='Y
MN%.C)M(C?UP2.EDK(HG3V+UDOX3>N)PI/_DP/<>:L2V O@$</>,%%2KFK*@B
M%2TS,S,/7-Y,CI/Y0+&DVNQ?U75HJI3U7NY;O\#'41Q/7^7*)"@+RDE^:3^'
MYL9O/K%L?;;21&M%&O8U ^;5M'*W %)MLU[U7--7:L.095SRR?K)]"EM4,60
MCNCM*3 P#'6)HX67KGMODB3HCNX8H5N=:-D$O2_G1<8YFV$=''(X4$GQ&.8
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MW)>3NB<K)"IV[X\?P;MZ]>HULFL,Y.0,]VZRW+SW;Q^XKP#U%3P8_BH!'B>
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M4CV^S ^R*VG[9;TXP-;EC"<5=$*5A ,4U(Z_ [RYD?_'&5]]#@[@F*Y"+^&
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M'B+' 6VN." WQH-V:)O]0,+'Y>(\[N*&'4%V;B0O\$^,(',$!ZR\0++#IW&
M4MJ&X]_.[?YR0Z$Z1R1]_.L'=YZ1U($]8!H,=)_!S.M)G'0,F"[;6:6RB]C
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MH37W\Y1#S:,:Y:;$YS>]8]_+'_=KLBI[RJ7Y9=2Y_5#B4RM/R8J8'M&'UNZ
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MB]SF$'5463'/M[)+<FO1PY)6]V[W63G]58$V(?C7$Z=X.<H*O7$/X;=,[&]
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MMI%X+K1W><GEM (''!E5IGQIN8X%L]/@@)9+I94[X/%/(_A/H[O>"D+%Y*#
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MLC\&Z.HTT%]P?7IFN8:KO/=5;]R#0\TXUA-W7Y?<9?/Y$C+_);JGO"!>&(9
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M>]]BTM4%]+9@\-'3L,;OR HM?ERNP1M\U39DSLC1O!2\.L]8N>QCP)YWHWA
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M;DE+%%9%"7]V_^HZU&QK:FRX6UNHET7Q('-T$GM:1TDI)!"6AYJ\=K.ONZ(
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MFJ 9C"&A\#0PTN8UP3:518/NJ7_X.Y(FA$-PN6L4U#Z54\B!+!4EZ),F!.K
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MDE4M3Y67O,:A5T=%ZO'QG$/85)22DP$<+0H/ )0WQ'_OWNB./J7)>TOH+P\
MQMS(?P/Q\3F)CA#Z ,+(4G8CDZ'Q_="JT0,Q830"\_\QAOH#0B]4$(9QJP_
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M0G0N3,R14Y'%17R"38@_5\^*D,+BAUT@[E7,UZ^TQ^_R9Y46?!T> #'A)P\
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M>M4[<_*_$$.@NW: F2MH2F37_+$I$;+WFUL+[?(3)D(:3P@J.S#1TP/0\]V
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M*/@J_P5:Z9X+G=F"L[<R%VV4"*LI5DRYW)61!,?NHJYH%S&RL8Z5*_(6MP?
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MJ,WW/Y8&/F]T@7V<@TF)>NDE)+R&)2J;:-:B8$9MQF$W*B_\V,]&4\\SY(8
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MHF2.1I\U)+69"_ASWBGYKU!=&#@IL?&B0*L*!V'U>T$7"SVU#B*E&K_DU;E
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M6F31%O.."7J)P0)HAQ:AYUUR&[,P)XD^G0<,$TYPPD,&I1<!C1:ML^7$)XP
MPO+RX7),KD, S=UYPH&8/4WH;'%J^B=TT/04+>2&:1ZYT3R\4V<'XCG1HMY&
M5P6&E<@;?E6]2GKO:Z,EZ3SVP6#_9,>Q XE7,!\1?J(AZ$IZ1IO41\\'U'*
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M*HE;HWD4WTTK+Y@S>O7V>51/H(!QR!A&@1,+>!7_<7Q)* S*-1K'%PO]R,?
MNH36=13HH9Z=U6(6(^P1L^G. YZJ@Y\_'_O7I,;7HB^.J=?O2X3G;6A]?BUB
M+RM[,S"+1M%I*L>6W)]]#<T/:H0BBB/:U,OM@SB:@DT7C<*21N&\3CF@9K6N
M+H9?=2]G/6)B3K^&ZM8D(=TS/#(U8CW/E4=<&7]5N^4&C6DOS:N]:L(,-4;?
M?1Y2V'V;:QEWQB!:D76KA:#;<ZIN^&']3%VKS_[:%.>J_OL7U4)3H<DP9W[0
M''\9(\NE0Q;;9#T!H#!=X2[*@F-]+4JY?_YP?Y"2BY/^^6O-;_?W\L4K\/H/
M@U<:EIK&_&+T,..8P5;,T"&D3K[H\FYVML@WV' K2ZVY"ER32?=[Q[T/,_4V
MTU*"F93%64ZM>NKOR2+O\8.NC9PU=[7<C!@+*#75()F_JA:-U:EO:FV 0N@#
MYE@Z2P/N.1;\V*)-26?JO7@MV "B[GBU)GLY)[NYU(;9U*Q'IO;O7@K9\+1.
MUFDJ2N 5Y(NE677=,<B5D=D<]],/;-M%8 &8N>C$\<=#C[4\Z4J\K[)JUCJA
M=5ZXIZ>L'W!VDAQ;'AJ';!\ZI*C[P6XL%NMP@/<WI7+-)7("Y,9/7$*7Y^D:
M8J3K ^W.1DJ:OW4_(RDEF[*,OW>T:[;<H_EJS1SEF;=#YVS5[".MMEE.S?,F
M</3G.('!?W1F;S;!/Z_.H$--:V,9#.RH%YF8*?L[L8Q4?!_!C6GFC@L5I-!6
M-3XZB#86B3RI%#\7.K'[+0]V*1Z4ZG[8G/5+A=2+:DZ4[DB>L=RR7"L7,^KJ
M(%WU;)6%W==9KISM UOGYW&"G#AW-2?52UE/#:X <L51/@N)O_:46N1CT1-T
MLW6J/L-P8DAC9ME;OC:S8)\/+-:YGGXTO!S!R%+<E=#88Q-5V54<I^0@H)8Q
M2O*+"EHED1AM-:NZ2A<E#RIRP )M7S,>RQ4N=KC6:L22+>6(;N_;@69_2]TC
MTZ< :[4WMKYCI@O17F%[$AU]9CKAL?NNL6/J]UY1\KZJY$[LLI*F;UMZ8&J(
MHL16M=TX3V9XLZVXZ7RO-*Q#K$G&//B8+;M2%^4)%V*"L3)-RS]8O4=_<%#O
M.%A[IZU.)[1>CP*Q1E#<6 CXWV2/C5?.:[M<V;B:'@O9J&Y-*TK6Z$COL[),
M&GCG-#;.' A\4?Z;K9);&J/"X$($.JE/INM+A*J^*_NDF;ZGM_)@#6_+/'8)
M'OV]5_:F-_GR_#K1:??70XB$G;0K'YPHD(_N["N!- 2L(T&@XS((HAQ-<>V1
M^[.OH[,MT##\NR(NT9K83EJRZ[S\^<5F_/1!>WFR1;@BD:J!!>DV_,,ZFTAN
M5<V?[65_730$1MI&HM4NPA-6S^M:']QB;U1]#Z@^/_SL;IYQ'7S0_;YTDOH2
M'6!&>I16$)8DR[RY^6*?Q'TW]'RVXY^:"VZ)&69^L Y)(J@$5-C009J8'2Q@
M;)1S5)UFI2WJ6N E>US6Z>L&<ZV5&.30?N,3< IJ](,JD:G,9VA(^#<:1SEQ
M&"R!G$^6(/W%><&4\=-\N&M?=QS:6\$9['96V@=-5+$>K)AIF[]U]RQ*XSJ8
MYDG ?S"_L)QMT 2$LM%^*I@]+;T7)#1=X;2\[&E<LO-!'9B/#G]LF2L;H[".
M!5RQ@,!&!^>-(-K=SAOJD\MO,7N>5!5?& Q/ SI#6R65:NZ\Y/GA"C"Y*[&Z
MEV_5["[7'LL%R%!E\BZI]; T6^F]=I^4@:T98KB1GX.X4!:L844+(]+04A6:
M#*.R(RHK@E=^3BN'"D'U6TM2#>E'78S3]76:=R;F!B)CIJ.>O[50".!%V$9)
M9D<QFFU@$CWQZH)LSIE)27.I<8ZK$BRO4O-^V%^&!J8LR;RYMZ<M<:$W_W\H
ME+=-?\ "/2KY+_:PP#N?HWCPS&RASK(DSH9Q1R%=<(?PHN-\BP9K1,4/&%&;
MVMP,0S* W\EM13'[8UJ!=PJM@G2)D5>VI2XM&"M@X1SR?9^3]LGZ,V@4!^/Y
MF[1L1V]*/"LG-E0)1U<@&-C" WSBDY&,P\HHNP"10"=?MF@AH:PNR8/:9E\V
M/)T/;T.:V$\NO+ZHH_QSQ^!CP-:%WL1><SCI$'31BR<2302#FW'$D8;<CS8E
MQ8=Q9O['AU99XIM=C%L@,%+D6LE5TM>.*VD#(:<!#1,OV+;I&-4,IY"I( &P
MJ.#$5@[%S594HK4_ HJAM*L\H(C>J&-\.1DT"I_1S"5A%6MD4'!8*BX>01P8
M(IZV>Y/6VK<$I5VEE@P3TQVJFS._1=^+0K?W^=.E9-FF57NO,56/*M:MXM!S
ML8\3),\YZ"_?Q AM^U7%UHSD;7DE$[39S=U2MV+RJEHAZNQ"4]3;^H#[C;U[
MA/B>(:!1^K_F#_MWC(2HE;X)KUE^_*'4KWX"LZCTE^-\E*NCI^M!+,IO]WTH
M1>55L8#:*#\H'*5>8&$?1"*QHRU)Y_?Q9^,8":DX@?R->\P A'%_ZW\J;F&Y
MPRDC;9IT?NFBJI,]X?#0YML?@>H*86Y!'+-M3G"S-SNH;:(J'_L!:XVGPDZ/
MEGPP'.^U@MI5+%%?]+ZB2E<&)KM31<T=: W<S!73W@0TON=U9[I]<26SJ\1X
MX=(/Q74PCO52+]$$/5ZP3%K%5[O.3]H7D'U^-#Z02)$VO;5*0I2-2'AET:"L
MKF-KT8U[KH0\J1NLF0F;YI.6SC/I@?6U:E9VKPR'LRJ40)(X"G_>-,*URA;5
M086H*INWJ2Z5:I_/:U9VX4+XO2E3 7R7_ZDO@@)!OL\T1N<SZL/FX3Y4T^_Z
M2'>0@^"$YH :1Y\_WV0[34=YONWM[N?ILA P"IUQ-8VI5_BW^L([?-R;A K*
MA7G!@C_**C^_U,6)[Z[0I84@M^DN_W[=_R?R78YL\_UR#>-Z;G H@4^0PK/#
M(2G_P>(/W#JT#'H[LK#V-^/;*4O2R(?SJM'RBAAZI(?V5=F"]J0U+/TZB%'%
M#=WW/Q0S,XA29-M]XY.WUAM$B:0[53F9%S#KXU9>S;#K;@Q@]F>LAE/@[!A;
M1/(BV:(\9V>D4B-^(T4U$WM8W]Q/</]][V(<__:LO#_B<F/V]UA4W4,L\"DN
M:765Y\3CX.3*<7)/V+*]-F1':,D461'5]&(E-C:AOR@_I_,?)LVO+#HQ]+-?
M1D[+\^87%VF(K3^^<94CWN+/H2!"4;B006,#'*G%RE2IAQGYM\JXDX&@^^WS
M_\Z-$H3_*W1^II8QRS3GO_%40 8+K!VZG!E<3)C%1@[?M@NU[F188\WL=U,B
MLB)J-"+]PO%RU$3*ILSD@W^X#SZ'X""(>&1/?^MO8YY%+;7"-$/,)P#$V),:
MA_KF)RK;]-&<%_B@A*'"O^O*$R@J+EG89M2;*?0R<MI[95\HT,RA:[7B7>XY
MZH,%,.J;D=#?+&!,L!WH&DC#SE:TSB_;L$"G?B6$+,  T1@C57*<*;"ZL5_P
MR/.6DN[+1UJ\3= P17[$TTS$VI/Z&2D67J9U\?,HMT:?;[&/WBB(F6?D.&#H
M9@K2-6^L/6U.(O6-<Z"[_7E-YJ0K!W>\S;+ )T%W6G)/3MUX[4GR4#,%@S83
MMZN6N>X,4@9WY;.?07P &Q9("D628*[3W]."C[\_X(SX.,+2Z:(/OKSVV"XR
M&>:*VMOG%&LY"NTZEF=[#%T%W[(/HOZ^/BWEG\ [1R\"NO/-#X]E#,5X1!$=
MQ-*!Z&AW0?+UJ,?$V(">O56]5:S92][KNOSVMZ;MUJX[LK6_M&)I89CBG4?X
M#28CBHOSKT0$S*QSIYW7@=2\9-PS,D?UAJG*)*N0#?F!WN\?7A7G=FUGU:>5
MH28??&]3*=JB\Q:Z*BP1O=D=:<(@@]>. QZ8RKJ#E(H(;9-R+U]ZSQ7F1JW1
ME3BVJ'QRA:_E@. _CC,7B5(D0K)%\KB7[38NV_D0=H:(ZC[ZM->UO?!V5A)G
M?TD .1N!ICNUV%N -5[J8P&^U\*7#6M@#^9 N.DF6@0,0,;-7="@5"P0575X
MI/EURBNP96A^T\;+%RFX-V9JY68NAF2<F>SMD)P,8O6!:-4T>',&/MUA\M"/
M%CNR9'>#*:Z7Y%!H:K&@_+0(&J-G3J#54^]MQ&1D*6KWU\#^\\W+*'/(=7RU
M)2*"P1G& KVS]Y -0N >,$G=&+DAYX+QL"?SXQQ;PN!JOJE-W(OD)S6H-,3^
M=*63<)N00F6B7KS@;J:X0CS0O[_)BAXG^&J?_K&JNG!^1_\9@Y!SOM&K-X7>
MMQD("!+U=TBX'&9$I5(_GNK'/5%48Y*F[/_I%FO @G3O34+9PA>O^FJ=6IK[
M*DC)B6L1:F<D3>/XFQ%H@V*?]$!UR2[Y1$.M4^\FJQNWF3T)W8\L9W_J;[CZ
M!?#!H5U]24M+LL*2EQ1U:G&=OFH_YV *ZNCRE,D.W@ EY*/XEN)P-(L33X%Z
M5$&6Q4D-11N76>=[.6_,!YS?=0;9*)/5K.Q*G^L<J+<E%G^P;F+0%[@7^0)?
M>O-R#@ M)_AM5BIRH1],'?<C:2)"]K*5&3P??3X_?"17<S2V LT$_,E>9M-L
M+R/2$HC+1B\2YH*F^K1][=)@? I^7ON"('A"PB;J[<O2)0UKE@*O647=Q['J
M H\>'4 *WRS13UO=A5)B.+A?0=C;V].;NVN4TG:W7*_Y^F 0:X\%J -\5YVH
M+I_W9%$VI,PO@8_3;-^_Y0Y-H11>40.Q%F47!A@CM6(K$@,XX)+I^[@CQZG/
M<4B=1FG('ZGW^X(C_("3RZBU^H:4U6</W3B\V&V#Q1T%NS&W)^4M"B .]B)<
M\^=QM%;W(US[?<#&ZP%\:W-H>SB$<F%'SOLTJ+((QFT@>L/KL#)$8F#]IJJ"
MPD[V[TLLP#T F?T-';0#3?W8>^;Z%-]5+KT/ 8NN6Z:U/US<[M<5?3*NA;M=
M8YCI5R[\5-"Y+=Y(*Q1J1S@ASYN]&O-Z(#0GTST<5GH-C6R2.+L?_EN\C[GU
M&N0F^O%D@-HIA@Z!OMOR(HKX&W(]!>P3B$27@-+_H?K<:A 70(U8CO((=._U
MGL>D\D1!;W/N]S/$R,ITR9/.UHSC&<Y;U+4R>1/#K_VT6+9?-9=XE<[=[">K
MF2J 0=VM D'FQ+UYL<S.7Q7_&Y9H_D1:Q_PRN=%4VL8\"WOWUH*[[^7)D6MO
MPNFY;:'782L;40 >7-,%WI **=WR2KW[AL%[F#-S)(J>'!-,?+Q(T9U.%QZ[
MJ3*Q]SOV,F#R9C_:EN'""N,Q1N1C,]O-RM3P_<ZO=#NAX8^^U4W[KV R@'=E
M"X"$AF*!0^T@#LCL-1]32>U);5588$4_+K#"PD&C:E?Z<.G;I-K7Q]'BO9\#
MESY/I;MT:0@)ZH1?+/1>G&43"3'X)@;+]+L:?-;&5^V-\[OL7^*+@$/#"]DE
MG*>=4_?[0Y.*?WB?R%@8#TZ:KZU >O$FA8M2+ AWUNF+D[-Y4$P)K^,CIM44
MRJ<"J!"7Z@A)@_!^C9B,<MBRU/0D?F)[#; F"WYN@#:#"TGTIY.F/RVIW*@E
MB#=$L/*Q,*@?3 42Y5#<17W,]QDV1LZD^A?;N3E<L&;%2-Z4WZE6OSUJ%+[R
M5.:T\TQJ #5L@EP<2Y#G<2M#V<S,/@NQD:;=%A6\YVP:XLWLGO"T_J"#<1P+
MP)G'G>H^=C2WQ\]YJ0H-XG6?F@;+L!#4:\^VT5BN4MS:2M_H&^EUW[[%P!$O
MWFJ:1#&2F+58K41WG'D?C;)A>6!6IR$X'5;0_);I#2PV.33YA]]L&IJL+M#8
MA=)G!N'<,G7 *#.X4T*^2M"@QH8@/@E\UB6ER7NDE:0:)YSCP[#6OT%:<$MB
M.7T$$1%6@6:"#TB:,-BD$QK]4)>^*V;#O0F0'^-$K5TY=LMY[D?8KU:*[#EZ
MN^K/&(29RY@($+U2ZUSW0PBX1.ML1\!3&J1H8@9-]$7W05%NE^T=E]71,TB#
M=\?9#'9[10X(!L[%CKL/ZM=<#F[_ACR&YZ*8B@:E6G:6.&?J-4A>D>H;4*%#
M60@FMZ.!!92,<"K\:;CPF?/ASZ+]5OG^A0M+UA]5+J=AS^1Y\H=Z1&%E'._]
M7_N=-+V,7B)<"9>*YY_BY(S%TQ8%6#]^0S]$#"*]W]8+"8@JC@_^,MG$^-T>
M2H#1H^UN@*->?T% >TD+:*2%E5D_E2C>RBONAE*$T>/_S.YMI=*59W$GZ 6_
MZ]%H3U&S/23/#*"ZH;:(/]FUI=:U[ET%[4EG@8:W*5CG&P]S?S56W<@?CNNU
MRG(%#I38[E96G+&1!'&0>+[BG$E2IU%%$&PBF-FZ.]XBXLN+1E;(>#$DD2G]
M]PC/%)4,NW-(*8I$E2_TB1!+F8CE[B!>:&-#RPQ'JU=S2]V'+]^*PT$DXS>T
M9+?-[:WST3S9JI@915YH;75BP'8=N"'V8#]#K+EY#5P)F*!<OG3EH660I_5.
M[^*$"_S=)O%2*1.^1>]*+E)O6=1F+M:6&A5.\#6G*GBKQ?Z\P@$AJBSAV<$0
M^&V4-<3%ZVC[E#&\3-A2SS2-4[G[:$$!"\Q]>3U]'"D5=^-(-3%+T+_<J]&2
M5;QLN#$6.1$L*Q+J5A; _?U&\%WN@LMDP5F%2_F\!+R=6 *ATL%D+  \/G8A
M]?%;Z.Y@JOLNQ)-B**3WT?S97>9JYVL9Z;91K92S@>P-& /#1GJ18ZZSI),?
M![AQW@;+K ;++W=9',JA#;% (!;X7%][J8@%!L793BY%#HUW)+\ VQ=/*U<5
M[C.5%R>;<_\4_-CKNW@F"IY7<#=]#:[=CW%A2R6(K/^1+#N?S)GPW0XT6SZ@
MR(\Y6_W2,_"*_:GP<#)F]!@+@,SX0C%T<S[WC)R>+AM/?V')M6MK;7[ 2T0@
M [CWO;!+S&9"OX8B;Z$OM"+R+LG*3XQXV?>Y9IDRL !+#H7Q?_T>Y_\6NA&7
M$E>T/9N:ZJ7OINSFMZJ1&N=J_?+GY:'#";7VC9N$[+&A4XR;W*C E7,7Q1D,
MXR3I1B/MI=QAH-M$-#\H[Z%:ON&:RD/M&V6Q ,&+VU/_EB02#K$P&/XU]5-<
M:,_H%?&B0<[LLW1*F09AGBEIEOK%=Q7 [/^!31!V[G\ 4$L#!!0    ( %M#
M:E1H6$(Y ! ! +5R 0 6    9V)K>60Q8G)M9G=P,# P,#$T+FIP9^R[!U14
MS;8NNDBB@B!*DM0J49*"Y-0BDB7G+""207(26E%0<@:)C>34(#F#@.2<D9QS
MSC0=;KOW^?^G[^USS[EO['OV'>?^J\<<HVJLU7/5K/#-^57-A9Y SP,WY:1D
MI0 L+"S@!>8'H*< ">#JE2OX5_"NXN/C7[MV]3HAZ0U" @+".[=N$Y/24H'H
M:*EH:.XR<#+?O<].3T/#PO^ _1$7#P\/B%E05(!;A/,Q#_=/)5C7KETC)""D
MO'&#DOL>S3WN_^4+_0T@N8K-B1>#@W4?P";!PB'!0G\'0 " A8?UMPOXMPL+
M&P<7[PK^U6O7"3 /E-\$L+%P<+!Q<?#P<'$Q=[TQ]P%<$KQ;][C$K]Q6,<:_
M[T#*_2[BRU7ZI\5-9*J#^PR/31Q]KUTGIZ"\0\7(Q,SR@)6'EX]?0%!(XIFD
ME+2,K)R:NH:FEK:.KNE+LU?F%I963LXNKF[N'I[O/_CY?_P4$!@9%1T3&_<Y
M/B$M/2,S*SLG-Z^DM*R\HK*JNJ:YY7MK6WM'9]?0\,CHV/C$C\F%Q:7EE=6U
M]8W-@\.CXY/3L_,+^$^[L  <K#^N?V@7"<8N;%Q<'%S\GW9A8;O]?( $%^\>
MUY5;XBKXQ@ZW[W._NTKZ-.)+<=,U^L>J^V0FCH/7R1EX%A@/?IKV-\O^<X;Y
M_O^R[$_#_A^[)@%"'"S,X.&0 &#@#,Z2]O;Z?U9R<ZQ<=34:H=Y.-"2GG!Y@
M\=EB7O M?05/N-;'>0JM[N\EE? <L>SJT^R-V5N5@4L[DV6]N7,I)8IBZFC
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MACB+V*BY(O^QYCXJ$28=5.O"35S+_:;P8_$5*(_9 9LGP0^-;)B@$::9*6C
MNU>(+>SR5=$"!4$.3T)L6!)!ZF-VT![1TAP:&#70@(U05 Q.3\F5M-SMJDEZ
MK\8BL#4P%&/&WW4<N8X&8'6=.6F![U^D!;( _VHI5-,<*3RIESVFI9*@RD9
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M L/H=3[]D2\T<TZ,$N%$ ULY*(VQ<<9Y\/E^+1HH3+_0TC/4@"P^WGP-WCW
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MK#D)#YNF5WZ5#^@#89*\5S-??HK1C8P32<FIS+7BIRI'Q,4QOAG_=D\* %X
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M&JY%P<X3%):$!=JFO"B^K5\C0.25NL_.1Y7T,=*6?$<#?OH?F\B#PH0VS='
M:SQ,@-N00C9T\\54*4@SHK$MU(;!50M4TL=JSPNJ/7[>A 8^#&$\"<)KRO:X
MQ?QB)'=)+VRI[!-\X1-L[USJ.,ET&X/]WJ"#+'Z_8W_0P;9T%49)F+4?Q!Q^
MV;+ID3>9AVJ0>G'@G9%?L:3$X/GR$=)*NQ A[#6 C.\WC<;,6-7>^6Z^3O]%
M"V0B(3CSU?2YT.E=W5GM+#JH,X:Y;"G%71--]MMQ\A3J8K5>@>LD2CR/HC/S
M.^Q(?I^$2D>P)3?:2DVU32J,]F:D4:;%Z"ISOPUWZ,BSI<O,D*\J&-MV[Y@'
MM7^!68/(^RD/]TQO?YG_2FF_SY-"I'*66_NE73!3)<_]4Q7/\&4R4C%E3B7P
MQ:/FPOPK-%3? N<41L9[ALUO]ER1(P)C2,!U\L,MI6A)]P_8KVD<8<>\S8N+
MV_V>9/2J(@-NTN*26KX;3,KJ@<4R7_^8VD5,!]D&$B@,9=L>W>)=GN79RH&,
M0Y )==OFEVT@A,4XZL4!:!X2T:PB27:*O]KT3\[J^R_><OHI6O9[#;,5NYL^
M@U0>CF!SG%UH(6L,:4&18W2"@AM&<_QO68Y:>RYX-<5?*TEB^'*Z],!>S+Q/
M Q68=E6C9#-_AG8O_?[!>J0P:;AIZ:3[_8.L,#&WTBF^)"A$-2U0ED$MRK7Q
M25K@@\A?C^'=?'Y%MD[W7]ETC-%Y,#R)^++N*0:R%/\<LW]^>@3K@\);9(PA
M@(P,3I3ZK@ME*CX[FY#\5M#&<SX+O23R=8I-J]Z&,,(7W>Z+YIMNWJ,(<-M;
M-N_"4V2Q-<D/Y.D"1"B6@V19N(A3IW$B[-W%\,,Z!;-7(K60N:KM)!8$I+FD
M8:9P<PU)2R<0]O2]!1IH"'%2(KO:H+V)"*UZL2GK)#]C:"YQZOU02?BS.#7Q
MHN,UI-6U-[)9K<VUG6&[S.>+I<;[T<%N!@:(]LB;YB>\V<0?>2:B<6[+>!N$
M'2]F0TE$T^)R]3]KVS,_?)KN7D*(B!T"Y6.I0,E#QR!)4*355-CSXK#=R:>B
M73AJ''4/SHQ#? +QP.:?O/KW*<I;.%)11X [S&L2A $2^"BK>]8$\IS1*.N&
M37EYK??Z?; Z&<Z&YBWO+9G&>;:P%6FF>[:,9_AE+:+SXSV!M/9*T#"1!\<.
M@5X;<)>UOOL! 2B6/N)5U@(4=7&XS]X;:61L!]+J0PJHOES,-KEME?;=Y(B7
MW,%Y.N3)J;L'@KLRUU.!W"+1);D3YS+2"3[R%+79>CKSO0O<(*AV/JI] I-J
M\C5L-H!,4H*3;28W8W5];0AQ'C6%*F8CK&5,[O';0N.3G_/*L.W6ILE[G6?C
M$+(.W#TNR$\F<UK5 4?=18$6P O*XCF]MBS^.X2V4Z+$ V/M@K62TJ2=K+Y9
M&?]H/FP\P1(@2X3D,M:$$^E]S=H4^N3GRLSI#KCPTI9'NT:4H](V::7V/B.*
MPPY2%3(*V_0V2F8J)Q]V:K??9S^!8[#;S%J,*W"$VH"%OB38H^I":UT8#;"V
M'A 'FHTR6'NI#OYX'R;!/#XU6;!.=S-VGZ,OE8J%Z'K[('1KG:TAA8YTJ5]O
M5PQ"\GFL5?V4DG'KX9:]45571=E(^67%2V+AJ*..-3\X=,/ )WZ^6]Z$H0Y2
MU@'^F$9\4!A*X&YKK)T:8AKBR1I\/;(T/RBI+/331O/RL:77B?>%QP[2,SB0
M93Y8FM3JDQ#F"6]2K7M;&9$EF#7_[H]E?,-9YV9ZCIFH!.%[;<^/?C:[):=H
M8/T04L*=C0DLKL^F%9(QX[N77C^WXEWJUN07F3Q2;!S,UGK=^?Y0[N/[\[&Q
MQ$7G9+S"O,".%CH[\/$]I#4LDB>6._)^#3^>]DNJ91<H 8]7(<^^CF>9:/OP
M^(;!8)%BS4I>P67*#?TKS%C,6E?VZ/+A<T<\3"4)[4BFUIZQ]M5)(KDP>Q6M
M;9>KN\HWI\=!Z=:E&XZ?EJ=/EQ?"T0!Q56&@EWH"5ZZES1V]V! O^-+<9+7U
MPHKL5O'F_&,J]XZ-C-CU6?S[L:7..^*<]#1'ND]6OXK^'4?LSIJS-D^M_6JO
M,IA,R9G?05AGI%4?4.IJ?\X9U9*9#/&,-MBHI<E&W.M' ^!\-."#61_'D&8:
M-' $;SS;P^"T@0%9)S+L/4JI%0W$#R+3 U#V3?_!'T@AIO-H(.H L@J:%("N
M(DBZ?GM ^K<_GXP.2I^*$5^ *5#&?VG_2_M?VO^YVBEKQ-XA8QR/$L,>E=@
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M*U1,!Q:@;/2'"U*-*"L6H/4$E#+7<F71ZUY<0V?ZWY4+_*/8"5BA#MSQE+$
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MC4*0W3 'Y#ABYNW<DD RSP9-U;I.U-)NT<N%119R'-]5_DLGQ-0S1LQ392S
M8/J<TZ&BS^57:&4<PRA13("^X89_7T6'[D_GP+]'K<DJ4NO0(IW2VZCBN\O@
MK^XG^\"4$.^>KLK94%^(^:M(V'BVEK0=%K#_S4,,"P"KPN:S,K  7]_%^?.+
M2,R5 -A8[5R[L<X/"T@)WI-5D[:;W_^&%L'EM/MWSL#%@?/+2 RZ@OMG3DR=
M'\;Q-$F#K!O6W+X_C_X9OMU+#\V*RPA?+/XC8]69RK8%C(.DZ T6D.2YCL,.
MVR]!"_RKR!@L@%#Y3(>>"H>O!KS7@\OJ].:X%WQ87(^"K$&-,%)"\\<'+)A/
MD&GPHHF+*<9K!0M <!H"<[HCM[349.PB7NYFTP4R:1F2WPUVEHV,'\]6Y5F)
M< _7G=.?,.AP-.=K$3=EW["1=I?UQCR<AGQ_+/#[9PL#BM*^HR.)^6@7'S4A
MLM?=+U[;W0!Q6)2GJUC8OK%52^7HL.H8B]**/&-<LA)OX&N]>]#<YC*/:]I9
M\<!X@\'/LP&$X9^?+2 31*UN]UY8D"WJB@_B3(<<07:C7H8JX^0Q->D069-'
M,XE4<F^53V6542J0B'N4@5Z'B836@5S78Q=U(OB\7TFFP F.^J3E<IYU'?%G
M*H[&>V_9BPIC 9_\VU4-Y>M20T,^ )\UPU<-_?6+/VRWBO+'/O)R71'' DJ%
M@460O")+8NK,WM.8;$-C%?DJ)J>PX!4"X>5"UP8$O(+2XSFGH[0WAWIT>FQ/
MR*J[:80[,D.+>PE\;1(U<I7[2!#Y_$V2E@WL)=S(C>=S,6ON*[>BI+:/N?XA
MB;9$,E7;4'TZWHN._FK!,MUEB7>^\L9(YGJ[Q=<2W-/IL+Q+U:L4ZU&'DS[K
M%#_JE+B/GN9ER+6!53C*0-;?@\0T=8:HYKV0EKR$)D>%V@;($^5=*"[#I:*:
MW0.=W'R5[_==1DE 9+=<D]5#&7C 4@H^.L"U*!ZQ?QQU)G_G1F?T]Y.U"G'I
M5.DENL>370\#??S#GO)5^%<-QJ^6@P%&F_&M%'9;=[ZD1KJH$RMX/FL'Z\XY
MH*2H=HQIL@KL1_(EL_ F^CU*E2ZMWIWYZ(Y6P,DJ(\F6IZ9OMM7Z0M.+;@JC
M-'&R=]T\GL1_EYNI+AY25O%VYBE^(-5R[C((9=SJ]1MUX>7\Q.SC>YUV&PL[
M+*.DG3D/SMQ!K2\=/345 B7) M4C<FR_=ZU<"1>9OX'(VZOY\[F+;815&[/*
MW)\53<S5W>34>WCVNJY00/KX'3!=2V!Q.FJP_KW?Y:D"+?S^)]Q$383JXGT#
M7G,R64J+FGY,@]QRDA8[X[0WGP]R9OPZPGH1=L<B1$M=4&L5G3U+RMY[6V1S
MH-%<Z=.B9*236O!D15&Z'W/22\5W18O\%7*;F6$);6Y]2;'^7*?*-*!63MH7
ME'<O_7A!-7VV\\3@%0'<Y-T0"[A\DA]Q=KM#>MC:NKC8:_!@NB94WO)5VPNZ
M?B7;H,+]1F;1)'231SYAKL3*"HQ10T0CF3<AIW"UYDDHY6OV/-6UPXHP)PAE
M1_!J:4-<83HD1C/V\FLRR4BX@6'J@H&88JE[?I_5X@/]W^7Q$B^="_?NGG$A
M6^]YYC(+GKZQT>>26LZ2/2YR OM39_2&&UH,7261_*8@ GQJ@R_U72DQ$VC:
M]S,@*)\TW%>[V1 9T:,!N9JB,;PQXI /KNC+LE!T*<77ZH9.ABR?(XUT+B3@
MYJF;*'.SZE=VO6YU;O&#Q<8DRI/#*A9S_CY!^3L0>?,J%&+!OI'S@/?,K>E&
MDWO71U*VC<8"R( '.'L*XA82.[66;WW_S8\E\S%#M<VN!7>,QL09_#N%**8(
MF:VJ/6+V/*15:1 ,U(_'=7E?/:$K?&.<TF%!0WK:5%O'BGL770JCA[874&]8
M%\\UE'1ZG$UABF%;'2K#1CWEWQI*/?,_!=V,^DSP]7HQDFIQ $\A%4(Z+W#Q
MDDS'Z4;0,24J?ALUVM*=D>I6LNH)!Y(1JN1:J*X9M"O>[2-J76;?4@]:]0!S
M3*#N:7?:T$9_Q^QO7KROG5KQ>)XUH.N]<YWH3=F6.A9PD2^N5=>CX0#[F$4R
MOY:&&4:K%!9)5776&Y94CE\ ,8C#0B(Y\<[[EVI6RQ2UE@&('\/BQ<B</%VF
MZ9T/(&G'1)F&^RI/B:.6!"7&PC-(^%3J<!QE1=MCR+*=G)HZIG+,.#"AXDES
MQN< 5KP^<8B=Z8'&G-)S=V/Z";(MZEM?2P8MH0?>WW*M3P.ZKA1=\0^O$&U"
MUX[B]^%-C1S33<T?-SCJR'9'/I'@L>J?!8W58P&";6E!')].NV-K#?PR$JPM
M%ZKIZENOP5-W=/;/I%H&Y1KX$^PF!_J)2#I7-&?)Y.WDN^*Z0T4DS*6%-@2%
MAUG'A8=4[K]F#_E-8Z\<Q:D$9#X99UO>NA:<Z EB'[L?:3Y3=7\L?G!@I!S$
M)_?8\G':QR]OXF1[9;.4^7OV2,RIHQJA:TG6CY-FLBBO7J!T'=36H_?L0-$2
MAH8:5N-LMX OR=^.7$J,3N.EL#9GVJ-"'$\SW*5'CNH"CA*T'T0:\YO3OE%O
M%.X$/M/*R>SMV%X>TOX!@=$]:CL+;HV73APJTH!/?G< R^2@#9;ZN-6''X[P
M)V@&\3QPDM!^RC,(D*C8C+VX'IG;>-DG,:>%.7\IM":24RC.DZ;=_:AJA'/\
M6>?;NH +TTS'O-%(U55G(]N5'KS@* ,A_A$4].4\8+-LLY'\D_Y#.69[KI%1
MO!'PASXK(W-=KZQ4:\O%%#KB@)M J5&-;HYX-2LEV6RE3V_D5&>9WFN?N<N.
MO#ODY$>Y9-#1,FM[L<2/I 7%3(_%RY!ZEVMX![%FJ,@K E_&H'94S<?AMM5"
M\8-LEF'G[?9:9FD)T-U']RN?J1@\Y^)D]O5['M -(U4=DA,3\Y'+Y^MQD.O+
M:K"8;']T8U[J.\9Q:AZ#,@Q%K&<8'PDT;Q%"'7NB:5V=;\$O44&[Q\DFWU)J
M.L%AMYR7H\]-9L[1OM5Y42FR6 #>D:"QR#-#M;\N'!CC[']KE.EJ])=?1<J_
MKR" 9_U78>7^$_EOR(4"(PL"7ZUA 8.*&H@A@?>C5G$./<-9I@^"G;ZO7&KJ
M4]S3[2W3ZV/B+9YUF<@G226#8>YRVF-\1/TQ^."S<2O>M359=0LUAVB1>9FY
M9"<L@!'2<C(,H>9*7^Q0K3)#V5L5?]<D@,"M2 X+@SG&(CNLH98352/;[RK]
M@=O%+*A$3/3 1KRO7U0$2G7K;E_^CF/03/N,V#MK4W'2>;*/9&.M]_@'!Q[;
M?7M0*Z+Z#-5Y7# KQ,*-4LM\2\8JA=BH/$>=,:;O&Y,9.'@_P_1&G@<I$V,!
MG0U+1A='1E>$-9U6II6'XH$KP;VJ\)+N7;6)Y9R3-(ZXA3#MI>07PRJ5TK(/
MA(\8&_1SYS!.Z-LN;^^K:U0J'X@6W]6>4U[<NZTO?3_B*:>@1Y#2>#],!9VO
M.4.C@+ANCL2C"!>38P V4)?0/#L2=RB@DVJ-Z#!.SXKV%.>=GG)5.S>)71M0
M=FNZA"*G,,B3N,:1.N>D^KV!(K=1=KLH2S06H);F$N^P92^K>>[)7W9U:X?N
M"UK:-_!1Z.4[+* IU%R.9M[%2+^\7/7TR1:4O^1!#Z\I58?-C2N.4(7 Y6H*
MTCZ&?AJ;<&T_ B3(7LGO9&L*M?-$OX]V)<)$]F$@R#4_6G 6&>XK+A^BKSN'
M!02)&E#/08 W($B*\/I72H'WY9=I5F:3?SO*.AN,F&)E^9@M_5&;8BH)D[&%
MK++7)[ML-(Z$9TH)]+7U#TBXFOP897 -T[,(^V#Z-57-8Z:7)0!>=J*BJ^,%
MQ60K+/NQM#HU)<=\^WBN6;$;1YY]<$_WGOB<_AVJ>-;;3 DW$ \NUJKE=JVX
MWMW55WY<"KC/'Z;]090X_K,%1=KI#@*2LJ,SD/A.[$KT.',[*4(Y,^ABE':5
MC2.;"8/" N+F7%Y)@V87R_?/2C[I=F:Y,CG;O5A\9@5^.%6_5<Z,=#1?EUL9
M+9K2/BRI7\.W1](>Z!R_\@F&'O,5&PHP4G9D7G+N#-$I>[_@V]J''T>8#W\Z
MW6R3V]^O1EKUNM=_-^::;;#_L4PVL$D=%:^4;^U)V158JG79[<)X<&VT2DON
M3?Z 8*"[N W/U71['PV^^ Z(A Y,&/>LZM',<+3+=TGE[:JS> 3TH.KTN/AR
M27D_?^XF1?[2=%:=SOA!H8G3H;K_8QO[ 9$BYU_[S)AMWA;#_FSP9:J=S,B3
MN*KPS3J1U!$K3K,BTM9FOI ]%M/1S7+4/$V2))E*;N,:H."@1%)L=X8G*'6I
M!6J\?'/^)1MEX! 6X."E\1F@!*;N]X3IA!/*Y1O5)A-6]'R&Z?9OV9FW)V4Z
M*;Z4=#B_9ZTW>W0$HG_G-[ZUWF[C2ZKPGLG7W3,3HW9^1^X"F5A&_K97[JV=
MW)X:34]6N9Z4/4^EYLQ#+B<\5%66:P[;B#\7%C#,0FJ@41%=B]"J(]QR]"EK
M,J0/Q)R[SLK:U(7:\[#7=\(?A%)],'WP.1T9!E%KI4YT\UU1T8T\H7GQB7PA
MY&YZ/M#.SKQ+Z-&*(ANK6H*G!N(^%B#%$,2:+]+\2]@*$KU?[B^QF2/  N E
MN"D88@Q24QS:#?N !;3BICK'Q-8=0.GS_\6GXM?0,7L</@?KZ$]0&"H<XSCD
MAV$0YN,^=?XA(LJ:UL"WYOU?!4^IXJ8$^QS-)C$F2\-.X8Q'!:)#)77^VQ2:
M%"R6=G!>H7:G%Z)>QD&!A2G&%KP*\=QY5:@+:M+V"X3ODO>$=4UI>+",Q.'#
M70*W[,R-6 JD=KS(@TKE>!T#)U\@W*TOR/SU9SEB.$U8B/\UC>!0)<PNF&OI
MA_F]RX*5H&0=CIS8';;N?HC&V<348#:YD]O*>&BU3/!J68X(E3"3!I6X8EX7
MS8,D1N(G+VWS4GJ)Q]\J/Y9CD.5(>_%DJ^#IFSV4RHCZV+1;X!)+9SKY&*)W
M;G_RD:.=*W.S\J:V )-:WVTL@%T+[A8-#9%9< >JJ(RQ3E8^SW:1 159&=X5
M9\G\;/-\^+/L>!4:S.36MEJ9]D)OVH1GAN1\X\9#W6JG>$W?-^;ZK9^B)3L(
ME?4)'2CN374USIDS>!@[6*HO[Q=DRA] BA"!#>*JOM+,1>7H6YZ\_23;>L&;
M2_&KJJ^\YX3813W7.BP&'5B^(W\0X9>%)O,&$=UML5E96:O)ATSG,W-";9FD
MJ\5HJ#+=434> [Q;[P^%/3J5]HH+A904YZZD"?=#H%:A#JCQ2W1HJ)MI9?W0
M>LCB<HFO_^@]K3V/?%;KBB_?\-$6E<O5W#T8[2(EG<PON3%:D6\_&6PKC=$!
M3C+-UUQ4*6)D B6VR)FX!YW2)\T^>YH8*DWOK.P89]:[I$@/KU%;S#W_=FY2
M53W1DO-0V2V[4+PG4UOJ4:)FR6HR:TN)#8F^WPIA=R6BKI1E&\G;4I<C\X!:
M/7+'N?,4>:OBBVN$R&-;](;ZE/--+35-O3JNE.2UF+H?$V8'P.-@2/75S<X"
M^;J\>3H9C%SS#MPW%%:;_H$]6O^>RFA[>536U/3/H$CYO/^;CB@L2;#".NM^
MWM& >[Z"G(Y;/5YA >%.2$PC$@MXZC9-@M9.%(F]S+@B8>$?4>(?,9S<WX#R
MIKS,Z)92%$PT+P^6NH5[53PN?S)R2WSD%K-9P%2Z */Z^\SX5+\Z^#6T=,W^
MX:.P-,/EERQA=OM80-T6",&^V"<#86N3TTFZ;]$?5?-U(-^R&%I!([R[O2;W
M-<I*5NJSM)*;5E_RO8/DU$6QOL%[G G?#@N_[,\M#UXB&S>\&$;J9;.(^B1>
MHT+$3??:/2F=BB4R60A6/,EI**BWIGD;!O:.Z[1K/US"%_BN.!B7'K5/Z]'8
M>%V6A1\!8+J3Y5=KC3C5<.T=?+C&FD:D^D QNN0RC9_R]+T()GIM[6[%]5@]
MQNGN90]YZ\S)Z8WQM 'ILBH\_+<&\ZJ\,/VQK:=/OKH1JR+UWZ:3D0TN)B9F
MK%SXWE?YM^^PBF?6O-> !.=Y^^RR2*XY\Y<IB$U:FGL  [14D5I(GP]@H>O\
M[#U9VYG_(EJT<#NV4HMAROSVNHQ^/M!0U*MB2D5[/%6IW-6"(]V",K[:U7[$
MR32>NR74\.W==0W_;GK?>>#'-J>IZQ\ABY?WK*UT)OLWF:P*8,T5YE1C=^J^
M:> Q17[@$!46Y3?I(\NM\/#T>.[*?+3MFY8>M$3U_4D?[0='UJ;E'[D<N6+;
MMN7CB]+/D9J;+#&'K<57PPO4,=$CUW^N=W[Y0^E]$]>YX2DH8GLHRV)DC)&V
M'C<-8#SD%TLY>?KFC%1[B;%/7J%S_A:7[I"7<;E(XU#:-,\6Q1OT;7"FRO!
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MR:LA:0?:#"U&A\>@?#%)2Z(<Y?VNND/@E<7H9Y,;!9[\YZ*M!\!SLSC@1RP
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M].K,?B]?@2S=+70D+^?!MS I2F>VXJF'P"#M(!SC%9"UYOW9*A^AP)]'*3_
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M,7';)OO[&NNC:;O=.&>RK%87/JPB(]"O_.;'/V!^XRM(]P1(M29DR#2XO5W
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MYS@'LY>EOH %Z,)W"5LIT+07H*Y98K255U'O$1#'_3N3!JY<@-TUBBMH(!;
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M@X-$;]04"F,JP49JY(0EFC?N.DAMZZ'*RKT8 ]?:=52_L&2+Y!-Z]SWY\N5
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MPD'5!*6+WXDO+![\8\);</"5#;2._=M9XQCBLJ6X#0NXY1M^(-0*I6/,.Y3
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MU9:2RV<&*J,DO+Z&&9-:@Q6#76?[&./<+6U]2*-<;SC+)4T:./&I,S^QRO[
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MI"P8Y1>37S6>R.\_W#]P*)B/5O*T7W 9M[R^,*]$GN\@HE9U J#KBI%^,O"
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M#6_E8S^-CX3<4$;@Q?";@ (>YN>]3W]V\=*O)R-_;$))=44DQU.Z![L:GP;
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MS\0"/O)BRJZZL("YQW.-?R<CAV9R@@X0@S#G.)0&J4\+WT)!^WC0!)_'H-5
M],W[U'_[_/?WA"3@\WD$%C +N@IU+U?]<_=/+P9.6;" #^E^?R\"W/OX PL0
MY\<%UE4<02\\@8'*<$/S-^X] NI@EJ![E Y&?R^2CKDK EH-Q*VV][C8+# S
M*'=B"UJ)Q=QHW01-A6.NA]WY.P%^: L^&WIO&,=#X9B.6M1C3!\"/80%-'WW
ML;R,P/VJ-O^=1/C9\R4L()D.>G6(!?P:]Y8!3I1C ?%&9Q2D^5B $^B,4)CG
M[T0&_]["NU;IEX+P0R4LX+KQ,7Q'#@NX)O=?.($2:C&,L8;.O9+\MPO^[8+_
M32[P?O[3CK^V,L8BV#K<)-_L(MQXW8"84DL32$HD+O*@),EF*(_;&@>>].+^
MC*)NMW+(91=RH8%>?:?;W_$Z%+  PFVK0GU9DN0''>KU8V-N4S,QS&^B%/LD
M+Q+ET \JDRO@<3@9T#QQW7$Y>N!,RU[&^"I.Z3_""0Y(QX"<A,//I.TE;$%\
M&$IH"[WGIO4Y?*]P!C<]=N@?L].#]@"K[_^+WH 3WQK_<'M!XW+X5!@+YN[D
M@!ZX%PL( .X%SGBA?"W1G)4X7W0;_<D7LP>=.W)D.$_;KA8@5J M?QF;:A)G
M'W.>/]G'_MSTE.4+S@&"AV/#AZ#YOQE\>RW]DC?V/U9.);KD,J+M+UJG_W5T
MMR/5/\_SZ<4D1ONJ:^$O:JO^=?A:K\>8WLS_6.FV6, 3WR7'ORC^^*\*&-3C
MEI_:GY;?OZWV_U&K?9R;_.E$7/3'!-C%2Z,&NW&=T;7_L$D'5M.*DL0*QMIR
MO%KKW85_323AU(5Q5H32#&;EM)HYC^9P1#G'_$YO,_+A_Q7J\;M]S3;V8[=*
M(>J9YN#\H#)CD^'N?N$XR9'PY?,K^'=?B4VO[_N<(4\IKR5N9T)PQK2L#A.1
M6NV.]C67G%W@C!O!T$WTOHJW[9FL1!]&K1@U'0,+7"IUQ=6=;A%K$.1, *=?
MF4FAR9U '<4%@9EZBZ']\30U1Z#/G+Y&CIU0R[/%Y]>XEN(]* (.IA2K3M2[
MT+G:#0\V[['UC)2W6=QWHGMTY012W(K5C^0+#A9BW$_$!.9#(>O#W!.L ,8\
M9N"F?J-J(BA M<A I7&;SA44J@ 22!?1;F#3(;O<EG0%;0G;[^7=V>>1 WFA
MCGS(P)@^/>7,,Z>]U:UX;_B)AM05.^FG(X);T#*N\YT4F$2RB"T_1FK;:;5>
MA"<.-DM^!)]'UH$T5*]L\F<I4H ;_!/T5^?/,<_'%<4Y4V3YKN+>X>=0L;K%
M$W_L==!^V5JE,7 V?*(]7C=TCE_1,S8R>6Q)/L.[SYWKMC[V@/(4QKQZ**X6
M3N2!,&#:B)5]?)A4I@#_H16^;-"SZ79;4D<IXB=S5'P^:NK@OMX$W/0!QB\\
M6P0+H+,S\J,^B?R\QYY]OH,Y!+W:NQ=M1K7C/MTMNCL/W8VX<M9SWKBG^]Z$
M<C*:1MN$ 922?W@KW0L*%>, SH&_:?08,-, SF5<A])5(LNIPCA^P9!)&XK+
M(H\:1_I_$MU-SD5$'0MX#2C!IN6Z^;0B!:0^L!_G?/D >,IN]<_KUO]MHP"<
M9/$_GG[SYMOKFQ:E 379V7I*'W#0. ]'5=Q/7@&G*8^'F8 M',>4UPS>+1C"
M.#2"J--@/I2 []>K;<$81<'/6(#A(93%0,.I!H[^9DN*J5_!R)9GUAY!(WJ"
MSTPQCS%6&]EIL-Z-OQMY8/0XCX%DT*YHR6K!\\;; *[#NV#[U +"!4EV+*"K
M!!<;C()_IVRP5N1P5K64Y,[/'HR6WPENW"L1%_I3];K /S:YB8?]G\K2$6.H
M%LJU4H\Y?"W[H;8+WCPXIA*W;?1_+:^*$S>^J@S::EC%6"*A+6U_KJ)'_T<5
MO:#YQC^JZ F=:<$&Y49RSC^?S+"57L+/DT=QU(:B%7IXRO8[TT,ZYAX;KOO5
M'?#O#!&&G#) -<0*<-(CN6<'NN*MA7X")L8"!J;@I_.-N BLG4S_IX)[K=
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M&G+.;O_69T+SX7?]ZP]E+,[H(N*JF?: ?I-(0\[:\^\^9K_K7A4I#9ED* P
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MW,;13<%DO>,"&&$>4^^7D[O#,)*/YBMF FVFQC?\?)H!:RX>(;G+[C;^@7>
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M*+]N86"@8V#]YA?:+=??!(@P;C/R8Q)+J6&]MB>Y+^"-3?HT/*VT!8=)4/V
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MNGV>6EJ/D,II"R1P1%")!* <<-_'N*OQ[.EAK7\8\(2X$ZQN#5)YZ32<L[T
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M\/?&A!+E[7S_U4B=B(I\XWUQ--IE9Z<WT!S.7CNI(K]#5W^Z^6ZQHJ[8(&<
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MM5:/?8YSI">_F!A99$-#.&0Z)A/&U#EF!#@L_/]L;)S(50!H%M3[\<UE.!(
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MAT53?1@.GLPF_FPUOA)5J^.8%]HQA5%^R94OW7Q3Z'T9'@JKG&6J^9@!'-;
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M*RY(K/77B#N?>,5]EG[;[V/&/WZT6]V]XBO;&YSK[M<WO"QQH^5YI7D/LJQ
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M^X!CC/8ZYLEHBL'A??ZK=.'!M)=TJ!.@%MK694DR"SC,/R:.!4#C+KE/(4"
M]1I"QA9L)#&Z1[\7A8^+"&LS]O)%W"S]0TP-^YB4=UIUT;Y=VQS!%RFY,W,;
M9PB=C9$'NF:,)>HYA" "OXH97;$E;O+)"_LE-BX(U-Q:RSOQSY17!Y_:9;^+
MAK.6*OO.J5,IF)TD4M<<F:H;A&&,9%4)5FLHXY._.Q4K_4KX'+_@O-^N\$*L
M8RIL1CR6<SO?]'EB1R=])E#:6Z?(T[(UG>5W$$HORVN#1O'>1*MD]4(&Q L7
M[HB0!YY2.Y09BQ47&@LY;DB=T@_4+N]L*<_6FWN>^I4'YZ09OLV#8 %XR+$=
M248LP*8YI_-V<NE(FY2]WA>G(&HO<:0KU.5/V44H2R3_1*\UQ+7)6NSM@E-Z
M_<D)M,JX+O9JT<Q8!5-F:*6/'ECM+IS'88D5?"]<= N\8BN(J+$2@R3E*IF,
MTM_)&5\&7= %U%LO]2NKC#T=Y4]42#JLU:)S[LR">K(>;^MY!^4NHTEF'1QR
M&6_*J4XDWO3&\X\Q]'MVV#Z;#N.WHQM_5D- G"R56K-!ZL>4W'8H$1QN*)U^
M;##&^*1+5W XIOL%8%&.4/24?U.6A71$=[^.B4RC1YOE7G?%]&O(?,V,IV$;
M_70C/0XFMC.;YTQ<U>")T$U &?<[TI\B3H-@!\C$9>9+F_RZ)/E#7GO\35T4
M!64CK<VBY.%Q*1;@UZY^\78HT@!M2.?T[=.@D>4:YL</)GP1@S-V[2WXV^<N
M GT5MDYNW&2>3=(55\_ %%&+$_RZU*1[>/G+JQ(-[6YS%(C<F@.O\0K%  I4
M1TR+?TN&E#X]F0%PQY!%^%BE0Q=!K0K*_=B\!FI)SN@=1,ZGT*5;]1/RI@G7
M&>S8Y+Z1?.:X[JP1;K-,WB[)>2B!ZLT$Q]UWJ9#^G%VY9H\%*-5D70SJC9ZN
MCH@K!' U"\7?[U*3=FHF"U\H77(HG:6]-7T7U;QV6>>2Z@2'V&!(#RWJ_*K(
MLX:A3W@RF,.:V)BC\,?@L9&2EOCF38^3TXR4O]E*]>/BF[-M^6)M.T76..4Z
M9;N6Q4RG)Z,!==8=1/8V>GCAGFU-VS<CYXU<-'73RB63H!_-NDZY\=3R/.VO
MM,>Y/D\/D69QD) F !)8"]9QWL"8O&7PDAS:M(W3U@T.@SD)G.YSJR-9,4$5
M<0?E&-GM$B02B+R/,"]4<J7^Z=(&#@;+T-_5,K5$#6Q5.U!88P&6C<IC],PH
MH7*B0_J>NN1^Q YF-MOH=5'-N,>O_9A!+,#PL-AQ7"+M]<#,($$IA;5\X;AW
M-K=RXC8=)6^5T),9O'DF\)HP1()Q?:!2*WV\VU/R? ?9]+WS@6,=:$$F!@T2
MW8#(3PKXA/N%USFCB?@/WUZRU[DQ/6^KO="KJAU&-2U0CVD2_JCX]S509Y/G
MATTH)M$?.J#)>>OCIR3[QY5FS!%FUB?%W!>&P--;6$!W$Z:E,HHN)WY$V,9"
MV,;%,;48@4.\3"/Y)3A4%5B.!:BKH5*P@!VVO[VQ-Q;I5JW(GU4276(!^!CY
M7 T36RS@@27F5\:E$!8PH?&WEU.#AB8&#+P9"P N8 %=)X4<_:#%3UC V&,L
M  >[K^X#__8F>=TW_=0$<!U%?TD7+^M5@N+,0'X%K<QC >_E__H\;G.&"K@R
MQ$=A 0'_-=%L2(C)_'>0[3LL(., M.*M3;;6=% )VKJ'!<2!T('T?WW6+IH^
M(MK]1'^,(4)%*V75(S!/!M%2P",'+.!W]E^?MRI\_*30D  ,"#>\F,VWNLE8
M0,LD%I#/BE'!R2<IZ*\OOCHE#EW BM^@P0O@D01[V+'I7Z8A^J_/A>.[E_C_
MC[W_%[#7F8[\<!#%7)N38#HY;S%Y[R<HHTF8P8Q:'N)V&K'()J:PDVV2YNDR
MZG%]JB;Y.H5%\1]I(C@+&!6)#$;[=!JZN0F9A+0$#8YCWE\?OPE1O6/[,'CZ
M-&2)B;?S^#?2%6UKL*?&=4=R7$8F(C&OUKZLB?YZRV@_P-QS68MGLAW<!O(2
MF5EPFQ(E:L,"V*>&^(=S-Q_]D=^G<(A#+V-H@?=7=N\=XD=-.1T;3E?N9.R5
MX!V+(T!&P@YSX_&6&]'RY%?)/+^J9I&_H?1M<P"JW)6?4Z[=!".T(_*LLQ:G
MMURA4[+SU,\49NYV[9I(619MF3P^E(F4 J<^,XLQ[IX)SC1"WRCH8U5DZX Y
M/#G?,=&_/Z"9=L] T6[&;+.1XV"2+VNVG>9S0NAYGH0")04R;$><<FG3K3-.
M;>PF.N?IQQ@YO!)'^1*) BX,L_7-_OYZK5Y>33): .6YR*;1>6NDJ-=I9]-]
MV?J[;ZL^=/XB:U;LB&)\U-K?+3&\ =<L"4Q[HRU R9F.X$-IY1ELSK'[<.CU
M2%TU_2B5>#4HL)6 H2LM&X&Z;G/SS7%$[)E__LULQI!Z1K:&D>B3?.E%J3H2
M4WT.,$-2;9]"_#@MFY/C.Z)Q=G0JROW['Q(ALP/6TZ)6T;=;\-IQD]Y>X]#V
MPG&KQ9W9-"C25-FHO6JTGO(7; F#D9"6=BR E4IM'AUFN(2M+527T[V$92A%
M*=CYC=,G1'GA,3$5G.\;^!%4'XS7DQ,5AS2.4+-92+?:BQ&8B122&P3FSD?^
M:JB,D+4^2PQ[6"<WSF!)6ZM+JR@[^BV[IV+2X=C2C:U?NX#214+(!_C:U?3Q
MZ3WQ;4X1O9 SRE20YSK>43-JV_#U@6H$\G9-;<6Q93J+Q_>:6R0O.T0_E&.>
M63LKTT+!5 EZS6%&A%^.B$9%4!O#F*<3!AN.4FXXO;'^RDMQ]P:1O_^@S:[]
M#Z<X9'OER'IJO/7"\V+.<X_*=:$<_32QI8<-2<X8V;D_G=64G9L&],0.J]6'
MM]P?/IOV)%85L[=71)7JUW*VG?M)5-;42,<INS6,1=BQLI(5'%*K)4\;!VL>
MM4KQY7=34O\L1?$B$51-XZS=54(+WH3SQN!=H544J"AN3F9!*ZO;P<[U]DC'
MYYK*[IH,&LN(=^GCMHM1F1R=7N"ZV)@EO>;==**3O/X2SQ?6SY8X^2:A/9\K
M.^8O&NYU\.XG3QYHCS=F.TC,4-%0>5*H\7%?6F]/. I#>^YS/\:GE+?+2I^S
MO,.HJ:=8T&&X_PSF9WI "(U)TE#FO?&JF_G@-J=74QN0N(<5TUX19\-V9Z%@
M):[+-(_'=K1MB2DX;YVIL^7]Q]#"@DZDK.F3BRQCOQ4KI!+L.WDS&Y^%_<09
M=+HEF?SL3EC"GHR1PIQY&\CS#'7;49(4<4)[DU[4UC;)(2/H.^/W[&&O$JDA
M<67+)99JP9B^="GUN7=X(@.\7WTY!O\,D+'[&,2J.GR<I,LSN_\C_XI*W2;5
MPW>RW A:1;V9W&;PC6G5)5;B*KI-5UM_:K5DZJ3@!T'MP^W3Z]JIV2'! D)V
M\/RCWQ6D[!P[)Q]L-'(Q\>ORO>RA9DR;&-):[:[D254?;;4'LZ&PM2\9R4\Z
M%[Q!!G8A5W2Y3K;#VF5-,EU%N9*>SSU>0E1&\Q<GYK*^.S^WE>'YKU)I@+_^
MY+YHEXY5H+WCK:GQJM>=ZC,RLC.><(C4WL,E4/;T&>RQ=%6U&5D>Q$%BT*JR
M;$_R2_I#,97+SQQ%9:!B3JJJ*USP= I_(2>;1,#RS3^HO\%EFNQGP[.=7;.L
MH6]F?26^(&HKIFQY)KDM[;%%_ZV'@E4OF(Y>G#Y4W:,772)_^S;5W-X^-]C;
MN]Z[(\;K1>5!IY-U!5SA.]>"ZET&)[54I4 XLJ[.B_O"[+9^3  'V?LNAH4P
MRJ2)<EX+"4619W4/BD(X49K\73N<GT-IGZ@,?S5TQ ^8+K'Y.J#L=6J;QK2C
MLS2N\UJK?/VVU+J'T:'6KFM#?3\=F>G/%$BCQ2WX0\(D.V\CLK0DZ>68RLRJ
M4(N:*-;X#SKO'E3)GD,#=HO,%HTE$N[F)/8RR,5[W*9<CTK:5 VC]IF$V<GL
M',J-JGY(%C!B>N2]O"D/L[9=HVOAA.H.BWE/HP;\EA1EZN\LYD92?/$@ =.V
M2QF+HM-'5<>A#W/XNLGV)@*@TD<@-9LB[\/Y"V^.\ZHPL6^U1Q0M*1[0F9/3
MO$*OQZ)4)L@I+" T4(>Q+,'P^1Z"[NUM&1*O;O$/M46>]G[C-T&6>@83I1JK
M1I^.*>AJ]N,T8$V32(N:6\3MJ\W.A?[?Z1[0U6SO:NTZE-K>3RCSMAWM6>=E
MJ65)?1DZG"[=G$6K1==D\+6*&:8(4Z'4UC9/]R).)53K _2K>!4TOR]HB-!Y
MTF_YX%*UA(+K8B%MU@5>H+)3,=,_K*RS T-I#WCI%=W1E,'[+K6BKL@<ZZRF
M9:P[ 7'-0\3OCKA5\L"D+CN6.Q>[!J'LJ65YX,7IE"2[7U$^UNH<+2G.U!&/
MV+2Y"PU B:M!3CH.QJXG39<4I-=G8/]]T8A0UWP SE'];F&9:21%EO1Z_\BM
MZ_4;[^A 7,QHB,,YKKBX0*YBFZD%"SCBQ,&.6M )D\'I\MC%?,'I!&BA\]\.
MQOXW]U[N/IWZ=J6C^D-\5FG+!<7^R$\\8X5#:;?R3^=4_D9X98]U]&%7YP$-
M2.:ZL)Q7=#C70.Y240D'9T7;70FE0]2Q2=7[3R]@5SX:(VSCP*<F$ID!H*4K
M&41?[3'1>FU#7IV3WU:$&-V3-PTYA0A?4]2C8J(GGA9 DLW>1]]E7>YQ/HCI
M4%/WC::/=Q@VBHD+KY5(AF7K$#[6?7-$;4?>:4!5T1 V\'MO@#%&WV7KQJ;F
ME"=UF^A:'I=;-QVS\-R1 F77B?K+Z%63<EE77QM?DIKU%WD)89IQRMG>E%1S
MT6=8 (&1M4ZS%L^W$#K ]-?L$[)U#.UP_<=L4_E;@D<R5L=%JD)/"6ZL-WI[
MZQ8-Z[>41QC9^:0)'*@7:0IPC1I'"QSJ!IR"+A2BRK.)!-+:JG5N9#N=;@GG
MS6_,\1\*A$/!J\TT'+7"Y%9\U9M#6,#+"]T\C;>E?(I6,+X$?<4>M:1<SO$3
M$:(;F[I(R1@/ZX+INU)QWK%_@FZ].Y&<A[B0S]T??R'@4.5IL<H2$CN<F'<C
M&[_*1-8[.ZN;6FZ9_<]7":F2%]4'0B&NG%J[R01?M76>\4$SQ^CZJ ,,- OZ
MGPN...R)'"9JWU?_&A ;_1:]>F%CZ0E^#8? JMU4W ]ZW9A;2,/==\._^J7)
M2QF7^!<O-QS<-!BH"5ONUZ%K#X':+[=*OCQ\<<@%W2;5.+&FY9%P+!A#VX[
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MYCX'AJ-6(K\<'TU:BP%K-_[T>YA![VV&B3^BQ(-^[."_2!%.54"Z6,"OSUC
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MZ)F/XG@N1#HOD_<H8O6VG::I !8 6'UQTINR,:?7PLSF.-*S2$K_)KFRDMS
M?"MV:GKF 8Q7NCT JHC'$+6,'(-7'LC\8IG=K$F_]^PI0^A9X6]:PSD86)O*
M+TAS&*(^]]',_853S( :Q"AOWS[H[89\ OI3QAP:J$6X-;*DD'L33C&0GB72
M9VZ>NNQTBAQ7* 8GPVU_O&DGUC9+7_]%5U%#VR*[=+7! JRI35"@Q]SR!*:S
MM]G213OE;);'WQI<GW'IV%D$W@B3R%9JWF%B=3^97O?AWNY.PF^M_:(I^/KC
M@^H_+%K/@+,#UK6^M:9ZQM->-EQ/326%.IF)ZL$'*[X<#GU!0.(?*B3NC8^?
M$-BKL0)]P$K@K,9]4J,>=4:[I#09\QL!'=8NW>U56[JE>7FQ6[MHJRCW,#9H
MP.!U^EY"_N_'K6(609=/=K" 62"2&.)]N/7980RY SPPV[A>L&)_^/6_&4IY
M%2)^AT(FG::*1XACPJ[+6CYI9FH<M7<MRJR1_L$T3G0!"O2B(9FY4&[_O-X'
M2[%U.A]M6GOH/;[@*WG)_8@V.QBO]AQJN23YM:J2=[LRP$7NEPK,=V5G/OA(
M<GP\,/]'#4NY>.HTT?-1[0*4.F+% X[@-3%H=\$+#M,FC! +T$0D?Q8\9##:
M^*GIQ@()1>LBHSL:N$J+5$9_<H@Y)B8N6;.'KV\)*I)0)"O2:O+?3DI< (C&
MO9TV&!GMG<V?XDY^26=AFNCCTB^_Q'WYI$(->?(3"W@E\&?3@"[2Z6!J#6.U
M;%L1]O^U]]U136C9WKFBHEB0IDB7(DVZ2!$(J'0! >E->HD0Z4V(6$"Z@(#4
M2"\A]- A"D@OTGOO)?104[YP9^:-=V:<-^M]<^>]66O^V&MQDK#/V>?LL\]O
MG[*WMM#UHXBA^SICG^?J['+Z0M+<)YL\0F05GLZ_-A IB%@I[J3D+RUN":0)
MB;7Z0K3V9-3NNLY,:,;X#5K?@VBFY[Y:"S=B==Q]*;=J:[YF!2D':(2<//+3
M/:?A_4(!#N.YAQMJTO=II#'*_U3MIG+674$Y93JI%H+5 E^-'#C 7&;YU.:L
M)-"GBM4Z,7A8$:77.\O+VF^OV0[A.7B<!O)B\!KX_D>4DG#H_* /'4YU&+$Y
MO?M6Q(%,D>F,4;''YI<"!0  0$V48:U-]J98O!"1JQV<&*F<U3J<XYJ[,JAQ
M8:, _OG#GAZ;%C "QFP3(O4B0B+/8:K"OCD?U/62/6-E='-_8;*(1L5UJ;CR
MPR[-7/;>9C=">YMB1/]0L*E9'ADSI^)=&]G6&5EC#9;QZW(,&\@J-!P/7'7V
M\;5+R.U%)"&&O"%&X7)E Z5KK8^UA_;[%,33G6",+30--4,;\!IW^XR[$6S!
M8W$6=_AE?@DW;O S7 HM#162Z=T;0]VZ/HIB5Z=M\G0L33S9(99"\^987H=O
MLRN_QO&T[)O.A^RQ<M,Q/N][QV&0D &=EC74 IW<UU=2'UG><"^+?Q=]:&[K
M?JYIJG9!@9;14)/7U4B\39UJ %TJR!#,FINU<[O"1VJ0AWLV::(VQ(Q:)4=*
MXP72554 O9BZI1V5"=H_3MHHH)DP1GS5(2_GJ""6&E^"VJF&:"R"58 4"G-V
MBKEVW/$H<&9 2KN[_96"T8R*0)XMTOBN,]-[2UE>::ZS/%RCD[97L+!2QYL2
MB#AW_B8YL4TLJ!-N&86C6GJ/TAI55O;^-'B>7>+F#5$LZ9S1U;B94%8/6E2H
M58$KVYO["HV1JB*D+7Y'3Y:;@!1K9N:A,.VV1)T&'Q]][!4\X-+A.XF'F=C/
M1^K=E>72X9'!B9<'48[(*WGPM*U>HW0E7C9K/59ZW?.B5"/:6AJ:=NS&5YV3
M+K1YE]*?5_$4"1)^F+?6P71;(4WJZ2U(<']X#BYZZ'#(F,8-NL]!%PSS&SND
MJ,1X^;IV>[ HZ#F8:%?1VJ,\'WC=0&. R=RP*U2J5TOKY*/B^CWB>[YJHB%#
M<P?T'*4TJ@&@]$:(#T='NBL:/!2>83_\Y9:?/,)R)*"?+WE'YI6'S'):!O@7
MOZ#9*"=WZTI5LBRJ"^OO4H,XK_]5@-=_,OU#9Q/$$;HZ(T7(H*W+N8G [VCX
M: [$@=W/CSZ;B*A97V'@+I'K#2']<&%'C#+FX<[25M8AK1ZN_WOD33K:8).)
MPFXVR%N<H2]51IJAU>WBV,V&+]VN>("$#K$G7?+Y[2##1M)A7D'',!**-JS,
MO"_5DAEP9.W.@Y$5OI[D_.O#B?<;@($@Q@&&-%GYL]N&7^FV*CS2G[0UI)Q/
M+Y"]OQK.DYD4U^$!:Q09Y=F/.Y<HT+F?:6GAF_[Z,\#;-1<V2P]2''J^CFZ!
M/Q;)>@X&0S_,7\7-^[IJ-C<YPCU>CG'8-N:;7WYQR9*?TX%'.)S2(T E<E>9
MH/_?#JKO^X\[727.?W'.4]BN?[_OB<,*C#>)SWDT0RZV\&UF='STE-%$GE[E
M]NT<'_BD[C(>8!IT7ZA,D3>!=DR4R9<)]S2@24300VI-(XPZ<G]0*^B1F&67
M= OFBM7$H:^]D#&R(DH:-UA:Y<PJ:W!>4%$4:]?9% AA]]N\I7+[$JAU0>[Z
M_LC\>;K$J&[]Y)<J2[4H7CR VQ;<K(%-OOZ]6+O&M6_)!WS(3<M AQQ"BX1M
M'-/JYK$%.)T]6:AH]@V(TL$\A-]^D];JU;K(?XOE\9PS W1I-*LG)7+L4='K
MIYRL+YB+DQM_B4^91=$8.<MXVP@LI06:GYTF%Q0XHC""/_6GWRE;<*CM%A/7
M_,;K\I&OKRCN?,[LL&5)\II:>06B@L7)X$T=OW>\;\HLC^I:HZ!-%27_32:5
M/A6I%^(NS?V^PL;T#[_%0LV* QZ#B,C4)1L_65H2$0/"%U2J"@=J@+/5<./Z
M;P4HAZ&E4-K+66\PS6N&^<X+!X9P5W=[MY4AGZX!52BP)JW3VB(YMBYV<,R^
M("<EQ<-_8TVCI@>MRQ*$FU"V8MFIVL8Q5X)))D%E..K*J,?^_09C+3L*N^3*
M,S*WI/>(T/EOI'L1M.'7)@_?:):=<+<SQEZF+9:>ML 1H3,/S97J2K:T4ZP=
MGV^/*RZNAZ#%'I,.9LCEC1O4)0[ZV&?D:T;3.,8'Z>\8N=25%W%L?U([+Y_7
MZG"EH>C]HZN4=6HK?O$PQUE2"IOO!JLTB"28GM(7\8<?MI<R/7.+/$S4J[;.
MNETA\]^G?2,HMW1S;6I9Y;X&F-PCOHGGM@K=2.BJ=87;D:HD$'HS@ROZ2-.]
M-CJOW,=!M+>!4YCJ!H.U=VVL,NCHABN2TDY[DJFD;Z_E69S#9YUP#Z:%\F=+
MDJ+G"VMT1P^24J_(KZ>:<PKDZ35A&PK*[N&LRAWN&I1N#X8[4E771B,* S/F
MB'[Y@C-+W^Y*\/&XVP[CMJH *0;?M>U_\P8/*.[1I[)638ORDKP1XQ>0(Y>D
MK\1IA_ !%XR[# +M3BA-',BP6>!-"60UU*Y(*X\]?K6),Y\G?M3ZIHWN? %"
MKT ?2%(TJXKIFC&DZH-2>"#L>\KUZQVC5TI]Y@Z3@5RCVPZE=T](B^L/*Q.?
MF><6.&,Y)ZEZY6(S:>.:1I9HI]QI;Q3B$,UZ)W:Y02-V>$#+9D,!K,=U<E,!
MEU<)5UG09TN7=OBT3M0C;[(%$W]YAM:5&J7G=M2/8*]F>M_<3@V<H*I+(SGG
MSO"B]-2>_?F=R]0JZZ_OZ[E^?>DB2X6"GC[.!RBR[BK3.;:R%,OQ!ZD^"+<C
MG[5)C>18< TS)'[B\=RE4UZ6^];$Y ),16F_D0SD?$>FZIT#Z8S*C0.S3=2#
M19-22+=*,S!))S66:UU' @Y:-XK5[K_MU&O\N#''I,Z+(34!G&LR^L7T]8;N
M'+ >?GIE*E==_HY;H;?BY(%%E)IP0T"\?,0KDDMTB23/V!28/L@S!2EQ1HXY
M+(P@?.1F29E!K<F\JP8%0X.P3D?A5LV[!;>T2#+"7A#;(=-7M@SEG3T]#/7U
MLZTO#K0NI^8U^*1-M/$L]9&/LA\]ZFE39D\16].;8$\=7G[RL=<YN@"Q87YG
M)YV4I*6>G:F8Z"M+INPU->'25%U6CWGZFU<OY$0V&00O(4K.S_O?TB,^>Q57
MG^29,;ERHM)Q.0C#;7$-0J;CL6[9?M]9;\3UEO_J["1$ZF:R&*0._D:MNI^/
M+R@!%L@V]EU@6BMC"Y=;_^#.U+PH"PLP0 )'1=WC>KU$Q&P \Z$Z<$X4W6RH
ML?AN,^5E="0BJ<Y<1Z=?8VQ]S5LTF'J4;F\O=_(ETIK?,W0^9E)3PF$ET6NP
M?GG3/658V?JY\:Q\5,<SCR\L-[O/Y,B;.X)R&^R=K;IOF9Y$.M9X$6%M.>4-
MKCZ!96Q:.V"5X(Y"7S[<S>^YQ78M^8;41P-#15M7JD9Y4MKS)O5PB)6QD9I
M>8D/3" D-7%=8OO0J]^]RG(Q\8F1M/G4@:H,\3;EYHV4J\(W:JVSGO3'3RH?
ML2',S&*71N5(*%I-OO2G&0Y<9^0PZ:+(%($NJ04W'*=_#]3HW"]L.?M*X9@B
M/KE=)GY-OKIJ!]H5^KJID@C9F7C\M/+!Z*HMM;:3 R=LK;\M:-;&>C<UNM<P
MJD9$XJ3?(M+)\W:^&L,$;Z]:L:=W'!X J9:R(GWL]DV1X4VNL@.[LA@)685+
M*\-GU]S%H(&X$[%:<J3&1Z%.AX69B#DSDL@L8N+L[-5OM>\&OG_X2H2,T=*]
M^CG*[YNR=X:)[7*XJT-+V M:II!C"\W%4%2_891C;5)0D^?C,T0LU%KE9[L!
MQ[,QE^)0P=1L'NWY@\/#+7O9V5D6:D*U[=I5T:B@XM'Q5O)R5L[I7DGL?,++
M]IP$T-$;YRA_@K]GQ^D$FVQ8BH;[$-<4*PHI;72RW)MMW%&#W^GK=!:(\610
MI(6)M0K34ZZKC'B?6&N< "/V5S!YY@Z[O4FV[E3)22[JNZXO)#[S^SY:;9;"
M<DL%&<+,!O0F4:?)4M+X_Q5!,SE2Z\8Q6Z]7SR5?U^#FJI>Y5!?G0O20Z9:(
M"Q-:?SQO0NF+H7REAVD+2]%G4N9M<$#F5E-QL<$- SW:CO(/#$_#9[JS\0"2
M/2CQ82X?F>Z%A5M\,^J+60<!!\U%6"[WH+%&&I<J[4QH3?.5[TLE?!4%[,C"
M 8F;!9PZ%I'W)BZW2>G=P*"IIJX775N D$OYYK''#.X7ZF3Q#('7LL:]I6II
MVV=02J(]29.#LEKJD8J:K\XYXABW>-X=!*#8D&$[DV[=2=><_-Z;A[;)9TIR
M>]?7W4%LT^?WE7$/-V^:=INXHAG;JK@6%Y-89THD@98/*0? @?I-1@<!+IT/
ME<)5DH<OV;PB.RO*&?Y0ZV[!!=MX%3Q@+ T4N/$ I<C+.OG$92YH*C5M5&FP
MLKJAUTG344?.(2%EU%8G=DA[44UP7_-.]1B+&'NX:F9I=FI&V<1(^BUJ;ED]
MNL&T:2-:]=I(U+M&<B5GIM<J*=T57^&DAW)[!>L":=B//B&0JZK.0V)K4*^!
MU)S^!$43<S;_U 0[;J,NJX8O\<+OYG584!2E[ )Y.QM/)0OYN5552+J,?.EM
M0Z"@("&:F3K#9V'00+@XA^OMB3&Z%_V?X=3PS5W!(>D2DVME99>1((MA7W L
M=?-C;VU[/,#O+NADA/=]1;FGJL4U183A0<LWE_XGN2KW,SE-LUOUU0VF%LV1
M_BX-,P<]Y+>#.K=T65XV^E])3#XZ4V!@NV5@&[&R?,D@W?C)92>E.;J!7$XQ
MQ8WV4 [9"=Z8(S>!N\!+NAZ^MNG%WF\60Z@B5=K..W_YIC>(AOF0JH'BNG2W
MZ9[MH%:4\]:TX^DC*JH<U"Y2GW3YG/.4G5C,F.VT?/%NP;E,-':C"3FS"DH-
MY=1ZN3N\Z_BIY=G,N@V?YWJLS/X'XT.8R:T$P8ZQ=-\6Y+0X:7TMB>YLD&@I
MZ-P8^,*9!_>A:JMVEVBI7PH_*[OW*>K))Z*[=="E0@S(Y''A-?G*2O-6]MH[
MLF ;%'V$I\.YF=DE3;UVR X>(#B1?H;ZM5]OWFF$CD^GN8%_9_KE-X^N?_ T
M=#1=ET,XGF--%@F+LDS%$T_JTYQ*_4R1@PM\3(R"=!&K]X.,#%1*M^7\S=C/
MAO8 /:8P6R!]W<;LIV&(]V''DG/D%\L^8+Y +J)S$EE$*]JM#-FYG#2#2^2Y
M9^B]C(B?1$D/M(82H4(_;=-Z0:J\\(#CM5[0IVT3_UO;5SY4(KCXS V;IK>9
M"%C!O^@EY^P1CZ71#8,)RHBDB';VLY#B$>P5SWX[Y4M 4ZT3I"4N!,W=&R;(
MJ)M:N[#--T#OEI&B;U=>IN-^A2.RL[V)[-79>0:/?:HL>7WNGB=!]AF5"VU.
MD>I@V4("[GCT-Y,IJ@\@#'R8O^5;2[6\VEGZKK$:#\^/L!JZH?9*:C6\IOF[
M#JFMO<^<B@%*YWYJ4<A<V"N(JX]:#AZPIG.;Y=HT-DG2 @^ E91?>J=I/)C_
MP>#HB+DYH'0%(Y/;FF='Y,)U],1+Z.HK;]+=R2H5X^6..;57"PE86_J K#E-
MHXF'&?KR]B":P'NH(('OI)KJ*S%LO\1HZ,N+64DJPOGWJ#C&W ZL//(>%MQ?
MCVDOYM4SN',MUV\4_EV44GN)_]>$TO_-0<A?:4%M^OFJ+1S,\AJ/V A7]NH7
M!M#MMB[06@O*5,-HC%[<*VHO>SK9P#;&AM5FWC@DZZQV2!W+ %O@AW$N,+5;
MF+ V.(=(."D]86'5A;/OHWFW#Y !R3Q_33@S&"Y[UF\Q[)&\QTFFJN/4S>R]
MXLZ9"5WE*)(C2Z'O4M[>@RH9J&]O<:ZEF2)-I#?/>EWS$!9>A'OZT#3???4H
MB_FN- QJ2!)[\3I,AO7D-KS/  ^(J\WNO+6]IUQ;&/DH5^@[U5D\0$A]I;>5
M/81/1$QL]V/(/F!;5\-.Q&GU#':AL^56.8I>&N 8XD8983+QT./ L;W,?:*R
M+,S==8XZ8QW*4Y.G,VC>W5GP#1(!<^LC);:=$;GPN!?<_'@I!(=PZR@JVUI)
MN&U26E8_X6;A&QU@#S<9K?\@R[^C*1H:H:>JJBI#U^]D%QLYQ;;6\7@[HJ@L
MA%?\F4O:2.O**DD-A9I1Y D<)S>^(^'%BR@*VD".OO"V&/"(40Z_V$ M!D$Q
M16Q("B9)Q>5E(BL];K_+Z'!67&RY%V8P&,_'>[U[/?7!+?*C%&E&"'67UUYF
M3FF=1=4V> '<N")@R_A^+FS1N[U6^G%NEY_Z+W/EAJ3UD7A ,)#,KXFW[W11
MCL3=ZD\WMGYR"&@IRG:2'+N9/3>(OI!OG61-NP$<7+AQY="<BBLQE($Y.<?$
M8&\C?C/G<[U0J@TS&&TUJW*T-RZD;K?I):'%6S_KR'_-;P4CNM_$S:M<N8 (
M&IGBKU>4_3*=7#/0@I')D2=O*GG]U%[O)F55N'2C%2Q266O1&I7"9NU:/@W'
M RZ#311XQKY=L1OS?&OIH]@ $=*[%](Y(ZFH&WG=YOW9/;$\1&V% N\M\J18
M:L'7O_"\B>@V+F4;WQY5M@M_;\E4->TDK^KU/:<4OG*HZ]3(J813VP9C3G.A
M#<_]Y;7O?\7><6H0-ZJ[^\QK04)=@H@K$I44#Y1:LK@:LG-UKHT<!GTK[=1F
MNHTCIJ/# SS5"A NCZQ*P'O]%49?3 .8@FQ+-P(_FHM6M!H)-2,*2%?KR/HU
M+*W)8%:7LHN)YY9]8(BMYD8#[U)E%<N82W[O*.8NX $F&]"^%8+>VS(HZZYN
M!<+'[7G;(\+W ]#Y?(V,5_7,01/GU:3.".T[C9CB5C;W)+"@,F';04.$BT_W
M58_'<B2JF3=TT29#&+%5I:\?!3\\W;D@:0MJN NE7/.E^3C&71X3ZE]6H>F'
MU=DJ>-@KQ6)S_.JBFWX36%'LX9XIUE'O:7T7#5Q]R+_31KM7+?J(,/^&U1^?
M9A[1>Q;-%NJOU>-'O"PK51FN<G_]O_:L-,BIE 4 OT2JV2VBU>B6X^T^Q#*"
M/KF$D2;L.D2KOTU'45IJ(\25X].*>H=X9AEI=5=^F2[C=O80'<Y:>(CKP;VN
ML+=N%L_/UZ<V6"_;_!+&LLM_X(",X6H*F 95?SLQSFUJ^N[T<&M=BF NCW0,
M7_2\7LS#R8?K".6\CRW^VK2)1!_']<CF>51KL?-(-&_>?Q%1L$<UM7+L4^!O
M7]=J<?8XY,U!"=D!Y'AR@*<R:'38]IB5X3'1IDIX7"T60J$?0V-FD*_0SJ H
MG/3\(;2:GFS K]U<YD0I/!Y<@#Z*6#GV?&#U,38B3"]< Z1[^?*3\\24B XO
MT[],0?L[T3\8,67FURRXAF-WMJ---7NDJ?D-E=.5%Y0NZ4=]W8!B[0IF34A&
M#R.'#:5;Z:=-(DU[FI]-3F)AOK,C[ _RN.E\8 I1 D1LE6("R5-J2EUP#JW@
MMP,]<)J^-&%QATZZF(C94.7Z W.E(;.(SX;GS-N9UF5P;'B U,!RF7O9Z+OB
M<?W'48\:_#5QCGH';EXZ@7DOJ]\WOG)>WH:N&,H.^2,(X-R(MI/<EI>G=>&)
M9=%R^]0J4&E:M8Y"?K-AVV312\5TNRJK5?,TI+ K5</R%!F<E^1K[K=]/:^;
M.FP7#^CEUXRB$1.UZ\P@O;EX(8QZ(7,UQZRMMLZ;RJ\FE_3?(!3&=FX39JIS
MXI]?6Q4C@.2V7DH5%56:A!G=3MVUQ-Y'CZ2)Z^+7B2KFI5Q2W_EJ%(_P*_#(
M;Y>3"]55<Q]E [ICYT8K@PLHUXR9H^%W07K,(2$"JB90[67D4OS0=\P5L$V[
M<TYA9477-/1+UM3)0/VV%K>4H?A1;9W\YT*7K;4$2C1."]E=%)VU? P-YAUZ
M,F!A@P*^=6G94Q_VQ@/$UQUX[4N]=5'PU"=?S$1URBNS-X6?9:WO Q39'\QM
M9!W&VX?%N\<MF>V4LR7 79XT- 75H3:ZGJMR:8T:R#Z/:;$/_1C9X9"ONF(2
MJ0:V&]4BX><@$"?H\\)_F41YHY;V50%E68 3XY8?P8QT[R$/OJ3AKG%#CG"Q
MN$.JH1X#'[,LY_!5:L@"INOA?WU!":D_!\8#@+UXP-29JF..XV^J,^C+P!V<
M]2T\X (5$H,'$.SC2Q+@S)ER/ "Z MGT,_*A)+!Z<>S/> 01^H 'O"69PD$R
M\("Z<S]4G5\7)%6D6>'SD!2#C&OYL9+P0VG"<K%T;'(RK6,BRZB;,RZ5$H S
MZ9C_H0IY#),V'K"+Y<-N<1>DAN<]W6!\0G S^19_*IW\()<[:;8I'A"[*T;Z
MYQK4?R/$VNDUH?L!_?P$Q3A*#/AS)1P_2N%Z>J<JJ>$_/?5_NJ=T5(J-[JOY
M]QA6-5VX+"?4!8'KIP:U$MS@(>KL])A3X/#PU_=LM(V,.X)V4/01'\[?)NW'
M0L%[&$;1JV1/'-@0GBJY&,114 Z4^-.$8DH>%.OW5]?CL70UO179]>"7U8!H
MX#N'WFND^H!%OME>UXJ:)+M&UHHO<?(LRPT1A]N&F6E;;7*:]T(A](W6.+VV
M%Y#S=(R]M5P@CDQBIZ!.'_I49[;2< J&9<?XP23;!BLG,_Z[ C1=X@>KGI?C
MP>\Q0!9&YN,A>F-F-QSHFTGI8< LK1;) =DXH<.3>UY#!-X8)Y;8E=4(* YA
M$5\QWS0J#2Y57C(Y])V4DS1DC@&&"1T/R0^F\86)2&RNQY<B_;0*UHZ7G1Q?
M:O53.=Y+>KXTH!>+L6LY+#SQ[(EU-]]/!N[1#-F3UI/3U44P4RP;0FYGJ_F_
MI#%@[IHFE=XQ/^K=_V2]#RFH@>AT# [<0.\(LA["O+X<Z5M<\';X4'ZH[=K<
M&.KKRBSR^O)!V!WHD/#@%:+ZBP=WXZ",*#&<O?;GLE[4,"WPZM@9<8F@BXPI
M.!=L&;T]F8\:/[19>Q*ZU;+KB =<)'U/BS/9)&+<#\(#7L%1P)G.M7.Q6E7^
M;;QK%4*05YA.=RLC[:5?E*3KWM?@K*+OFG,'\EK8&@R$V5F&1,.IS%;F2Z,6
M8>SL6(C!IW@)\>OQ=#9E33N+(AQ#Y&$AXM,1F( Y_35+5PA3Y,Z#+RXR]>'U
MJ3THECXT2JF9FIS,^48%T!N='P(0UZ:B=:IVE[PC&&)J S,H.GL]HOXSEY\V
M1VJ)R-_"GK\7"=PYVG9+E;=A.5^V1BI]FEFC'\';UUT,/*!X!:$9A^5LZS:0
MYO%-E!_^(;'@GW!8<Z@%M:D:X?\=2C,5)=:L!5K$J3("=".)%J8:Y8 +N5>!
M9 ;"9\N*.OC;.(C8-;8V F>I,2/,#PFS,68K461N[7"(TWF:WN#QI^Z45=:3
MZP+(/I8WQSH&O&'FSFPEI6JK693!GCFC5XJ9QSDV/( 93H-?U7./XDLV2JWM
M+_MX<<?PKI4,T$$PK,:"/;[*)[>3;ARF![#@CE6Y%LH;#W>#:P6&Z!]K$!U?
M R:Y.JX5FE,TW.&9"FW8I8QL3UF5,(2G9^$2FH3P@'"2YM6*]Y"KL",8[O:4
M8<-3' _5CAOFLNQA5&IRD5$!!@ )E<#(?6^6K0+N=T!";2'U8C.57KIZT -'
M+"?QNY>B-7B ]9@O*QX02O=I<S%\O '*B]/S66Z.G37^!#N!*>?0?D>I8];$
MU=['1\\][]O+N.QE41JP=Z8*T?M2Q,[=)TI- UB3"TG2PPWWI1A%2$DO%S4Y
MJ@V;+6P_+4\ES7N6LJ4!'DA4&\;8%Y!.M>Q_+[<RO88) ";9K2"OKG\>/7Z[
MZ<RN$;R3=0CM+4O0CW\8#+K'<M)+Y_NZ$*,AK/A2&'(WEN\:&78X[+L88RC[
MFXRSJT]KXC<N,>JG1W-IOW8894D%==Y7?&_PY;U +S6E;QTT5,.];N#J8 <_
MX[1FZW%\@F*OJ7_3..JF0 Z6VXCE*?69ZCF0C6=O[42;6[R+VRI_:@'@' ]E
MZ[]2:_^G%O9/="U;4I:_X>9J:GKJ*^X$4;4M$K7"!NS7(ZUXCC,5)6\A@)RS
M @6R5&R4 #_IY=-\GP*NRY9^GP?@'TH' Y;4!^: 'K[T(.W11>YJFPVF%]L*
M@GE<QFGG*U=,*[;0';'W(FZ6CM"Z%/)-OC_@DI2$R6YRNXHM>&DX+Q_L[.(!
M0BFIGTMKRNO*]5 9>BRF_0Q0DX>:@_8&SBY].J>95OC_,KKY[T%Y/EY'<^^>
M\UP%.^ >$1WJ5#-*<QFIZ86UP&NX'/@L9D4I"OJ/21RB,EK!K.7E^<53W0?#
M+C+8@7TX<Z7/"AWZ]B(V40I<CB%'A::[7><?;932'6+4',>YF@5QT597BRBR
M61 ,Q5_E4#UW-[5<7970Z[6):@.RVC[,$P0SK!U*^4O8Z)5*')DBU@^,'1TA
M^+]1C\I-IJDL[PY3I))4R@+D"N5J*;5%0J09R/H]"#;$' ]X0%6M:RR !T3(
M$W!$_J\?A+$<"NU!(NIN'&ZA3>+@A,\8KD^A6R$?<E8O,1YNE1%^IXQYIZ8O
M/R.G>7CJRSSZ3?MNW7H:]?URO/Z?SP]_6;> U.NE0KHW<0\@6VDX\DX*' 2R
M0X$'O/,,I5K&:M"/$ 9T=*":KQG3K4K $"6/".AB"O,6#YB1Q[#%LV-P>, \
M.\$GV:7A.$Z_7X@;A(_X A>]W'_S)7#F3@]PZ0 /N 4\U(EK(E+ZO,=*I$^#
MS;NGO]!96_4\D 1E&!7^D0$-U,KR-OI8(HX)<S.J(M04,?FSYKT8NO="?J::
M&Q%.T<X-*U-C<IG+>'@].$?%@3VL2RXDY,UXN&E_[W$MM_%ZUB<SL"7E7ET@
MP0.?P@-^)F\GXMW /)R^AI2%;Q+@,U60(;ZK4M/7ALT]'R(R(7'-]ZVCVFK_
M)B@*FQ&XL+B@O0=9]&+_N9146<LBH=XV0]H:/O&*E%(>]Q4WB)E+P.8*X WF
M$%-R;:V;R[_<O2-\>SV!2R_LML#B1XTCX*XDXX\M8MR*L8'NGN !'Z 8[NX]
M;]T"5Q#(=CC/28J6^.8^!J2L45R&:XV?'\;ZVV3M1+@+[!+[UC;#V0,R,^R5
M_(%D'&+II:<AK?+__KBM:#XLJ][JIQ@+L3MGK%+)WJDE\4K2RR55U\L1,78[
MQO1]CN_3TJ&"HR2UGTM[*7WDJ[-]CD3/AHU]<',KK8&D'3PSP=.7>DRZEPOM
M & ,G(4.Y*S!O@-+':^KR-X_E97BI[)VL954^B^M]\HP=R:>Y6X]]NH_$+^7
M9DV<) E+-X=9T",-73 VQPC>>3S ULSU0#M9#=,M_?>$G$%P4Z>6]^(ZR79Y
MF2Y_(5>^YWCJ7E_?&>WXWI7 :E*3OI=BFE.7Y]Q1=,TKXY"@)RO 'QK$\5O>
MAN>CK&)U^%@;[NTO6\8F6ER="IS-L]W7/B";6-5YE9%(C#4TO&[FH8Y2G%G)
MSW/L$"!'1 X-91EU3?U4XM#RRIZ"S.M]MFM6X?6J40(<W@[=9]731_4\:=*'
MGO ,(YX\N7CSH9.<$Z>$!/D@'N '8C16X:A ;_:9:!;_/<GG]] ]Z&!$D9$P
MG/4#?63Z^B$318MD1>X'W7H7>CE/ELY&\E1N!PF+Z1,:R7>227@ X'C_%JPY
M&NZ]UX\B</OS&!.,T$4KPA0"(H\N$B9135/5_9[TE<(1[A5F]_@)"VN1JS50
M4U5=&W9[R!G.1>',A ,-8V3*P$_GVXL;[M?=S437]P;*/I1/4I1L["]E/,1"
MW?>GBK!)N+Y$3X^EP?CZOC77@XN+6IL;Z5@*R1L_GQVS/>B+^Y_@1M$E_BW-
MQ,3)27:UG7G[SM0.S#;SC/7U[_S3)Z(H.HHXC;X9])P.+^/?&]X(2A&1U%Y+
MZ@H&?;'54 S[[MQVKE/35L>V:$,:E>D&)U8[">5&*E30EF'YJZY ?L[,V%P6
MF/NPFOU$O_P/OYWZN[]E?!K@QOA'<VN&J/+?'^'EF7JI*@A_+734/_#;#=GI
M^-)XR38-YZR;4MD$URQ*^G^4H/[T$N]?I1OY&T3$L-2P?;.S"RHT;,A8T^,S
M>%SP4#VP1M;N7BL(Y)66UG1"C969 RJ-IQ:,2E5]JB*KG1W=PP-X0M10]N:X
M=P0=^A)]:C40B/#C&_-_+(VE0B4@L8051L";$P^XCP&V-.(&!X'+)E%XP!D=
M#,>/!6Z'(+$Y#!)Z%% ,W44V8/[(^ BXQ0:I#__A[[+EM&1@^Q$>\.D_3/_#
M]#],_XV8]@\FO/NN!-6N--14*:O-=G1TO?+69**<-A&KN'*HC:)T'K-X,UR^
MK8ALV%%(RUJYYV5S^\(NM\^1X<+4JAV:\NF]L6KA$',J&QA3:A GY3]R09CJ
MW1SC$:4KX_$B<.^6 >+'DNXL\ U0_HAV!A).JG44/PC<GK'' PQCCTB2/Q<1
M/.M+X.-Y9,M3=+HOI24PD "TGRK\>#;\WQXD'R*'V$_JJ^ 0D^J2P0W[N;#A
M5*JO'C) %P9$ZVLM/WJ9EAR'C<S:*N\$_PGN.<<FH29N,1DEQ1(OUT2FN1M6
MHUC5X"?5)[YO,E1<R+3R=:6^C0I U3*48:U9S;/DEC0?*N74J8.MOHN.E8]6
MQM8D*XO";^Y>?JQW@_[BFH[9]OFTRPK!@N4Q_&';,,%P,SD0T&)PT@H/T NI
MX^.3C"APIVEQ54Z(LRXI\APP/BMK;?U%8M=O;:A6M]A *'UE4J-['X*2)7&X
MT'JDE@6P/AX2ML\S'CT:8[M:0M][)Y=. +U4>T/\&WJ<Y_*N0TCALVII$OG'
M7KZ4WIS/-1K[U.)'\8"OR(F=NRBV&L(B.$S7ND0;68#;\&1\K"V70< ;RLAC
MPD)W3 8S;_3Z="FP"?UE]]Z5QJN-<[=++",RHQ><8]WN-/?'5\AFN9EJIQMZ
MFHT-'L>/4I)YBI1O7DM"L9#2R:>PHJ7JR^P'^:X;P#NGHZU*SRHQ$Y/S7J3U
M)HI?N+/I<(>=PD#)_.6SN12&M^ZP2(\W&A&SIL 89ONV(@YUJ :Q?EQ?E+O<
M1U!?"*5%Z6HU05--<N(]S/CE):^XW+BA,6)31=_!4Z8P^H 40U*8%;?!'FFK
M:A$1+-#LK!:SX0E/*7?O>++TK/DQ&L[& *)^D!H@7(4ZR'0-!%^.H4F&69T9
MF]"_1U@(DYT@UW (5?#ZWM9D3#DC:.?3?<82U*B)Q$8W1*F^O)\7;I]5YJ]1
MV"7 /,?4MXX&55/'<Q@]?NQD[G*Y$OTUK_9CK&;6&K\/3V9=>66_GC)E\;#G
M-<. L%%3>YZF\<IF@'E?_.)S@R?.'CQQ=3:?QJWI"EXN(=<>0Y_65M0HY["#
MQ26><S=-?:;G,DARPFT0^RM2LF"Q[RF1_7Z=HGV1MUUGI. &VSU\,9/6*F#A
M7 -;Q^L")BI6&A>[!&Z*-<^J436-R]X1$905-14LNDJ;;]MGK"8N72SUZ%*Q
MQ.5GZIZ>DAB<3\/Y#Z\NG2,217][RC3; M<79HX%[]S=RY< PB,.]A\1]T'N
M8B55IMYMHDQI,\.T$IZMMG_'::G)5RGPLKYV&P.[WO27PVUXB4P[:J540-6J
M=WD6QU@M7BT[D1X&J?*4'X0)DX<8C'8"FS'?"HL2GM2&#9+MWG^6^"*M4K@R
M=;T8,70VD+[M4="%UM%#,R!7=T*CU\?O-7*6TG.7S:73<<S9#9Z2-10-M+-B
M_7?>T$MG<;0I=3Q)$G=2%?'&&87*S)XMU[XG;HG(Z\AX]#G&LCO32V,8#VC)
MR,4#AG212:;]VY-J](EEV8?^&I?RQ2-Z$S+A61$"^9N;;I @IOP"[?[X+GIQ
MX9*2A'OOW54N. %I%KCU@>1V$0_IE 7794D^-V4!?"E5>57X4]1E%$5 T>""
MT0,K>_O/(U TV=DN'Q]0#KB4GBR@%8O8-X$6Q,U;XP$/FN<,%[JJ(6XL% HA
M+([,X3Q>84FYI"CNHFPLL@M<NC&!Q.SG1-_K73%7T EAG1A#MB^M#?<B;0/>
MED8;32IZNL]EHL:MT>D#!_<"4N,$K04JEO(GIOA6--KS%:^&9L%K>N+<'UN_
M_\P2>]:"0=)13W!5Q]F$;3XR)NX"A\*,8Q]1)J><X%1G&%R!#32YRKW#C)CD
M>S82P13AAG76>2E;Z.%_8*TFA-X\7HQ5K90;2%"OB5#[^'C>11#X#$C3%:]3
MD:R8+N9)7>*CHE\=W6&@%%V-;+&D5->G_C4=6-IO@&[+CV&\/=!2(JL^;HR'
M GLF'TY/:[^>AJYZX_$&)Z>BB3N-2?*]D_(W):IM*D@@G[9O@/RAXYY\38\L
MU?[2DM^_Z,CY=Z&_W!;Z9^\3"8+1Y) J2+14G,AQ(' "V/:6O6CNJ;JLMW73
MW[KP12.NG1A;YW) _@G.,^22?UZMD&$17E]U9;Y^Q*RJS/J^AOL'_F[[AMY8
MY8ZZFP/3(5;2YA_\^K,E!B5KR(T,Y<\J5RE2<X5[M<\Z; R*YZ=0ZXL@CT8;
MD@?5W?9[PN_)FJ6U'Y6;]U%&C1KJ?^!EBF3V(M80,HAQ5,Y8$:]NDJX)[*5@
MIONHX?GU(%-7A6<I "VZD6ZK01\I9[@$LJ:CD4R;^NQ]8?W %EEU&J8[5'PO
M@+G7B6*3\<XV.C.8.PV\[V?/^1;2KA( 7C+2PF)[#V>IR3VO4T4*7\A[L/,Y
M67+WR<I!+/EAY@9Q7 =UG$0>)D5:E'I%$\4&&LOH9*"!BO!,[@L:*.W>]:8-
MMLF(F77_()C=3>+Q)??%V*?-.?_5BW5;I#3Y=.&F:P84$^-CAP^^,D7,*;)%
M>6J^?N%Q$^:6?R#@X;LX$SSNDY%V=<KS X.@]VR8)UO!)V]J)44>U(V%/DR7
M/<HBTE:J&RP0HJ NHZ&P1SP9)PG_!CM7\5HA<)[0'48LANV@=)#:I6*QNK%*
MU0NMDEPP1<F#=[=V;V9&N_Y"9]FE2N*"6<D-GW^4+9\V.(1YG-Y7D!'<&=;E
M%A*R01;)U9D?SM,5[>J1PVD3IT6F>;_8$P-S[]A!MYR;+.*L)F>F];;I^K9\
M;TFT&2ZXHV=:O'TA2%XZUK:4FRRDJ$L*(=6K)KMP%)]WE\4-<^*&W MSTITU
MDIH8Y(S1MII<EY)K5D$.QL?<B'RXQ);7><-H5E!^R>!R(&_ Y^9;C?:.S.7?
M"SMOPW/LKGE$JE,6LT?=;DG5>("B/R_9O)NK"99=.HI3^JBQ&!LS:4<PN<Y7
M;L5HF=,YS"B<S5VZN:*6W+LX!![E60AV5UF6 \$K(.LK$H_WW]XR8;<UF;GC
MV;P(XJ(-S*]AS[X4:&S"9=,&-G.+]&RRT:(='+4]#-/U:)X &P"_(G?X;?Z7
M+T;],4C\OR45UA",#'-8&@$@-^/><KO]19E.?LMZ&0]@><FW/;.*%-)OQDGP
M(-<B"4!/L__Z#\"Z-+P^)&O[--A'X&\&X<\[UC["0R[/TRJ8_23#;Z96%1S*
M\.$!2ZMCN^"M--PU0N\>'9=AQC#< _M[)U ^-)W\3B*<:@!2?Q&"!P"UIQ(@
M[QBW7IO@ =T#Y8M3,_+E6>-2:>]QFM$_9\5!X!30[\C8YE2JHX4'7""L*1BL
M@:\]CO)'K@R3T!?'82Q'JMI!J\B9LT@\  H#=R+KPW_D.M:WP:C>".%LZS'2
MP3#%X@&[:/NC\M.=M1^X>GOY-*R*AB^(C=T?"[X4G3SZ(/*JY/L]E@HXZ:'"
MQE.!UX-MDSK4@@T7=#!KRC^VDX"CR?$ G"\<>0\/((G5"!XH49C9?J$=9'4N
M)LW15*B5@MOS55X@TWB^9+-7S)I.\N*PP9T7!E^K'</.CE(?0_5'?\L!^(,8
M4$2:][CRE6#U!<7A^EBMB@1MFJCUW0;N%Z)MKX@9W['2)'VK2V%;?;Z;6"1&
M]W("D@3^:9<CTD"&4O#@VO4#9$=S^>#&LV)E(3KRL13V]AC)+Y'.G?>,S%8-
MEGG#8VBF&)[:53PB*J1"_+3;^6SEO<-7#ZOU.[[Z*,TJ@][36K4'OER:2YKL
M[T<FW9&-O\9"<?$KT>+E\^)#,C_E @0I5]3!@G#:5B+O\^/!I1=XKL^CD\R.
MNI$2ULN<@?D3K =.=[5W>'K.Z\Z'.Y&+TVF7_W3X*I>CUP62XKJ5O>^6/=&_
M-\5[IN,3'6;";N<P:%U084N_]<6;2_>_Q3(D#D)_RD/\H_&Z,FEP6.LG(HW*
M'3YFJ\N\;7%Z :QO(H[[S&OCN6^N#X&CA;BEY"5<\@-^K@*^@[%.OJ=B_5W-
M!8+5*H'_N%;J<^?^7$W"P6H5/O)DF"QN65>3'P?]1[ZHE0/2[%G@QP6;?-C/
M&R]9*S7S#T_?K!\1HGK/.E2U%XYBM;0.N::T)Q&%M4-[1KE'V1PK<38E:JX3
MS'..\#_CE/7?BNJWPS%!XN%89\;C:_#1'TMYCHQ?H6F8T"UD<T NIA/T T!\
MHHL'-+\KQSJ9S'-Y]0))!*&-IXD'6'_OX.[_HT#O?WKZ]*]LW#^;N"\U 7<X
M5H'H#LCR@W+0CZ6B1LAYW_ =$0(486" [0KG0>;JQW"5?#M4DC(_ /PU!0Q'
M&X2",.;9'_X5Y^Q_.A[XW0X>_L]2'A\U'M"2EDV I *GL7LG\H#49R;)^Z7Q
M@&0]K*SY>]QE+.,\^!U.0E)GT6[XAYE4\,S==C#=/9!TF>N;+>.[FVJSIK*4
M6N2_=S"$'^FW6:Y4AZ(3&O73.%AI*U] ID_'"G80B08^2,4#W!D?>==2JILX
M^'K]*]OWSR8J99U2D6-AU.>3WOIEI(8HU@Y%F4'%VK?ZU&*.C>U[RU;M=-W6
MP%MD8]&%<8;JV 5@&V+M4Z_!"45CK)<$E <Q1YL@)RG"6/=F98BJ;U#44T2%
MO:H'$UJDKI3F.+):RXA^]A=WIG]?XHQ2*FQ@S7^1G1&X3WF\)*'CS/K]8:J^
MP(GQY[&KP-=\<^:H,*!X%US-FIA%_RXV0Y9Q=>*Q"D6#XVK58_VWRY=C+^^0
MRQM6WM5QM@?3P_.TMWF'9Z6#) '4E#H2_$\_:D3VK^9\TG9VX&V)">+(;WCU
MOVT7_W^I;:C4,4^/*]V?ML*@H_R3JSQC;\IW=)]7IZGOZZFG;P)-)<!X@*V/
M#+RJ?? NK8HI63K/E7[#!F>RAB:?\"R$J;B3QO['@]5J/."KN&U_2,IZ+JIG
M'P]X9:=N6+]*LQ]X4BO7L:H-^U*%8*QIAK$?:L$@U,LZ5TJG[O!-6&O>9(12
MWE&13%\_D006?%"^I#T4M&@TB-R:$G(+ZB+ GC>R>,#GV@#<V:Q?8_">#\8#
M9+Q),1?5MF'[I7A G,^B\:_Y*GM22Y S3#V093Y3/,"/\S3VKPQABGXW;L #
MSFAB;/[PXS]DT NEX;Z/([]R _=ZG_&0'#HGCV&EX<.>([BI;,"F<)#:4>PD
MPW^8_H?I?YC^NS MRG^IEZ(?#M4L=QY^,&D*/.BR"_8(T!R04KFD'&4ZAW)_
MU4Q]0 1[JDRA:),T90F[&W8=IF/77MWC>[NL*&_,9C#Y^8@G'2J(<F$>+,T5
MYI=AF+<+HLF_FN;$3U%*MB^#M3W6"2#O73MY@)LI0#,#AUI$U2SHWSEHA+")
M<?;WCO$-'.%D5=,YO_6E;_I,+=<@^0E+W@_/9?[=::;&DP"C[??NJAMZ;$XK
M;+9#)LT\70G0A\GGR^_]E'STD!3K>3R4>_5U$/>J$W*:D3X1#Z@1(*#DO?!?
MO2W\R/\#4$L#!!0    ( %M#:E3L05G!_Y,  (BP   6    9V)K>60Q8G)M
M9G=P,# P,#$V+FIP9]2[95A<T98F7+A#(+B[%1(TN 9-</?@[NX)! @57$/A
M[A8H7(-#<'?WX*[UD7MOSUR9;[JGI_O'')[]YYSS[/.NM==^U[O6+J!ST#7
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M)7:AB+6K1^#W,X^*A<R0%D%+HF76GTA. DEP'Y_D"K5UV;\\TR\L,/6TG)7
M'38Z0P'9H%(KX(%;TTF$(S<4@+^PEZ1Y.K3S?7K^(D;[@>(#\>_#P4M]6PH\
MQ\JT':!F[,4B*B_663'EM)_DIK_)/G>KY(-([VHV?'"0UP@_[4:\6,H!KA;<
M>O2K@[H,AN0NGZV?WHA^Q6&JS@VN2]C#ZE/NP[;=*\RI4N-LSWV.C@U"66OI
M+3A*ABT )FU/8?J&([6>&P\17L@XS@I^D$4$@=TQ23OQX.15JV-7 '.PU,QQ
MSW;KR#AI7QQ7!__A;!"&I5?!!E )I.GYND$VAT.P^C<"-^2U9>FXH:-IF6T
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MXCG0D_Y=S2+ZD^O\U-<T YA[&I!LB=C@P*V$73;C=5=.2O:;8T2&#,M/99!
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MAXH_6OL6RBDSR83ZNP(%P(0F]>$FH=Q1/'M%#;"I,7$4^J/=%'<X[E@/EE!
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MSPJ:<%\X_5C$Z_]6<-76%E"K GDAW+4CNC6EIUSU; H;-*:MI\G?V-S0JF_
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M\N'3_^DV+Z8)R1-"59AS_A;_@R:_W-:?<!C;?UF8">&+E2]X=%'B6E#3P'
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M'+D"R?1O$=.<"HHR=NJ.D2T:/;0*FML-2\DD>MEEW[X^-LJ62RBHMRHMAYZ
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M4 N:9 N]G2A+@V@X0QK+J9VG-:=J"'Z]594-1@A1(,(@#L%#_U)JDN_@2)O
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MEF"WV.](Q'HS#Q&)GK"'W>QRP@ZSA6"^LKFR!8:!48A>E"2) X5'8PGM\J3
MM[IG'?2([S>EU]=U.R/2 7H0\W"54$GW Z#$"C];HNJRW$XC<Z'M2K?L0.J[
MN'U==<E:3;SEW(5VI:16:FT"Q2IRLSF+ TC? 8RYCLA'&=U5M/"$U5A18O[>
M=+V(C]-R?3Q\J/I/-DRMI3-1$1>E;QF7H^IB0OKRWSN]+7+6^.B8"6K %7JW
MFYVC*QCUS;5P4 ,.%'$6J_9Q)X42#ISWBX&,S5P?7=Z&N=K]^4?I[ </(=3!
MR3___VEA^>\69#S9]L]%FOZ&M:)LS S5TU\"6U@+5W"OM_=+)]*CN/1'79=
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MRS4OW%C)?J4?N?A+$QGMF"3 N%%]ISMW?]]MW(C$]@C_N4X9R;B@5X-E9/R
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M(<^]PIX$MY])<MYRA<BF1;@PJ6V0B9M^,/"*6+B=56@!B'W@,,X*,KN+2AR
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M4OZ2N?EQ?;7P^D8C]XQTAR'JTMWOQ(AGEQ_T?$$,I.UF8G7#I=P?:],"-;U
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M"W'[ZFJ'JK&NS]VB3:Q;Z(I94"7!Y9[9MN+WT]6J[&7P*PY>H@G>P?!H+Z3
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M?,]"U7>;(7]M0V0C^IJDI+H&8TPRREYRH%V[#F,=&WAA<"]0G62E?]75D4W
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M@/JZT[OGQM=D"XPZMA5\]H.] $[7<_^8Z^>6O "LK=8NG[[^BWVJQ46WQQ>
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M"O,622U7)9[8,D7W*=MR@TLS(@9=]7?E+YS=K/CMUV6-A7"/B^5"F3&8<J&
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M%"A)3 QK)X@"N)8;M8;RPX[9XNWSSLM6T(25NI437.%29[]H@^2[%S%/2@_
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M593@G:Y'33357L)7XBRBD*5X$A789G? V9K%W"ESL20[NE7_F'6W2V.XK6O
MX-34S(:M7GMN$73=#GY %F3:HH^/R&]09I 0?+^]C'XY_N,+7L/9;-Y7AZ+
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M3%P+9@AHN:_=^LS-!NLXK65GH!P=3T\_SYWCS&"&?5A)1U[HM8($J==.#:]
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MF1IH)(\[K;Y#VXO)WO45!+C H0W;,;'>,PR9DSC])7/PH8RK^![!4%0O+W>
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M5MTU(N/4%$XH^D=V+Z1\=60OSS)..B)#_A.-OK^@2?&[DZ1V.;V?ZXY-7UX
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M?+X\/;W6QJ;&"-H$@Z"M@"6H(I6JC+&U=1$Z43SX=Y1<%SC3:OTNAH Q9K)
M=G7;L>QS2Q+'OL!4&]:[AFA'_"N41Q:U=2O2%#S9#]K]!DO*A_JKOR<N;X-Y
M>,>'EG%EE18Q^^XS.*99G9>4:2>"JL8 NUEJUHD);LULPV_5^,<XIM65R#*O
M^/4S]? S9#RE%-B5/6OF5ZY*;TD.!%3DN>S>DH!B.#.M=1UE01D?UC<* N+7
M3>\U2<1CFA[R8);+S&:+;9I28C^@@.(MN%YU$_L1KZLR6Y)Q_6FUCPV<HW-5
MV:Q:8FI4)95N?\%1?S_2]#]>^^U^(=>X$XI4](KJ?K>T/B_%\3#W[%)'F:^G
M7IT+91%#9\KU_Q_B])9ZX'8#/UT_NPQ(?+Q@*3\7X$YE*;UF[QAK;F7A(C5K
M!L7?\A16_/CSW8%<*UV.[@L059NBU.;M:O9,3NS@I09GDP8C]QTJ @I,+2D]
M$$(\"504<>30,-O"ZX.-!A.K_IWA_9$1( RTL8&:(Z><Y4&;*;(6;JK(9P[=
M$_"--&([ANN@J[BJG!E:*S%:YO#"/1O-HW+K\/;62C<?!\;AFX6E]C"7)]-^
M!B@)*PA_V:M>Q#1EF9[C)#'X4=H-U<._IMR%AC<@\4?A3PQFY\M2D:=F>!3C
MF\X$WTG*+ #]F3=4^$H?QCB@J4Q=!OTPA(:@KF&+JK)97!*SE:AXS7?ZY%K'
M^1*"WK>TWT+C:BB8MQVT;=2=.^1&5U*P!&;'DN#$3,&]9#5?0B=7ZJ56/T^O
M.I9[Z9UJH+\9;'97E9OGQ-I)CK'!V4,#N?ZFT8^;K ULC<ZMA]DZX+!-M7,S
M#"J,2,V(,A5HT=MR+Y@J? M5#>G4-YJNDJC-:LDCX,S17-[%1_RL3G\"/E1P
M$_0%_]4XTMJ<&*9*+$ 05@8A\M-!T]$1>_MMIB2V0XMPH02R-I-OHJ,/YB&^
MRG+IE96Z(6+2(O%()WP8X3O1<*H](UL[F896_;J(O=Z\)+UB_>1O4YV:A)G#
MQ=8C+7&NC!OB'X=#1-EHV9%X)"WXA)BR8]"H'$5\#D !X$'RZA*Y8(7W^".;
M,)J4BT42BS4NO/;$0ES_#_YP^^K\X^(J/$?7O0#W_E 0O/XWFZ#9JCIKAFD7
M#40SC:T)+^98*?J=%F7$1;-,+>+=(%G+R!^"=$T-C9]A2>%&)M77[U;G*>N;
MF9?0*&>B\[Q[&FGC./12U&@T$(B+-Q0&(_L:*MBZ,3:AA8D=[<37^:,FEI^7
M_-.A,XT22)H-!M\0=*N96#KS&T$?P2JPT<^<P$(477..Q:QJ5Z?IF3)\K825
M*F!!)SVXWE(FT]"W7LX&G G4>Y.2AB ;F5R2JPF7?+FONLL^3\ ))J;-^LAS
MS:"C(OUX*+ =EK%PKS$E4UVB.N8U@_8.,3P3Z2,B?S)6$7%IU[=;,J>+R&O$
M6P;M^< *W24X',93C?FZ,-?=H?6K8^W;$/$ZK8[OW&6V<I.:T=X'?.7-Z]96
MJT)@:R,M_'.<#%DUO7[[%OKPQVX_<>68H XJ9TU'9;E,^ODUWH]Z 2)$D"-1
MW5@)A#[LCU)@^](\Y/1SBF[R %T\6=K'38N/"A\"F(0_>)2QXO?EDW\HWF(T
MQA#(K$O% Q?0 ,SXN?]6#>]$HAYJK!!3V^Q4+.'0LC"2X+M0E/\ :#UM1&9
M1NS?)^Q4CO@ \UFVJO6W%77#6^0OJ.+/H=:*@[&6-N&9N@E_ G;*\X\.B*\I
M#FPE)HG9\#=WA'9J_^#A7U.4D0N[ST8)\1#$?;I]IX?4N>P#Q 6H$6=%7R,G
M4%O-'S.RS($$8S[@7@%97(-,-9EHXC"?RR^85_42EOEUM<VI)8%/J]="X"%
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MD (+5<C3>*1%BEJ+.Y'P5I0_>AKA F]ZV@9V$?K4#7MI9,P6.76?$*R">AN
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M^L7?VM74UB!.;X_NAVD$WR*+HU>"<W/62)]%0?FS[+OZWUALY2EDCS:*;&,
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M\%T#$U7T $G6VXCS.L"-7!EE0)"UL\RW07APU4OVK/E4NYZ+5_GBBD..\VP
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M3<299E-IE?D/0VK7'1=5'U&6RF&V)GGA#!.T1CC,\Q<+Z:;G+BY7Z"Q'Y4W
M[X-DCNZN$1%"NBXW;VIL?^EMR"IH)MX)5A['T4$VJ8M&5I*7I@49D>-^-*G
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M8$U$!/@MK;]I*N:U"#=6]N>&[U8%U!?7E@ \$A/U^0MH-QC&.+P@I"-B[JK
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MS#/F6@DKD-)-CNI^;!\ 3:#BH5)G[_1NP.[_5[N<^CB>_RE8*KSA;$-DOV,
M_@KV[_QZ^6$3N3]R7R&E?!9T\^5M:X_=X?:U2D#5'CJ819)LGHK#/QKQ.I#C
MI9:O#LX6=TMOEY#;;M2/F(S:-00[V\L>G1, ]EHD#6&:E4QA.R:2NMU!43.2
MSLKUP-+S^YSVIN$\O2WU4R)#FK/*_.S9@<6T1M5O7C5<I17OTU46JJ42]>+&
MZ5W_KC"MU[DC^>P7.0@%1D^J\J8YU^K8J]W0?4-4:FY>+ZEN#EJZ4W>]A6N0
M@=,IH!*F2KP$+>BN3&ZBEO6PB%3!!W#]DF_]+#KO[YP/F5:SEB8&!=@U9]Q3
M$0VQ0IKNH4'#G^W=[7T (42$(-F7W6R]'30SSV2XL,Q:6Z/P4'(YY%M*0#D<
M'00=5"NU5P[<J!$;;TGE=+62ZCY >WI ;#9$(T"(7,OM#V9K5=:2M;<R[ L2
M;9W"-PY-K-8*P>CYO+"1X@YP>(WM]<6E^=)V.L1:\9/<&QHFT'ME74CJYE5-
M3XQZ\0>CBV40A];QL.=X@;"%JQ,L8LX)\E<NK88&ZSQ\65'7<R';D8$DBKGB
M%1,ME7>-C/ITL?Y1D$D'PYU)6P>WY$((8!);PS(&N-FU9$^0>E=5A0BXQU0V
MTL9<P3JR^#MJ&L YFJJ-12)LXS+F9G@8&USN]9:G!8RV@Y4.+.U7U-.U4Z A
MPAL/5#D*;L)3$M=-8\O\?LGWL6197(-.6)F8Y4J,#$"S9DGU8EO:G I'YUGW
M;'1+E1S@P/P[LN)W?E%@4BQQB.!E#38K1[S^!6T*J\A9)3BL_$"7_D3PI&[T
MOS2DZU/GI?_&Q>K4M;OGJTKQ4^G_O>W^L_5DW^ *[H3;+N>=O2O2+CHW_-DU
MI_;R;^W$GP9G[_A581GMDVHIEN,[ >[Y7$%&HO8P!K6*+^HA>,-$S(:=D'*L
M<]PH/B ]KAM4]=8+9W'8-!5B],:'5?V0R<\Y>C0UNX%7FS(L3-?=C_1J<4UB
M!*FO&MD9BP=CNR$79*HW'#V#0RQNY_]$#LW#@(_<[++UQ(>KWF#A:IZW0RP7
MV]?!2+G'*T4O25-[1VZH1'9+ /ZU.B9+=$8"!J3=. S1Y5]HR#MOC;*7'(:7
MJB[AYM 9K29FS8*\+'4,67B'G7YCD@B-(V23"TLX4OD"P2PG;WRU*R\$Q NJ
M*5+E.+"HHE:7H2H=V^X*<ZG:>T66.L(H:<WY]I) OQ;GW-KT)3-6,-MLN[A1
M+HSMF@;%JX:#\;3ZG4IK7_S-3N+S?0)Q*[U!XAXDE=,E2=%/DUA?S@?K!GD+
MXHCC#+*, <.5QIVOL(F94&ON)B6-:?%G])F#Q'2P.I,)CX3V.(*9&9,)"\;J
M16,OGE0VN/K1_?I4F85X*>1_4JP/%5 3.J:P3@+SZ9J0Z!X$ S%E"$QTXAZ/
ML?7$;:5/K4^J\3=.T%6:IP.<'X^NRY"S$YG7ZV0^8;6[=OZBM#BS8(47LHT^
M7XYAW",<$(M=@J,!HJW6_B;JK&L-XL(&4?;L!I3<J[AID.C!Q[=K)/0PYR_5
M6KAPU,Q2)BF#7OU8,M]&^4"*^.KCU81K*2;2(C?D&D?,4GC@&W:Q:O*=6K3A
M=@E%%<MNOR%;/!L?[-'3J/+4:RL!P WC%(=7V&#Z5)VO(!R#T"D@T%9E6*V2
M+6G@?0!:8*;BU<K[/@>[S<6%^/J*-#?WS;@)2S@#;'AGQ^(V"GGG,<1OKEQ"
M_.NOG?'ND:(GU1("GIE8U#.WA8C/""^SW9>IG&9MEQ-Q4B"GLK[S+#HY/()#
M(7'Z82)9EXUQ4H@Y".8=;_6BBDD"]P]TQ)>OZ]K<?X58,3+E\%NU15%9[06
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M-%O@6IS@$#:T]T#XW6ML'3!^<(RUWZI_T,X%CR3 &#T*E#]K1O?9X6H0W;Z
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MB$WJNMB3.VJ33JMM:]?^3F82YTDG;?_W^\<T/CY5#*)!,R7.^*IHSL<BZ7\
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M_<6'$/O:0QV4)1HP4^,]7'G+Z#ZGIK3XP4G=G/XC0.AG)_5\AACG*0)AK2[
M\])PXHK 29U<A$2:] QKV>5U4&UC.MT@R)8]-8,[UV3=YNQU.WQ7,XJVW^=K
ME6/VH4GT [6*U^H@UYLN)(MF9RRH59Q>%)=ASV>?:>LOQ$D-?6A624?D1")R
M#H%N1$7-IA^659F1TMD?',YH>8W&WNS1(>-*2^2L;*T$N,[Q8^7QX.O?$=W
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MXG,J_:HG95I(WXYBINR4]BKN<\AU7(49LYR07+NB%034+=UF:^]D^K-K]]D
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MXLI44%\--=#4Z^/"H <$IML8*OFDJL,@N]_7=2>W+;74L>]@W\BU6<\_P(/
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MON'XK[ORW\S@J?^3&>P>T;*N2WQ9H:S.L-*%&F"YG5BIME']Y@UTQ\DZQ#'
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M0J:F#UMWYYZ>IY.:3<IR>'D^&L\92=NOK1V*&"".K'S\' WX,A*4R.9E^&G
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M89+J.DI[N&UH#@N<QCQD;?%\!XQBK]_A='MZ+D?DX&6>8+P[U#4N+8%;X.!
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M=XMM8K]6Y:O5(!<HP>$6=FL DUVSX-?H#@&$:_M$<GR1W7%B@GT&G?YJA+_
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M:R2;F5CSX/0>$]9VS2RH2#^'3:M+@)XK6H$V;_C4: 11V)+P^G1/.H" <./
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MAP:&$N+WD;+#4O*^_I2O573BY@THIBR9N<R89:UB^NW$'$ _%Y.F2<.TR-$
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M\G<<2WJXVY5LY9W*L7<5XSI[QHFTAI#S%TPIUV4_:ZJBJ>P":!KHS>J(HF_
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M9M.R,?\[Q=IF6<_=[W=/B(@0^O&$(T2$$&W@KBA5\P$$7G5GV85'\W$SC<?
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M#FOMD@)H5.<&BNY?/H(<"_M*VGO_F@+YF<05CZ/=^L?@71%NW<O>:FT(#2)
MMKZD#@VX):!T?W;#ZGO\KQ5=43N<1<Y(D>'$:\M))S3@ * >11EQ%Y':1OC*
M\2=Y0$!>[I)F4FB@@0(:HO-A1>-MBSO?XC89:*)8 9,^M<-/:^(@Y^LBCF!<
MA ]_0TX;=($-#0@I'>B_JA$Y#;OJIY/E-"B[;))=1A5G%JK E=-.)0W.%L40
M!/NL,%0TS=S(/EY+7,NRWDCOA,"[_0SS<XL;43YJ>Z'EG4T[]XZDMY"*$_=
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MF+YOA9[MOD^3DXN#.BKM5SUMFQ3?;U)H:FN,G/NJNO])\2$DNO)"GS5S.45
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M(8%+(5@$! 1$A$24Q,24 G=H[PC\JU_HSP#IU2M/L'NQL9B *Z18V*18Z Z
M 0"P<+%^O8 _O["N8./@XN%?);A&B.D O0%<P<+&OH*#C8N+@X-I#<"T SBD
MN#?O\,OAW=)^@L_D0B;P,C[[*K-\12NYSA"<1?"I:S#!-8K;E%34K'?9V#DX
MA83OBXB*B2L\4%125E%5TWVDIV]@:&1L:67][+F-K9V;NX>GE[>/[ZO7(:%A
M;\(C$A+?)B6GO'N?FI/[,2^_H+"HN+*J&EI36U??T-;>T=G5W?.E=WAD]/O8
M^,2/R87%I>65U;7UC<V]_8/#H^,3Q.G9Y;JP &RLO[S^[KI(,>NZ@H.#C8-_
MN2ZL*UZ7'4AQ<._PX]V4T\9_XG*+2>#E53+Y^.R*5@)F01TX^5/7H6L4+$(+
MK'N72_NULG_9PH+_32O[Z\+^:5V3 !$V%N;#PR8%9("3,_:<H&M_E']<6O<\
MFV;IOTVNDI%X,+_)TA$@I$<< V-'+A8WL2)!P[M&ZHJ._M%W\;S7D/R($9/P
MGWJO%J8VO^6-OX':_RBG=>*@"6(>=)*[N,>Y$UU@;TZSA^/KG;JD-?1<7E]5
M[/ZR.\Z9YU*96PS7IY@'R2P)]XEBLI/"Y$D4'CE[E/!(HP:Z%I5NS?(;)CVJ
M<8FI6Q?+^<G]AJ\)E&M;-4B\LJ_ @O4PHO?':3WE4F:[L)#O<0IOG+"V#_7$
MA\7GN%BMW?[TT/X?DYTRG=%*MC<$Y6RBZ95G6-A[3KK XI)R1%ZSDM_<^][J
M/BMB06DS<+60:,\5'!SE]/ ZVL[R??,PR79\7MAUP- 051K2DA8TN&!PQ*/?
MK5)SKI3M1DOZ'*A8SI3%9[G@(NP^?J&ZH!Z94)PXZ9A H$P4]F+=[UG1YIE3
M>;%BEGT-OYR'A^-5+VAFT,I;5\&7F7VU>11RGDX;&9S?CMXC(XGEQ9YMTW Q
M,V0]%D0\.BMKS+>)+]D4B?_,L!-,\.P,*\'^;:9%9>:C"N=;"-\MS?K0)\=^
M"1U=-!='7<JU3&7VJ?H5SHN%_G)YDR9SBR2LD)7'I4UKG"!L-##>+?3SMHA[
M.:FM^.Q"@86R!/N7A^2/I3SCKDMM3)8UYZV_@13.*N.A@88"UM@A)0TW?>/5
M]UZ+]JK"CC>WU,<,*><3S*9,W;N4L#UV.&;I(B30 "TB]'A#7SW2Z":E"-&[
M\8R,]]T'1WF/ZX<VC(]3(+GWTWUHSZ7W@_3"OJO@D]_-+/YA5R)HI+'J<Y/R
M(RZ5VJ?->[)EEAT5>6%12 FP'85$Y/M4@IHH*JUYMZTH-,"G%I#;G>6]9!BC
M6SEV/&'!\?/:&GAI=.AQ_;!B\0]0,2B_\_Y6'9EDQ6OGM[26'RQA#\<<QZ/]
MQ9Y[CHW8Q1,\F@_1?T&2S7GUPC[IY4X6_&[CHL U<SLG,Q4V#BK'K$"@=L.@
MFBO=KEL6"JV&VZDZ#''P763?.'"5WL/Q.BEX7/\C<DN_0N2+N%2A EMJV M.
M\?@8Z-L6 ?CYM,E4_L=HX:XY#@H1EIUU$MI;&6'D(3FV9_GI.8AH/B$T\,E8
M+9:G^HIUW%V]6L"@%GNXN@GK.0X]485UM)=Z@X&$#T_=/ H@Z4V*,]UDSXE0
M^+_2R(%QJ-6W0W6(W+C76QCGVB[_/,G7B*$R@T46$IG@G>,K#QUB9.E>$5WJ
MXM,);^F#3OWXS4#FT9TJT0.FFM<AI$4;HS=$MV.[(%,VOK6OH9'\>=-F%ANW
M8"G"36%W22]V08' 85FY4D/$R8/*^J!7M'%%E-O=H/8\$?VQTFK#)\G'2GJI
MVC=Q=3HJCFF'/"D>I":7//EH$I"KU1 S*SE/(9FXCJ\3F&2@MB<=#5$;LCW9
MZV>*>LO9,W%,A"43\OA4>].";$4=:G2SJT>JR4D ^Z;T8RD?E/E;V U+=1,S
M&8,@;J^Q$YN*'CRJEP,&T^"C"YM/INN[POTBH&83]<;JT&=1O=C!>$.C.UWX
M(..B D2CW.B.\>R(3OB*EHD]UUW9K>C/SV.\2Z6<!@C10'@JMQ=_:3RDI*6+
M"B>ZX_E>OK]L56W]:),XZQL& ;C\6KV\ ?.&8IQ96@U* '[T'5X9]BB\X-ED
MKCVNY3IE%,- 99,9]PM$0=M^[Q:MK5#I0#>6TNT$VT!FX\^2U#\KF-)\F/D=
MM>[[?W;9:"V>O5<=J3,NR>'HBJW(7=[$L$BI$-M-F?^Z?XN/TANLU421//E!
M0TQ"S\C(BT%6!4"1I2+%']6>2=B)"+0+F&';%0JP),:0]'HCBVMCN'GRX %3
ME/'&W[$_]]ZS9(QMW-@PHN[OJ'5!W%UU.*V<?K";J5.LP1+JD9)ZG%(P>Y&P
MLW<GK5?P22OV,Y?TB6[M$;%"H3ER&]_F+S45H\S)3CUZ;S/SYP41^G@EUK@G
MG1K\O,Q&-R5N,>I3X83Z!S:-M@B%,X])BKA'4("W<6*_8B=\C!'<T.SA=6](
MACS)G3H]"QGUW,O LNP+ )91Y*"'>^9AI:8!&=U:JL^ZY,FMV-8IB5#D2>5F
M-L?F'-"&NIASK='%L!L_3)18K@H$!M3-GZ_!2_EN6$Q;(&+;:T$YTX:.S0^,
M"CCI6JU/U6)>2%W8J- (0<LI)R>\)WLG-11S*FJ5;]LP.^"W3GT@RLC-5W28
MYHUU681P;NSD4;]\V5\MISDN?UWU-$"J4^L[>#G?QN)HFV_?3MCBE"/U]H6?
M.C+U)<W? SEJ_>:\+9O^ G-EZ<&F+/(G1SI8G6X9_QC<<O\9N-*GZS\OO[E^
M;""B?R+RA:PF^V'Q9CM-J-)U,;9OSU+4]NCCRP3+TGT3Q8DJ'Y=@;84"2[/U
M_=*]A)D1#1T'2F5P.=+8%P/#>C[T:&!)9[."A>&6.\=3K5A)@=(\)9&@ JHC
M-+"E6TF8GO3BMIM=H. >^>I[:]]C8XU(AU25J@;]=>55DEJJU<:S!23>EF,Q
M(E(S<:5.O2L1YW$22Q!XL/#CR[A^^+)MG/#8R^(YN<!7KKLNT#TD&^!QTG-<
M5J70U-3P;7M'6,+-WJ/JI&>)DAGV22J@1/$=9_+3*R\30'8+_F;EK27>U.K1
M]Y_? +VHV9?@,"4Z0+CGZM/06, _>-MO6SQ#C45^'9C>=LP\&;N/$BOT]^]%
MX8U2J5AS4>'0!HM ''AC"Z)I;3.M(W\&F@_R.5,>G9T,&A_T%"1;O!9_JZ-B
M9>*#?#=QHLU$BG#3P!;OD;1<.*?Q4U>/UF1]]R#B,][C NQ@6<; NPW"J6RO
M'U8R/S!X\6*.@\XM4ZVC9K@T!V[\@] ;F6B;;):[ZEC/'7 P8!^9O..!D+#*
MT<FQ]4]Q?G! $UL :-N'#'2C;L42!Y3\G)L<\GD_E0ZI0IUUS74+5_@4&F\<
MDP2XW5.WTNIGQ TE4>AR&\LV8P!1BXY(]]V>0#9GF,_R;QWM9D _&X.X803"
MHA_C>FKVA?@K=K+?QK:GZC_D]=CWGFJO,)4D+KH33U:%$ST%$&7(=M,G)<Z#
MR3J+T]),2HY3S]3#6:*I2,ZR\/B[@..R5^TU+XR]O30BV$=Q:Y5Z+!:Y$@(+
M[E8$TH-[, \#JNTF&E 3^F3G<:BM>">$3%L6]U];R,.7"!LC2?#M3CPKWY7=
M@7I%CQ?'B0I'PC/U8>/2=+;C9TE]TS,J5G-<&9JT+\^T\.T5R;2P?EOT/.BD
MIQY]2NW=D8*K-1J"M7<XOY-A?>Y< %&LST^M9]R)_.ES>G/%5<L7T M;B<VS
MLZ$G3>[6$6^I")P,S3>PJS^ON'X.%MP8W3/3(]OAHM1/Y?E*+P ;HUJ\?T*Q
M<9.=S9N93HD_1LIF[W;8E*&]2:-Z9J7=?<<6@IIEOU"Z5L@D>]U/U]O&^&_\
M99FAX^7<3"/?7S7I<Y[G=\NJNS.HP<J\?>W[TG@4U.K5I>1[R*,JK>E(X/<.
MT< MA#N9MHOA,F\UR0WO5U]JQ\NJUW]:QJGL&>8F<M!A\7P+X)PMR;)  XZ\
MT!RS=MR%R-YDKI"['&_=!\1P_'ROIY^IL=<9KNC*C@F;Z?>>=-S6-S=+/(V;
M^L'LR/<CW"E M&"3GGZ4<9QEK)JPQ-OIN5;M#=,B?O68,*X>F;5Q*2DR4VXW
M"FGZ42>/.H_TP,U9DT@/+F=GNX^*]+X?:EF&EAB(IKU#:72M)5^8/O@:M:-)
MI'FO/<C5-Q Z,J38ULDV#&$90@.5&8R.DIELST$IE,BM].IA2:/<*4)B":T1
M)^Z1E?!=TH[X\B?[<)==-#!6UA+!2R&V+='.4[#>$(6WMBT>@O#,6.CZ-O#Y
MY>=U/'#F<)FWFT::,OPH(_/%4/6G;'W^A$?[("KL,:A-GLL$AHX _WNIDXF:
MVU?SB#W9AAWFB .[[(7<L*6V.50]WSZY%$"FK?A_+E^R8U8)&-]C=S(E>3QI
MQ2\L&)*EO0%W?B-D])&>>ER?QD#LAFG4ZS/_4I+Q*V6V@20MB7IA>GOT!<?G
MA=>?A.,Q1YT=,L1A%_C^M"GPY&).'T-*N;D5MY9NB*@Z%LEG&!T8\/=FSCBX
M(=# 47$A_+BBU.Y^K31S0]4]8]$$+A-6QYBE[*?3*/(Q;<6V+O*Q2#>9J)\>
M(=XAS<V-';VJLZJ#<E&6F<;.;PXETI\>**?.JN@YE(WYX+P.?D0Z AQT0YTQ
MGT876Z207[17^\C&<?E-=>8[>#KR\,_'^,.%B)1VD8;O [&LT$F3@#=50A]V
M=$-:M:-HR===S#0P#P#FP25Y<]2ISF.'ZA1:>3Q,*.3",D\?W?ARJ]/&/I7L
M+'HVDK5$@5;_-I.! 8M_+BTOUEJLW5Q.9$@41[7)>TE'1PA^Y,\A8THJ58F3
MFZ"'EK1G0XM2%&L&=<-6M=YOC699]GU>1Q7^O$<BW*AXFY"V*R]K,QX1#NV_
MOCKDQ/I:04C$KI/R^FOR97>&)*W1)I[RS5KCP%ROPDFIF;RVGIKUTKB<8(+6
MUJ>JV!#/4>T7%?U;9W<+/$HWSEKBA8MGC+FRU;.FJ S!5?W2CA1G2YW4FA"6
MY'-'QTFQ[ZI?7$EF*#<2I\<5?MTX>V%;GMA5PUZVH39TU8/0!;<WD:QNW;7I
M%2K U1#AIUT_MC#F<5[BX\0S"FEN+HXG\]ETG4XTNU22)X;KM?=G^;X+>WE'
M-T]K?[3[N(,KB\],N;VEE)LS/8.H4OUNZ?V:PI:IIU1SJ>X&?Y>,\0QFAX+K
M03<04E >10]'SM/#"PTEHLCTR@"74Z\EJ(>[3MT  9)OB5A/NJ_4.X+4:EI\
MBN_KTC>,Z\:V8<:"HAK)AX\?W\Q6ETU[%-M4(#9S-"A<I2@1T<TH5$[%$S>"
M5Y1_\8XOY1C&@[Q(%P^87L(X4?I\_G=O?][W!FNXZS^N2W@J^VR6,C$H0$J*
MJP SFXAPNZV//-E<JU<EFXX'I@/U0@J\'Y)@%X0=B2@YW#>_J:)C^HF9T;UG
MVTR1S-13#"O/^XM#Z#MA#9&?K?XPZ*GSVL^-D9TU!E0#U&-!+[958)W:C?W9
M0X*[HM-3+UGFJ3=L<A8KS-OPH2,0Q^G@/?DWG;XW 5H#F84+$L-O4)IW^GX<
M0N\+?+J)[N*&88_0<17F)'7]BY3SS^6Q=VT'#!ZYP>5!G^E1:-K/&$IH;]4G
M$>>2*==MO((BLS\[;O"7GV5TY<UJOLHXV =T>5X[?(K%&'==W" -R2<Z[O_"
M)1.1QG"!%\2_..JONV3FUQ$ZWM$M7SN4Q]_N$%_$$Z2Y(8AD(P>K(9+\I6^8
M>B>C6!*U@I6@\J\()(,6#/UH44F#",O6!J]. NCNC:T4MV[/\01C[ON5/O(L
MFK=?,'A_.#DL[4LKB1P,/BO+0)E^0H#U59)M= E95-H38Y 'LG1W<T5B)&FR
M?B!J3CJ4=:)314:%-NX0TMI<>)+V=-F/,<.@"9-42,3WNW),3H\%KO:4$2[&
M9#NRM6Z%*>O?_M9.UR(3G8:#I6N7250]1V%K?.?[\^90/PG*^2FB1E_V >4R
M&VS+;@//_GDI%_W%FQH?WF%UYSU%8@QT@FX>N)D/%66WTJ0-UVV?!(5 ->1I
M9E3S:FM\;DB>XKR<-M" J[&B@1#=/%<?'Y"%$3'@RT,VR!& !L0E\TZ0ZUB'
MNK^N^RES!UGX0P\OK[F]%N"!( 9%P<MK[*^^0,!_VT'CN'L?0A"@TH07V":W
MT,!+TG&/%3[8FBE;UR/L!>G*9CE[AS54"W,6<20:(/^Q[IGJVT=6Y?.-JRB6
M[IZ472R2.UT$Y;\# ^V5@NB*B]<WLP >62"0O-O D5:2#?>N=UU3@+'P!V9[
MYA&9!:L-V,&:QQDXF@%>Z3YW>M!P(=/5-! QOED]X+QMC%+.![=]&0&O#6QA
M. +U;[K[I),%Z+\#VXWO2T7*[YGE-TL.*1!54+[E%[#\D#I]<.M\ZW3\@[\P
ML"ER2G4QC%GG873)Q="I ;%AH48G_>S-TN(AW>2?('Z9%E@Z_5-P %C<[+)=
M&PIND.'\NG[K*VBW?$WY7>:<Q4"*'1IP#WSD:+$3VQOT1\,?#?^]&]3C-]DG
M83,,293T;X'JWY@5\M@<[^<@^,58GHOUFD\JQEFVR?P:T ZNS8)$L&.'?0\D
M7Z=.+G$I5+R?7=#O@088""U=GZH&J%)N[9J<.8>XFW&U%\A!*Z)L?^99A=<?
M"(Y6[( @#AC^>#<-GM*>ZI1K[UYI=YMT4N:]H[V+JSEEV@^7*:B7N[8L[6ZL
MS++\.'BK%[1BB@9:^4Y9Q4%C%A?$)5E[:\@WQKL7/JK(DDP$!I59"E3/^M!
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M@CWGCMJ3FA04-1P98CXY,6.7HO;B3I3[0\Q&Q3JK-18A(G;;Y[ =G'].1_Z
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MW)L)H,WX8%^_[[OT&^(/+?"7J^$_@OVD> WSIQP9$W?NF[!X2"Y_PS.O7X"
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M:&L6QJ_DDV:)7<TZOZ83T<U=#*HKRR,"L=8G7<C,9UA"DOVLOG/LFSAY^)W
M>&?UN;H#B"IQ='Y("; GG%%^9.^LO5Y'+OH _PX9@Q8[^^OEG,1-1=IW&>IN
M7&?NY^U3UAE3:3] "5-N);/G<RGV[K5?0[EZGL4Q.4W[6AFX9'FO*0[[2TYZ
MC$P3!IG25=P4.RD38N+HS7GUDVL$R6QM*_(J*F&R;3_P8-6F52;=;3'7X@?+
M<GG@'!RDS%V2TF3ZP;8O,<7)VF\.QK'B8M8I&:)5X[O/$:95J\_,T]H]4R)!
M;KBM)?:30[*:C?7V?EG,0Q"3FAI&ST!2^GU2U1^*0(DY:P8P,Q^5A88(UU9"
M*Z(/$9'G2G/?T<!N:C6YP4XA@]Q?/KWL]EN]"0DP,YGY"/+*3GU-]X*^O!3Q
MAEVOOO+D,>:(38ZDB,00*C'RV\?1+3*QJ-,2.;W S9>'9".TWFA 'Y9T,Y0M
MR?6+11E&R=,=*AZEI7/4-1JYE92=^#>@\+-GO3-&M!!@[DGW ^;)-SEQVYQR
M@'L9-NIF9/G957/PW+-FP0ZMSMOM/6.B0^2Y;^** ;8K3>V]L2B?@HL#T[<<
MXV^E?O"EPC9]Z[YJ7DEWGI5WE(((0;9V-@TM;LQ6$]\;Y3WF:#T=L.-#J/'"
MUN_X8-RF5*?OA-7LW?D<DH5H8"T5/"<\(BZ<:EHF';B+O#68&_69C<_^6K2%
MN@87[^#,]]-DF07&YGW)W6U"R/ONL_;4R'^:6QK4<WOR_IEE!(A7YG0U\Z3_
M5J[15%(G>*HY$)X=]9G7V?Y:K($]1D[X>0-,YO/WX29MGHSLYWX^ >YCD8R\
M(A0]9P8N&*A7;[>8:T0#,+RZ6&)%V@R6D5SO[W%?L?2I&)*\4&S?'?RE6!N(
MZ<><16^E1_#'MM7S/RH1#Y>#-();I4S+R5_&T.N64\GX7)2E&OFS7BAW42NE
MY!MOWKZIOFSVN+.2275)2D(?A.3A(P8'[J*0U%\3%VG=E)A3E,*_N>L_ED7R
M:X/;W*PQUNJH?!FV8-1''.$\4SN#4?/UO/<K:C)-&C VYXOJ+6@LI2TU[?W*
M657>J;R9VRFD8I3X,A!KMDX2XL;B<-[01;R'>)6KB##RMI TI0C99NQ/HLC.
M!Y(>STJI_&4<KHKA."X=YA@ZZ 9N0R[!D^.9CTY(\=VYQ%K4I$?J6E1U+$D_
MD<&P1HO5;(YHI(L1QGVY)2GAYD9&P-KC0\N4'+1TM_(N(H1\0/*"@LKS<+:U
MXC1B EY3^[QL]F'D1Y,I(4Y:\>+$\0VU/*('%L+#YIEPM?:E_2^=<IWUIQ)\
M%RSU$,2<TC<^_>&CM8,(_ X7"H :8KE'TWX6C:1X\<65]7W;W745*BFN_-3A
MR857(&>RCT17UFD8TN]+$(I^D/2,8XZ)J@A2M%HR2-TH\06WBEOJXA49:Z4(
MUZ[JP_*BZ"RZ4^G#"YNCIP;7LG"#Y56H-OH%U1$OL^W.HO3O#YOZ#*\Y(53P
ML:7L<Y)[Q[SFA*L%[O/7+^&@JA4M;;%W0\>N3H-O*F'E)I<+[_S:'O*'#)55
MK^LA, 'H!;=;:DH'#[[:Z+.*NH3Y?H+)\SLLV$=%[F"Z]=35K!I]9YD/O8;X
MKX-<=DTJ)R8U[O@X/HX?U/=N%?KT8W*J!>&8'?VF2^<>R89\M+G]C G&+(J_
MD[&V)G S";2V/S-<=99F\?;M.K97M:H7D%^A<<")BJC/\1Y7VL-=FIQHFK6[
MN\_RIDS)Y<+^F3HAAVE3<IQ$1NE0,&A#,W1X<CH1MTG[5BO[2[=3K5R#U.W+
MK2$8;6WPC&+)FWMOC$H64VVYBW E6 [YV,!#0\XBZQ+G8FS,%N4>'5!@PG'W
M*V$SLB=BS[B_P+"1PD_"\ZFK:KBJ3)XJ,;2YQ?\-4Z27V9O;,DFDT>;./I>2
MKR7=<THO:E,SFTZ",<<Y1TA3ZW.MFM'26LG:FZCNA<9#C&=,C57Y4NQ$U%N8
MKE(.+@U#KZ<]5KW;.Y'XY2XKANXE<]DPZGQJI[6;D6<$4(^4A'5/4FL+D#=*
M='$6[%XD!+J"#C$\!F%L3HVZF+M ")<_62)FUA[FA:JPIOP<JS_P>B#WO]I[
MZ[BHOV]?>!0004($)*04) 5$0)I1D!:0EA:0;I".$140!$9 D)RA0TJD6[JD
M2^GN&G* F>'YC'[SGO-[SKWW.>?>WWG.^>/S>DWLO?;:L>*]/VNO34VS-ET&
M+KD#7FF;P*!YD9K%$XT4LNQSX<P2:IH@""$S;>[9(. ED8WDOG)&3[+ DV)G
MG %-VC2X.W:\#>C7Q@)/7Y,,U12E I8H=,0MK1*R*5@RE^H9/_9=TPW'L[V&
M.0WNVBOX49_;;DD\80<\1.H18XJ/6('D'&X4J$MB*1O=TW=;!13';FFM(/JL
MX6S7UK#6)(,W^*/!/:6C^_;IQW+NKF&FI>>@$H%ST FB'% M7!A*H1^S=[TN
M4:.2S+K'[V,[[U;[BZIFHYB+E)*AWU+%Y-^(&NVTT<K @AWSE5@:S"N9Y,IO
M/8V&S004@#=[P!A?^X:=+L"??GRTJW Y<"X\C?YJ#B<8Z'ZY1]19PVR@8ASK
M0B?!;;\_J*)^HVJL <Q4QMIHQ=@]I<4IHM\5%/S( GX.DKP_<[P$:<J*G29(
M)^LF<F%:+4P)D K7%^O$.MUN=U74G-\4C$WKG5JY,&(9A3=X )XJL<V&Y-U!
M ?8MV)Z"LTM-^MX\=V0[N, F_-Y7NG<W[*"GSQOFU'OL\;Y>]&3^P/L *]:$
M@G8[MR&JR)N<<6S"E4W:&SO</OK2D=!Y2-!BY%6%%U?N/GF,3S<*JUJ08&P^
M)GOHN^\5E75(UJ(?$5-8;1_ZV?Q+!1')0S(>N35U95M'IX>PRYD30]Z7VE<
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M&&DA9T6H5E=)JG-09+K*.:BPJ=HQ!() 9)^#JL]!WW18SD'3S&@/"3WP-CG
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MO>''3JH._5].0&;?[JCB4!?IE0]L+@SE;UE6!$%*'KS/$\5I>BF&9L?I\M5
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M'SOXR*E%1\@7@N?:,O$#?4G-,HRW;>.48OG"BN[(KR **_ZRM^0Q^R6_X8I
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M3:F+@4D:CZ<1!MS3-;8<^9AWG6CV:;>M#B0T5HJ\SBU$[W#1>2CR;@Q=FF+
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M"X#8Y5A0@. [6G]5Y"D(9 89_K;GRKY]+D7NO)AKR3]-,,@&>D%MOA<5Z<.
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MTU(:?6L,#^ITU7")+_)S:>.\:F/KZCL<L6VU1 ?\@&OF/8:K:8X3&NN'YO@
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M"-+OCGILZ6(:)T7U<Q^,\;&]?V4,LJH[BQLIFOUYVZ3A0&KAZWE*;FXA77U
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ML9T(-N_' J\/28MHZ.2"GL$<6N+KH83;J(P-:RU?[28I\@]FGP:-R ]+<V0
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MCV=/R[99/K >R8 *Q.9]2:'3/X15:RP?$/]JPO@$I^NE7[W,X6:?7>8$FXP
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M;&IA[8U]X ?P<LDVC=6.7G;!/O)ST59PQ<#-[G@O36L-G:$''Q-SYO+Y^Z!
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M ?A>/FB__(78;E,QIK_Q0UB:O$?YH=8+*)=R#FG'FJHCGU:]Q%:)DAVN9YN
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M0&>/!/" '+"V+=G'JVTA,-.1L*!^><;_ SO?^\;KM;'DQO;]L4?)ZV\<3_%
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MMX$]<9R<*&]#3N+*BPR@[ Y/-4!8]M[^ANB.,<>CU/S/5[WT)_C)G4*^%YU
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M?R:]$?1]+(F*YOL9I,KY-I*1)PK2"0MIXBLOQ(S<&4*X1VI-M\9M_&+\<9E
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MM^C9G"(\8#DU9S$3N^<5SA4%<GT$NZ[,HB0:<PV&M&QS-<)6TWV^B7)V]42
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MO;];,&*3U,)X9)!X]<KSVM ],5R=E_]' ,<P!OW4K'1C&.O&&U5/[O92:-L
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M0=P?1" D!:GZ]W M!V??LF<%BU(^?!J1(,K^,V]%_#<Q4OS4_P-02P,$%
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M6W/-4<3/!X0Y#C_7M-2VU^FE"/ZT^^*]GT",4QH0X,^'4$^+3^9,)8]U=+,
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MFI,E%9^_K<7@2+PE15.O :A($OZWF^I+4KD*-#Q_7) N$TJ,),7+'.6^RKX
MZZP73ZG\U+;_OMA1D-7H;^$"47>3" *<96)8_K=7-2  9OZ\R$5ZAC(\=%7K
MLE]%8E]^FK2I\H53@:GEU@_9M]H2O4<Z;HL$V 11P*I0TZ8%HC:3X%^B/4O+
M+,QO3?TE8QF9$.,0,\(>5UV[9LH^NL8>IS/L.S;DLSK@&(N1 O1U#9SP.I;*
M[P& /UDQ6@6))%UM")''"I88A\1&_S\+2\=D]QX6X!B5H8>AEU+U !:G!'^*
M0WPP'_Q;0'AZ?JZ;ZW+]#<5-?GB+28$V5UENKF*B6Z^2:DX"R6''VCRN;H.D
MX'Q7RP:64WIY[E7QK7P?6=NW"W;V6WZ5E@< KXCY,NY"/Z6/@HOKFB'Z,8&U
M[YMC^Q"VE9Z(_)PN^K'1 D[AOF7+"6\.DU7J8*@AR_2A7<[LPILT>X5N5!3Q
M.0"J']].Y)T))!\MZ649;,H N>[%1K0&/=D5V.IFP^T=S3TWH++G&X@TBS!Z
MH71_DG./;5#?'K6*WDLNRP8?F:C1ENR*N=35[*2.='P >)/I!WJYNI2VEIX*
MJS:VDWM4(U_NOV*3WC,"GKY[1<T^<G(<W<_?B=SWC.@RNJKN;:,#EN,.E+']
MV'RN;NT_K5/ B@(X9[1SGJ*9IJ)IF-ZZ$C1-SCF>EW]61!^IWA2YYH3VE7.[
M!Y]3FE$(TSJYJ1&_AY=X,,I#K5'LG#0WKQ]9ZNN?ID-I_+_)VZ@O.#B&/GU/
MSRDHL^@)"?5\*:E!960<N=F4O'&G\ "@KG@ 0$5WK3(Y'B/P*^8>M^57VS=/
M)GXQ4,E%J>G[N($8[[[M(X,? .+</XGC\416F;?&OZ9)$@81JD@"_F<F+30!
MUQL0*GG%%]U<N0<8*&/L-,(W/O8M% ZP&C&AZ]WLTK5%6@<$W-&3K$';<QE[
M6VUVJ#"2GV?87!ZP02G=SL'C)LBGAB8/ (R$8+/B*\U+:?\3XBFZ5Y?FVC/>
M<[<QM9%*[SS/2XVQ^K9>6]_%X[?!,SY!>7C#O,NIX5=Z>SJGI1'],._%#*^(
MA@> 19D7E'TM G89=<>_,I2T;D"V^2%=,E(\RXGW)6[]H.AA-B3;+%MWVXB"
MU:;$4,V&E30;(JNKQ&!K_^/50#]IG]>DBN9TX4PB3W;MI+ =Y(0=T_)#QDLM
MW9D[:;8>J*S;D1AU^F\V=8"8,BZEU[KC>0FPU?!2_8H%3+FW[V1S_K0>LA+Y
M.>0Y/6.[T89T]2P4M\1JQ.[BFFI?IQH(<R';KX-,!13HT\M4% Q@HO"+!$!.
MQ@BW+Y $DRVBJSYTN^N[50KX"ER?A^T"WJQ%*W)TD%!\N6>VU>L64+CLN_62
M3^&<O70+VE3GY%MX0YX:$',IC1K)I*SWO5C>M+;I3NGSE+VK? IBN[PFJE*O
MZ]8V_U9NX")PX+HN4LT/![>\U@H:Y>$E&=5#EM_CP]9Q?S]*SWBE+Y2KM/RQ
M!%&.9W 5W*6+[K_\M2GU]#[VVG.![-,<Z1V \7Y*Z<]"J%:-'10\.BL\^#@H
M%&&)QV[!*X(&_(<UOTNZRY(3P>8$R^])G>_'_=80NJ(XV=-G2P363?H)A29Y
M(3TQ.UMJD3O[1O21Y [H#"?"_.?I"N]T2SU/YLX&F;(RY_\Q-S9$0020^2MC
M+_06K;1$+=(.)C^ V8R8-4))OD@;*[ T$_ 72 ZDM7ZU\GU5.<FSKZ9=G[!2
MQH/_8HC^K63_Y4= 5$]RT .@GXIBDOU-U;2KS/Y!9H@\G8"H1+A).,>Z Z=/
M0]'(,7T7UI?Z?/V  3<F@#1[#+*/%^4P7$WN4^-46ZFE0N85H]S19GF!]8=G
M#I=_3NG<U,A,MS !:+B%/"GL7?L8&S\EG OA.HJWFU/+S2SVM)?Z%B>BGS4W
MH&$N+,*8E':VDJ+5YE\J1T-&,?C7,#'VO!PA^<0]HA@*/J^3@75M-E]B%9=_
MHC+B2$U=D;FGK]=*S;KQ$BM4*[#?<K!-V+24,XBC#U63]&_HB! >N24MW\J'
M^?#GQXW%>0T(OK5[!OB-^FULT]J H(\,/>3@=8#L='9#,FWC%/!M_V>_#E.O
M*-T,Q>-7\<42GFP1T.0$56YW]"&SN:%IIV?@%Y.7"8'OI*8T3SC.P<$PQ>+"
ML8+7H[_RY_7+AN*,'3<P^AW6T/D/$:K6OB@3KNPO8%?>&/LVMCGX?6SSS^91
M=K4IMAS?E$2177E<>2.ZE1\ H5_BAKBN.7WVULC=#NZ96<#4'KH(]3"% )UO
M![DT=($V^"#L.7B&S9:0VN5 +36;8CAV$6"/0UX;=AC&S8Y-TE=>T&\S>1):
MFQ9R#LM,]9I98->HF"U1O51HBMQ<N,();O]%*7;!\\&M,9_;'KBKGP5Y2_B_
MRD9$XK>R <KQIO'KJL4U-O1WS/>$*!$/@.<S&7?G&<@;ZA7I.WI-\.DL^'8;
M'&@S\9%DZ2A"YP$P]FB'OY!$^4";A(0!-#-(GH->N?[T]/^6*3][5;HBCPTT
MG.(!#MA]3G:V"R(R.QFRX*<G9:1QIWRJ"SUC$<6WG-IQO[T+K9"7^FA&L_Y2
M1NCQ1I*"59[T92FI;;^6V1C5)LX61%:!'3?61;!%:2:=*9+^X6>". M%PBPK
M%_$Y5T%L3BRM4E[KX=G"(_U)F['/67O"MZB^XZ 3S:J[$_0#;=EZ1NJ8HILS
M/CY3$+&H%!DE;HU44[ERSEZRYN6M,-@%.2\\KHA)[?EK*]&RE8##*4H%\ZL'
M0#<0>#1RYH.N$#_+;_+V:8LM/74*PW&LSXC9G]T' )Z0%6%R60!/4'P>NMFW
M-\HC[]$IY>KS1+]K&:U@Z^DW3YC']5P\Z=K\,UA3(IX#$6CCZA-,#RZXJ!^N
MM3<A&A#,*?6M8WI48C@N+HU3A_EQRDFV&H98Y&'^XQ^OT#?$.?FW2/MK+8%M
M6%/G"X9P#6#S+<NMR\FLU]N[.I8Q](!=D$GIN[2U):Q=6/1426V(:9-)K7(Q
MD\EV2<>S.UR>X:6K8MW@?I&W4R:MO;F1T9<?CJ]E3V3PGMNL,<9Z,$ ,;\UX
M9:45U 06"+KJ!' *BW9?5>NWP%*S=+Z7Y*IO1 WYO1<Q@?+HCG7<"$>%'7C+
M/T_9KPX:Q&_33>C3D>+$Z#R<G_*EMH;"MOQM>+"EP"*[:F^N/S!OX70X9.+X
M:2FIPA6R9?KP(5:>/PUICQ*25C7K$[;GQ=QMG)\NE*3K5][C/@!TTU8.L:R0
M9/(!UE""^?FZV[#B0J$!,]%]WC4]%]7F6LAZ%"]/[2-%C1%[!%F_5W\M23Y:
M"WS-XBXTH?T<F7&#"LV9 2X(]*M]EP!;V+N_M.UD##55]G&0-E10-TC[78CC
MP7<IM-E'DGMU[C8I539A-;BM;0&T%8LY])=>4_9X,OGG?(SJE3^G[_BQS]+R
MF\_EXP\ N;.9J1+5^_+9P05[4C>>CM!/@3Y8)GS+CONR]GESNL+=<!T]\4OL
M)K?(UVIOMQ(ZUD] -S/\.R:OI2;;4\">RY.QOD_@_B#K[[BS34L4<[ H_*MG
M<WJ?:$X_^1IVUEMRK#CN[!M&W =DIZ!\<4G!K0Q>9$,.IVO;&S3T^>Q:G<&Q
M"DLW&ZKJDO5,?E+)Q"?3]S/+7(-PTG_<Y]6_-EYB*X<?\;W%,[FZQ/A(V):8
MV'],)2T:?5=,WMETD)(%NQJ<4FT)@JWM5W-*T!NO_Z;';-5>=Z&JW=U2JN)=
MO?L#3^E(>=K_0ZBC+:4RU4M=U1*F7M]WH\ Y<O"[,RU3C9:D?[$/I+JE6<TR
M-WBI5'RGA*]TS?M'%/$ >&0/1.-72!@6&->#92"4_N3 6)VY@?E#P+>K;X:)
M]\$Y8(O'+@\ ,^W[D+K#:I\TH9:;_3XN5?T=D,^Z0[^KB:W 1XE/55TE]/2_
ME*6I T6M2@=NFC=J;UY?4BF5^E1!UW!^,:331HEQZ;+_*3M@FU0W[=H0<WIR
M0IZA+ U:O%*S)>LN-8 OZ1OJS1L\ $IC1VPGYBV<:;2^B/W>:U]96+)*($L%
M4OTRL74G2PUL"#4%W#\O_.7/8JE*0B>3)1;X2;DH>QQE,BYM[6NVU-1F.[@G
M%L)4,NKW#T7-).X)>,_DX H>*$XIDWW\;[";)\_J\&E2;C<D^_7/9<Q-'FJB
MU)][+TV0H :DQ!TPD2 \.RAB5S11#41B';^0&9DN:Q*(-;@+$:BFP!QJ.'Z3
MA-*1E"L24P8VC.]1<A:>3MF*7[?7Y"\H[BC-F+:;SDHLRR]5>NN/9"C?=CU<
MPW( NP-9<"]^XA[G@;M,J.^N>>_O'@ (+49)1Z$MTKLE?P%PM</2T%5U35AO
M'7M/C )U&PKU:,U^K1YY%QHQ1S451!%W'3C*5 ;1N:!C7Y)%4D/GS82*PJ[T
MI LG#,$FY4;:T6AYVOU'LK_O!"$([A$GJ"H*RDG^(3E5N\1B:\L;H 3^M5NB
MQ0V5(3V*9F1SMBJ$J?SSZM\4(S,6\+==>!CYW7&EEL2,S'GA]K^4AHO(%N)V
M=5_],B&W]4JQHE/U>J6*?EI\IORFK,23]]L=.-L#V W\Y?%MLZ)]:F'-<A'=
M]L]7#QBNT&6O[FR+BFA$&PD0*F"7XFD7\U[#G.:Z@.(5/?7>.760 NCI06C.
MKAHK%&80/UWTOERX21!E3Z8XII>"@U6%+L?Z?4$V /<CB_1K+[C:4SGOEH@=
M(!4V75YNUI7=%)( %;3/\'6R:TS^^Y#-,A@/GP4@8)H..IVMJQ6]?IO^8>P>
MP/  F%"!%NE9PC32X NPG3H'_?;%9"8B@[:<%U,I,E.&NUZ)4_MDJZM<A),_
MU5M"/I)KKS%\P<'-%;64ZVZV<WH 8(JNI^R =<!G0"TK95T=V)P>6VU:S8?Q
M-VZ]F&@: P,=%*Z%"'[!YK274:SJ7H]*42;S'T=OL\6K#!NU,SD05O<G7?0-
MA>OB'>J5$QC3RF N25;RPQA7V[%FD[>\Z^H0\#;AZ#P]+R'"KIKWQT#X*W@J
M%?]-1;GV,7IHB3=_9MK7'?-D*!-Z-(I)\R]2&I/C<J;*(_0HZLYLA6"5*?K)
M V7%6;MV$45RM$<Z&RT:5OOA4L]';UD-/O_JUC##F;+D5Q .49O1G3OJ$4\U
MQ*VR%S/.WWVWO-SY40B:A]Q$1!3#K1TDO<7A"R/6JJ08_2BA ^O?HCD.(6,S
MOG0&<U=(-AQA,J2\]DQX%HO/Z6<'A]]<R!+7L<JS+:Y5&M3N-FP X.DT  6Y
M7.@M[V6?Z6TV>>XCFTY.7,F!T5)GMG0:[H K%#4:"]G3+U(RORGOV7%5"A&P
M2RO4GY,P+MI5TWTQ?^\/'=;F&QMVXGA<'\455V.?4KKR>[ZNEZ5F;YI+-'QP
MK*=J7'M,%H86A=:R/JM&+W4\BA#:5AH0JV2#^I]T#6K-]H-ILM>>#!;"MRHU
M4V7G2M^<)$RC&&9!8;)"3(U?LPOZZY;!F,+)5<3U:0N/NAMU'+=7@92^QNIL
M_^M"V8;Z-\;:YZ9J=];R7\H5Q<;H(7^.T<-=QG -Q"PX#0R6YE_T6I@1I[#@
MZCL>+E6>E7\X+H<\4G^K-C(!4RZB2"0[#PP_#,ODWE"F4_1@W;M=#CYS@/X=
MR3*P2JG[MKW*GO4[EDL,L3:)[4H%I\@C66AKJVG$,X3I(N!JY1-"QGG NOI8
M/:R0_&JT>5U]Z2K+(Z[!+?ALA=KJ8O";Q/OL5QDE W;E=1;RRII4'HOPNO ;
MTPSKP0FTY,L((8G58J;783*QG:6K\>/Y,#W+:S]AZ4'/&TWWH(_4@',GP(8%
MXU*NB$QP;0I\[$A@["7BYG-]&U$#<GS6)!+I8 NN7L>@^//VVWN^UYX4KAM%
M?;^.B>6KI@]*;/=X#.3DN<+R*VI/\0GF.7[W2UR3G<++KY]YLST RK\] ++I
MBPUI;5$_'TME.^-4EWGHJ5OQMFV_B%Z@4MQXKKBL))3J/%5*$9*HJUN[<4T)
M#A6A[31>;CC??[4H/],@2!?=Y]V0PB=B(<Z_C+-9W\)2*EMN^>$R3F=13TY#
MHW=:1"=Z'ZTI_"1?B.QT7Q'10T5_Q>(C4FJ]N6^F*5X1;_552ZVE8&<IL^\9
ML/G(L-*DY$JS3QZC9<:?T%\IN@RJKA\IO<M7^$,U-)>_44DK-]+_+R@1_=><
M!DHH!.;JD1X8H5ZI^VR*^&FP.?=\@ EY\27L! ^]%!8>RRSG;VMOG+;37=T5
M/P"!F,Y0*\H@?.["AOT9X?U]4<W89M>41 FYCJM*^'",W_*6*2/:8LLF^=-;
M1(O0L+-2/79\ZSH^O 6N3"2&K_'-B2CF=G&P4SV[1 #63V;WB]"ZF_1\2>,K
M9X,478@)6U7?UXYWI=T$^_#3TL&5'_H&20=JA60Q:I'#S+7G9V0^U4J"QM(
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MMA:=QW=E&,\C-;+=M-Y#G-RDLSQ4A_9 :/PDGNV@I2BE*:)ZF:("".1]T7O
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M;/\5M_( P*DY)4_9'NPGB->&7_VD<M[#W3*@&(5]'[/">$1>FY/"/J5+P@<
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MA'[[=YL0'7M]UWL86.VNN*"\:H!)P,/7O:7VVD7$F:MX3"_>Y1$@6@-&_T7
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MU4W_>*J7'KI2;21:3C[0&JS9'[2K;4T_Z&;,,_O"M^,Y:$"=.!-H$U^C%$&
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M5!KT]K%^;FPDY).HO+!!L=Q;83T:32YLN)U?.C%1%9M3EVDC L%<2]?B\M3
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MM?:3ZI%S(A47,0G]GB_"[*0&[B0;^QS6A"Z"KBO#&0'RHP:6*SQ$#*_AXIN
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MKD3%)AHE"EU"7[E8;"KY/%[%>%_;>X>Y&3;V5LQ<Y)EB#)H7F\N#A(UN)"!
M@+AY=H)"1/EJE#\/"6PF0A8IO/#^Z +HY5#F'_:GN3NC/<F\-[LI$O@:]-\M
M-$YN 3D=!A^FB\6"X*>RMVMRZV)(@'\4<?T,<"U# H,?[S,*O[^$_A+Z2^CO
M*93WI^>]3]<]L/YY3H;3@Z\WH)<]::C_-''_TT*8/@][UDAH 12OM^C/ #F1
M_SB4W)-VW>6?BUT/?I2+ WOE53&TFV-]/]X4MTG8WX'@'15A)WW?H\3Y950;
MLZZ8JC'^XP82J3I>E)Y>1<_LE@2>E1A3'PR_PH6DJ/K*U=3:> >)NU'YHMWQ
M@=KJ0)5F"E\77$*<5%>)0*G2#Q NGAIC:ND'.[6&ES^7$/YUF<'.8]MQ>-*X
M&T'](X<XF3U1LF_]%DD3!LZ0P*[M8&TQ_4%(3.QP.]7*7ENIL775CATKC^I@
M7//4[@T2>*TQ/DAOT50?&/8H,GQI+GQ3=?)*GC/]F$NWHCK?<9/K:S;5AY08
MMSO98NWGJ,:2@Z,:O0]HB%P&NC#+2$GF7SQ:/R_!D@LYV*S;&HM)-WP<PH.Z
M77&7PWB,*,,4TT8"X>DE,+%X.D9@G0"/& D85G1OX&UJ-N>^9:W&D" "G&G2
M2L*% S-/GYU0AG$'#AX#]O#N30U=AR0I?5+U1@+WI&=R(FZ8R7_;ZNEGF2&-
M]Z>R+/%/<2HJOP%@7HS K9)['MR-W13]J<I8;D1MW@LL@LE]$ZFVVL7;\T7-
M4K9@SQ8)5"C+5,I-DCXV99@Z<V.('H'KFSK2MT((9L2[4>!M^F"%V>/5A?HT
M+U*?Q6 "%6(ZLS"WF&SI&<GV0LP.P3<!(@^((J1=5AG(7>1V%I<7JJUH-,Q-
MC2%U3U]8IQ'#R.H:7:4',NU/?ZWU+*R=@61\,HJNE0-$\7 +>NLL@B<1%&,'
M8%?G_%ZLZ+:.#=8S%%=PL4) A\+/VXSQ@Z&+N0.5$RLP;V\03:HP8ZY#Z-B-
M.YY9Y82OM>3&AH?:;H%M58Q2V.V'XX2XCS7C."YV:,YT;=&(2=US4@^&"AAZ
M2))$&_2<C6M2NUU@=Y*?TO.R_BECD;J4\]L*\J4OX4-!"S&SPZE&['A$S"XF
MUG(BA'6;?L_DWJ/_1\"FFIE($Z0Z(3Y':& ;\?." BH"&$':WJ5#AE[(((&?
MBD@ J\PTQ_3&G5U-=5:#/835GU!Z41.K1@10K!\YN]U^+M6 K1&@39CCIQF>
M(Z*NI/@Y+UU)%$ %L-3_8XSK_S"@$LCKS92_OBU\2'FL#UUC>+!T73_?:KW$
M0'(+H" ,)J4*.Q2[G3*_71NL7LD*7X$V-1'YJ-VV%U<QE19IGS"IQ;<6/SG>
MJ*0$!3<(X##&1F:CT947Z'Q,EQ;&R&A6?>V-F8Y1.+? <? Z\%-4S;S0&!+P
MNBS*EG_J%[=QG,O]:Z]E>8.G1C-9C#\2=ML@T;U[HZ*A2D(8$-,;1?3^D3&H
MD]*QNQ0-H5>S.]3>66"VF?(]RO&ED-I,:'1/GSWPN^!MW]TQ@J*DC_\M\W:V
M^.3X%%:@X\LW7S)V2%-]738JH^25C6RMF+<VF(OD3Y13%X0>]ZR(?+'I@+@X
M8BX4>D0K8%I'W[L DT^L"'"VDX*ZQAQ\I*/(UFL>5S ST<\AB9-G:G,ZVPY,
M81ZE^G%^(&]E1IFG@8Q9V*%HKV(.1E\(96:Q<X>>H#LZ5>^:/^C*I2ED15"X
M)7ZU%<-""R1\XJ!$1!CN[G!94=7X21F-3X/46@ )X&VJ=[U-)Z"3<5S3B5>L
M" Q*J'G+3<')Y'L8%A-<J,;^Y9?"_% >O*?3GFW')$RWW,]PQL9 _]M@6K?.
MD")DYD5?7[O5[AR@B'#EC.Z<3F*D'A^8>O+^E0_>!SKS'Z..G)J-*-_,(!Y6
M\RH"]^Q6 S91;_CE%[$XO:@0V6Y!B@BG@]U8SM)>9T80?<^_NDM[.DAL%J6]
M$R =^KVFNNL(''J#2/;D@0G#J,>4)CM(OG\]N%7\9CR4'#Y*&.HT)@-OQE*R
MNB%R?B$OQ2YDU4DI7)7B5G;H.Z4(F=X1E5Q+W8S^5-HUG-J$:-K5E=PK44G?
MH^XO9/M6/@W]41F!!)ZR#F#67*GDNE JNQ>J,5)'N[]/7]9SZW+W!/4$G;J7
MUY9D+@]!]FD'=8VF;ZPTE6-2LL(T-0FR#H?.F&3F2\X*^QQN1WYN"6:+PTAJ
M%=XDT'YV!EZ27;V"KFLO:N(%PM\)5*TEAGZ3IFX,^%J6UAO:$,'G.SF[/:H^
M;*E%JHHU[&L3K_"](M8&U^ST4P-]2!SX78+1SK,3??WN)4@V^]YEMR\)2UV$
M_EF))9X65ZR_)N)&,=#SM!3U%*9XQ/$ID>,4_Z3?YG?J$M#RFV2%7V Y*51R
MDS5*)2N>VE.1K.T&>F*K#;,V?5Q<I#R4+Y[QN0"5'#I1D_G"4[^_6RF<I6)'
M5D1W5_M5Z;!XZ.]HS<A('"L[S'R>)146EI!S-=!;(6LL-U9GRN,>4+8Y?638
M)ADCDV3!L3IYH(CK'2S4.C)@EHDB@;W7;_HAO!?SK*1%:JRHRMV:=T*%>WGX
MA[_PEJAI5T9<6Z%_OI0:I6C0^[=OV:^21\:3E_]8G/H;@&8O35CY5)8_F%0N
MW]B)&PO37JT&03U2N<N@47<@&^^ XJO'SN%+W ,8IX-2V#N5W_'&^[/L,V$8
M1X%C(4T^N&!2O5)&Z87<E6<3N2,LQ465#12E&GW/J5Q9!\8/NU&/<B*2>._
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ML<@F'3)KURJ&]6A'S,R4:\^K2<1V0H>0_T7>XNRT^JZ@8>?O0AR)"S7_33V
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M1XKXA0F,[G94SIV\2&"JCNE7]':0"C6&F/"<8MP+^\!/S)TEK\D-V-XIHQ9
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MP_<*. VX$]$OYHY;EGF5>*HP>C:XS^"^E:DBQ-8US(:#VQ1^?9F>(UODHG6
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MXQ"W:>MSW:&^]V7GEH=O>T\&$Y+V;#48:X 3R-M[L+<<VB@ [/IE<Q^4N<-
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MY8&:RL-;:!I_V&%XOA(IB4Q01 %\AX:>7Y, 7O+&(\\R_N6_:""]IXR4\7%
M'!A>XL%U^"\S*^V=37@,-;*V.)QI+!9;CY]5YEK5[X8G^+>[,- :UTU6FY#T
MB)6&+68K>=.]]55! 6XJ![(?@;ZTVQVGH !5>"O7)S;K?3 D/<1%1[OB$S&S
M7(",;561.S$45E3,?!^PJ%]6$V!*B=<5IS>[<"7QSDA7GA"!9G"=_0KJL@FI
M4[?#T+)!HY?+8>M^]1AKAK\^4O]OSYT8LM]K&_3;4_%[_?KHWY-W?WLH+\&F
MD]D%71-H_"6>IW'DHO<18I\K!+C/-PD<340!UASTM9074C5<D!N7*DV:\G/W
M)Q?UQ>:2O9*O]"+*B^RK# ' MIT<X*3R)>GPVC"2NI;B0$CR) 2X8)BP]4>U
MDBS0N?]EK]1HMH*K6ZI>?Z/8/Z4''=D8S!O<740!SFB.Z,XM4(#TD6INPR;_
MH/!48'7KA6&&</ZZV+5)7YN<9*)(OE?"*(#&</?H[SWH&R@ OD'8V13=>;/D
M'E?7,>B/2MHCJ/Z;/FA_D?E'QN^O\AE@+1"!"#=RKIGOVQ.<K]0%0$ UTB@
MO008!3", :Z95W^1)!*C/CEU/.)C@YX:G8LI.KN7 M-@V'P75GKJ/P<>5NW1
M-5B$QP-KI8:.@'\B3"3LKX0Q%/JS *A^)'%[Z;GADGMOS(D,L-[ Z2\\\FNI
M?^R6)3KSO^R6.B=(%MM*U2&WI,V2[S80!>!$ C]K%EYPQUL$%LFT.ARV+,L
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MHV1]LCZ!94PG9+[#V9KH+3\@2&&PWPZ*P[P,K8DR"^2]1FBQPK;S;.&+5;-
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M4.PD_QB[/]X'9T)<91.A/S6*4$I9;BZ84!)CH9]L3^GG <0* Y9<UUBG/1^
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MJ5!7 XP;F V>GXCEIXOE;[JRWZ$4UEG:O<.IZR*6Z2,< !4Q5=]*6/L\E'9
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MWA0^JJ\[>L)9%'P7G8G(OO%YYBBRM4]( U'?\>2<8W32F1+C*1]\7+,7G'G
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MZ>0>%2$!%C&'0\^X&QCB2OT?"-W:,==C5S<X<HF4:DE5;'%W81LEV'MM3Y'
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M$_3L$]PE5AEP9X5R*[Y/-+;V7@Y-BB>Y/>@IP105^Z"PNV_TQ9FALB2AJ4D
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MKYV7EV$>[S(W/G$R5!FP<E<>*/2_:L)F0AUHH81$[+4_X2TUT:B<V)Y\F:;
M,Q=OSX<$6I<^,ZL1A7:L08V;'P)@G4!?-B20% HMOV\/V-?7:9_]UQUJF.WC
M_][^Z7\<4,[+CQDM_.Z+<U;C=U7/*)Y(W&@;S0M>/X^[VYH-U5FAZ(O*AX6\
M2U69MMULJOGB.SX@?!LR1>LT[$3AT'&*NM_TM8V$>RG9;A#OS^*&!N)$\);/
MZM%L9[%P,VVH-X\'>.!/E1+%ZRUZ82[$AY-;0J/MYRB:+($/!MP][]_9=/Z/
M!'.2 I6: D-I'<_[/_-[P-88IKC+IC#927[PQ&_U*7V215;=17)B@A^"Q#]R
M#F<H+G,-=0?ZS>P2^8W*PL? .S7**N=W(G+K ;AHDTJ5L3[IV<VQ7B]5=!&6
M>7)K&DY(X#%I9.]L(N-Y_,!SAFS;-J=,FQ+6-#7/NW?-]>?L;+6L15P>DNAM
MUQ+X7',"P#W(3&;6UNU0MJ'*_06E><1A;4(K5EG ^G?Y3!)K8@EK#L/*RS[@
M5YI7"KM9O_BG@00U'M. ULK1W30*J<9*\9B:O9/\L(5)M39=_/G\FGHN.?+3
MI*QMO16\EF DT"OVLKDV7@&M%(<^*#J:U]KS,9TJ^O[.<S&+3\["=9O?9SP^
MTX71DL**G@.RC-%KKFBGC)?#U-V5"[,940HB/AN@B^:&9!X[(57F%]&;?_R_
MB2<(7G24ORTC[=3(S]I@#Y!I>,&!-Y[YNC]58Q_V <$3/V^I!G/*4?BT.C^N
M8.&9Q:/!,.+8G>^L2G[166"S^=XDS,.Z&)VTV*%.JC1CCAY3K.'PU,CPO!?D
MP' ^4-E+D>)A%@B4R6G-Y$(QNS,4$:Q>IC$)R6^_WE1TF)O5PS1T\+ NQ%$]
MG<\E)D\L)^N'>6OLCW<'N'HE&5$J-5]6B*%!M;->?JX*,#_@\N+J^",ONX::
M=#EPVDD\!P,A9.P8$:UT#[F&C(N80+*#VRG!_I.,68R]=VMN6IA%]P$LSZ:,
M,#P7F.Q%5',[2X:@5K8E>D$L^<:>9HO1+GO*:G<T,06PW[)(X+/*FDCLEI&<
MPYMDD;*M1-5V\HM]_:86$T@\;,]*9W(@S94D)^ %57GF/+6?TSU+6?//!1C7
MKLI4#?W+9B7G"B5;!DN]+[N5@J.P2=0Q4%8K1#6\%J?1_J0&"7!Y&;C49SP?
MO,7H=26B24:GL5MKQ]K3KXOA[;V,2V=95B!SX)W=)NM8#_4F3LYHR[(DSBOQ
M-R3DF#),"KH4F7T#V47(+,;=WJ?>ZA@IM[ZM8[*Y'8Z-M+Q*WV^I8;0I)+<4
M"_3@S2J -?7=(H3)[<I+.%Z2AW)^.(.O7GL)EBQ[,K0_@0L2;;[^I;A'( 7;
MA*[Y)U>7EX&++9Q*4.Z*0^^X\>X^MU;6)TWN]P(*): K(;H^#GVY-+.(TG7E
M,WF_4,T*J%W,\9F>JH-/P;("XA?KGD@NXUVKC$NJG$[JAM_IE>/D<(\VF.[.
M'8[VW-)^Y881,BS>HTW#V%[]V<;#GZI&OD"/_KL"FX6A*TI:1GR9E4W[F08/
MY^U5Z@TO2<"9YB7M'6;!N3[ONX<$_/>8R^Q1%1*@E\F")XO*(3KWX3.!0E'=
M3^>6> [T"9^1JD^5"=(FF^XOM"7EPUA$5886-MCY&-CB+QWYX[TK3T\-* K@
MP0X!AR%(8.]5PT/NL!5%>[L1<&''P&>OM#G,^YR44.] AR0;]64/WV)N7+XT
MGU-"IE-:6@#%/OA'27;;5.H'#Q"K\\9K6=D-IY#893GOS 6L' B/XR\"SCMA
M2J?./[[3M.'RD6OI=+]0W!.^!DV=THO'$UE1I%WIWX?EYK05@^@5'"BX7Z/B
M\D7'2Y[J,6\N\X%D&FHJITYF[?=)5E:]PLM7!3M$+$LM/&W1(==1A)Y:38V
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M\3K\7XKV4RI1(H%;6]F5:>K38EUF435'Y$^38WRG2GLU[G"T8@6GJ> ](@2
M]\K/Z48$(.#EK/WQ::* ;D)BM5SVGE0S1G7 &VI1Y;A3!&#'Q!@O$(G1J2-R
MQ71C_$-5 M"L U%D?F[F#$(AO(4)P!TD]GW\+_7ZC-L!R!5FHEZ@(P!HK?Y?
MB,6?[D[#C4GY!@&@/&R8WJ,B &TA<,PG\*P11A_O!S^Z0=R.T5"6P3#@7SJD
M/-L:JMEJU5R[9_UE:E0AW/9R"H$4%V?*"UTTB;N5_W< 18<HW0E =!N:"E]'
M5.M]@0@'! U&C0!<B9ECQL&Z"4#6^3M<L[]K%/GO+(H;J$/\/5L)_!@!6!DN
M2JV,#$+N<%LC#X8)@%*MR][4G/YI!HW[S_^-N_RGEP'QXLM TSUN3=TNK=XO
MO_EJ4>E"=5M$!? RPLO9\+23T36,>P9F^E'_5BFB1(4SM.HC;=L78S?1BL@D
MC/)=?M(.\<@QIMU'E2<TK["R0OU@VC:GK,G($J+I;@9EF8("0;1UW&NT:S[\
MB>=EI<@K%'49:<S#*5::V(ZIE%!;X;/C<&[E?N$7F>"7;6&GIK>Y/N+4K'O(
M)0)DY%*94'5I'Y0=AJFLN;K%XZV]HU5:[4J+?ZUHJ?-R/>!/4[<;=*22R7>V
M*$*ADDNG;,,29*B5?SCOB=<:.<\C M)0,="A.N[>4D\QF-,$R?('.SJ2?LF+
MKR)$NY3)'E&P?E#@:X1$W,(S]!;QQ-\;S*1KL[_&FGE%GTS"P#_ML&U9%EJ)
M29HU9O%(.A'!TZJ]/!'<P-N/P?MY7W5,%ML??W8.+QS.AJV!3GL+2U$$%\FH
M(6RZ"Z%]"\*-V;U,2GU**FWC+1[?9BCW;  4#48KC0B[%1@!^-$\30!HB>R
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M9'W,5]8_%$6#L48<OX/O9!& L5P"$)A( /*4"8" ,>Z3KRSV+3D$T.D$L\C
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M%AR'030RS-:VPAW'SR)8WE575L8#U"HG@[/' XF:51\1F>/=IZ/ EQ^>)!&
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M5H2ZF/%,A[@[1%MB3P ^9_[Z1=$ZGK:6"N];Y8X_E8/1( !GI@((P!U#:0)
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MH--?=PY5BGSM+4N=1DLC[;,S9P [HC'^Y@)ZL%G_N'P;]'U'](7:].?(? +
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M3Z0WXBMPS(V@7R8@TR.)1JIG..-_M7?=44TNV_Y#$%!*+/0613PH49 F"(&
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M&,F!-"6$J^&:4'2FZ=CX M^O1U2=ZN^[C( P:9)C@KLF,633C]T158IH-BJ
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M(DDU#1>>D0*"TKKUBVTKPP[S35A]9W0ACC:/S,96#A+2/M?$*&&U?3\W_L6
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MQUJ4 GGZ#-0I2J'JRS)1A"^QTP![^[&58]];X6N-J!C_[5;ES\UKQ4"4,]!
MO<(W*Y%6DO'BC<F\2LVP+$=+6^W?GI^1Q>)V/KW$''<.:2T$\2<)[QKH2KH)
MFZ[T\T9ZE.JO<R.0/>&A$H'L!0BV@-F;!P<D&'<V5Z"Z7PY@=,UU8UR,C=,F
M3?[.QWZ*LG6_7R174-.Z.Q?=';GK-\>1&1=-BXI]L>]0*B&3Y5/=RAR[FJC(
M.#V O145@,TCT'VF-+<<2AM,YU\\1J(J!44C1]DQ7RS]I:::69AC;>7]\$'!
MX!0.-%@?O_*:1^"'"@;%&7Z/&B57H%/N8*/<X($9?00OC*"]=/N2QKN^F"Z
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M87]!+(D:0KD7ER@EJN/KCA6:C.2)]E^B:'L:^E:?@["L\^Y/JN;P;UUC=^!
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MQHG *H]W_57NVU"Q3&06TFGZ3T@3O^G3[K<^@%:EQ\OS%^(2+E=NZ7,39<G
MX_K;1S>DQ4?^.<6V 1SB@T+[O]V8SQ@2?Y2K<G2CH3"D3M:DN7?N@RN(4+%:
MC2<>]RX/0FZN,::KK=[P2RE]R"Z%&9IW2C 5"&&&U8>Z4#T[B-W5IA";I2E
M>>0 =OEQM(ZV+DW>#KO'UW^]<##V*T_1Z6<'::'+VV_@8M$?]^[X?1,H<"!O
MQ4W7JN0';VHDLV+;ZPXQR"5?@N2#[LTEK(G*S.5!T_D*UA0>W!ST9?($2?KS
MK_<.E,Y*QQYWJ<)8!3E/P0(:+6Q-'8[]:^HTWC_(:;M W:9MPQ6%I8G?'N)7
MB'3*C\'^H)$+$KOVUL9S8OS*A>AMHZSZW;;7D_>K[M-@XNHYJ^V[MNBL&Z/2
M\),MVM =F,0AO;-9&:-RI0Z!JH9]D-BNV(/"5#A7%GM)@Q\*+$Z0E184.-7Z
MM6Q3."1^>U,[TR=7!A$I.K8B+VGS:AA+*H*J*\MCUA5:(1MSTNET#^[+\_;<
M:5>+.ZVMX_J,#XZ, 0P((6M$913^)O\2,/BXFUDC.T_/M.!B^#X1H142U; I
M6;\PEQ/+\ZJ=47R)I@]WKZH%"G&9K[,K&.Q^<1)^BZ0O4'I*7>CC1B\2.Q%Q
MFY]\E+E8_^:NI:VL.^E#\#1I?8KLHH[ C]4K)2@[0I:4*K@W2!)OT*I^,F9F
MMLT,80O^QV4TQ19M)+OQ8LQ5ITM#QT-:YR!^;##K\-5MPR+ZV U5 0*1N-?Q
M ]A/KQ8^GNYT(V56;!E,,LUM>QA[PX$)PR(X@.W-[?JUVYNU[G2YP,;*.X(!
M0\F7D@>9GG];QR#@"5+G%90]>K1ZY)OMHE==-^QEXW09]=;D_&(?A=C.E^N[
M8SK9:Q FY&!M:>BH+A#*Z61#/6%]7I)>$4^PH%+!\!U%$'4S$3@Q_>L-D716
M%NZX@FPZNI^83>;PFK-SH7 ^LPJ=;2BVX;L1IL>=NHPD\$<^>D;^;.6(<"WE
MHYS?,?FSROBE^#T2C?*(M4K^*AS#/K#6'5XSN!MT[BCV&+&3/R(8HH#JX3\_
ME!J!G,!D3H+!AR1.<" SL0$.^.F?OW,$W;LB^.JY^NN-MEOF5D9$3ZHSL!#S
M'=@C</_343APM $'I/O%:7WUR K?GD-?3S' R(^I8\!/0",Y'CEN"(WYC4]Z
MFOO8L%9=.WA>?/E3F)_KOA=[ HU:]O.J<):E?NV3E5/>+D5_'556E;@LC*$;
M*TBR?TUVE&OFA J7R(^\"&E%;TM6"I13VIJ]E=,4L[2+S@L81!_&UG"@@+&?
MI5*>:F&L6M<0\6GY4S*:@8+$GEZTC@:H3"6#?-BSN5&S+W-!>]]9/0(KSFV
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MSP7#XQI8&PJH$-O/4T>GC((B.=IZ4H7[BS3^@[S+CNXO>+^PLZ.21[C^9:Q
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M,?$<Q&726_W+UN!LGD?BR>1HGX6M;H6M9=5C:NE!RH%'Z)RHQ\+^MQ/A$0'
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MD-;1X"/TM%4'!YY>"8S5+/3E#:&)_#A?[W9%"N=%R<(:;5GYV]L33P#2)\"
MT#G+HW]IVY6*ALB9+$P&,_@)8$M^+_QI3_#O98#2(8[_>[AOK16../J+G)\
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ME/Z:N6DCXKUQ@&8: Q;_#F&5]8LYC5RXE[%*N0?G4&;'%,=4-K(.5J;X"TD
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M,;%'M'#\Q+Y'3EJ%45T"^Z^W7TT$?A0QO*<?'!2E\']!$3F-D'@S1@@:1_L
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MN;+W+F1R#V:3<G/HCZJJ*W_(7PRZ*8J;(?(>WJ<QU":]*#4T-PNA#NDE(OW
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ML#.*OP8O)\(0)*R#O^4TDK/%9_+F_4?7B:;B\O!%\9CZA3R[?L;NF/#MJE%
M'H2ATZ,VK,"BQ">&BE\]]MZ2G]>V&C_>P(V\DSMC[3)!^)>0?-P&D%@WNB]W
MM<\.]DFA1@RI=]4Y2+2_GY(RDU!PMN;?B_3&)!(U]/@VIW);\2O['RC:N"O?
MFL\C(A..K5P3H@A>"<GA(FR/NS%T=PW5M24Q##"O?DXZ>1AYB+)N[W\A6 ',
M0FF5MU^=_M]E@*[#*"&K:F=".:G'"?Y<LEI+/92,.=JTO5((\F* R^-3O1Y<
M!#BP]!?F/&PE&\<(;Q0:K5UQ%%G(;73HHO!J<V[T]@1KK8T1N97U@?"='IX
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M6LMQ%1U+J(^K3E_MS&-1V=;_99+3P'/HH?/->Q,BU3A'^HJU,T*SS/LW!4^
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M0;G.KV?DXF[D\?H3UP\80*H'RL81[.[R3X%4X0\!\AV.\J$[Y+VS3P#KQMH
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M%=(LM3YOY"]#&>J.'IDO+:KAKV"I)S4>UZ,=L9*,G#0;>_<5*$YG<B<VR.W
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M]65)DW3I64..N0Q@+T9,K/>+L81YDO!H*8]M09DS\2> 4GUK7 >,LDZ._MZ
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MK[HN+['+F)-1'0%U:41^U 2?#?ULT73I'(*:9!*S&\ 3#\E5BVRD6TU%_C;
MG:=PCDHS/O[3'VQ/!E:XSSUWW[3-"!#FC%?YU+P3BRF6^CS7.%TD.)4CVMV
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M[,O[M^>-=A*,8'N98[0DX'(%6GQ9"O0[38[&Y\,'=*B9^4!'X4+:^F+D*L1
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MZ( [1_EZ,*C--C;6%GT'A/C0W@</1AL.+U=45$=KEBBX=]RS9M=/DP_:Q-_
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MD4)I]_ZHCZ)K9R>GZLH+Q&LWSKE(R%KX=+RR*/E:X#)Q1$?=>ZIB-,5,A-?
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M#/2P?EB=WVS-E51Y>O9=V=Z8)=%=1(HE# H9+D\JP"9JIE\,MT4$(J52B&Z
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MYP1>):537:+7>A(JP:C)RO=>+SW-SA? ^'Z.P;4]/2O389+#G*@4!V)+O_8
MQOJ&Y8.C* &643MD$P3UO!T0;0!O::%_T:_P3GZ^-'PI  ']_/W V]2QA>">
MU/R1FT63!=I^2\+0@#L]4"BX>MNQ,==LVJ[\=I*MNW5I]0FP?NN[23],T)67
M 9&]C'\7Q'.GS]G4\/V^=PJ'5K46+F3:=&;J95>IA%5X-Z_RP"/2.3JI@/L<
MV#_P[/>,-!Y8J,9NCQ8::P*_\^=/9KNL/@_F"Z0,Y[1R[6<:&",O/KZV>P'
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M)MEBJI2):-H<#43G#:R(=]#!IK(Q8HM&DH(3XE-R3VQOLZM\:^J16A?"-7F
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M-@A@H,U?@'P-',@?(I'@\&()+:W[SRN] $7$A6=4OEV=5'7!N<?\4Y@<W80
M<WD;7(Z".(3AG8)P&W'N \T:WYZX _R2GHAWIRRCH84 N>Q?SC_]N?O]X'@]
MN-N=H\IJM7-7>U;D@M5N[JZYV'MS1^RQB_T[#W%]?:=S-^$V_'D9X%?K[T'S
MS>Q!\ZGWH'/'A>V&#*3 4B_V1X"7UJ<UE_OCSI,M]PES!3$A$'[CL5Y[1?;W
MK.IRO>-1:_X+##S"WUD4A^:=\W)A.D?]U!?<OIT_F\WOZYZ6C[O5]KW*]LTQ
M][T_6]^7'[X\48\< Y-8\"US4^<D^P=K.<LV]?? @\=X;C2]  U:;=ES(=^&
M;N/,*;0<;KMCYH4_;W5/3[:^-+8_-1MKR^_YFYHO-E>;^NQG,V=3=Y]H4S_E
M"RM/M:D7;GA](CCOPBH+$!O?[I;>>TX;C;V])]K35K6GFW%,&XW6IS6-$Q_G
M;.:;(0]ES,EEW,PY<7;_S^;:NLB< ;S:O-<19O?_;.T]D2R;;[]Z9K%'[M@;
MP]/[9=G]@R=BD?EVLFI37T.6_?A4LFR^)>A9Y9XWN:7WR[+-UOX3[6F^>:C:
MTY>799N[.VO*LI\V5);=2-O> ]WS.6;8I>[YG%W:4*&U5+LT)Z NWZ65\?&@
MTO6?_4CEZ?6-)[+5'+R"S%+Z_5O!+M-LKLO+\ET:KXZ2&ZG:/QDO:ZT96_?I
MZ4)[JEU:F9<MWZ75L?!5E/+2H^&]W.QC<[E@O_H&/J\SJ>A6E6?;P(/6$YG%
M#BIM^S6DR>93>?X.\A7N:O^>5YIL[GW,W3_ZTDB>PNVDB&?,?@C5%F..WV%(
MB7BP=A;E$1YB]MO/6Z$+(\*L//IN)'!I*1DL202["QW],Q.V"#"C:^5LPC42
M&E?-4_SRTX?L?-)UF)FX7(LPB$6Z%$33AXJ0B*SO2TNB^_2-G%*NU'?Z2]?!
MKP<N%Q8-BN<F_AUU?\OF6\W>K-_T(>=5ZDT3RL.8>7T8,1%ANM47G6#3:.J'
MI+]E[^$R04O>H=*NLK]D!V.^6'^G%C&SL(@>M*H*/4(\0N',(HXYP]3Y+VJ(
M=(E^J/XM\R9\ZLK[UVKL-'8+L&TR(S;ZHA/]&[O)L]4OC]X"(T<B?P?4!8=P
MQ=-M0+.QO],HU@; D=FO[S2>9@.6KDU!,"6S-AE\>+ZU:11O;1I/N3:Y!W<)
MC#KN#4QF9G#XD%-97"#0,US[V&</_MSCC%<=<S\8N_ZRE]V+\MFWS3]1_VK.
M]T' -&M4V'A*RW#VQMJ<O?&4G'WAPFK15V<8=_Z.,2L=5(' I^Q%0_S%I,;
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M^2F_M#"$X>.-%Q.&'D@$$DLK(GA&B3B#'1M)!(@$*NNU@H3GY242%-9,T<W
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MN8R9&+I^O1]$43 ^;$RBS^J;*)C01WQVW?615@X;__P\@+?5!VSL>M/#2R"
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M1;8GY(*%6<2^*PGQQY4;!KOPFA^]XRT3 ',B'LX)F$^\@-WKN-W'J#:'VS
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MHY2)"&S9U@0[Y.$-LG2^9TWBON?:<,V "[Q#.V4' *?!;3WPDY\JP"\RV5:
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M2.9."BT,/ N3X=#@1Y8YH\F(,8XD37O=W+/9I@RK99K-M6E8(_5L_D"OV-!
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M/:H?P6@C=V#9(S[&KJ,X0 RJ@SW9M=ZI3JU'1Q>[JO/J>WB=?+1Z! 7=)\5
M8(TP,*,O A@*J&/8JE %H*^V>0O.V(KBY=[VI]?M2;K>QKE9NDFHR\/5&KE]
M5_:G&[M#J>"37H'=#EO6I37BW@05'!1:DIVZ'+7D-WJ[9)"E' V^!8VZG-K;
MJ0N)TI->=)A%AT7(!!E]<_<K&S4#Q\/&PF4X4WAX,I#VL4$P830:LQK0F @
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M0E(K./X=D2,#:!-.KBJ$2F*/='-HWP:Z!Q3DZ)_@"QUQD=,?0<8[2W^O"&)
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M15B67 I:6G2K61Z3A<(15X8(XV0Y1*IP[\CBKTH0*(E+%FOJ_; H8YYJ*&"
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M!TOZAP?72I)H#J3G+]W%Q&Z;9W\7$[N3V-]?8F_CS?F#)?;!$8!)VYX#V=8
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MIZ?BXV7&70_K=<G=+(-/O'Z+OT_I%>@.+F])$]J%RX_9<OB8(0NY:YQAAZ2
M.L>.,\K_B1.W="?N>369(O([7R^6,QGYRWNN#WS_KZ_MSS3:,R&!XI$'S(OJ
M;_AP2;25'%8QPF(..C#_U.Y,^V!YHF<\\$06_[><UHRLH=6<OHRP-)*N$DUQ
M5R-9MJ-YT<R0EJO:>JP.U[@J3XMZ(6(5AV5&9V8ZXWXSQ:I-9NM174RLKPZN
M#9*ZH*7B8P6":++ ZCI#0 )<H[>O2\C#+8I>7M-._9-W"7FATG+L73G8A.1Q
MT07T1[YG)]YU!;F);(FWU4=[= 4?[<'A$^^C'1T\NFX>Z9KB073J-UZB#^QP
M9$LRT4;5&7L0<VG#GLRK*7U\->-.<,QM!WP- @/9I^*ZK0"WX*AO#RN\"^B_
MXH;&R9LS&$;TI"WWMM\'P5EC3^<PKUADGA-RQG9W7B:+;")]][AWB&O(%OKD
MZKS"9>-8EKH&$M+?M73![H@19$)WRFW9WN6T5A\YFNE\;4=46G-#:/8.>!R=
MGG#V(O<X-OU<A$V36^02+ENA&'=Y .G1U]+CI),"6H^0\5\S] P^J46ZX^%C
MN5!.JV.*",<GK?2OL\$KXWA%OCU/#A@3\H7F2!*0D;JJ6_%#/JK9&L[30!,I
MC66%>0.#DB4<#"G)8B5;N\FGMN[L'?;F:EZ9X2.!"JG=\(3^7GWOLD+'D6!3
MGL/13#LQ_>R2J+YVTEYDOU>UQE+$SD;GP2;PV.)T0I1-X&3H) @D6]0F+QBL
MP[UIA4E^RK.O^>!6BU%1:NM&G Q+LLS(D5-LI^2<\#[SE)?Y@G9]+AUD\21!
M!O*#KRMWGVR[W+UQ+62?FS/^&L[X>W/&3^",GSA7>\LE,8<2HCR>R"$RZO,I
M$N7 I+%4=@&8HM'"0@/7KEP2DC_AA0BCHE@,9[08"IM5OST.==3YE'OVR'"R
M\;AJ$5CC^SQ"2O/H!^TWXT:CS_E[64"VO%^QH);"1K)>FE6Q8*'SX'Y*5B"]
MY9R^:3+Q8#]]_'"?;GBVFC62Z;)N(Z<DEW;7#%IK2=>>01D@KH>A+/,*72,D
MA!B-7Q47UE=?(:V>&NXQDC.B(D$R"M=_D7V43)J#6FQZ*5889- KZ<>:T9MH
M;5K\;;[>2UXQPHYG18NC:U=SC]6FF!CU] @"=)YIY@^!$,C%:H15%J3>N)I5
M<X8A<_:O AH1_W[^]A];GRC]X&P)[*"LT9BC0@*8I+E.2:FEM. 3;97A^Q3-
M2+VZGSK*?LUK%TG^D&!!NM(&L?G:Y0$LR\I63T;'HJB#;MS\^5V$,:'HN.D7
MZ8,FM6-#;U\DV0JG05K(\+#DKHBQ$*C1UP60.-:4/-8W@;+7K"T_@XRLMN9;
MC:_<LFC4HRV*1EU^T;[CM;IJ@=(?/0XR 3,NE!CKW1Y9@8BDABRM!@#0K"[*
MC^X^<G<F:<+'1B2FH\*7])#+TSCQP5+?C$ V_10OP8S]&<M/;1BEEU[?F$DM
M"5^R3ZR52 L>//C!B0M &GCLAH5#<F'"<37K5\YQX\<=+IY)I0@WV-,3-:99
M,DFF)>MV5A.+V3DY;#*K;;WW68&Y\,*C;$S%_: =^EULN-=QAD0C_ENNTEZ_
M/1$,I+G+V&E\RQE%9H^I:^;S1)_4T9'F]DF[7#(^J'9>'%Q!>MHHGQ6:K2LK
M9 E?,$[(FU5RNN(C??B$32T,SZ,ZJWH^.2=C1."GR-;@@6(Z/3I,GW2_,"DD
MMT,6V>,]@:BX-]SOE$IGT1/Y@L+.H87%G:/'!D"QU06V'<WL_N,?T,^^F!N.
MK$ +C^1CB:SA.%.KB1_Y[)=_#&4IR3E&1B]T/MDTVWH+ZKUU4%M%IA2?PI+,
MB[.\N<QXXMU62XOM(EG@!GDW:^TI1PI/[80-O#\=A$',1S[NEH[T(,7>GD'"
MS:L+O.D4A:%LB(]^UY!-%/G!)AX^_,''F]X^W3WPGGQL4-GYH1.[*! C2+MA
M#;=N.+ATE>8B@T6-:,V-\PDZ41QZ3<7="4U%W2Y!;<G@EY8,_M*6-]_;K^XD
MMU,6T'D-W$+&W9+T$PS.?O1S8_V(TTBTJU3FI_"I;=;-*E\$KCC+_!#2:\__
MQ8 OSU]V'.I8:N\[S]K&JDU<HX_M@RJHXX%[T6NY>(F8X<Y"[--CRA8^?U>.
M/TX/2.RK-SWHQ^."!,J&G=B.I*=IJ>.>#KC]!ZR*Q,'?8Y'M0LD]P1WKF/U=
M)B*'0_URZV6W2*1XAH\>Q%I4Q2W"P[HBKF=F&-9VL=/ X8T=Y $E@(#\+G?9
M[*L#G&-&MO!4EG,T_96>JEVQ*;XS7NY/&)V)#@.A-VRK=D6CS,4%3TZ>TIXZ
M\#/\Z5$U6>]*V4!5_MY.(>E'4!$M%FF4D"M<K=#E?,%I%VZGG!Q/QCFIF.9>
M<))"O]G ?]D$\9I8!XWG=.AX:'1JK<GH^/E+:S!ZL:..Z7<\^WZD3:#1=-%S
M*XF1T2'N--2ZN3- &I<^LC&-R0'[H+>MD$FZWJE+-!]EA)0+>82@*- LD*:6
M#T3[:UD)/</\AZZ?-; ;Z-%;2ZOTSO(@"&?+ET;-LF-E+I*FD7#8THS0.C^M
M.3"WYE7@QGK1?7GXY(?0(:3'9W@\69A(N%C@)VAMIV_A=NUL, 37J"&OL6FD
MI#1+8(NFZJ*MK4#"93+0NZ\H >[GEMCCS[,E;[+6?QW P"[3_-LB<E\_?XE:
M/$GE7*S&4_$RQ$WGG)(: <FH7>',<JQ!2YF#0'S&X%86QJSQ]?%J!<BSPT0?
MJJXS*2&43!A<&3KK+#^DPCPAL:%WF &O$MO'E=&<% (EX?W6\ HYD%G-#0S)
MDE:N64:U-6,2TZE^;%'-<^EI>$K7''E(^PO-[1PWFBM52O=K*5NRDG'(:XEI
MF)2@V9%)4\M(^,(EKS.%ZJF3_Z(D8V#5HB)LV,2(E>)1>K@?]'GL>*LLE%X[
MD^.Q9!&>I$_"WI#LNDI?3F[G;<OLO-F+\@MT$AX=[!T->J&BO (W%$>L8(]<
M<,?(JY#R^ZB])FGTV<<<:._H2$CKZ'R*5.KY+ _65I+*4"M5A;H96NV1'&@U
M"L?KU2WP9)WCF24<DO#)=F]JG&7%G+/H@UH3VRF9'9P\/9Y-.\*ULFOH#7F$
M**93K20L.=JO014],\[X-X4E57V6.K <Q:5F5F@=K%UZ&6U=QW.^$VKU%+AX
MPSEIAK/."FYU:4D'!EPL Q2]LUU.CM_MZN_,ANDE2"P3MM'0VTN>NJ5LE[J8
M#J0K(0->V72C 4]'5:HL."'I52N\&J#R0P:')_L_<-/9;M3J!W>E8)N(:K]M
MBO;$ -6W(P)Z$N/#G5!C=\XDE] XN9BHPY1+<'2/%$1?*Z3)P?WTX-%^'&.\
MQ!/MH-7-+1W^(VJ756N1RGG@?=1+E,/#!WL(479GCHLB3"N2M^H73W0*-P9S
MNEN>U7M\J[)Z-^JFW90\W[%X0+W2$,YD:*!XM(ZC#$AF=W7E7O*VDP3O^O(L
M+A"Q\/Q^<(PM7T\.W<L#GV7,-/Y\Z,///M\0NY_P+)D\,##QO),.EWS#R$KS
M_UQZ)S1).@N27CU7*$D@M2!\PC',&-85J55!%CA&J,],%=XH7&U;>[*,]]6\
M91+(Y'8P9%AE>\.)#0"/I#A-G;#<5?U_'7:,/[IL,>#0Z%-H_/$O_YI$&W_T
M:+\*'<<KN'\. J04 ;E2*PBZX=LL/$LZQE%PG$)\:A'0XL^2H_(MRF9YTAR7
M%I=D/ N793"E8(1-RC*D)V?''#/$1GG=B]7Z'ANB5FF86NS0OR" :0V8=FYT
MN)^#)R]5A615YU*>#%U%.SHO%G+1444-K&$V'B"_V++<VQ80RERT9M_%0=25
M>4L>OV514 J[Y2>!;M8RF!%(QS@$4I'^CVFC-)+9='4A29T5Z'\'1"5?PDA.
M<> S+\^*NBK9/+-PR8=7SRQ,XG2'R3 ]H'R-H=1,7_QSD#<B 'Z.7;$E2((E
MM\MESHV/)PM03;!N4>8.@.M%[GQF02X+:H53+..J!'U<H=$CBR1VJV>2*2);
M'.DZS<XJJ3_I$L=9R4PQN!O\=%KZ^5IQ._WM"CA'.=ZV+G,Z=IAU4G(XF8T3
M&L,BA]-?- M.54O3.:X(#ZID.J-8<&DX>.?FVQ_@_&<>M(MC\VUX0<+51*Q/
MCB^?*X4NZ9';88QSN%ZKJIH+*PC">-.*'KZZQ^KZO$H^%@QY/QU88;TAO,[>
M4#$K1"@A0-5'PU?'QM&49!M83734P@ABA" A5\1XW"Y:0;Y_.Y.%[CI=Q?F\
M.I=*HWZP-4QC7-^'NM%A1IR+8W<NDO<BA8Y9"AV[@W9L!XV+X%[Q^7B%DR&5
M<%'%^+9?R0\;KUC6O48D^:I&E(XKU]![R%GIII%$O!&%9N7^8?]V[25OX/-E
M$[+_"V$1\GS%W3=&DC'2&7'73GZ\Y.K,GKR0$'^^#JJ#.#9/FBYG.F;D%)B?
MXRRGY\RY6F55DU")F?+Y7CO5,;""_'XR7Y%51-*KO*CFCHSL!6A0>6B2Q.\4
M;L DZ*Z.L[(';W'HD.3E3,)3_8'NT<'WO",F(>@[O"(1R'%H#-IM,[N@^8"#
ML>O! /_13]_$W\3J^<X4M O=/66/23?)[5SXA4VKRYP];OW[JWK]/;S@='@D
MD:[DY#NLHV0 W%[:A?VV>QG( [8B9\7IRA/IB D8QG_"B[>++ G4K?2F=58P
M)@;&*7Z!Y^XEPSHS3IU143'4BG,G8@MT>>YQDEQ(-!);*QS!6F2FP:UB(-BM
M2W@\V:*$QQVISA=84#]U3*CK&4YW3#LWL0S^MC+M/+Y*QX:#^YYIY_!H_W/8
M4&_6@MR=T2_>DMNZB-OMRP^XZV:3QE:W^K&!VR]4<,[.?N'L[$!MB8X2Y77G
MXFM2HLLBDPV[*W!]?9S/O+X/AP^'H@%B0.QJ)#@:W*5N+1[!^]F;G#0;8>!1
M61FU4 22'P^>DBP^)5<8PV:_MQ,P",/"0_$"+.@#7^W$[C>\:RUJ"0NWR3LR
M2F1=W?S3,J\+#NHSDRQG[5PMA/\KHM4.18A7H695_IQS@*#[@KWD52\.T%T^
MRP8**MG&*MF) L4ZS ]2(]8[G^? M+K'--E")Y4:6ZDK*H\]:VTXYD(ND[:V
MZ*S'FRP9[(+SISX?5\X;U58W08F*Q5U2'@MSOA?DMZ$"E-8.OKJ<5A?FO]*I
MN>A>1&ZA<'Q$@1%Q0<-$J>%::?G^>!][#^DUJ9FQW <G=X6:6+<D\I1+P^54
MM435*^ ."\8T,DQ;*P)"8'XE LK!@>C-6(55P ,<,!2GR71>5*-YUJRX2A$
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MUM)C1,!#0/!P3X_*^L*  #GT7##=L"<2LI 5M[;+71ZS84?7.=4>)!<AX6+
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M7N$P#,YAZ- D;\KP'/>]I<YH"K"<L,O'UC?63:9QL.7G[P+M]^ *VN_!T<-
M^QT\^JS@YDW'-?$YM8Z^6Q[3NE@Q2G,P5B-</.I0)A*R01PT#C_%5SARI@?P
M&T!&1)!;R?<Z&BDEZ8X(@,K<1S%GE:^KR[AA]6CNJWHY!$QV:S'V 6..H7:C
ME@OI@4$>=!BZS*23< R7X<+=<:'H3--TL[PS\7ZHJ"> *U6OZ,Y!"G69<=UK
M[G!P^C4R,^)'7R%X=<L\VZ/;ZME^]\M_4_H?_I*C4!<1YV*137-7@=N,R;QD
MNB8!%NW*G5U6#8I:RR0G0[<1PW%13>FVS=;)CN6?;\C<%(EUPT;U]MF'&S8B
MA:G=L%'=HS.8F3-XP\:VFFU4A1>H0,G9V/>*YJ;-*DL>W.<NP;O5?!(8%:__
M]J/P&3I5F%X4M_>-4L/Z#TN]JJ>NS<Q!70AX\AH]MMDK(>V-+^2S0M4[[% 8
M0I:C8W@AQP-6*/U(=D;R$XP9D,701T9U5I#I\K&8E/E:8&*C>38!?T?&3A<F
MG(RR\<=I3<[=Y)X!14.#B(P-1_(HS\8T 'G-/\;9U=#(2GN M L.A 4 0'Q2
ME*U8-MH1%2_#!5 61S(&[]^W=ZL%M7?#SL]-.\]O9]5*=)-7:^UHW*ZR,@>(
M4H[<\%D#"K%G([MH3-"UED_76=$4L']I8[7IJ^3C!='0UMIWPZ7COPY0Z_N3
MIG4"Y9%WEKQ504<*+WD/4?Z'EGG^&8/B#Z^">7H8U)/>/]H4%KB51^\G=*X
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MP? 79K:]);;7F  N&5#JC('01KN.;05F5$5;#57G%-K5(QI'E&R]W!A+/46
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ME9?>Z9(R*;?J]'\U_@\RA?Y+8N=.^MQ)GSOILT5'R;/^6R !QHIPJ[\HS^#
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M\Z)9"/E/0#IRF1=. E*"C>(;</L>\0HYDE>-"[8J>5)D0H,DGPDE63AGZ"1
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M%:YH @'N2T#5F?FHW9;+"5(_ YU6HSG"2IC2P]B^%72Y?<SNO_[YHCIV*]A
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MH)_IKYKM%;<%)N/%^>P3;5>WY4?<69<6>?T-DNT]^O%]*9.UW>1.Q;Z!;>A
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MWQBD EAX9ZZTI]@6)@T%Z;LJA7:)#9X>35S9F)ZWSHO@2:3P'9A;#XZ>!7P
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MOP^]*GP*7YF&_JNP6WY**)H?I :31_S</>?BI]C$QHXI)16R,QTZ>1B0LNE
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MV(@P_(%S9AOK7'_2QL[B&GG<G(FU]>KL7N#G4D@1!@!CYYZT!<.;]5U0F6O
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M6&&<F%^=%XJI6WB_0SXN]M!,!. Q"AZQ'>9&0A5V' 5>LV&47I5,21]X@",
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MYBE)Q %Q("=Q@O\\UY$!+:T_R6BE**>&:ZE050S ICZFI//WAZHY.C?"EXV
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M+SIJ4M%3:OR4.84[  +G =.9Y)Q5V]W2OU86,SQEU)]Y;/63BXFM/B:W\W&
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M,!&^%%"H"U_]!@JLWM+8?Z@KX'2%3WV-X VD'M6G8 $OU2:?4MS%5<^Y(08
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M=IAYN^&((?\FR'*47D7 V:S^\L-KRN?7]=K":L# 6/'5&,(QPIT6<PW'%HR
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ME?4LVB&'/8OWLSRDLWB?Q?LLWB]#O!?53WT5"DN&##FKXK9 KJ%54P#G2QF
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M[LM\Q41&Z7BP3@L$58,LM7J,X@M[XX540>>,VPU+:4X%\Q:F937BU9/"C_7
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M;= /;[_?8&_@KX?B(0Q;D7HY9U8T4^2MM1I[6".5VS9OEDC06G?<TP,65P:
M(LI:8D0K&X=K8LD&RUC"7=G[ST,C@!Z-JM>Y][6_"1*5NS,(RGS4^\"7B5,N
M-IQ_?ORC3Q:X4O@^9SEW2K]J-VS9O;)T&D1[BJY23E$H6"*['.BBIW/W>U\2
M(2U[<WO_FNZJWEQ!MX;,LDKEHT^45=T4/^.-A6Q6 ]X%F51ZA6AY#]J(!(F>
MY>#$JXUN?M (LJJ]%ZYENDYH2/[-WS0,+#][0K9RMGCQPUL3V$ &V&+'EBGX
M^.%0P:J&D A>+$VR_E"WW>*[_+8&RJJ_T09^Q*&?'[[[&\=Z/DYO0YPS\R(B
MV)IX9+X.)F=T,*7_T96<&0?O)19Y#O:4_CJUK&;]4PITTDCL08"CWC$==;Z^
MI:"FTHUE"^4\3!;QZ?6H1DBS\\]#WP2,X.M)5-]<:(/]TGBQNP9AY7][RK._
M\4*!=O#S4SXNH2S8Y7TO;9;RDUZ%9^"4#](Y8=JRUDO*]2G?<B=]*EZF4[XA
M9_*DIP_/._+R_)_>GXP01AV53UX!$AGU=#P0'79_::%?B;]$Y"(1\4SN3044
M)=PHBS+A>()Q!%:DG3(3O9@G31LGI)=W<"G]2-ZZ?4<'[4L;4/[^^[=FXM[H
MW/GQ;YF8YS5(?KBGWII&4]2?\N^]\;/X!I3H:S)X<6GJO@.^2N :]:L$:Q.I
M=:MM*5A"2L5U2%CG7XQ$@43N'KBN;. FCOV)<2SP#6]9]!$18'C(1)<FF#CX
MV1"D(+3#;<[AG=:9:5R36_:W^B3@A0UNX!'T9B7FM((!,GA!S!NE,\.^#Q2W
MA<6+5A(FF!.<\Y3C(>Q3:)P9\^.4[UX_,I-93$.QBM$PE*W!""CN %/+^\4"
MRK <\R-V SFO1GL2R/IP"XUYC2E9B.8E1A)\75I]$-TEL3F)71T,2M)7AL8X
MMH0U>\D$R*BTJ M,1,813#AZ$\>T8RY/2!;C0\J:Z"(A7&SM?XT28SL@(!^L
M=X!:0N8F.VTD[L? .$&(C05'ARGF\ESVY7NXA%X=PI)+S ^LIC*_:[GU0#![
M8P9$$THT]IF-Q@4N+Q/YYIYJ,07N:8@%AE*M^K;S"\"F&/72PQ-#/(N!M=8B
M&92%NQC)"HQBT(9!T=3&A0,M=JZ&-/U]6SMOU5Q_"';B\46&?@S=1).5HJM,
MF7#RNH[D-[1U1ARIIQW-A._3'@G*9F'$=X>WBP8P=+'#CO%KO*V*6LP,1UQ4
M^IIK@%"U35F8Y6!+O-5O(\Z.BV13(D94)KH:(N/!CL I__..W-A1.U=LU<O-
M?529V9#%CC?0)%7&Z$K-]JLTBWQ/>C%V=AEC6'5 .,@-<-A,B$^,012:+@+,
MP"VMMOC$ 5.R(3]5*F703_B;QNW[COWD\X9;?1]=.]Z@E)C:WU%LGAIGH^GZ
M H(7V!&+';A\7HT[$1>1D2Y)<NA3M Z1ED$CA#9NTL#,JT,(JO?,#4LOWGPZ
MB5%\ (_6V$SBN:J.2J<(FPY5/:WPO2-LJCQ(C3X(B 35-*Y'Q\YT "#'\"J%
M^M56/4;SHB>%6&*K,35=N=#BCA8OHW,=-9)SDZW!3]F -]9\HI"579:!Z+_W
MB@LR 76-]+>:>2D?:X7'7!LUUT;-M5&741ME$T'/O65W]7^+U?LE=-@&7([7
M%&),>>&_+99%UXXGQ7+ RK04O $+L6-(!W J4YQ NKI2D] 6(TY$B5U#-P>F
MTSYPY@P:#S S)JELBG'M^HJ=17#H_<<PC]P@=SK]"SUO[W1OZ<>+]P5XXQ D
MJ@34W+@[:#7/53R4GO,C:*2C]\+ +_V!R 2NQCZX@Y (-KFF^!\I:&'FQN<G
MY@YY3C=8IN1-9"Z \?)P9^SDS.A?CN,'OO<U(=/OMF!FT<3 KLD@)Y2/>7:<
M&@RI&W7W_;<%AW>]>#[<-FV+43D*5Y#73W@>V,[2K6^TK6E+IP3G 2C.3;$B
MN#D:Y[=%72+"&3TVCO;R$V&-BHX H/0YM*KC#N3A-PKF'3ND&&Q$5Q;MJ!P:
M/2))^/#[LE;?Y:7?PA=E7NQ:Q/]\!+&='F-92^\:W'W\$'J.2P'O?/GXP3NS
M.?C(E-IL#L[FX&P._FIS\"%;_J!M_N<1U[(JI?)YC*=(_?P&M>N*M*LZ_?1!
M;STZ9"</W8S@$S%0:%I1&X,4(CF,=< G^U^T7>F6@&9 2^P??;'H\ET(#%*J
MF4J^PNNE3BW8?:T:1(*A"H8LA+<8X %OSGM,W5(M(O_.D<EIIQ'"QYFL"R)G
MV-+3GINT<M@X)._7?<F]J'8Y]2OEWV-@9<=65GY;%VM(,5'#9Z[;6SD,PI@>
M6H@W\A8E;,!A>GR)#8:%?P%SAG7SWDIJ9,PT&[-Y8-?&(7R.VJ.)#$Y!'@QN
M,&W!-IRTTR;L/2FI@MT;73,:55H_A"R=R8&::=C.6(3.QL=L?,S&QV7$HKY_
M^?KY<U'OI*3;8%($ Z(L))&W04POXK%0.;:K+52K8GY/TC-17;; 1#4\$FGV
M.$0%6J784$"*]:GH?%"'\/=^;^$0D/VTNAHI5.AW_#BKN"%,54-Y)5</=E2Q
MNG9EP=W)LH4Q$# 0-9Q)F[&^#8&D]GKQUJ\9M$%/=/Q$@&\D=O>[!H%FA7S&
M8F56R+-"GA7R12ED*-+84?7P\K#X_N6[;U]\3R5)0"8153R,I/7%G_\.M?BK
M754L^W;Q!D#P 6-?&$8)+->U1D#4!MK -5$-N[7HK.T(HB53-I<RYW;+EO\'
M^ #\^+8U=MPU"&<J,@S<2](QO14:&(2N>GT(53OH!WL5B@D(&9SZOD5U6Y>W
ML@H].:H&1^IU:(@[ .,+EOMM"M1>RJF@757MLH;>;C(<4,_^$.[:3-J"MGL&
M2D&%S8U?8=T0I)^!OJ2M-Z"H6ZY 6KGCZ\/'1M .I)8 \P%Y;"3T0$ L;G0L
M81:#!1DT6]_H8D+^P9MVU(%61OO P<U6Q1G+QMFJF*V*V:JX#*O">J2)4]R*
M*SE G3Q>+SUQTD_TT6=M=,9W:M9&LS::M='E::-I.E+0/I4P(,C'7TMA_>*U
MU-V_[0&67SE*5!.)WMI6E#Y_H1%N?D&K7DY20;.A F=(['(AE!1%<F$*HOA*
M:B<H:>H8/UCX3][F18E:@I#Z@@/,!FQ\+[9%N6Y,I3.5B"Q>*J'?:^8;00I$
M;'F25Q4Y7_Y'R(T0_"VJ4Z#HL?(2A!H).FT\47_T>X(Y$LF%]Z?9J8<ORS*W
MBX_6;E-P%:44#:QK],)AF?Q76M"V]1ZJ.KJ&_K6OU]YUQW]0$F%;-/6>G?>/
MLV'-!A"5"S>0?Z<@*,TX<O];)(*E)U90<;K 1V+2W,_J8W*FP6U%MLJZW4.%
M5AM17_@SY3\*E#!4PWGKVHZM#N!H@ %O78E1%_MRXBDL@'@%S@#$UNG^^2,!
M1>AS]YES%Y.S@3$;&+.!<1D&1NZU2'U3]^VBK+VZSFQ%=MWX-:PFJN)$[\CG
MN^+JO>1N\=L#C%UH;++?DTZVE.2I"QK($IA::E@M&3$M1%SEI&(F9Q194F%L
M$AH>T&"Q.7&*^3!B. "1U8@2-X6>YA>"ZLM,;2/4SE?K@B@N$F85FBDS8@QF
MDE!70&5S7BE-] V2+:F!YW;[LCX (;VK;O(;RGN8"DM@4:+8-U>$EM)&E-H>
MA*IIC-^/,\&K^79;EWV%0,O0Y&5QTQ<0NZ@,WS$PU-SF2)<1?0S_XI=QUY<W
MN!/,/S9$# 9[8^)LTT>3Q -#!$,T?QBSQ_"+9'N*9M7OP.I:T>99,H)U 35$
MA"X$FXO/ ^1A IT^D/2S";KI@**(^^/L&^=WII/T%N:\NFW?\H+ %B#_AZZ.
MV_@1=@_O#77>Q2%?/'G\Q2'GRM_Q6 B O@7Q3O<T[RR;2TB%CI?9HX,+DLM*
M*5,5?E])/'$U4*[4V3X;TJ3E)34&"V0QA)8&Y<[8ZQ1%K!SO,=<]-ZF*622L
ME%!<N-5_$0S-?GH*T^[]T7SGKP<P1,/*9;:JL-AY&=C6# =?%^U-W=":9E$J
M5Q\1>">@S"\'6DWWLQ];J\Q!N/ZK8J]RTV"VAW6!.)S.W9#H#>EU^+$VR\,Z
MS+PLR6C@UJBAQRE W#LBXL>78R@BM,'6#U*QIJN8M!].QKK)[ZC:TLO>JZ !
ME8!)6F1G:G@D4'X@9.C]J0>1;18VJ@!0-5KE.\6J61R^Z>N: ^L <SV@:";R
M;XRMA/1Z="3, IO?1WQ+8-0,&KJA @+B)+BUT*K-G,/</ZH!UG8TM62#\AO0
M4%P)T#*V+_P038T6+PX0)BI28N/O=75E]):8#JVYA+ F7@5[%5O*&Y >JP?K
M##,IZ<4;Y0$:[>!F^%;HZV[8THI854;;6CWWAQ:Y+0+#I)F,-K> VL\=L482
MA82_6N\)'0 !%2E^8#K@%M&BS-VJ\D** WAE,OX[/*F5QH-+QSU;_"1=B>(
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M[U>#=X"#13GVBUT<ZC[4QH2KJ0&7\1N"P9NX?@\[D*^),Q?W=63@UXN_U=4
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M+*0M&^0V0P8$AO(;>3S2[<*TKXI8;OUM'S\_O\7:2'+Z?-,S/_B=K+'^*@F
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MC#%<_Z]_^^S+KQ;I8?!_-/ '2';_7R_\9QWP"$_RK -F'3#K@,O0 28C/"#
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M0#W6=Z*N4@@'_]P@;A\\L]"C@IQ>V&#N=GK!Z06G%[9#+TS//401#90H]6Q
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M4)&EL4?71@WB @?Q3^D!6NOP@C&P/I@2FR[7\*3A)/IE@9!RX*P"6\E3#L%
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M*';#X-S;'*"4R]F753%H+H3'U')H.K[MPO:9L.T=9O P1L/==&C9YF4D ZM
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MF"!.C<S'8GD")&%08*K'EU6VQ5 V:9/ IR[MVD=P00(#'8MM'ZUB&MTLP(U
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MJ'J'L%513!TR 0*3::,BL_L?"$C9:H((9$_(4"0:@DIV39#7C5\Q%"*8VSB
M2Y[WT<'N!6!L,>BQBCO7WL?:J$B=U"'2P LJT35"'S,R4H8^E*PD&PG7*]&W
M*E7X.4:4"8._CR*&! MC;0<$?N=E>*GH%7+-:JBF6NX\^2O#-)3OY[G7ICGI
MD6K\E\2"[R$['ERK!-S<9XC>BW^>O]_I''M?X!#$*.IO4U!8!2Y[.)4WHCU+
M'&#D*\/9#&BM_BY!CF^X,W@LST4U?JK4D!Z)CEYE;LY1CT'0^5MX'H\CD;EC
M[D[$[^'L:>F\JM<0U]LK WL\*F00,JJ2#?V\]O'/\-)4]LW)/JNI9C=6AJ:>
MROLUE;,<TK(@RW9Z<VH3"A *;QR&81"J/!]3$1$=K HFRT2,6E\R+:A[Z$K"
M3F[D+2V&W,.72Q\C$_T,1+C*2I%"FK8'".6=:FA2"\E03WPAW=)/1U*WH0N&
M8I2*I1CV3^7Q8V[PP]K<J*^^"2O*PAV4'A/U%]7JD^5V"#P'\I54(!6+[Q%*
M;7K5$ &Y6%]F*?BJ:9S+;J&"=-B0L"GC8CBS<H5GCNETVB/J;FN+-N'>"P7-
M!6<\!(+$J?30-)LJWB&9"]HT*E3::T#J"W_.%\5*IR.+*K0W3L'O)RUE !6-
M>AUBVU5R(YMS)0A8'-#D\WEL@:I2V24QY5BQ4"N14U@H/0J_2G%7T:S HG<0
M+#KV>1:$0WZ;HJ&IJA!,YL98@TI[LBM=.7S)Q=B4*D6!7RLKIC_GF^DJ,JJH
M5)HU? "U/-S$J==SIW<.',7:,R\SJAQ "NN-PLZX3"XNHU!E&,B,EV$:1GRS
M<E$D>-C70&,XKUHYO.I<&>/6 +B*F/ ]E;D-]&=K>T7K:PZ7G@'O?12 $5)@
MNW=*_;S2D*D*%)E.,5W#/6'#\H=,EZ0$Y8[9XTJ]7_V9OM&:71;!M3R[<$["
M\G,PBPH)WSY![]AZ\L 84H0_)Y4R6S@;67O[0_I_;H=<I:3VP?;!/79YR2['
MXMW8X:@-,&?DG@@U 6[-OXGU=:B=PWF8-P/)G!#C"JXN2^54!LNYH>OY41K/
M)E1M!Y;_'B2C:#:HK$UD<CZHFJ.0-2;\C2_5DL"/1=C2V1SZA'X2B&@=C27P
ME!^JFWPP[ZUVY^Y%)ZL:X+WE,IW)@,@CV-CKCY$AY_30D#2S]0AQ0?XPOR1"
M3H!1LW]DC"C(3($!V5L(-O!-SDQ9[9FZ/@&EMQJR7./E68-0# ($OPX_K?>S
MY'6]R6SZ/Y>V/VL.NXP$?A]E:O.(2S 9<V!-&=1!/P,+RQLAR.H8S*SI16]X
M4A"KBON4 >6L5)KL@ X&O4R1#Q43U5 ,^)F;%.59FAE3G66/S'>4LA9>!EWG
M4LL$_9 ^FN$H-$*.'KW&.(HZ]PMOUA]2/H'YV)A!%5#.!M*I 9M:?T%!>T1H
M$8?WQ+5L'OE.JV6EAH\#BHV10<&(/G.HH,Z=[K:2'_P8C8%5?8=%-W/6Y)R#
MJZ8"/78@3W]?+R+-;H)$AJ9R4^5\>9%K)61<@QFW3]WG244X^1Y7O],8--.'
M(CUH<@9-P8/V9.)HH,>@ 4T18*2DWIHR)%\EH-F/U4F+UI0L$]FC\RMI6(#&
MGC L2[ZL%F!P;'F:)$(Z0&61(W+%S#XI$"<W(L&M:HBMA?.69?P.MCSCUY0<
MWQK7<;;4@-!: 7O@HKRPJL^H!F'&O)B.AL^)>UNX:^\V:ZK8:F.[[]URN1)I
MI9$>E$6Z.IE!X *5=^0YK=:1_.1CS9_^?!9<J_^<VO-__M!AUEWGE>YHB"!_
MI*?XA;,-,K21=6UJ'BC&BJ]'Q@%3XN#G>S9^;]'-6=+^9!8SS0GUIS\=@)Z2
MOESE9:4ZN;X.;#JT!6_1D+D)N/<N4B(8I3KX54%2R+Q+0JG&FCR##.$+_6O\
M&9T5_0LTV<#P_#__L7\\0_/Z!G4GZI<RK"2V$_;+3FC;Q/T:MK6- O^Y[\\3
MBWSY&9;\E#FBT@_=0"[S<JKT2U I4ZR:Q.M$NBK9(=EM!PT&F/D:!U$H%0-A
MG$Z5E<T)(WPR8032!O@BIPHVC96=*G"JP*F"S5 %*K'"M5,@\4W E"$[K(B,
M52!M U,_9(K6"D',N:GB]40USU?,89G8E M*-=&UWCSEY()23C$UX>8\L5K*
M@Q@6+*J0>"13;>>"B@(E6A8J+)'DIOP&3@'$L4X]<+>F2=E%>E)JO0 ?2/R^
MW/(]7#1J SG5R7@GXYV,;Z",#P4F B(CL3F(%,1QVF>,5-E8H,$PZ$.W(AMB
M09>N>%E-+F^'XV$::!<J+YUOY\;1C-'6*G!,5FEK N_W!K %AI/@]MI<B&_:
M$10%OE?..N*D>U1@Z8S=^CC34B);&^M::2W</'C:AX__LW>X7^W>Y7:S++W)
M@E%.5; LR.M:=UO\IPM5#53=D-WLR)UP.OWD>Y5$U)SX9/UI5MK[N 67&__N
M9 5O%=0)6^7@P'""H0@CAGNP,7$SB020R(J@RME7,FGR4/ KRQIV<5,4NYU8
MO;L$$XQ8!@B-JWMVN+,D[6.7<4]0XP<^<T1XHURV_U3S79Z]@O@WZJ)EFI^$
M</XTZ93HMZ2&^#X8LXT1&O9V@^IVZPIS$H19CKDT1]O+54 BN[TWF"#>"[,:
MVN.R;:[&*I\QP,5WT2]Q';YJ0?:]80DG8K#@_&J;G8%SF^Z5E<JCNKTI(QZQ
MO@3!JV"GMI#YC%C<D"3@)+:Z-K*:UFYEXX=DU3=*)171&9)_,D>OW4@JF-EO
M^O"Q0)H^=$<=R'&04SL9]A>M4/&YZ%9NHH*SA@5203**M9L56)@*EQ^B[2HX
MX44P&%B##?F%6L>A?(0_]2>*V%83EZJ\UU6E%#CM">(HA<#55XA#Y@8AJ#'K
MNA]A3E6=H3JK*)<F%RG?$,$S,JX#S\0H*D=V[LX*^#*\T+8(^PO:'@(\C4"\
M?!;%-HEV&L;\ % CKKA&?N$B_Q&\8Z*')N-44+\B:WN%]6W?!C09!PCMAF_Z
MO775LENQ [BT_0J&H,>TB"0M$E'X2O'DU9)0JK&&U=% 4D8Z3Q^Z58H@2?1A
M6M@-]7OB[Q7*)NDFH$HBFR!AV170B:UI3E0HZ"=&@- ,7*+JE84I\H\RO#%#
M*7YG8_!,E>-OW15:.IK#:DS)!.,SU[05\!5@7860MX0](BKR6AI8"-*B*AWH
M6[^=G'Q1Y0[<N\LOTM8]MX0O7ZG,QN6(?X( !\$W,37/ W%31V.%\8)@*(.!
MZJ+7*,_!B.$4L6\8+HED!- 0%;Q=-4$7+I+$]N96[AL2 '.^)P?O:K2S%795
M[9:VUZG5O_:T+%UOQI3*]DW&]+>. T=S![F1,,,(52C=$7QR%HE$=9PG'C(/
M=D!7A^RJCDT%.!=0MU0 9BZ)(@.;UX^R/BC= OE%(C!9S=W<*8_L2G^!545L
M @ %<0=_FAO92TL^PWZ0982V &*P% MHQ636\U:#$.4L>.-!IG'>90D/F]TM
MD!"5$2XT,ICGLTA !^1&<Y"\2_Z$I+WF,8*&4?.1*]A\"NN@<D&D/+(FLL#'
MTSM:OA[C@/@^^$J"EU>]^1;Q C/3>FS&\ZJ6HUR8UU3;>$>(TVZ#*P5(2CGU
MAM&&9B8Q_5F1E?I,9H%&-[R5YW#S6GDVTPE:!MZW)M=L&,4<BJK<CYJ;RU-;
M<KBL/3./@ =:2:2+%03^78V8,+"96A#,>_\(8VC1".6_!*>MR@NZJB@VV1?G
M<*K4*15,>A1_&H!Y6YRBQ?@-&S))"56Y0BCCX% %@L&T,*C@%NA'^7D?H6+1
M6Y:@D5DZ">)B8AJD%=!>J%'PIELB##X=]LHF0L*:K(SCID:@*6 VNX$>S3^)
M5C<@!"@-(8%Z6%85><%TFW<Y!MV,^EP(WVS%ZJ<-^D.\4*JE3I]!;AU"Q Z1
MQ#6FI1&F(,'E!1X95-HBQ174+\" %^F%Z#9:,&Q,ED?6!4MT1$M9>VDOIEX3
MM"&,%55[+C[#':C%$7XNFN8<0PL5F)A"2I08Y KF@\)L_!=J,'^#&('Y6WJ=
M-1ZJ?FWX,@QPYABQ>Y1@W'K#;_I<JF=R)]@E'G"H:A0A4]5 "  U2^"I$=X'
M,OQ*-'04;B#Z3(GT+2K3!W/M!T2A!#GB7 H:Q16PRIY@D+>858OXWA\&X&_(
MRX>C_&9617.#%**1\@TH%P7>&&6Q>$'48,][+B0FHN(1TD>2 :9445Z(<?[.
M>Q.]]2*D(FE&^XXL."ZI&P,# X,AYC<1/$NM5S\*R""!$!8^,JB:O/8MLJ..
MUM.X 3^D]%Y?SRW"2XFA4KF)V27"&NVHBOR<%3=AN"[[I9A,0AK#AW#4D72I
M2'142*_><?M6"0KK.&?>0$AP<^2&=NZ461X2N*4>46#*>[PW\#9)</6Z6JF
MR5&Z[Q-&0:E_]>-)@HIQ\&.RX1Z20*(7U6'9V;+EU2_O6"_84*$2Y27&BUUR
MQA(."5'C<AM8C.^8YCOE5RJU,8>BZH[)"$Q%":@),+,R3#^\HK#\BL:JZ"1&
ME> ]:=01]0O8AQ*&V<S'#;ZC_@4J/(U*RW_O@8$QB*Q=RP^WJL<)W^S!8F.5
M3EAX-G0 )8U=%-HK901-Q*GC_0>%C-3(N3L]HL6\TR:$5TFQB@1:^DV4*5HO
M2J0.G'(F\7?EM#,4-OA;C:FM/N?/".D1O)P!]5GL2$1JH'XNIU>6V3B54Y,4
M!S#\)?$ 0Z.PR<] '-9(.OT@NM+3<2.]O$1@$CW($' S_+/,BYGG6*=AURYF
M57 Q*2&6^A0;("@^:4-:&7HKB@S;K)4F;<[#YF1))\:^9A[.U1R*BC9'RCEU
M]K>8"Y5J$1@3^X:(CBQYI#4<5L(VS';20&'D6C7>5RK&6?U3YLJH(*]3OD0^
MA-F6KC6!@^)<++D*"LK50GGC_V8Y%\K(26*8ZYSB(K1=&4J9ZC;XRNA0X!3&
MS=*3Q;4MW6O+.UOZG$JP$:66PIQ-:3:,_M,*!TO8YV2B] 0FC>H)N"4WZ5+Y
M7S]R@<A7D^0Q#MV41F)%+$9:";--*7 ":H)\&"%LI[:_*5*MG\4B;9&RE=$:
M_!A.KR'36.M0)1$E4#TS+C 2&;T&WZO>U])+8@C?3$T5-"N4@W,Q4V/TN?Z5
M44AO4HEFSB!QZO=O'YV7UN/(S9G&8\V$FG&*<5[0ZTYKOSJ]:+_5GC>]*-6.
M@HGE]8*8:)8/A2CLAK)TM6"-!779PI'G]QUS94E&/>1O4)G!M&1;6U/WL!0F
M<]X<M(W,XEXNP</,=*$0A7L,%.:2+]8"5E6Z4Z0AGR^$Y]-E;[XWTVIIOJ01
M^?P*1HINJY^IL*6NS-F23R/X=+4TY<.FZZGE'+&F8$=N6;KL:#/39?57OS$7
MO9FYL5G84W7'[@E_FC\(_725]-3&94$W 1,5<;&:BG&Z.KXIVTV"*J8?!>%4
M1U-062H-84Y4SS\Q*UR(B6K&2%!'Q9!+3*IS"+@K!:LTJO4;& :3$RJWQ;*[
MHK;77XF%3NT">VG9;95A-V6<S&_YS3), UD)VNKD#;1JS&]JKLO)U:EWV#GR
MO7G>MZ2P//_*R4OQV_*NK.4%=T$6YFH^,DB1LEI&J Q*'FV2CJVI:!@ E4\A
MQ#UN$+)\XNH?6VKQIOB/55 EF5$Y+BD.?1F["G *6L:Q(_ELCEMQV_2,S8IN
M=SZSUY9W;8>+"?T;J%+L4*V?>0,7VL^<U)RM5Z+:^,Q?XP"^>M4?IA1!&.N
M$=5GI2%:V2PP,*(U-7>JNHJ9:=96F2&+=)6@LGI>L">EH B6&BA4I+[,4.(/
M@E*$05&_1XJ8X,@9DJ>R',7Z>F4Y' :SYNYH;4!OD=I@]CT^C579&628?%"U
MU)FN -4O(RT"CG6.?6E1FIGT343#;.;-#3__<F'&(!<T;AB'51%G)ZGZFJHG
M5\K6VAG-"\:</0<M37;.T*=^W+B5C]=S@::.6&25^35!P4%]8D4N.^WQI+Q>
M"E_ MX1P9ZB8TV<FC))Q*5,SIM[/-\E$5L%&@7Y+TKO$S!S4C._QW (K 8I1
MB0ADIQS'@VH7+95;73[(@PRFQPFIIYIS,@/5%W-TR_LG%SE1)6;-@=)QZ:)F
M.)G LZ=UW:IO>X,H&\W#4K\IHU".D"QB.G49TST9"2S(3+QS-=J+IDSA@&\*
MPWUA3I'UZ(0@>BWZ0[8%OF S)EZ DP@$D=X'/@&X]9:'QO]=Q*$:Y*UFCE^9
M\O]S.9X^KZI*>Q2+_1I3@OU!)_CQR(#A_1KY08S%9)@>IFTQJBWAF3$HV%YA
M)RRAUEGI6D+)#WX.\C#XE_<;S\_[Q%<L4 .CS0-5?36];[N:Q#ZD]1=_GOZ8
M:S3(.B$9,-2R52;]9"$YJQ*,MN-K.)MK#\N49G"EJ&.J*J5&1/M2:.AZ=G@@
M(NH:ZYH7\:;,2PI14VY'&@/\M[<4@@VH$@W/=H=F(%/A.,=.YYW17$.BCL7)
M4,<O3YV6&?9A_-*I^K(I&]^.Z6/])FPBD'D=;/\!?N:4/%LD/+HUEE5X00&.
M :A=I)K*J.$6:42.17/"%Y[97IV"M'ZW$*:@UFZ:.HO*3;:.S])"M;=R*_WV
MLVF'=JGA%^B/6CK:)%67VWL<%J N%JG#K/:#3-S 6UC[)B7E#J0U'(OOQKYK
M>:=T94U1EO4,U&"XIXS315;#C+4YY#ULTARQ8L(!DB.L2IPK?FJ9B:H_R4$'
M&T26492]/SD_0>\P#492#%4+LL%QGV#O"'[4+@*1H9'9Y[];Z!D_/''ZF!QY
MKW$4EB&^-)5*1D"G\S/5W%9M^$S(86^YK15T3W(-(Q/[<H&K>10E6"U;GT,5
ME4HHP^MYA&VX9!K)>I<W%>$RBL PH\J9GBCNA)2[2B_0Q5'1%9&$5G\5 5M@
MO A?^M:,7 6=-]%^C-5 8YNWUIAGJ[&)=ZBJ?:@G2<;[Q7>L=L8FFP 1:-2D
M<W B=]1*V15GUK3*''L"%H5^B/(9ZIS,)\WVKYMIC:^W.NM>162,2XJF2:P<
MBUC734PWH!-%S,<#X\IF@>Q*SPFRI<YYDS[;[)(IAVQ\E KGPKLR\*1L'K.^
MR%&&$38\(F_Q8F-JP\6L;R]*Q]7!AWID?,5EKS:!3?O-@;S#&!Y KT>/B_>Q
MEYB[RHH9,3#7R>8Z?6O59DWD5/6Q&CFIG$*$S3/ 30'^[[^%ST'=_J2//<L%
M'@_6-, E(TTY1AB)N)AL)\OC1-B=#QBA.%<1BDM@FR5L/V]^LKH+]_PZ4G!.
MJ&3&1:,^W>N,BOTFWK]%AIT+%,.G&!\;_FP9R H8+GB4UI["/Z$QHN!"\R1A
M+L96?O3*G#>'(38\97J\F2G3S;M[2V+<ZU:"[V584FNX^6A^BRZWLG$2K*;D
M*00ZX*DA)2K17Z44,889!US_/*;6YP5?(SV0"820X%@UE3C-!EF]282Q*KC5
M*#NVT_F[K@^1C<NL/T18'M/'I9(Q*M*M/H'GKN/,9U=?OIB!QK9M(25L3\#9
M4$^/%)8Z5"W-]?NXD=L5)3NQ_-<[4Y,3(!S<HC/9J;K6Q71*IRY6KP*6U5R6
M=H=D7G9!ZE86^\=6Z]1T%I>3N"<&KXDJ\A4* \XD5A<.7!$.*LD@'+Y WLLJ
M;-]<O *=E/=I6X+"RG4N?)_*K\'!LZ(#^JF/5$O8!-%\RO*.4Y]61F&;4LV5
M#)@.^%LAJ26YP[N@XM3/33)51M!&C <BL19EJHFK^!(L\Q!C08<U)RDC?01X
M"GLC#UXMRTGS8(X^ &EN-'Z(RL&JSF7KSM@Y+H[D2G^0J"/%,V>Y?,LM\]E"
MAB./HW^5$LK2QPL^QR2G<R%D$%T1$--@\8%&?^(7O_F( 0MO5X:YWM:V@"X^
M(5_V]MCG0$+4KG8AZ4 =KAD&//AAG%+3Y2Y\M)4'^=S9!*JQ!I-'UISJ:FA<
MAIVC8DJ;YTUF9?02VNO."[F/^@/A()+>FZH4D%E=M0&5:[?JF,K,?E)O8B=
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M=3E="4:LVCWJ*C-5CP>7,,O>:8I-^E=<^;?*;$1^%:V2\O4R2&28"(,0/,S
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MCDE9'=N&'EI4^H"JC' ;1#$-#\2=#<H"E(('ZRG)YB'JTIG5'$9+W:,_4#C
M$H.<W4SZ!][Y6_B"X@8^='J3D0,\V?CHN'4X.S7^+LV^T0%)0<L?W6WM37VT
M<B)5#3QUQ7Z=%Y\!BP"99O5E]X%:8/BJTQ09F(2Q-PY (/J6:]!+DY ?\WOK
MJN7=X CXA%1N<$/*U):(I_CZ""UW'.&.CX[@R2'-@,UP6:RM<QQP&26WH/9I
M #T9KUE(Y&*+M,SDW^E-XQ3$)/"=D=#TJ<"[C<2='B@?5W2;.O(Q1@^R6Y+Q
MFMIS=0/\"HV$D.Z'M"3P:0G8V>0@T $/0&3E[,89_3$W%K"1VO.DF,./\JQH
MSC:0K1R5?+E#,8CZ$;'3Z^[17JM=8?$66-YZ"C ]0OIC[&<!N2TG2[HIP!<4
M,.39V D*F_FA(+3F;IFQ$X',ASH'OB@_(_U=Q>9PI%LW9;N[>5.VY]^,QMR#
M92.0U[,JE(]3<4G0JZ$9LBV%WQW</J^'@0H1LB]$VK (O@G4B!A;,?>&%)8@
MARRASV9!1-$/N&[J@;9EK#4L7/G O%L:RBD:"#VP-BBV(F[ S@UB#D/D4LCK
MZ$20D![-Y*^D,X+/95L=5&C+^SNXB[>HFZ)!=4V@2S!X;*P ,)&"$):!6B?&
M^\_/)GD% I\^ ]<!XR=DCY9@C_6T@J*MYR &(A!H<.R@;3*T=(05)]%A(A9#
M<4#[E1\CKZ$/'X8-D/<MXF@$^\# =(XNKC3P;/%E LI@B/3@"_ WM@+)9RT>
M9)@HZN?E &6S8*MP4";L^J"P[4=CDMYT3+0PXP\I6L-QQN!I%R;DU>EZ8'T5
MP]P:68U_'$0QF=!X\/"L8ABA'PZ&1+&5,[O_$'S$H)R *S@ *YFH,O%>W1VC
MC6KN+]&1:6-(H&(3&,'(A6 ;E^Q;8I11@.:7^&8NZ_0]!8OIEJB1J<A>]7J:
M"Y:CT1?#!4IE*%1?QR"#T[B1AEO=S24F5V]<=(5/U*VT3@>WC$R#>\%K#/QJ
M;C(*K+SNYN(;\9K'<<M#NW< WT"K?^8@ BG7AB)14I O/)E[@3'L(M@,QH<3
M(HY<--DB":^5/1N\-SU@\X*L"_*V^*+VRCQ*T.A5\D[P93:W#(X(EGPGF087
M8PM98_W,LHXOLUF6 0T'>S>,0 K2PT(Q1ID-BP2VG\!I](LTRZT8\CLS:EU=
M/39U,$?*Z=6'CE]?-G(=8X\_U\]<MTM6^<-\PV<SP'.S];3^I>;$2C=?RA6:
M([^R%(A% 0RY(\_IW4J&0+U]5).;;^[Y++!]_G-JS__Y0X<Y98&M+L)#T4]9
MC/(+9QUGVLBZ-B75X<S>5GP],LY1MWOPLZ57YS#0MMZ<)6$1LYAI3J@__>G8
MI;;B?"^3]@P9:2CBV9G,"QVK(UU.D4.P4"E0(?I@"F%AP1POU?>DJDW13Q4Y
MI]_PN>I[!1Q7S"9 C;GP?_YC_WB&^%0\,E,ZXF1^PSC7R7PG\YW,;ZC,3TK*
M2J H5DZ\D<G*3:>:-=&/0F&\ ">1-Y>OG$1V$ME)Y(9*9!;#%9L;EE)BD(/S
M[Q4+NY+GF?J@,;^=L-Y<EG/"V@EK)ZP;*JSAVS+/),/3F&+DE$B*-1T[<=2G
MHF[.$]0E00K1'R;PZ!LGIS>:VYR<=G+:R>F&RFDTI7VOP,*$&YG9+/JR."$3
M-UC4A9%I;-:#==IA;A>#W@86<\+9"6<GG!LLG-D49OF,[2<YRLDH'^+/.16Q
MF\(O66+.A2F47(P&'A:"U,MMU35A?9O:)X!Z3J1O+F,ZD>Y$NA/I#1;I.1>1
MB'& T6A?E<M*0 DLW"59C+6"&,D>C^.HSX6@OI?VBB!*Z&LC^(?\@;XK$CB>
M/NF)DOMIXUCTBY+SE6.1%6#'XZFK<N6!X)++VH^:!K\XB$;.QM]@MG8*P2D$
MIQ :J!"FJLBU;2]->A;O=CD^]@(@2DQP"S]:[2MHYE,5O!/3F\ML3DP[,>W$
M=$/%M(*.0S&=#+G=4?5G@=6<3_)"C/*ZWJ"@0#B[PO>&U ]&8!4DU_\%YG8T
MB,#$UHA5-MJ3@;'"/L1RC.USU/]CE[FX@/RV\;+3 DX+."W00"U@HC>K(?>1
M$$9Y[P3Q1K*3$\1.$#M!W&!!/".';5P?%0:?LHPI5 (/F"S(?;96$]A; QBT
MNRV 04_ZRLV$)KD2@G<E40,OH_R;]X%A(21H(/\=VXLMP(D,/E<#$#R-SR7!
M-6Q$BA^$"F[8^9T/L'*9L3FFP$H(<!ZQCP@(:!H5U.?#0ES"81J#&983L@D"
M!F61P/!!&,4E@]&=(%0'HQ56L5CH*]%HG,+;RW&:( @*MI;#GS$4@3 B")F;
M11+0VB#&V($$1!TJ3/!X*CS!J&LQK(G!5,PF&;9I#$L B1<!=1 P-!/C,NL/
M"8%["IP2,Y+?0#0CKA1AC"O<OERF)V] K"":F_H$".L;!AE,:*('HWWC(O)<
M%(RX:D/T\DG- ZZAPT(('GPT@\/0"2&X/P+*6$%S1I/)9DC4\IC>^)4R49^=
M0WT+2H;PH_#U4^A1A CE:]BHC)9%"% 2 "K#F/TB'*@Z*  -^0/_3F< JP0^
M$ G*Y?7P*ZZP'P<9-SP==3N'/ZM$L(U%E$T!X]55#&GH&L+.&6=BP+A\'-)Z
M GADZ_;^*&[X?<1F.1HA<."IYDPXW2NX1 9UAR N/R  Y"/@AS=&WET3R)3&
M\I)(8@7!3Q0,]\;@FQ,-[80<6N82CG4N.AGJ%Q'TAXP')C"Z&:5ASK"<"1YO
M#[CPSGN#EW>8ECD\)7_[;GWZ7UIY#_6]>5GOR-9=YH<?K>2&/]DLSX/6["C/
M%2=//\($GC4R^WKGENFA<FL\_,;(G5I2P.K0$?O;JX-7#9A#MMMN'2T9T6Y\
MU)7\PQ^^-DOF"!"YCE;RWA](MO_%60EG]2,@UCYG[#GFAS6## T;#KU>A=)L
MF>;42V-(H=5+MPGJI;-;&:F^ZIC+EZU_$(C>Z9DUZIGG/_#N@Z;!.IGG9-Z6
M7$*<'^1DWL;9UJ<?/K0_G#[!)6)S>WOE&(YHI'#BFS*G*4%O,3J."8G0ZTW>
M/?0J/!D]R.3>7G+\F WP=*>^@AI9TT!Q1R>;3MW55+ZC50-H]3QZWI%A,1G8
MXW''[C2*HY/3*)M-JQ>O4=:3F'FQSN.%'M5G,)_7%3QQ'F.S3OV%R:+7S:,
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M2C3S;\0?W[\(@R?7 W$R2RSYFFJ1=6BL>N!"*<LN#[QTZ=<]<+^MPA7P_V^
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M??8F_L=;)?(+VNVH[?XXX?W!^?#8J7<) P*'B]5+5B?*UWMT="<0H("'PR-
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MSONC/8P?I?UB8;]XWAX<9LXK7]H!^O1']J/E6/?#S',L&-<=@:D9"L/SWHB
MD  (4@<I4-@/&="JD^Q+CP)1@21 D#I(@0)1 <E^0U'8D I*A+X(&E*0.J!
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MM?WV(LUR]GMR;5AF7W#E0<DUWS]+[;/RR9BD!H(8E!B4@"(&/3B#=@[&H!>
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M8'3C#94<,)!?4L(O*<S._B@LWF5D\![PON)JL<?RGJ%5?-!_'6ZXMM8?4;Y
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M\=>#_(5S$:44B>BRN -@.EC;2*[GO.X >W8YU:*MA_<1,H>-R<^KQ1,,LQ$
MA%&.'JO:,?YE6KR:B7O&/-B6@<'+?W\[.US(OUQBVLF)"G*_6/[W2^!(*\!_
M-=THYY8&L19+H^#:<!QON83CCP+7KTY4I892>/H6/-.^#>[(O[@!Q>)0)^0I
M(%@0C[^Z#TZ"K?,8N=#Y59WXJ)N12C+=PZ[TJ)4_KB]6E4D8\#@R.A["$(KP
M,$;,^0TFO HPB2QG(MRXE^?7F+N^;_$<O6[9F*"')P753&UG='81:%+>GOI+
M[R5,&Q\2@%T2/_!6>%2R:-+G*0'8V9B<UN *W*@&%MA)/SM@P 'D F8\\9$%
MHIO><>!B7(OS]P6%!V/G3T/T1;-#"82I?4P?*HZE1^'^9;8N>D0AH/!#$#5.
M\C5)1PPDC_9\KESG_5/3!=@0D]QS18OCL4<<%(!C#>+541>>F<])\ *'5V<^
MQP'W94L'NA5G2,(H'N,F32J)&>9&,?ZZSXLLT"8:3T@E^(<IV C.!<^5)+&.
MJ(4?$Y_$<L#C#X53PMES#DCR3!6J4:R=^>B5+FH*LA;,$!8,]99[8\#G2;9W
MNY0%;O"3;!GNF6Q[>5:$)Y)A4\%LSH1K$J"8X+R&][2"$/^4RX+FYQ7?< MT
M.TW6)_>U<DGTQ1*\%KPK)M!_PDX16/WL7?#3+69+ISF$HD?@BP.D;8+#X*.P
MS_1GWF:,=<@@Y^P75LLI4V9&&T[X;HA;4V[U"ID_S%I'CN0B/)83#_@0?5PS
M$*;GV#B(X"9W^C %WL)LVXK\$QHM$ JQIXZ5%]1VC@F_I%1>F;CQ%<6.&7MS
M')'[!#4UGK/RL9U?4JB:N&>/>.$OW.<Z8(SGI#R4:)'JL%V,Q5UD==%1QM(H
ME$@[F^KUQ1OG5"2U-4 !T\R'4;GYW _<(F+F&E8*PV&6R446Q/B2?^/J%X@M
MKYRZQ<P ?E3LY?RE)BVMB>'I[/RVEN\%N8/ =P8AJ(XO*EQP&($A'@R>P0T]
M@_%-(Z\1*3ZTT+-H(XE_2$T-?)8;*C#N6ZI9H63F(^P;>>_5@C&-N$;H6]/5
M#!=)^4>\N4Y).;-0-=! 0_<\'N,0^^!5#N5TF4^2[1&,.W5X ,@REY[-HF8[
MCOUL],(4!3EP9\O+\U:PEEEJ7#S1I>()*IYH?/'$-CG4=4G826?4,P8]K34U
M1\-6K\/Z+7W$>JV)/M FVK0[&3'M; V%%LXLQXK3"\=<*#PE3S4?2\.=2V9Y
M:L"7Z5 8!SU*S^=[X&@[9O,>B6CS-DMG1+J>!>\%Y)GR&1+MN*V88, QD&$S
M/U,2$=="@"-I/.D^Y\8)*VP$MPT#%QJ4/R?;PG0X CE_HG0XV3"G2W/:TOMY
M:0Q@[H$WYEGV<RXRM%$T8+-AD(MC7E^,(41%/_EX"'; &+;N^];48B)SOCRF
M@1O(N!JY!6O2PEAA%-!Z%DWBHN8ZOP:NE_$_ Q%527W/W*/\L-A//[K(R\\@
M0KMSC&<DM<*9K20/O\7OM>J=N W)F(X)>P80E(ZF1+54>EJ'+))CRW?**Y[6
M8_$KZT&2<C(S[GE<9F!A;-OC$]VXJ4+)GC,NWGSH$M^JBRVN(G*-0.;_#EV\
M&A_*Y(LR#+[I%@\C-LUQ+B$;:/SJ@*>+H601^X[R?5'?DY?)R_&0 8:R0/;%
M!@;V'>$L%#G5M*+=8T^P"\%;6[SU2'F%5WNM\N8FW/;HOY)4HQ?P&V,[ /YI
M^<+A@&+S7Z$?)P>C[^EII)W-K'"6Y),]%O\E[17EF6P.['-FE;.G7HH7$(\<
M/:M3S*MGLM?N--N_LQU#%.87W'EXK> 9F_P"\'>0S'F]/'DZ.>,:KY,80ALO
MTHG[.[F78LE+Y8EB'F)3=/)750&SATR!R:'L;W%"-$[N4*P99HPRI1;3T',L
MWE/+?[)^X;]],:"%UX)BV9:P3JB0JG"6LDH.9@@^90G-X]J64<5SY<.Z/W-C
M8NBV$5TK].-.2:RVPK5LX8P;9<:")]?D$T9%+C,QE*'/IJ$-SM\/EI1YX;3L
M:%"QL,AJIM)LI?Z--]>_K_RFGZSI5MW9EI/ISEZBF(N9$#/TXDQ(?G=U^4T?
M]29&N]=OM2?3::O7ZX];^E0W6F9[.AX8P]ZT-VF?O0N>/,86[0]:O=5K4)CX
M4/$:Y#K4MUN#=U, =.EV==/UX.VW_I)BYH4E.E<^K5 8+TM0B33RF)E(S^./
M7-MXHU4\K'^)N$Z3]''V#J>>/5VO[!/VB"Z(R)J*04%/D8JBK9G;NB%H%T<A
M@,>"W6"\"T^/:YYX?-,30,#FS'L4Z?LHQJED.K7!AYGC# %T0'EG6F!YT=R[
M:6(5!)/[071M.RX:W<RV19[0S$U\,KQ>KM(I*71*YX'P6@+<=&)'-[>P4UL4
M+45U&G%9TBZN1$&-KV>X<'P0M??!\N<N+,SM])/K/'Y"E_*"+PBY%?D9B\F:
M(1:X5BV^6(I8K1/W+[*[JGSMI(UO:HO9T>)->?%-NAJZ Y:35Z1$\^ZF6"?*
M>*?H3_#SL6E5P=*1@(=7Q*$ HM(T6UN(6QC+$$=>1$8A28@D=951CZYX#MQ%
M8EG,1-1HPFUP6W"N?(E_X"4HA:^!ELW )O-\_T2,%-:3D0Q+<C"\T%"8I>C0
MA&CL")8[B<T#,[,C'W)F#(V1$564)I4TG"LL7@,[ P. ]T,.2"I_DF_'H2WQ
M_0F+UAUGYJ4%D]R&8:%"BDGV'77Q1**BD=>+3ECP$ZO+EZQQ;*'RY:P1,?$[
MBX<[QVFAR1 +?]44"WZ]X@0JTUH[@&II(WZW79@CEC%CB\;KP7W/A&5CYNUT
M;R4IV[]$H9FFHI?8?+15X26<8EE-X1=!Y/LO"EH4!8!7+]B)[4BJ7T#W$VPM
M&..^%W'1P@ @<7Q1?2C'%B_D\NH/A1\Z*X),Z086'/BXO%Q4I\.U6P92APCN
MI04<PN/6X[E/<0TYK^+_3Z;&GP?I8F>1%Y+DMYFBDB3QZX4+GW'JP0:*BE?\
M[8I-=73>Q6+X#YQ"TT9ULORX)R&.7&$(C3NY0?9*O'CE9\;SC3?BF7 C3B#"
M-8E^-AG8>R]^S\4VA,S&9=6;\T?QQ(@U$2S+K]CJA7EIFL)^!35_GN_B]JY.
MA0D]*DR@P@0J3-BBKF!=84)W.)J..M-)J]_IF:U>MSUL30:#;FO:T74V[!F]
M$5ON/QSBY9<[305O\HNHT?^2]JR1ZY379;% I^TZ?0(OB4>X^'A3._*2>(0[
M]7HRN0%;?%[%V6+,#W X/?<BW&?=AAWR7'\67TG/(XD'6F6N)X[83,9512TE
M::EM;A+7PFF>:?]#4INXV'TB$GY\()78T*;WYCO]N*U;YTZ.Q["X7O0JSJ>>
MBZ-$&+Q@\BHBZ1G.^;PKWID2AVZ2-? SBV")34PTFS?M;.%;<EWA-?!I'RT\
MP?('2-LNDP=)3MZR_+@"6>SF(TO$>U'3>N+<I).T#7/INJBB-3%^N%R"QL_Z
M?Z)O)^<&\X_$?\$PC?**>Y^OT_/9Q+FBRY^-]Z3!OWRL 3CU.'5V)Y+;)V16
MQPI$C_X411Y$9&:A?#VZV':*:7,1HQ9S[4(0KQE^#L-=W+?W4%NB[CM$4,1M
M>* KBOCZ22(9XSUBC>%:(@^=C9V(@)(?Q8.P!2FP1;B8Q0=N"HUTP4 4G@_D
MV0')0'$2<2<>1IJ+3C3>SY>$E.+7%S=*!2<?RHG$0SR^.(1+G [ YOX;Y97U
M6N'%_GSZ2%:%UBQA%/G6TY,G^N.W<"FX5OSDR:4 &ZYN+UP28_,KE"Q;.9VY
MVK,XDM?"3D4P!E:2Z$>YBE^B^(CPC%'@+38W7'O3Z0ZB^B)[T[B$#7=@XB >
M+J%H67+B$-_CQ^NDDR%=SL(=$+959B4I"$DS4?&I#J(V1-R*G\H!=\LTP&?E
MHF TDOGRD5WP1>AT^5.LG\:\E='(^1"[F9'M.=C/E5X5S=#9NS>"0B(.CF/(
MBQ$!S&S9: BP%WT>9_MYF8\0^20$G,ADDF2*&&<%VK'^19-7<OQ1&(R<J'F^
MV[- >FJ.]7*\QL, T<MR&<G^ EXH-J->X>-I^#GY!9)F5+H51@[/!)R4J95Y
M_>C#Y_EUAF].X&'1-F;F::XT MF5"/E!X" Z_PK-QWC*!08U?6'F'#V(NIJ%
M39A-.#RK ( O)R#F#-:+W^3U8#'+1@$73)2* 6CHEJ#%0-N$OX7%X<-!D\^I
M!>L>5TY,(RLE5-X%@?"C ]4S_5*Q+(B&*2X-^?*[-%&$]XGL7M38+"[)#8 7
MMQ!&<QJ2!W48MC/S$3NB>JMXH<S"9+.R2V9S9">4G;!9^9QXZ+$'N:&!R?K+
MD:_LB[1;-&P$TW.%B^<%/P4T*Z9I[B[K.GLLFYVRK>]X<*&P4)'#+3J/TL$9
MF8Q5E,S*U-8M)[&T FB&B?GH+M%%A#!SM;=XRBMTXL?@(V>R4VLS$@/:X8MA
MT%%F'_=-"P*%_K$8A.L:1NB)5<JEP\ <N%@*@#U5+RWR8AWATG<]5ZY>O(YX
MKVC2+UJUC%OBN79AL%7TR0W6&1C"%F[/A/&*S*6 UD3'OL1;OEU4BV\/([32
M/>0"@0D"AV_&Y"W\5&:ZZ,3BY0(VR_OYZ;6$L=N(I*.$.7Z>%QZAWYUP;VPT
MHU$-0J!!P+A'G7QJQ3XO>38QK-GC/19Q95T4/\"*<#ZN+/4#DE^E]/4JFD,1
MC4R(?_^Z,%IRHW1A89[9EV@J^(5C?D@C$5<B64&=%"+VE1F<GEDDD"[_Y"M8
MOJR:"B\&R:,MC#)79KXR[(4OQF&TM#L#3Z?1;?AWI.^10QKY3"LN!NKENX[#
M^'06/UB8-!9_*1D^K^8&YO@!;!7Y;)O%<3FF%SYBKWPXA>\*?XYG]Q)%1&?P
MB>F"BZ,<ZG-RD'C<#ISWZY)!B>@1+D3;=/,'-Q$))^%GEH1!D*F263*^X)ZH
M;F:C^?U^.@(L,5'B-NETQ"2T!G=./A0]0FJ!(L.&9EJ/?!JPZ*G=$R_"2V9T
MDU6X+SV.'ESF)]2ETK_0F;$2A>4RD: A+A@/8"K,PTL03)>=Y\ MSU2B(%BN
M5SW^?O(XKO>H.U'$.!WU>?GEUL]-^13;N1CL:+*TAZ7J?AJ^B95<S8:#,Y/<
M!(WA,2&9D^63O':N+-<QX<7,,%+&YV5#3#,N81HVSZ]BR*?Z.:(:AX=1@UB*
M_;B1!RC<$3,FA,$0KQL&/A^=O?C"O. U>B/A"R[#/[%V*UOW:YLC[U..G'+D
ME"/?(L6]+D<^U<R)-F1ZRQST.JT>.,NM27NHM7IZ1YN,>D.M,UK7O-\OC+_D
MYQV^1^M\F1F&>LN':X(K?\WGIX%YY$?;D1O/AT[Q";)\S93LHIVX Y_ER2@$
M"$X@L++['$6&30NX$H\=7S5#-ZE-FT8;U>P']9^Z9V:2'Z+#^-'#;3CO\L_4
M/*=QI_>V#E>X-YY<OGGF<MF*.VQGKLEL40J]Y$XB81X1-AY>9<4SJ^QG]>5W
MB-*Y430J\4KX$&;?"C*^@(BJKN^6XT\Y9;RY+^[:S::"N<_$8P,G[P'?;R(=
M>(%8MI9@ERN@#\J+QHK4\D8"G.\5*U;DXV0+3!ZDM0G9EXI?Q!%^^B8=RG'9
M1J8_&^N[SY475S2SF5VRF/#;S)/Y"_-L/=;*I4R3/KJ<>,<MV;FQ5?$JI+F%
M^@MO/FX 3KXA(.6GXR;"F\D:I@*[3I@*H_RRI^Y&;>[Q+!1A,Y,1>\+\9"<W
M*-=WMT+V\S=:]<#\@B@O_%3GZ (+KY&UV]&W1>QZV<.)FR]]7\PH)K7/NK]\
MD5<(81+\Q\?>LK^A,& 3[#&(C7/)R[6-YX?,"1#@^/ ?;:&75,*7GP8H%DZ)
M5T[)+ET-G*!IZ!CQN97Q*X+@;78*R3)=7GFPB25,:'(=1S&QFM [YZ<$>1BA
M05<%/2D<;,L'5:\8^1]I1GIU[F,$D13S^!_8!CYQ1MS#CY,6<;^"4+$6PYQA
M7,GD)2/[,0Q9>(;\'82ARQV1D+T,EC[QU!;/2D:*SNQ,,S<R4,3YB\^:&E$=
M6PL?V>(S8OV5../"3 ]XCCGI"\LRW(H9*FGE7G;.B/(J>E0Q':5.I79Y-V :
M:74B\GQ&-O>AHPD._)S8;,R1ISUU@Y\>ZKC9@W+$-;A<IB%?1"0#ZKER%\>P
M76?UM1:>*Q[3@['B6(+]N1LHHK$SYB*NL5%H69!1)MDLBAVX+*2=X$DY2Y!:
M?KS(TF-1(II-*RN25<L6@28C:];,W-F2Q0KS:X5./>B_B*3R[>)BD6%A3KY1
M+WJ5@+\*SR3D.M;2(F71MIQEAN=D]_DAKD:&RZP\'B>_*XT=S"AMA%_$;0QO
M+N=%G0$XDY,PB O$T@YG/]?BO$2#%ON\HS-G++&56'-ZCP@:9$;*X%.)PWIX
MF#YM0L2!#OP;^-ABZC^_*;P5=WHW7Y*$E 0),4<7#>7P+<$]V1YSV!^)L@WX
M,U^82-NCT@_1K6TY2<&!RX>3S'"BG/><6\(X8QI?.6VS%QDW>%ZL/(Y<;<%]
MKI.6G:]Y*ZQCCP8!\ =+WB0?\\"]:^[I(R^<5[W'7TH&"O#G%6MS\KO %6&#
M(+/2TWAM<"'X,0=)< EKZP2RZ>^Y(.%TAK1$RN'%00)9'PA)QWV6&)^0 +#D
M#CF13 I//( @R!6V6[BO8WH0TV^__5N^JB@>*G>N7*8S(7+%QEZNF%J8AX7Y
M*)%(9"2:920K*>#DD2W0N7^(:>ZNDS;41I*3.;./YX:3XD2QT^9'F2^3;=2Y
MR(:L6=_T7:\QZ\&B*3/@V>6*?:(CZ3,ZP.U+7&!0#-LM)'4S@$5NXY;\7ARN
MFW4=!!/021!+SZK*NEB?T/J?-NM?%N* :>T;MDDE!!>W=&4&N_#P##;#,\^/
M=J&H.Y9A!6D-(VR@1%4B]WSC2ZJ90IMPS=Q)_J454S0=L[B;R'K5J?^]9I9]
M;1/B TJ(4T*<$N+5Y+,+<[RO= _[ZOP[YO'4-M%D7F; S'-RA/51^ *=.$WB
M,=]&2HAS+$KCKV7Y\4A67@''R\?BN&#R\6@\C'@>].BBX&)ZPF.<A\%K^KP,
M+-#%T)E"G%'ET3+XR$(;*4:BXL/JX#EL<=)2=L#S!_PEW#[W&MD[;_4V?IB,
M@ZGFQ92Y'4:=5\G7U[[1"Y?+C)A=4L8G8G!\W_$<)9J2(,:R=4H6B+^[/N.#
M)R>KQ *V\ 9;V,AECQ)<]C:8LH*_M^*_;>G3%R;9@G)<) <AWWFN _\T6.:\
M*3):"Z7E2,U*NF9*?M%.W(1]Y)%G/H#5C?H&\;#4[%G9^=<5\NZ'<6TORQS)
ME5FD>]1 GM]][\)_DEK>CQ?W[Y-:WF1@@A]]FL>5^*'>KID,JS+=>9#>+:E3
M3]-.XMAKK&CG6H4*A EAG%T?1R?_-YS-X29>H-R&GO(>@VG8HGB/OPKG/IX#
MC9?# 7J\BAA4A@\U?(5?CA[]?V_?W^,'X\?/-^?,^&G6/ $ FYVT8UIW%%@Y
ME(%'Y=%S?X*1,>)7<$2O#(NB&MPP_ K$G3E\XBJ1Y9JZ(I@O1C-P<X50\9&V
M/WCO>P8U/UG_>>CYH2[Z[NZC\V<[[>&KR>MX >,7V]*TC'.G@@H]L9^ON6RL
M,C$W;O!_++@0D)*EV<[2P.(IL'I*M'RG;7BN'>4CFW@A!ME [09"F] \Q.;E
MXOZK<.=OW'/Q#_Q<JZVID9>_HH$O@BR>E)B<8Y)<+[J,^(&7U*$78O.1D[Z(
M^/%QEZ+M-)I.&-<,YH<Z_WRR[#0LQR/T<04?3M:#=<23ES-G=/-428IPFC])
MSB82$PP?0TNX):\>W#GHW:C7?KWP"FB'VN.W;4VD-N(.T>A%HA;6M%U0CZZ<
MIF?B'$N^XP^/ZXP^FO3Y<#L<K1<O+@S<5N@S\1N1^8DOQO\>M^SC+S+C9/*?
M3(>C%['ATW,3:QY_HW@:HH^I8,QKB(GB?*J)*"1*QM%V^IEQM.+D<TXIT2";
M.=88!4&<RT@/_D4[+"*\^.G(V?V94I4@H/_5'2["8N:M=IX_C6?QT!V\0W+S
M>)Y0]J*\:XHW.:'PP'OPHQ[AD8SDO)%BL5;N -3<R/%EC\CY[2=;["9-L&NY
MTU:83DQ>3-\@%BYPZ,+(3=A(_#-.&654*"]R<?HG+>.SGP7L?]M^F&ZA"?0V
M?B*N]Y]B,=_I7(;%>;JMP9F",@>W'9R]&Q6/I&XI)5ZE4!A?P:L4CE=8_RKC
MXJN S;+YZ!D$*%>!-\>&+:"J7!%A.LYZ)I:13PSE1U=%5D2D,..YV4IRTG!T
M@47O[9\X6\1WBT(%_X-)6%=L\98);65"5BC<RR/S!>]]._WJ,SZT>8^B-E@F
M:MN_3R'%4]G[;"EOPY7RIN:K/1='^^82Y-ECGT(G+>W,C[_E)HQ_V8H[2O*M
M>:KRY/[$V1"J8KJ8XG"#6.J*9C@N1-JBJ'KE)Y/!\94/5SB:4_>_H<-6.W3@
MPY[SO[8ZW4W=N.5'/G/^Z[Q5+D5YQ2>1&8J\I:XV>/U&^9P?QI7_)(C7T@MG
MW<7X29/M8.*5N4ZV_DI<.$Y.\:E8W P],9MGR1=.,HLF+*-/53PBSV23(!>?
MPP:3ES^G+CQ%W'X=F>HH89S)?.<:HGDR^2=<B;5,]Z?#!\5=S#W+QA48KT5R
MW&KW5.5%$"]A0Y^,@;O.3LD&?4I 4Y=CPK'6WN8 5*-OC="_^X#'X?'Z.K&N
M?S$3-]SB[*KH<UI_Q=4CQ%6NV8[AB0GB/W6P'1@CB,N^4012;S@Z:L;$7AQK
MU>OP=?RL/V^TBOT-5G'KU8&'2%Y/M US@>5F+SG2$.X9N:2X F W?[@&"-NS
M"$R(,JI,*;_X*(]&1-G?M,@J$OPY1B3<T+>?<]4BR_2 &V)8<%@,'ZPOM[U1
M#8>8;H/3^SS Q9K;B:^1Z"'</*.G8G0=GHS.=#&JT,\#Q]O"XP"+BR<^>M94
M!&(B$(7Q3D\/B5\QP.44$Q1O$&O<6:Q$M;AM';<Z[2KQS1JZE>*?[!T[_=="
M%:*S Y(]I096\BIQNSZ@0Q:)"_]X3D [G6.H>2*]HL*'$_L2;S&[F<H8PF1C
MM;C#1)ONF-$Q+-%A3WDYJ7;WJ6VY^TPF^]O/T?"Y.(T16+/HU('L1C)'5M$8
MHMA?X5&!^+/I!M-=TARVM-XX.WL-G7=86.PC7+O173?79^=D,/=?!HOYWK5U
M&Q7>9U4\M%O8D'X$HXDU9WB.2[QJ540[E_9H:U%.VS GX[;6;VEMS&EK$Z.E
M#]I&:VP,Q^W!L&/ 9U>&2U\.&RZ+EI:.C>[D:G;!,T)2X@N<=?4JR<CL]DY5
MYF=2XLV$#=%]G,]M*]KZ8(].@8,7 S=)[56VL=B+-;K0ZFJMK)_VQ:DA'OJ>
M/+LJ_-E7N@B6IH>"O3[/V'DKX[O'X[SY]H=OD? ?+]F*4Z^]&E+M%=5>-;[V
M:AN>6D=TP\%$&XVZD]:0F5.X@#YMC2=CV"!WM,G8-+5)=VNBD\;HKW&MCOA4
MF"@#;A"38V/_3LHG75H:+/DS)W/WYOJS&+87G5:/>TJIGSR>#B?U0T;N3YH4
MR/HZ9AB/9N?]7:)3$^>4XFG.& !.@G$5AFFE69J+Y?YB]KSW;/AGF>\7.8L+
MV4=^H'O 'EV/.YN9,7PB_0MKC'O7I$\G,T,O*<:SG'G(4T<B8A./!Q=0I8_E
M1[N!9,P#+\))IMND#=O1^0A\0B5/D(O.-C%*DOO23I2F%O]FOZQ@Z9?FNB5&
MV$<3[?GT^3AP%/<GB;@5#ISV1#4!GZ 9@-OGAG[4P9#$%Y+;YJZ#P3F/9]!S
MHYOC'L?H&GRZ(MXJ<L_Q>MGV*9%1X^GG, "IM@+1C9P-:&= GF6W4VEW%#^>
M$$^2;X&$9)=?>8*?<8*C*"I(HP2\B7G%=74_.C/$?[/]EBWZC<VFL3XMN"[2
MJ-<G+N>=*+AU+>19YT<(Q_DK5?EWZ/)Q/EY\"(HN8D\"WFCD)C_+P4AW>!E1
MX=FP8"GL(BA:^P76B@OL3G""2W1B1;+8&ZUU7+&S=*777"V/TTL7PIO'=\V-
M=X^>**F/C*Q@\IGTS?@Q0SK: YX6=_EA8*):,O.AR$J ..CB]<()1D:CLF/1
M9VW;N<,\D[#HL@=/SXBIO5QU([GZZF36<Q&/[&$#49'7DI. BH.7EDM%>MEP
MCCE& 2?\,1!X.VX6T%53099O\KA[LFH@/U]*;9.M:Y6>V9*DPM(]]"7LUB>>
MA654+K=L^0)<K*1%W4G]EOQIU>  8)]R'/=>WCX8>8)<ZUJ8&FUE^N/Y3.ZL
MU@HP"\=JQ>=GZ/%7T"')SB*)+YE_@;AQP^=G0*&#@'.]72\W,UEX3LXC'FHS
M38Y^$67#0?XP@>PSIA.Q;7&0C3B(+).-4Q?"?<G,0C&!A^FP'F@>P('VQ2%D
M\71D3'MY2=9AV=E&40U&[-7P2AZ>5;-X,!"GN$7G*V2OR+VQ[/ M?%D_Q&.B
MK>AE>38[<MN>>9\$^D#BD!@^K>"Y -9Z#[ZLTJR2U:J5)9LDRA^NDO&%13-X
MO*I<7D$EYIP9EM0-)$<U@A<YCY#,Z>1[W?C^Z,'NU&Q%QODC_S];F.JS=WSX
MSB-BX@AG_Y&WYF9T+T)&5(G]B'OUX6TF8CI!/"7'\LP6^KO/2CQO,3W@[D%X
MW;G?QD<ZX1QO'';UG)9;)G<1(QMSF@:B\!3WU..2""F*AQOB1E(WGG !IWP"
M/9]/B%-',U1@+?=%F,5M@9AHBF<*>'S$N/A)S0WU3E&-\^31->,0NJA"$?T"
M)H=>9'HGGON=>;^;3+?A5MQ)0=.GIHU*&><D*PZ1\D5)5'_N,=V$7T\ K2=<
M@MR'X:]1=1_<::J'-C]!\U_,6#AK+C.7B_L@Z1#W JF>%^E@I4QEM^,K\W*#
M]F)>[@.HP'WR%A=Q;<U'U[N'U7K ?^\K33=HB^BE8;0U0QM.6MU1=]SJ#8?M
MECYJ3UMM4YOJ/6/:[8ZFZXX;SD89Y+)0EYC*R80*,[I3",A%Q\E$RH/A AL\
M(M'+@R5)Q:JGA4[_%6-:E\4HU/@P#Y9,<DQ/K'S%F0<H%R[JOWX3D8-I_<#_
MB.>>\%WX'V<@30:S;9 [-#+)SW/=-..?<XB]@0VW^U9\N\7/ZYW[[$W\C[?*
M3\L,GMZ,P/'E> <>_U]NFL"2_'$F $\N.EEEBZ,'$(XU@AW_@M=TOFF?#_N9
M7SY@O%_\2CQ MW?>^>UM]):QE/'" $5\3D0?YE@5%;S=\B3LK,^//^==?OS%
M,?W\; U!8!YG^3OGW5'9Y2^1R7H9D$VR_!R2T3XS73) ,SIOEX:&@" =.0HT
M\"3H&?UQUNF='0ZG^%?OTT45T/5[YVUM/79I[5A#<+O@^[2D4+ KVK,Z1]:Q
MW]Z"-Q:P%OHW^%8_/7W>'*/V>^1^-=,)DQ45HAJ"9AV[O.RA-8Y<TM+8"NK>
M3N6E_XJ3T UZ9YZD(F,I(3+K_7)-!K>\TSD?ILCA B^UFF19LVY[G#5KD)'!
M(Z)I7](0-VN942]E&LCJD]6O"ZQ?DVG4#3+[?^+<;;+[9/<;K/ADSVL):R/M
M>3Q1X<@&?5.?D0P_&7[),"'#?^JP8F"\028_20&0Q9<*E\U3S_!F:R"Z_/BQ
M_?%R#[9%I*(K7WUIFGL^+HQ+>5-62?:&@"#D^B*PF].SMV7/)Y,W](,(%U*'
MFB[[!KIP"-HFG%[ J;W17N!%J#*^,!^L784K3-B]J&.D0A+ 0 Q##$,X$</4
M$#MB&"E@((8AAB&<B&%JB!TQC!0P$,,0PQ!.Q# UQ*[Q#%,N1;RW\I.ZIX@_
MP]^>DR&]L*+Q 45;3]4_H9<64B?^=V$<D[$PV4FZ/F!R?H[8?GV "C)I@(A&
M.DN'!"G <9:]89[)W^1#@/OUS7;;MS\,>K0X&'-Q%.;"H,RX\QG;@=_C3,4U
MPS&C2^(TR O'Q/]<I9X#/S0Z\XG,GZ(#I*,_)B?HO7_FIU1<HD.2_3;WT3YS
M%^TC>F@KOY[\,QD2P8UX]EK)1\0(>?[WSKH#K;MG./MUI@=_G%F_ ,1P9KI!
M]/?DK.ONV3M-4P?]XEGQ\FE1P^R8K'1"+$[23RS>3!;/A!CDPJ9AVB&KD2)N
M(.DG;B!ND J;AFF'K$:*N(&DG[BAF=RP=?2O\V+T+XW\Y>. %/6CJ-\):PJU
MWA\9@,O<673RU1F1&W6\OOOF51%HTB%!"D#UC0V&@383)4H)QOLO)7AQ5Y#X
M%?E[5;TYT*K8'/0U==CN5;8Y(*-4<Z-$E$S2WUP8B))WS?V0BM1<18@@2/J;
M"P,1Q+M7VV> >EMNV@PCG(4V;+#,/SW7]],9^CA8_CV#1V0/^J_Z[.32[5JG
M.Z:]FFP2_UH^!(B%2?";"P.Q<(DRC!<CI^7+,$Z%9S>-F/8'?6)AV22>QE0<
M&0"NVBU<4&8J?J+$\M49D7-$TQE.H*Z"%*!>"D"$+ <,M#LHL3MH2U!7P7_[
MGOL7DN\1M*XZ&FE4<BV;W,MJDHB02?J;"P,1,G742H.#G"I"!$'2WUP8B"#*
M5%7T9:VJD&(?E]FL=6BC)INXERZI( JNF>UOF.#+"@-1\/9!4^W%H.D>2RJD
M(-F-@Z4#XF#IY)WF4QP9@$MW-F.>8>FV,M?GS).OQ(A\(II0<0*5%*0 ]5(
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M[FW66I5>NTTX*YM$RI*V*V]X@>D^&[NVJ5B3J>>^,-ZR2[JJ8G)\Z+IUB=G
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MX7$"G>,QC;1%ZQ9(0Q)_#:>N<!+T.:DXT,3$FFN@R!>\,MOF>0.>!:R:P.A
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M1//LZY<HUY:^R!Q;Y;YCWLYM<O2&Y5G3'1+EK4I#S2?*I9-QNFTC!1NHPIU
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M_[/G3FY$BA%X\CAEGAC8N9 B8WZ<)-NGNM?G E;== I:N])L-Z4I'Z+&,I$
MOI.. ^+ 5ZX1V@2RE\ G MG+Y-OV(*OFYA8>#6175^9N![+-7J775@ED91/
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MWF!35*B:LO@X;%OFL9$-2@_/Q-]&5\'Q=K@?&N."]RB&[GDS>-6K[IFX(B6
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MM+PLX1\=Y3,;>J$.+G&/FU"MHMP@QKJ>8Z$,.6B$/N':5+6A1$[8TR?\*?+
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M]U.8N(YH9N K;ACX@>X@?>0+"Y(K0"-(R\L&FM*[JLGMSZ%G6\*(90+>K<6
M=VP ^\+^/838"N!QQ#OR^/>^'S*3-^;9-;]<7Q4!_ZAU*HU>O=+0#C="CQ3_
MRA6?8(^DO[QL(-C;!?9R;>@. WO+4\!K8*]94=O-2E?K$NS))ETEN#^L=6J-
MEMQ<^,)\_[WR&FEI-3Z=A\X+\_&XSG3/GFW=9/#"B"!$4?ROPGXRS["P#VHV
M1.&'PW_SCM1NJ<CAL6GH&6/=9_(%,LE#I?AQ>=E 'NI'WHM?DY WI")2L($
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M."V;-LART[N\ :$[/P MP4KFJ!$@QH1X&7 V"J3</7W[)M\%&W*HJ)-I>=E
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M85$DET# D7ZB+V+K6S@:_2 =C%4^U!3E10^A[F"$%:)Q$N2(Q =F([7O8@P
MT$R=GQ+\UM.<""EE:=)..%!^[/:[Z/HCK !YU0?[(?P!K]"5VTBKA8GB5MEQ
MN BDG^3(_B%2MXT4PXNP+? 1CAP+:PS!6(7 :,"4&<==%7ADYJ3CPXJ*%M#.
M#/V#Y9"VZ,*XFQ7<<)"[V7L G19J=MC(P/\)>;0314JLR"BHBO61+V,VT>8
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M?$D)XS 3U I9Z*C=7C?JEZ?UZY,+?!K;U8_+&R6.GYTU ;PW_ET_W?DX>IS
MZ$%LXEQF^: IXWM@[=NB?Z\';"^G3!0OK_.C4U^^9,$R>LG"YH9WN49LX%%_
M8ZLD_ITODOAW(8$0/^WQ:1:Z7\2G/5K[MV=_?:U_JM\T;\_KER> 0@"$-&^
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MXS@L:1E(-<EX#X)%PQ@N0;=A28MS#@E:SI(62UH;KA4:0X]9+J%*RGB,3&!
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M$?@_93 0NFRA@C;U55&CX\1=D4:BGPB_+7K]5N"[<*#G)VX0)=+C .8 UNW
M<II=^Z!1EO[WA5,=R9B^P2JAA+AN8P"KZ';2U'$[.E;/L@BOVF5+!=W8%[9P
M7(PI)QSH=' 2AGV(S8;L0:(0$(3GT"!A57:_J2(A!K G87[T5.U1%PM5 #>E
MVX\A,*&I^AYN!V=2<1IUNWZBUBKC]_E%(&Y;6-!THQCNE*>=6+9E+$-7E3HC
M@:V"VT"08;IJG%S?".@KA(#LI[Z;E$0]=,L"Z(F,I]MP@I-\6UC'U6H)C>#
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M>K"96+V]ZXKV$6L"?@!&C80^R 69OC+J^HF3-=7&?P%1(Q6[)XY#R*[5"@*
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MKJ7*-CU&X G9LJ-.J@@E (9P 5EYUA1NH.-!"?W3)*AI'J9)/&@5JX$,(:I
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MWT)V7D 82^49"Q S)%2A.V7H.\]^(#WO5-]@2/P'!):.[VU&8^U#(CPR]^\
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ME\FB97I*\:/6>[XF:^SP<NU$(!UDX7!F&Z_NQ/1BC*=C^1OP9W-J>+P Y,R
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M;?IJ;;E7QH7=11I;1B[9OC9&V 32CS*MQ0>S&0(S<H@SUXFO!I.=&(2,(.9
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M+"0<79)E.?5I:[ UBP^ \!;YA-/0VWBC%?PBM5ZC5$2[68UC0,:-HDK><H4
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M_BEC?[S%(<-(02[0^0GZVUGQL3/ZI[,/'\]^^/#V:Q9]1[0! -='BA&\AQM
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M770#9>/+X]R[1LR^J9;.SOD PHB=-<UOM/U0X$$M>:?V9GA5UK@]L[Z.LS!
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M!TF;G?T@+H3PPQC'X(LM*':!6*(:C( *  H) !4!%#* 4@A02#%'*N=Z!].
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M7X5Y_,KWW0:1WH3ZJ&:)FMP<--(K6X(')3<_)H,12./Q.EX>JJ@Z+&%3?"$
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MAWOIFP V1F$Q<!?'T)RKG(]$P*S.GQEGY>9]_K?9K/6C&MEC<^FZ0 TU,"E
M(<9@]96K037T1?0,AF^?\>N[",8LF/_MC_3',_XCB^#DU[]>BM:!5#DXI<VT
M<WI%<T^+'D#B^(_P:WZ.%+-;- GJN[(6 P>U+PK60.9-;PE+[O,&9#-$L9%B
M%X$>Z@7N7 (._$99 \9[\OW".GT.$E%J_P(G&49Q5!3\OR/C+GI[KC=BX@A0
MV2[5:'UEB:'Y9&Q% +M16I((U$1B05D6BB9$E6*!2B[O>O#:M2OL!+Y)ND=_
MHD\@X7IC=@W3]NT1Z] C:@Y67A(^?IAB#P)X6#?^:;M8WC/R-""H')L[ZFS(
M%Y%DA7E'_# T[4_80V5$R[=.JG8;MY5L0,''NV"L !-65]PD8?,A?D[B31S2
M=W9'\FAM#70ICCB,5N+@XDAGNPW2 SW!D40 +9;IASEJ8HO--+P,'(L[A7[<
M9MTB7 =Q^FN ]O"R.BTT"?/]=$;TH.BA:[?I!&$$&"<@L?(NVBOAA77T-TG$
M;Q/#*- /$+)K: [#NF1NO\" <MOZDX^IAM: E5F+V!,@,Q #9HS/G44)3(*T
M K%13V'ZB=M^%=-9,L&[H*T.(M;6YR3ANU.6RDV,HKD>70>VV<+'R6.[JEJ+
M0F$/+TRS#UD5*^W4[))05 DV%?-Y)PI^TY<5EXX!,EK']Y(956RGBZSMZCJ,
M3W7A23CY-Q\H8(4UE#?)'*#25V3D=&#,8O1!HBY+)_UT%&_G9SA<- ;]^.31
M3-,+!;A^C#S8#,>7N81698AS?JF61!<L(?X9)F%-52:SBR;A$:\R=!C9?591
M<68PUWC7 /9L4C(#'8_2^203EY)<1O.5+F7']NQP=I+X+\A:>^<C$Y4N"T#M
MB&0RY=!\2.9Y'SX*OV,9DA<8D>]B?G6]>DZA?E*1&AU]2%3HV@$@$OEAC D%
M0N()@I+IVWE=2@LOK*,_G[$IG4/&I&(VXRL?2:17N$I3^HK=PEF;%MDQ@4Z9
MC8MIJAU-7^8L?6#Q",TN",1C;WPENZ2*L2\[(WKLEQ],MC[-;YJ#4Z=D5?^<
MM'=;DPZMXWZ=3)/*1.NQO6 4D2C$A?B$<S@R5&L0'9$(H\K$S6YBN.KCI%E+
MVC!B8TTN!K(B?4GB"D2$H'Q]B<F5&*R"*3T^9?/_/43T.09['?7P$J3P*<A@
M5-3?-XGA8SF9(S^.L]U'+Q7JO(!K*0P0TH@':94\H&QZX-O,8LEVL%VD)IFY
ME 4]EP4UFL]&LYK <=I9.\CGI='TC'&K.<_"_&' *$P<H@^!A1N 4>@$YXW8
M.>,<6U:<&'?_TTO&0CT,QW<[56$,GR]R5+!J*T\RZR5-BQ1&4TT_':LFYG"2
MD"NP>&M4O5%_6%\^8]'O[W.>/P4I+1=)B[BR.<+H)*J3QH@SJ0Z:=D^G!!-:
M_E5,D;[%WD%\L*K.)HFZ31&,0FX/$7L&Y3#8TF+9MSB3S,I/6^J-MP/Z\A:(
M'M>>,<R2E7><K3>-!X('_K]&3J)*T1PH-0[VW8?QI<]3Y0(-?GB0)HS83)G+
M@ S):)'=9_,AZJ'XSYQ^]SDCN_2K+(^W9#.L54NC^4US4.J4[/O+9]["M^3@
MAZMT:![WZ\4O+:-*P6LE!;O*WR#:3G*>A' ?9[]?I#"*<_J37KY&#YDQ5_N=
M9%U<]$G,J-5S9H!R8Z^AUOD+F?#IKQG[_3/Y?)H'<>)//R05.+&&?CV&#K6A
MQK"2<)N\'#E\IN>?]W"'4RM+,46"(ZYI51@XN%G@;#UQ&SW8L)'V%@$1JJ$#
M2I8>+;O*%_927;6;),M37MV02ZCC8HH$+=0$Z&/@M&H#EFOU2:S]\#X]1-LJ
M.0PK=A'HH2/@UAW "4><HT<4?1'0:-)E/KTI$AS7\6:0@:-F !)#/QQ-#SYL
MI,5%0(4DE-@KDZ.>;?//<[\$Z>\PIR\P'V"X3]F;2_W)K8^*.53=5.V[4L4+
M5,S\\"<%B+"ZTOR% _4@,=-,U%E>8\1DI$[305D0YU/2(@N[*,Q->AI="G*H
M 5I;,1</)JF;[8XL5JDTZ[1H3[?>W.+D^39^A=$JR^"H]:$9_1'9&@;\'&34
ME%+0G1OE?L;8 \[?#Y\=!3VVH?(EPHR.$%ZG53?*-4<;R&C[X.:WD(@";VG7
MXC'>W$O&',T>LO9]D[/QPP558,$:>O(8 E1HG_(!G)$/GG$/7V&RA_<PQ,])
M3.\@1OB' C%SB :)V_<5P=(/9U%'"FLKS7M44 T0(+'SPXDR2)"DIS^71$*$
MV?I6%!?3/_-0(C<&LD'R+ER),V6[-XDM?X/ABX>IPX@-]+D R% #K54#+<%R
MID.3ZNF0_)QGO1--BV[833I9>M+-IL%9HQ'Y$=>B^NP<W&-3(;Q](3<&<&Q!
MTPL$%TFX@F-< 1>!.78I!#N=F>LD]!JG,'Y.+O8I[>%W>$R)*$'(FC 1(=FO
MB/=D&K$R'<%DQ,VK*5,'=^E<%%#( F1A_/#U\7: K:E^L9@C!;B9[\N2^+"$
M+I^9C3EL[:1AX?F;^T-3?Y\AJIR"]NK)5_VCINI]< 4Z7:?PA<S89&KFHHU.
MPU2G.:KJIA(/)R6.*L[L>9D?#J2-)#;5YE)00VV "??S)T6S^0QOA.,-DK+W
M6-"YFRWE[::"=RGISG-HA"^UO.;TP(4^P2_22[L4)^3'$$H9IR-\2I_VB-;#
MFKQ<G)S277KM"6%-##]\T!AO/%;72\,6%<'T2S>F-N;"CEKAW)S0X2;+]C#J
M&O\GG/\%YJL([W(8&;BJ-5:&5:W'LW92E+P0"\1,+A!4!K"K&T""<W @\VW
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MKN S-;H<BWS5STE$7WM)TZ#O2R4+9C80P,:">%HF-1"^ROT7"U'U]50I8LT
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M!3"LH4&/P4%C<5%RF2S-)7<AOS5=A?SIKP\D1K''(S]#_$P<^24. Z3ZZGR
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MCZOH-<[83U05%SC)]BCO/]1QLYVL)8&IA\+>KYNOPEO(N<JV>[B[\V-_U8<
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M8;/P^:O/;FS,69VXG)*-6)N;^/\*$8&0<988]#2LWZ>F?J^^[F+>;)%+KAV
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M!F1 ?83M:',;:1H_<M-(X#.]TS (.L6AC"]AQ]P8\'@8%@1\(R8P3$5?-BY
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M$N?9_<-G_<;@ X3,;;R7L'TD*G:B !-E"+[_CK#\[@]^1#XUS+"6"KW&!_5
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MX)<AZUYN8 V^^AA8"ZG\MFTNI>/ RIE\.X&U89 3!U89TF_'^.8+K$/6O8#
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M%@B>SK+.['<DR5.0._:+T.OLWD-*;%(^1[P6]-3(>Z*:5;V'S-Z>XW6/QP,
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M:VZ.UV@_9#(=,OP^C&8$D /#81M-2)/D*([C:#\4IMEQ6#58D4X[*S[&C5F
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M.IWEM!5\*8M0TR-6]!Q@!UO^.L<2=*U7$-%=D!H7L*]C?Q5>>E9%1L\.S@4
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MOHOW?0E8_W\1PMK:*.?T.KP95 D!+<SSQTX9%]0F[3!3_%.XC,W&T3:/^RQ
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MBR -9J ;Y$NW(GO0%5Y0(42N6\'.UHP7: V%$#G-=>'E8$.K*,1I=CMW,A$
M 6*=GY#$!2Z\!ZV;-'XP&LJ]D>#6$.D^E]_@0SFQ0Y2G"(9Y[=]BY]K#P+#
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MYR0(;TGX.PKOD4WF'OZ+*FQ$5S1;^NF/V.^=@&)IFCG3$UIL2ZCDWCVQ=KU
M>9LA+>!NLECSK,4"/2=ORW'/(FO]>1[YS RD:;3)7T#9AZJ&[,>=:IG'M8FN
M4$\VBJ69A@OD/RXL+YWA;(4DJ5E*+UK5,=5OD*\L[/]JN1&:4#=AF8C GK5B
M1X=-0A=_K$D#P#"&]('[7"_+\ZXLZ9+X-5X/UUYJ S8"@@Q3>SST>WU.-RL
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MSC1YS-3[-'VX:IHXU'..V;_VJ.^\5)/.+T*U5U=%E0SKB#(\>7[6MX-RM'$
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M-/_E5&&'.%K^S9/_SZ9JY__G^0=02P,$%     @ 6T-J5&*>,ZQ<"   FT(
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MV[_H?""]/WO=S\/^[STH!HG>X*YF__-G].+SX-/GSMF0#,_)IUX7;2]GM]Y
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M1E(N 52(SQ6( L [B$.U7JOG$E6BF&W"[U@4"?0)0%U#3  @YUK,20XX0XI
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M2-M\W;$E@LN,CAZ!.DT%WN[9EQXI?<8->$PBQ@0M;52*@:5E+NR86I!8AA$
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M>60Q8G)M9G=P,# P,# Q+FIP9U!+ 0(4 Q0    ( %M#:E0YDQ7PK_8  $L
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M8FMY9#%B<FUF=W P,# P,#4N:G!G4$L! A0#%     @ 6T-J5%P8.*7/N0
MHKX  !8              ( !'YH# &=B:WED,6)R;69W<# P,# P-BYJ<&=0
M2P$"% ,4    " !;0VI4D-A4:8'[   5$P$ %@              @ $B5 0
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M+FIP9U!+ 0(4 Q0    ( %M#:E3.B,_=<]L  *G>   6              "
M >$-# !G8FMY9#%B<FUF=W P,# P,3<N:G!G4$L! A0#%     @ 6T-J5-D^
M5U@^F   ;\<  !8              ( !B.D, &=B:WED,6)R;69W<# P,# Q
M."YJ<&=02P$"% ,4    " !;0VI4Q7=J;?B$  "XQ0  %@
M@ 'Z@0T 9V)K>60Q8G)M9G=P,# P,#$Y+FIP9U!+ 0(4 Q0    ( %M#:E1;
M?T>C^G\  !*G   6              "  28'#@!G8FMY9#%B<FUF=W P,# P
M,C N:G!G4$L! A0#%     @ 6T-J5-X=10\M5@  A&$  !8
M ( !5(<. &=B:WED,6)R;69W<# P,# R,2YJ<&=02P$"% ,4    " !;0VI4
MBY ;.KJ8  "KU0  %@              @ &UW0X 9V)K>60Q8G)M9G=P,# P
M,#(R+FIP9U!+ 0(4 Q0    ( %M#:E3?V[I(UIL  %G/   6
M  "  :-V#P!G8FMY9#%B<FUF=W P,# P,C,N:G!G4$L! A0#%     @ 6T-J
M5'\$NA=YW@  7PH! !8              ( !K1(0 &=B:WED,6)R;69W<# P
M,# R-"YJ<&=02P$"% ,4    " !;0VI41Q^J.E]< P#@RRL %0
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M%0!R87!T+65X,C$Q7S(S-"YH=&U02P$"% ,4    " !;0VI42U+M#)T$  !
M)   $               @ '*1A4 <F%P="UE>#(S,5\X+FAT;5!+ 0(4 Q0
M   ( %M#:E1BGC.L7 @  )M"   0              "  95+%0!R87!T+65X
M,S$Q7SDN:'1M4$L! A0#%     @ 6T-J5%MSR/]."   F$(  !
M     ( !'U05 ')A<'0M97@S,3)?-BYH=&U02P$"% ,4    " !;0VI4-&X*
M(+L$  "2'   $               @ &;7!4 <F%P="UE>#,R,5\W+FAT;5!+
M 0(4 Q0    ( %M#:E1[>IXXKP0  (L<   1              "  81A%0!R
F87!T+65X,S(R7S$P+FAT;5!+!08     )  D &4)  !B9A4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
